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ABSTRACT 
EFSA was asked to deliver a scientific opinion on acrylamide (AA) in food. AA has widespread uses as an 
industrial chemical. It is also formed when certain foods are prepared at temperatures above 120 °C and low 
moisture, especially in foods containing asparagine and reducing sugars. The CONTAM Panel evaluated 
43 419 analytical results from food commodities. AA was found at the highest levels in solid coffee substitutes 
and coffee, and in potato fried products. Mean and 95th percentile dietary AA exposures across surveys and age 
groups were estimated at 0.4 to 1.9 µg/kg body weight (b.w.) per day and 0.6 to 3.4 µg/kg b.w. per day, 
respectively. The main contributor to total dietary exposure was generally the category ‘Potato fried products 
(except potato crisps and snacks)’. Preferences in home-cooking can have a substantial impact on human dietary 
AA exposure. Upon oral intake, AA is absorbed from the gastrointestinal tract and distributed to all organs. AA 
is extensively metabolised, mostly by conjugation with glutathione but also by epoxidation to glycidamide 
(GA). Formation of GA is considered to represent the route underlying the genotoxicity and carcinogenicity of 
AA. Neurotoxicity, adverse effects on male reproduction, developmental toxicity and carcinogenicity were 
identified as possible critical endpoints for AA toxicity from experimental animal studies. The data from human 
studies were inadequate for dose-response assessment. The CONTAM Panel selected BMDL10 values of 
0.43 mg/kg b.w. per day for peripheral neuropathy in rats and of 0.17 mg/kg b.w. per day for neoplastic effects 
in mice. The Panel concluded that the current levels of dietary exposure to AA are not of concern with respect to 
non-neoplastic effects. However, although the epidemiological associations have not demonstrated AA to be a 
human carcinogen, the margins of exposure (MOEs) indicate a concern for neoplastic effects based on animal 
evidence.  
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the Panel on Contaminants in the Food Chain 
(CONTAM Panel) was asked to deliver a scientific opinion on acrylamide (AA) in food. The Panel 
developed the draft scientific opinion which underwent a public consultation from 1 July 2014 to 
15 September 2014. The comments received and how they were taken into account when finalising 
the scientific opinion were published in an EFSA Technical Report (EFSA, 2015).   
AA is a low molecular weight, highly water soluble, organic compound. It is used inter alia as an 
industrial chemical and in the production of polyacrylamides. Heightened concerns about exposure to 
AA arose in 2002 when it was discovered that it forms when certain foods are prepared at 
temperatures usually above 120 °C and low moisture. It forms, at least in part, due to a Maillard 
reaction between certain amino acids, such as asparagine, and reducing sugars. However, several 
other pathways and precursors have also been proposed to contribute to AA formation. AA forms in 
numerous baked or fried carbohydrate-rich foods, including French fries, potato crisps, breads, 
biscuits and coffee. AA is also known to be present in cigarette smoke.  
The analytical determination of AA in food products is most frequently performed by high 
performance liquid chromatographic (HPLC) or gas chromatographic (GC) separation methods with 
mass spectrometric detection (MS), either in selected ion monitoring (SIM) mode or by tandem mass 
spectrometry (MS/MS) in multiple reaction mode (MRM) using isotope labelled standards. 
In its exposure assessment, the CONTAM Panel evaluated a total of 43 419 analytical results from 
food commodities collected and analysed since 2010 and reported by 24 European countries and 
six food associations. Data provided by European countries and those provided by food associations 
gave overall consistent and complementary information. AA was found at the highest levels in 
‘Coffee substitutes (dry)’ (average medium bound (MB) levels of 1 499 µg/kg) and ‘Coffee (dry)’ 
(average medium bound (MB) levels of 522 µg/kg). However, due to dilution effects, lower levels are 
expected in ‘Coffee beverages’ and ‘Coffee substitutes beverage’ as consumed by the population. 
High levels were also found in ‘Potato crisps and snacks’ (average MB level of 389 µg/kg) and 
‘Potato fried products (except potato crisps and snacks)’ (average MB level of 308 µg/kg). Lower AA 
levels were found in ‘Processed cereal-based baby foods’ (average MB level of 73 µg/kg), ‘Soft 
bread’ (average MB level of 42 µg/kg) and ‘Baby foods, other than cereal-based’ (average MB level 
of 24 µg/kg). The CONTAM Panel explored the possibility of performing a temporal trend analysis of 
the AA concentrations in certain foodstuffs across Europe on the basis of the data submitted to EFSA 
by the European countries. Because of gaps in the databases and the fact that results for different years 
are not always comparable, a reliable Europe-wide temporal trend analysis is not feasible. However, a 
dataset of manufacturers’ measurements of AA levels in 40 455 samples of fresh sliced potato crisps 
from 20 European countries for the years 2002 to 2011 showed a substantial downward trend for 
mean levels of AA, from 763 ± 91.1 µg/kg in 2002 to 358 ± 2.5 µg/kg in 2011. For other food 
categories, a similar downward trend was not observed.   
Estimation of human exposure to AA revealed that infants, toddlers and other children were the most 
exposed groups. Depending on the survey and age group, chronic dietary exposure of children was 
estimated to be on average between 0.5 and 1.9 µg/kg b.w. per day and the 95th percentile was 
between 1.4 and 3.4 µg/kg b.w. per day. Chronic dietary exposure of adolescents, adults, elderly and 
very elderly was estimated to be on average between 0.4 and 0.9 µg/kg b.w. per day and the 
95th percentile was between 0.6 and 2.0 µg/kg b.w. per day depending on the survey and age group. 
The main contributor to the total AA exposure of infants was ‘Baby foods, other than processed 
cereal-based’ followed by ‘Other products based on potatoes’ and ‘Processed cereal-based baby 
foods’. The main contributor to the total exposure of toddlers, other children and adolescents was 
‘Potato fried products (except potato crisps and snacks)’ representing up to half the total exposure, 
followed by ‘Soft bread’, ‘Breakfast cereals’, ‘Biscuits, crackers, crisp bread’, ‘Other products based 
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on cereals’ and ‘Other products based on potatoes’. These foods groups were also the main 
contributors to the total exposure of adults, elderly and very elderly together with ‘Coffee’.   
Scenarios were designed in order to assess the influence of specific behaviours (preference for 
particular products, places of consumption, home-cooking habits) on the total dietary exposure to AA. 
Scenarios on the preference for particular potato crisps and coffee products resulted in a variation of 
less than 4 % and 14 %, respectively, of the total dietary exposure to AA. In scenarios on home-
cooking behaviours, degree of bread toasting resulted in variations of less than 8 %, while for 
conditions of potato frying the total dietary exposure to AA could be increased up to 80 %.      
In both experimental animals and humans upon oral intake, AA that is not covalently bound to 
components of the food matrix is extensively absorbed from the gastrointestinal tract. After reaching 
the systemic circulation, AA is rapidly distributed into the tissues. AA is also able to cross the 
placenta and is transferred to a small extent into human milk. AA is extensively metabolised, mostly 
by conjugation with glutathione (GSH) (primarily mediated by glutathione-S-transferases) but also by 
epoxidation to glycidamide (GA), which is widely distributed into tissues. The formation of GA 
represents a metabolic activation pathway preferentially mediated by CYP2E1. Mice are more 
proficient in converting AA into GA than either rats or humans.  
Formation of GA is considered to represent the route underlying the genotoxicity and carcinogenicity 
of AA. Covalent DNA adducts of GA have been amply demonstrated in in vitro models and 
experimental animals, and these have been used as biomarkers of AA exposure. The N7-guanine 
adduct derived from GA (N7-GA-Gua) is the most abundant DNA adduct following AA exposure. 
GA-DNA adducts in experimental animals are found at similar levels in various tissues of the body, 
although CYP2E1 is primarily located in the liver.   
Covalent adducts of AA with DNA have been generated in chemical reactions, but have never been 
detected in vivo or in vitro in animal or human tissues. 
Detoxification of both AA and GA can proceed through conjugation with GSH and the GSH adducts 
are subsequently converted to mercapturic acids, which are excreted in urine. The mercapturic acids 
of AA and GA represent the major metabolites and their urinary excretion levels can be used as 
biomarkers of AA exposure. AA and GA can also react with proteins to form covalent adducts, e.g. 
with haemoglobin (Hb). Also these Hb adducts represent important biomarkers of AA exposure.   
Several studies have reported various approaches to physiologically based pharmacokinetic (PBPK) 
modelling of AA absorption, metabolism, and disposition with the goal of predicting human internal 
exposures to AA and GA (i.e. area under the curve, AUC) for use in reducing the uncertainty in risk 
assessment inherent in animal to human extrapolations.   
PBPK models allow derivation of human-equivalent doses (HEDs), which could be used to convert 
external doses of AA that produce critical effects in animal studies to the human external doses 
required to produce equivalent AUC values for either AA or GA, depending on the toxic endpoint 
used. The HEDs derived from equivalent AA-AUCs in rats and mice suggest that endpoints related to 
AA-mediated effects (e.g. neurotoxicity) require 4- to 6-fold higher doses in rats when compared to 
humans, based on inter-species differences in toxicokinetics. However, 0.5- to 0.7-fold lower doses of 
AA would be required in mice to produce equivalent GA-AUCs for genotoxicity-related endpoints 
when compared to humans.  
Toxicological studies with AA have been conducted in rats, mice, monkeys, cats and dogs, using 
various dosing protocols and routes of exposure. Oral LD50 values for AA were reported to be 
> 150 mg/kg b.w. for rats, 107 mg/kg b.w. for mice, and 150–180 mg/kg b.w. for rabbits and guinea 
pigs. 
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Adverse effects reported in repeated dose toxicity studies of AA in rats, mice, monkeys, cats and dogs 
consisted of loss of body weight and effects on the nervous system reflected by hind-limb paralysis, 
reduction in rotorod performance and/or histopathological changes in peripheral nerves and nervous 
system structures. In mice, effects reported in addition to the neurotoxicity consisted of effects on the 
testes, including the degeneration of epithelia in spermatids and spermatocytes, the reduction of 
spermatozoa, and the presence of multinucleate giant cells, as well as forestomach hyperplasia, 
hematopoietic cell proliferation of the spleen and preputial gland inflammation, lung alveolar 
epithelium hyperplasia and cataract and for female mice ovarian cysts. 
In rats, effects reported in addition to the neurotoxicity, included atrophy of skeletal muscle, testicular 
atrophy, distended urinary bladders, increased prevalence of duct ectasia in preputial glands, 
hematopoietic cell proliferation in the spleen, bone marrow hyperplasia, ovarian atrophy, degeneration 
of the retina, exfoliated germ cells epididymis, hepatocyte degeneration and liver necrosis, bone 
marrow hyperplasia, mesenteric lymph node cellular infiltration and pituitary gland hyperplasia.   
Thirteen-week and 2-year studies in mice and rats dosed with GA revealed adverse effects that were 
generally similar to those reported for AA. Rats were more sensitive to the neurotoxic effects of AA 
and GA than mice, and neurotoxicity in rats (such as hind-leg paralysis and peripheral neuropathy) 
was consistently associated with lower AA doses and greater severity when compared to equimolar 
concentrations of GA.  
Rodent studies have demonstrated adverse effects of AA on male reproductive parameters including 
reduced sperm counts and effects on sperm and testis morphology with a no-observed-adverse-effect 
level (NOAEL) of approximately 2 mg/kg b.w. per day.  
Rat and mouse studies have shown some signs of developmental toxicity (increased incidence of 
skeletal variations, slightly impaired body weight gain, histological changes in the central nervous 
system, and neurobehavioural effects) at exposure levels that in some cases are also associated with 
maternal toxicity. The lowest NOAEL reported for developmental toxicity was 1.0 mg/kg b.w. per 
day from studies in rats exposed gestationally and neonatally.   
The genotoxicity of AA, as well as of its reactive metabolite GA, has been extensively studied. In 
vitro genotoxicity studies indicate that AA is a weak mutagen in mammalian cells but an effective 
clastogen. GA is a strong mutagen and a clastogen. It induces mutations via a DNA adduct 
mechanism. In vivo, AA is clearly genotoxic in somatic and germ cells. AA exerts its mutagenicity via 
metabolism by CYP2E1 to GA. AA can also induce gene mutations by a pathway involving the 
generation of reactive oxygen species (ROS) and oxidative DNA damage.  
AA is carcinogenic in multiple tissues in both male and female mice and rats. In rats, the major 
tumours produced by AA are adenomas, fibroadenomas and fibromas of the mammary gland, thyroid 
gland follicular cell adenomas or carcinomas, and in F344 rats, testes or epididymis tunica vaginalis 
mesotheliomas. In mice, the major tumours produced by AA are: Harderian gland adenomas, 
mammary gland adenoacanthomas and adenocarcinomas, lung alveolar and bronchiolar adenomas, 
benign ovary granulosa cell tumours, skin sarcomas, and stomach and forestomach squamous cell 
papillomas in females, and Harderian gland adenomas and adenocarcinomas, lung alveolar and 
bronchiolar adenomas and carcinomas, and stomach squamous papillomas and carcinomas in males.  
A similar spectrum of tumours is observed when equimolar concentrations of GA were administered 
in drinking water to rats and mice, which is consistent with GA being the proximate carcinogenic 
metabolite of AA. 
AA is an electrophilic molecule which can undergo Michael addition-type reactions with nucleophilic 
target molecules. In particular, activated thiolate moieties in cysteine residues of enzymes and other 
functional proteins, e.g. in neuronal cells or spermatocytes, have been described as targets. The 
neurotoxic properties of AA are considered to originate mainly from this type of reactivity. 
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AA shows some reactivity towards nucleic acids, whereas reports on the formation of DNA adducts in 
vivo suggest that GA is mainly, if not exclusively, responsible for the formation of DNA adducts in 
AA-treated animals.  
Evidence from the available studies in the literature on hormonal and endocrine effects of AA is 
equivocal. This is particularly true for changes in hormone levels in AA-treated animals which were 
reported in some studies. Mechanistic hypotheses on local endocrine effects of AA which may explain 
tumour formation in certain hormone or paracrine-regulated target tissues lack experimental proof. 
There is a wide range of epidemiological studies investigating possible effects of AA in humans. Two 
cohort studies considered occupational exposure to AA and did not indicate an increased cancer risk.  
Associations between AA exposure through diet and cancer risk have been analysed in at least 
36 publications, based on 16 epidemiological studies considering several cancer sites.  
For most cancers there is no consistent indication for an association between AA exposure and 
increased risk. A few studies suggested an increased risk for renal cell, and endometrial (in particular 
in never-smokers) and ovarian cancer, but the evidence is limited and inconsistent. Moreover, one 
study suggested a lower survival in non-smoking women with breast cancer with a high pre-diagnostic 
exposure to AA but more studies are necessary to confirm this result. 
Two studies reported an inverse relation between AA exposure (measured by levels of AA and GA 
adducts) and birth weight and other markers of fetal growth. The CONTAM Panel noted that it has 
not been established whether the association between dietary AA exposure and these outcomes is 
causal. 
Studies among workers occupationally exposed to AA showed an increased risk of neurological 
alterations, including mostly the peripheral, but also the central nervous system.   
From all data available, the CONTAM Panel identified four possible critical endpoints for AA 
toxicity, i.e. neurotoxicity, effects on male reproduction, developmental toxicity, and carcinogenicity.  
The data from human studies were not adequate for dose-response assessment. Therefore, the 
CONTAM Panel considered the data from studies on experimental animals to establish the reference 
points. The CONTAM Panel performed benchmark dose (BMD) analyses on data for neurotoxicity 
and on the tumour incidences induced by AA in experimental animals. The CONTAM Panel selected 
the value of 0.43 mg/kg b.w. per day derived as the lowest BMDL10 from the data on incidences of 
peripheral nerve (sciatic) axonal degeneration in male F344 rats exposed to AA in drinking water for 
two years as the reference point for non-neoplastic effects. Based on the fact that this BMDL10 is 
lower than the NOAEL of approximately 2 mg/kg b.w. per day for adverse effects on male 
reproductive parameters and of 1.0 mg/kg b.w. per day for developmental toxicity, the CONTAM 
Panel concluded that using the BMDL10 for neurotoxicity as the reference point is conservative when 
considering possible non-neoplastic effects of AA. 
For neoplastic effects, the CONTAM Panel selected as a reference point the value of 0.17 mg/kg b.w. 
per day derived as the lowest BMDL10 from data on incidences of Harderian gland adenomas and 
adenocarcinomas in male B6C3F1 mice exposed to AA for two years. The CONTAM Panel noted that 
the Harderian gland is an organ absent in humans, but that in rodents this organ is a sensitive target 
tissue to detect compounds that are both genotoxic and carcinogenic. Taking into account that target 
tissues for tumour formation by a given genotoxic carcinogen may differ between rodents and 
humans, the CONTAM Panel considered the most sensitive target tissue in rodent bioassays, the 
Harderian gland, a conservative endpoint for assessment of the risk for neoplastic effects of AA in 
humans.  
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 6 
The fact that AA and its metabolite GA are positive in a variety of genotoxicity tests indicates that AA 
is of concern with respect to genotoxicity. Therefore, the CONTAM Panel considered it inappropriate 
to establish a tolerable daily intake (TDI).   
Risk characterisation for non-neoplastic effects was performed using the margin of exposure (MOE) 
approach and the BMDL10 value of 0.43 mg/kg b.w. per day for the most relevant and sensitive 
endpoint for neurotoxicity, i.e. the incidence of peripheral nerve (sciatic) axonal degeneration 
observed in F344 rats exposed to AA in drinking water for two years in the NTP study. MOE values 
for the neurotoxic effects ranged from 1 075 (minimum LB) to 226 (maximum UB) for the mean 
exposure, and from 717 (minimum LB) to 126 (maximum UB) for the 95th percentile exposure 
estimates across surveys and age groups). Taking into account differences between species and within 
the human population, the Panel concluded that the MOEs across surveys and age groups are not of 
concern. However, the Panel noted that the MOEs for the 95th percentile UB exposure estimates for 
toddlers and other children are close to the value that might be of concern for neurotoxicity. 
For the risk characterisation for neoplastic effects, the MOE approach for compounds that are both 
genotoxic and carcinogenic is considered appropriate, using as the reference point the BMDL10 of 
0.17 mg/kg b.w. per day, i.e. the lowest BMDL10 from data on incidences of Harderian gland 
adenomas and adenocarcinomas in male B6C3F1 mice exposed to AA for two years in the NTP study. 
Comparison of the data on human exposure levels to AA across surveys and age groups reported 
above to this BMDL10 of 0.17 mg/kg b.w. per day, reveals MOE values that range from 
425 (minimum LB) to 89 (maximum UB) for the mean exposure estimates, and from 283 (minimum 
LB) to 50 (maximum UB) for the 95th percentile exposure estimates across all surveys and age 
groups. The EFSA Scientific Committee concluded that, for substances that are both genotoxic and 
carcinogenic, an MOE of 10 000 or higher, based on a BMDL10 from an animal study, and taking into 
account overall uncertainties in the interpretation, would be of low concern from a public health point 
of view. Since the MOEs calculated are all substantially lower than the value of 10 000, the 
CONTAM Panel concluded that, although the available human studies have not demonstrated AA to 
be a human carcinogen, the MOEs across surveys and age groups indicate a concern with respect to 
neoplastic effects. 
The CONTAM Panel noted that AA is a germ cell mutagen and that there are at present no established 
procedures for risk assessment using this endpoint. 
Finally, the CONTAM Panel makes the following recommendations: the reporting of AA occurrence 
data should be improved regarding the mode of preparation of the products before analysis. Duplicate 
diet studies are recommended in order to improve exposure assessment, since they provide a more 
accurate indication of AA levels in food as prepared and consumed at home. Data on urinary 
metabolites levels from individuals participating in the duplicate diet studies should be generated for 
the purpose of validation of the biomarkers. An up-to-date OECD compliant extended one-generation 
or two-generation reproductive toxicity study investigating the effects of AA on sperm parameters and 
including a detailed histopathological examination of the testis and accessory glands as well as 
investigating the effects on development until puberty should be conducted. If further epidemiological 
studies are conducted to assess possible associations between dietary AA intake and risk of cancers 
(e.g. endometrium, ovary and renal cells), they should have improved measurement of AA exposure, 
and should be sufficiently powered. Further epidemiological studies are required to confirm or refute 
the inverse relation between dietary AA intake and birth weight and other markers of fetal growth 
observed in two studies. Improved approaches for the detection and risk assessment of germ cell 
mutagens should be developed, and applied to AA and GA.   
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Acrylamide is a carcinogenic substance that is formed in foods that have undergone heat treatment, 
e.g. roasting, baking and frying, and that are high in certain amino acids and reducing sugars. 
Acrylamide is therefore an issue in French fries and potato crisps, but also in other foodstuff such as 
biscuits, coffee, etc. 
Industry (Food and Drink Europe) have developed a so-called ‘toolbox’4 containing measures that can 
be applied by the different sectors of food industry to bring acrylamide levels down. Sector specific 
brochures have also been developed.  
The Commission is monitoring acrylamide levels in food via specific monitoring recommendations.
5
 
The results of the monitoring are compiled by EFSA. Despite the fact that the industry toolbox is in 
place since 2006, levels in food are not systematically decreasing in all concerned food commodities, 
as demonstrated by the results compiled since 2007. 
Therefore a second Commission recommendation
6
 was adopted in January 2011 which asks Member 
States to carry out further investigations at food operator’s premises in case high acrylamide levels are 
found. Indicative values have been established in that recommendation. If an indicative value is 
exceeded, an investigation should be carried out. The indicative values are not legal limits and do not 
require enforcement action if they are exceeded. 
In the near future, the Commission will assess the approach taken and decide about the need for 
further appropriate measures.  
However, since the Statement of the Scientific Panel on Contaminants in the Food Chain to a 
summary report on acrylamide in food of the 64th meeting of the Join FAO/WHO Expert Committee 
on Food Additives (Adopted on 19 April 2005) and the ESFA Scientific Colloquium on acrylamide 
carcinogenicity,
7
 new scientific information had become available.  
In order to assess the need for further measures as regards acrylamide in food, EFSA is requested to 
assess the risk related to the presence of acrylamide in food.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Art 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the 
European Food Safety Authority for a scientific opinion on the risk to human health related to the 
presence of acrylamide in food.  
                                                     
4  Food and Drink Europe Acrylamide toolbox available at: http://ec.europa.eu/food/food/chemicalsafety/contaminants/
ciaa_acrylamide_toolbox09.pdf  
5  Commission Recommendation 2007/33/EC on the monitoring of acrylamide levels in food (OJ L123, 12.5.2007, p. 33) and 
Commission Recommendation 2010/307/EU on the monitoring of acrylamide levels in food (OJ L137, 3.6.2010, p. 4) 
6  Commission Recommendation of 10.1.2011 on investigations into the levels of acrylamide in food (document C(2010) 
9681 final, available at: http://ec.europa.eu/food/food/chemicalsafety/contaminants/recommendation_10012011_
acrylamide_food_en.pdf  
7  EFSA Scientific Colloquium no. 11 on acrylamide carcinogenicity – new evidence in relation to dietary exposure, held at 
Tabiano (PR), Italy from 22–23 May 2008.    
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 11 
ASSESSMENT 
1. Introduction 
Acrylamide (CH2=CHCONH2) (AA) is a low molecular weight, highly water soluble, organic 
compound. AA is used inter alia as an industrial chemical and in the production of polyacrylamides. 
Heightened concerns about exposure to AA arose in 2002 when it was discovered that it forms when 
certain foods are prepared at temperatures usually above 120 °C and low moisture (Biedermann et al., 
2002a; Tareke et al., 2002; CODEX, 2009). It forms, at least in part, due to a Maillard reaction 
between certain amino acids, such as asparagine, and reducing sugars (Mottram et al., 2002; Stadler et 
al., 2002). However, several other pathways and precursors have been proposed to contribute to AA 
formation (reviewed by Keramat et al., 2011). AA forms in numerous baked or fried carbohydrate-rich 
foods, including French fries, potato crisps, breads, biscuits and coffee. AA is also known to be 
present in cigarette smoke.  
There is widespread human exposure to AA. The toxicological properties of AA have been well 
studied and include neurotoxicity, genotoxicity, carcinogenicity and reproductive toxicity. AA has 
been classified as a Group 2A carcinogen (probably carcinogenic to humans) by the International 
Agency for Research on Cancer (IARC, 1994). AA is an α,β-unsaturated carbonyl compound with 
electrophilic reactivity. It can therefore react with nucleophilic groups on biological molecules, which 
may contribute to the generation of its toxic effects. Reaction of AA with proteins is extensive (and 
such reaction products have been used as biomarkers of exposure to AA). In vivo, AA is metabolised 
to a reactive epoxide glycidamide (GA), which is thought to have a major role in the genotoxicity of 
AA through its binding to DNA. 
In view of the known toxic effects of AA, the discovery of its presence in certain foods stimulated 
many new studies of its metabolism, bioavailability, toxicokinetics, DNA adduct formation, 
mutagenicity and experimental toxicity. Many new investigations of human exposure to AA have 
recently been made and a large number of epidemiological studies have also been initiated. 
Many European countries monitor AA since 2002. In 2007, the European Commission (EC) launched 
a Recommendation that the Member States should perform the monitoring of AA in foodstuffs that are 
known to contain high AA levels and/or contribute significantly to human exposure. Based on the 
results of the monitoring in the Member States from 2007–2011, the EC has set ‘indicative values’ for 
AA in various foodstuffs. The ‘indicative values’ are not safety thresholds, but only intended to 
indicate the need for an investigation if the values are exceeded in order to explore whether 
appropriate measures have been taken to control the AA formation. 
In order to assess the need for further measures as regards AA in food, EFSA has been requested to 
assess the risk to human health related to the presence of AA in food, taking into account the extensive 
new data on AA exposure and toxicity. 
The CONTAM Panel based its evaluation on information submitted following public calls for data, 
original studies published in the open literature that have become available until March 2015, and 
previous evaluations performed by international bodies. The methodology for the literature search and 
selection criteria for the consideration of scientific data for the risk assessment of AA in food are 
described in Appendix A. In addition, the draft opinion underwent a public consultation from 1 July 
2014 to 15 September 2014. The comments received and how they were taken into account when 
finalising the scientific opinion were published in an EFSA Technical Report (EFSA, 2015).   
In this opinion, the terminology ‘potato crisps’ refers to crunchy thin slices of deep-fried/baked potato 
usually eaten as snacks, whereas ‘French fries’ refers to batons of deep-fried potato usually served as 
an accompaniment during a meal. When citing literature data, the original food name is used. If it is 
different from the standard terminology used in the opinion, then the standard terminology is also 
indicated in brackets, when possible.   
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1.1. Previous risk assessments 
In light of the findings of high concentrations of AA formed during the frying or baking of a variety of 
foods, several international bodies and scientific groups had carried out risk assessments related to the 
presence of AA in food.  
In 2002, the FAO/WHO (Food and Agriculture Organization of the United Nations/World Health 
Organization) held a consultation to collect the views of an international group of experts on the health 
implications of AA in food. The objective was to review and evaluate the new and existing data and 
research on AA, to identify needs for further information and studies, and to develop and suggest 
possible interim advice for governments, industry and consumers (FAO/WHO, 2002). Based on the 
available data at that time, food was estimated to make a significant contribution to total exposure of 
the general public to AA, with estimated average intakes for the general population ranging from 0.3 
to 0.8 µg/kg body weight (b.w.) per day. It was anticipated that children would generally have intakes 
two to three times higher than those of adults when expressed on a b.w. basis (FAO/WHO, 2002). The 
FAO/WHO consultation recognized the presence of AA in food as a major concern for humans based 
on the ability of AA to induce cancer and heritable mutations in laboratory animals. Neurotoxicity was 
the key non-cancer, non-genotoxic effect of AA in humans and animals, although it was concluded 
that those effects were not to be expected from the levels of AA encountered in food. A range of 
recommendations was provided for further information and new studies to better understand the risk to 
human health posed by AA in food, as well as some advice to minimize whatever risk existed, such as 
avoiding excessive cooking of food and investigating possibilities for reducing levels of AA in food 
(FAO/WHO, 2002). 
That same year, the Scientific Committee on Food (SCF) was asked to assess the implications for food 
safety of the new information on AA in foods (SCF, 2002). The SCF had previously evaluated AA as 
a monomer in food contact materials and maintained its previous conclusion that AA was a genotoxic 
carcinogen. The SCF recommended that levels of AA in food should be as low as reasonably 
achievable. Due to the lack of detailed knowledge about a number of aspects in relation to AA and 
food safety, the SCF provided only general advice on the scientific issues relevant to risk management 
and endorsed the interim advice given by the FAO/WHO consultation (FAO/WHO, 2002). 
In 2005, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) at its 64th meeting 
performed an evaluation of the data available on AA. The full report was published in 2006 
(FAO/WHO, 2006). Dietary intakes were estimated at 1 and 4 µg/kg b.w. per day for the general 
population and for consumers with a high intake, respectively. These estimates also included children. 
JECFA concluded that the epidemiological studies and data on biomarkers in humans and animals 
available at the time of the evaluation were inadequate to establish a dose-response relationship, and 
therefore performed the assessment on the basis of available studies in animals. JECFA considered as 
pivotal effects for the risk assessment the genotoxicity and carcinogenicity of AA, but also considered 
other non-cancer end-points of concern, such as effects on the nervous system. Increased incidence of 
tumours at a variety of sites was observed in two long-term studies in F344 rats administered AA in 
drinking water (Johnson et al., 1986; Friedman et al., 1995). Benchmark doses and the 95 % 
benchmark dose lower confidence limits for a 10 % extra risk of tumours (BMD10 and BMDL10) were 
derived for both studies. It was noted that although the pathways of metabolism of AA are similar in 
rats and humans, quantitative differences such as the extent of bioactivation of AA to GA or 
detoxification of GA could result in species differences in sensitivity (FAO/WHO, 2006). The lowest 
range of BMDL10s was found for total mammary tumours from the study by Johnson et al. (1986) 
ranging from 0.30 to 0.46 mg/kg b.w. per day. The no-observed-effect level (NOEL) for induction of 
morphological changes in nerves observed in a 90-day study in rats was 0.2 mg/kg b.w. per day 
(Burek et al., 1980), while the overall NOEL for reproductive and developmental effects and other 
non-neoplastic lesions was higher (2 mg/kg b.w. per day, Tyl et al., 2000a). Margins of exposure 
(MOEs) for the general population and for consumers with a high intake were calculated by 
comparing the estimated intake with the NOELs and BMDL10s derived (Table 1). Considering the 
NOEL of 0.2 mg/kg b.w. per day for morphological changes in nerves, MOEs of 200 and 50 were 
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obtained for the general population and consumers with a high intake, respectively. Comparison with 
the NOEL of 2.0 mg/kg b.w. per day for reproductive, developmental, and other non-neoplastic effects 
in rodents provided MOEs of 2 000 and 500, respectively. JECFA concluded that at the estimated 
average intakes, adverse effects based on these endpoints were unlikely, but that morphological 
changes in nerves could not be excluded for some individuals with very high intake (FAO/WHO, 
2006). When considering the lowest BMDL10 of 0.30 mg/kg b.w. per day for induction of mammary 
tumours in rats, MOEs of 300 and 75 were obtained, respectively. JECFA considered these MOEs 
were low for a compound that is genotoxic and carcinogenic, and that they may indicate a human 
health concern (FAO/WHO, 2006). JECFA recommended that efforts to reduce AA concentrations in 
foodstuffs should continue, and that AA be re-evaluated when results of carcinogenicity and long-term 
neurotoxicity studies become available. JECFA also noted the potential of physiologically based 
pharmacokinetic (PBPK) modelling to better link human biomarker data with exposure assessments 
and toxicological effects in experimental animals. 
In April 2005, the EFSA Scientific Panel on Contaminants in the Food Chain (CONTAM Panel) 
adopted a statement to the summary report released on 2 March 2005 of the above-mentioned risk 
assessment carried out by JECFA at its 64th meeting (EFSA, 2005a). The CONTAM Panel noted the 
use of the MOE approach that incorporated data from European countries, including information 
gathered under collaborative initiatives between the European Commission and EFSA. The Panel 
agreed with the principal conclusions and recommendations of JECFA and concluded that an 
additional evaluation by EFSA was not necessary at that time. 
The French Food Safety Agency (Afssa, now Agency for Food, Environmental and Occupation Health 
and Safety, ANSES) was also asked in 2002 to give an advice on the presence of AA in food 
commodities with regard to the safety of food for consumers and published two reports synthesising 
the knowledge and available data at that time (Afssa, 2003, 2005). The last report published in 2005 
included a refined estimation of the exposure to AA of the French population for different age groups. 
For adults (>15 years old) the exposure estimates were 0.5 and 0.98 µg/kg b.w. per day for average 
and high consumers, respectively. For children (3–14 years old) the exposure estimates were higher 
than those of adults, with values of 1.25 and 2.54 µg/kg b.w. per day for average and high consumers, 
respectively (Afssa, 2005). French fries were identified as the food commodity contributing most to 
the AA intake for young age groups. Afssa referred to the summary and conclusions of the sixty-
fourth meeting of the JECFA published in 2005, and concluded that at the time of the report it was not 
possible to make special recommendations about the preparation of the food commodities or food 
consumption (Afssa, 2005).  
In 2005, the National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction 
(NTP-CERHR) Expert Panel published a report on the reproductive and developmental toxicity of AA 
(Manson et al., 2005). The report concluded that there were no human data available on developmental 
or reproductive toxicity of AA and that available experimental data were sufficient to conclude that 
AA can produce developmental toxicity in rats and mice, and that AA is a reproductive toxicant in 
male rats and mice bred to untreated females. The NTP-CERHR Expert Panel also concluded that 
there are sufficient data to conclude that AA induces transmissible genetic damage in male germ cells 
of mice in the form of reciprocal translocations and gene mutations. Lowest-observed-adverse-effect 
levels (LOAELs) in the range of 4–45 mg/kg b.w. per day were established. The NTP-CERHR Expert 
Panel indicated that the data suggest that at these exposure levels (5–14 mg/kg b.w. per day) AA has 
no effect on female reproductive function in rats or mice. Considering the low level of estimated 
human exposure to AA derived from a variety of sources, the Expert Panel expressed ‘negligible 
concern for adverse reproductive and developmental effects for exposures in the general population’. 
In 2008, EFSA held a Scientific Colloquium on AA carcinogenicity and new evidence in relation to 
dietary exposure (EFSA, 2008). The objective of this EFSA colloquium was to debate the state and 
future challenges regarding the potential toxicity and cancer risk associated with dietary exposure to 
AA considering the new information that became available since the last risk assessment carried out 
by JECFA in 2005. In particular, four topics were considered: (i) epidemiological evidence relating 
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AA exposure to cancer risk in humans, including discussions on uncertainties, (ii) the applications of 
biomarkers for AA and models in relation to the exposure, metabolism and elimination 
(toxicokinetics) and the mode of action of AA in experimental animals and humans (toxicodynamics), 
(iii) the state of the art on the genotoxic and non-genotoxic mechanisms of carcinogenicity of AA, and 
(iv) the current knowledge on dietary exposure to AA across Europe and the exploration of any new 
potential food source contributing to dietary exposure.  
Concerning the epidemiological data, it was concluded that there was some evidence for an 
association between dietary exposure to AA and some types of cancer. However, the relative risks 
were low and the totality of all the epidemiological evidence was not consistent. It was cautioned not 
to expect tumour site concordance between animals and humans. For epidemiological studies the need 
to develop food frequency questionnaires (FFQ) that would focus on food processing, including home-
cooking, was identified. The FFQs should be supplemented by biomarker measurements. The 
relevance of understanding and controlling confounders such as smoking (EFSA, 2008) was 
mentioned.   
In the area of biomarkers, and to help in interspecies extrapolation, the importance of a better 
understanding of the overall fate of AA in humans was recognised, as well as the measurement of GA 
DNA adducts in humans. It was noted that biomarkers are indicators only of relatively short-term 
exposure and that they can be confounded by factors other than the diet (EFSA, 2008). 
On the genotoxic/non-genotoxic mechanism of carcinogenicity, it was recognised that genotoxicity is 
an important mode of action, but there may be other, non-genotoxic mechanisms for certain tumour 
types observed in animals. Accurate dose-response analysis and the derivation of BMDs for each 
tumour site, together with information on mode of action, were found helpful in assessing which 
tumours are the most important for human risk assessment. Animal data also indicated some 
intermediate biomarkers that may reflect the biologically active dose of AA that could be useful 
(EFSA, 2008).  
For dietary exposure, the analytical methods for establishing occurrence data and estimating human 
exposure available at the time of the colloquium were found to be adequate and, it was not anticipated 
that better data would change dramatically the margins of exposure estimated by JECFA in 2005. It 
was recommended to refine the FFQs to enable studies to focus on subpopulations considered to be 
more at risk. It was also noted that mitigation measures may prove to be more important than advice 
(EFSA, 2008).  
Overall, the EFSA Colloquium concluded that it was not possible to improve the existing risk 
assessments but that the data anticipated to be available in the following years (e.g. a NCTR/NTP 
carcinogenicity study) would be valuable in adding weight to the current risk assessments and in 
reducing the uncertainties.  
In March 2010, the United States Environmental Protection Agency (US-EPA) published a 
toxicological review on AA (US-EPA, 2010) to provide scientific support and rationale for the hazard 
and dose-response assessment to chronic exposure to AA. EPA used dose response data from animal 
toxicity testing to produce human health reference values for carcinogenicity in multiple tissues and 
degenerative peripheral nerve damage, the most sensitive non-cancer endpoint. Oral reference dose 
(RfD in mg/kg b.w. per day) values and inhalation reference concentrations (RfC in mg/m
3
) were 
derived for the non-cancer endpoint and cancer potency estimates were derived as either an oral slope 
factor (the plausible upper bound on the estimate of risk per mg/kg b.w. per day of oral exposure) or 
an inhalation unit risk (an upper bound on the estimate of risk per µg/m3 of air breathed) using 
methodology extensively documented in US-EPA guidance documents (2010).  
The increased incidence of degenerative lesions of peripheral nerves was selected as the critical effect 
for derivation of the RfD for AA and the RfD value was based on the dose-response data from 
Johnson et al. (1986). BMD modelling of the incidence data for microscopically-detected degenerative 
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nerve lesions in rats was performed. The 95 % lower confidence limits of the estimated dose 
associated with a 5 % extra risk (BMDL05) for nerve lesions of 0.27 mg/kg per day for mild-to-
moderate lesions was chosen as the most sensitive response, and was selected as the point of departure 
(i.e. reference point) for deriving the RfD. An internal dose metric of AA-area under the curve 
(AA-AUC) in the blood from an oral exposure in rat was estimated from in vivo rat data, and the 
administered dose in humans that would result in a comparable internal AA-AUC was calculated using 
conversion factors developed from human adduct data and second order adduct formation rate 
constants. The estimated AA-AUC in rat blood following exposure at a BMDL05 was used to derive a 
human equivalent dose (oral exposure, HED) of 0.53 mg AA/kg per day as the point of departure (see 
Section 7.1.5). The point of departure was divided by a total uncertainty factor (UF) of 30 (3 for 
animal-to-human extrapolation to account for toxicodynamic differences, and 10 for intra-individual 
variability in human toxicokinetics and toxicodynamics) to derive the RfD of 0.002 mg/kg per day.  
For the oral cancer effects, an oral slope factor of 0.6 (mg/kg per day)
-1
 derived from male rat data 
from Johnson et al. (1986) and the BMDL10 of 1.5 × 10
-1
 for the combined risk of thyroid tumours or 
testicular tumours was selected for calculating a point of departure (i.e. reference point) and deriving a 
human oral slope factor. The rat BMDL10 was converted to a HEDBMDL10 based on comparable levels 
of GA-AUC in blood between the rat and human relative to their respective administered doses. The 
resulting HEDBMDL10 (1.9 × 10
-1
 mg/kg per day) at the benchmark response (BMR) of 0.1 was used to 
derive a human oral slope factor of 0.5 (mg/kg per day)
-1
.  
In 2010, JECFA at its 72nd meeting reconsidered the studies described in its previous risk assessment 
carried out in 2005 (FAO/WHO, 2006), as well as new information on occurrence, dietary exposure 
and the completed toxicity studies on metabolism, genotoxicity, neurodevelopmental effects, long-
term/carcinogenicity studies on AA and GA and new epidemiological studies. The full report was 
published in 2011 (FAO/WHO, 2011). JECFA noted that although mitigation measures applied after 
2003 might have reduced the exposure for some individuals or population subgroups, neither the 
estimated average AA exposure for the general population, including children, of 1 µg/kg b.w. per 
day, nor the exposure for consumers with high dietary exposure of 4 µg/kg b.w. per day, had changed 
since its last evaluation in 2005.  
As in its previous evaluation, the available epidemiological studies were not considered suitable for a 
dose-response analysis and therefore JECFA based the assessment on the available studies in 
experimental animals. JECFA reported that the increased incidence in the morphological changes in 
nerves in rats remained the most sensitive non-carcinogenic end-point (Burek et al., 1980), as no new 
studies in experimental animals observed non-carcinogenic effects at doses lower than 0.2 mg/kg b.w. 
per day. Therefore, the MOE relative to this end-point calculated in 2005 remained unchanged (200 
and 50 for the general population and consumers with high dietary exposure, respectively). JECFA 
noted that although adverse neurological effects were unlikely at the estimated average exposure, 
morphological changes in nerves could not be excluded for individuals with a high dietary exposure to 
AA (FAO/WHO, 2011). 
For the cancer effects, JECFA considered the just completed 2-year NCTR/NTP study in which 
B6C3F1 mice and F344 rats were treated with AA in drinking water (Beland, 2010, as cited by 
FAO/WHO, 2011). It noted that the sites of tumours (thyroid and mammary gland, peritesticular 
mesothelium) induced in male and female rats were in agreement with those found in the two previous 
long-term studies in rats (Johnson et al., 1986; Friedman et al., 1995). Benchmark doses and the 95 % 
benchmark dose lower confidence limits for a 10 % extra risk were derived for the induction of the 
different tumours observed in both mice and rats. Although the range of values observed was similar 
to that obtained in its previous evaluation in 2005, the lowest BMDL10 values were obtained for 
tumours in the Harderian gland in male mice (0.18–0.56 mg/kg b.w. per day) (FAO/WHO, 2011). 
Although humans have no equivalent organ to the Harderian gland, JECFA was not able to discount 
this effect and considered it appropriate to use a value of 0.18 mg/kg b.w. per day for male mice (the 
lowest values in the range of BMDL10s). For rats, the lowest BMDL10 was observed for mammary 
tumours in females with a value of 0.31 mg/kg b.w. per day. When considering the induction of 
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mammary tumours in rats, MOEs of 310 and 78 for average and high dietary exposures were obtained, 
respectively. For Harderian gland tumours in mice, the MOE values were 180 and 45 for average and 
high exposures, respectively (FAO/WHO, 2011) (Table 1). JECFA noted that these MOE values were 
similar to those determined in its previous evaluation (FAO/WHO, 2006), and still considered that for 
a compound that is both genotoxic and carcinogenic, these MOEs indicate a human health concern 
(FAO/WHO, 2011).  
JECFA also concluded that ‘there was a poor correlation between the estimated dietary exposure and 
internal biological markers of AA exposure (AA-valine and GA-valine haemoglobin adducts) in 
humans and that worker cohort epidemiological studies did not provide any evidence that exposure to 
AA resulted in an increase in the incidence of cancer’ (FAO/WHO, 2011). JECFA recommended that 
longitudinal studies on intra-individual levels of AA and GA haemoglobin (Hb) adducts should be 
measured over time in relation to concurrent dietary exposure, to provide a better estimate of the AA 
exposure for epidemiological studies to inform the risk associated with consumption of certain foods 
(FAO/WHO, 2011). 
In June 2011, the Federal Institute for Risk Assessment (BfR) produced an opinion on AA (BfR, 
2011). BfR summarised the available human and animal studies, and estimated the AA dietary intake. 
BfR concluded that the results of the evaluated epidemiological studies that reported on various cancer 
types in connection with AA intake, were inconsistent and hence, a correlation between AA intake and 
cancer development can neither be assumed nor excluded, and this risk, if existing, could hardly be 
proven given the intake level estimated (BfR, 2011). BfR compared various exposure estimates of the 
AA intake of consumers on the basis of German and European data representing the AA contents in 
food and the consumption frequency of specific food items. Estimates of 0.14 and 0.39 µg/kg b.w. per 
day for average and 95th percentile intake, respectively, were obtained. However, for the risk 
characterisation, the dietary intake estimates reported by EFSA (2011a) were used as they were 
considered more representative (0.34 and 0.83 µg/kg b.w. per day for average and 95th percentile 
intake, respectively). BfR considered cancer risk as the critical end-point, and used a BMDL10 of 
0.30 mg/kg b.w. per day for mammary tumours in female F344 rats, and the BMDL10 of 0.16 mg/kg 
b.w. per day for tumours in the Harderian gland in male mice as points of departure, both based on the 
outcome of the 2-year NTP study. To characterize the cancer risk, BfR calculated the MOE between 
the estimated AA intake and the points of departure (i.e. reference points). For the induction of 
mammary tumours in female rats, MOE values were 882 and 361 for average and 95th percentile 
consumers, respectively. For the induction of Harderian gland tumours, the MOE values were 471 and 
193, respectively. BfR concluded that the MOEs for consumers and children eating large amounts of 
foods with high AA contents may pose a health risk. 
BfR noted that ‘blood and/or urine biomarkers may be more suitable for determining the AA intake of 
consumers than the estimation via the AA contents in food and consumption data’ (BfR, 2011). It 
recommended efforts to minimise the AA contents in industrially processed food, and other measures 
such as consumers and restaurants following the advice of ‘baking golden brown instead of charring’. 
In 2012, the Agency for Toxic Substances and Disease Registry (ATSDR) prepared a toxicological 
profile on AA (ATSDR, 2012) and derived acute-, intermediate- and chronic-duration oral Minimal 
Risk Levels
8
 for AA. The male-mediated infertility was selected as the critical effect for acute-
duration oral exposure (14 days or less), and a Minimal Risk Level was derived based on results of 
fertility testing of male rats administered AA by gavage for five days prior to one week mating 
sessions with untreated female rats (Sublet et al., 1989). PBPK modelling (Sweeney et al., 2010) and 
BMD analysis were performed to predict a HED of 0.31 mg/kg per day, that was divided by an 
uncertainty factor of 30 (3 for interspecies extrapolation using a PBPK model and 10 for human 
variability), resulting in an acute-duration oral Minimal Risk Level of 0.01 mg/kg per day. The 
intermediate-duration oral Minimal Risk Level was derived based on a no-observed-adverse-effect 
                                                     
8  According to ATSDR (2012), the ‘Minimal Risk Level is defined as an estimate of daily human exposure to a substance 
that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.’ 
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level (NOAEL) of 0.2 mg/kg per day and a LOAEL of 1 mg/kg per day for ultrastructural changes in 
peripheral nerve fibres in male rats (Burek et al., 1980). PBPK modelling (Sweeney et al., 2010) was 
used to estimate the rat internal dose metrics for blood AA and GA at the NOAEL and for estimating a 
HED of 0.038 mg/kg per day, that was divided by the uncertainty factor of 30, to result in a Minimal 
Risk Level of 0.001 mg/kg per day. The chronic-duration oral Minimal Risk Level was derived based 
on degenerative changes in sciatic nerves from male F344 rats receiving AA from the drinking water 
for up to two years, as detected by light microscopy (Friedman et al., 1995). PBPK modelling 
(Sweeney et al., 2010) and BMD analysis were performed to estimate a HED of 0.042 mg/kg per day, 
that was divided by the uncertainty factor of 30, to result in a Minimal Risk Level value of 
0.001 mg/kg per day.  
Health Canada published in 2012 a revised exposure assessment of AA in food (Health Canada, 2012). 
Food samples were analysed within a monitoring program that started in 2009 to assess the 
effectiveness of AA reduction strategies. A probabilistic exposure assessment was conducted resulting 
in mean  AA  intakes  ranging  from  0.356  to  0.609 µg/kg b.w.  per day  for  the  age  groups  from 
1–18 years old, and from 0.157 to 0.288 µg/kg b.w. per day for adults (>19 years old). The 90th 
percentile exposure estimates ranged from 0.591 to 1.516 µg/kg b.w. per day, and from 0.307 to 
0.740 µg/kg b.w. per day, respectively. The age group 1–3 years old was the one with the highest 
intake estimates. Restaurant French Fries was the food commodity contributing most to the dietary 
intake. MOEs were calculated based on the NOAEL for morphological changes in nerves in rats and 
the BMDL10s for mammary and Harderian gland tumours in female rats and male mice, respectively, 
proposed by JECFA (FAO/WHO, 2011). In the first case, the lowest MOE was obtained for the age 
group 1–3 years old with values of 328 and 132, when considering mean and 90th percentile exposure, 
respectively. For the cancer effects with the lowest BMDL10 (0.18 mg/kg b.w. per day), the lowest 
MOEs were obtained for the same age group, with values of 296 and 119 for mean and 90th percentile 
exposure, respectively. Although Health Canada noted that those MOEs are higher than those reported 
by JECFA (FAO/WHO, 2011), it concluded that dietary exposure to AA is a potential health concern.  
The Danish National Food Institute (DTU) published in 2013 a report with the results from the food 
monitoring of chemical contaminants for the period 2004–2011, and estimated the exposure to AA of 
the Danish population and calculated the MOEs (DTU, 2013). For adults, the mean (95th percentile) 
AA dietary intake was 0.21 (0.46) µg/kg b.w. per day, while for children (aged 4–14 years old) it was 
estimated at 0.39 (0.89) µg/kg b.w. per day. For adults, the food categories contributing most to the 
intake were potato products, followed by coffee and cocoa (of which coffee contributed the most). For 
children, potato products were also the highest contributor, followed by ‘crisps, potato maize’, 
chocolate and bread. MOEs were calculated based on the NOAEL for morphological changes in 
nerves in rats and the BMDL10s for mammary and Harderian gland tumours in rats proposed by 
JECFA (FAO/WHO, 2011) (Table 1). The lowest MOEs were obtained for children for the 
carcinogenic effect on the Harderian gland in mice, with values of 466 (mean exposure) and 202 (95th 
percentile exposure). The report concluded that the exposure to AA is of food safety concern (DTU, 
2013). 
The Food Standards Australia New Zealand (FSANZ) published in 2014 the results of its 
24th
 
Australian Total Diet Study (TDS), which included AA among other compounds. The study 
focused on 94 foods and beverages likely to contribute to the dietary exposure to AA. Mean 
(90th percentile) AA intake estimates were 1–2 (1–3) µg/kg b.w. per day (lower bound exposure) and 
2–4 (2–8) µg/kg b.w. per day (upper bound exposure). The highest dietary estimates were for the 
population aged 17 years old and above. The food categories contributing most to the exposure were 
cereal and grain-based foods (excluding cakes and biscuits), vegetables and pulses, and snacks and 
condiments. MOEs were calculated based on the NOAEL for neurotoxicity and the BMDL10 for 
mammary tumours in rats and Harderian gland tumours in male mice as established by JECFA 
(FAO/WHO, 2011). The MOEs for the non-carcinogenic endpoint ranged from 30 to 310, and the 
FSANZ concluded that adverse neurological effects cannot be excluded for individuals with high AA 
dietary exposure. The MOEs for the cancer endpoint were in all cases lower than 500, and FSANZ 
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concluded that these suggest a human health concern for a compound that is genotoxic and 
carcinogenic (FSANZ, 2014). 
The International Agency for Research on Cancer (IARC) classified AA as a Group 2A carcinogen 
(‘probably carcinogenic to humans’) (IARC, 1994).  
In 2011, the National Toxicology Program (NTP) determined that AA is reasonably anticipated to be a 
human carcinogen (NTP, 2011) and the US-EPA characterized AA as ‘likely to be carcinogenic to 
humans’ (US-EPA, 2010). The American Conference of Governmental Industrial Hygienists (ACGIH) 
has classified AA as an A3 carcinogen (confirmed animal carcinogen with unknown relevance to 
humans) (ACGIH, 2011, as cited in ATSDR, 2012).  
Furthermore, AA is listed in Appendix 2, Entry 28 – Carcinogens: category 1B of the REACH 
(Registration, Evaluation, Authorisation and Restriction of Chemicals) Regulation. Since 2010, AA 
(EC No 201-173-7 and CAS No 79-06-1) is included in the Candidate List of Substances of Very High 
Concern (SVHC) for authorisation.  
AA is classified as Carc. Cat.1B H350: May cause cancer, Muta. Cat. 1B H340: May cause genetic 
defects and Repr. Cat.2 H361f: Suspected of damaging fertility according to CLP Regulation (EC) No 
1272/2008. 
 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 19 
Table 1:  Summary of previous risk assessments performed by international bodies 
Reference Critical end-point  Key study 
Reference point
(g)
  
(mg/kg b.w. per day) 
UF 
Health-based 
guidance value 
(mg/kg b.w. per 
day) 
Exposure estimates 
(µg/kg b.w. per day) 
MOE 
FAO/WHO 
(2006) 
Morphological 
changes in nerves 
(rats) 
Burek et al. 
(1980) 
0.2 (NOEL) n.a. n.a. 
General population: 1  
Cons. high percentile: 4 
200  
50  
 
Reproductive and 
developmental effects 
and other non-
neoplastic lesions  
Tyl et al. 
(2000a) 
2.0 (overall NOEL) n.a. n.a. 
2 000  
500  
 
Mammary tumours 
(rats) 
Johnson et al. 
(1986) 
0.30 (BMDL10) n.a. n.a. 
300  
75  
FAO/WHO 
(2011) 
Morphological 
changes in nerves 
(rats) 
Burek et al. 
(1980) 
0.2 (NOAEL) n.a. n.a. 
General population: 1  
Cons. high percentile: 4 
200  
50  
 
Harderian gland 
tumours (male mice) 
Beland (2010) 0.18 (BMDL10)
(a)
 n.a. n.a. 
180  
45  
 
Mammary tumours 
(female rats)  
Beland (2010) 0.31  (BMDL10)
(a)
 n.a. n.a. 
310  
78  
US-EPA 
(2010) 
Increased incidence of 
degenerative lesions of 
peripheral nerves  
Johnson et al. 
(1986) 
0.27 (BMDL05) 
0.53 (HED) 
30 
(3 for inter-
species 
differences, 10 for 
intra-species 
differences) 
0.002 (RfD) n.a. n.a. 
 
Summed risks for 
thyroid or TVM 
tumours 
Johnson et al. 
(1986) 
0.15 (BMDL10) 
0.19 (HEDBMDL10)
(e)
 
n.a. n.a. n.a. n.a. 
Table continued overleaf. 
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Table 1: Summary of previous risk assessments performed by international bodies (continued) 
Reference Critical end-point  Key study 
Reference point
(g)
  
(mg/kg b.w. per day) 
UF 
Health-based 
guidance value 
(mg/kg b.w. per 
day) 
Exposure estimates 
(µg/kg b.w. per day) 
MOE 
BfR (2011) 
Harderian gland 
tumours (male mice) 
NTP Report
(b)
 0.16 (BMDL10)
(c)
 n.a. n.a. 
General population: 0.34  
Cons. high percentile: 0.83 
471  
193 
 
Mammary tumours 
(female rats)  
NTP Report
(b)
 0.30 (BMDL10)
(d)
 n.a. n.a. 
882 
361 
ATSDR 
(2012) 
Male-mediated 
infertility  
Sublet et al. 
(1989) 
0.31 (HED) 
30 
(3 for interspecies 
extrapolation 
using a PBPK 
model, 10 for 
human 
variability) 
0.001 
(acute-duration 
oral Minimal Risk 
Level) 
n.a. n.a. 
 
Ultrastructural changes 
in peripheral nerve 
fibres in male rats 
Burek et al. 
(1980) 
0.038 (HED) 
30 
(3 for interspecies 
extrapolation 
using a PBPK 
model, 10 for 
human 
variability) 
0.001 
(intermediate-
duration oral 
Minimal Risk 
Level) 
n.a. n.a. 
 
Degenerative changes 
in sciatic nerves in rats  
Friedman et al. 
(1995) 
0.042 (HED) 
30 
(3 for interspecies 
extrapolation 
using a PBPK 
model, 10 for 
human 
variability) 
0.001 
(chronic-duration 
oral Minimal Risk 
Level) 
n.a. n.a. 
Table continued overleaf. 
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Table 1: Summary of previous risk assessments performed by international bodies (continued) 
Reference Critical end-point  Key study 
Reference point
(g)
  
(mg/kg b.w. per day) 
UF 
Health-based 
guidance value 
(mg/kg b.w. per 
day) 
Exposure estimates 
(µg/kg b.w. per day) 
MOE 
Health 
Canada 
(2012) 
Morphological 
changes in nerves 
(rats) 
FAO/WHO 
(2011) 
0.2 
(NOAEL) 
n.a. n.a. 
Mean intake/1–18 years old: 
0.356–0.609 
Mean intake/> 19 years old: 
0.157–0.288  
P90 intake/1–18 years old: 
0.591–1.516  
P90 intake/ > 19 years old:  
0.307–0.740  
 
562–328 
 
1274–694 
 
220–132 
 
 
270–651 
 
Harderian gland 
tumours (male mice) 
FAO/WHO 
(2011) 
0.18 
(BMDL10) 
n.a. n.a. 
Mean intake/1–18 years old: 
0.356–0.609 
Mean intake/ >19 years old: 
0.157–0.288  
P90 intake/1–18 years old: 
0.591–1.516  
P90 intake/ >19 years old:  
0.307–0.740  
506–296 
 
1146–625 
 
198–119 
 
586–243 
 
DTU (2013) 
Morphological 
changes in nerves 
(rats) 
FAO/WHO 
(2011) 
0.2 
(NOAEL) 
n.a. n.a. 
Mean intake (adults): 0.21 
P95 intake (adults): 0.46 
Mean intake (children): 0.39 
P95 intake (children): 0.89 
 
930 
438 
518 
225 
Table continued overleaf. 
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Table 1: Summary of the previous risk assessments performed by international bodies (continued) 
Reference Critical end-point  Key study 
Reference point 
(g)
  
(mg/kg b.w. per day) 
UF 
Health-based 
guidance value 
(mg/kg b.w. per 
day) 
Exposure estimates 
(µg/kg b.w. per day) 
MOE 
 
Mammary tumours 
(female rats)  
FAO/WHO 
(2011) 
0.31  
(BMDL10) 
n.a. n.a. 
 
1442 
678 
873 
391 
 
Harderian gland 
tumours (male mice) 
FAO/WHO 
(2011) 
0.18 
(BMDL10) 
n.a. n.a. 
873 
391 
466 
202 
FSANZ 
(2014) 
Morphological 
changes in nerves 
(rats) 
FAO/WHO 
(2011) 
0.2 
(NOAEL) 
n.a. n.a. 
Mean intake (LB): 1–2  
Mean intake (UB): 1–3 
P90 intake (LB): 2–4 
P90 intake (UB): 2–8 
310
(f)
 
130
(f)
 
150
(f)
 
80
(f)
 
 
Mammary tumours 
(female rats)  
FAO/WHO 
(2011) 
0.31  
(BMDL10) 
n.a. n.a. 
480
(f)
 
210
(f)
 
240
(f)
 
130
(f)
 
 
Harderian gland 
tumours (male mice) 
FAO/WHO 
(2011) 
0.18 
(BMDL10) 
n.a. n.a. 
280
(f)
 
120 
(f)
 
140
(f)
 
80
(f)
 
BMDL: the 95 % benchmark dose lower confidence limit; b.w.: body weight; HED: Human Equivalent Dose; NOAEL: no-observed-adverse-effect level; NOEL: no-observed-effect level; 
PBPK: pharmacologically-based pharmacokinetic (model); RfD: Reference Dose; TVM: Tunica Vaginalis Mesothelioma; UF: uncertainty factor. 
(a):  Results of the LogLogistic model. 
(b):  NTP Technical Report on the Toxicology and Carcinogenesis Studies of Acrylamide (CAS No. 79-06-1) in F344/N Rats and B6C3F1 Mice (Drinking Water Study), as cited by BfR (2011). 
(c):  BMD modelling performed by the BfR. Results from the LogProbit model. 
(d):  BMD modelling performed by the BfR. Results from the LogLogistic model. 
(e):  The HED BMDL10 at the benchmark response of 0.1 was used to derive a human oral slope factor of 0.5 (mg/kg per day)
-1 (US-EPA, 2010).  
(f):  MOEs reported for the age group 17 years and above. 
(g):  Defined as ‘point of departure’ by some international bodies.  
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1.2. Chemical characteristics  
AA (CAS No 79-06-01) is an odourless white crystalline solid with the molecular formula C3H5NO 
and a molecular weight of 71.08 g/mol (Figure 1). Synonyms are inter alia 2-propenamide, acrylic 
amide and ethylene carboxamide. 
Figure 1:  Chemical structure of acrylamide (AA) 
The melting point is 84.5 °C and the vapour pressure is 0.9 Pa (7×10
-3
 mm Hg) at 25 °C (ATSDR, 
2012). The physical properties, including solubilities, were summarized by IPCS in 1999 (IPCS, 
1999). Solubility at 30 °C is high in water (2 155 g/L), methanol (1 550 g/L), ethanol (862 g/L), and 
acetone (631 g/L). AA is less soluble in chloroform (26.6 g/L) and benzene (3.46 g/L). The Log KOW 
is −0.67, the log koc is 1, and the Henry's law constant at 25 °C is 1.7×10
-9
 atm-m
3
/mol (US-EPA, 
2010). 
AA is stable at room temperature but readily polymerizes if heated to melting point or if exposed to 
ultraviolet radiation (WHO/IPCS, 1999). 
The stability of AA and its reactivity with various food-relevant nucleophiles at elevated temperatures 
in model systems were studied by Adams et al. (2010). The results showed that AA was quite stable in 
aqueous solutions, but much less in dry reaction conditions. Buffer type and pH had a significant 
influence on the decrease of free AA. The presence of amino acids with a nucleophilic side chain 
considerably decreased the free AA. The highest reactivity was noted for cysteine, leading to the 
formation of the mono-addition product cysteine-S-β-propionamide, as well as to the double addition 
product. Other nucleophiles, such as lysine, arginine, serine and ascorbic acid, were less reactive, but 
yielded comparable condensation products (Adams et al., 2010). 
1.3. Production, use and environmental fate 
1.3.1. Industrial production and use  
The industrial production of AA started in 1954 (WHO, 1999) and different methods have been used 
for its production. Initially, the reaction of acrylonitrile with hydrated sulfuric acid was used. Due to 
the relatively high levels of impurities this method was replaced by the catalytic hydration of 
acrylonitrile with a copper catalyst to form AA, a process with a lower yield of impurities (US-EPA, 
2010).  
AA is available in solid form with a purity reported to be greater than 98 % (w/w), or supplied as a 
30–60 % (w/w) aqueous solution (EU, 2000). In the EU, AA is produced as a 30–50 % aqueous 
solution via the catalytic hydration of acrylonitrile, and the production capacity has been estimated at 
between 150 000 to 200 000 tonnes per annum.
9
 In the US the annual production capacity has been 
reported to be 137 000 tonnes (Habermann, 2004, as cited in Beland et al., 2013). 
AA is produced for a wide variety of industrial applications. In the EU the majority of AA is used in 
the production of polyacrylamides, with a residual content of AA in the polymers of < 0.1 % (w/w) 
(EU, 2000). Polyacrylamides are primarily used as flocculants for clarifying drinking-water and 
treatment of industrial effluents (FAO/WHO, 2011; ATSDR, 2012). AA and polyacrylamides are used 
                                                     
9  Recommendation from the Scientific Committee on Occupational Exposure Limits for Acrylamide. SCOEL/UM/139. 
September 2011. Annex December 2012. 38 pp. 
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in the paper and pulp processing, in the dye synthesis, in cosmetics and food packaging (NICNAS, 
2002; FAO/WHO, 2011). Other applications include its use as a grouting agent and soil stabilizer in 
the construction of dams and tunnels (ATSDR, 2012). It is also used in the cosmetic industry and for 
the preparation of polyacrylamide gels for electrophoresis (IARC, 1994).  
1.3.2. Environmental fate 
The release of AA into the environment may occur during its production and direct use, as well as 
from the production and use of polyacrylamides. Drinking water treated with polyacrylamides as 
flocculants can contain residual AA (US-EPA, 2010) and therefore a parametric value for AA in 
drinking water has been established (see Section 2). The use of AA as a grouting agent can cause the 
contamination of ground water and soil (WHO, 1985).  
AA is not considered to be highly persistent in the environment (ATSDR, 2012). Due to its high 
solubility in water and log Koc of 1, AA is expected to be highly mobile in water and soils (US-EPA, 
2010). A higher mobility and lower rate of degradation in sandy soils than in clay soils has been 
reported. It is not expected that AA is removed from soils or water by volatilisation. The available data 
indicate that AA concentrations in the atmosphere are very low (ATSDR, 2012), and when present, its 
low vapour pressure makes it unlikely that AA will be transported in the atmosphere (US-EPA, 2010; 
ATSDR, 2012).  
AA is not expected to bioconcentrate considerably in aquatic organisms (EU, 2000; ATSDR, 2012). 
Petersen et al. (1985) reported bioconcentration factors (BCFs) of 1.44 and 1.65 for the carcass and 
viscera of rainbow trout, while Fujiki et al. (1982, as reported in EU, 2000) estimated for carp and 
Japanese medaka BCFs of 0.77 and 2.53, respectively.  
Biodegradation is likely to occur in soil to different degrees depending on the soil type, pH and 
temperature (NICNAS, 2002). Enzyme-catalysed hydrolysis is one of the main mechanisms of 
removal of AA from soils, while in water, non-biological hydrolysis may play an important role. 
When present in the atmosphere, AA is highly reactive with hydroxyl radicals, and a half-life for this 
reaction has been reported to be 8.3 hours (EU, 2000; ATSDR, 2012).  
1.3.3. Formation in food 
The main formation mechanism of AA in food is the reaction of the free amino acid asparagine with 
reducing sugars via the Maillard reaction, as was demonstrated by Mottram et al. (2002) and Stadler et 
al. (2002) soon after the first reports of the AA occurrence in certain foodstuffs. The temperature 
above which the formation of AA starts is dependent on the moisture content of the food matrix. 
Biedermann et al. (2002a) demonstrated that cooking wet potatoes at 120 °C under pressure formed 
< 20 µg/kg AA, while it formed about 10 000 µg/kg when heating dry potato powder, indicating the 
importance of evaporation of water prior to AA formation. The Maillard reaction, also denoted as 
‘non-enzymatic browning’ is long known to be responsible for the brown colour of processed food and 
the formation of a multitude of characteristic flavour compounds formed during food processing of 
bread, meat, coffee, nuts and others at higher temperatures (Maillard, 1912; Hodge, 1953). Besides the 
formation of these desirable substances, the Maillard reaction was also identified as the formation 
mechanism of a number of undesirable compounds, such as AA. The CONTAM Panel concluded 
however, that data on other undesirable heat-processed products are too limited to perform a group 
evaluation for all these Maillard reaction products formed in addition to AA.   
Becalski et al. (2011) showed that substantial amounts of AA can be generated in model systems even 
at temperatures lower than 100 °C under conditions that resemble the drying of foods, such as prunes. 
The authors concluded that AA in prunes and prune juice very likely originates from sugars and 
asparagine which is present in considerable amounts in the starting material, i.e. plums. 
Mestdagh et al. (2008) reported that the ratio of fructose to glucose impacted both colour and AA 
levels of fried potato strips, with a relative higher fructose concentrations favouring AA formation.  
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AA can also be formed from 3-aminopropionamide, a transient intermediate during thermal 
degradation or enzymatic decarboxylation of asparagine (Zyzak et al., 2003). The occurrence of 
3-aminopropionamide, a minor but potent precursor in AA formation, in several potato cultivars in 
different amounts was described by Granvogl et al. (2004). 
Other pathways of AA formation that do not require asparagine are also described in the literature. It 
was shown that AA can in principle be formed from acrolein and acrylic acid, especially in lipid rich 
foods. The different pathways via acrolein and acrylic acid in the formation of AA were summarized 
by Stadler and Scholz (2004).  
The pyrolytic AA formation from purified wheat gluten and gluten-supplemented wheat bread rolls 
was demonstrated by Claus et al. (2006). 
Casado et al. (2013) investigated AA precursors in sterilized table olives in model systems based on 
the aqueous fraction of olive pulp from untreated and lye-treated green olives, and demonstrated the 
formation of AA from commercial model peptides containing protein-bound aspartic acid, alanine and 
methionine, respectively, at 200 °C and different times in the absence of any carbonyl sources. The 
authors concluded that their results strongly support the role of peptides/proteins as precursors of AA 
formation in sterilized olives. 
Granvogl et al. (2008) reported that in addition to AA, also GA is formed during the heat processing of 
foods, although only to a minor extent. In potato chips (i.e. potato crisps), the amount of GA was 
0.5 % of the amount of AA, whereas this proportion was only 0.2 % in French fries without showing a 
clear dependence on heating time (see also Section 4.2.1). 
In summary, although several pathways of AA formation in food were investigated and demonstrated, 
especially in model systems, AA forms predominantly from free asparagine and reducing sugars 
during high temperature cooking, such as frying, roasting and baking, and processing (Halford et al., 
2012a). 
2. Legislation10 
In order to protect public health, Article 2 of the Council Regulation (EEC) No 315/93
11
 stipulates 
that, where necessary, maximum tolerances for specific contaminants shall be established. Thus, a 
number of maximum tolerances for contaminants, natural plant toxicants as well as for process 
contaminants such as 3-monochloropropane-1,2-diol (3-MCPD) are currently laid down in 
Commission Regulation (EC) No 1881/2006.
12
 AA in food is not regulated so far under this EU 
Regulation. 
Commission Recommendation 2010/307/EU
13
 which replaced Commission Recommendation 
2007/331/EU
14
 recommends that Member States should perform the monitoring of AA levels in 
certain specified foodstuffs and report the data annually in a prescribed format to EFSA. The 
monitoring exercise is targeted to those foodstuffs that are known to contain high AA levels and/or 
contribute significantly to the human dietary intake. Besides the type of product, also the sampling 
points and procedure, sample numbers and frequencies, analytical requirements as well as minimum 
                                                     
10  In this scientific opinion, where reference is made to European legislation (Regulations, Directives, Decisions), the 
reference should be understood as relating to the most current amendment, unless otherwise stated. 
11  Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. 
OJ L 37, 13.2.1993, p. 1–5. 
12  Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in 
foodstuffs. OJ L 364, 20.12.2006, p. 5–24. 
13  Commission Recommendation 2010/307/EU of 2 June 2010 on the monitoring of acrylamide in food, OJ L 137, 3.6.2010, 
p. 4–10. 
14  Commission Recommendation 2007/331/EC of 3 May 2007 on the monitoring of acrylamide in food. OJ L 123, 12.5.2007, 
p. 33–40. 
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additional information to be provided for each product, are each laid down in the two Commission 
recommendations.  
Based on the results of the monitoring in the Member States from 2007–2011, the EU Commission set 
‘indicative values’ for AA in various foodstuffs. The most recent indicative values (Table 2) are laid 
down in Commission Recommendation 2013/647/EU.
15
 According to the Recommendation, the 
‘indicative values’ are not safety thresholds, but are only intended to indicate the need for an 
investigation. Enforcement action and/or the issuing of a Rapid Alert should only be undertaken on the 
basis of a sound risk assessment carried out on a case by case basis, but not merely because an 
indicative value is exceeded. The Recommendation states: ‘Investigations should continue to include 
the food business operator’s Hazard Analysis and Critical Control Points (HACCP) or a similar system 
with a view to exploring with the food business operator whether relevant processing steps susceptible 
for the formation of acrylamide have been identified and whether appropriate measures have been 
taken to control them. In doing so, the competent authorities should assess the extent to which 
currently known options for the minimisation of acrylamide levels, e.g. those proposed in the Code of 
Practice for acrylamide adopted by the Codex Alimentarius Commission and in the acrylamide 
‘toolbox’ developed by FoodDrinkEurope, have been implemented by the food business operator’. 
These harmonized ‘indicative values’ provided a more uniform approach across the Member States 
than the application of values at national levels, such as the German ‘Signalwerte’ which were 
introduced in 2002 as part of a national minimizing concept for AA in foodstuffs (Section 4.5). 
Table 2:  Indicative values for AA in foodstuffs according to Commission Recommendation 
2013/647/EU 
Foodstuff 
Indicative value 
(µg/kg) 
French fries ready-to-eat 600 
Potato crisps from fresh potatoes and from potato dough 
Potato based crackers 
1 000 
Soft bread 
- Wheat based bread 
- Soft bread other than wheat based bread 
 
80 
150 
Breakfast cereals (excl. porridge) 
- bran products and whole grain cereals, gun puffed grain (gun puffed only relevant if 
labelled) 
-  wheat and rye based products
(1)
 
-  maize, oat, spelt, barley and rice based products
(1)
 
 
 
400 
300 
200 
Biscuits and wafers 
Crackers with the exception of potato based crackers 
Crispbread 
Gingerbread 
Products similar to the other products in this category 
500 
500 
450 
1 000 
500 
Roast coffee 450 
Instant (soluble coffee) 900 
Coffee substitutes 
(a) coffee substitutes mainly based on cereals 
(b) other coffee substitutes 
 
2 000 
4 000 
Baby food, other than processed cereal based foods
(2)
 
(a) not containing prunes 
(b) containing prunes 
50 
80 
Biscuits and rusks for infants and young children 200 
Processed cereal based foods for infants and young children
(3)
, excl. biscuits and rusks 50 
(1):  Non-whole grain and/or non-bran based cereals. The cereal present in the largest quantity determines the category.  
                                                     
15  Commission Recommendation of 8 November 2013 on investigation into the levels of acrylamide in food, OJ L 301, 
12.11.2013, p. 15–17. 
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(2):  As defined in Article 1(2)(b) of Commission Directive 2006/125/EC.16  
(3):  As defined in Article 1(2)(a) of Directive 2006/125/EC. 
Council Directive 98/83/EC of 3 November 1998 on the quality of water intended for human 
consumption
17
 has set a parametric value for AA of 0.10 µg/L. Parametric values are based on the 
scientific knowledge available and the precautionary principle and have been selected to ensure that 
water intended for human consumption can be consumed safely on a life-long basis, and thus represent 
a high level of health protection. The parametric value for AA refers to the residual monomer 
concentration in the water as calculated according to specifications of the maximum release from the 
corresponding polymer in contact with the water. 
According to Article 6 of Council Directive 98/83/EC, the parametric values shall be complied with: 
(a) in the case of water supplied from a distribution network, at the point, within premises or 
an establishment, at which it emerges from the taps that are normally used for human 
consumption; 
(b) in the case of water supplied from a tanker, at the point at which it emerges from the 
tanker; 
(c) in the case of water put into bottles or containers intended for sale, at the point at which the 
water is put into the bottles or containers; 
(d) in the case of water used in a food-production undertaking, at the point where the water is 
used in the undertaking. 
Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles 
intended to come into contact with food
18
 lists AA in Annex I as an authorized substance to be used as 
monomer. It is not authorized to be used as an additive or polymer production aid. A specific 
migration limit is not set for AA. The Regulation stipulates that AA shall not migrate in detectable 
quantities, whereby a detection limit of 0.01 mg substance per kg food is applicable. 
Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 
on cosmetic products
19
 lists AA in Annex II as prohibited substance in cosmetic products. Annex III of 
this Regulation provides restrictions on the residual AA content in polyacrylamides used in cosmetic 
products. For polyacrylamide used in body-leave-on products, the maximum residual AA content is 
0.1 mg/kg and for polyacrylamide put into other cosmetic products, the maximum residual AA content 
is 0.5 mg/kg. 
Annex XVII of Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 
18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH)
20
 provides that AA shall not be placed on the market or used as a substance or 
constituent of mixtures in a concentration, equal to or greater than 0.1 % by weight for grouting 
applications after 5 November 2012.  
                                                     
16  Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
17  Council Directive 98/83 of 3 November 1998 on the quality of water intended for human consumption. OJ L 330, 5.12.98, 
p. 32–54. 
18  Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into 
contact with food. OJ L 12, 15.1.2011, 1–89. 
19  Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic 
products. OJ L 342, 22.12.2009, p. 59–209. 
20  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the 
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals 
Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation 
(EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 
93/105/EC and 2000/21/EC. OJ L 396, 30.12.2006, 1–849. 
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3. Sampling and methods of analysis 
Detailed requisites for sampling points and procedures, sample numbers and frequencies, information 
to be provided for each product and analytical requirements are provided by Commission 
Recommendation 2010/307/EU on the monitoring of AA levels in food. 
3.1. Sample collection and frequency 
According to the Commission Recommendation, the sampling of the products should be carried out at 
market level (e.g. at supermarkets, smaller shops, bakeries, French fries outlets and restaurants), where 
there is a good traceability, or at production sites. Products with origin in one of the Member States 
should be sampled wherever possible. The distribution of samples per Member State is based on 
human population size with a minimum sample number of 4 per product category and Member State. 
A total of 10 different product categories have to be sampled. Depending on the population, between 
40 and 230 samples have to be analysed by each of the 27 Member States. These numbers refer to the 
minimum number of samples to be taken annually and the Member States are invited to take more 
samples when possible. In order to see time trends, it is considered important that products with the 
same specifications (e.g. same type of bread) are sampled every year where possible. For each of the 
10 product categories, the Recommendation gives detailed provisions concerning subcategories to be 
sampled and in case of French fries from potato dough also the time point (March/November) for 
sampling. 
In order to ensure that the samples are representative for the sampled lot, Member States should follow 
the sampling procedures laid down in part B of the Annex to Commission Regulation (EC) No 
333/2007 of 28 March 2007 laying down the methods of sampling and analysis for the official control 
of the levels of lead, cadmium, mercury, inorganic tin, 3-MCPD and benzo(a)pyrene in foodstuffs.
21
 
3.2. Methods of analysis 
3.2.1. Legal requirements 
According to the EU Recommendations, Member States should carry out the analysis of AA in 
accordance with the criteria laid down in points 1 and 2 of Annex III to Regulation (EC) No 882/2004 
of the European Parliament and of the Council of 29 April 2004 on official controls to ensure the 
verification of compliance with feed and food law, animal health and animal welfare rules. This 
implies that the methods of analysis should be characterised at least by the following criteria: 
accuracy, applicability (matrix and concentration range), limit of detection (LOD), limit of 
quantification (LOQ), precision, repeatability, reproducibility, recovery, selectivity, sensitivity, 
linearity and measurement uncertainty. The precision values shall either be obtained from a 
collaborative trial which has been conducted in accordance with an internationally recognised protocol 
on collaborative trials (e.g. ISO 5725:1994 or the IUPAC International Harmonised Protocol) or, 
where performance criteria for analytical methods have been established, be based on criteria 
compliance tests. The repeatability and reproducibility values shall be expressed in an internationally 
recognised form (e.g. the 95 % confidence intervals as defined by ISO 5725:1994 or IUPAC). The 
results from the collaborative trial shall be published or freely available. To ensure comparability of 
analytical results, methods should be chosen that can achieve an LOQ of 30 μg/kg for bread and foods 
for infants and young children and 50 μg/kg for potato products, other cereal products, coffee and 
other products. Results should be reported corrected for recovery. 
                                                     
21  Commission Regulation (EC) No 333/2007 of 28 March 2007 laying down the methods of sampling and analysis for the 
official control of the levels of lead, cadmium, mercury, inorganic tin, 3-MCPD and benzo(a)pyrene in foodstuffs. OJ L 88, 
29.3.2007, p. 29–38. 
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3.2.2. Analytical approaches 
3.2.2.1. Food 
A number of comprehensive reviews on analytical methods for the determination of AA in food 
products were published during the past decade (Wenzl et al., 2003; Stadler and Scholz, 2004; Zhang 
et al., 2005; Keramat et al., 2011; Oracz et al., 2011; Tekkeli et al., 2012; Arvanitoyannis and 
Dionisopoulou, 2014; Elbashir et al., 2014). The following paragraphs give a short summary on the 
general procedures and main conclusions, but do not claim for completeness. For more specific 
details, the reader is referred to the above reviews. 
The low molecular weight, high reactivity and lack of chromophore are challenges in the analysis of 
AA at low concentrations in food products. The choice of optimal extraction conditions and 
subsequent clean-up steps is dependent on the food matrix of interest. Water and mixtures of water 
and organic solvents, such as n-propanol or 2-butanone are preferred extraction solvents, mostly at 
room temperature. A special aspect of the extraction procedure is swelling of the dry matrix in order to 
get better access of the extraction solvent to potentially absorbed or enclosed AA. Depending on the 
matrix, swelling yielded a recovery increase of up to 100-fold (Biedermann et al., 2002b; Wenzl et al., 
2003). To enhance extraction, it was also proposed to increase the temperature of the extraction 
solvent or to treat the sample in an ultrasonic bath for several minutes. For example, ionic liquid based 
ultrasonic assisted extraction (ILUAE) was developed to determine the AA content in food samples 
(Albishri et al., 2014). In any case, care must be taken during extraction to avoid artifactual formation 
of AA, particularly if conducted under reflux conditions in a low moisture environment (e.g. 
methanol) and for longer periods of time (Stadler and Scholz, 2004). For clean-up of the extracts, a 
number of combinations of solid phase extraction (SPE) materials were reported. These include inter 
alia reversed phase materials, anion exchange, mixed mode anion and mixed mode cation exchange, 
and graphitized carbon materials. Depending on the fat content, food samples may require a defatting 
step in the clean-up procedure. Although classical clean-up methods, such as SPE, are still widely 
used, other procedures, such as matrix solid phase dispersion methods (MSPD) and solid phase micro 
extraction (SPME) become increasingly popular as they require less chemical reagents and often allow 
a faster sample preparation (Oracz et al., 2011). 
The analytical determination of AA in food products is most frequently performed by high 
performance liquid chromatographic (HPLC) or gas chromatographic (GC) separation methods with 
mass spectrometric detection (MS), either in selected ion monitoring (SIM) or by tandem mass 
spectrometry (MS/MS) in multiple reaction mode (MRM). A few authors also report on the 
application of high resolution mass spectrometry for the determination of AA in food products. As a 
low cost alternative for the determination of AA in various food stuffs, the application of HPLC 
coupled to a diode array detector (HPLC/DAD) was described (Michalak et al., 2013; Can and Arli, 
2014). 
HPLC based methods were reported for both ion trap systems and triple quadrupole systems after 
electrospray ionisation (ESI) as well as atmospheric pressure chemical ionisation (APCI). The HPLC 
separation is mostly performed on reversed phase columns or by ion exchange chromatography and 
the identification and quantification preferentially in MS/MS mode. In recent years the use of ultra-
performance liquid chromatography (UPLC) became more and more popular. Because of the high 
sensitivity and selectivity without the need for derivatisation, HPLC-MS/MS and UPLC-MS/MS 
methods have nowadays become the methods of choice for the determination of AA in food products. 
Modern methods based on these analytical techniques fulfil the EU requirements regarding LOD and 
LOQ without any problem. 
The determination of AA in food by GC-MS methods is either done with or without derivatisation. 
Derivatisation is most frequently done by bromination, but can also be performed with silylation 
followed by SPME. The brominated AA is less polar than the parent compound and thus better soluble 
in non-polar organic solvents. A subsequent liquid-liquid extraction between aqueous and organic 
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phase can then be applied as an effective clean-up step. The advantage of derivatisation procedures is 
that the molecular weight of the derivative is increased which results besides the higher volatility in an 
improved selectivity. However, derivatisation is a time consuming process, since for example, the 
excess of bromine has to be removed after the reaction.  
The major drawback of GC-MS methods without derivatisation is the lack of characteristic ions 
because of the low molecular weight of AA. In electron ionisation mode (EI), the major fragment ions 
for identification and quantification are m/z 71 and 55, respectively. Co-extracted substances, such as 
maltol or heptanoic acid produce almost the same ions and may therefore interfere. This makes higher 
efforts for clean-up mandatory. An increase in selectivity and decrease of interfering signals is 
possible by the use of GC coupled to tandem mass spectrometry (GC-MS/MS). LODs in the range of 
1–5 µg/kg can thus be achieved. Alternatively, the selectivity can be improved by applying positive 
chemical ionisation (PCI) mass spectrometry with methane or ammonia as reagent gases.  
Isotope labelled standards of AA are readily commercially available, either as AA-D3, AA-D5, 
13
C1-AA or as 
13
C3-AA. Addition of these internal standards at the beginning of the MS based analysis 
can improve the accuracy of the result as losses of the native analyte AA during sample treatment are 
corrected by use of the isotope labelled standard. The spiking approach is based on the establishment 
of equilibrium in the matrix interactions between the internal standard and the native analyte. As long 
as the equilibrium is not established, differences in the extraction procedure might have a great 
influence on recoveries (Wenzl et al., 2003). 
In recent years several methods were published for the determination of AA based on electrophoresis. 
These include capillary electrophoresis (CE), capillary zone electrophoresis (CZE), non-aqueous 
capillary electrophoresis (NACE) and micellar electrokinetic chromatography (MEKC). To increase 
sensitivity of the CE methods, the field amplified sample injection (FASI) was used and a tandem 
mass spectrometer was coupled (FASI-CE-MS/MS). Thus, LODs and LOQs of 8 and 20 µg/kg for AA 
in crisp bread could be obtained which were in a comparable range as from HPLC-MS/MS analyses. 
Further details of these analytical techniques are summarized by Oracz et al. (2011), Tekkeli et al. 
(2012) and Arvanitoyannis and Dionisopoulou (2014).  
Other analytical techniques, such as pyrolysis gas chromatography/mass spectrometry (Py-GC-MS) 
and Fourier Transform Infrared Analysis (FT-IR) were frequently applied in the analysis of model 
systems in connection with studies to elucidate the formation of AA, but do not play a role in the 
determination of AA in food products.  
Although a number of analytical approaches applying different analytical techniques have been 
published in the past decade, GC- and HPLC-based MS(/MS) methods are primarily used by private 
and official control laboratories for the routine determination of AA in food products. This is 
underpinned by the Scientific Report of EFSA ‘Update on acrylamide levels in food from monitoring 
years 2007 to 2010’ (EFSA, 2012a). While 56 % of the submitted results from the Member States 
were reported as performed with HPLC-MS based methods, about 37 % of the samples were analysed 
with GC-MS based methods. 
3.2.2.2. Biological matrices 
Analytical methods for the determination of free (unbound) AA in biological matrices, such as blood, 
urine, tissue or human milk, have been reported in the literature. The HPLC-MS/MS procedures for 
sensitive quantitative determinations follow the same general approach as used for the analysis of AA 
in food.  
Sörgel et al. (2002) reported on the analysis of AA in urine, human milk and placenta perfusion 
medium. Following a liquid/liquid extraction, the analytical determination of the concentrated extracts 
was performed by HPLC-MS/MS. The authors reported concentrations down to 1 ng/mL for urine, 
2 ng/mL for placenta perfusate and 5 ng/mL for human milk.  
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Doerge et al. (2005a, b) reported quantification of AA and GA in serum and tissues, and Doerge et al. 
(2007) reported quantification of AA and GA in urine after oral and intravenous dosing in mice and 
rats. Methodology included SPE prior to HPLC-MS/MS quantification. The LODs in serum for AA 
and GA, respectively, were 3 nM (0.2 ng/mL) and 30 nM (2.6 ng/mL), tissues LODs were 0.1 nmol/g 
for AA (7 ng/g) and GA (9 ng/g). In urine, LODs were 10 nM (0.7 ng/mL) for AA and 100 nM 
(8.7 ng/mL) for GA. 
Fohgelberg et al. (2005) reported on the analysis of human milk for AA. After addition of a deuterated 
internal standard, AA was extracted with solvents and after clean-up on an SPE column measured by 
HPLC-MS/MS. The LOQ was 0.5 ng/g. 
Annola et al. (2008a) developed a rapid and sensitive method using HPLC-MS/MS for the 
simultaneous determination of AA and GA in placental tissue and in perfusion medium from human 
placental perfusion studies. After addition of the internal standard 
13
C-AA to the samples and a single 
step sample preparation, HPLC-MS/MS determination was performed. LOQs for AA and GA were 
reported as 0.5 µg/mL for the analysed matrices. 
Motwani and Törnqvist (2011) used cob(I)alamin, (Cbl(I)) for trapping of GA. The trapping of GA by 
Cbl(I) results in the formation of an alkylcobalamin (GA-Cbl) that was used for quantitative analysis 
of the epoxide. The alkylcobalamin was analysed by LC–MS/MS using an electrospray ionisation 
source in the positive ion mode. The Cbl(I) method was validated for measurement of GA in liver S9 
fractions from human and rat. 
A number of papers have been published that describe the analysis of Hb adducts of AA and GA, and 
polar metabolites, such as mercapturic acids and their sulfoxides or 2,3-dihydroxypropionamide. 
Further information is given in Section 7.2.    
3.2.3. Analytical quality assurance: reference materials, validation and proficiency testing 
Certified reference materials (CRM) containing AA in crisp bread at a reported certified level of 
0.98 ± 0.09 mg/kg (ERM
®
-BD272), AA in toasted bread at a reported certified level of 425 ± 29 ng/g 
(ERM
®
-BD273), and AA in rusk at a reported certified level of 74 ± 7 ng/g (ERM
®
-BD274) are 
commercially available. Complementary to these CRMs produced by the German Federal Institute for 
Materials Research and Testing (BAM) and the Institute for Reference Materials and Measurements 
(JRC-IRMM), Kim et al. (2010) reported on the development of a CRM containing AA in potato chips 
(presumably potato crisps) (KRISS CRM 108-10-003) at a certified concentration of 
0.455 ± 0.012 mg/kg. 
Several proficiency tests and interlaboratory studies comprising AA in various food products were 
performed, in particular shortly after the first reports on the occurrence of high AA levels in food. The 
results of these studies are published in a number of reports (Clarke et al., 2002; Klaffke et al., 2005; 
Owen et al., 2005; Wenzl and Anklam, 2005). In general, there was no evident trend in performance or 
bias in results obtained with GC-MS or HPLC-MS based methods. However, in some cases the results 
for samples with low concentrations indicated a bias of the results obtained by GC-MS without 
derivatisation. Moreover, each study revealed a number of laboratories for which results were outside 
the acceptable range for accuracy.  
An inter-laboratory comparison study with 11 laboratories from eight EU Member States was carried 
out by JRC-IRMM (Wenzl et al., 2008) to evaluate the effectiveness of a method that was standardised 
for the analysis of AA in bakery and potato products for the determination of AA in roasted coffee 
with the intention to extend the scope of the standardised method. AA levels in roasted coffee ranged 
between 160 and 585 µg/kg. The calculated method performance parameters were found to be 
satisfying with regard to internationally accepted criteria as Horrat values for reproducibility were 
between 0.5 and 0.6, which is much below the broadly accepted maximum value of 2.0. In September 
2010, the European Committee for Standardisation (CEN) received a mandate to develop two 
standardised analytical methods for the determination of AA in food. These standardised analytical 
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methods are ‘Determination of acrylamide in potato-based products, cereal based products and coffee 
with HPLC-MS (Deadline for requested deliverable: 31 December 2014)’ and ‘Determination of 
acrylamide in potato-based products, cereal based products and coffee with GC-MS (Deadline for 
requested deliverable: 31 December 2016)’. 
4. Occurrence and patterns of AA in food 
4.1. Current occurrence of AA in food – Occurrence results reported to EFSA 
4.1.1. Overview of the datasets 
Two sources of data were considered:  
 data submitted by European countries in the framework of the EFSA continuous data call,22 
 data submitted by six food associations in the framework of the ad-hoc EFSA call for AA 
occurrence data in food and beverages intended for human consumption collected outside 
official controls launched during spring 2013.
23
 
4.1.2. Data management and validation 
A detailed data quality control was performed in order to check for duplicate submissions, to correct 
errors in the food description and/or reporting the results, to assess the reliability of analytical results, 
and to ensure the overall comparability of the data. The quality control targeted especially the values 
greater than the 75th percentile plus 1.5 times the inter-quartile distance, or less than the 
25th  percentile minus 1.5 times the inter-quartile distance within each food group defined in 
Commission Recommendation 2010/307/EU. This data quality control was performed in close 
cooperation with data providers and laboratories. The data which could not be corrected due to lack of 
information and those which were considered as unreliable were not further taken into account. 
4.1.2.1. Sampling requirements 
Only samples taken from 2010 and afterwards were considered in order to avoid any bias related to 
recent improvement in the analytical methods, and not take into account products no longer available 
on the European market. 
Samples taken in a country not belonging to the European Economic Area (EEA) were not taken into 
account, unless the data provider specifically indicated the same product (based on same supply chain, 
same recipe and same processing) to be also available in the European market. 
When results were corresponding to different sub-samples of a same sample, an average was 
determined at the sample level, and this value was retained for further analysis. 
4.1.2.2. Analytical requirements 
Only results for which the analytical techniques were based on HPLC or GC were considered, 
provided that the laboratory was accredited and/or the method was validated.  
Cut-off values for left-censored data were set at the indicative values defined in Commission 
Recommendation 2013/647/EU on investigations into the levels of AA in food (Table 2). Results 
associated with a LOQ above the corresponding cut-off values were not considered. In absence of an 
indicative value, the cut-off value was set at 50 µg/kg, which corresponds to the objective analytical 
performance set in Commission Recommendation 2010/307/EU on the monitoring of AA levels in 
food. 
                                                     
22  http://www.efsa.europa.eu/en/data/call/datex101217.htm  
23  http://www.efsa.europa.eu/en/dataclosed/call/130425.htm  
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4.1.2.3. Food description 
The data were classified according to the most detailed items available in the FoodEx1 system for food 
(EFSA, 2011b) and according to the food groups adapted from the food description used in 
Commission Recommendation 2010/307/EU on the monitoring of AA levels in food and in 
Commission Recommendation 2013/647/EU on investigations into the levels of AA in food.  
In this opinion, and in line with the Commission Recommendations 2010/307/EU and 2013/647/EU, 
the terminology ‘Potato crisps’ refers to crunchy thin slices of deep-fried/baked potato usually eaten as 
snacks, whereas ‘French fries’ refer to batons of deep-fried potato usually served as an 
accompaniment during a meal.  
‘Potato fried’, ‘Potato croquettes’ and ‘Roasted potatoes’ were classified together with the ‘French 
fries’ in a category called ‘French fries and potato fried’, the potato pancakes, patties, fritter and rösti 
were gathered in a category of ‘Other potato fried products’ and the other potato products (‘Potato 
baked’, ‘Potato boiled’, ‘Potato powder’, etc) as ‘Other (non-fried) potato products’. A distinction was 
made between the ‘French fries and potato fried’ sold as ready-to-eat and those sold as fresh or pre-
cooked. It was also attempted to distinguish the products analysed as fresh or pre-cooked from those 
analysed after having been prepared for consumption. 
Regarding ‘Coffee’ and ‘Coffee substitutes’, the terminology ‘Coffee (dry)’ and ‘Coffee substitutes 
(dry)’ specifically refer to the solid form of the product. In accordance with Commission 
Recommendations 2010/307/EU and 2013/647/EU, which refer to the products as sold, most of the 
AA occurrence levels available for ‘Coffee’ and ‘Coffee substitutes’ are reported on the solid form 
equivalent. The solid form is consequently further retained to report AA occurrence levels in ‘Coffee’ 
and ‘Coffee substitutes’, although this does not reflect the AA levels actually found in ‘Coffee’ and 
‘Coffee substitutes’ beverages (as consumed). 
4.1.2.4. Data submitted by European countries 
All the data related to the presence of AA in food collected since 2010, submitted to EFSA and 
checked on 13 November 2013 were taken into account. This represented a total of 8 240 samples, 
originating from 24 European countries (Table 3). 
The data quality control process led to the exclusion of 10 % of the available samples: 
 35 samples submitted twice, 
 6 samples for which the food description was too ambiguous, 
 3 samples corresponding to sub-samples, for which an average value at the sample level was 
retained for further analysis, 
 197 samples for which the analytical technique was not indicated, 56 results for which the 
analytical method was not validated and/or the laboratory not accredited, one result not 
generated by HPLC or GC, 
 312 samples associated with a LOQ above the respective cut-off level,  
 182 samples considered as unreliable from an analytical point of view.  
The final dataset contained 7 448 samples.  
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Table 3:  Number of analytical samples for each sampling year by the respective country 
Country 2010 2011 2012 2013 Total 
Austria 99 73 82 - 254 
Belgium 169 192 175 - 536 
Bulgaria - 44 - - 44 
Cyprus 41 43 42 - 126 
Czech Republic 45 78 63 - 186 
Denmark 120 117 118 - 355 
Estonia 30 42 12 - 84 
Finland - 120 10 6 136 
France 56 165 176 - 397 
Germany 812 986 1 065 - 2 863 
Greece 80 52 50 - 182 
Hungary 30 36 48 - 114 
Ireland 66 54 49 - 169 
Italy 165 155 217 - 537 
Lithuania 10 42 40 - 92 
Netherlands 62 - - - 62 
Norway 51 - - - 51 
Poland - 141 - - 141 
Romania - 80 86 40 206 
Slovakia 125 99 115 54 393 
Slovenia 41 128 77 - 246 
Spain 107 41 76 44 268 
Sweden 56 104 96 - 256 
United Kingdom 93 199 250 - 542 
Total 2 258 2 991 2 847 144 8 240 
 
The source of the data was indicated in 89 % of the samples. From these, 91 % were generated in the 
framework of official monitoring programs, the remaining results in the framework of other surveys 
and combinations of several programmes.  
Information on the sampling strategy was provided for around 82 % of the samples. When it was 
reported, it appeared that overall 30 % of the samples were coming from random sampling and 70 % 
from selective, suspect or ‘convenient’24 sampling. Due to the overall targeting strategy, the data from 
the monitoring programs may overestimate the levels of AA in products available on the market.  
Analytical techniques based on HPLC were used for 61 % of the samples, and techniques based on GC 
for 39 % of the samples.  
4.1.2.5. Data submitted by food associations 
A total of 37 552 data were received following the ad-hoc call for occurrence data on AA in foods and 
beverages intended for human consumption collected outside official controls. The data were 
submitted to EFSA by six organisations: four European food associations (European Coffee 
Federation, European Breakfast Cereals Association, European Snacks Association, 
FoodDrinkEurope) and two national associations (Finnish Food and Drink Industries’ Federation and 
the German Plant Bakeries Association).  
The data quality control process led to the exclusion of 4 % of the available analytical samples: 
- 205 samples taken before 2010, 
                                                     
24  Strategy based on the selection of a sample for which units are selected only on the basis of feasibility or ease of data 
collection (EFSA, 2010a). 
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- 1 361 samples taken outside the EEA, without sufficient indication the corresponding product 
would be found in the European market, 
- 15 samples for which the LOQ was missing.  
The final dataset contained 35 971 samples.  
The sampling point was indicated in more than 99 % of the samples. Most of them (97 %) were taken 
at the manufacturing or storage place, the rest being taken at the retail level. The four European food 
associations were asked to provide an indication of the overall representativeness of the products for 
which results were provided, regarding the entire European market. The information provided is 
summarised in Table 4. The data provided by the food associations covers a large percentage of the 
respective products in the EU market.  
Table 4:  Overall representativeness of the food products within the European market 
Food category Estimation of the EU market/volume share 
Baby food 80 % of the market in the EU by volume 
Breakfast cereals  75 % of the market in the EU by volume 
Coffee products 70–80 % of the market in the EU by volume 
Potato crisps from potato dough 
80 % of the market in the EU by volume (tonnes). A total of 20 countries 
are covered and in each case, the market leader is represented 
Potato crisps from fresh potatoes 
40–50 % of the market in the EU by volume (tonnes). A total of 
20 countries are covered and in each case, the market leader is represented 
Pre-cooked French fries 
Around 50 % share of the marketed pre-cooked French fries in the EU. 
Data were submitted by the biggest French fries producers in the EU and 
some smaller companies   
Crisp bread Less than 50 % share of marketed crisp breads in the EU  
 
Analytical techniques based on HPLC were used for 99.9 % of the samples, and techniques based on 
GC for 0.1 % of the samples. 
4.1.2.6. Comparison of both datasets 
The distribution of the LOQs for AA across the food groups, after the exclusion of the LOQs above 
the cut-off level, are illustrated in Figure 2 for both the data submitted by the European countries and 
the one submitted by the food associations.  
The median LOQs of the results provided by food associations are at 10 µg/kg for all food groups, 
except for ‘Potato fried products (except potato crisps and snacks)’, ‘Soft bread’ and ‘Coffee (dry)’ for 
which it stands around 30–40 µg/kg. The 95th percentile is below 50 µg/kg in all food groups, except 
for ‘Potato fried products (except potato crisps and snacks)’ for which it reaches 100 µg/kg. Overall, 
the LOQs of the results provided by European countries are higher than those provided by food 
associations.  The  median  LOQs of results provided by the European countries are in the range of 
20–30 µg/kg for all food groups, except for ‘Coffee substitutes (dry)’ for which it stands at 80 µg/kg. 
The 95th percentile is around 40–50 µg/kg for ‘Soft bread’, ‘Baby foods’ and the ‘Other products’, 
around 70 µg/kg for ‘Biscuits, crackers, crisp bread and similar’ and around 100 µg/kg for the other 
food groups. 
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Figure 2:  Distribution of the limits of quantification (LOQ) in µg/kg for AA across food groups and 
according to the origin of the data (European countries (EC) in light grey/food associations (FA) in 
dark grey) after applying the qualifying criteria (Box-plot: whiskers at 5th and 95th percentiles, box at 
25th and 75th percentiles with bold line at 50th percentile) 
Table 5 shows the distribution of AA levels across the food groups, according to the origin of data. All 
the samples reported as below the LOD/LOQ were replaced by half their respective LOD/LOQ 
(middle bound (MB) estimates).  
The two datasets are not directly comparable, as they have been generated for different objectives, 
with different practices regarding the sampling design, the preparation of the samples before analysis 
and different methods of analysis. Some high levels observed in the dataset provided by the European 
countries compared to the dataset provided by the food associations may be attributed to a selective 
sampling strategy towards food products known to contain high AA levels. The results provided by the 
food associations for ‘Potato fried products (except potato crisps and snacks)’ reflect levels of AA 
expected after the product has been prepared according to the instructions given on the package using 
both home and professional fryers. Regarding data provided by European countries, some of the 
‘Potato fried products (except potato crisps and snacks)’ samples have not been prepared before 
analysis, and there are uncertainties relating to the exact conditions of preparation in a number of other 
samples of ‘Potato fried products (except potato crisps and snacks)’. Such discrepancies in the 
protocol of preparation may explain differences in the AA levels observed between the two datasets. 
Samples provided by the European countries overall are associated with higher LOQs than those 
provided by food associations. This may explain the higher number of left-censored data observed in 
the dataset provided by the European countries compared to the one provided by food associations. 
Finally, differences in the number of samples, as observed for example for the ‘Potato crisps and 
snacks’ (33 701 samples provided by the food associations vs. 800 samples by the European countries) 
can also explain differences in the final estimates of AA levels. 
0 10 20 30 40 50 60 70 80 90 100 110
Potato fried products (EC, N = 1378)
Potato fried products (FA, N = 316)
Potato crisps and snacks (EC, N = 800)
Potato crisps and snacks (FA, N = 33 701)
Soft bread (EC, N = 535)
Soft bread (FA, N = 8)
Breakfast cereals (EC, N = 561)
Breakfast cereals (FA, N = 669)
Biscuits, crackers, crisp bread and similar (EC, N = 1974)
Biscuits, crackers, crisp bread and similar (FA, N = 91)
Coffee (dry) (EC, N = 682)
Coffee (dry) (FA, N = 775)
Coffee substitutes (dry) (EC, N = 88)
Baby foods, other than cereal-based (EC, N = 348)
Baby foods, other than cereal-based (FA, N = 68)
Processed cereal-based baby foods (EC, N = 394)
Processed cereal-based baby foods (FA, N = 342)
Other products (EC, N = 688)
Other products (FA, N = 1)
Distribution of the LOQ in µg/kg
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 37 
Table 5:  Distribution of acrylamide (AA) (middle bound (MB) estimates) according to the origin of 
data, expressed in µg/kg 
 Food category
(h)
 Origin
(a)
 n
(b)
 LC
(c)
 Mean
(d)
 Median
(d)
 P95
(d)
 
1 
Potato fried products (except potato 
crisps and snacks) 
EC 1 378 13.9 332 196 1 115 
FA 316 15.8 201 170 493 
 
French fries and potato fried, fresh or pre-
cooked 
 
     
1.1  / sold as ready-to-eat EC 877 12.7 308 218 904 
1.2 
/ sold as fresh or pre-cooked, analysed as 
sold  
EC 
74 40.5 367 88 1 888 
1.3 
/ sold as fresh or pre-cooked, prepared as 
consumed
(e)
  
EC 241 14.5 288 103 1 059 
FA 316 15.8 201 170 493 
1.4 
/ sold as fresh or pre-cooked, preparation 
unspecified 
EC 
90 15.6 368 174 1 468 
1.5 Other potato fried products EC 96 2.1 606 544 1 549 
2 Potato crisps and snacks 
EC 800 7.0 580 389 1 841 
FA 33 701 0.0 384 310 920 
2.1 Potato crisps made from fresh potatoes 
EC 498 6.6 654 431 2 050 
FA 30 969 0.0 388 310 934 
2.2 Potato crisps made from potato dough 
EC 63 7.9 316 191 870 
FA 2 732 0.3 338 298 747 
2.3 Potato crisps unspecified EC 216 7.9 519 348 1 465 
2.4 Potato snack other than potato crisp EC 23 4.3 283 149 - 
4 Soft bread 
EC 535 49.5 40 17 137 
FA 8 0.0 181 180 - 
4.1 Wheat soft bread EC 302 45.0 38 15 120 
4.2 Other soft bread
(f)
 
EC 99 43.4 46 25 203 
FA 8 0.0 181 180 - 
4.3 Soft bread unspecified EC 134 64.2 40 25 141 
5 Breakfast cereals 
EC 561 29.1 113 67 348 
FA 669 1.3 201 128 661 
5.1 
Maize, oat, spelt, barley and rice based 
products 
EC 149 32.9 73 50 230 
FA 61 4.9 172 120 540 
5.2 Wheat and rye based products 
EC 33 21.2 142 140 - 
FA 118 0.8 178 141 460 
5.3 Bran products and whole grains cereals 
EC 151 9.3 164 135 413 
FA 369 0.3 230 135 770 
5.4 Breakfast cereals, unspecified 
EC 228 40.8 100 50 350 
FA 121 3.3 148 103 423 
6 
Biscuits, crackers, crisp bread and 
similar 
EC 1 974 18.8 264 120 1 077 
FA 91 0.0 277 278 520 
6.1 Crackers EC 162 12.3 231 183 590 
6.2 Crisp bread 
EC 437 25.2 149 89 428 
FA 91 0.0 277 278 520 
6.3 Biscuits and wafers EC 682 21.1 201 103 810 
6.4 Gingerbread EC 693 14.1 407 155 1 600 
7a Coffee (dry)
(g)
 
EC 
FA 
682 
775 
7.5 
0.0 
317 
703 
221 
666 
878 
1 110 
7a.1 Roasted coffee (dry) 
EC 
FA 
566 
29 
7.2 
0.0 
244 
363 
203 
360 
563 
- 
7a.2 Instant coffee (dry) 
EC 
FA 
116 
746 
8.6 
0.0 
674 
716 
620 
670 
1 133 
1 115 
7b Coffee substitutes (dry)
(g)
 EC 88 6.8 1 499 667 4 500 
7b.3 Substitute (dry), based on cereals EC 20 5.0 510 522 - 
7b.4 Substitute (dry), based on chicory EC 37 0.0 2 942 3 100 - 
7b.5 Substitute (dry), unspecified EC 31 16.1 415 377 - 
8 
Baby foods, other than processed cereal 
based  
EC 348 70.1 24 15 70 
FA 68 50.0 24 8 123 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 38 
 Food category
(h)
 Origin
(a)
 n
(b)
 LC
(c)
 Mean
(d)
 Median
(d)
 P95
(d)
 
8.1 Not containing prunes 
EC 294 70.7 21 15 60 
FA 63 54.0 15 5 46 
8.2 Containing prunes 
EC 8 0.0 81 31 - 
FA 5 0.0 133 127 - 
8.3 Plum content unspecified EC 46 78.3 33 9 - 
9 Processed cereal-based baby foods 
EC 394 48.2 103 15 200 
FA 342 4.7 38 17 154 
9.1 Biscuits and rusks  
EC 173 38.2 115 45 287 
FA 62 0.0 97 65 256 
9.2 Other processed cereal-based foods  
EC 208 53.8 99 15 62 
FA 24 66.7 8 5 - 
9.3 Processed cereal-based foods unspecified  
EC 13 92.3 13 15 - 
FA 256 0.0 26 14 86 
10 
Other products based on potatoes, 
cereals and cocoa 
EC 568 32.6 97 36 370 
FA 1 100.0 5 5 - 
10.1 Porridge 
EC 8 12.5 33 16 - 
FA 1 100.0 5 5 - 
10.2 Cake and pastry EC 198 30.8 66 25 219 
10.3 Savoury snacks other than potato EC 135 13.3 171 88 690 
10.4 Other products based on cereals EC 143 53.1 68 25 293 
10.5 
Other  (non-fried) products based on 
potatoes 
EC 
40 60.0 108 8 - 
10.6 Other products based on cocoa EC 44 11.4 104 65 - 
11 
Other products not based on potatoes, 
cereals, coffee and cocoa 
EC 120 45.8 330 36 1 510 
11.1 Roasted nuts and seeds EC 40 55.0 93 25 - 
11.2 Black olives in brine EC 3 0.0 454 313 - 
11.3 Prunes and dates EC 18 27.8 89 47 - 
11.4 Vegetable chips EC 11 9.1 1846 1 511 - 
11.5 Paprika powder EC 30 56.7 379 25 - 
11.6 Other EC 18 55.6 68 25 - 
(a):  origin: EC: European countries; FA: Food associations.  
(b):  n: number of samples.  
(c):  LC: percentage of censored results.  
(d):  Mean, median, P95: mean, median and 95th percentile contamination level presented as the middle bound (MB) 
estimate. In case of too few observations (less than 60 for the 95th percentile), the estimation may be biased and is 
consequently not provided.  
(e):  Product prepared as consumed under laboratory standard conditions or at home. Results provided by food associations 
correspond to pre-cooked products dedicated for home-cooking but also for restaurants, which have been prepared 
according to the cooking instructions on the pack using both home and professional materials (fryers, oven). Pre-cooked 
products dedicated for restaurants can differ from those dedicated for home-cooking regarding the solids content (higher 
level of solids in products for restaurants than for home-cooking) and cut size of the potato. The final cooking is also 
different between home and restaurants as professional fryers have higher power than home-fryers and quicker cooking 
time. 
(f):  The samples of ‘Other soft bread’ provided by the food associations all correspond to pumpernickel. 
(g):  Results available for coffee beverage were expressed in powder equivalent, according to the dilution factor used to 
prepare the beverage before the analysis as indicated by the data provider. When such information was not indicated, the 
following dilution factors were considered: 0.02 for instant coffee, 0.05 for filtered coffee and 0.2 for espresso coffee.   
(h): The food categories are coded according to the food groups adapted from the food description used in Commission 
Recommendation 2010/307/EU and in Commission Recommendation 2013/647/EU. Product category number (3) ‘Pre-
cooked French Fries/potato products for home cooking’ does not appear in the table since it is considered under category 
(1) on ‘Potato fried products (except potato crisps and snacks)’. Product category (11) ‘Other products not based on 
potatoes, cereals, coffee and cocoa’ is not present in Commission Recommendation 2010/307/EU but has been added to 
make the best use of the data available. 
 
Despite these differences, the two datasets overall provide consistent information. In both datasets, 
‘Coffee (dry)’, ‘Coffee substitutes (dry)’ and ‘Potato crisps and snacks’ appear with the highest MB 
levels, comprised between 317 and 1 499 µg/kg at the mean, and between 878 and 4 500 µg/kg at the 
95th percentile. ‘Potato fried products (except potato crisps and snacks)’, ‘Crisp bread’ and ‘Breakfast 
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cereals’ are in an intermediate position, with MB levels between 113 and 332 µg/kg at the mean, and 
between 348 and 1 115 µg/kg at the 95th percentile. The ‘Processed cereal-based baby foods’ and 
‘Baby foods, other than processed cereal based’ have the lowest MB levels, being between 24 and 
103 µg/kg at the mean and between 70 and 200 µg/kg at the 95th percentile.  
Moreover, the two datasets provide complementary information. The dataset provided by the 
European countries gives information on the AA levels in a number of food products currently not 
covered by any indicative value, and these food products are not included in the dataset provided by 
the food associations. The dataset provided by the food associations contains less uncertainty than the 
dataset provided by the European countries regarding the mode of preparation of ‘Potato fried 
products’ before analysis. Altogether, the two datasets cover all food groups potentially containing AA 
and consequently contributing to the dietary exposure of AA. 
The CONTAM Panel considered that both sets of data are suitable for exposure assessment and 
provide complementary information. Therefore, the CONTAM Panel concluded that the datasets can 
be combined in order to perform the exposure assessment of the European population. 
4.1.3. Description of the occurrence levels 
Three estimates were produced depending on the assumption made on the results below the 
LOD/LOQ: (i) the lower bound estimate (LB), replacing all the result reported as below the 
LOD/LOQ by 0, (ii) the middle bound estimate (MB), replacing all the results reported as below the 
LOD/LOQ by half their respective LOD/LOQ and (iii) the upper bound estimate (UB), replacing all 
the results reported as below the LOD/LOQ to their respective LOD/LOQ. Mean and 95th percentiles 
of the three estimates (LB, MB and UB) were computed for all food groups (Table 6) and according to 
additional information available at the food groups levels (Appendix B, Table B1), such as the degree 
of roasting of the coffee, the main cereal composing the bread or the cooking of the French fries. 
Table 6:  Distribution of acrylamide (AA) levels in µg/kg 
 
Food category
(k)
 n
(a)
 LC
(b)
 
Mean 
MB [LB-UB]
(c)
 
P95 
MB [LB-UB]
(c)
 
1 
Potato fried products (except potato 
crisps and snacks) 
1 694 14.3 308 [303–313] 971 
1.1 
French fries and potato fried,                                     
fresh or pre-cooked, sold as ready-to-eat  
877 12.7 308 [302–314] 904 
1.2 
French fries and potato fried,                                      
fresh or pre-cooked, sold as fresh or pre-
cooked, analysed as sold   
74 40.5 367 [362–372] 1 888 
1.3 
French fries and potato fried,                                    
fresh or pre-cooked, sold as fresh or pre-
cooked, prepared as consumed
(d)
  
557 15.3 239 [236–242] 656 
1.4 
French fries and potato fried,                                       
fresh or pre-cooked, sold as fresh or pre-
cooked, preparation unspecified 
90 15.6 368 [361–375] 1 468 
1.5 Other potato fried products
(e)
 96 2.1 606 [606–607] 1 549 
2 Potato crisps and snacks 34 501 0.2 389 [388–389] 932 
2.1 Potato crisps made from fresh potatoes  31 467 0.1 392 949 
2.2 Potato crisps made from potato dough  2 795 0.5 338 750 
2.3 Potato crisps unspecified 216 7.9 519 [516–521] 1 465 
2.4 Potato snack other than potato crisp 23 4.3 283 - 
4 Soft bread 543 48.8 42 [36–49] 156 
4.1 Wheat soft bread  302 45.0 38 [33–44] 120 
4.2 Other soft bread  107 40.2 57 [51–62] 240 
4.3 Soft bread unspecified 134 64.2 40 [31–50] 141 
Table continued overleaf. 
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Table 6:  Distribution of acrylamide (AA) levels in µg/kg (continued) 
 
Food category n
(a)
 LC
(b)
 
Mean 
MB [LB-UB]
(c)
 
P95 
MB [LB-UB]
(c)
 
5 Breakfast cereals 1 230 14.0 161 [157–164] 552 
5.1 Maize, oat, spelt, barley and rice based 
products  
210 24.8 102 [96–109] 403 
5.2 Wheat and rye based products  151 5.3 170 [169–172] 410 
5.3 Bran products and whole grains cereals  520 2.9 211 [210–211] 716 
5.4 Breakfast cereals, unspecified 349 27.8 117 [109–124] 367 
6 Biscuits, crackers, crisp bread and 
similar 
2 065 18.0 265 [261–269] 1 048 
6.1 Crackers  162 12.3 231 [229–233] 590 
6.2 Crisp bread  528 20.8 171 [166–176] 486 
6.3 Biscuits and wafers  682 21.1 201 [197–206] 810 
6.4 Gingerbread  693 14.1 407 [403–412] 1 600 
7a Coffee (dry) 
(f)
 1 457 3.5 522[521–523] 1 054 
7a.1 Roasted coffee (dry)  595 6.9 249 [248–251] 543 
7a.2 Instant coffee (dry)  862 1.2 710 1 122 
7b Coffee substitutes (dry) 
(f)
 88 6.8 1 499 4 500 
7b.3 Substitute coffee (dry), based on cereals 20 5.0 510 [509–510] - 
7b.4 Substitute coffee (dry), based on chicory 37 0.0 2 942 - 
7b.5 Substitute coffee (dry), unspecified 31 16.1 415 [414–415] - 
8 Baby foods, other than cereal-based 416 66.8 24 [17–31] 72 
8.1 Baby foods, not containing prunes 357 67.8 20 [13–27] 48 
 Infant formulae 33 97.0 14 [3–26] - 
 Fruit purée  24 62.5 22 [15–29] - 
 Juice 3 100 12 [0–23] - 
 Ready-to-eat meal and dessert 291 64.3 20 [13–26] 51 
8.2 Baby foods, containing prunes 13 0.0 101 - 
8.3 Baby foods, unspecified regarding prunes 
content 
46 78.3 33 [25–40] - 
9 Processed cereal-based baby foods 736 28.0 73 [70–76] 175 
9.1 Biscuits and rusks  235 28.1 111 [106–115] 287 
9.2 Other processed cereal-based foods  232 55.2 89 [84–95] 60 
 Cereals to be reconstituted 159 54.7 125 [119–130] 86 
 Ready-to-eat meal cereal-based 73 56.2 13 [8–17] 30 
9.3 Unspecified processed cereal-based foods 269 4.5 26 [25–26] 83 
10 Other products based on potatoes, 
cereals and cocoa  
569 32.7 97 [92–101] 370 
10.1 Porridge 9 22.2 29 [28–31] - 
10.2 Cake and pastry 198 30.8 66 [61–71] 219 
10.3 Savoury snacks other than potato-based 
(mostly maize-based) 
135 13.3 171 [168–173] 690 
10.4 Other products based on cereals 143 53.1 68 [61–76] 293 
 Grains for human consumption 73 56.2 46 [39–54] 152 
 Grains milling products 17 35.3 117 [112–121] - 
 Pasta 9 88.9 13 [0–25] - 
 Beer 11 100 14 [0–27] - 
 Composite dishes containing cereals 25 32.0 129 [122–135] - 
 Fine bakery wares for diabetics 1 0.0 139 - 
 Other
(g)
 7 28.6 107 [104–109] - 
10.5 Other (non-fried) products based on 
potatoes  
40 60.0 108 [104–112] - 
 Potato bread 3 0.0 570 - 
 Other
(h)
 37 64.9 70 [66–74] - 
Table continued overleaf. 
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Table 6:  Distribution of acrylamide (AA) levels in µg/kg (continued) 
 
Food category n
(a)
 LC
(b)
 
Mean 
MB [LB-UB]
(c)
 
P95 
MB [LB-UB]
(c)
 
10.6 Other products based on cocoa  44 11.4 104 [103–105] - 
 Cocoa powder 13 7.7 178 [178–179] - 
 Other products based on cocoa 
(i)
 31 12.9 73 [72–75] - 
11 Other products  120 45.8 330 [321–339] 1 510 
11.1 Roasted nuts and seeds 40 55.0 93 [82–103] - 
11.2 Black olives in brine 3 0.0 454 - 
11.3 Prunes and dates 18 27.8 89 [87–92] - 
11.4 Vegetable crisps 11 9.1 1 846 [1 843–1 848] - 
11.5 Paprika powder 30 56.7 379 [365–393] - 
11.6 Other
(j)
 18 55.6 68 [59–77] - 
(a):  n: number of samples.  
(b):  LC: percentage of censored results.  
(c):  Mean MB[LB-UB], P95 MB[LB-UB], mean and 95th percentile contamination level presented as the middle bound 
estimate (lower bound estimate; upper bound estimate). When the middle, lower and upper bound estimates are equal, 
only one estimate is given. In case of too few observations (less than 60 for the 95th  percentile), the estimation may be 
biased and is not consequently not provided.  
(d):   Product prepared as consumed under laboratory standard conditions or at home.  
(e):  Potato patties (kartoffelpuffer, n = 52), potato pancake (n = 28), rösti (n = 12), unspecified (n = 3). 
(f):  Results available for coffee beverage were expressed in powder equivalent, according to the dilution factor used to 
prepare the beverage before the analysis as indicated by the data provider. When such information was not indicated, the 
following dilution factors were considered: 0.02 for instant coffee, 0.05 for filtered coffee and 0.2 for espresso coffee.   
(g):  Malt extract (n = 2), unspecified grain and grain-based products (n = 3), unspecified snack food (n = 2).  
(h):  Potato flakes/powder (n = 20), potato boiled (n = 12), unspecified potato and potato products (n = 3), potato-based dish 
(n = 1), new potato (n = 1).  
(i):  Chocolate and chocolate based confectionary (n = 30), unspecified cocoa beans and cocoa products (n = 1).   
(j):  Composite dishes vegetable-based and unspecified (n = 7), confectionary (not chocolate based) (n = 4), seafood crisps 
(n = 2), unspecified legumes, nuts and oilseeds (n = 2), dried bananas (n = 1), oil frying blend (n = 1), rhubarb and 
unspecified vegetable and vegetable products (n = 1). 
(k): The food categories are coded according to the food groups adapted from the food description used in Commission 
Recommendation 2010/307/EU and in Commission Recommendation 2013/647/EU. Product category number (3) ‘Pre-
cooked French Fries/potato products for home cooking’ does not appear in the table since it is considered under category 
(1) on ‘Potato fried products (except potato crisps and snacks)’. Product category (11) ‘Other products not based on 
potatoes, cereals, coffee and cocoa’ is not present in Commission Recommendation 2010/307/EU but has been added to 
make the best use of the data available. 
 
4.1.3.1. Potato fried products (except potato crisps and snacks) 
The AA MB levels in ‘Potato fried products (except potato crisps and snacks)’ were on average at 
308 µg/kg and at the 95th percentile at 971 µg/kg. The lowest levels were observed in the group of 
‘French fries and potato fried, fresh or pre-cooked, sold as fresh or pre-cooked and prepared as 
consumed’ (MB average at 239 µg/kg) and the highest levels in the group of  ‘Other potato fried 
products’ (MB average at 606 µg/kg) which gathers rösti, kartoffelpuffer and pancake (Table 6). 
However, such observations may be biased by some misclassifications. In some cases the information 
on the condition of preparation of the French fries before analysis was collected separately from the 
transmission of the individual results. Moreover, the food classification used for the data collection 
only distinguishes the French fries sold as ready to eat taken in small outlets, fast food chains and 
restaurants, from the pre-cooked French fries/potato products for home cooking. This lead to some 
difficulties to handle the fresh/pre-cooked French fries/potato products sampled in restaurants before 
cooking and analysed as such or prepared under laboratory conditions and the fresh/pre-cooked French 
fries/potato products taken as ready-to-eat at home.  
Higher AA levels were observed in ‘Potato fried products (except potato crisps and snacks)’ made 
from fresh potatoes (MB average at 275 µg/kg) than in ‘Potato fried products (except potato crisps and 
snacks)’ made from potato dough (MB average at 197 µg/kg), but no substantial difference was 
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observed between ‘French fries’ baked in the oven (MB average at 257 µg/kg) and those deep fried 
(MB average at 243 µg/kg) (Appendix B, Table B1).  
Insufficient information was available at the sample level to compare the levels of AA in French fries 
according to their size, the conditions of frying, whether the pre-cooked product was frozen or not, and 
the storage conditions of the potatoes 
4.1.3.2. Potato crisps and snacks 
The AA MB levels in ‘Potato crisps and snacks’ were on average at 389 µg/kg and at the 
95th percentile at 932 µg/kg. AA was found in higher levels in ‘Potato crisps from fresh potatoes’ 
(MB average at 392 µg/kg) than in ‘Potato crisps from potato dough’ (MB average at 338 µg/kg). AA 
levels appeared to be lower in potato crisps from batch process (MB average at 327 µg/kg) than in 
potato crisps from continuous process (MB average at 387 µg/kg) (Appendix B, Table B1). However, 
such observations may be biased by the differences in the number of samples between the different 
categories of ‘Potato crisps and snacks’. Lower levels were observed in ‘Potato snacks other than 
potato crisps’, including mostly puffed potato snacks (MB average at 283 µg/kg) than in the ‘Potato 
crisps’ (Table 6).  
4.1.3.3. Soft and crisp bread  
The  AA MB levels were lower in ‘Soft bread’ than in ‘Crisp bread’, on average at 42 and 171 µg/kg 
and at the 95th percentile at 156 and 486 µg/kg, respectively (Table 6). Samples of ‘Toasted bread’ 
taken as such from the market show similar levels as ‘Soft bread’ (Appendix B, Table B1).     
Lower levels were observed in soft bread and crisp bread mainly made from wheat (38 and 126 µg/kg, 
respectively), than in soft bread and crisp bread mainly made from rye (57 and 245 µg/kg, 
respectively) (Appendix B, Table B1). No comparison could be made with the other varieties of 
cereals (barley, maize, etc.) due to the lack of data. 
4.1.3.4. Breakfast cereals 
The AA MB level in ‘Breakfast cereals’ excluding porridge was on average at 161 µg/kg and at the 
95th percentile at 552 µg/kg, whereas it was on average at 29 µg/kg in ‘Porridge’. AA was found in 
higher levels in ‘Bran and whole grains breakfast cereals’ (MB average at 211 µg/kg) than in ‘Wheat 
and rye based breakfast cereals’ (MB average at 170 µg/kg) and in ‘Maize, oat, spelt, barley and rice 
based breakfast cereals’ (MB average at 102 µg/kg) (Table 6).   
4.1.3.5. Biscuits, cracker and gingerbread 
‘Gingerbread’ contained higher levels (MB average at 407 µg/kg and 95th percentile at 1 600 µg/kg) 
than ‘Crackers’ (MB average at 231 µg/kg and 95th percentile at 590 µg/kg) and ‘Biscuits and wafers’ 
(MB average at 201 µg/kg and 95th percentile at 810 µg/kg) (Table 6).  
4.1.3.6. Coffee (dry)  
AA MB level in ‘Coffee (dry)’ was on average at 522 µg/kg and at the 95th percentile at 1 054 µg/kg.  
AA MB level was lower in the ‘Roasted coffee (dry)’ (MB average at 249 µg/kg) than in the ‘Instant 
coffee (dry)’ (MB average at 710 µg/kg) (Table 6). However, when considering the respective dilution 
factors (from 0.035 to 0.125 for ‘Roasted coffee (dry)’ and 0.017 for ‘Instant coffee (dry)’), some 
coffee beverages made from ‘Roasted coffee (dry)’ would contain higher AA levels than beverages 
made from ‘Instant coffee (dry)’. 
Despite the limited number of samples, the level of AA was found to be higher in light roasting (MB 
average at 374 µg/kg) than in medium (MB average at 266 µg/kg) and dark roasting (MB average at 
187 µg/kg) (Appendix B, Table B1). Such observation is in line with the literature, which showed that 
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AA levels increase during the first minutes of roasting, and then decrease with the continuation of the 
roasting (see Section 4.4.2).  
Whereas lower AA levels are observed in regular roasted coffee (MB average at 245 µg/kg) compared 
to decaffeinated roasted coffee (MB average at 319 µg/kg), higher AA levels are observed in regular 
instant coffee (MB average at 718 µg/kg) compared to decaffeinated instant coffee (MB average at 
630 µg/kg) (Appendix B, Table B1). These comparisons should be interpreted with caution, due to the 
different numbers of samples, brands and roasting conditions between the regular and decaffeinated 
coffee categories. According to the literature, decaffeinating was not found to remove or lower the 
amount of AA (Andrzejewski et al., 2004).  
4.1.3.7. Coffee substitutes (dry) 
AA MB level in ‘Coffee substitute, (dry)’ was on average at 1 499 µg/kg and at the 95th percentile at 
4 500 µg/kg. Higher levels were observed in ‘Substitute coffee (dry), based on chicory’ (MB average 
at 2 942 µg/kg) compared to the ‘Substitute coffee (dry), based on cereals’ (MB average at 510 µg/kg) 
(Table 6).  
4.1.3.8. Baby foods 
AA MB levels were higher in ‘Processed cereal-based baby foods’ than in ‘Baby foods, other than 
cereal based’, on average at 73 and 24 µg/kg and at the 95th percentile at 175 and 72 µg/kg, 
respectively (Table 6). ‘Biscuits and rusks’ (MB average at 111 µg/kg) were found with AA in higher 
levels than ‘Other processed cereal-based baby food’ (MB average at 89 µg/kg). Higher levels were 
observed ‘Baby foods, containing prunes’ (MB average at 101 µg/kg) than in ‘Baby foods, not 
containing prunes’ (MB average at 20 µg/kg).  
4.2. Temporal trend analysis of AA occurrence data in certain food categories 
The CONTAM Panel explored the possibility to perform a temporal trend analysis of the AA 
concentrations in certain foodstuffs across Europe on the basis of the data submitted to EFSA by the 
Member States. Because of gaps in the database and the fact that results for the different years are not 
always comparable, a reliable Europe-wide temporal trend analysis is not feasible.  
In 2012, EFSA compiled results from annual monitoring of AA levels in European foods carried out 
from 2007 to 2010 under Commission Recommendation 2007/331/EC of 3 May 2007 (EFSA, 2012a). 
Twenty-five European countries submitted a total of 13 162 results for the four-year period. During 
the monitoring period, time trends in AA levels for different food categories were estimated using a 
linear model. However, the trend analysis did not show any major changes in AA levels. It was 
concluded that a more accurate trend evaluation of AA levels in European food categories would 
require an extended monitoring period and more detailed descriptions of sample sources. Specific 
recommendations to improve any future monitoring program for AA in foods included: consistently 
sensitive analytical methodology across the contributing laboratories; repeated sampling of the same 
type of products in different years; and sufficient number of samples per food group. 
A dataset of manufacturers’ measurements of AA levels in 40 455 samples of fresh sliced potato crisps 
from 20 European countries for the years 2002 to 2011 was compiled by Powers et al. (2013). 
Analysis of variance was applied to the data and showed a significant downward trend for mean levels 
of AA, from 763 ± 91.1 µg/kg in 2002 to 358 ± 2.5 µg/kg in 2011 (Figure 3). This was a decrease of 
53 % ± 13.5 %. The yearly 95th quantile values were also subjected to a clear downward trend. The 
proportion of samples containing AA at a level above the indicative value of 1 000 µg/kg for potato 
crisps introduced by the European Commission in 2011 fell from 23.8 % in 2002 to 3.2 % in 2011. 
Nevertheless, even in 2011, a small proportion of samples still contained high levels of AA, with 
0.2 % exceeding 2 000 µg/kg (Powers et al., 2013). The results of samples from 2010 onwards were 
submitted to EFSA through the industry call for data and are included in the occurrence and exposure 
assessment of this opinion. 
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Figure 3:  Overall mean acrylamide (AA) levels (ng/g) in 40 455 samples of fresh sliced potato 
crisps from 20 European countries over years from 2002 to 2011, with standard errors and with trend 
in 95 % (Q95) quantiles (red) (figure from Powers et al., 2013
25
) 
4.3. Previously reported literature data on AA in food 
AA number of studies providing results for AA in different food commodities have been published in 
the literature since AA was first detected in food. Many of these have described the AA concentrations 
in different food groups while studying the influence of processing and/or approaches to reduce the 
AA content (see Section 4.4). Several international bodies have reported the occurrence of AA in 
different food commodities when estimating the dietary exposure to AA, both at a national and 
international level (see Sections 1.1 and 6.3). The paragraphs below, which do not claim for 
completeness, give an overview of some of the occurrence values reported. 
In Europe, Wenzl and Anklam (2007) reported the results collected by the Joint Research Centre 
during the years 2003-2006 to build up the European Union database of AA in food. Afterwards, 
EFSA has published a total of four scientific reports summarising the results from the annual 
monitoring of AA levels in European foods carried out from 2007 to 2010 under different Commission 
Recommendations
13, 14
 (EFSA, 2009a, 2010a, 2011a, 2012a).  
The last JECFA evaluation in 2010 reported the AA occurrence data from more than 12 500 samples 
reported from 31 countries, with 61 % coming from Europe, 28 % from Asia, 9 % from North 
America, 1 % from the Pacific, and 1 % from Latin America (FAO/WHO, 2011). National mean 
concentrations of AA in major foods ranged from 399 to 1 202 μg/kg for potato crisps, from 169 to 
963 μg/kg for potato chips (i.e. French fries), from 169 to 518 μg/kg for biscuits, from 87 to 459 μg/kg 
for crisp breads and crackers, and from 3 to 68 μg/L for coffee (prepared as ready-to-drink). JECFA 
noted that other food commodities generally had mean levels < 100 μg/kg. It also noted that since its 
previous evaluation in 2005 (FAO/WHO, 2006), AA levels in rye products had decreased 
significantly, but no differences were seen in products prepared using potato, barley, rice, wheat, 
maize or oats (FAO/WHO, 2011). 
The Danish food monitoring on chemical contaminants 2004-2011 (DTU, 2013) reported the highest 
mean AA values in instant coffee (580 μg/kg), popcorn (483 μg/kg), French fries sold as ready-to-eat 
                                                     
25  This image has been reproduced from the publication: Powers SJ, Mottram DS, Curtis A, Halford NG, 2013. Acrylamide 
concentrations in potato crisps in Europe from 2002 to 2011. Food Addit Contam A, 30 (9) 1493–1500, doi: 
10.1080/19440049.2013.805439. It is subject to the terms of the Creative Commons Attribution License 
http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. The moral rights of the named authors have been asserted.   
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(472 μg/kg), potato crisps (448 μg/kg), potatoes prepared at home in the oven (312 μg/kg), biscuits 
(278 μg/kg), and roasted coffee beans (275 μg/kg). BfR (2011) reported the highest mean AA values 
from its 2010 monitoring of AA in coffee substitutes (739 µg/kg), followed by potato patties 
(Kartoffelpuffer) (692 µg/kg), soluble coffee (686 µ/kg) and ginger bread (Lebkuchen) and derived 
bakery products (522 µg/kg). Potato crisps and French fries were reported to have mean AA levels of 
385 and 256 µg/kg, respectively. Afssa (2005) reported the highest AA levels in French fries 
(790 µg/kg), followed by salted biscuits (390 µg/kg) and potato crisps (298 µg/kg).   
The survey carried out in Poland (Mojska et al., 2010), found the highest AA levels in potato crisps 
(904 µg/kg), followed by crackers (859 µg/kg) and French fries (from pre-cooked products, fried in 
the laboratory) (827 µg/kg). Crisp bread showed a mean value of 430 µg/kg and for the remaining 
food categories considered mean AA levels were lower. In Finland, Hirvonen et al. (2011) found the 
highest AA levels in crispbread (674 µg/kg), followed by potato crisps (539 µg/kg) and sweet biscuits 
(443 µg/kg).      
In the US, Tran et al. (2010) reported the AA content in several food categories as part of a dietary 
exposure estimate. The highest mean values were reported for ‘potato/other chips’ (i.e. potato/other 
crisps) (512 µg/kg), followed by ‘French fries, fried potatoes’ (442 µg/kg), ‘other fruit juice’ (limited 
to prune juice) (224 µg/kg), crackers (221 µg/kg) and ‘tortilla/corn chips’ (190 µg/kg).    
In Canada, mean AA levels in snack foods (including potato crisps) ranged from < 10 to 3 203 µg/kg, 
while in cookies and biscuits it ranged from 23 to 1 401 µg/kg. The mean AA levels in French fries 
ranged from 41 to 766 µg/kg (Health Canada, 2012). In another study in Canadian study, Normandin 
et al. (2013) reported mean AA concentrations of 1 053 µg/kg in deep fried French fries (prepared as 
consumed), while lower concentrations were found in potato chips (i.e. potato crisps) (524 µg/kg) and 
oven-baked French fries (prepared as consumed, 358 µg/kg). The levels in coffee (brewed) were 
< 10 µg/kg.     
In the national updated exposure assessment of AA completed in 2012 for New Zealand (MAF, 2012), 
the mean (range) AA levels in potato crisps was 581 µg/kg (112–1 460). The level were lower than 
those found in previous surveys (mean 1 570 (range: 370–2 320) µg/kg). Potato oven baked or roasted 
showed higher values, especially those from supermarket wedges (1 278 (range: 435–2 252) µg/kg. 
Mean AA levels in biscuits and crackers was reported to range from 100 to 600 μg/kg. Conversely 
mean AA levels in cereal-based snacks products ranged from 150 to 600 μg/kg, representing an 
increase in levels from approximately 300 μg/kg compared to previous surveys.  
In China, Chen et al. (2012) reported AA levels in several food categories, with the highest mean 
values found in fried potato (604.3 µg/kg) and in other fried products such as fried prawn strips 
(341.4 µg/kg) and fried rice crust (201.5 µg/kg). Potato crisps were found at mean levels of 
137.9 µg/kg).   
Sirot et al. (2012) and Zhou et al. (2013) reported the AA levels in samples within total diet studies 
(TDS). Within the second French TDS, 2 280 individual food products were collected and further 
grouped in 192 analytical samples grouped in 16 food groups and prepared ‘as consumed’ (Sirot et al., 
2012). The highest mean AA concentrations were found in potato crisps (954 µg/kg) followed by 
French fries (724 µg/kg) and salted biscuits (other than potato crisps) (697 µg/kg). Coffee showed 
mean values of 37 and 74 µg/kg for brewed and instant coffee, respectively. Bread and bread products 
showed values of 34 µg/kg while breakfast cereals showed lower levels (16 µg/kg). Zhou et al. (2013) 
performed total diet studies in four regions of China, analysed a total of 144 food composite samples 
grouped in 12 groups and prepared ‘as consumed’. The highest mean concentration were reported in 
sugar (72.1 µg/kg), followed by potatoes (31.0 µg/kg) and vegetables (22.3 µg/kg). The levels in 
cereals were reported at 6 µg/kg. Cereals and potatoes were found to contain AA at lower levels 
compared to those reported in other countries, and the authors concluded that this was probably due to 
different cooking temperatures and raw materials.   
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The AA levels in infant foods have been reported in several studies. Mojska et al. (2012) analysed 
111 commercially sold Polish baby food products, including follow-on formula, infant cereals, biscuits 
for infants and jarred baby food. The highest mean values were found in infant biscuits (219 μg/kg) 
and powdered cereals (148 and 129 μg/kg). When corrected to reconstitution with water to reflect 
ready-to-eat products, these levels fell into the 3–50 μg/kg range. The range of the mean AA levels in 
the remaining food types was 23–73 μg/kg. In another study in Poland, mean AA levels in instant 
cereal-based food and in cereal-based foods for infants were 34.7 and 13.4 µg/kg, respectively. Levels 
in candy-bars for young children were up to 53.5 µg/kg (Michalak et al., 2013). Mean AA levels in 
baby food products of 604 ± 694, 495 ± 403 and 290 ± 249 µg/kg were reported for crackers, biscuits 
and breakfast cereals purchased in Turkey (Cengiz and Gündüz, 2013).    
Additionally, there have been studies to address local or individual food issues. Bent et al. (2012) 
analysed AA levels in commercially-available and home-made ‘Caribbean’ foods, including biscuits, 
breakfast cereals, banana chips, and home-prepared foods (breadfruit; Artocarpus altilis, banana 
fritters, and dumplings). Biscuits, breadfruits, and fried dumplings showed the highest levels, up to 
approximately 4 000 μg/kg. Sanganyado et al. (2011) determined the levels of AA in traditional foods 
in Zimbabwe with mean AA levels in roasted maize, roasted groundnuts and roasted soybeans of 460, 
140 and 70 µg/kg, respectively. In boiled maize AA was found not detected. Özer et al. (2012) 
analysed the AA levels in Turkish traditional desserts reporting values of up to 150 µg/kg for baklava 
samples. Delgado-Andrade et al. (2010) determined the AA content in Spanish typical dishes such as 
lentil stew, paella, Spanish potato omelette and churros, with mean AA values per serving of 
105 ± 32, 263 ± 38, 240 ± 15 and 160 ± 13 µg/kg, respectively.   
In conclusion, a direct comparison between the occurrence data in the current assessment and the 
previously published occurrence data in literature should be done with caution, especially for 
processed products due to different analytical methodologies applied, and ingredients and processing 
methods which are not always reported. Nevertheless, the results of the various studies from different 
regions worldwide identified the same food commodities, such as processed potato and cereal based 
products that potentially contain high AA levels and thus are contributing substantially to human 
exposure. In addition, the results broadly suggest that AA levels have not changed considerably, 
despite efforts by food producers to improve and develop new processes that would mitigate AA 
formation during preparation. 
4.3.1. Glycidamide in food 
Using a stable isotope dilution assay and derivatisation with 2-mercaptobenzoic acid, Granvogl et al. 
(2008) reported for the first time on the occurrence of GA in processed food. Application of the 
method on several potato samples revealed amounts of GA between 0.3 and 1.5 μg/kg depending on 
the processing conditions. In potato chips (i.e. potato crisps), the amount of GA was 0.5 % of the 
amount of AA, whereas this proportion was only 0.2 % in French fries without showing a clear 
dependence on heating time. In a model experiment, the formation of GA by an epoxidation of the 
double bond in AA, that is, by a reaction with linoleic acid hydroperoxides, was established. This 
result was in good agreement with data showing that French fries processed in sunflower oil, which is 
high in linoleic acid, contained more GA as compared to fries prepared in coconut oil (Granvogl et al., 
2008). 
4.3.2. Data published by consumer organisations and consumers’ magazines  
Besides the determination of AA in the frame of official food control and by food business operators 
as part of their self-control, analyses are also carried out by consumer organisations and consumer 
magazines. Following a consultation with the EFSA Stakeholder Consultative Platform, EFSA 
received information on the work undertaken by some consumers’ organisations and published in 
consumer magazines related to AA (see Section on Documentation provided to EFSA). The main 
focus laid on the determination of AA in potato crisps and French fries as these products initially 
showed relatively high concentrations and thus were a primary target for mitigation measures by food 
industry. To follow the contamination trend, between 2003 and 2012, a number of surveys, including a 
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preferably representative range of products on the respective markets were conducted and the results 
published in consumer magazines. In general, the data indicated a decreasing trend of AA 
concentrations from the different countries where the analyses were performed. On the other hand, 
products such as gingerbread did not show a similar trend, possibly due to the use of traditional recipes 
and production processes often in small bakeries that are not applying the same mitigation measures as 
the bigger food industries.  
A few consumer organisations also tested various deep fryers available on their market and examined 
the impact of the different cooking processes on the AA concentrations. For example, a national 
consumer organisation used a single brand of frozen pre-fried potatoes which were cooked in the 
various machines according to the respective instruction sheets. The main conclusion was that the hot 
air machines produced more AA (average: 710 µg/kg) than the conventional deep oil fryers (average: 
518 µg/kg) tested (OCU-Compra Maestra, 2013). A similar result was observed by another consumer 
organisation when they tested an air fryer in 2011. The AA values were four times higher than the 
applied ‘acceptable’ value of 500 µg/kg (Test-Achats, 2008). As a follow up of the published results, 
the producer adapted the instruction sheet of the machine. The effect was that the AA concentration 
was indeed much lower (below 500 µg/kg), but it affected the taste. In February 2013, another 
consumer organisation published a comparative study on fryers. The main conclusion was that the 
potatoes fried in conventional oil deep fryers were lower in AA formation (average: 477 µg/kg) than 
the potatoes fried in fryers that use hot air instead of oil (average: 710 µg/kg). For this study, a single 
brand of frozen pre-fried potatoes was used (Proteste, 2013). 
4.4. Impact of raw material, storage and processing on AA levels in food  
Shortly after the first report by the Swedish National Food Administration in April 2002 on high levels 
of AA in certain food commodities (SNFA, 2002), numerous research activities were initiated inter 
alia on the formation mechanism of AA, effects of processing and possible mitigation measures. It 
became soon clear that the main pathway of formation is the reaction between the amino acid 
asparagine and reducing sugars via the Maillard reaction (See Section 1.3.3). In many cooking 
processes, the Maillard reaction is the predominant chemical process that determines colour, flavour 
and texture of cooked foods, based on highly complex reactions between amino acids and sugars. In 
this process, the thermal input is pivotal for the AA formation, i.e. the combination of temperature and 
heating time to which the product is subjected (EU-Toolbox). The formation primarily takes place 
under high temperature, usually in excess of 120 °C, and low moisture (Biedermann et al., 2002a; 
CAC/RCP 67-2009
8
). Therefore, AA is generally not detected at elevated amounts in boiled foods, but 
can be found at considerable concentrations in specific processed foods, especially where deep-frying 
or roasting is involved.  
During the last decade, numerous research activities, e.g. HEATOX
26
 and Prometheus,
27
 have been 
carried out to study the influence of various parameters that have a potential impact on the AA levels 
in food. The current status has been described by Pedreschi et al. (2014) and Xu et al. (2014) in their 
comprehensive reviews.  
The following paragraphs, which do not claim for completeness, give a short summary on the major 
findings.  
4.4.1. Impact of raw material and storage 
Early results on AA occurrence in food demonstrated considerable concentrations in carbohydrate-rich 
foods, in particular potato crisps and French fries. Stadler and Scholz (2004), Vinci et al. (2012) and 
Bethke and Bussan (2013) summarized the substantial findings of the various research groups 
concerning key factors that may impact AA formation and resulting potential measures to minimize 
AA in the final product. Following the finding that asparagine and reducing sugars are important 
                                                     
26 http://heatox.org/  
27 http://processing-contaminants-prometheus.com/index.php  
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determinants of AA formation, it was demonstrated that relative reductions in AA concentrations are 
possible by controlling the reducing sugar levels in potato cultivars (Biedermann-Brem et al., 2003). 
Besides the choice of the right cultivar, also the appropriate storage conditions are important. In this 
context, it was shown that storage below 8 °C will mobilize sugars in the tubers, e.g. concentrations 
can increase by up to a factor of 28 after 15-day storage at 4 °C (Noti et al., 2003). In their analysis of 
40 455 samples of fresh sliced potato crisps from 20 European countries, Powers et al. (2013) showed 
that the effects of seasonality arising from the influence of potato storage on AA levels was evident, 
with AA in the first six months of the year being significantly higher than in the second six months. 
Kumar et al. (2004) reported that in addition to temperature, also atmosphere can have an effect on 
sugar content in potatoes, because low oxygen levels supress sugar accumulation, while an increase of 
carbon dioxide concentration has the opposite effect. 
Halford et al. (2012b) studied the effects of storage of nine potato varieties on precursors 
concentrations and their relationship with AA formation, and showed the potential of variety selection 
for preventing unacceptable levels of AA formation in potato products and the variety-dependent 
effect of long-term storage on AA levels. The study also highlighted the complex relationship between 
precursor concentration and AA formation in potatoes. 
Asparagine is the dominant free amino acid in potato tubers, typically accounting for approximately 
one-third of the total free amino acids. Its concentration is influenced by both genetic and 
environmental factors. Experiments by Elmore et al. (2007) with different potato varieties grown in a 
glasshouse in pots containing vermiculite showed that sulfur deficiency in the medium to water the 
plants caused an increase in free asparagine accumulation in one variety but a decline of asparagine 
concentration in two other varieties. However, in all three varieties, the glutamine concentration 
increased, indicating that potatoes preferentially accumulated free glutamine rather than free 
asparagine in response to sulfur deficiency. This resulted in asparagine concentration as a proportion 
of the total free amino acids falling and a concomitant reduction in AA formation during heating 
(Elmore et al., 2007; Halford et al., 2012a).  
The effects of nitrogen and sulfur fertilisation on free amino acids, sugars and AA-forming potential in 
potatoes was investigated by Muttucumaru et al. (2013). In their study, 13 varieties of potato were 
grown in a field trial in 2010 and treated with different combinations of nitrogen and sulfur. Potatoes 
were analysed immediately after harvest to show the effect of nitrogen and sulfur fertilisation on 
concentrations of free asparagine, other free amino acids, sugars, and AA-forming potential. The study 
showed that nitrogen application can affect AA-forming potential in potatoes but that the effect is 
type- (French fry, chipping and boiling) and variety-dependent, with most varieties showing an 
increase in AA formation in response to increased nitrogen but two showing a decrease. Sulfur 
application reduced glucose concentrations and mitigated the effect of high nitrogen application on the 
AA-forming potential of some of the French fry-type potatoes (Muttucumaru et al., 2013). Results 
from further agronomic practices, involving genetic modification and other genetic techniques to 
reduce relevant precursors in potatoes and other plants are summarized by Halford et al. (2012a). 
4.4.2. Impact of processing  
Potatoes and potato based products 
The influence of frying temperature and processing duration on the AA content in French fries was 
analysed by Matthäus (2002). Figure 4 illustrates the substantial AA increase with rising temperature 
between 195 and 225 °C and processing duration between 16–24 minutes. The results show that the 
rise of temperature has a more pronounced effect than the increase of the processing time at the steady 
temperature.  As  a  consequence,  the  frying  temperature in oil-fried products should not exceed 
170–175 °C to avoid extraordinary AA levels in the finished product. Matthäus (2002) also analysed 
the influence of the type of processing on the AA concentrations in fried potato patties (Figure 5). 
Although the highest temperature and the longest processing time is applied in the convection oven, 
the AA concentration in the finished product is considerably lower than in the fried potato patties 
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prepared in the cooker at 215 °C for 6.5 minutes. This confirms that the efficacy of the heat transfer 
into the product is an important determinant.  
Fiselier et al. (2006) investigated the influence of the frying temperature on AA formation in French 
fries. They demonstrated that AA is formed towards the end of frying, indicating that the temperature 
during the second half of the frying process is especially important. Thus, the profile of the frying 
temperature was optimized regarding product quality (crispness, flavour) and AA formation. An initial 
temperature of 170–175 °C dropping to 140–145 °C and a virtually isothermal frying at 160 °C was 
found to be optimal. 
There are a number of further investigations on the impact of various parameters on AA formation in 
heat treated foods, such as type of frying oil, frequencies of oil use or addition of additives. The key 
findings of these studies which often showed minor effects on the AA levels were summarized by 
Stadler and Scholz (2004).  
Figure 4:  Influence of frying temperature and processing duration of the AA content in French fries 
Source: Matthäus (2002), modified. 
Figure 5:  Influence of processing type on the AA concentration in fried potato patties   
A: pre-baked; B: conventional baking oven 180 °C, 12 minutes; C: conventional baking oven 215 °C, 
6.5 minutes; D: convection oven 220 °C, 17 minutes; E: deep fryer 180 °C, 3.5 minutes. Source: 
Matthäus (2002), modified. 
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Truong et al. (2014) studied how the AA formation in sweet potato French fries (SPFF) is affected by 
processing methods. AA levels in SPFF from untreated sweet potato strips fried at 165 °C for 2, 3 and 
5 minutes were 124.9, 255.5, and 452.0 ng/g fresh weight, which were reduced by about seven times 
to 16.3, 36.9, and 58.3 ng/g, respectively, when the strips were subjected to processing that included 
water blanching and soaking in 0.5 % sodium acid pyrophosphate before frying. An additional step of 
strip soaking in 0.4 % calcium chloride solution before par-frying increased the calcium content from 
0.2 to 0.8 mg/g and decreased the AA levels to 6.3, 17.6, and 35.4 ng/g, respectively.  
Lim et al. (2014) analysed the influence of deep frying using various vegetable oils on AA formation 
in sweet potatoes. The sweet potatoes contained 4.17 mg/g glucose, 5.05 mg/g fructose, and 1.63 mg/g 
free asparagine. Sweet potatoes fried in palm olein contained a lower AA concentration (1 443 μg/kg), 
compared to those fried in soya bean oil (2 019 μg/kg).  
Yuan et al. (2014) examined the effect of immersion in different solutions on the AA content in potato 
slices after microwaving and frying under laboratory conditions. The results showed that immersing 
potato slices in water reduced the amount of AA by 8–40 % after microwaving and 19–75 % after 
frying, respectively. For microwave processing, immersion in a NaCl solution at a concentration of 
0.5 g/L caused a considerable reduction of the AA content by 96 %, followed by a treatment with a 
CaCl2 solution of 2 g/L (80 %) and a citric acid solution at a concentration of 1 g/L (58 %) . For the 
frying process, the most effective method for acrylamide reduction was the immersion in a citric acid 
solution at a concentration of 1 g/L (77 %), followed by a CaCl2 solution at a concentration of 2 g/L 
(72 %) and a NaCl solution at a concentration of 0.5 g/L (64 %). The authors concluded that optimal 
soaking treatments could effectively reduce the AA content while reasonably retaining the sensory 
attributes of the potato crisps. 
Cereals and cereal-based products  
One important determinant factor for AA formation in cereals and cereal-based products is free 
asparagine, which shows a broad concentration range in different cereals depending on type of grain 
and year of harvest. Therefore, attempts were made to decrease the asparagine content in raw food 
products before heat processing by adding the enzyme asparaginase which hydrolyses asparagine to 
aspartic acid. A substantial decrease of the AA formation in the final product by using in such a way 
treated raw materials was especially demonstrated for a number of cereal based products, and also for 
certain potato based materials (Zyzak et al., 2003; Ciesarova et al. 2006; Hendriksen et al. 2009). An 
influence of the sugar levels in the flour may result from the extent of milling. In contrast to the 
processing of potato-based products, the processing of cereals and manufacturing of bakery products is 
more complex, because of the varying composition and moisture levels of the products and the baking 
technologies. Baking temperature combined with moisture content seems to be an important factor for 
AA formation. For example, the AA concentration in crispbread could be reduced by optimisation of 
the oven inlet and outlet temperatures, adhering to a maximum moisture content of the product at 7 % 
and also by decreasing the average longitudinal oven baking temperature and increasing the baking 
time (Stadler and Scholz, 2004). As mentioned earlier, the heat transfer during the baking process into 
the product is not as efficient as in products that are oil-fried. 
Gingerbread may contain high AA concentrations. This can be attributed to the addition of ammonium 
bicarbonate which is a common baking agent in the production of gingerbread. In model experiments, 
Biedermann and Grob (2003) demonstrated that ammonium carbonate or bicarbonate, which are 
applied to rise dough, strongly increase AA concentrations by enhancing the yield of AA from 
asparagine and reducing sugar by 10 times. Other trials with gingerbread showed that the AA 
formation is proportional to the amount of ammonium bicarbonate added. The removal of ammonium 
bicarbonate resulted in a gingerbread with only traces of AA. The reaction pathway obviously does not 
proceed via amino-dehydroxylation of acrylic acid, as confirmed by spiking experiments using a stable 
isotope (
15
N)-labelled baking agent. Rather, ammonium favours the reaction by accelerating the 
degradation of sugars and generating more reactive carbonyls that can condense with asparagine via 
the Maillard route. Amrein et al. (2004) investigated the influence of ingredients, additives, and 
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process conditions on AA formation in gingerbread. They demonstrated that a substantial reduction of 
AA in gingerbread can be achieved by using sodium hydrogencarbonate as baking agent, minimizing 
free asparagine, applying asparaginase and avoiding prolonged baking. The research on the role of 
ammonium and addition of other additives in baking processes was summarized by Stadler and Scholz 
(2004). 
Toasted bread 
As part of the HEATOX project,
28
 AA levels in toasted breads (two white soft breads baked from 
wheat flour and two from wheat and rye flour) were investigated in order to estimate the AA intake 
from home-prepared foods. The bread loafs were toasted in a common household toaster for four 
different roasting times (‘1’–‘4’). The degree of toasting varied from no visible colour change to dark 
brown with black parts (see Figure 6). The two rye containing breads developed more browning than 
the white breads. The authors attributed this may be due to the fact that the ingredients for the darker 
breads included syrup, containing fructose and glucose in addition to sucrose, while ordinary sugar 
was used in the white breads. The AA levels before toasting were 3–8 µg/kg (fresh weight) in the 
white breads and 29–42 µg/kg in the rye containing breads. The levels for ‘medium’ toasting (based 
on colour: toasting time ‘3’ for breads made of wheat flour and ‘2’ for bread made from wheat and 
rye) were 16–61 µg/kg (Karl-Erik Hellenäs, 2014, personal communication) AA levels in bread 
toasted at toasting time ‘4’ ranged between 31 and 118 µg/kg. 
 
Figure 6:  Left picture shows soft bread made of sifted wheat flour, right picture shows soft bread 
made from wheat and rye. The loaf on top is not toasted, those below are toasting times 1, 2, 3 and 4 
on a common household toaster in order from left to right. AA levels reported to range from 3.0 to 
31 µg/kg (left) and from 41.6 to 118 µg/kg (right) (Karl-Erik Hellenäs, 2014, personal 
communication). 
Analyses by Jackson and Al-Taher (2005) indicated that for most types of bread, toasting to a 
‘medium’ degree of doneness results in small to moderate AA levels (< 100 µg/kg). However, bread 
made from potato flour showed considerably higher AA levels after toasting than toasted bread made 
from wheat, rye or multi-grain flour. For example, ‘dark’ toast made from potato bread showed AA 
levels up to around 600 µg/kg, presumably due to the higher concentrations of asparagine compared to 
bread made with other flours. The same authors reported that scraping the surface of darkly toasted 
potato bread to remove the browned portions reduced AA levels from 483 µg/kg to 181 µg/kg. This 
                                                     
28 HEATOX – Heat-generated food toxicants, identification, characterisation and risk minimisation. Project No 506820. 
Deliverable reference number: 59. Guidelines to authorities and consumer organisations on hme cooking and consumption. 
Available at:  http://www.slv.se/upload/heatox/documents/d59_guidelines_to_authorities_and_consumer_organisations
_on_home_cooking_and_consumption.pdf  
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finding supports earlier investigations by Surdyk et al. (2004) who reported that more than 99 % of 
AA in bread is found in the crust. 
Coffee 
Time and degree of roasting have been reported among the main factors affecting the levels of AA in 
coffee. During roasting of coffee both formation and reduction of AA have been reported, with 
increasing roasting degree resulting in a decrease of the AA levels (Stadler and Scholz, 2004; Lantz et 
al., 2006; Summa et al., 2007; Alves et al., 2010; Arvanitoyannis and Dionisopoulou, 2014). AA is 
formed at the beginning of the roasting process, reaching an apparent maximum, and then declining 
towards the end of the roasting cycle, with the levels in the final roasted product being only a fraction 
of the maximum levels observed. 
4.4.3.  Concluding remarks 
The different pathways and the various factors, including processing, that have an impact on the AA 
formation in the final products indicate that it is impossible to totally eliminate AA from food 
commodities. Therefore, the objective must be to control those parameters that have a potential impact 
on the AA formation (such as selection of raw material, storage condition, and food processing) in 
order to reduce the AA concentrations in food where feasible.   
4.5. Initiatives for mitigation measures 
An important initiative aiming to reduce AA in various food categories is the development of the 
FoodDrinkEurope ‘Acrylamide toolbox’. The background and the aim of the toolbox are described in 
the summary of the latest toolbox publication 2013 as follows:  
‘The FoodDrinkEurope Acrylamide ‘Toolbox’ reflects the results of > 10 years of cooperation 
between the food industry and national authorities of the European Union to investigate 
pathways of formation of AA and potential intervention steps to reduce exposure. The aim of 
the Toolbox is to provide national and local authorities, manufacturers (including small and 
medium size enterprises, SMEs) and other relevant bodies, with brief descriptions of 
intervention steps which may prevent and reduce formation of acrylamide in specific 
manufacturing processes and products. It is in particular intended to assist individual 
manufacturers, including SMEs with limited R&D resources, to assess and evaluate which of 
the intervention steps identified so far may be helpful to reduce acrylamide formation in their 
specific manufacturing processes and products. It is anticipated that some of the tools and 
parameters will also be helpful within the context of domestic food preparation and in food 
service establishments, where stringent control of cooking conditions may be more difficult’.29 
Besides scientific publications on formation and reduction of AA in food and updated results from 
respective projects, the latest revision of the toolbox takes also into account the publication of the 
CODEX Code of Practice for the Reduction of Acrylamide in Foods (CAC/RCP 67-2009). The 
toolbox is not meant as a prescriptive manual nor formal guidance, but should be considered as a 
‘living document’ with a catalogue of tested concepts at different stages that will be updated as new 
findings are communicated.
30
 The latest 2013 toolbox focusses especially on the categories ‘potatoes’, 
‘cereals’ and ‘coffee’ which were found to have a higher risk of AA formation. These are then sub-
divided into compartments and the individual tools.  
In addition to the AA toolbox, FoodDrinkEurope, in close co-operation with the European 
Commission and national authorities, has published pamphlets in 24 European languages. These 
pamphlets are short extracts of the toolbox in form of five sector specific brochures for ‘Biscuits, 
crackers and crispbread’, ‘Bread products’, ‘Breakfast cereals’, ‘Fried potato products/Potato crisps’ 
                                                     
29  http://www.fooddrinkeurope.eu/uploads/publications_documents/FoodDrinkEurope_Acrylamide_Toolbox_2013.pdf  
30  http://www.fooddrinkeurope.eu/documents/brochures/ac_toolbox_20090216.pdf  
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and ‘Fried potato products/French Fries’. The brochures are designed to help food business operators 
to implement those parameters of the toolbox that are relevant for their specific sector.
31
  
In November 2013, the US-Food and Drug Administration (US-FDA) published for comments a draft 
guidance for industry on ‘Acrylamide in Foods’.32 As indicated in the draft document, the guidance 
‘provides information to help growers, manufacturers, and food service operators reduce acrylamide in 
certain foods’ and ‘is intended to suggest a range of possible approaches to acrylamide reduction and 
not to identify specific recommended approaches. This guidance also does not identify any specific 
maximum recommended level or action levels for acrylamide’. The document focuses on categories 
such as potato-based products (including raw materials, French fries, sliced potato chips (i.e. potato 
crisps), fabricated potato chips (i.e. potato crisps) and other fabricated potato snacks), cereal-based 
foods (raw material,  processing and ingredients) and other foods (i.e. coffee). It also tackles the 
preparation and cooking instructions on packaged frozen French fries and information for food service 
operations.      
In Germany, a concept of minimising AA concentrations in foodstuffs was already introduced in 2002 
(Göbel and Kliemant, 2007). Foodstuffs analysed within official food control were compiled and 
classified into certain food groups. Those foods which make up the 10 % most contaminated products 
in each group were identified. The lowest of the AA contents of these upper 10 % is the so-called 
‘signal value’ for this group. If the signal value is higher than 1 000 µg/kg, the signal value will 
automatically be 1 000 µg/kg. Additionally, an observation of single products stemming from 
producers with an important market position was performed. If AA concentrations were found above 
the signal value, the competent authorities contacted the respective food producer and entered into the 
minimisation dialogue to check whether ingredients or processes could be changed to minimise AA 
contents, and which changes this could be. The signal values were updated annually by the German 
Federal Office for Consumer Protection and Food Safety (BVL). Once calculated, signal values were 
not raised as long as this minimisation concept was pursued, but were maintained or lowered. This 
means that AA contents in relevant foods will be continually reduced if the minimisation measures are 
successful. Food with AA contents of more than 1 000 µg/kg and from food groups for which no 
signal values have been set will automatically be included in the minimisation dialogue described 
above. The effects of the minimisation efforts undertaken in Germany are documented by the 
continuously lowered signal values (Raters and Matissek, 2012). The German national minimising 
concept with the calculation of signal values was widely replaced in 2011 with the introduction of EU 
wide indicative values.  
In 2009, BVL summarized the AA concentrations which formed the basis for the calculation of the 
German signal values in order to explore the effectiveness of the mitigation measures.
33
 While the 
decrease of the mean AA concentrations in potato chips (i.e. potato crisps) pointed to a successful 
application of the toolbox by food industry during the standardized industrial production of this potato 
product in the observed time span, the course of the mean AA concentration in French fries and potato 
patties showed either a stagnation or considerable variation. This may be partly due to the inclusion of 
samples from households and small snack-bars with no standardized food preparation. The  
minimisation measures implemented in potato crisp production in Germany since April 2002 is 
documented by the regularly updated weekly mean values  that show a decrease over time (Raters and 
Matissek, 2012).
34
 
                                                     
31  http://ec.europa.eu/food/food/chemicalsafety/contaminants/acrylamide_en.htm  
32  US-FDA. Draft guidance for industry: acrylamide in foods. Available at: http://www.fda.gov/Food/Guidance
Regulation/GuidanceDocumentsRegulatoryInformation/ChemicalContaminantsMetalsNaturalToxinsPesticides/ucm374524
.htm  
33  http://www.bvl.bund.de/DE/08_PresseInfothek/01_FuerJournalisten/01_Presse_und_Hintergrundinformationen/01_Lebens
mittel/2009/2009_03_05_hi_erfolgreiche_bilanz_acrylamidminimierungskonzept.html;jsessionid=B191D082209442465A
623E43DE06C474.1_cid322  
34 http://www.lci-koeln.de/deutsch/verbraucherinformation-zur-thematik-acrylamid-bei-kartoffelchips  
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A similar variation of the mean AA concentration over time was seen for gingerbread, a traditional 
spicy Christmas cookie and crispbread, which is probably due to the use of different traditional recipes 
and manufacturing processes, often in small bakeries, that are not applying the same effective 
mitigation measures as the bigger food industries.     
AA is not only formed in commercially produced food but also in considerable amounts in food 
prepared in restaurants and in home produced food, especially in fried potato products (Michalak et 
al., 2011; Sanny et al., 2013; see also Section 4.3.2). In parallel with the increasing knowledge on the 
formation of AA in food, a number of recommendations for mitigation measures of AA concentration 
in food have been published by national authorities and the food industry. Comprehensive 
recommendations in newspapers, journals and the internet for frying potato-derived products and 
toasting at home were sometimes accompanied with punchy slogans, such as ‘gilding rather than 
charring’. In addition, web pages were set up dealing with all aspects of AA, such as 
‘http://www.acrylamidefacts.org’. While these web pages are primarily addressed to the general 
population in the context of domestic cooking, tools, such as the FoodDrinkEurope ‘Acrylamide 
Toolbox’ are intended to assist industrial enterprises to keep the AA concentrations in foods as low as 
reasonably achievable. 
5. Food consumption  
5.1. EFSA’s Comprehensive European Food Consumption Database 
The EFSA Comprehensive European Food Consumption Database (Comprehensive database) 
provides a compilation of existing national information on food consumption at the individual level. It 
was first built in 2010 (EFSA, 2011c; Huybrechts et al., 2011; Merten et al., 2011) and then updated 
with new data available at the national level. In view of performing a chronic exposure assessment, in 
this opinion only individuals with at least two days of reporting were considered (Table 7). This 
represented 66 531 individuals from 33 surveys and 18 different European countries. There were six 
surveys available for infants (< 1 year old), ten surveys available for toddlers (≥ 1 year to < 3 years 
old), 17 surveys available for other children (≥ 1 year to < 3 years old), 16 surveys available for 
adolescents (≥ 10 years to < 18 years old), 16 surveys available for adults (≥ 18 years to < 65 years 
old), 13 surveys available for elderly (≥ 65 years to < 75 years old) and 11 surveys available for very 
elderly (≥ 75 years old). Two additional surveys were covering specific population groups: the 
pregnant women in Latvia and the lactating women in Greece. According to the surveys, consumption 
data were collected either through repeated 24-hour or 48-hour dietary recalls, or through dietary 
records covering 3 to 7 days. 
In some surveys, potatoes were reported as raw ingredient and/or without any indication regarding the 
preparation method. For all age groups, except infants, the following assumptions were made. If 
during a same meal both potato and oil or fat for frying were consumed, the oil/fat representing more 
than 5 % of the total consumption of potato and oil/fat, then the potato was assumed to be fried. Some 
commercial products of ‘Potato croquette’ and ‘Roasted potato’ available on the European market are 
indeed indicated to contain oil/fat at levels close to 5 %. If no oil/fat was consumed during the meal, or 
if it was representing less than 5 % of the total consumption of potato and oil/fat, then the potato was 
assumed not to be fried. The following oils/fats were considered as used for frying: ‘Ghee’, ‘Corn oil’, 
‘Cottonseed oil’, ‘Lard’, ‘Olive oil’, ‘Peanut oil’, ‘Sesame oil’, ‘Sunflower oil’, ‘Rapeseed oil’ and 
‘Oil frying blend’. Regarding the infants, it was considered that potato fried products were not yet 
introduced in their diet. The consumption events of potato raw/unspecified were assumed to 
correspond to non-fried potato products. Overall, such assumptions were considered to be 
conservative, as the oil/fat consumed during a same meal as potato could also have been used to 
prepare another food, such as meat or fish, or used as a salad dressing. 
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Some consumption events of coffee beverages were not described very precisely, i.e. without any 
indication whether it was ‘Coffee drink, espresso’, ‘Coffee drink, café americano’,35 ‘Coffee drink, 
cappuccino’ or ‘Instant coffee, liquid’. In the adult age groups (i.e. adult, elderly and very elderly), the 
amount consumed was on average 103–332 mL per consumption event. According to actual market 
practices and advices for product preparation, one  ‘Coffee drink, espresso’ is 30–50 mL, whereas the 
other coffee beverages are in the range of 100–250 mL. It was consequently assumed these 
unspecified consumption events to correspond to coffee beverages which are more diluted than 
‘Coffee drink, espresso’.   
The average consumption level was estimated at the individual level for the different food groups 
taken into account (see Section 6). Due to different methodologies, the data from the different surveys 
cannot be merged to produce one single estimate for the European population. The exposure is 
assessed at the survey level for each age group covered by the survey. 
 
                                                     
35  According to the FoodEx classification (EFSA, 2011b), ‘Coffee drink, café americano’ refers to coffee drinks of average or 
weak strength, which are more diluted than the ‘Coffee drink, espresso’. 
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Table 7:  Dietary surveys considered for the chronic dietary exposure assessment and number of subjects in the different age groups 
Country Dietary survey acronym Period
(a)
 Method Days
(b)
 Number of subjects
(c)
  Age ranges (in year) 
Belgium Regional_Flanders 2002 Dietary record 3 661 2.5–7 
Belgium Diet National 2004 2004 24h dietary recall 2 3 083 14–105  
Bulgaria NUTRICHILD 2007 24h dietary recall 2 1 720 < 1–5  
Cyprus Childhealth 2003 Dietary record 3 303 11–15  
Czech Republic SISP04 2003–2004 24h dietary recall 2 2 353 4–64 
Denmark DANSDA 2005-08 2005–2008 Dietary record 7 4 120 4–75 
Denmark IAT 2006_07 2006–2007 Dietary record 7 1 743 < 1–3  
Finland DIPP_2001_2009 2001–2009 Dietary record 3 1 750  < 1–6 
Finland NWSSP07_08 2007–2008 48h dietary recall 4 306 13–15 
Finland FINDIET2012 2012 48h dietary recall 2 1 708 25–74  
France INCA2 2007 Dietary record 7 4 079 3–79  
Germany EsKiMo 2006 Dietary record 3 1 228 6–11 
Germany VELS 2001–2002 Dietary record 6 800 < 1–4  
Germany NVS II 2007 24h dietary recall 2 13 926 14–80 
Greece Regional Crete 2004–2005 Dietary record 3 838 4–6 
Greece DIET LACTATION GR 2005–2007 Dietary record 3 65 25–39  
Hungary National Repr Surv 2003 Dietary record 3 1 360 18–96 
Ireland NANS_2012 2008–2010 Dietary record 4 1 500 18–90  
Italy INRAN SCAI 2005 06 2005–2006 Dietary record 3 3 323 < 1–98 
Latvia FC_PREGNANTWOMEN  2011 24h dietary recall 2 1 002 15–45  
Latvia EFSA TEST 2008 24h dietary recall 2 1 911 7–64  
Netherlands VCP kids 2006–2007 Dietary record 3 1 279 2–6  
Netherlands VCPBasis_AVL2007_2009 2007–2010 24h dietary recall 2 3 819 7–69 
Netherlands VCP-Elderly 2010–2012 Dietary record 2 739 70–94 
Romania Dieta_Pilot_Adults 2012 Dietary record 7 1 382 19–92  
Spain AESAN 1999–2001 Dietary record 3 410 18–60 
Spain AESAN FIAB 2009 24h dietary recall 2 1 067 17–60 
Spain enKid 1998– 2000  24h dietary recall 2 382 1–14 
Spain NUT INK05 2004– 2005  24h dietary recall 2 1 050 4–18  
Sweden NFA 2003 24h dietary recall 4 2 491 3–13   
Sweden Riksmaten 2010 2010–2011  Web record 4 1 797 18–80 
United Kingdom DNSIYC_2011 2011 Dietary record 4 2 683 < 1–1.5 
United Kingdom NDNS 2008–2011  Dietary record 4 3 073 1.5–94 
(a):  Starting and ending years of the survey.   
(b):  Maximum number of reporting days per subject.  
(c):  Number of subjects with at least two reporting days.    
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 57 
5.2. Specific consumption patterns of the total population and of ‘consumers-only’ in 
European countries 
Consumption data for ‘French fries and potato fried’, ‘Potato crisps’ and ‘Coffee’ were analysed in all 
dietary surveys used for the exposure assessment as described in Table 7. The ‘French fries and potato 
fried’ referred to the consumption of ‘French fries’, ‘Potato fried’, ‘Potato croquette’ and roasted 
potato. For ‘Coffee’, both coffee consumed as a beverage and coffee consumed as an ingredient of a 
recipe was taken into account. The ranges of mean and 95th percentile of average consumption levels 
determined for the total population (all subjects of the survey) and for the ‘consumers-only’ as well as 
the percentage of consumers are detailed in Appendix C.   
5.2.1. French fries and potato fried 
According to the Comprehensive database, the percentage of ‘French fries and potato fried’ consumers 
varies from 0 up to 85 % across the surveys (Appendix C, Table C1). When considering the 
consumers only, the highest consumption levels are observed in the groups of adolescents and adults, 
with a median average consumption levels at 66–67 g per day and a median 95th percentile at 147–
153 g per day. The lowest consumption levels are observed in the groups of infants, with a median 
average consumption levels at 10 g per day and a median 95th percentile at 23 g per day. When 
considering all subjects, the highest consumption levels are observed in the adolescents age group, 
with a median average and 95th
 
percentile consumption levels respectively at 27 g per day and 122 g 
per day. After the group of infants, for which the consumption levels are almost null, the lowest 
consumption levels are observed in the group of toddlers, with a median average and 95th percentile 
consumption levels respectively at 7.5 g per day and 34 g per day.  
5.2.2. Potato crisps 
According to the Comprehensive database, the percentage of potato crisps consumers varies from 0 up 
to 59 % across the surveys (Appendix C, Table C2). The highest percentages are observed in the 
groups of other children and adolescents. When considering the consumers only, the highest 
consumption levels are observed in the adolescents and adults age groups, with a median average and 
95th percentile consumption levels at respectively 20–21 g per day and 48–50 g per day. The lowest 
consumption levels are observed in the groups of infants, with a median average consumption levels at 
2.6 g per day. Not enough data were available to derive a 95th percentile in this age group. When 
considering all subjects, the highest consumption levels are observed in the adolescents age group, 
with a median average and 95th percentile consumption levels respectively at 4.1 g per day and 23 g 
per day. After infants, for which the consumption levels are almost null, the lowest consumption levels 
are observed in the groups of elderly and very elderly, with a median average consumption level at 
0.1–0.3 g per day. In these age groups, the percentage of consumers being below 5 % in most of the 
groups with more than 60 subjects, the median 95th percentile consumption level is estimated at 0 g 
per day.  
5.2.3. Coffee 
According to the Comprehensive database, the consumers of coffee (both as beverage and as 
ingredient of a recipe) represents from 50 up to 100 % of the population across the surveys in the 
adults, elderly and very elderly age groups (Appendix C, Table C3). The percentage of coffee 
consumers is comprised between 2 and 35 % in the surveys covering the adolescents age group, 
between 0 and 14 % in the surveys covering the other children age groups, between 0 and 2.8 % in the 
surveys covering the toddlers and between 0 and 0.2 % in the surveys covering the infants. When 
considering the consumers only, the highest consumption levels are observed in the elderly and very 
elderly age groups,  with  a  median average and 95th percentile consumption levels at respectively 
17–21 g dry equivalent per day and 40–45 g dry equivalent per day. Consumption levels are lower in 
the groups of infants, toddlers, other children and adolescents, with a median average consumption 
levels standing respectively at 0.1, 0.3, 2.9 and 4.5 g dry equivalent per day. When considering all 
subjects, the highest consumption levels are also observed in the elderly and very elderly age groups, 
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with a median average and 95th percentile consumption levels respectively at 14–19 g dry equivalent 
per day and 37–43 g dry equivalent per day. In the groups of infants, toddlers and other children, the 
average consumption levels are below 0.1 g dry equivalent/day and the 95th percentile below 5 g dry 
equivalent per day. In the groups of adolescents, the average consumption levels are below 2.7 g dry 
equivalent per day and the 95th percentile below 13 g dry equivalent per day. 
6. Human exposure assessment 
6.1. Methodology 
6.1.1. Food grouping 
Exposure was assessed considering 112 food groups (see Appendix D, Table D1): 12 at Foodex level 
2, 48 at Foodex level 3, 46 at Foodex level 4. Six specific food groups defined for a best matching 
between the consumption and the occurrence data: 
 ‘French fries and potato fried’: French fries, potato fried, potato croquette and roasted potato; 
 ‘Other potato fried products’: potato pancakes, potato fritter and rösti; 
 ‘Non fried potato products’: potato boiled, baked, mashed, flakes and potato-based pasta; 
 ‘Other potato snacks’: mostly puffed potato snacks; 
 ‘Fruit purée for infants and young children, without prunes’: fruit purée made from fruits other 
than prunes; 
 ‘Fruit purée for infants and young children, unspecified’: fruit purée without any indication 
regarding the kind of fruit. 
In particular,  
‘Potato fried products’: a distinction was made between ‘French fries and potato fried’ and ‘Other 
potato fried products’ as previously defined. 
‘Potato crisps and snacks’: a distinction was made between ‘Potato crisps’ and ‘Other potato snacks’. 
‘Soft bread’ and ‘Crisp bread’: a distinction was made between ‘Soft (including toasted) bread’ and 
the ‘Crisp bread’, and according to the main cereal used (wheat, rye). ‘Potato bread’ and ‘Potato-rye 
bread’ were considered apart.  
‘Breakfast cereals’: a distinction was made according to the main cereal composing the breakfast 
cereals. A distinction was also made between the ‘Oat flakes’ and ‘Oat bran/wholemeal flakes’. 
‘Wheat flakes’ were considered to be made from both wholegrain/bran grains and from refined grains, 
whereas the flakes from the remaining cereal varieties were considered to be made only from refined 
grains. ‘Grits’ and ‘Porridge’ were considered apart. 
‘Biscuits, crackers and similar’: a distinction was made between ‘Gingerbread’ (including lebkuchen 
and speculoos), ‘Crackers’, ‘Biscuits and wafers’ and the ‘Other pastries and cakes’. The ‘Fine bakery 
wares for diabetics’ were considered apart. 
‘Coffee’: concerning dry coffee products, a distinction was made between ‘Coffee roasted’ and 
‘Instant coffee, powder’. Concerning the coffee drinks, ‘Coffee drink, espresso’, ‘Coffee drink, café 
americano’, ‘Coffee drink, cappuccino’, ‘Coffee drink, café macchiato’, ‘Iced coffee’ and ‘Coffee 
with milk’ were assumed to be exclusively made from roasted coffee with the respective dilution 
factors of 0.2, 0.05, 0.05, 0.10, 0.04 and 0.04 applied to the occurrence estimate expressed in dry 
equivalent. A dilution factor of 0.02 was applied to the ‘Instant coffee, powder’ in order to estimate 
the AA levels in ‘Instant coffee, liquid’.  
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 59 
‘Coffee substitutes’: a distinction was made between ‘Malt and barley coffee (dry)’ and ‘Chicory 
coffee (dry)’. A dilution factor of 0.05 was applied to the ‘Coffee substitutes (solids)’ in order to 
estimate the AA levels in ‘Coffee substitutes, beverage’.  
‘Baby food, other than processed cereal-based ones’: a distinction was made between ‘Infant 
formulae’, ‘Ready-to-eat meal and dessert’, and ‘Fruit purée’. The ‘Fruit juice and herbal tea’ were not 
considered in the exposure assessment as all the occurrence data available were reported as < LOQ. A 
distinction was made between the fruit purées which were explicitly indicated as being made from 
another fruit than prunes, and the fruit purées without any indication regarding the kind of fruit, which 
were considered to be made either from prunes or from another fruit. A conversion factor of 0.14 
(Kersting et al., 1998) was applied to the consumption events of ‘Infant/follow-on formulae, liquid’ in 
order to express them in powder equivalents.    
‘Processed cereal-based baby foods’: a distinction was made between the ‘Biscuits and rusks’, 
‘Cereals to be reconstituted’ and ‘Ready-to-eat meal cereal-based’. Conversion factors of respectively 
0.1 and 0.2 were applied to the consumption events of ‘Simple cereals reconstituted with milk’ and 
‘Cereals with an added high protein food reconstituted with water’ (Kersting et al., 1998) in order to 
express them as ‘Cereals to be reconstituted’ equivalents.  
‘Other products based on cocoa’: a distinction was made between ‘Cocoa powder’ and ‘Chocolate 
products’. A dilution factor of 0.028 was applied to the ‘Cocoa powder’ in order to estimate AA levels 
in ‘Cocoa beverage’. 
‘Other products based on cereals’ and ‘Savoury snacks other than potato-based’: a distinction was 
made between the ‘Savoury snacks other than potato-based’, ‘Grains for human consumption’, ‘Grain 
milling products’ and ‘Cereal-based pasta’. Regarding the ‘Composite dishes containing cereals’, the 
occurrence level of ‘Soft bread’ was applied to the bread content (55 %) of ‘Sandwich and 
sandwiches-like meals’ and ‘Pizza and pizza-like pies’. The breaded meat, fish and vegetable products 
were also taken into account. The ‘Beer’ was not taken into account in the exposure assessment. 
Indeed, the data for eleven samples of beer available were all reported as < LOQ. From this, the 
CONTAM Panel concluded that there was insufficient quantitative evidence to take this food group 
into account in the exposure assessment. 
‘Other products based on potatoes’: this category included the ‘Non-fried potato products’. In 
addition, the occurrence level of ‘Non-fried potato products’ was applied to the potato content 
(47.8 %) of other potato-based dishes (mainly potato and vegetable/cheese/meat meals and salads). 
‘Other products’: ‘Peanut’, ‘Tree nuts’ and ‘Oilseeds’ were considered in the exposure assessment, 
with this assumption they would be entirely consumed in their roasted form. The occurrence dataset 
available for ‘Black olives in brine’ was applied to the consumption of ‘Table olives’. The occurrence 
dataset available for ‘Prune and dates’ was applied to the consumption of ‘Dried prunes’, ‘Dried 
dates’, ‘Jam, Plum’, ‘Canned fruit, Plum’, ‘Fruit compote, Plum’, ‘Juice, Prune’. The occurrence 
dataset available for ‘Paprika powder’ was also taken into account. Occurrence data available for 
‘Vegetable crisps’ were not further considered, as such food is not present in the Comprehensive 
Database. 
6.1.2. Exposure calculation 
Chronic exposure to AA was assessed at the individual level by multiplying the mean daily 
consumption for each food with the corresponding mean occurrence level, summing up the respective 
intakes throughout the diet, and finally dividing the results by the individual’s body weight.  
This resulted in a distribution of individual exposures from which the mean as well as the 95th 
percentile were derived for each population group (i.e. [survey and age group] combinations). The 
contribution of each food group to total exposure to AA was determined for each population group, as 
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the ratio between the average AA intake resulting from the consumption of the food group and the 
total average exposure to AA.  
In order to estimate the mean occurrence level used in the exposure assessment, the left-censored data 
(i.e. results below the LOD/LOQ) were treated by the substitution method, as recommended in 
international guidelines (WHO/IPCS, 2009; EFSA, 2010b). Two scenarios for the treatment of results 
below the LOD/LOQ were considered. Under the LB scenario, occurrence values below the 
LOD/LOQ were set at 0 for the food and food groups with more than 60 % of left-censored results, or 
were set to half the LOD/LOQ for the food and food groups with less than 60 % of left-censored 
results. Under the UB scenario, occurrence values below the LOD/LOQ were set at the LOD/LOQ for 
the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for 
the food and food groups with less than 60 % of left-censored results. 
The mean occurrence levels calculated under the LB and UB scenarios are detailed in Appendix D, 
Table D1. These are the values which have been used to estimate exposure to AA under the LB and 
UB scenario, respectively. 
6.1.3. Exposure scenarios 
6.1.3.1. Baseline exposure scenario 
In the baseline exposure scenario, all the occurrence data available were used to estimate the mean AA 
level of each food group taken into consideration in the exposure assessment. Specifically, all the data 
on ‘French fries and potato fried’ were used together, without distinction between the products sold as 
ready-to-eat, those sold as fresh or pre-cooked and analysed as sold or as consumed. For ‘Potato crisps 
and snacks’, all the data were used together without distinction between ‘Potato crisps made from 
potato dough’ and ‘Potato crisps made from fresh potato’, and between the kind of process 
(batch/continuous). In a similar way, all the data available for ‘Coffee’ were used regardless of the 
degree of roasting and caffeine content.  
6.1.3.2. Scenarios reflecting specific consumption habits 
In addition to the baseline exposure scenario, specific scenarios were designed in order to assess the 
influence of specific home-cooking behaviours and to reflect preference for particular products and 
places of consumption on the total dietary exposure to AA (see Section 6.2.3).  
6.2. Results 
6.2.1. Acrylamide exposure levels across the different population groups 
6.2.1.1. General population 
Table 8 presents the ranges (minimum, median and maximum) of the mean and 95th percentile 
exposure levels across the different surveys and age groups representing the general population 
(detailed results by survey and age group are available in Appendix E). Whereas all surveys and age 
groups were used to derive the ranges of the mean exposure levels, only the ones with more than 
60 subjects were used to derive the ranges of the 95th percentiles. 
Infants, toddlers and other children were the most exposed groups. The mean exposure levels ranged 
from 0.5 (minimum LB) to 1.9 µg/kg b.w. per day (maximum UB), and the 95th percentile from 1.4 
(minimum LB) to 3.4 µg/kg b.w. per day (maximum UB) depending on the survey and age group. 
Adolescents, adults, elderly and very elderly had mean exposure estimates ranging from 0.4 (minimum 
LB) to 0.9 µg/kg b.w. per day (maximum UB), and the 95th percentile estimates from 0.6 (minimum 
LB) to 2.0 µg/kg b.w. per day (maximum UB) depending on the survey and age group. 
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Table 8:  Exposure to acrylamide (AA) in µg/kg b.w. per day across the surveys and age groups 
representing the general population 
Age group 
Mean 
Median [Minimum–Maximum] 
P95 
Median [Minimum–Maximum] 
LB UB LB UB 
Infants (n
(a)
 = 6 / 5) 0.8 [0.5–1.3] 1.0 [0.7–1.6] 1.8 [1.4–2.3] 2.1 [1.6–2.5] 
Toddlers (n = 10 / 7) 1.3 [0.9–1.9] 1.4 [0.9–1.9] 2.3 [1.4–3.4] 2.4 [1.5–3.4] 
Other children (n = 17 / 17) 1.2 [0.9–1.6] 1.2 [0.9–1.6] 2.2 [1.4–3.2] 2.3 [1.4–3.2] 
Adolescents (n = 16 / 16) 0.7 [0.4–0.9] 0.7 [0.4–0.9] 1.4 [0.9–2.0] 1.4 [0.9–2.0] 
Adults (n = 16 / 16) 0.5 [0.4–0.6] 0.5 [0.4–0.6] 1.0 [0.8–1.3] 1.0 [0.8–1.3] 
Elderly (n = 13 / 13) 0.4 [0.4–0.5] 0.5 [0.4–0.5] 0.8 [0.7–1.0] 0.9 [0.7–1.0] 
Very elderly (n = 11 / 9) 0.4 [0.4–0.5] 0.5 [0.4–0.5] 0.9 [0.6–1.0] 0.9 [0.6–1.0] 
LB: lower bound; n: number of samples; P95: 95th percentile; UB: upper bound. 
Note: In order to avoid the impression of too high precision, the numbers for all exposure estimates are rounded to 2 figures. 
(a): Number of surveys used to derive the minimum/median/maximum mean exposure levels / number of surveys used to 
derive the minimum/median/maximum 95th percentile exposure levels. 
6.2.1.2.  Specific population groups 
Exposure was also assessed for two population groups representing Latvian pregnant and Greek 
lactating women (detailed results available in Appendix E). Mean exposure estimates were 0.4–
0.6 µg/kg b.w. per day, and the 95th percentile estimates were 0.6–1.1 µg/kg b.w. per day. These 
estimates were in the same range as those estimated in the adult population groups representing the 
general population. 
6.2.2. Food groups contributing to the total AA exposure of the general population 
The contribution to AA dietary exposure for 11 food groups and 6 food subgroups was assessed for 
each survey and age group representing the general population. The results are reported as a number of 
surveys for the following contribution ranges: 0–5 %, 5–10 %, 10–25 %, 25–50 % and higher than 
50 % (Tables 9 and 10). For each age group, the minimum and maximum relative contribution in 
percentage to the overall LB and UB mean AA exposure determined across the surveys are also 
provided in Appendix F (Tables F1 and F2).   
For infants, the main contributors to the total exposure were ‘Baby foods, other than processed cereal-
based’, ‘Other products based on potatoes’ and ‘Processed cereal-based baby foods’, representing 
respectively up to 60, 48 and 30 % of the total LB average exposure level in some infants groups. 
These were followed by ‘Other products based on cereals’, ‘Biscuits, crackers, crisp bread’ and 
‘Breakfast cereals’ and ‘Soft bread’, representing respectively up to 29, 20, 19 and 19 % of the total 
LB average exposure level. The ‘Potato fried products (except potato crisps and snacks)’ was not 
representing more than 8.8 % of the total LB average exposure, whereas the ‘Potato crisps and 
snacks’, ‘Porridge’, ‘Cake and pastry’, ‘Savoury snacks other than potato-based’ and ‘Other products 
not based on cereals, potatoes and cocoa’ were not contributing to more than 5 % of the total LB 
average exposure.  
For toddlers, other children and adolescents, the main contributor to the total LB average exposure 
was ‘Potato fried products (except potato crisps and snacks)’, representing in almost all the groups 
(42/44) more than 10 %, and up to 51 % of the total exposure. The ‘Soft bread’, ‘Breakfast cereals’, 
‘Biscuits, crackers, crisp bread’, ‘Other products based on cereals’ and ‘Other products based on 
potatoes’ could also contribute to more than 25 % of the total LB average exposure in some population 
groups. ‘Baby foods, other than processed cereal-based’ and the ‘Other products based on cocoa’ did 
not contribute to more than 10 % of the total LB average exposure in any population group, whereas 
the ‘Coffee’, ‘Coffee substitutes’, ‘Porridge’, ‘Savoury snacks other than potato-based’, ‘Other 
products not based on cereals, potatoes and cocoa’ did not represent more than 5 % of the total LB 
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average exposure. ‘Processed cereal-based baby foods’ represented up to 14 % of the total LB average 
exposure in the groups of toddlers. ‘Cake and pastry’ represented up to 15 % of the total LB average 
exposure in the groups of other children and adolescents. ‘Potato crisps and snacks’ represented up to 
11 % of the total LB average exposure in the groups of adolescents. 
The AA exposure patterns were more various in the groups of adults, elderly and very elderly. The 
two food groups always representing more than 5 % of the total LB average exposure were ‘Potato 
fried products (except potato crisps and snacks)’ and ‘Soft bread’, contributing respectively up to 49 
and 23 % of the total LB average exposure in certain population groups. ‘Coffee’ was another main 
contributor representing up to 34 % of the total LB average exposure. ‘Biscuits, crackers, crisp bread’ 
and ‘Other products based on potatoes’ were found to contribute up to 24 % of the total LB average 
exposure, whereas ‘Other products based on cereals’, ‘Cake and pastry’, ‘Porridge’ and ‘Breakfast 
cereals’ respectively represented up to 18, 14, 11 and 10 % of the total LB average exposure. The 
other products (‘Coffee substitutes’, ‘Potato crisps and snacks’, ‘Baby foods, other than processed 
cereal-based’, ‘Processed cereal-based baby foods’, ‘Savoury snacks other than potato-based’, ‘Other 
products based on cocoa’ and ‘Other products not based on cereals, potatoes and cocoa’) were not 
contributing to more than 8.7 % of the total LB average exposure. 
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Table 9:  Number of surveys split according to their percentage contribution to chronic dietary exposure to AA using lower bound (LB) concentrations 
across the children age groups 
Food group Toddlers Other children Adolescents 
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Potato fried products (except potato crisps and snacks) 1 1 6 2 - - - 11 6 - - - 9 6 1 
Potato crisps and snacks 8 2 - - - 10 7 - - - 6 9 1 - - 
Soft bread 1 3 5 1 - 1 4 11 1 - 1 2 13 - - 
Breakfast cereals 4 2 3 1 - 7 7 3 - - 9 5 2 - - 
Biscuits, crackers, crisp bread 2 1 6 1 - 3 - 13 1 - 4 1 11 - - 
Coffee 10 - - - - 17 - - - - 16 - - - - 
Coffee substitutes 10 - - - - 17 - - - - 16 - - - - 
Baby foods, other than processed cereal-based 8 2 - - - 17 - - - - 16 - - - - 
Processed cereal-based baby foods  8 1 1 - - 17 - - - - 16 - - - - 
Other products based on cereals, potatoes and cocoa - - - 9 1 - - 2 14 1 - - 4 11 1 
Porridge 10 - - - - 17 - - - - 16 - - - - 
Cake and pastry 6 4 - - - 5 10 2 - - 4 10 2 - - 
Savoury snacks other than potato-based  10 - - - - 17 - - - - 16 - - - - 
Other products based on cereals 1 4 4 1 - - 9 7 1 - 3 7 5 1 - 
Other products based on potatoes - 3 6 1 - 2 5 10 - - 4 4 8 - - 
Other products based on cocoa 9 1 - - - 10 7 - - - 11 5 - - - 
Other products not based on cereals, potatoes and cocoa  10 - - - - 17 - - - - 16 - - - - 
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Table 10:  Number of surveys split according to their percentage contribution to chronic dietary exposure to AA using lower bound (LB) concentrations 
across the adults age groups 
Food group Adults Elderly Very elderly 
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Potato fried products (except potato crisps and snacks) - 1 9 6 - - 2 9 2 - - 1 8 2 - 
Potato crisps and snacks 14 2 - - - 3 - - - - 11 - - - - 
Soft bread - 1 15 - - - - 13 - - - - 11 - - 
Breakfast cereals 13 2 1 - - 10 3 - - - 8 3 - - - 
Biscuits, crackers, crisp bread 1 6 9 - - 1 4 8 - - 1 2 8 - - 
Coffee 5 3 8 - - 2 2 8 1 - 4 - 6 1 - 
Coffee substitutes 16 - - - - 11 2 - - - 9 2 - - - 
Baby foods, other than processed cereal-based 16 - - - - 13 - - - - 11 - - - - 
Processed cereal-based baby foods  16 - - - - 13 - - - - 11 - - - - 
Other products based on cereals, potatoes and cocoa - - 4 12 - - - 2 11 - - - 1 10 - 
Porridge 15 1 - - - 11 1 1 - - 10 1 - - - 
Cake and pastry 6 8 2 - - 5 5 3 - - 5 3 3 - - 
Savoury snacks other than potato-based  16 - - - - 13 - - - - 11 - - - - 
Other products based on cereals 3 9 4 - - 7 3 3 - - 5 3 3 - - 
Other products based on potatoes 2 3 11 - - - - 13 - - - - 11 - - 
Other products based on cocoa 16 - - - - 13 - - - - 11 - - - - 
Other products not based on cereals, potatoes and cocoa  15 1 - - - 12 1 - - - 11 - - - - 
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6.2.3. Exposure levels resulting from home-cooking, preference for particular products and 
places of consumption 
In addition to the baseline exposure scenario, specific scenarios were considered in order to assess the 
influence of specific home-cooking behaviours and to reflect preference for particular products and 
places of consumption on the total dietary exposure to AA. The occurrence levels used for each of 
these scenarios are described in Appendix D (Tables D2 to D8). In each scenario, the exposure is 
assessed in a similar manner as for the baseline exposure scenario (see Sections 3.1.1.2 and 3.1.1.3). 
Detailed results for each scenario are provided in Appendix G. Tables 11, 12, 13 and 14 present the 
ranges (minimum, median and maximum) of the mean and 95th percentile exposure levels across the 
different surveys and age groups, obtained from the different scenarios and expressed as percentage 
difference from the baseline exposure scenario. Whereas all surveys and age groups were used to 
derive the ranges of the mean exposure levels, only the ones with more than 60 subjects were used to 
derive the ranges of the 95th percentiles. 
6.2.3.1. Home-cooking habits and places of consumption 
French fries and fried potatoes  
Three scenarios were considered in order to reflect the cooking habits (according to instructions in 
packaging or consumers’ preferences) and the places of consumption of the product. 
Scenario A1 simulated the situation where all the ‘French fries and potato fried’ consumed at home 
and in restaurants would be prepared according to the cooking instructions on the pack of pre-cooked 
products. For this scenario, only the dataset provided by food associations was used to estimate the 
average AA level in ‘French fries and potato fried’ (Appendix D, Table D2). Indeed, the 
corresponding products have been prepared as for consumption according to the instructions, whereas 
high uncertainty relies on the conditions of preparation of the ‘French fries and potato fried’ for the 
results provided by the European countries. As shown in Table 11, compared to the baseline scenario 
where all the data available on the ‘French fries and potato fried’ were considered, this scenario 
resulted in a decrease in the mean and 95th percentile exposure levels up to respectively 16 and 22 %, 
depending on the survey and age group. 
Scenario A2 simulated the situation where all the ‘French fries and potato fried’ are consumed in 
restaurants and prepared according to the current cooking practices, as reflected in the samples taken 
by the European countries in the framework of the official monitoring programs. For this scenario, 
only the dataset on the ‘French fries and potato fried, fresh or pre-cooked, sold as ready-to-eat’ were 
considered (Appendix D, Table D3). As shown in Table 11, compared to the baseline scenario where 
all the data available on the ‘French fries and potato fried’ were considered, this scenario resulted in an 
increase in the mean and 95th percentile exposure levels up to respectively 3.1 and 4.8 %, depending 
on the survey and age group. 
Finally, Scenario A3 simulated the consumers’ preference for crispy and brown ‘French fries and 
potato fried’. In this scenario, it was considered that the level of AA in all consumed ‘French fries and 
potato fried’ was at the 95th percentile of AA level observed in ‘French fries and potato fried, fresh or 
pre-cooked, sold as fresh or pre-cooked and prepared as consumed’, i.e. 656 µg/kg (Appendix D, 
Table D4). Figure 7 shows the AA levels according to colour and cooking time of some pre-cooked 
French fries products for home cooking to illustrate the appearance of ‘French fries and potato fried’ 
containing 656 µg/kg.  
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Figure 7:  Level of AA according to colour and cooking time of some pre-cooked French fries 
products for home cooking (Lauren Jackson, 2014, personal communication) 
As shown in Table 11, compared to the baseline scenario where all the data available on the ‘French 
fries and potato fried’ were considered, this scenario resulted in an increase in the mean and 
95th
 
percentile exposure levels up to respectively 64 and 80 %, depending on the survey and age 
group. 
This specific scenario illustrates the influence of the cooking habits of ‘French fries and potato fried’ 
on the total exposure to AA. 
Table 11:  Exposure to AA obtained from Scenarios A1, A2 and A3, expressed in percentage 
difference from the baseline exposure scenario 
S Age group 
Mean P95 
n 
Median [Min; Max]
(a)
 
n 
Median [Min; Max]
(a)
 
LB UB LB UB 
A1 Infants 6 -0.3 [-1.8; 0] -0.2 [-1.4; 0] 5 0 [-7.6; 0] 0 [-2.9; 0] 
A1 Toddlers 10 -4.7 [-9.9; -0.9] -4.3 [-9.7; -0.8] 7 -2.7 [-16; -1.0] -4.9 [-16; -0.4] 
A1 Other children 17 -6.2 [-15; -3.2] -6.0 [-15; -3.1] 17 -8.6 [-20; -4.6] -8.5 [-18; -3.9] 
A1 Adolescents 16 -7.0 [-16; -3.1] -6.8 [-15; -3.0] 16 -10 [-21; -3.8] -11 [-22; -4.3] 
A1 Adults 16 -6.4 [-15; -2.9] -6.1 [-15; -2.8] 16 -11 [-16; -2.6] -10 [-16; -2.9] 
A1 Elderly 13 -4.6 [-9.8; -1.9] -4.4 [-9.6; -1.9] 13 -6.0 [-14; -2.2] -7.4 [-13; -3.0] 
A1 Very elderly 11 -3.8 [-8.2; -1.9] -3.7 [-8.0; -1.9] 9 -7.2 [-15; -3.1] -8.7 [-13; -0.7] 
A2 Infants 6 0.1 [0; 0.4] <0.1 [0; 0.3] 5 0 [0; 1.3] 0 [0; 0.6] 
A2 Toddlers 10 1.0 [0.2; 2.0] 0.9 [0.2; 2.0] 7 0.3 [0; 1.9] 0.4 [0; 3.1] 
A2 Other children 17 1.3 [0.7; 3.1] 1.2 [0.6; 3.0] 17 2.3 [0; 4.3] 2.1 [0.5; 3.9] 
A2 Adolescents 16 1.4 [0.6; 3.1] 1.4 [0.6; 3.1] 16 2.5 [0.7; 4.8] 2.5 [1.1; 4.3] 
A2 Adults 16 1.3 [0.6; 3.0] 1.2 [0.6; 3.0] 16 2.0 [0.3; 3.8] 2.01[0.6; 3.6] 
A2 Elderly 13 0.9 [0.4; 2.0] 0.9 [0.4; 1.9] 13 1.4 [0; 3.5] 1.4 [0; 2.8] 
A2 Very elderly 11 0.8 [0.4; 1.7] 0.8 [0.4; 1.6] 9 2.3 [0; 2.8] 2.5 [0.6; 2.8] 
A3 Infants 6 1.1 [0; 7.6] 0.9 [0; 5.6] 5 4.2 [0; 17] 1.8 [0; 16] 
A3 Toddlers 10 20 [3.8; 41] 18 [3.4; 40] 7 37 [4.7; 65] 36 [3.9; 63] 
A3 Other children 17 26 [13; 62] 25 [13; 61] 17 41 [29; 79] 40 [30; 80] 
A3 Adults 16 26 [12; 62] 25 [12; 61] 16 48 [25; 80] 48 [25; 76] 
A3 Elderly 13 19 [7.9; 41] 18 [7.7; 40] 13 44 [20; 60] 41 [18; 57] 
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S Age group 
Mean P95 
n 
Median [Min; Max]
(a)
 
n 
Median [Min; Max]
(a)
 
LB UB LB UB 
A3 Very elderly 11 16 [7.8; 34] 15 [7.7; 33] 9 48 [20; 64] 47 [20; 65] 
LB: lower bound; n: number of population groups used to derive the corresponding statistics; P95: 95th percentile; 
S: scenario; UB: upper bound. 
When the median, min and max are equal, only one estimate is indicated. In order to avoid the impression of too high 
precision, the numbers for all percentages are rounded to two figures. A ‘0’ means that the percentage difference is null. 
(a):  Expressed in percentage difference from the baseline exposure scenario.  
Toasted bread 
Scenario B1 simulated the consumers’ preference for well toasted bread. In this scenario, it was 
considered that the level of AA in all toasted bread was 100 µg/kg (Appendix D, Table D5). 
According to Figure 8, it corresponds to almost highest value found in toasted bread (see Section 
4.4.2).  
As shown in Table 12, compared to the consumption of toasted bread taken from the market, 
consumption of such toasted bread would result in a percentage increase of the mean exposure levels 
up to 2.4 %, and of the 95th percentile up to 7.6 % depending on the survey and age group. 
 
 
 
 
 
 
Figure 8:  Level of acrylamide according to the toasting time. The picture corresponds to soft bread 
D (made of wheat and rye flour). The slice on the top is not toasted, those below are toasting time 1, 2, 
3, 4 in order from left to right. Source: HEATOX project.
28
 
Table 12:  Exposure to AA obtained from Scenario B1, expressed in percentage difference from the 
baseline exposure scenario 
S Age group 
Mean P95 
n 
Median [Min; Max]
(a)
 
n 
Median [Min; Max]
(a)
 
LB UB LB UB 
B1 Toddlers 10 0 [0; 0.2] 0 [0; 0.2] 7 0 0 
B1 Other children 17 0 [0; 0.6] 0 [0; 0.6] 17 0 [0; 1.6] 0 [0; 3.0] 
B1 Adolescents 16 0 [0; 2.1] 0 [0; 2.0] 16 0 [0; 2.4] 0 [0; 2.1] 
B1 Adults 16 <0.1 [0; 1.3] <0.1 [0; 1.3] 16 0 [0; 1.9] 0 [0; 1.7] 
B1 Elderly 13 0 [0; 2.0] 0 [0; 1.9] 13 0 [0; 3.6] 0 [0; 2.0] 
B1 Very elderly 11 0 [0; 2.4] 0 [0; 2.4] 9 0 [0; 7.6] 0 [0; 4.0] 
LB: lower bound; n: number of population groups used to derive the corresponding statistics; P95: 95th percentile; 
S: scenario; UB: upper bound. 
In absence of any consumption event of potato crisps reported for infants in the available consumption surveys, no specific 
scenario was performed for this age group.  
When the median, min and max are equal, only one estimate is indicated. In order to avoid the impression of too high 
precision, the numbers for all percentages are rounded to 2 figures. A ‘0’ means that the percentage difference is null. 
(a):  Expressed in percentage difference from the baseline exposure scenario.  
Toasting time 
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6.2.3.2. Preference for particular products 
Potato crisps 
Two scenarios were set in order to reflect the preference of consumers for particular products. 
Scenario C1 simulated the situation where all the ‘Potato crisps’ consumed are made from fresh 
potatoes through continuous process, whereas Scenario C2 simulated the situation where all the potato 
crisps consumed are made from potato dough. Only the occurrence data corresponding to the 
characteristics of the potato crisps considered in each scenario were used to estimate the average AA 
levels, as reported in Appendix D, Tables D6 and D7. As shown in Table 13, compared to the baseline 
scenario where all the data available on the potato crisps were considered (absence of preference for 
particular products), these scenarios on preference for particular products resulted in deviations 
representing less than 1.3 % of the mean exposure levels, and less than 3.9 % of the 95th percentile 
exposure levels. This low impact is explained by the fact potato crisps are not a major contributor to 
the total AA exposure. 
Table 13:  Exposure to AA obtained from Scenarios C1 and C2, expressed in percentage difference 
from the baseline exposure scenario 
S Age group 
Mean P95 
n 
Median [Min; Max] 
(a)
 
n 
Median [Min; Max] 
(a)
 
LB UB LB UB 
C1 Toddlers 10 <0.1 <0.1 7 0 0 
C1 Other children 17 <0.1 <0.1 17 0 [0; 0.2] 0 [0; 0.3] 
C1 Adolescents 16 <0.1 [<0.1; 0.1] <0.1 [<0.1; 0.1] 16 <0.1 [0; 0.2] <0.1 [0; 0.2] 
C1 Adults 16 <0.1 <0.1 16 0 [0; 0.2] 0 [0; 0.1] 
C1 Elderly 13 <0.1 <0.1 13 0 [0; 0.1] 0 [0; 0.1] 
C1 Very elderly 11 <0.1 <0.1 9 0 0 
C2 Toddlers 10 -0.2 [-1.0; 0] -0.2 [-1.0; 0] 7 0 [-0.4; 0] 0 [-1.0; 0] 
C2 Other children 17 -0.5 [-0.9; 0] -0.5 [-0.9; 0] 17 -0.7 [-2.3; 0] -0.2 [-1.6; 0] 
C2 Adolescents 16 -0.7 [-1.3; -0.2] -0.7 [-1.3; -0.2] 16 -1.4 [-3.9; 0] -1.2 [-3.9; 0] 
C2 Adults 16 -0.4 [-0.8; -0.1] -0.3 [-0.8; -0.1] 16 -0.2 [-2.3; 0] -0.3 [-2.2; 0] 
C2 Elderly 13 0 [-0.3; 0] 0 [-0.3; 0] 13 0 [-2.2; 0] 0 [-2.2; 0] 
C2 Very elderly 11 0 [-0.2; 0] 0 [-0.2; 0] 9 0 0 
LB. lower bound; n: number of population groups used to derive the corresponding statistics; P95: 95th percentile; 
S: scenario; UB: upper bound.  
In absence of any consumption event of toasted bread reported for infants in the available consumption surveys, no specific 
scenario was performed for this age group. 
When the median, min and max are equal, only one estimate is indicated. In order to avoid the impression of too high 
precision, the numbers for all percentages are rounded to 2 figures. A ‘0’ means that the percentage difference is null. 
(a):  Expressed as percentage difference from the baseline exposure scenario. 
Coffee 
Scenario D1 simulated the consumers’ preference for light roasted coffee. In this scenario, only the 
data corresponding to light roasted coffee were used to estimate the AA level in the different coffee 
beverages (Appendix D, Table D8). As observed in Table 14, compared to the baseline scenario where 
all kind of roasted coffee were considered (absence of consumer’s preference), the consumption of 
light roasted coffee would result in an increase of the average and 95th percentile exposure levels of 
respectively up to 14 % and 13 % depending on the population group among the adults, elderly and 
very elderly age groups. Coffee not being a major contributor to the total AA exposure of toddlers, 
other children and adolescents, this scenario poorly impacted the total AA exposure estimates: less 
than 1.3 % of the average and 95th percentile exposure levels. 
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Table 14:  Exposure to AA obtained from Scenario D1, expressed in percentage difference from the 
baseline exposure scenario  
S Age group 
Mean P95 
n 
Median [Min; Max]
(a)
 
n 
Median [Min; Max]
(a)
 
LB UB LB UB 
D1 Toddlers 10 <0.1 <0.1 7 0 0 
D1 Other children 17 <0.1 [0; 0.7] <0.1 [0; 0.7] 17 0 0 [0; 1.3] 
D1 Adolescents 16 0.1 [<0.1; 0.9] 0.1 [<0.1; 0.9] 16 0 [0; 0.4] 0 [0; 0.5] 
D1 Adults 16 2.1 [0.3; 10] 2.1 [0.3; 9.9] 16 1.7 [0; 12] 1.8 [0; 13] 
D1 Elderly 13 2.7 [0.2; 12] 2.6 [0.2; 12] 13 3.7 [0; 12] 1.4 [0; 13] 
D1 Very elderly 11 1.6 [0.2; 14] 1.6 [0.2; 14] 9 2.3 [0; 9.1] 2.3 [0; 6.6] 
S: scenario; n: number of population groups used to derive the corresponding statistics; LB: lower bound, UB: upper bound; 
P95: 95th percentile.  
Due to the very low number of consumption events of coffee reported for infants in the available consumption surveys, no 
specific scenario was performed for this age group. 
When the median, min and max are equal, only one estimate is indicated. In order to avoid the impression of too high 
precision, the numbers for all percentages are rounded to 2 figures. A ‘0’ means that the percentage difference is null. 
(a):  Expressed as percentage difference from the baseline exposure scenario. 
6.2.4. Considerations on unspecified and/or raw potato products 
A total of 7 562 out of 137 278 (6 %) consumption events of potato products (potato crisps and other 
snacks excluded) available in the Comprehensive database were indicated as raw or unspecified 
potato.  
In the framework of this assessment, and for all age groups other than infants, these consumption 
events have been considered as ‘French fries and potato fried’ when more than 5 % oil/fat for frying 
was consumed during the same meal. They have been considered as not fried potato and potato 
products in the other cases (see Section 5.1). To assess the impact of such assumption, two extreme 
scenarios were considered:  
 Assuming all these consumption events as non-fried potato and potato products: under this 
scenario, the average and 95th percentile exposure estimates for a few consumption surveys 
could be up to 31 and 33 % lower, respectively, than in the baseline exposure scenario.   
 Assuming all these consumption events as ‘French fries and potato fried’: under this scenario, 
the average and 95th percentile exposure estimates for a few consumption surveys could be up 
to 49 and 78 % higher, respectively, than in the baseline exposure scenario.  
For infants, in the framework of this assessment, these consumption events have been attributed to 
non-fried potatoes (see Section 5.1). To evaluate the impact of this assumption, a scenario considered 
the possibility that all these consumption events correspond to ‘French fries and potato fried’. This 
resulted in average and 95th percentile exposure estimates up to 9 and 13 % higher, respectively, than 
the baseline exposure scenario, although for one consumption survey it resulted in estimates 55 and 
121 % higher.  
6.3. Previously reported human exposure assessments 
Several international bodies have estimated the dietary exposure to AA while performing their risk 
assessments related to the presence of AA in food (see Section 1.1). The highest estimates were 
reported by JECFA, which concluded in 2005 that AA dietary exposure estimates were 1 μg/kg b.w. 
per day at the mean, and 4 μg/kg b.w. per day for a consumer at a high percentile of the distribution 
(FAO/WHO, 2006). These estimates also included children. In 2010, these estimates were updated 
using data submitted to JECFA and taken from the literature. Additionally, regional estimates were 
prepared using GEMS/Food data. Brazil, China, France, Ireland, New Zealand, Norway, Spain and the 
UK provided AA occurrence and dietary exposure information. The estimates of dietary exposure 
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from these national data ranged from 0.2 to 1 μg/kg b.w. per day for the general population, including 
children, and from 0.6 to 1.8 μg/kg b.w. per day at high (95th to 97.5th) percentiles. The major foods 
contributing to dietary exposure were potato products (crisps and French fries), breads and rolls, and 
pastry and sweet biscuits (cookies). No trends could be evaluated between the 2005 and 2010 
estimates. The regional estimates for the 13 GEMS/Food cluster diets ranged from 1.1 to 4.8 μg/kg 
b.w. per day. JECFA concluded that because of waste and collection of information at the household 
level, these estimates were comparable to the high percentile estimates made using individual data, as 
submitted for the national estimates. The JECFA further concluded that no changes had occurred in 
dietary exposure to AA between the 2005 and the 2010 evaluations and retained the 1 μg/kg b.w. per 
day and 4 μg/kg b.w. per day estimates for safety evaluation purposes (FAO/WHO, 2011). 
Since then, studies of dietary exposure to AA for populations and sub-populations in several European 
countries and others have been published and are summarised below for the general population 
(adults) (Appendix H, Table H1) and for infants, toddlers, other children and adolescents (Appendix 
H, Table H2). In addition, other studies have focused on the intake of AA through typical dishes 
(Delgado-Andrade et al., 2010).  
6.3.1. General population (adults) 
Dietary exposure to AA in the general population of Poland was assessed in a study using a 
probabilistic approach using a household survey of food consumption and analytical values for AA 
levels in 225 food samples (Mojska et al., 2010). The highest AA levels were found in ‘potato crisps’. 
The mean (95th percentile) exposure to AA for adults (19–96 years old) was 0.33 (0.69) μg/kg b.w. 
per day. ‘Fried potato products’, ‘breads’ and ‘coffee’ were the major contributing food groups. In 
another study in a chosen population of South Poland, a 2–fold higher AA dietary exposure was found 
(0.85 μg/kg b.w. per day) (Zając et al., 2013). The authors used a semi-quantitative FFQ 
(1 470 participants) and the concentration of AA in each food group were from the European AA 
monitoring database from June 2006. The main contributors to the AA intake in all age groups were 
‘bakery products’ followed by ‘crisps’ (i.e. potato crisps).    
Claeys et al. (2010) estimated the AA intake of the Belgian population (15 years old or older) based on 
the AA monitoring data of the Belgian Agency for the Safety of the Food Chain. The consumption 
data were obtained from the Belgian Food Consumption Survey of 2004 (3 214 participants) based on 
a repetitive non-consecutive 24-hour recall in combination with self-administered FFQ. The intake 
was estimated using a probabilistic approach resulting in an average intake (middle bound) of 
0.35 μg/kg b.w. per day, and for high consumers (P97.5) of 1.58 μg/kg b.w. per day. The main 
contributors to the intake were ‘chips’ (i.e. French fries), ‘coffee’, ‘biscuits’ and ‘bread’.  
In Finland, Hirvonen et al. (2011) estimated the dietary AA exposure of Finnish adults combining the 
Finnish occurrence data reported in the literature and the food consumption data from the FINDIET 
2007 survey (2 038 adult participants, 25–44 years old). The estimated median (97.5th percentile) 
exposure for adults was 0.44 (1.16) μg/kg b.w. per day for women, and 0.41 (0.87) μg/kg b.w. per day 
for men. The main contributor to the AA intake was ‘coffee’ followed by ‘starch-rich casserole’, ‘rye 
bread’ and ‘biscuits’. 
Data from the Second French Total Diet Study (TDS) were used to estimate dietary exposure to AA 
for adults from different regions in France (Sirot et al., 2012; ANSES, 2013). A total of 192 food 
samples were prepared ‘as consumed’ and analyzed for AA. The highest concentrations were found in 
fried potato products and salted biscuits. The mean dietary exposure to AA was 0.43 μg/kg b.w. per 
day and the corresponding 95th percentile exposure was 1.02 μg/kg b.w. per day. The main 
contributing foods were ‘French fries’, ‘potato crisps’, ‘biscuits’ and ‘coffee’.    
Chan-Hon-Tong et al. (2013) estimated the exposure to AA for French women before and during 
pregnancy. The consumption data were obtained from the EDEN mother-child cohort by means of a 
FFQ in the year before pregnancy and during the last three months of pregnancy (n = 1 861). The AA 
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occurrence values were taken from the Second French TDS study as above. The mean (95th 
percentile) UB exposure before pregnancy was estimated at 0.404 (0.969) μg/kg b.w. per day, while at 
the third trimester of pregnancy the exposure estimates were lower, at 0.285 (0.712) μg/kg b.w. per 
day. The authors attributed the decrease in exposure partly to the increase of body weight that was not 
compensated by an increase of food intake. No significant difference in the intake of the major 
contributors to the AA intake was observed before and during pregnancy, although a decrease in the 
consumption of coffee was observed during pregnancy.       
Within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, Freisling et al. 
(2013) estimated the AA intake in 27 centres of 10 European countries. A total of 39 994 participants, 
aged 35–74, completed a standardized 24-hour dietary recall. The mean intake (minimally adjusted by 
gender) across centres ranged from 12 to 41 μg per day for women and from 15 to 48 for men. The 
main contributors to the intake were the food groups ‘bread, crisp bread, rusks’, followed by ‘coffee’ 
and ‘potatoes’. It was observed that intakes were higher in northern European countries.  
In New Zealand, two exposure assessment methods were employed by the Food Standards Australia 
New Zealand in their updated dietary exposure assessment for AA (MAF, 2012). The first was a 
deterministic method that employed model diets based on the New Zealand TDS. The second 
assessment used a dietary modelling approach with food consumption data from 24-hour dietary 
recalls taken from a national nutrition survey. The dietary modelling mean estimates for males aged 
11–14, 19–24 and over 25 years old were 1.36, 1.01 and 0.84 μg/kg b.w. per day, respectively. The 
authors stated that it was not possible to say whether these estimates, which are higher than other 
national estimates, differed because of true differences in exposure or modelling methodology and 
assumptions. Using  published  ‘usual intake’ methods yielded 95th percentile estimates (1.15–
3.31 μg/kg b.w. per day) that were within the range of equivalent estimates from other countries. 
Potato products, bread, breakfast cereals and beverages were the major foods contributing to the 
dietary AA exposure. It was noted that the contribution of potato crisps to AA exposure appears to 
have decreased between 2006 and 2011 and the contribution from potato, hot chips (i.e. French fries) 
and oven baked/roasted potatoes appears to have increased (MAF, 2012). 
In the US, Tran et al. (2010) estimated the mean exposure of adults at 0.39 and 0.33 µg/kg b.w. per 
day for male and females, respectively, based on the NHANES (2003-04) 24-hour dietary recall 
consumption data and the occurrence in food products performed by the US-FDA.   
In China, the average and 95th percentile AA dietary exposure (middle bound) in the general 
population has been estimated at 0.286 and 0.490 µg/kg b.w. per day, respectively (Zhou et al., 2013). 
A total of 144 food composite samples were analysed, based on TDS studies in four regions of China. 
The consumption data were collected by the Chinese Center for Disease Control and Prevention in 
2000 based on a three-day household dietary survey and 24-hour recall. Levels of AA in most foods 
were similar to those reported in other countries, except for cereals and potatoes which were found to 
contain AA at lower levels. The authors concluded that this was probably due to different cooking 
temperatures and raw materials (Zhou et al., 2013). The main contributors to the dietary AA exposure 
were ‘vegetables’, followed by ‘cereals’ and ‘potatoes’, again showing a different pattern compared to 
other countries, pointing the authors to different food consumption habits. Dietary exposure to AA for 
adults 20–85 years old in Hong Kong was assessed using data from the 2005–2007 Hong Kong 
Population-based Food Consumption Survey in combination with 95 food samples analyzed for AA 
(FEHD, 2012). The highest AA levels were found in ‘potato chips’ (i.e. potato crisps) and ‘snack 
biscuits’. Exposure was 0.13 μg/kg b.w. per day at the mean, and 0.69 μg/kg b.w. per day at the 
97.5th percentile.  
6.3.2. Infants, toddlers, other children and adolescents 
Mojska et al. (2012) analysed 111 commercially made Polish baby food products including follow-on 
formula, infant cereals, biscuits for infants and jarred baby food. The estimated AA dietary intake for 
non-breast-fed infants (6–12 months old) considering the minimum, average and maximum AA 
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concentration found in those products ranged from 0.4 to 0.6, from 2.10 to 4.32, and from 7.47 to 
12.35 μg/kg b.w. per day. For infants aged six months, jarred baby food and follow-on formula were 
the major contributors the AA intake despite their low AA content. For infants older than six months, 
cereals were the major contributor to the intake.  
In Poland, Mojska et al. (2010) estimated the mean exposure to AA at 0.75 μg/kg b.w. per day for 
children 1–6 years old, and at 0.62 μg/kg b.w. per day for children 7–18 years old. The corresponding 
95th percentile exposures were 2.88 and 2.45 μg/kg b.w. per day. The authors noted that exposures 
were higher for boys compared to girls. Zając et al. (2013) estimated the mean (95th percentile) 
exposure to children aged 6–12 years old at 1.51 (2.86) μg/kg b.w. per day) in a chosen population in 
South Poland.  
The dietary intake of Finnish toddlers and children (1, 3 and 6 years old) was estimated by Hirvonen et 
al. (2011). The highest median (97.5th percentile) AA intakes were estimated for three year-old 
children at 1.01 (1.95) µg/kg b.w. per day followed by the 6 year-old group at 0.87 (1.53) µg/kg b.w. 
per day. The 1-year old group showed median intakes of 0.4 µg/kg b.w. per day. The major 
contributor to the intake was casseroles, biscuits, chips (presumably potato crisps) and other types of 
fried potatoes. 
In Turkey, Cengiz and Gündüz (2013) estimated the mean (95th percentile) AA intake  for toddlers 
(1–3 years old) at 1.43 (3.76) μg/kg b.w. per day. Bread was reported to the highest contributor to the 
exposure, followed by crackers, biscuits and baby biscuits.   
Sirot et al. (2012) also estimated the AA intake for French children from 3 to 17 years old. The mean 
(95th percentile) dietary exposure to AA was 0.69 (1.80) μg/kg b.w. per day. The highest exposure 
was estimated for children 3–6 years old with a mean (95th percentile) exposure of 0.89 (1.864) μg/kg 
b.w. per day. Older children had lower estimates of mean exposure. The main contributing foods to the 
exposure were potatoes (French fries) and biscuits.   
The mean exposure to AA of US children (3–12 years old) was estimated at 0.86 µg/kg b.w. per day, 
based on the NHANES (2003-04) 24-hour dietary recall consumption data and the occurrence in food 
products performed by the US-FDA (Tran et al., 2010). Katz et al. (2012) published a study comparing 
estimates of dietary exposure to AA for teenagers (13–19 years old) from Western diets and 
‘guideline’ diets (suggested food consumption from ‘Dietary Guidelines for Americans, 2005’). The 
means from these analyses were 0.44 and 0.50 μg/kg b.w. per day, respectively. The 95th percentiles 
were 0.64 and 0.73 μg/kg b.w. per day, respectively.  
Delgado-Andrade et al. (2012) estimated the AA intake of 20 Spanish male adolescents (11–14 years 
old) that participated in a 2-week trial consuming a designed diet based on their eating patterns aimed 
to compose a balance diet. The mean AA intake as estimated at 0.534 µg/kg b.w. per day. The highest 
AA intake was provided by the breakfast (32 %). 
The mean dietary exposure for 10–17 year old non-smoking adolescents in Canada (using a 2-day 
food diary and a 1-month FFQ) was 0.58 μg/kg b.w. per day, with a 95th percentile exposure of 
2.19 μg/kg b.w. per day (Normandin et al., 2013). The mean (95th percentile) estimates using the FFQ 
were 0.20 and 0.44 μg/kg b.w. per day, respectively. The authors noted that these results were similar 
to those published in other countries and attributed any differences to dietary survey design and 
differing dietary patterns between the countries. The highest levels of AA occurred in deep-fried 
potatoes (French fries) and potato chips (i.e. potato crisps) (Normandin et al., 2013).  
6.3.3. Comparison between dietary exposure estimates made in this opinion and previously 
reported exposure assessments  
The estimates of AA intake in the current assessment ranged for the mean exposure from 
0.4 (minimum LB) to 1.9 µg/kg b.w. per day (maximum UB), and for the 95th percentile exposure 
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from 0.6 (minimum LB) to 3.4 µg/kg b.w. per day (maximum UB) across survey and age groups. 
Direct comparison between these dietary exposure estimates and studies published in the literature 
should be made with caution due to the different methodologies used (sampling methods and food 
consumption surveys), food categories/products covered, as well as consumption habits in each 
country/region.  
Considering the data above (see also Appendix H, Table H1 and H2), the exposure estimates in the 
current opinion are in the same range as those reported in the literature, both for adults and infants and 
children.    
6.4. Potential non-dietary sources of exposure 
Until AA was found in food, the main sources of human exposure to AA were considered to occur via 
specific occupations and smoking. 
Occupational exposure might result from the manufacture and use of AA and polyacrylamides at the 
workplace, resulting in the dermal absorption of AA monomers from solution, or inhalation of dry 
monomers or aerosols of AA solution (IARC, 1994). Studies which have measured AA- and GA-Hb 
adducts in different populations (as biomarkers for AA exposure) showed that occupational exposure 
to AA has been considerably higher than in the general population, either in non-smoking or smoking 
groups (Moorman et al., 2012) (see Section 7.4.1.2.7). The NTP-CERHR Expert Panel estimated the 
mean occupational inhalation exposure to range between 1.4 to 18 µg/kg b.w. per day (Manson et al., 
2005). The CONTAM Panel noted that the uncertainties in the magnitude and routes of exposure in 
the workplace make it difficult to compare these estimates to dietary exposure. A detailed evaluation 
of the occupational exposure to AA is beyond the scope of this risk assessment.    
AA is a component of tobacco smoke (US-EPA, 2010; FAO/WHO, 2011), and hence smoking as well 
as passive smoking are an important source of human exposure to AA. Diekmann et al. (2008) 
speculated on the formation pathways of AA in cigarette smoke proposing three possibilities: (i) the 
(reversible) reaction of ammonia with acrylic acid and acetic acid (all present in mainstream smoke) 
that would result in AA (and acetamide) formation, (ii) through the Maillard reaction from the 
condensation of asparagine and reducing sugars (both reported to be present in tobacco), and 
(iii) through the oxidation of acrolein to acrylic acid, that would then react with ammonia to form AA. 
The levels of AA in tobacco from cigarettes have been reported to range from 50.3 to 119.6 ng/g, 
while other tobacco products (snus, strips or sticks) showed levels ranging from 69.9 to 366.7 ng/g 
(Moldoveanu and Gerardi, 2011). Pérez and Osterman-Golkar (2003) reported concentrations up to 
34 nmol/g (or around 2 420 ng/g) in snuff portion bags (water extract).  
In mainstream cigarette smoke, the levels of AA have been reported to range from 1 100 to 2 340 ng 
per cigarette (Smith et al., 2000) or from 497.1 to 4 168.8 ng per cigarette (Moldoveanu and Gerardi, 
2011).  
Given the presence of AA in mainstream cigarette smoke and the consistent presence of 3-4 times 
higher mean levels of Hb adducts in smokers than in non-smokers (Schettgen et al., 2004a; Vesper et 
al., 2008; von Stedingk et al., 2011; Phillips and Venitt, 2012), the CONTAM Panel concluded that 
tobacco smoking represents a more prominent source of AA exposure than the diet in smokers.  
Non-dietary exposure to AA for the non-smoking general population is thought to be low (ATSDR, 
2012) and it could result from the ingestion of water treated with polyacrylamide containing residual 
AA monomers (ATSDR, 2012). 
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7. Hazard identifications and characterisation 
7.1. Toxicokinetics 
The characteristic features of the fate of AA in mammals were elucidated in one of the first 
toxicokinetic studies, which was performed in male Fischer-334 rats (Miller et al., 1982). After oral 
administration of doses of 1, 10 and 100 mg/kg b.w. of 2,3-
14
C-AA dissolved in water, 53–67 % of the 
administered radioactivity was excreted within 24 hours and 65–82 % within seven days via urine and 
faeces. More than 90 % of the excreted radioactivity appeared in the urine and consisted mostly of 
polar metabolites with less than 2 % as parent AA. After intravenous (i.v.) injection of a dose of 10 
mg/kg b.w., urinary excretion of 62 % after 24 hours and 71 % after seven days was observed, which 
was virtually identical with that after oral administration. This suggests complete absorption of AA 
from the gastro-intestinal (GI) tract. When 
14
C-AA was administered i.v. to bile duct-cannulated rats, 
15 % of the dosed radioactivity was excreted in the bile within six hours, again containing only trace 
amounts of parent AA. 
In the same study, the kinetics of tissue distribution and elimination of radioactivity was studied after 
i.v. injection of 10 mg AA/kg b.w. After one hour, the level of radioactivity plateaued in whole blood 
for seven days. Blood plasma contained 3.4 % of the dose after one hour, which declined thereafter 
with time in a biphasic manner. The administered radioactivity was rapidly distributed to liver, kidney, 
lung, muscles, brain, testes, sciatic nerve, spinal cord, skin, fat and small intestine. All tissues reached 
about the same concentrations of radioactivity, and no difference in distribution and elimination was 
noted between neural and non-neural tissues. Elimination from tissues was biphasic with half-lives of 
5–8 hours for the initial phase and about eight days for the second phase, which was believed to be due 
to the slow degradation of covalent adducts of AA with tissue proteins. A significant proportion of the 
radioactivity, i.e. about 12 % of the dose, was retained in red blood cells, which might be due to 
covalent binding of AA and its epoxide metabolite GA (Miller et al., 1982). 
The propensity of AA for extensive absorption from the GI tract, rapid distribution into all organs, 
extensive metabolism, preferential urinary excretion of metabolites and covalent binding to tissue 
macromolecules have been confirmed in numerous subsequent studies. 
7.1.1. Absorption and distribution 
AA is rapidly (t1/2 < 10 min) and extensively absorbed following gavage administration of aqueous 
solutions in mice (Doerge et al., 2005a) and rats (Doerge et al., 2005b). The determination of AA 
bioavailability is complicated because of the similarly rapid and extensive metabolism to GA in 
rodents.  The GA/AA AUC ratios observed after i.v. and gavage administration of a common AA dose 
(100 µg/kg b.w.) were 32–52 % in mice and 60–98 % in rats (Doerge et al., 2005a,b).  For 
comparison, the oral bioavailability of GA, for which no complicating metabolic conversion occurs, 
was quantitative in mice and rats (Doerge et al., 2005a,b). Oral administration of AA increases the 
metabolism to GA, relative to i.v. administration, by increasing the conversion efficiency. In mice, the 
GA/AA AUC ratio went from 0.42–1.1 following i.v., to 2.4–2.9 following gavage, and 1.7–
2.7 following dietary administration (Doerge et al., 2005a), and from 0.14–0.13 following i.v., to 0.57–
0.96 following gavage, and 1.0 following dietary administration in rats (Doerge et al., 2005b). The 
route-dependence of GA formation was interpreted as reflecting pre-systemic metabolism by CYP2E1 
in the liver following portal vein delivery from the GI tract.   
In a recent study by Kim et al. (2015a), a dose of 2 mg AA/kg b.w. dissolved in water was 
administered orally or i.v., and the plasma levels and urinary excretion of AA and GA were measured 
by LC-MS/MS. AA was rapidly and extensively absorbed after gavage administration, reaching the 
maximum plasma concentration at 0.5 hours. Plasma half-lives of AA and GA were 1.3 and 1.9 hours, 
respectively, after oral gavage. Metabolic conversion of AA to GA was more rapid and extensive after 
oral than after i.v. administration, supporting the assumption that orally administered AA is subject to 
a significant pre-systemic metabolism. 
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Using the formation of Hb adducts in blood (see Sections 7.1.2.1 and 7.2.2) as endpoint, a study in 
Wistar rats of different age and sex suggested that the absorption of AA may be higher in female than 
in male and in younger than in older rats (Sánchez et al., 2008). The CONTAM Panel noted, however, 
that this study was conducted with very high doses of AA (25-100 mg/kg b.w.), which lead to 
systemic concentrations possibly causing enzyme and metabolic saturation, and may not reflect the 
absorption of AA at the dietary intake level.  
Studies in various mammalian species (Table 15) have confirmed that AA is rapidly and virtually 
completely absorbed from the GI tract. Due to its high aqueous solubility and distribution in the total 
body water, AA is freely distributed into tissues. AA also reaches the fetus and human milk (see 
further in this section).   
The high absorption of AA from the GI tract in most experimental animals and in humans after oral 
administration is also indicated by the high recovery of the dosed AA as urinary metabolites (see 
Section 7.1.3). 
In comparison with other animal species, hens appear to be less efficient in absorbing AA from the 
GI tract because the percentage of the dose found in tissues was almost an order of magnitude smaller 
than in rats (Blumenthal et al., 1995).  
In vitro studies using differentiated Caco-2 cells, which represents a well-established in vitro model 
for human intestinal absorption, also indicate that AA is readily absorbed and permeates through cell 
membranes via passive diffusion (Schabacker et al., 2004; Zödl et al., 2007).  
When AA was preincubated with chicken egg albumin as a surrogate of dietary proteins, the AA 
uptake through the Caco-2 cell monolayer was significantly lower than without albumin (Schabacker 
et al., 2004). The authors assumed that AA reacts with nucleophilic groups of albumin and concluded 
that the food matrix may have a significant influence on the intestinal absorption of AA.  
Distribution of AA into tissues was measured in mice at one and two hours after gavage administration 
and GA levels were consistently higher at both time points (Doerge et al., 2005a). In rats, tissue levels 
of AA and GA were measured at two and four hours post-gavage dosing and AA levels were generally 
higher than GA (Doerge et al., 2005b). The levels of AA and GA in the tissues sampled (lung, muscle, 
brain in mice and muscle, brain, testes, and mammary in rats) were similar to the respective serum 
concentration, reflecting the distribution in total cellular water as suggested by the volumes of 
distribution of 0.6–0.8 L/kg b.w. and high aqueous solubilities (Doerge et al., 2005a,b). Tissue levels 
were similar to each other except that AA and GA levels in liver were consistently lower. This 
difference was interpreted as reflecting the high metabolic detoxification capacity in liver (e.g. high 
glutathione (GSH) levels).  
The tissue distribution of AA and GA under steady-state conditions was determined by LC-MS/MS in 
plasma and fourteen tissues of rats after i.v. infusion of AA (2 µg/minute/kg b.w.) for 12 hours. 
Steady-state concentrations of AA and GA were reached in plasma within 2 hours after infusion was 
initiated; GA concentration was about 30 % of AA concentration in plasma. AA concentration ranged 
from 30 to 56 % of the plasma concentration in most tissues, with a minimum of 12 % in the small 
intestine. GA concentration in most tissues was between 58 % (in kidney) and 135 % (in thyroid) of 
plasma concentration. No GA could be detected in liver, testis and small intestine (Kim et al., 2015a). 
These findings indicate that AA and GA are rapidly cleared from blood and easily distributed to 
various tissues. 
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Table 15:  Studies on the absorption and tissue distribution of acrylamide (AA) in various species and strains after oral administration 
Species  
(strain, gender) 
Label of 
AA 
Dose of AA 
(mg/kg b.w.) 
Major findings Reference 
Rat  
(SD, F) 
1-
14
C 50 
Peak plasma concentration of RA after 38 minutes, then decline with t1/2 of 6 hours; concentration 
of RA comparable in various target- and non-target tissues but higher in blood  
Kadry et al. 
(1999) 
Rat  
(SD, M) 
2,3-
14
C 20 
Peak plasma concentration of RA after 60–90 minutes, then decline with t1/2 of 2 hours, equal 
concentrations in muscle, spinal cord and sciatic nerve but 2-fold higher in erythrocytes after 12 
hours 
Barber et al. 
(2001) 
Rat  
(F344, M and F) 
None 0.1 
Peak plasma concentration of AA after 60 minutes (F) and 120 minutes (M); F have higher 
bioavailability and plasma concentration of AA; M have longer t1/2 for plasma elimination of AA 
Doerge et al. 
(2005a) 
Mouse  
(SENCAR, M) 
(BALB/c, M) 
2,3-
14
C 100 
Comparable concentrations of RA in lung, stomach, skin and liver, elevated in testis; no strain 
difference in concentrations and time courses of RA  
Carlson and 
Weaver (1985) 
Mouse  
(SW, M and F) 
2,3-
14
C 120 
No notable accumulation of RA in peripheral nerves, but in the male reproductive tract (testis and 
epididymis), in epithelia of oesophagus and stomach, and in fetal skin 
Marlowe et al. 
(1986) 
Mouse  
(B6C3F1, M and F) 
None 0.1 
Peak serum concentration of AA after 15 minutes, then decline with t1/2 of 1.5 hours; 
concentration of AA similar in serum, liver, lung, muscle, and brain after 1 or 2 hours 
Doerge et al. 
(2005b) 
Dog  
(Beagle, M) 
1-
14
C 1 
Dosed RA mostly found in muscle, liver, and blood, little RA in brain, testis, lung, kidney, spleen, 
heart, bile, and fat; uniform distribution of RA in various areas of CNS 
Ikeda et al. (1987) 
Miniature pig  
(HH, M) 
1-
14
C 1 
Dosed RA mostly found in muscle, gastro-intestinal tract, liver, blood, and fat, little RA in brain, 
testis, lung, kidney, spleen, heart, and bile; uniform distribution of RA in CNS 
Ikeda et al. (1987) 
Hen  
(White Leghorn) 
2,3-
14
C 50 
Peak blood and plasma concentration between 4 and 12 hours; minimal binding of radioactivity to 
erythrocytes; 0.5 % of dosed radioactivity in eggs within 5 days in non-extractable form 
Blumenthal et al. 
(1995) 
CNS: central nervous system; F: female; F344: Fischer-344; HH: Hormel-Hanford; M: male; RA: radioactivity; SD: Sprague-Dawley; SW: Swiss-Webster. 
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Effect of food matrix 
The effect of the food matrix on the absorption of AA has been studied in experimental animals and in 
human volunteers in vivo. AA is virtually completely absorbed from the GI tract when ingested as an 
aqueous solution. When AA is formed during food processing, it can, in principle,  undergo covalent 
binding to food amino acids, peptides and proteins, due to its electrophilic reactivity as an 
α,ß-unsaturated carbonyl compound, by forming Michael addition products. For example, Rydberg et 
al. (2003) reported that addition of various amino acids (35–140 mmol/kg of potato) or varying 
proportions of fish during the cooking process of potatoes could reduce the levels of AA found in the 
final food. Since only that proportion of AA that is unbound may be absorbed and is analytically 
determined, it is important in the design of studies on the effect of the food matrix on absorption of 
AA, to use food in which AA has been formed during food preparation and determined by chemical 
analysis. Spiking, i.e. addition of AA to the food, may lead to loss of part of the added AA due to 
covalent binding to food constituents, suggesting an apparent reduced absorption (Berger et al., 2011).  
For example, in a study with male Sprague-Dawley rats, various food items containing AA due to their 
preparation at levels resulting in an oral exposure of 50 or 100 µg AA/kg b.w. per day were fed for 1, 
3, 5, 7, and 9 days (Berger et al., 2011). The AA levels were analytically determined. The food items 
were French fries prepared by frying potato sticks from raw potatoes or from potato starch dough 
(dosage 100 µg AA/kg b.w. per day), bread crust from wholemeal rye loaf bread (dosage 50 µg AA/kg 
b.w. per day), and gingerbread made from a wheat and rye flour mixture (dosage 100 µg AA/kg b.w. 
per day). Positive control rats received the same doses of AA in water by oral gavage. Twenty-four 
hours after dosing AA for 1, 3, 5, 7 or 9 days, the amounts of AA, GA and the mercapturic metabolites 
of AA and GA (see Section 7.1.2.1) were determined in urine by HPLC-MS/MS, and the Hb adducts 
of AA and GA (see Section 7.2.2) were measured in blood by GC-MS of the N-terminal AAVal and 
GAVal. No difference in the amounts of urinary metabolites was noted between ingestion of AA from 
water and from French fries or gingerbread, whereas the excretion of urinary metabolites was about 
20 % lower in the bread crust group. This suggests that among the food matrices studied, only bread 
crust causes some reduction in the intestinal absorption of AA in rats. In support of this notion, the 
levels of AA-Hb, which increased about linearly with the cumulative AA uptake via the food items 
and water, were nearly identical in the groups receiving AA in water and those exposed to AA in 
French fries and gingerbread, but about 17 % lower in the bread crust group (Berger et al., 2011). 
These results indicate that the absorption of food-borne AA from the intestinal tract of rats is not 
substantially influenced by the food matrix. 
As discussed above in Section 7.1.1, when rats were fed a chow spiked with AA to achieve a bolus  
exposure of 100 µg AA/kg b.w., a reduced AUC for AA as compared to i.v. injection or oral gavage of 
an aqueous solution was observed (Doerge et al., 2005a). However, administration through the diet, 
relative to i.v. or gavage, also increased the conversion to GA, by altering pre-systemic metabolism.  
The AA content in the fortified chow was measured and did not change during the course of the 
experiment. The loss of AA from the fortified diet was determined to be slow at room temperature 
(half-time 41 days) and undetectable over 28 days at 5 °C (Twaddle et al., 2004).   
In male C5BL/6J mice, the amounts of the major AA metabolites were determined by HPLC-MS/MS 
in the urine excreted during three days after subcutaneous (s.c.) injection of AA (at doses of 0.05, 0.5, 
5 and 50 mg AA/kg b.w. per day) and after dietary AA exposure from crisp bread (at doses of 24, 143 
and 289 µg AA/kg b.w. per day) (Bjellaas et al., 2007a). The AA in crisp bread was formed during 
baking. A linear relationship between AA intake and excretion of urinary AA metabolites was 
observed for both routes of administration. From crisp bread, 55 % of the ingested dose of AA was 
recovered as total urinary metabolites, whereas the respective recovery from urine was 54 % for the 
three lowest doses injected. The authors concluded that this indicates virtually complete oral 
absorption of AA from crisp bread (Bjellaas et al., 2007a). 
The relative absorption of AA from water and from feed containing commercial potato chips (i.e. 
potato crisps) with preparation-related AA was also determined in swine (Aureli et al., 2007). The 
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levels of exposure were 0.8 and 8 µg AA/kg b.w. per day, and the AAVal of the Hb adduct of AA was 
used to assess the amount of absorbed AA. Although the variation of these values was quite large, no 
statistically significant differences between the mean concentrations of the Hb adduct from swine 
receiving AA by drinking water or by potato chips in the feed were detected, again implying no 
restriction of absorption from this food item. 
Home-prepared potato chips (i.e. French fries) were fried to contain an AA concentration of 6.2 µg/g 
and fed to six young healthy Caucasian volunteers (three females and three males) at a dose of 12.4 µg 
AA/kg b.w. per day (Fuhr et al., 2006). AA and its major metabolites were quantified by HPLC-MS in 
the 72-hour urine and found to account for about 60 % of the dose. The authors concluded that most of 
the AA present in the potato chips was absorbed by the human subjects, because the 60 % fraction of 
the dose excreted in urine is similar to that excreted in rodents and humans after oral exposure to an 
aqueous solution of AA (see Section 7.1.3).  
In conclusion, part of the AA formed during preparation of food could react chemically with 
components of the food matrix to form stable adducts. However, the proportion of free (unbound) AA, 
which is the amount that can be determined by chemical analysis, is extensively absorbed from the GI 
tract even in the presence of common food matrices. 
Placental transfer 
In pregnant rats, rabbits, beagle dogs and miniature pigs i.v. injected with 
14
C-AA, radioactivity has 
been demonstrated to reach the fetuses (Ikeda et al., 1983, 1985). Transfer of AA in human placenta 
has been reported in an in vitro study by Sörgel et al. (2002). The authors perfused the maternal side of 
three post-partum human placentas with AA at a concentration of about 1 µg/mL without recirculation 
of the perfusate and found concentrations of about 0.2 µg/mL in the fetal perfusate after 5 to 
30 minutes of perfusion. In a later in vitro study, a dual recirculating human placental perfusion was 
used and the transfer rate of AA (at maternal concentrations of 5 and 10 µg/mL) and GA (5 µg/mL) 
through the placenta determined (Annola et al., 2008b). Antipyrine (100 µg/mL), which is known to 
pass through human placenta mainly by passive diffusion, was used as positive control, and all three 
compounds were determined by HPLC-MS/MS. AA and GA crossed the placenta from the maternal to 
the fetal side with similar kinetics as antipyrine, and the concentrations of AA and GA in the maternal 
and fetal circulation equilibrated within two hours. No metabolism of AA to GA was detected during 
an incubation time of 4 hours, nor was a DNA adduct of GA found by HPLC-
32
P-postlabelling in the 
placental tissue perfused with AA or GA (Annola et al., 2008b).  
In ex vivo perfusion studies with human placentas, AA and GA were also found to exhibit a high 
placental transfer (Mose et al., 2012).  
In addition to the evidence from in vitro studies that AA and GA can easily cross the human placenta, 
trans-placental exposure has also been shown to occur in vivo. When the blood of 11 pregnant women 
taken a few hours before childbirth and the corresponding umbilical cord blood of their neonates was 
analyzed for the Hb adduct of AA by GC-MS analysis of AAVal, this Hb adduct could be found in all 
blood samples of the mothers and neonates (Schettgen et al., 2004b). The level of the Hb adduct was 
highest in a smoking mother, and its concentration in the blood of neonates was about half of that 
found in the blood of their mothers. Likewise, the mean ratio of the Hb adduct of AA in cord blood to 
maternal blood was 0.48 in another study involving 219 neonates and 87 mothers from Denmark (von 
Stedingk et al., 2011). Again, a highly significant correlation was observed between cord and maternal 
blood with regard to the Hb adducts of AA and also GA, for which the adduct ratio of cord to maternal 
blood was around 0.38. Similarly, in a study which included 1 101 cord blood samples and 
172 maternal blood samples from Greece, Spain, England, Denmark and Norway (Pedersen et al., 
2012), the median AA-Hb adduct levels in cord blood were approximately half of the levels in paired 
maternal blood. Hb adduct levels in cord blood were positively correlated with both maternal AA-Hb 
adduct (r = 0.95) and GA-Hb adducts (r = 0.94). In vitro studies showed that the extent of Hb adduct 
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formation of AA and GA with cord blood is about half of that with maternal blood, which was 
explained by structural differences between fetal and adult Hb. 
The results of the studies of Schettgen et al. (2004b), von Stedingk et al. (2011) and Pedersen et al. 
(2012) indicate that the in vivo doses of AA and GA in fetal and maternal blood are about the same 
and that the placenta provides no protection of the fetus to exposure from these compounds if present 
in the maternal blood. 
Transfer into milk and eggs 
In cows’ milk, a mean concentration of 175 µg AA/kg was found in a study administering a daily dose 
of 3.1 mg AA/kg b.w. in a gelatine capsule for 10 days (Pabst et al., 2005). After termination of the 
dosing, the AA concentration dropped below the LOQ of 5 µg AA/kg within two days. A mean carry-
over of 0.24 % of the AA dose into the milk and a mean half-life of AA in the cow of 2.8 hours were 
estimated from these data. In three commercial cow feed samples, AA concentrations in the range of 
140–180 µg/kg were determined. Based on the carry-over rate of 0.24 %, a maximum AA 
concentration of 0.2 µg/kg would be expected in the milk of cows fed such feeds (Pabst et al., 2005).  
The carry-over of AA from food into human milk was first reported by Sörgel et al. (2002) for two 
mothers who consumed potato chips (i.e. potato crisps) containing about 1 mg of AA (approximate 
dosage 15 µg/kg b.w.). Concentrations of AA in the low µg/kg range were observed in the human milk 
between 3 and 8 hours after the meal. When a series of 14 individual and four pooled human milk 
samples from non-smoking Swedish mothers exposed to a daily dietary AA intake of about 0.5 µg/kg 
b.w. were analyzed by HPLC-MS/MS, the concentration of AA was found to be below the LOQ of 
0.5 µg/kg, except in one individual sample (0.51 µg/kg) (Fohgelberg et al., 2005).  
A low carry-over into eggs (0.5 % of the dose) after oral administration of radiolabelled AA to white 
Leghorn hens was reported by Blumenthal et al. (1995). The radioactivity found in the eggs could not 
be extracted and was assumed to be protein-bound. Kienzle et al. (2005) reported on a carry-over of 
about 0.4 % of the dose into eggs of Japanese quails after i.v. injection of AA. 
7.1.2. Metabolism 
7.1.2.1. Metabolic pathways 
Due to the broad industrial application of AA (see Section 1.3) and its neurotoxic and carcinogenic 
effects, this compound has been of interest to occupational medicine since the 1950s. Therefore, the 
metabolic pathways of AA in animals and humans are known for many years (Dearfield et al., 1988; 
Calleman, 1996) and are depicted in Figure 9.  
In mammals, AA is converted to 2,3-epoxypropionamide (or GA), which is, in part, hydrolyzed to 2,3-
dihydroxypropionamide (DHPA, also called glyceramide). Both AA and GA are conjugated with 
glutathione (GSH) and the GSH adducts subsequently converted to mercapturic acids (MAs). AA 
gives rise to only one GSH adduct (AA-GSH), with the thiol group of GSH adding to the C3 position 
of AA in a typical Michael addition reaction. In contrast, GA forms two GSH adducts, because the 
thiol group of GSH can open the epoxide ring of GA either at C3, leading to GA-GSH, or at C2, 
leading to iso-GA-GSH. The conversion of AA-GSH yields N-acetyl-S-(2-carbamoylethyl)-L-cysteine 
(AAMA, also called N-acetyl-S-(3-amino-3-oxopropyl)-L-cysteine in the older literature). GA-GSH 
and iso-GA-GSH give rise to different mercapturic acids, i.e. N-acetyl-S-(2-carbamoyl-2-
hydroxyethyl)-L-cysteine (GAMA, also called N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)-L-
cysteine) and N-acetyl-S-(1-carbamoyl-2-hydroxyethyl)-L-cysteine (iso-GAMA), respectively (Figure 
9). Another mercapturic acid, which has so far only been reported as an AA metabolite in humans, is 
the sulfoxide of AAMA, i.e. AAMA-SO (Figure 9). In rats, small amounts of the non-acetylated 
precursor of AAMA, i.e. S-(2-carbamoylethyl)-L-cysteine, have been found (Sumner et al., 1997). The 
mercapturic acids GAMA and iso-GAMA exist as diastereomers due to their chiral C-atom carrying 
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the hydroxyl group (Figure 9). The relative amounts of the AA metabolites differ among species, as 
will be shown in Section 7.1.3. 
Metabolic studies using AA labelled with either 
14
C, 
13
C or 
2
H have unambiguously shown that the 
metabolites depicted in Figure 9 are derived from AA. This includes DHPA, which is thought to arise 
from GA through epoxide hydrolase (EH)-mediated hydrolysis (Miller et al., 1982; Sumner et al., 
1992). When 
2
H3-AA was ingested at a dose of 13 µg/kg b.w. by a male volunteer, 5.4 % of the 
administered dose was excreted as 
2
H3-DHPA in the 46-hour urine (Hartmann et al., 2011). However, 
the concentrations of DHPA in 30 urine samples from the general population were approximately ten 
times higher than expected from the metabolism of AA via GA (Latzin et al., 2012). Therefore, 
sources other than AA appear to contribute to the formation of DHPA, and DHPA cannot be 
considered a specific biomarker for the oxidative metabolism of AA. 
As shown in Figure 9, both AA and GA can react with proteins to form covalent adducts, and in vivo 
adducts with Hb represent an important biomarker for AA exposure (see Section 7.2.2). AA itself has 
electrophilic properties and is intrinsically able to react with nucleophilic targets. Covalent adducts of 
AA with DNA have been generated in chemical reactions, but have never been detected in vivo or in 
vitro in animal or human tissues (Doerge et al., 2005c). In contrast, covalent DNA adducts of GA have 
been amply demonstrated in vitro and in experimental animals, and are used as biomarkers of 
exposure and thought to mediate the carcinogenic effects of AA (see Sections 7.2.3 and 7.3.6.4). 
Therefore, the formation of GA from AA represents a major metabolic activation reaction, although 
the reaction of AA with proteins may also significantly contribute to the toxicity.  
Figure 9:  Overview of the metabolic pathways of AA in animals and humans. Asterisks denote 
chiral C atoms. AA: acrylamide; AAMA: N-acetyl-S-(2-carbamoylethyl)-L-cysteine; AAMA-SO: 
sulfoxide of AAMA; DHPA: 2,3-dihydroxypropionamide; EH: epoxidose hydrolase; GA: 
glycidamide; GAMA: N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine; GSH: glutathione; Hb: 
haemoglobin.   
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It is of interest to note that the first conclusive evidence for the epoxidation of AA came from the 
structure elucidation of the Hb adduct of GA in rats dosed with AA (Calleman et al., 1990; Bergmark 
et al., 1991). 
In addition to the identified pathways depicted in Figure 9, there appears to exist a yet unknown albeit 
minor pathway leading to the release of the C1 of AA as carbon dioxide. This must be concluded from 
the observation that about 5 % of a dose of [
14
C]-AA administered to rats is exhaled as [
14
C]-carbon 
dioxide when AA is labelled in the carbonyl carbon (Hashimoto and Aldridge, 1970), in contrast to 
when AA is labelled in the vinyl carbons (C2 and C3) and no [
14
C]-carbon dioxide is exhaled (Miller 
et al., 1982). A possible intermediate of this decarboxylation pathway may be 2,3-dihydroxypropionic 
acid, which has been identified in small amounts in rat urine after oral gavage of AA (Sumner et al., 
2003). 
In all species tested the direct conjugation of AA with GSH eventually yields AAMA and AAMA-SO 
(in humans only), in contrast to the ‘oxidative pathway’, which involves epoxidation to GA and 
subsequent formation of GAMA, iso-GAMA and DHPA. Because the formation of GA represents a 
metabolic activation, whereas direct conjugation of AA prevents epoxidation, the ratio of the oxidative 
to the direct conjugation (‘reductive’) pathway is a measure for the extent of metabolic activation of 
AA. This ratio, which is an indicator of fluxes through activation and inactivation pathways, differs 
between species including humans (see Section 7.1.3). 
As mentioned before, AA labelled with radioactive or stable isotopes was used in most studies on the 
metabolism or toxicokinetics of AA. The purpose of this approach was to circumvent the problem of 
‘background’ levels of AA and its metabolites in urine and tissues. Several studies found that 
experimental animals and humans excrete AA metabolites in their urine even before the administration 
of AA (Kopp and Dekant, 2009; Watzek et al., 2012a). This may be due to the presence of AA and its 
reaction products in feed or food (see below).  
In an animal diet prepared in-house no AA could be detected by HPLC-MS/MS with an LOD of 
0.5 µg/kg (Watzek et al., 2012a). Based on this LOD, a maximum daily AA intake of 0.1 µg/kg b.w. 
would result from consumption of this diet by rats. However, female Sprague-Dawley rats on the 
AA-free diet excreted amounts of AAMA and GAMA corresponding to a daily ingestion of 0.6 µg 
AA/kg b.w. This caused Watzek et al. (2012a) to assume that small amounts of AA may be formed 
endogenously.   
Tareke et al. (2009) reported the formation of AA when the amino acid asparagine was incubated with 
hydrogen peroxide and another study has shown that Hb adducts of AA are increased in mice treated 
with compounds known to induce free radicals (Tareke et al., 2008). The CONTAM Panel noted that 
methodological deficiencies in the Tareke et al. (2008, 2009) studies precluded conclusions regarding 
endogenous formation. As an alternative to the endogenous formation of AA, the possibility should be 
considered that adducts of AA with cysteine in dietary proteins are present in food and feed, which 
may be absorbed from the GI tract after proteolytic degradation and subsequently excreted in urine. 
Preliminary evidence for this possibility has been obtained from in vitro studies (Schwend et al., 
2008). 
7.1.2.2. Enzymology 
Enzymes for metabolic activation 
As GA is considered to be the ultimate genotoxic metabolite of AA (see Section 7.3.3), the enzymes 
involved in its metabolic formation and inactivation are of particular interest. Sumner et al. (1999) 
administered a single oral dose of AA to male and female mice and quantified the metabolites excreted 
in the 24-hour urine. GA and its hydrolysis product DHPA, as well as AAMA and GAMA, derived 
from conjugation of AA and GA, respectively, with GSH (see Figure 9) were found as urinary 
metabolites of AA. When mice were pretreated with 1-aminobenzotriazole, a nonspecific inhibitor of 
cytochrome P450 (CYP), AAMA but neither GA nor metabolites derived from GA were detected in 
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the urine. In mice devoid of CYP2E1 (CYP2E1-null mice), again AAMA was the only urinary 
metabolites of AA (Sumner et al., 1999). This study clearly indicated that the formation of GA is 
mediated by CYP enzymes (and can therefore be suppressed by 1-aminobenzotriazole), and that 
CYP2E1 is the predominant, if not sole, CYP isoform mediating the epoxidation of AA in mice. 
Consistent with this notion was the observation by Ghanayem et al. (2005a) that the plasma levels of 
GA in CYP2E1-null mice were only 5 % of that in wild-type mice after a dose of 50 mg AA/kg b.w. 
Moreover, only trace levels of DNA and Hb adducts of GA were detectable in CYP2E1-null mice at 
this dose, which gave rise to high adduct levels in wild-type animals. 
Two in vitro studies addressed the enzymology of GA formation in humans (Settels et al., 2008; Kraus 
et al., 2013). The study by Settels et al. (2008) demonstrated that GA was generated in incubations of 
AA with liver microsomes from two women and also with microsomes from insect cells expressing 
human CYP2E1. Moreover, genetically modified Chinese hamster V79 cells expressing human 
CYP2E1 were shown to convert AA to GA. The enzymatic activity for GA formation was highest in 
the insect microsomes containing human CYP2E1, followed by human liver microsomes and 
recombinant V79 cells. Microsomes from marmoset liver also generated GA from AA with an activity 
between that of human hepatic microsomes and recombinant V79 cells. A monoclonal antibody 
against human CYP2E1 and the CYP2E1-specific chemical inhibitor diethyldithiocarbamate (DDC) 
were shown to almost completely suppress the formation of GA from AA by human and marmoset 
liver microsomes and recombinant V79 cells, respectively. 
Following this first report by Settels et al. (2008) on the involvement of CYP2E1 in the epoxidation of 
AA in humans, the formation of GA from AA was studied in vitro with four different specimens of 
human liver microsomes pooled from various male and female donors, and eight microsomal 
preparations expressing human CYPs, i.e. CYP1A1, CYP1A2, CYP2B6, CYP2C9*1, CYP2C19, 
CYP2D6, CYP2E1 and CYP3A4 (Kraus et al., 2013). The maximum formation rate (Vmax) and 
Michaelis-Menten constant (Km) were determined using an AA concentration ranging from 0.2 to 
20 mM. For human liver microsomes, the mean Vmax was 199 pmol GA/mg protein/min and the Km 
was 3.3 mM. No difference was observed between male and female donors. For the human CYP 
isoforms, pronounced GA formation was only observed for CYP2E1 with Vmax of 5.4 nmol GA/nmol 
CYP2E1/min and Km of 1.3 mM. The activities of CYP1A1, CYP1A2, CYP2C19 and CYP2D6*1 for 
GA formation were only measurable at 20 mM AA and ranged from 0.7 to 1.8 % of the CYP2E1 
activity, whereas CYP2B6, CYP2C9*1 and CYP3A4 did not lead to the formation of detectable 
amounts of GA. 
The dominant role of CYP2E1 for the conversion of AA to GA was supported in the same study by 
the observation that GA formation by human liver microsomes and recombinant CYP2E1 could be 
suppressed by DDC (Kraus et al., 2013). At higher concentrations, DDC completely blocked GA 
formation in both enzyme systems, and the similar IC50 values obtained for microsomes and CYP2E1 
(3.1 and 1.2 μM, respectively) further suggest that CYP2E1 may be the only human CYP mediating 
GA formation in this experimental setting.  
Consistent with the importance of CYP2E1 for the bioactivation of AA is the observation by Taubert 
et al. (2006) that the formation of GA from AA in rat liver slices is greatly diminished in the presence 
of diallylsulfide, which is a specific constituent of garlic and a potent inhibitor of CYP2E1 (Brady et 
al., 1991). 
In support of a major role of CYP2E1 for the metabolism of AA to GA, Kurebayashi and Ohno (2006) 
reported that the rate of GA formation was 4-fold higher in primary hepatocytes from male Sprague-
Dawley rats treated with acetone, a known inducer of CYP2E1, than in hepatocytes from untreated 
rats. 
In order to study whether AA itself could induce CYPs, cultured human HepG2 cells, which are 
derived from a hepatic adenocarcinoma, were treated with 1.25 and 2.5 mM AA (Sen et al., 2012). A 
2.0–2.6-fold, 2.4–3.2-fold, and 1.4–1.9-fold increase in CYP2E1-associated enzyme activity, protein 
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level and m-RNA level, respectively, was observed. A somewhat more pronounced inducing effect (up 
to 5.7-fold, depending on the endpoint used) was noted for the induction of CYP1A2, which is, 
however, not involved in the metabolism of AA. The expression of CYP3A4, another important 
hepatic CYP, was found to be slightly inhibited in HepG2 cells after treatment with AA.  
Nixon et al. (2014) reported that the expression of the CYP2E1 gene was upregulated about 2.5-fold in 
spermatocytes of adult mice after treatment of the isolated cells for 18 hours with 1µM AA. The 
expression of CYP1B1 was elevated 3.3-fold under these conditions of exposure, which did not affect 
cell viability or morphology. 
As ethanol is an important substrate of CYP2E1, the consumption of alcoholic beverages might have 
an influence on the metabolism of AA to GA. Ethanol has been shown to influence the carcinogenicity 
of several N-nitrosamines by competitively inhibiting hepatic metabolism, which increases 
distribution to other organs where bioactivation can occur (e.g. Griciute et al., 1981). Similarly, co-
exposure of B6C3F1 mice to 5 % ethanol and 90 ppm urethane in drinking water decreased levels of 
1,N6-ethenodeoxyadenosine adducts in liver DNA. However, the co-administration of ethanol had 
minor impact on the carcinogenicity of urethane in mouse liver and lung observed after two years of 
exposure (Beland et al., 2003). When the ratio of the Hb adduct levels for AA and GA was compared 
to questionnaire data for alcohol intake in 161 non-smoking Swedish men, a linear trend for a decrease 
of the ratio of the GA-Hb adduct to the AA-Hb adduct was observed with increasing alcohol intake, 
suggesting that ethanol competitively inhibits the CYP2E1-mediated epoxidation of AA (Vikström et 
al., 2010). Likewise, GA-Hb adducts were significantly lower in high alcohol consumers as compared 
to moderate consumers in a study involving 510 subjects from nine European countries, randomly 
selected and stratified by age, gender, and smoking status (Vesper et al., 2008). A weak correlation of 
alcohol consumption with increasing AA-Hb adduct concentration and decreasing GA-Hb adduct 
concentration was also reported in a representative sample of the US population, although only the 
AA-Hb adducts were significantly correlated (Vesper et al., 2013).       
The role of CYP2E1 for the metabolism of AA in humans has also been addressed by an in vivo study 
with 16 healthy Caucasian non-smokers of both genders (Doroshyenko et al., 2009). A single meal of 
potato chips (i.e. French fries) corresponding to a dose of 15 µg AA/kg b.w. was ingested by the 
volunteers without pretreatment and after inhibition of CYP2E1 with a single dose of 500 mg DDC or 
induction of CYP2E1 with ethanol (48 g per day for one week prior to ingestion of AA). Inhibition of 
CYP2E1 gave rise to an increased cumulative excretion of AA (1.34-fold compared to control) and 
AAMA (1.15-fold), whereas urinary excretion of GAMA was reduced 0.44-fold. Likewise, the ratio of 
urinary GAMA to AAMA dropped significantly from 0.026 to 0.010 after inhibition of CYP2E1. 
Induction of CYP2E1 with ethanol did not result in significant changes in the toxicokinetics of AA nor 
in the formation of Hb adducts. However, a low dose of ethanol was used in this study, expected to 
lead to only about 30 % increase in CYP2E1 activity, and the CYP2E1 induction was not measured in 
the human subjects. The authors concluded that the interindividual variability is too high to detect 
small difference in the AA toxicokinetics at CYP2E1 induction of this low level (Doroshyenko et al., 
2009). In human hepatoma HepG2 cells in vitro, treatment with ethanol at concentrations of up to 
240 mM gave rise to a weak induction of CYP2E1, as demonstrated by Western immunoblotting 
(Lamy et al., 2008). When the ethanol-treated cells were exposed to AA, the level of DNA strand 
breaks was about  two-fold higher than that in AA-exposed non-induced HepG2 cells, demonstrating 
that the DNA strand breaking agent GA is formed to a larger extent when the level if CYP2E1 is 
increased (Lamy et al., 2008).      
Based on all the evidence, the CONTAM Panel concluded that CYP2E1 is the predominant isoform 
for converting AA to GA.  
In view of the importance of CYP2E1 for the formation of GA, it is of interest to consider the activity 
of this enzyme in different species and organs and its dependency on age (Overton et al., 2008). 
CYP2E1 is a highly conserved enzyme and constitutively expressed in the liver and in extrahepatic 
tissues of many species including human, mouse and rat. The highest activity of CYP2E1 is invariably 
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found in liver, exceeding that in other organs by a factor of ten or more. Male rats and humans express 
CYP2E1 in liver in greater quantities than do females. In rat liver, CYP2E1 expression begins within 
one day after birth, whereas male and female human fetal liver at age 23–40 weeks exhibits about 1 % 
of the expression of adult livers (Nishimura et al., 2003). In the study by Nixon et al. (2014), the 
authors found that CYP2E1 is expressed in mouse testis at different developmental stages. Expression 
was low in immature testis from day 2 or 6 after birth, but reached high levels between day 11 and 18, 
dropped to about half at day 22 and stayed there during adulthood. Spermatogonia had about 3-fold 
higher levels of CYP2E1 expression than spermatocytes or spermatids. This observation may be of 
interest for the reproductive toxicity of AA in male rodents. 
Large inter-individual variation in CYP2E1 activities has been reported in humans and the basis is 
complex, relating to gene-environment interactions including enzyme induction and inactivation by 
dietary constituents, disease states, drug interactions, physical and hormonal status, and significant 
ethnic differences (Bolt et al., 2003).   
Enzymes for metabolic inactivation 
The reaction of AA and GA with the thiol group of GSH is generally considered a detoxification 
reaction, as is the hydrolysis of GA to DHPA. Conjugation with GSH appears to be more important as 
a detoxification pathway than epoxide hydrolysis for two reasons. Firstly, GSH conjugation of AA 
prevents epoxidation of AA to GA. Secondly, GSH conjugation of GA occurs at a faster rate than GA 
hydrolysis, because higher amounts of GAMA than DHPA are excreted in the urine in humans and 
rats (Table 16).  
In view of the rapid and extensive urinary excretion of AAMA and GAMA, it is commonly assumed 
that GSH conjugation is mediated by glutathione S-transferases (GSTs). The participation of GSTs can 
also be concluded from species differences observed in the pattern of urinary metabolites (Gargas et 
al., 2009). For example, Fennell and Friedman (2005) found that 59 % of the urinary metabolites 
originated from direct conjugation of AA with GSH in rats orally dosed with 3 mg AA per kg b.w., 
whereas the same conjugation accounted for 86 % in humans under the same conditions (Fennell et al., 
2005). Therefore, humans appear to conjugate almost 30 % more of the same dose of AA directly with 
GSH than do rats, thus producing lower amounts of GA. 
To-date, it is unknown which GST isoforms are involved in the GSH conjugation of AA and GA. 
Studies on the in vivo toxicokinetics of AA and on the formation of Hb adducts of GA and AA in 
humans with different genotypes for GST isoforms have not provided a clear picture. For example, 
significant associations were disclosed between different genotypes for GSTM1 and GSTT1, and the 
ratio of Hb adducts of GA and AA (Duale et al., 2009). In general, individuals with null variants of 
these enzymes had a higher ratio of GA-Hb to AA-Hb in their blood than those with the wild-type 
genotypes. On the other hand, no obvious difference in the urinary excretion of metabolites was 
observed between individuals with different GST genotypes, including GSTP1 single nucleotide 
polymorphisms and even GSTM1- and GSTT1-null genotypes (Doroshyenko et al., 2009). When 
peripheral blood leukocytes from human donors with different GST genotypes were treated with GA 
in vitro and the extent of DNA damage measured by the alkaline Comet assay or the sister chromatid 
exchange (SCE) assay, no differences were observed between GSTM1- and GSTT1-null and wild-
type genotypes (Pingarilho et al., 2012, 2013). However, the SCE results from the study of Pingarilho 
et al. (2013) suggest that GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) polymorphisms may influence 
the detoxification of GA. 
Data on the induction of GSTs by AA are also very rare. Sen et al. (2012) studied the effects of AA at 
1.25 mM and 2.5 mM concentration on the activity and expression of GST-mu and GST-pi isozymes 
in cultured HepG2 cell. A slight induction (2.0–5.1-fold, depending on the endpoint) was observed for 
GST-mu, whereas the activity and expression of GST-pi were reduced. It would be important to know 
whether and to what extent GST isoforms are induced upon chronic exposure to low levels of AA. 
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Another gap of knowledge concerns the stability of the thiol adducts of AA. It is known that the 
conjugation of α,ß-unsaturated carbonyl compounds with a thiol group via a Michael addition can be 
reversible (Monks et al., 1990; Van Bladeren, 2000). As has been shown with several chemicals such 
as acrolein and benzoquinone, GSH adducts and mercapturic acids may not be final detoxification 
products but serve as transport form for the toxin to various organs, where it can be released to exert 
systemic toxicity. No studies exist on the reversibility of AA conjugates. Although the high amount of 
AAMA commonly found in urine as an excreted metabolite of AA does not imply a significant 
instability, the situation may be different for AA adducts with thiol groups in tissue proteins.    
As metabolic activation to GA is important for the genotoxic effects of AA, the ratio of GA formation 
to GSH adduct formation is an important aspect in the susceptibility of various species and organs to 
the carcinogenic effect of AA. In primary rat hepatocytes, the rate of AA-GSH formation has been 
reported to be 1.5–3 times higher than the rate of GA formation (Watzek et al., 2013).    
7.1.3. Excretion 
Early studies in rats using 
14
C-labelled AA have shown that the major route of excretion is the urine 
(Hashimoto and Aldrich, 1970; Miller et al., 1982). In the study of Miller et al. (1982), more than 
66 % of an orally administered dose of 1–100 mg AA/kg b.w. was excreted as AA-derived material 
with the urine and only 4 % with the faeces after seven days. Urinary excretion after 24 hours 
accounted for about 54 % of the dose. In later studies with rats, mice and humans, the 24-hour urine 
was invariably found to contain between 40 and 60 % of the orally administered dose (Table 16). 
Only metabolism studies using AA labelled with stable isotopes (1,2,3-
13
C-AA or 2,3,3-
2
H-AA) are 
listed in Table 16, because metabolites cannot be accurately quantified in low-dose studies when 
unlabelled AA is used, due to background metabolites being observed in control animals and humans 
not dosed with AA (Boettcher et al., 2006a; Kopp and Dekant, 2009; Watzek et al., 2012a). These 
background metabolites most likely to arise from AA present in feed and food, from tobacco smoke, 
protein adducts of AA in food, or possibly from exogenous or endogenous sources other than AA, as 
may be the case for DHPA (see Section 7.1.1). 
The pattern of urinary metabolites is depicted in Table 16. Parent AA and its oxidative metabolites GA 
and DHPA account for only a minor portion of the excreted material. The predominant urinary 
metabolites are the mercapturic acids derived from AA and GA, i.e. AAMA, GAMA and iso-GAMA 
(Figure 9). AAMA usually represents the major and iso-GAMA the minor MA. For example, 51.7 % 
of a single oral dose of 13 µg AA/kg b.w. was excreted as AAMA, 4.6 % as GAMA and 0.8 % as iso-
GAMA with the 46-hour urine by a human male volunteer (Hartmann et al., 2009).  
The amounts of metabolites of AA shown in Table 16 refer to the 24-hour urine. However, it should 
be noted that significant amounts of AAMA, AAMA-SO and GAMA are also excreted during the 
second day after oral administration to humans (Boettcher et al., 2006a; Kopp and Dekant, 2009). For 
example, the total urinary metabolites of AA excreted in the 46-hour urine of humans dosed with 
0.5 µg AA/kg b.w. accounted for 71.3 % of the dose (Kopp and Dekant, 2009) as compared to 52.4 % 
after 24 hour (Table 16). Thus, 18.9 % of the dosed AA was excreted as urinary metabolites during the 
24 to 46-hour time period. In contrast to humans, urinary excretion of AA metabolites in rats appears 
to be virtually complete after 24 hours (Kopp and Dekant, 2009). 
Other studies on the profiling of AAMA and GAMA in the urine of human volunteers also indicate a 
relatively slow excretion of AA metabolites in humans. After ingestion of self-prepared or commercial 
potato crisps with AA at dose levels of 0.6–14.8 µg/kg b.w., elimination half-lives of 12–17 hours and 
20–38 hours were observed for AAMA and GAMA, respectively, and considerable interindividual 
variations were noted (Fuhr et al., 2006; Doroshyenko et al., 2009; Watzek et al., 2012b).    
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Table 16:  Excretion of urinary metabolites over 24 hours in male rodents and humans after a single oral dose of acrylamide (AA) dissolved in water. Data 
are molar percentages of dose. 
Species – Dose AA AAMA 
AAMA-
sulfoxide 
GA GAMA
(a)
 DHPA 
Total 
excretion 
ΣAA(b) ΣGA(c) 
ΣGA/ 
ΣAA 
Method Reference 
Mouse – 50 mg/kg NQ 21 ± 1.1 ND 8.6 ± 1.1 17 ± 0.6 2.7 ± 0.6 50.4 21 28 1.3 13C-NMR Sumner et al. (1992) 
Mouse – 0.1 mg/kg 0.6 7 ND 16 16 ND 40 7.6 32 4.2 
HPLC-
MS/MS 
Doerge et al. (2007) 
Rat – 50 mg/kg NQ 34 ± 1.8 ND 2.8 ± 0.5 12 ± 0.6 1.2 ± 0.4 50.7 34 16 0.5 13C-NMR Sumner et al. (1992) 
Rat – 50 mg/kg NQ 38 ND 3.9 10.5 0.6 53 38 15 0.4 13C-NMR Sumner et al. (2003) 
Rat – 3 mg/kg NQ 29 ± 4.5 ND ND 21 ± 2.4 ND 50.0 29 21 0.7 13C-NMR Fennell et al. (2005) 
Rat – 0.1 mg/kg 2 31 ND 6 28 ND 67 31 34 1.1 
HPLC-
MS/MS 
Doerge et al. (2007) 
Rat – 0.1 mg/kg NQ 35 ± 7.4 ND ND 27 ± 4.6 ND 62 35 27 0.8 
HPLC-
MS/MS 
Kopp and Dekant 
(2009) 
Rat – 20 µg/kg NQ 30 ± 5.1 ND ND 25 ± 6.2 ND 55 35 27 0.8 
HPLC-
MS/MS 
Kopp and Dekant (2009) 
Human – 3.0 mg/kg NQ 22.0 ± 5.3 4.2 ± 1.1 0.8 ± 0.2 ND 3.3 ± 1.1 34.0 26.2 4.1 0.16 13C-NMR Fennell et al. (2005) 
Human – 3.0 mg/kg 3.2 27.8 ± 8.0 7.2 ± 2.4 0.7 ± 0.2 0.7 ± 0.2 ND 39.9 35.0 1.4 0.04 13C-NMR Fennell et al. (2006) 
Human – 1.0 mg/kg 5.0 34.4 ± 5.2 8.7 ± 1.2 0.6 ± 0.3 0.8 ± 0.1 ND 39.9 43.1 1.4 0.03 13C-NMR Fennell et al. (2006) 
Human – 0.5 mg/kg 4.7 31.2 ± 6.5 8.3 ± 2.4 0.4 ± 0.2 0.8 ± 0.2 ND 45.4 39.5 1.2 0.03 13C-NMR Fennell et al. (2006) 
Human – 20 µg/kg ND 37.4 ± 2.9 6.3 ± 1.8 ND 3.2 ± 0.7 ND 46.9 43.7 3.2 0.07 
HPLC-
MS/MS 
Kopp and Dekant (2009) 
Human – 13 µg/kg ND 45.1 ND ND 2.8 ND 47.7 45.1 2.8 0.06 
HPLC-
MS/MS 
Boettcher et al. (2006a) 
Human – 0.5 µg/kg ND 41.4 ± 3.5 7.2 ± 1.4 ND 3.8 ± 0.8 ND 52.4 48.6 3.8 0.08 
HPLC-
MS/MS 
Kopp and Dekant (2009) 
AA: acrylamide; AAMA: N-acetyl-S-(2-carbamoylethyl)-L-cysteine; GA: glycidamide; GAMA: N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine; DHPA: 2,3-dihydroxypropionamide; 
NQ: not quantified; ND: not determined. 
(a):  Includes iso-GAMA if determined. 
(b):  ΣAA, sum of AA+AAMA+AAMA-sulfoxide. 
(c):  ΣGA, sum of GA+GAMA.   
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From the rodent studies conducted with different doses of AA (Table 16), an inverse relation appears 
to exist between dose and epoxidation of AA to GA, i.e. the proportion of GA decreases with 
increasing dose, possibly due to enzyme saturation. However, the assumption that higher doses of AA 
are less efficiently metabolized to GA is not supported by a recent study in female Sprague-Dawley 
rats, where over a dose range from 0.1–10 000 µg/kg b.w., virtually the same value of about 0.4 was 
observed for the ratio of GAMA to AAMA excreted within 16 hours (Watzek et al., 2012a). In most of 
the studies involving humans, virtually the same ratio for the sum of all GA-related metabolites to the 
sum of all AA-related metabolites (ΣGA/ΣAA) of about 0.05 was determined for AA doses covering 
three orders of magnitude, i.e. ranging from 0.5 µg to 1 mg AA per kg b.w., which also speaks against 
an effect of the dose on the ratio of the metabolic pathways (Table 16). 
Of particular interest is the sum of all excreted metabolites formed through the GA pathway, i.e. GA, 
GAMA and DHPA, and its relation to the sum of AA of excreted parent AA plus metabolites 
generated from AA via direct conjugation with GSH, i.e. AAMA and AAMA-SO. The ratio of ΣGA to 
ΣAA reflects the extent of oxidative metabolism, i.e. activation of AA to GA, in comparison to 
‘reductive’ metabolism, i.e. direct GSH conjugation and inactivation of AA (see Section 7.1.2.1). 
Marked differences in the extent of oxidative to reductive metabolism appear to exist between mice, 
rats and humans (Table 16). Whereas oxidative biotransformation exceeds direct conjugation in mice, 
resulting in ΣGA/ΣAA ratios of > 1, reductive metabolism appears to be somewhat more efficient than 
oxidative metabolism in rats with ΣGA/ΣAA ratios of 0.4–1. Humans exhibit ΣGA/ΣAA ratios of 
0.1 or less, apparently forming the smallest relative amounts of GA but the highest amounts of direct 
AA conjugates (Table 16). 
The ratio of urinary GAMA to AAMA was studied in a group of 91 male and female Caucasian non-
smokers of different age ranging from six to 80 years, who were exposed to AA through their normal 
diet (Hartmann et al., 2008). Each of the seven age groups comprised 11 to 15 individuals with an 
even distribution of males and females. The median value for the GAMA/AAMA ratio was 0.3 with a 
large range (0.004–1.4). There was no gender-related difference in GAMA/AAMA levels. In young 
children (age 6–10 years old) the GAMA/AAMA ratio was higher (median 0.5, range 0.2–1.3). The 
higher ratio in young children and the large range probably reflects the differences in the enzymatic 
status of the individuals, as discussed in Section 7.1.2.2.  
7.1.4. Conclusion on absorption, distribution, metabolism and excretion of AA 
The proportion of AA that is not covalently bound to components of the food matrix is virtually 
completely absorbed from the GI tract of rodents and humans. After reaching the systemic circulation, 
AA is extensively distributed to all organs and transferred into the fetus and to a low extent to milk.  
AA is extensively metabolised, mostly by conjugation with GSH but also by epoxidation to GA. The 
formation of GA represents a metabolic activation pathway preferentially mediated by CYP2E1, the 
activity of which can be affected by dietary components, lifestyle choices, disease and physical states, 
and genetic polymorphisms. Mice and rats appear to be more proficient in GA formation than humans. 
Metabolic inactivation reactions comprise the hydrolysis of GA to DHPA as well as the GST-driven 
formation of GSH adducts of AA and GA, which are further processed to the respective mercapturic 
acids and excreted in urine. Conjugation of AA and GA with GSH appear to be the predominant 
detoxification pathway, while GA hydrolysis plays a minor role. It is presently unknown which GST 
isoforms are involved in the conjugation of AA and GA with GSH in animals and humans.  
The AA metabolites are rapidly and almost completely excreted with the urine, mostly as mercapturic 
acids of the GSH conjugates of AA and GA, and there is no indication of tissue accumulation, except 
for residual protein adducts.  
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7.1.5. Physiologically Based PharmacoKinetic (PBPK) modelling 
Several publications have reported various approaches to PBPK modelling of AA absorption, 
metabolism and disposition with the objective of predicting human internal exposures to AA and GA 
for use in reducing the uncertainty in risk assessment inherent in animal to human extrapolations.   
Kirman et al. (2003) used male F344 rat data to model the distribution of AA and GA to five 
compartments (arterial blood, venous blood, liver, lung, and all other tissues lumped together) and 
linked the enzymatic metabolism by Michaelis-Menten kinetics of AA to GA in the liver by CYP2E1, 
epoxide hydrolase-catalysed hydrolysis of GA and glutathione-S-transferase-catalysed conjugation of 
AA and GA, followed by elimination in urine of their mercapturate conjugates. The reaction of AA 
and GA with Hb and other tissue macromolecules was also included. Physiological parameters for the 
rat (body weight, organ size, organ blood flow, etc.) were obtained from the published literature. 
Tissue/blood partition coefficients for AA and GA were estimated using chemical-specific properties. 
Input data were derived primarily from rodent measurements of total radioactivity from [
14
C]AA 
administration in blood and tissues (Miller et al., 1982), AA concentrations in blood and nerve tissue 
(Raymer et al., 1993), and urinary excretion data (Sumner et al., 1992). Despite limited input data, the 
model parameters provided an adequate description for most of the kinetic data available for AA using 
a single set of input values. No kinetic data for GA were available. Although no human modelling was 
attempted, the reported rat model was considered by the authors as ‘a first step in providing a tool to 
assist in developing (human) exposure limits’. 
Young et al. (2007) used a general-purpose PBPK model to simulate a more extensive number of data 
sets. The PBPK model contained sub-models for AA, GA, and their GSH conjugates. Each PBPK sub-
model was comprised of 28 organ/tissue/fluid components that were maintained independently or 
connected through metabolic pathways. Partition coefficients for AA and GA were derived from 
measured values obtained following gavage administration to F344 rats and B6C3F1 mice (Doerge et 
al., 2005a,b). Tissues other than those specifically analysed for AA or GA were partitioned equally to 
the blood compartment. The specific organ/tissue weights and blood flows were based on literature 
values for the respective animal species, sex, and total body weight. Optimisation was based on 
minimizing the weighted sum of squares of the difference between each data point and its simulated 
value. The model was fit initially using a comprehensive plasma and tissue data set for AA and GA in 
blood and tissues from low-dose studies of AA (100 μg/kg b.w. single exposure by i.v., gavage, and 
dietary routes (see Table 17); 1 mg/kg b.w. per day repeated drinking-water exposures) and equimolar 
GA administered by i.v. and gavage routes (Doerge et al., 2005a,b). Urinary excretion of parent AA, 
GA, and mercapturates for AA and GA was also measured (Doerge et al., 2005a,b). Subsequently, 
available rodent data from the literature were also modelled. In addition, a pharmacodynamic (PD) 
module was used to link circulating concentrations of AA and GA with the formation of Hb adducts 
(AA-Val and GA-Val) and the tissue concentrations of GA with formation of the major DNA adduct, 
N7-GA-guanine. First-order kinetics were used in all cases because of the very high Km values for 
oxidation of AA to GA (4–14 mmol/L) reported from rodent and human hepatic microsomes (Tareke 
et al., 2006). The PBPK/PD model of Young et al. (2007) fit all of the data available for low and high 
doses of AA and GA in rodents and dietary doses of AA in humans. GA data were fit first because it 
was the simplest simulation, then the GA parameters were held constant to optimally fit the AA dosing 
data. Finally, adduct formation and decay data were simulated in the PD module holding the PK 
parameters constant. Inclusion of generalized tissue macromolecular binding parameters for AA and 
GA was evaluated but found to have little impact on the data fits. Human simulations focused on 
available exposure and elimination data from the literature that were specifically related to dietary 
administration of low AA doses (about 1 μg/kg b.w. per day). When possible, allometry was used to 
scale based upon body weights as an alternative means to validate parameters. No serum concentration 
data from human exposure studies were available at the time of publication of this study, so the 
individual urinary excretion kinetics for AA, AA-GS and GA-GS from a low-dose AA dietary 
administration (12.4 μg/kg b.w.) to three male and three female volunteers reported by Fuhr et al. 
(2006) were used as the foundation for the human model. An estimate of the excretion of GA and 
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DHPA was made based on the ratio of total GA to AA-GS excretion from a single oral AA dose of 
3 mg/kg b.w. reported in Fennell et al. (2005).  
Table 17:  Experimental area under the curve (AUC) values for acrylamide (AA) and glycidamide 
(GA) determined following AA dosing with 0.1 mg/kg b.w. by gavage for F344 rats (Doerge et al., 
2005a) and B6C3F1 mice (Doerge et al., 2005b)   
Species/Sex AA-AUC
(a)
 GA-AUC
(a)
 GA-AUC/AA-AUC Reference 
Rat/M 2.4 ± 0.51 1.3 ± 0.20 0.5 Doerge et al. (2005a) 
Rat/F 4.5 ± 0.31 4.4 ± 0.46 1.0 Doerge et al. (2005a) 
Mouse/M 0.87 2.6 3.0 Doerge et al. (2005b) 
Mouse/F 0.83 2.0 2.4 Doerge et al. (2005b) 
AA: acrylamide; AUC: area under the curve; b.w.: body weight; GA: glycidamide; F: female; M: male.  
(a):  Mean ± standard deviation provided when reported by the authors. 
 
The Young et al. (2007) model produced statistically significant differences in the metabolic 
parameters when comparing sex, dose and route of administration in rats. The values of metabolic 
parameters for the mouse were within the same range as the rat values. Human parameters derived 
from dietary administration studies, when at odds with the rodent parameters, appeared to scale 
appropriately based on allometry. Internal dosimetry in humans consuming dietary AA was simulated 
as steady-state concentrations in blood and specified tissues, using as input data the estimated mean 
dietary exposure and measurements of urinary metabolites and Hb adducts from AA and GA from 
non-smokers (Doerge et al., 2008). Steady state concentrations were converted to daily AUC values by 
integrating over a 24-hour time period.  
Walker et al. (2007) used a recalibration of model parameters from Kirman et al. (2003), in order to 
improve upon the original model. Specifically, by reducing the uncertainty about the assumption for 
total urinary elimination of AA-derived species based on 24-hour urine collection, by incorporating 
Hb adduct measurements, and using a more valid partition coefficient for GA. Data for Hb adducts 
were incorporated by adapting methodology to calculate AUCs for AA and GA (Calleman, 1996). 
Partition coefficients for GA were assumed to be equal to those for AA and were used for both rodent 
and human simulations. These modifications led to recalibrated sets of model parameters that were 
used to fit rat and human data sets with the goal of simulating human AUCs from defined exposures to 
AA. The human model was calibrated against human Hb adduct and urinary metabolite data sets 
derived from human volunteers given a single oral dose of AA (0.5–3 mg/kg b.w., Fennell et al., 
2005). Walker et al. (2007) also modelled the effect of perinatal development and inter-individual 
variability based on the ontogeny of CYP2E1 activity and hepatic GSH concentrations. These 
PBTK/Monte Carlo simulations suggested modest differences in internal dosimetry for AA and GA 
between children and adults, with early-life differences predicted to be greater for AA than for GA.  
Sweeney et al. (2010) reported an updated physiologically based toxicokinetic (PBTK) model for AA 
in humans and rats that reportedly included all the relevant kinetic information available at that time. 
The resulting model parameters were expanded and refined from those in Kirman et al. (2003) and 
extended to humans. This modelling used all the male F344 rat data sets, including partition 
coefficients, blood and tissues, Hb adducts and urinary metabolites, previously fit by Young et al. 
(2007) and Walker et al. (2007). The human model was fit using the Hb adduct and urinary metabolite 
data from Fennell et al. (2005, 2006) derived from human volunteers given a single oral dose of AA 
(0.5–3 mg/kg b.w.); time courses of urinary mercapturic acid metabolites derived from human 
volunteers given a single oral dose of AA (20–100 µg/kg b.w.; Kopp and Dekant, 2009); urinary 
metabolites derived from human volunteers given a single oral dose of AA (12.4 µg/kg b.w.; Fuhr et 
al., 2006); and urinary metabolite and Hb adduct data derived from human volunteers given a single 
oral dose of AA (15 µg/kg b.w.; Doroshyenko et al., 2009). Output data for internal dosimetry (i.e. 
steady-state concentrations or AUCs for AA and GA) were not reported except for an interspecies 
comparison between male rats and humans. Using simulated AUCs for AA and GA as the 
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comparators, administration of a single dose of 100 µg AA/kg b.w. to rats was reported to be 
equivalent to a human dose of 23 µg AA/kg b.w. for AA and of 130 µg AA/kg b.w. for GA. This rat-
to-human equivalent dose relationship was reported to be linear up to doses of 2 mg/kg b.w.   
DeWoskin et al. (2013) compared internal dosimetry for AA and GA as AUCs derived from either 
PBPK modelling (Sweeney et al., 2010) or Hb adduct measurements in rats and humans (Doerge et al., 
2005a,b,c; Fennell et al., 2005; Tareke et al., 2006). The human equivalent doses and reference values 
(i.e. points of departure) derived from rat and human data using both procedures were similar to each 
other for neurotoxicity and carcinogenicity endpoints and essentially identical to those reported in the 
IRIS review of AA (US-EPA, 2010, see Section 1.1).  
7.1.5.1. Comparisons of PBPK model simulations of internal dosimetry  
Although the format of model output data reported by Sweeney et al. (2010) was not directly 
equivalent to those reported by Young et al. (2007) and Walker et al. (2007), some comparisons of the 
three models’ output for rat and human internal dosimetry for AA and GA are possible. When 
compared to the experimentally measured serum AUC value for AA and GA in rats treated by gavage 
with 0.1 mg AA/kg b.w. (Table 17), the predicted AUCs (Table 18) from Young et al. (2007) were 
similar, but the predictions from Walker et al. (2007) are consistently 2- to 3-fold higher than the 
measured values. Sweeney et al. (2010) did not report AUCs for rats.  
Only Young et al. (2007) produced a mouse model (Table 17). The relative metabolism of AA to GA, 
as estimated by the GA-AUC/AA-AUC ratios, was higher in male and female mice than either male 
and female rats and particularly higher than in humans (Table 18). It should be noted that the GA-
AUC/AA-AUC ratios are similar to the ΣGA/ΣAA ratios derived from analysis of total urinary 
metabolites in rodents and humans (see Section 7.1.3, Table 16).   
Table 18:  Physiologically based pharmacokinetic (PBPK) model-simulated areas under the curve 
(AUCs) for rodents and humans treated with a single oral dose of acrylamide (AA, 0.1 mg/kg b.w.) 
Species-Sex AA-AUC GA-AUC GA-AUC/AA-AUC Reference 
Rat-M  2.4 1.1 0.5 Young et al. (2007) 
Rat-F  4.3 2.8 0.7 Young et al. (2007) 
Mouse-M  1.5 3.3 2.2 Young et al. (2007) 
Mouse-F  0.91 2.3 2.5 Young et al. (2007) 
Human 15 ± 3.0
(a)
 1.6 ± 0.43
(a)
 0.1 Young et al. (2007) 
Rat-M  6 5 0.8 Walker et al. (2007) 
Human 25 6.2 0.2 Walker et al. (2007) 
Human 
Not reported 
(10 calc.)
(b)
 
Not reported  
(1.0 calc.)
(b)
 
0.1 Sweeney et al. (2010) 
AUC: area under the curve; b.w.: body weight; PBPK: Physiologically Based PharmacoKinetic (PBPK) modelling; 
SD: standard deviation; M: male; F: female. 
(a):  Model-predicted AUCs (mean ± SD) were determined from urinary time course and Hb adduct data for three men and 
three women from Fuhr et al. (2006).     
(b):  Calculated from HEDs reported by Sweeney et al. (2010) using experimentally determined male rat AUC values from 
Doerge et al. (2005a).  
 
It was also possible to compare model-predicted human AUCs across three models. Human AUCs 
were directly available from Young et al. (2007) and Walker et al. (2007) but were estimated by using 
the human equivalent doses reported by Sweeney et al. (2010) of 0.023 mg/kg b.w. for AA and 
0.130 mg/kg b.w. for GA and the respective experimentally derived AUCs from a dose of 0.1 mg 
AA/kg b.w. in male rats (Table 17). Human AUC values for AA and GA were highest from the 
Walker et al. (2007) model, lowest for the Sweeney et al. (2010) model, and intermediate for the 
Young et al. (2007) model (Table 18). Simulated human AUCs for AA were consistently higher than 
the rodent values in all models but the human GA AUCs were similar to rodents from Young and 
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Sweeney models but higher from the Walker model. This finding for AA is in accordance with inter-
species predictions from allometry (see below), where larger animals typically show higher AUCs for 
the parent compound from identical doses, when administered on a ‘mg/kg b.w.’ basis (US-EPA, 
2011).  However, the AUCs for GA in different species also vary due to inter-species differences in 
metabolism, as well as allometry (e.g. epoxidation of AA, conjugation by GSH, hydrolysis by water, 
excretion by the kidney, etc.). 
7.1.5.2. Inter-species extrapolation of dosimetrics for AA and GA using a Human-Equivalent Dose 
(HED) approach 
A critical aspect of this risk assessment is the extrapolation of findings from animal toxicology studies 
with AA to predict the potential for effects in humans. This extrapolation includes uncertainties 
surrounding inter-species and intra-species differences in toxicokinetics and toxicodynamics, which 
are often incorporated by using default uncertainty factors to convert reference points (e.g. BMDL, 
NOAEL) into health-based guidance values (e.g. tolerable daily intake or TDI). Derivation of a 
human-equivalent dose (HED) is an accepted method for incorporating toxicokinetic data from animal 
studies to reduce uncertainties in estimating human dosimetrics (US-EPA, 2011). The US-EPA default 
dosimetric adjustment factor uses the body weight ratio to the ¾ power as the scaling factor 
[(b.w.-human/b.w.-animal)
3/4
] when toxicokinetic measurements from different species are not 
available.  The HED concept is best understood as a prediction of the dose, that when administered to 
a human on a mg/kg b.w. basis, produces an identical AUC for the toxicologically important molecule, 
either the parent compound or an active metabolite, as observed in the test species used for the 
toxicological evaluation at some specified dose. For example, if the BMDL10 in a rat toxicity test is 
determined to be 1 mg/kg b.w. and that dose produces an AUC for the test compound in the rat of 
1 nM × hour but the same dose produces an AUC in human of 4 nM × hour, the HED is 0.25 (1/4). In 
order to incorporate inter-species differences in toxicokinetics into the derivation of a health-based 
guidance value, one would multiply the rat BMDL10 value by the HED to give a reference dose of 
1 mg/kg b.w. × 0.25 = 0.25 mg/kg b.w. for a 70 kg human (or lower if additional uncertainty factors 
were included, as is typical). In this example, the allometric relationship between rats and human, 
based on the difference in b.w. (0.25 vs. 70 kg), also predicts that a lower dose is required in humans 
to produce an internal exposure that causes a defined degree of toxicity in the rat model.   
Since target tissue concentrations of AA and GA are thought to determine different toxicological 
effects observed from doses used in the critical animal studies (i.e. AA is associated with neurotoxicity 
and GA is associated with genotoxicity, see Sections 7.3.2.7 and 7.3.3.3) and measurements of serum 
AUC correlate with formation of the respective adducts (i.e. Hb adducts of AA and GA, and GA-DNA 
adducts, Tareke et al., 2006; see Sections 7.2.2. and 7.2.3.2), the AUCs for AA and GA derived from 
PBPK models for animals and human can be used as the basis to characterize inter-species differences 
in toxicokinetics.  
HEDs for AA and GA were determined for rodent species and humans using simulations from the 
three PBPK models as shown in Table 19 for a common dose of 0.1 mg AA/kg b.w. The Young et al. 
(2007) model simulated data from male and female rats and mice and the Walker et al. (2007) and 
Sweeney et al. (2010) models simulated data only from male rats. HEDs were calculated using the 
data in Table 18 by dividing the rodent AUC by the corresponding human value. For example, the 
male mouse HED for AA was calculated from the mouse/human AA-AUC ratio of 1.5/15 = 0.10 and 
the corresponding HED for GA formation was determined from the GA-AUC ratio 3.3/1.6 = 2.1. The 
male rat-associated HED values for AA were similarly predicted by all three models (0.16-0.24) and 
for GA (0.69-1.3). The Young et al. (2007) mouse model produced HEDs of 0.06-0.10 for AA and 
1.4-2.1 for GA. The HEDs for AA are similar to those predicted for rat (0.24) and mice (0.14) based 
on allometric relationships between pharmacokinetic parameters and body weights alone (i.e. using the 
US-EPA (2011) default factor of (BWH/BWA) raised to the ¾ power). However, the HEDs for AA 
metabolism to GA are larger than predicted by body weight scaling alone, particularly in the mouse, 
meaning that larger doses of AA, on a mg/kg b.w. basis, are required in a human to produce equivalent 
AUCs for GA (Table 17 and 18). 
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Table 19:  Human-equivalent doses (HEDs) from PBPK modelling. HEDs were calculated from the 
Young et al. (2007), Walker et al. (2007) and Sweeney et al. (2010) PBPK model-predicted rodent 
AUC/human AUC ratios for a common dose of AA (0.1 mg/kg b.w.) and represent the multiple of the 
AA dose to a rodent that a human would require to obtain an equivalent AUC for either AA or GA 
(e.g. an HED of 0.1 means that humans require 1/10 of the dose given to an animal, on a mg/kg b.w. 
basis, to produce an equivalent AUC value).   
Species-Sex HED-AA HED-GA Reference 
Rat-M 0.24 0.81 Walker et al. (2007) 
Rat-M 0.23 1.3 Sweeney et al. (2010) 
Rat-M 0.16 0.69 Young et al. (2007) 
Rat-F 0.29 1.8 Young et al. (2007) 
Mouse-M 0.10 2.1 Young et al. (2007) 
Mouse-F 0.06 1.4 Young et al. (2007) 
AA: acrylamide; AUC: area under the curve; GA: glycidamide; HED: Human Equivalent Dose; M: male. F: female. 
 
PBPK modelling predicted that a 1.4 or 2.1-fold higher dose of AA was required in a human to 
achieve the same GA-AUC as that in the female or male mouse, respectively (see Table 18, Young et 
al., 2007). This reinforces the idea that mice are more proficient in converting AA to GA than humans 
(see Table 19). The HED for GA-related endpoints derived from the three PBPK models for male rats 
ranged between 0.69–1.3, whereas the HED from female rats was intermediate between the HEDs 
from mice.    
7.1.5.3. Use of PBPK modelling for human cancer and neuropathy risk assessments 
Three publications have used internal dosimetry simulations from PBPK models for risk assessment of 
neurotoxicity and cancer in an effort to reduce uncertainty in extrapolating across dose and species 
from animal toxicity testing to humans exposed to AA in the diet (Doerge et al., 2008; Tardiff et al., 
2010; DeWoskin et al., 2013).  
(i) Doerge et al. (2008) interpreted results from rodent studies as being consistent with a genotoxic 
mechanism for AA carcinogenesis by virtue of its metabolism to GA, DNA adduct formation (N7-
GA-Gua), somatic cell mutagenesis, and ultimately, tumour formation. This study used the Young et 
al. (2007) PBPK model to simulate the levels of N7-GA-Gua DNA adducts in rat target tissues using 
BMDL10 values (0.40 mg/kg b.w. per day for female mammary, 0.66 mg/kg b.w. per day for male 
peri-testicular mesotheliomas, 1.2 mg/kg b.w. per day for male thyroid, 1.3 mg/kg b.w. per day for 
female rat central nervous system (CNS), and 1.5 mg/kg b.w. per day for female thyroid) as the AA 
dose from BMD analysis of the chronic male and female F344 rat bioassay tumour incidence data 
from Johnson et al. (1986). These adduct levels in tumour target tissues were then compared with 
simulated N7-GA-Gua levels in the analogous human tissues predicted to result from daily 
consumption of AA in the diet at a level of 0.4 µg/kg b.w. The MOEs for thyroid, central nervous 
system, peri-testicular mesothelium and mammary gland were in the range of 260–960. These MOEs 
were consistent with those previously estimated by JECFA (FAO/WHO, 2006, 2011) for mean and 
high levels of AA consumption of 1 and 4 µg/kg b.w. per day, respectively.  
Similarly, Doerge et al. (2008) used the Young et al. (2007) PBPK model to estimate the 
brain/nervous tissue concentrations of AA from several studies reporting neuropathy in rat bioassays 
(Burek et al., 1980; Johnson et al., 1986; Friedman et al., 1995). Dose-response analysis using the 
generalised multistage model provided BMDL10 values for neuropathy of 0.65 mg/kg b.w. per day for 
males and 0.60 mg/kg b.w. per day for females from Johnson et al. (1986) for 2-year exposures; and of 
0.37 mg/kg b.w. per day for males and 0.90 mg/kg b.w. per day for females from Friedman et al. 
(1995) for 2-year exposures. In addition, Doerge et al. (2008) reported a NOAEL of 0.20 mg/kg b.w. 
per day for males derived from the data obtained by Burek et al. (1980) upon 90-day exposure of male 
rats). The PBPK model then used those doses to predict rat brain/nervous tissue concentrations of AA. 
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Those concentrations in rats were then compared with the predicted value of brain/nervous tissue AA 
in humans from daily consumption of AA in the diet at a dose of 0.4 µg/kg b.w. to calculate MOEs. 
Using male and female rat neuropathy data from lifetime (two years) exposures to AA, the MOEs 
were in the range of 130–320; for a 90-day exposure to AA, the MOE was 54 using the BMDL10 
values (Doerge et al., 2008). These MOEs were similar to those previously estimated by JECFA 
(FAO/WHO, 2006) for mean and high levels of AA consumption of 1 and 4 µg/kg b.w. per day, 
respectively. 
(ii) Tardiff et al. (2010) used PBPK model simulations of internal dosimetry for AA and GA from 
Sweeney et al. (2010) to interpret results from chronic rodent studies as being primarily consistent 
with hormonal dysregulation in the carcinogenic mechanism. A nonlinear dose-response approach was 
applied for carcinogenicity (mixed: genotoxicity and epigenetic mode of action (MoA)). Using also 
the dose-response data for rats exposed to AA in drinking water (Johnson et al., 1986; Friedman et al., 
1995), the authors calculated a geometric mean reference point from the BMDL10 values for thyroid 
tumours, CNS tumours, mammary gland tumours and peri-testicular mesothelioma data which 
amounted to 0.022 mg/L*hour for rat using the AUC for AA as the dose metric, equivalent to a human 
equivalent dose of 1.8 mg/kg b.w. per day. From these BMDL10 values the authors derived TDI and 
MOE values. The TDIs for cancer were estimated to be 2.6 and 16 µg/kg per day based on AA and 
GA, respectively. MOEs were calculated for average AA consumers to be 300 and 500 based on AA 
and GA, respectively. For cancer, the MOE for average AA consumers was estimated to be 200 and 
1 200 based on AA and GA, respectively. The CONTAM Panel noted that the establishment of a TDI 
is generally considered inappropriate for a chemical that is both genotoxic and carcinogenic.  
Similarly, Tardiff et al. (2010) also applied a nonlinear dose-response approach for neurotoxicity (non-
genotoxicity) and calculated MOEs for rat neuropathy results from 2-year exposures (Johnson et al., 
1986; Friedman et al., 1995), of 300 for mean human consumption and 80 for high consumption, 
assuming that AA is the toxic species, and 500 or 130, respectively, assuming that GA is the toxic 
species (Table 19). The TDI for neurotoxicity from AA was estimated to be 40 µg/kg per day and for 
GA was 70 µg/kg per day.  
(iii) DeWoskin et al. (2013) used HEDs for AA and metabolically produced GA derived from either 
the Sweeney et al. (2010) PBPK model or a Hb adduct-based approach to determine reference doses 
(RfD, see Section 1.1) for AA-induced neuropathy based on a BMDL05 of 0.27 mg AA/kg b.w. per 
day from chronic exposure in male rats (RfD = 0.002 mg AA/kg b.w. per day), and for AA-induced 
carcinogenicity based on a BMDL10 of 0.15 mg AA/kg b.w. per day for combined incidences of 
thyroid tumours and tunica vaginalis mesotheliomas in male rats from an oral chronic exposure study 
(oral slope factor of 0.5 per mg AA/kg b.w. per day).  
In all cases, the reference point from rat dose response data was multiplied by the appropriate HED to 
determine the human equivalent reference point. The reference points reported were essentially 
identical to those reported in the US-EPA assessment of AA (US-EPA, 2010, see Section 1.1). 
7.2. Biomarkers of exposure/effects 
Biomarkers of exposure for AA include its urinary metabolites (notably AAMA, GAMA and iso-
GAMA) and its adducts with Hb and with DNA. Data gained from urinary metabolite determinations 
reflect exposure to AA over recent days. As globin adducts are not repaired they are accumulated over 
the lifespan of the protein, which is circa 120 days in humans, and their measurement thus represents a 
more chronic exposure to AA. As the lifespan of Hb is lower in experimental animals than in humans, 
the lifetime of globin adducts is shorter in experimental animals than in humans. Loss of Hb adducts in 
mice and both sexes of rats follows apparent first-order kinetics, the half-times for loss of AA- and 
GA-Val both being 8.8 days in mice, and 12–13 and 11–12 days in male and female rats, respectively 
(Tareke et al., 2006). DNA adducts are less persistent than globin adducts, the half-life in mouse liver 
being 2.6 days and in rat liver 4.1 days (females) and 4.5 days (males). In leukocytes the half-lives for 
loss of the DNA adduct are 6.7 days (females) and 7.4 days (males) (Tareke et al., 2006). 
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7.2.1. Mercapturic acids  
The urinary metabolites most commonly used as biomarkers are the mercapturic acids derived from 
AA and GA (AAMA, GAMA and iso-GAMA) which are stable compounds and which can be 
quantified with high specificity and sensitivity (see Section 7.1.3). In humans, AAMA can be partially 
sulfoxidized to AAMA-sulfoxide (Fennell et al., 2005; Kopp and Dekant, 2009). The metabolite 
DHPA has been reported not to be a specific biomarker for AA exposure (Latzin et al., 2012).   
Data gained from urinary metabolite determinations reflect recent exposure to AA (i.e. up to circa two 
days prior to the biomarker measurement). 
7.2.1.1. Analytical methods 
AAMA and GAMA are generally analysed by HPLC methods with detection by tandem mass 
spectrometry (MS/MS) using multiple reaction mode (MRM). The procedures involve addition of 
stable isotopically labelled standards (d3-AAMA, d3-GAMA) to a urine sample, and HPLC-MS/MS 
with either positive or negative ESI (Bjellas et al., 2005; Boettcher and Angerer, 2005; Boettcher et 
al., 2005; Fennell et al., 2006; Kopp et al., 2008; Schettgen et al., 2008; Berger et al., 2011; Huang et 
al., 2011a,b; Chiang et al., 2015). In most procedures SPE column purification of the metabolite prior 
to MS analysis has been used, although column switching techniques with an on-line trap column have 
also been developed (Kellert et al., 2006; Kopp et al., 2008). Metabolomic analysis of urine from rats, 
using nuclear magnetic resonance- (NMR)-based and HPLC-MS-based methods, has detected the 
mercapturic acid metabolites, together with changes in endogenous metabolites (such as an increase in 
creatinine and a decrease in taurine) showing that metabolomics analysis may have potential to 
provide biomarkers of effect (Sun et al., 2010). 
7.2.1.2. Use of mercapturic acids as biomarkers 
Determination of AAMA and GAMA in urine has been widely used as a biomarker for AA exposure 
since the evaluation of AA by JECFA in 2005 (FAO/WHO, 2006). Studies which are particularly 
related to food consumption or oral administration of pure AA are summarised below. 
Experimental animal studies 
Dose-response studies by Kopp and Dekant (2009) and Watzek et al. (2012a) for the excretion of 
mercapturic acids in experimental animals following the oral administration of AA are reported in 
Section 7.1.2.1. Studies on the excretion of mercapturic acids following administration of AA in food 
matrices by Bjellaas et al. (2007a) and Berger et al. (2011) are reported in Section 7.1.1.   
In summary, these studies show that the urinary excretion of mercapturic acids from AA and GA 
increases in a dose-dependent manner following administration of AA. 
Human studies 
Detailed data have been obtained on the extent of excretion of mercapturic acids in humans following 
the oral administration of a low dose of stable isotopically labelled AA (see Table 16).  
Boettcher et al. (2006b) studied the influence of an AA-free diet on the excretion of urinary 
mercapturic acid metabolites derived from AA in three healthy volunteers fasting for 48 hours. 
Urinary AA mercapturic acid metabolites were considerably reduced after 48 hours of fasting, 
confirming that the diet is the main source of non-occupational AA exposure in humans (apart from 
smoking). 
In a study of 47 non-smoking individuals the estimated AA intake did not correlate with urinary 
biomarkers (Bjellaas et al., 2007b). The median (range) total excretion of AA as mercapturic acid 
metabolites in urine during 24 hours was 16 (7–47) µg for non-smokers. The median intake estimate in 
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the study based on 24-hour dietary recall was 21 (13–178) µg AA. The total AA-derived urinary 
metabolites correlated with intake of aspartic acid, protein, starch and coffee (n = 53). 
In a study of 119 pregnant non-smoking women by Brantsæter et al. (2008), the dietary median 
(95th
 percentile) intake of AA was 0.48 (0.92) μg/kg b.w. per day as estimated by FFQ, 
0.41 (0.82) μg/kg b.w. per day as estimated by food diary, and 0.42 (0.70) μg/kg b.w. per day as 
estimated by probabilistic approach. The total 24 hours AA-derived urinary metabolites was 0.16 
(0.50) μg/kg b.w. per day in non-smokers. A significant correlation was observed between biomarker 
and estimated dietary intake. The total AA-derived urinary metabolites correlated with intake of crisp 
bread, potato crisps, cooking oil and garlic.   
In the study of Heudorf et al. (2009), the internal exposure to AA and GA was studied in 110 children 
with regard to their exposure through diet and/or environmental tobacco smoke. Median 
(95th percentile) urinary levels were 36.0 (152.7) µg AAMA/L and 13.4 (55.9) µg GAMA/L. Based 
on the metabolite levels, the median uptake of AA was calculated to be 0.54 µg/kg b.w. per day. A 
number of associations with the consumption of French fries, various potato products, as well as fried 
cereals were found. No correlations between the exposure to environmental smoke and cotinine levels 
in urine were found.  
The effects of genetic polymorphisms in CYP2E1, GST and mEH on excretion of mercapturic acids of 
AA and GA were studied in 85 workers exposed to AA (Huang et al., 2011a). A high interindividual 
variability in the metabolism of AA to GA was observed in the population and the results suggested 
that mEH and/or GSTM1 may be associated with the formation of urinary AAMA and GAMAs. 
The excretion of mercapturic acid metabolites was measured in human urine collected up to 72 hours 
after consumption of potato crisps (Watzek et al., 2012b). The intake was of home-prepared potato 
crisps corresponding to ca. 1 000 µg AA per 150 g portion (a protocol similar to that published by 
Doroshyenko et al., 2009) and also commercially available potato crisps corresponding to an uptake of 
44 µg AA per portion of 175 g. Excretion of AA-related mercapturic acids was detected (see Section 
7.1.3). 
In the study of Ji et al. (2013) the levels of AAMA were measured in urine of Korean children. The 
concentrations of AAMA in urine ranged between 15.4 and 196.3 ng/mL, with a median level of 
68.1 ng/mL. Children exposed to environmental smoke had significantly higher levels of urinary 
AAMA. Median (95th percentile) values of daily AA intake in Korean children were 1.04 (2.47) μg/kg 
b.w. per day (Ji et al., 2013). 
Brisson et al. (2014) studied the relationship between dietary intake of AA and biomarkers of exposure 
to AA in a group of non-smoking teenagers (n = 195). AA and its metabolites, GA, S-(2-
carbamoylethyl)-L-cysteine, AAMA, AAMA-SO, GAMA and iso-GAMA were quantified in urine 
samples by HPLC-MS/MS. The method was sensitive enough to detect AAMA, AAMA-SO, GAMA 
and S-(2-carbamoylethyl)-L-cysteine in almost all urine samples. The most abundant metabolites 
detected were AAMA and AAMA-SO with respective geometric mean concentrations of 81.7 and 
39.7 µg/L (31.2 and 14.2 µmol/mol creatinine). The daily intake of AA during the two days before 
urine sampling (based on a 2-day food diary) was significantly correlated with the sum of AAMA and 
AAMA-SO urinary concentrations (p for trend < 0.0001). 
In the study of Lee et al. (2014a), urinary AA and AAMA were determined by LC-MS/MS in a 
population of 1 873 South Korean adults. Levels of AA and AAMA were detectable in 98.7 % and 
99.4 %, respectively, of the urine samples, with population-weighted geometric means of AA and 
AAMA being 6.8 ng/mL (95 % CI: 6.4–7.3) and 30.0 ng/mL (95 % CI: 28.2–31.8), respectively, and 
creatinine-adjusted geometric means  6.2 µg/g creatinine (95 % CI: 5.8–6.7) and 26.4 µg/g creatinine 
(95 % CI: 24.9–28.0), respectively. The urinary AA concentrations varied significantly depending on 
sex, education, BMI, and smoking status, and the AAMA concentrations varied significantly 
according to sex, BMI and smoking status. The AA and AAMA levels of men were significantly 
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higher than those of women. The strongest predictors for AA levels were lower education and 
increasing age, and for AAMA the strongest predictors were increasing smoking status and lower 
education. Smoking increased the level of AA 1.3 fold and AAMA 3.0 fold compared to the levels 
found in never smokers. 
The relationship between AA intake, assessed using duplicate diets, and excretion of AAMA and 
GAMA was studied in a group of volunteers (n = 14) by Ruenz et al. (in press). On days 1, 2 and 3 an 
AA-minimised diet was consumed, the maximum AA exposure not exceeding 41 ng/kg b.w. per day. 
On day 4 a diet resulting in a low AA intake was consumed (0.6–0.9 g/kg b.w.). On days 5 and 6, as 
a washout period, the AA-minimised diet was consumed, and on day 7 a diet resulting in a high AA 
intake was consumed (1.3–1.8 g/kg b.w.). Finally there was another washout period on days 8 and 9 
with an AA-minimised diet. After both low and high AA exposure the urinary excretion of AAMA 
was 58 % of the ingested AA amounts within 72 hours. The excretion of GAMA was 10 % of the 
ingested AA amount after the low dose of AA, and 7 % after the high dose of AA, within 72 hours. 
The baseline level of AAMA after the initial three day washout period suggested a baseline exposure 
level of AA of 0.2–0.3 g/kg b.w. per day. 
7.2.2. Hb adducts 
Adducts of AA and GA with Hb are formed at several nucleophilic sites, the major site of reaction for 
AA being the cysteine SH groups. Cysteine adducts were the first Hb adducts to be determined in AA 
biomarker studies, although the analytical approaches were complex and sometimes not specific for 
AA. Specifically, rat Hb contains a reactive cysteine residue that is not found in other species, 
including humans. For this reason, studies of AA-Cys are not useful for human risk assessment. AA 
and GA adducts are also formed at the N-terminal valine residue of Hb, which is conserved across 
many species including laboratory rodents and human. Therefore, determination of these adducts is 
now the optimal approach for biomarker purposes, in view of the development of sensitive and 
specific analytical approaches for these products (Section 7.2.2.1).  
Globin adducts are not repaired and are accumulated over the lifespan of the erythrocyte (120 days in 
humans) and their measurement thus represents exposure to AA over this time period. A theoretical 
relationship between Hb adduct formation and circulating AUCs for AA and GA was published by 
Calleman et al. (1992) that was subsequently confirmed experimentally by linear correlations between 
Hb adduct levels in mice and rats dosed by oral and injection routes with 0.1 mg/kg b.w. AA or GA 
and the corresponding serum AUCs for either AA and GA (Tareke et al., 2006).   
The EFSA colloquium (EFSA, 2008) noted from the study of Bjellaas et al. (2007c) that Hb adducts 
did not correlate well with estimated dietary intake of AA, and that there was only a weak association 
of Hb adducts with estimated dietary AA in two other studies of non-smokers (Kütting et al., 2008; 
Wirfält et al., 2008). JECFA also concluded that ‘there was a poor correlation between the estimated 
dietary exposure and internal biological markers of AA exposure (AA-valine and GA-valine 
haemoglobin adducts) in humans’ (FAO/WHO, 2011). However BfR noted that ‘blood and/or urine 
biomarkers may be more suitable for determining the AA intake of consumers than the estimation via 
the AA contents in food and consumption data’ (BfR, 2011). The reason for this conclusion is that the 
urinary biomarkers and the Hb adducts currently used as blood biomarkers reflect the internal dose of 
AA/GA that is present in the experimental animal or human subject, and it is likely that they may be a 
more reliable indicator of dose than that derived from dietary estimates, in view of the number of 
potential variables which might affect the accuracy of the intake determination for AA.  
7.2.2.1. Analytical methods 
Törnqvist et al. (1986) described a sensitive and simple method for the analysis of Hb adducts using a 
modified Edman degradation procedure. The method used a fluorinated Edman reagent 
(pentafluorophenyl isothiocyanate) to specifically detach the adducted N-terminal amino acid in Hb 
(valine in the α- and β-chains in adult human Hb). This reaction produces a thiohydantoin derivative 
suitable for chromatographic analysis (Figure 10). The procedure has had widespread applications for 
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monitoring environmental and occupational exposure to alkylating agents. GC-MS/MS procedures 
(Paulsson et al., 2003; Schettgen et al., 2004b, 2010; Urban et al., 2006; Berger et al., 2011) and 
HPLC-MS/MS (Fennell et al., 2003) procedures have been developed for the analysis of Hb adducts 
with AA and GA. A typical HPLC-MS/MS procedure involves precipitation of globin from red blood 
cells, which is then reacted with pentafluorophenyl isothiocyanate, followed by addition of stable 
isotope-labelled analytes as internal standards, SPE purification and ESI HPLC-MS/MS (Fennell et 
al., 2005; Tareke et al., 2006; Bjellas et al., 2007c; Huang et al., 2012). In the procedure of Vesper et 
al. (2006) the analytes were isolated using liquid-liquid extraction on diatomaceous earth. Phenyl 
isothiocyanate was used as an alternative derivatising agent by Chevolleau et al. (2007). 
Further developments of the assay used modified derivatisation methods. For example the ‘FIRE 
procedure’ uses the modified Edman reagent fluorescein isothiocyanate (FITC) (von Stedingk et al., 
2011) and has an LOQ of 1 pmol/g Hb for the GA adduct analysis and 2 pmol/g Hb for the AA adduct 
analysis. In summary the procedure involves the incubation of lysed red blood cells with FITC, the 
addition of deuterium substituted (d7-) fluorescein thiohydantions as internal standards, SPE 
purification, and analysis using positive ESI HPLC-MS/MS. 
 
 
 
 
 
 
 
 
Figure 10:  Adducts formed by acrylamide (AA) and glycidamide (GA) with N-terminal valine in 
globin, and the thiohydantoin products that are used for their analysis which are formed by a modified 
Edman degradation procedure. RNCS: pentafluorophenyl or fluorescein isothiocyanate 
Apart from the modified Edman degradation, other methods for the analysis of AA-Hb adducts have 
not been as well established. Preston et al. (2009) described the successful development of monoclonal 
antibodies specific for AA-adducted Hb, which was hoped by the authors to have potential for use in a 
high throughput analytical method; however this approach needs further development. Using MS/MS 
techniques to analyse whole globins or protein tryptic digests, Basile et al. (2008) characterised the 
sites in Hb that form adducts with AA, and suggested that this proteomic approach to analyse these 
adducts has potential for use as a biomarker. 
7.2.2.2. Use of Hb adducts as biomarkers 
The detection of background levels of Hb N-terminal valine adducts corresponding to AA in humans 
gave the first indication that there was a regularly occurring exposure to AA in the general population 
(Bergmark, 1997). Rats fed fried animal standard diet for 1 or 2 months showed an increase in the 
amount of the AA Hb adduct compared to control rats fed unfried diet, indicating that heated food was 
the probable origin of the background exposure to AA (Tareke et al., 2000). This was confirmed by 
demonstrating that AA is produced by heating a range of foods (Tareke et al., 2002). 
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Since then the modified Edman degradation technique has been widely used to determine the amount 
of the N-terminal AA or GA-adducts in Hb as a biomarker of AA exposure. Some of the key studies 
particularly related to dietary exposure to AA, or of oral administration of pure AA, are summarised 
below. In addition to these investigations, Hb adducts of AA have been used in epidemiological 
studies (described in Section 7.4), and PBPK modelling (described in Section 7.1.4). 
Experimental animal studies 
In the study of Tareke et al. (2006), F344 rats and B6C3F1 mice were exposed to AA by repeat dosing 
with drinking water containing AA. The average daily doses of AA delivered were 2.59 ± 0.69 mg/kg 
b.w. per day (mice), 1.07 ± 0.28 mg/kg b.w. per day (female rats), 0.96 ± 0.28 mg/kg b.w. per day 
(male rats). AA-Hb and GA-Hb adducts accumulated to apparent steady state levels (Tareke et al., 
2006). From an analysis of Hb adduct formation and serum toxicokinetics after single dose 
administration of either AA or GA by different routes of administration, significant linear relationships 
were observed between the AA- and GA-Hb adduct levels and the corresponding AUCs (Tareke et al., 
2006).   
Vikström et al. (2008) investigated mice (male, C57BL) fed diets containing five different levels of 
AA, with administered daily intakes of AA between 3 and 50 µg/kg b.w. per day. A linear relationship 
was observed between AA exposure and AA-Hb and GA-Hb adduct levels (Vikström et al., 2008). 
In the study of Zeiger et al. (2009), AA was administered by gavage to male B6C3F1 mice for 28 days 
at 12 doses, ranging from 0–24 mg/kg b.w. per day. The levels of both the AA-Hb and the GA-Hb 
adducts increased with dose. The GA-Hb  to  AA-Hb  adduct  ratio  decreased from  approximately 
12–13 at the lower doses to 5.4 at the highest dose (Zeiger et al., 2009). 
Berger et al. (2011) investigated if food matrices affect bioavailability and biological activity of AA in 
rats (see Section 7.1). Although AA-Hb adducts increased with increasing cumulative dose, there was 
no evidence for significant treatment-related effects on GA-Hb adduct formation.    
In summary, these studies have shown that levels of AA- and GA-Hb adducts increase in a dose-
dependent manner after oral treatment of experimental animals with pure AA or AA in food (Tareke et 
al., 2006; Vikström et al., 2008; Zeiger et al., 2009; Berger et al., 2011 (AA-Hb only)). Administration 
of AA by intraperitoneal (i.p.) injection to mice and rats has also shown dose-dependent increases in 
AA-Hb and GA-Hb adduct levels (Paulsson et al., 2002). 
Human studies 
A dose dependent increase in the level of AA- and GA-Hb adducts was seen in a study of humans 
orally administered [
13
C3]-AA (Fennell et al., 2005). 
Schettgen et al. (2004b) determined the AA-Hb adduct levels in the blood of pregnant women (one 
smoker, 10 non-smokers) and the umbilical cord blood of the corresponding neonates. There was a 
good correlation (r = 0.859) between adduct levels in non-smoking mothers and neonates. The Hb of 
the neonates contained approximately 50 % of the adduct level that was found in the Hb of the mother.   
Hagmar et al. (2005) studied AA-Hb adducts in samples from a blood bank of the Malmö Diet and 
Cancer Cohort. The authors selected 142 individuals chosen to obtain the highest possible variation in 
the adduct levels from AA (none, random or high intake of coffee, fried potato, crisp bread and 
snacks, food items estimated to have high levels of AA). The levels of AA-adduct ranged between 
0.02 and 0.1 nmol/g in non-smokers (n = 70), with considerable overlap between the different dietary 
groups. A significant difference was observed between men with high dietary exposure to AA 
compared to men with low dietary exposure (p for trend 0.04). This was not observed for women. A 
higher level of the AA-adduct was found in smokers (range: 0.03–0.43 nmol/g) (Hagmar et al., 2005). 
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AA-Hb and GA-Hb adducts were analysed in human Hb samples by Chevolleau et al. (2007) using 
ESI HPLC-MS/MS and phenyl isothiocyanate as derivatising agent. After assessment of the method 
on rats administered acrylamide by gavage (50 mg/kg b.w.), the procedure was applied to 68 Hb 
samples from the general French population. Mean levels of 33 and 23 pmol/g globin were observed 
for AA-Hb and GA-Hb adducts respectively, smokers giving higher mean values than non-smokers.  
Bjellaas et al. (2007c) showed in a study of 50 subjects that, using multiple linear regression analysis, 
a significant positive correlation was found between the AA-Hb adduct concentration and the intake of 
chips (presumably potato crisps)/snacks and crisp bread. GA-Hb adduct levels did not correlate with 
consumption of any of the main food groups. Neither AA-Hb nor GA-Hb adduct concentration 
correlated with total dietary intake of AA as calculated from the reported food intake (Bjellaas et al., 
2007c).  
Wirfält et al. (2008) showed a significant association in non-smokers (n = 70) between Hb AA adducts 
and estimated AA from foods (p for trend 0.006). In smokers (n = 72) both AA from foods (p for trend 
0.006) and the calculated amount of tobacco consumed (p for trend 0.003) were significantly 
associated with Hb AA adducts. 
Kütting et al. (2008) showed a strong correlation of AA-Hb adducts with smoking and a weak but 
significant correlation with estimated dietary exposure in non-smokers (n = 828). Risk implications of 
these data were discussed in Kütting et al. (2009). The effect of smoking (n = 16) which increased the 
levels of AA-Hb and GA-Hb adducts compared to the levels observed in non-smokers (n = 13) was 
also reported by Schettgen et al. (2004b). 
The study of Vikström et al. (2008) aimed to measure the relationship between dietary exposure to AA 
and internal doses of AA and its genotoxic metabolite GA at low levels of AA intake through the diet. 
A linear relationship was observed between the exposure to AA and Hb-adduct levels from both AA 
and GA at these low exposure levels. 
Naruszewicz et al. (2009) carried out a pilot study to investigate the effect of eating potato chips (i.e. 
potato crisps) on markers of oxidative stress and inflammation. AA-Hb adducts were used as a 
biomarker of exposure.  Fourteen healthy volunteers (eight women and six men) with a mean age of 
35 years, including four women and two men who smoked more than 20 cigarettes per day, were 
studied. They were given 160 g of potato chips containing 157 mg AA daily for four weeks. In the 
non-smokers (n = 8), AA-Hb levels increased after potato chip intake from 43.9 + 31.3 to 
87.0 + 47.1 pmol/g globin, and in smokers (n = 6), from 202.8 + 185.8 to 261.8 + 191.1 pmol/g globin. 
Significant increases were seen in oxidized LDL, high-sensitivity interleukin-6, high-sensitivity 
C-reactive protein, and γ-glutamyltransferase concentrations, and also in reactive oxygen radical 
production by monocytes, lymphocytes, and granulocytes and in CD14 expression in macrophages. 
Further larger studies are needed to corroborate these results. 
Vikström et al. (2010) also investigated whether alcohol consumption could have an influence on the 
metabolism of AA to GA in humans exposed to AA through food. Alcohol intake estimates were 
obtained from questionnaire data (161 non-smoking men) and compared with the ratio of Hb-adduct 
levels for AA and GA. A negative, linear trend of GA-adduct to AA-adduct level ratios with 
increasing alcohol intake was observed. The strongest association between alcohol intake and GA-
adduct to AA-adduct level ratios was obtained in the group of men with the lowest adduct levels 
(< 47 pmol/g globin) (p for trend = 0.02).   
In order to assess human exposure to AA and GA in the general U.S. population, AA- and GA-Hb 
adducts were measured in 7 166 subjects from the National Health and Nutrition Examination Survey 
(NHANES) (Vesper et al., 2010). Exposure to AA was detectable in > 99 % of all participants. There 
was a high variability of adduct levels among individuals but modest differences between population 
subgroups. AA-Hb and GA-Hb levels ranged from 3 to 910 and from 4 to 756 pmol/g Hb, 
respectively, smokers having higher geometric mean levels than non-smokers. Tobacco smoke 
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exposure in non-smokers had a small but significant effect on AA-Hb and GA-Hb levels. In non-
smokers the highest adjusted geometric mean levels were seen in children 3–11 years of age and 
lowest in adults aged > 60 years.  
Von Stedingk et al. (2011) used the adduct FIRE procedure to determine the adducts of AA and GA 
with Hb in maternal blood samples (n = 87) and umbilical cord blood samples (n = 219). Adduct 
levels from AA and GA were increased in tobacco smokers, and there was a significant correlation 
between cord and maternal blood adduct levels (ratio cord: maternal 0.48 (range 0.27–0.86) for AA 
and 0.38 (range 0.20–0.73) for GA).  
In the study of Outzen et al. (2011), 537 non-smoking women aged 50–65 years were investigated to 
assess the dietary determinants of AA-Hb and GA-Hb adduct levels. Information on dietary and 
lifestyle variables was obtained from questionnaires. The median level for AA-Hb was 35 pmol/g 
globin and for GA-Hb was 21 pmol/g globin. Only a few dietary determinants of Hb-AA and Hb-GA 
were identified. Intakes of coffee and chips (i.e. potato crisps) were statistically significantly 
associated with higher AA-Hb adduct levels and intakes of coffee and biscuits/crackers were 
statistically significantly associated with higher GA-Hb adduct levels. The authors concluded that the 
study implies that dietary intake measured by an FFQ explains only to a limited extent the variation in 
AA-Hb and GA-Hb concentrations. 
In a study of Vikström et al. (2011), AA-rich foods were given to non-smokers and Hb adduct levels 
from AA and GA were measured in blood samples donated before and after exposure. These were 
used for calculation of AA-AUC and GA-AUC using reaction rate constants for the adduct formation 
measured in vitro. Two treatment schedules were used: a high intake of 11 µg AA/kg b.w. a day for 
four days or an extra (medium) intake of 2.5 µg AA/kg b.w. a day for a month. The AA-Hb and GA-
Hb adducts both increased about two-fold after the enhanced intakes of AA. The AUCs for the high 
and medium groups, respectively, were for AA 212 and 120 nanomolar hours per µg AA/kg b.w., and 
for GA 49 and 21 nanomolar hours per µg AA/kg b.w.  
The intra-individual variations of AA- and GA-adduct levels measured in blood samples from 13 non-
smokers, collected over 20 months, were up to 2-fold and 4-fold, respectively (Vikström et al., 2012). 
The corresponding interindividual variations between 68 non-smokers, with large differences in AA 
intake, were 6-fold and 8-fold, respectively. The intra-individual variation of the GA- to AA-adduct 
level ratio was up to 3-fold, compared to 11-fold between individuals (n = 68). From AA-adduct levels 
the mean AA daily intake (n = 68) was in relatively good agreement with that estimated from dietary 
history methodology, 0.52 and 0.67 µg/kg b.w. per day, respectively. A low correlation of these 
measures was observed at an individual level (Rs = 0.39). The authors concluded that dietary AA is 
the dominating source for measured AA-adduct levels and corresponding inter- and intra-individual 
variations in non-smokers, and that measurements from single individual samples are useful for 
calculation of average AA intake (Vikström et al., 2012). 
Huang et al. (2012) studied 51 AA-exposed workers and 34 controls to explore the effect of genetic 
polymorphisms of CYP2E1, mEH3, mEH4, GSTT1 and GSTM1 on AA and GA-Hb adduct levels. 
The results suggest that mEH4 and the combined genotypes of CYP2E1, GSTM1 and mEH4 may be 
associated with the formation of AAVal and GAVal (Huang et al., 2012) 
The effects of prenatal exposure to AA measured by determinations of AA- and GA-Hb adducts on 
birth weight and head circumference (Pedersen et al., 2012) is described in Section 7.4.2. In this study, 
which used cord blood samples from Greece, Spain, England, Denmark and Norway, it was observed 
that the median AA-Hb and GA-Hb adduct levels were higher in cord blood from children of mothers 
who smoked (n = 129) than in children of non-smokers (n = 972). The respective adduct levels were 
for AA-Hb 30.5 and 13.8 pmol/g Hb, p for trend < 0.001), and for GA-Hb 20.7 and 10.1 pmol/g Hb 
(p for trend < 0.001).   
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Brisson et al. (2014) studied the relationship between dietary intake of AA and biomarkers of exposure 
in a group of non-smoking teenagers (n = 195). The geometric mean concentration for the AA adduct 
with N-terminal valine in Hb was 45.4 pmol/g globin and for the GA adduct 45.6 pmol/g globin. The 
daily intake of AA during the 2 days before urine sampling was not correlated with the Hb adducts. 
However AA intakes (based on FFQ) during the month before blood collection and passive smoking 
were associated with the sum of AA and GA adduct levels (p for trend < 0.0001 and < 0.05, 
respectively). 
The adducts of AA and GA in Hb have been measured as biomarkers of exposure in the NHANES 
2003-2004 sample of the US population (Vesper et al., 2013). Adduct data for AA were available for 
4 093 participants and for GA for 4 152 participants. The population was estimated to consist of 48 % 
men and 71 % non-smokers. The association of sociodemographic and lifestyle factors with these 
biomarkers was assessed. Smoking was strongly and significantly correlated with both the AA and GA 
Hb adduct concentrations, and age was negatively correlated with both biomarkers. BMI was weakly 
negatively correlated with AA-Hb adducts levels. Alcohol consumption was weakly positively 
correlated with AA-Hb adduct levels but negatively associated with GA-Hb adduct levels after 
adjusting for sociodemographic and lifestyle variables. 
In the study of Ferrari et al. (2013), dietary estimates of AA from questionnaires and from 24-hour 
dietary recalls were compared with levels of AA adduct in Hb in 510 participants in the EPIC study. 
Estimates of total AA intake based on self-reported diet correlated only weakly with the AA-Hb 
adduct levels used as biomarker.  
The levels of AA- and GA-Hb adducts were compared between vegetarians (n = 29) and non-
vegetarians (n = 24) by Kotova et al. (in press). Micronuclei (MN) in transferrin-positive immature 
peripheral blood reticulocytes were measured by flow cytometry as a marker of genotoxic damage 
(vegetarians n = 27, non-vegetarians n = 26). There was no significant difference between vegetarians 
and non-vegetarians in the mean Hb adduct levels of AA and GA, but vegetarians showed a lower 
frequency of MN than non-vegetarians. As there was no significant relationship between MN 
frequency and Hb adduct levels, this indicates that AA intake does not contribute to the observed 
difference in MN frequency between vegetarians and non-vegetarians.  The ratio of GA to AA adducts 
was lower in non-vegetarians compared to vegetarians suggesting that there was an influence of 
dietary factors on AA/GA metabolism. 
7.2.3. DNA adducts 
DNA adducts derived from AA and GA have been investigated in in vitro studies and in experimental 
animals, particularly for mode of action studies (Section 7.3.6) and for their use in PBPK modelling 
(Section 7.1.5). AA reacts extremely slowly with DNA in vitro, producing a range of Michael addition 
products (Solomon et al., 1985), whereas GA is much more reactive by virtue of its electrophilic 
epoxide group. The N7-guanine adduct derived from GA, N-7-(2-carbamoyl-2-hydroxyethyl)guanine 
(N7-GA-Gua), is the major product following the incubation of AA with DNA in the presence of rat 
liver S9 (Segerbäck et al., 1995) and in vivo following the administration of AA to experimental 
animals (Figure 11). Minor amounts of adenine adducts of GA (N3-(2-carbamoyl-2-hydroxyethyl) 
adenine (N3-GA-Ade) and N1-(2-carboxy-2-hydroxyethyl)-2'deoxyadenosine) (N1-GA-dA) are also 
formed in vitro when DNA is incubated with GA (Gamboa da Costa et al., 2003). N3-GA-Ade is a 
minor product in DNA of tissues of mice and rats administered AA (Doerge et al., 2005c). 
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Figure 11:  Adducts formed by glycidamide (GA) with DNA 
Kotova et al. (2011) reported that N1-GA-dA, which was analysed by postlabelling after conversion to 
N6-(2-carboxy-2-hydroxyethyl)-2'-deoxyadenosine, was detectable in DNA reacted with GA and in 
DNA from cells exposed to GA, but not in DNA from mice treated with AA (7 week-old male CBA 
mice, single oral dose of AA (two animals received 60 mg and two received 40 mg/kg b.w.)). 
Thus N7-GA-Gua appears to be the most suitable biomarker of exposure for the genotoxic metabolite 
of AA, GA. In vivo N7-GA-Gua is removed from DNA, the reported half-lives for this in rats and 
mice being in the range 2.6 days (mouse liver) to 7.4 days (male  rat leukocytes) (Tareke et al., 2006). 
The use of N7-GA-Gua as a biomarker is thus likely to be more appropriate for detecting exposures to 
AA within the week prior to the biomarker measurement. A causal link between internal exposures to 
GA and DNA adduct formation was inferred from the linear correlation observed for N7-GA-Gua 
adduct levels in liver DNA from groups of mice and rats dosed by oral and injection routes with 
0.1 mg/kg b.w. AA or GA and the corresponding serum AUCs for GA, but not AA (Tareke et al., 
2006).   
7.2.3.1. Analytical methods 
Determination of N7-GA-Gua is carried out by HPLC-MS/MS with positive ESI. DNA is subjected to 
neutral thermal hydrolysis to release the N7-GA-Gua adduct which is quantified using MRM with 
[
15
N5]-N7-GA-Gua as the internal standard. N7-GA-Gua has also been determined in urine using 
HPLC-MS/MS with [
13
C3]-N7-GA-Gua as the internal standard (Huang et al., 2015a). 
7.2.3.2. Use of DNA adducts as biomarkers 
Experimental animal studies 
AA was administered to male Sprague Dawley rats by oral gavage at doses of 18 and 54 mg/kg b.w. 
(Manière et al., 2005). Tissue samples from brain, liver and testes were analysed for N7-GA-Gua 5, at 
24, 48, and 72 hours after dosing. N7-GA-Gua adducts increased with dose and a relatively consistent 
organ distribution of the adduct in brain, testes and liver was observed, but there was no accumulation 
of adducts in the liver where the activating enzyme CYP2E1 is primarily located.   
In the study of Tareke et al. (2006) (see Section 7.2.2.2), F344 rats and B6C3F1 mice were exposed to 
AA by repeat dosing with drinking water containing AA. The level of N7-GA-Gua in DNA 
accumulated to apparent steady state levels (Tareke et al., 2006).   
In the study of Zeiger et al. (2009), AA was administered by gavage to male B6C3F1 mice for 28 days 
at 12 doses, ranging from 0–24 mg/kg b.w. per day. The levels of N7-GA-Gua in liver DNA increased 
with dose (Zeiger et al., 2009).  
The effect of age was studied in rats by Koyama et al. (2011a). Three and 11 week old male gpt delta 
transgenic F344 rats were treated with 0, 20, 40 or 80 ppm AA via drinking water for four weeks. 
N7-GA-Gua levels were measured in DNA from liver, testes, mammary gland and thyroid, where they 
all increased in a dose-dependent manner. Adduct levels in young and adult animals did not differ 
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significantly in thyroid and mammary glands, but were higher in liver and testis of young compared to 
adult rats. The effect was particularly notable in the testis where young rats had a 6-fold higher level 
of N7-GA-Gua.  
Watzek et al. (2012a) carried out a dose-response study with AA in female Sprague-Dawley rats. After 
a single oral dose of 0.1–10 000 μg/kg b.w., N7-GA-Gua was determined in DNA from liver, kidney 
and lung 16 hours after dosage. Adducts could not be detected below the dose of 1 μg/kg b.w. but at 
this dose were detectable in kidney and lung (significantly different from control p for trend < 0.001). 
Adducts at doses of 100 µg/kg b.w. and above showed a significant increase above those at the next 
lower dose level (p for trend < 0.001) (Watzek et al., 2012a).  
In summary, levels of N7-GA-Gua in DNA have been shown to increase in a dose-dependent manner 
after oral treatment of experimental animals with AA and GA (Manière et al., 2005; Tareke et al., 
2006; Zeiger et al., 2009; Koyama et al., 2011a; Watzek et al., 2012a). Administration of AA by i.p. 
injection to mice and rats has also been shown to cause dose-dependent increases in N7-GA-Gua in 
DNA (Gamboa da Costa et al., 2003; Doerge et al., 2005c). 
Human studies 
It is known that N7-guanine adducts are susceptible to spontaneous and enzymatic depurination and 
that the released modified purine is excreted in urine. Monitoring of such urinary adducts has been 
suggested as a biomarker for the extent of DNA damage caused by a compound, although it should be 
noted that this approach cannot determine the nature of the tissue or the chemical structure from which 
the adduct in urine originated.   
In the study of Huang et al. (2015a), N7-GA-Gua was determined in the urine of 30 smokers and 
33 non-smokers by HPLC-MS/MS using MRM with [
13
C3]-N7-GA-Gua as the internal standard. The 
adduct was partially purified by SPE prior to the MS analysis. The subjects had no occupational 
exposure to AA. Urinary AAMA was determined as a biomarker of AA exposure and urinary cotinine 
as a biomarker of smoking. Other recorded parameters for the subjects included age, BMI, tea 
consumption, betel nut chewing, exercise habit and medication. In non-smokers the median N7-GA-
Gua level was 0.93 g/g creatinine and in smokers it was 1.41 g/g creatinine, which was not 
significantly different. Urinary AAMA levels were significantly increased in smokers. There was a 
significant correlation between urinary AAMA and N7-GA-Gua (g/g creatinine) in non-smokers, 
smokers and all study subjects. Multiple linear regression revealed that urinary N7-GA-Gua was only 
significantly associated with urinary AAMA. The authors concluded that the analysis of urinary N7-
GA-Gua could be considered to be a noninvasive method to measure the DNA alkylation by GA in 
vivo. 
No data are available on the effects of dietary exposure to AA on adduct levels in human DNA.  
7.2.4. Correlation between biomarkers  
In F344 rats and B6C3F1 mice exposed to a single dose gavage administration of AA (0.1 mg/kg b.w.) 
or an equivalent gavage dose of GA, a significant correlation was observed between GA-Hb adducts 
and N7-GA-Gua adducts in liver DNA (Tareke et al., 2006). Significant correlations were also 
observed in F344 rats and B6C3F1 mice between urinary AAMA and N7-GA-Gua adducts and 
between urinary GAMA and N7-GA-Gua adducts (Doerge et al., 2007).   
In a dose-response study AA in female Sprague Dawley rats, which encompassed human diet related 
exposure, levels of urinary AAMA and GAMA and of N7-GA-Gua in tissue DNA all showed 
significantly higher levels than controls at oral doses of 1 µg/kg b.w. (and above), and generally 
increased with dose. However, no calculated correlation between these biomarkers was reported. 
(Watzek et al., 2012a). 
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In the study of human volunteers carried out by Hartmann et al. (2008) (Section 7.1.3) no significant 
correlation was found between AA-Hb adducts and AAMA (Pearson, p = 0.02, r = 0.25) or between 
GA-Hb adducts and GAMA (Pearson, p = 0.03, r = 0.24). The authors thought that this might be 
because of the different exposure periods being monitored by the two biomarkers. However urinary 
N7-GA-Gua adducts were shown to be associated with AAMA in smokers and non-smokers in the 
study of Huang et al. (2015a) (Section 7.2.3). 
An association of the urinary levels of AAMA with a biomarker of oxidative stress, 8-hydroxy-
deoxyguanosine (8-OHdG), was observed in adolescents and young adults by Lin et al. (2013). Eight 
hundred subjects (mean age 21.3 years, range 12–30 years) were recruited, and urinary AAMA and 
8-OHdG were measured by HPLC-MS/MS, the mean (SD) concentrations being 76.54 (76.42) µg/L 
and 3.48 (2.37) µg/L, respectively. Urinary AAMA was positively associated with urinary 8-OHdG, 
and  sub-population  analyses  showed  the  association  to  be  significant  in  males,  subjects aged 
12–19 years, BMI ≥ 24, homeostasis model assessment of insulin resistance (HOMA-IR) ≥ 0.9, non-
current smokers, and subjects who did not consume alcohol. 
In the study of Zeiger et al. (2009) in male B6C3F1 mice, a linear correlation was seen between 
GA-Hb adducts and N7-GA-Gua in liver DNA, following the administration of AA by gavage for 
28 days at doses from 0–24 mg/kg b.w. per day.   
Very few correlation studies have been carried between these AA exposure biomarkers and 
biomarkers of biological effect. In the Zeiger et al. (2009) study in male mice described immediately 
above, micronuclei (MN) in normochromatic erythrocytes (NCEs) increased linearly with dose. 
However when Hb or DNA adducts were used as the dose matrix a non-linear dose-response 
relationship with a threshold at low doses was claimed by the authors to be the most appropriate 
model. Paulsson et al. (2002) showed that male CBA mice treated i.p. with 25, 50 or 100 mg/kg b.w. 
AA showed dose-dependent increases in both Hb adduct level and MN frequency in peripheral blood 
erythrocytes. In male Sprague Dawley rats treated with 100 mg/kg b.w. AA-Hb adducts were 
increased but no effect was seen on MN frequency in bone marrow erythrocytes (Paulsson et al., 
2002).   
The study of Hochstenbach et al. (2012) primarily investigated gene expression in cord blood and 
relationships with carcinogenic exposure in utero, and is described in detail in Section 7.4.2.2.  In this 
study a biomarker correlation was observed (in males only, 45 newborns) between both AA-Hb and 
micronuclei and GA-Hb adducts and micronuclei (correlation coefficient 0.75, p for trend 0.019, and 
correlation coefficient 0.73, p for trend 0.025, respectively).  
7.2.5. Conclusions 
Urinary mercapturic acids, Hb adducts and DNA adducts (N7-GA-Gua) all have different advantages 
as biomarkers for exposure to AA. Urine is non-invasive to collect for the mercapturic acid analysis, 
compared to blood/tissue collection for Hb and DNA adducts. The biomarkers reflect different 
timescales for the detection of exposure. For mercapturic acids this is only recent days prior to the 
biomarker measurement. For N7-GA-Gua the half-lives of the adduct in mice and rats are in the range 
of 3-7 days. The Hb adduct will accumulate over the lifespan of the erythrocyte, which is circa 
120 days in humans. N7-GA-Gua is the most appropriate biomarker to use for the interaction of GA, 
the genotoxic metabolite of AA, with DNA. The weight of evidence is that there are correlations both 
between these types of biomarkers, and between them and exposure to AA (see PBPK modelling, 
Section 7.1.5). Some evidence also exists for a correlation of these biomarkers with biomarkers of 
effects (e.g. MN in mice) but further confirmation of this is needed.  
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 105 
7.3. Toxicity in experimental animals 
7.3.1. Acute toxicity 
Oral LD50 values for AA were reported to be >150 mg/kg b.w. for rats (McCollister et al., 1964; 
Fullerton and Barnes, 1966; Tilson and Cabe, 1979), 107 mg/kg b.w. for mice (Hashimoto et al., 
1981), and 150–180 mg/kg b.w. for rabbits and guinea pigs (McCollister et al., 1964). 
7.3.2. Repeated dose toxicity 
In this section, the toxicological studies with repeated doses of AA conducted in rats, mice, monkeys, 
cats and dogs are reported. These studies were carried out using various dosing protocols and routes of 
exposure, mostly via oral exposure or injection. Some studies evaluated only neurotoxicity, while 
other studies also examined other effects, e.g. reproductive and developmental toxicity (see Section 
7.3.5). A few studies examined the time course of AA toxicity along with overt, morphological, and 
biochemical changes. Only those repeated-dose toxicity studies using oral exposure to AA are 
presented and discussed in this section. The biochemical changes observed are presented and 
discussed in Section 7.3.6.   
7.3.2.1. Mice 
ddY male mice (6 per group) were given 0 (control) or 36 mg/kg b.w. AA by oral gavage two times 
per week for 8 weeks (Hashimoto et al., 1981). Exposed mice showed weakness and ataxia of the 
hindlimbs. Rotarod performance showed a progressive decrease from 3 weeks onwards. Relative 
testicular weight was reduced by 17 %. Microscopic analysis of the testes revealed some degeneration 
of epithelia in spermatids and spermatocytes, reduction of spermatozoa and the presence of 
multinucleate giant cells.  
Female BALB/c mice (5 per group) were given 0 (control) or 26 mg/kg b.w. per day AA in drinking 
water for 12 days (Gilbert and Maurissen, 1982). After a 44-day recovery period the treated animals 
were given 20 mg/kg b.w. per day for 19 days. Some body weight loss and reduction in water 
consumption were noted. For the exposed mice hindlimb foot splay was increased from 6 days 
onwards, and rotarod retention time decreased from 8 days onwards. After the 44-day recovery period 
all these parameters were again at control values. A similar pattern of effects was noted for the second 
exposure period. 
Chapin et al. (1995) investigated the neurotoxicity of AA in Swiss mice via application in the drinking 
water at concentrations of 0, 3, 10, or 30 ppm (estimated doses: 0.81, 3.19, or 7.22 mg/kg per day) for 
14 weeks. At the highest dose level, male mice exhibited a deficit in forelimb and hind-limb grip 
strength in comparison to the untreated controls. 
Tyl et al. (2000a,b) treated male mice with AA in drinking water at concentrations resulting in 
estimated doses of 0, 5, 15, 30, 45, or 60 mg/kg per day for 5 days. Hind-limb grip strength was 
significantly reduced in the 60 mg/kg per day dose group, while forelimb grip strength was unaffected 
in any dose group. No histopathological changes were found in the sciatic nerves of any dose group. 
The NTP conducted a 13-week study (drinking water and diet) and a 2-year study (drinking water) in 
B6C3F1 mice administered AA (NTP, 2012). In the 13-week range finding study, groups of eight male 
and eight female mice were treated with AA at a concentration of 0, 0.14, 0.35, 0.70, 1.41 or 3.52 mM 
in drinking-water (0, 10, 25, 50, 100 or 250 mg/L equivalent to 0, 3.2, 6.9, 13.3, 32.8 and 70.0 mg/kg 
b.w. per day for males, and to 0, 3.5, 7.8, 16.4, 31.4 and 83.1 mg/kg b.w. per day for females) or 0, 
18.5, 37, 74, 185 or 370 mg/kg diet (equivalent to 0, 3.3, 6.6, 12.0, 32.1 and 59.4 mg/kg b.w. per day 
for males and 0, 3.7, 7.5, 13.9, 35.1 and 64.0  mg/kg b.w. per day for females). Small body weight 
reductions were noted at the two highest dose levels in the drinking water study and at the highest dose 
in the feeding study. Hindlimb paralysis was observed in all mice treated with AA at 3.52 mM/L or 
370 mg/kg diet. Radiculoneuropathy involving the sciatic nerve, lumbar spinal cord or both was 
observed in all mice treated with 3.52 mM/L, in one out of eight mice fed 185 mg/kg diet and in mice 
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fed 370 mg/kg diet. The neuronal degenerative changes were accompanied, at times, by atrophy in 
skeletal muscle of the hind-limb and urinary bladder dilation. The NOAELs were 0.70 mM for 
exposure via drinking water (equivalent to 13.3 mg/kg b.w. per day) and 74 mg/kg diet (equivalent to 
12.0 mg/kg b.w. per day). 
In the 2-year study (NTP, 2012), group of 48 male and 48 female B6C3F1 mice were administered AA 
ad libitum in drinking water at concentrations of 0.0875, 0.175, 0.35 and 0.70 mM (equivalent to 1.04, 
2.20, 4.11 and 8.93 mg/kg b.w. per day for males, and to 1.10, 2.23, 4.65 and 9.96 mg/kg b.w. per day 
for females). Control animals received the same tap water with no chemical added. A trend towards a 
decrease in survival was observed at the highest dose level for males and females, and for females also 
at the second highest dose level. Changes in body weight were only sporadic, and food and water 
consumption was generally not affected. Cataracts of the eyes in both male and female mice were 
observed at the highest dose administered, and for female also at the second highest dose level. A 
dose-related increasing trend in forestomach epithelium hyperplasia in both sexes was observed 
(significant at the highest dose level). Increasing dose-related trends in hematopoietic cell proliferation 
of the spleen were reported for both sexes being significant at the highest dose, and for females also at 
the second highest dose. Other non-neoplastic lesions in male mice included: preputial gland 
inflammation (significant at the two highest doses) and lung alveolar epithelium hyperplasia 
(significant at the highest dose level), and for female mice: ovarian cysts (increased at the lowest dose 
and the two highest dose levels) (NTP, 2012). A NOAEL could not be established for the non-
neoplastic effects in this study based on the increase of ovarian cyst observed at the lowest dose. The 
neoplastic findings of this study are described under Section 7.3.4.1. 
NTP also conducted a 13-week and a 2-year study in B6C3F1/Nctr mice administered GA in drinking 
water (NTP, 2014). In both studies, the concentrations of GA in drinking water were equimolar to 
those used for the respective AA study (NTP, 2012) (see also Section 7.1.5). In the 13-week study, 
groups of eight male and eight female mice were administered GA in drinking water at doses of 0.0, 
0.14, 0.35, 0.70, 1.41 or 3.52 mM (equivalent to 0, 12.2, 30.6, 61.2, 122 or 306 mg GA/L, and to 0,  
1.0, 3.2, 9.1, 19.2, 36.0 and 81.5 mg GA/kg b.w. per day for males, and to 0, 4.1, 10.8, 20.1, 45.3 and 
96.5 mg GA /kg b.w. per day for females). Significant body weight reduction was observed in males 
given the highest dose. Necropsy body weights were decreased in males and females at the highest 
dose. Necropsy body weight and liver weight to brain weight ratio were increased in male mice 
receiving 0.35 mM. Brain weights were decreased in male mice receiving 3.52 mM. Two of eight 
male mice at the highest dose of 3.52 mM displayed hind limb paresis. Marked dilation of the urinary 
bladder was noted in one of eight males at the highest dose. Peripheral neuropathy (axon degeneration) 
was observed in the sciatic nerve of one female and one male at the highest dose, Minimal to mild 
degeneration of the germ cells in the testes was observed in seven of eight male mice given 3.52 mM 
GA. The NOAEL was 1.41 mM, equivalent to 36.0 mg GA/kg b.w. per day based on hindlimb 
paralysis, axon degeneration and germinal epithelium degeneration observed at the highest dose. 
In the 2-year study, groups of 48 male and 48 female mice were administered GA ad libitum in 
drinking water at 0, 0.0875, 0.175, 0.35 or 0.70 mM (equivalent to 0, 1.20, 2.65, 5.13 or 9.55 mg/kg 
b.w. per day for males, and to 0, 1.37, 2.89, 5.64 or 12.99 mg/kg b.w. per day for females) (NTP, 
2014). No significant changes in body weights were in general observed. Food consumption was 
significantly increased at later time points in the two high dose group males and in the highest dose 
group females. Water consumption was significantly increased in the highest dose group females. A 
significant dose-related decreasing trend in survival was reported for male mice at all doses except at 
the lowest one, and for female mice at the two highest dose levels. Cataracts were observed in both 
sexes (significant at all administered doses except the lowest one). In addition, corneal inflammation 
was noted in males and females at the highest dose. There was also a dose-related increasing trend in 
epithelial hyperplasia of the forestomach (significant for males at the highest dose level, and for 
females at the second highest dose level). An increasing dose-related trend in hematopoietic cell 
proliferation of the spleen was reported for both sexes being significant at the two highest dose levels. 
Other non-neoplastic lesions for males were degeneration, ductal dilatation and inflammation of the 
preputial gland, and for females ovarian cysts, hepatic angiectasis and necrosis, and axonal 
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degeneration of the cervical spinal cord (NTP, 2014). The NOAEL for non-neoplastic effects was 
0.0875 mM, equivalent to 1.20 mg GA/kg b.w. per day. The neoplastic findings of this study are 
described under Section 7.3.3.2.  
7.3.2.2. Rats  
In several studies, male rats were used only, while both genders were treated in others. In those studies 
directly comparing the neurotoxic effects in both genders, no substantial differences in sensitivity were 
found in most studies, e.g. by Gold et al. (2004) while the dose-response relationship suggested 
possible differences in another study (NTP, 2012) indicating that male rats may be more sensitive than 
female rats. 
In a study by McCollister et al. (1964), Dow-Wistar male and female rats received AA in the feed. The 
calculated doses were 0, 0.3, 0.9, 3, 7, 9, 11, 30, or 40 mg/kg b.w. per day for up to 90 days. Up to 
7 mg/kg per day there were no, at 9 mg/kg sporadic, and at 11 mg/kg slight but consistent signs of 
neurotoxicity characterized by hind limb weakness. Higher doses resulted in complete loss of hind 
limb function which, however, recovered after cessation of treatment. 
Fullerton and Barnes (1966) investigated the neurotoxicity of AA in male and female Porton rats. A 
single oral dose of 100 mg/kg resulted in fine tremor, a second dose of 100 mg/kg 24 hours later led to 
general weakness and most rats died within the following three days. In repeated-dose experiments, 
male and female rats received 12 daily gavage doses of 50 mg/kg over 15 days. Treatment resulted in 
severe weakness and rats died within days. When rats received 25 mg/kg applied 5 days per week, leg 
weakness became apparent after 20 doses and severe weakness developed after 28 doses. When the 
AA administration was stopped, the rats almost completely recovered within four weeks. After daily 
treatment of female rats with 10 mg/kg for up to 116 doses, no neurotoxicity was observed.  
In the same study, male rats of 6 to 8 weeks of age were exposed to 0, 100, 200, 300 or 400 ppm AA 
in the feed (estimated doses: 0, 5, 10, 15, or 20 mg/kg b.w. per day) for up to 48 weeks (Fullerton and 
Barnes, 1966). In the 20 mg/kg per day dose weakness of the legs was observed after 3 weeks, in the 
15 mg/kg b.w. per day dose group after 4 weeks, and in the 10 mg/kg b.w. per day dose group after 
12 weeks of treatment. The 5 mg/kg b.w. per day dose group exhibited symptoms of slight leg 
weakness after 40 weeks. In the dose groups having received 10 mg/kg b.w. per day and higher, a 
significant decrease in nerve conductivity, and histopathological signs of peripheral nerve 
degeneration in the sciatic nerve, posterior tibial nerve, and sural nerve fibres were reported.  
Hashimoto and Ando (1973) investigated Sprague-Dawley rats fed a diet containing AA at a 
concentration of 500 ppm (estimated dose: 25 mg/kg b.w. per day) for 4 weeks followed by 4 weeks of 
recovery. Animals were sacrificed on weeks 1, 2, 3, 4, 6 or 8. Weakness in the hind limbs and walking 
perturbations were observed after 2-3 weeks, complete hind limb paralysis after 4 weeks of treatment. 
Tilson et al. (1979) administered AA by gavage to male F344 rats at doses of 0, 5, 10 or 20 mg/kg b.w. 
per day, 3 days per week, for 13 weeks. Neurotoxicity was assessed by determination of hind-limb 
extensor ability, locomotor activity, and forelimb grip power prior to the AA administration and after 
1, 4, 7, 10, and 13 weeks of treatment. AA treatment at 20 mg/kg b.w. per day resulted in decreased 
hind-limb extensor strength and locomotor activity during weeks 7 to 13 and weeks 10 to 13 of 
treatment, while forelimb grip power was not affected. Microscopic examination after 13 weeks of 
treatment revealed mild distal nerve fibre (sciatic and tibial) damage and moderate (Schwann-cell 
column formation) damage at 10 mg/kg b.w. per day. These changes were moderate to severe in the 
20 mg/kg b.w. per day group. No histopathological examination was carried out in the 5 mg/kg b.w. 
per day group. 
In a study by Tilson and Cabe (1979) in male F344 rats, AA at 200 mg/kg given as a single dose by 
gavage produced a significant perturbation of hind-limb strength, while 50 and 100 mg/kg had no 
significant effect. The authors also investigated the effects of repeated administration of AA at 10 or 
20 mg/kg per day, 5 days per week, for up to 4 weeks. Statistically significant decreases in the hind-
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limb strength were noted with 10 and 20 mg AA/kg per day, while the effect was sustained in the 
20 but not in the 10 mg/kg group when dosing was ceased. Forelimb function was not affected by the 
treatment, indicating a more severe effect on distal axons than on proximal ones. 
Burek et al. (1980) investigated AA in a 90-day toxicity study and a 92-day toxicity study with 
recovery periods in groups of 6-week-old male and female F344 rats, administering AA in the 
drinking water at concentrations designed to deliver doses of 0.05-20 mg/kg b.w. per day. Group sizes 
of 10 males and 10 females were used. Effects were observed mainly in the highest dose group 
(20 mg/kg b.w. per day in both male and female rats) and included reduction in body weight, dragging 
of the rear limbs and decrease in packed cell volume, total erythrocyte count and Hb concentrations. 
The primary target tissue was the peripheral nerve with lesions consisting of severe degeneration, 
characterized by demyelinisation and axonal loss. Slight spinal cord degeneration was also noted as 
well as atrophy of skeletal muscle, testicular atrophy and distended bladders. The electron microscopic 
substudies of the 90-day toxicity study and a 92-day toxicity study with recovery periods processed 
and examined the left sciatic nerves in a dose-response design with three animals per dose group 
where three blocks of nerve fibres (two longitudinal and one transverse) were selected and in each 
50 fields were examined. The authors reported no treatment-related effects at 0.05 and 0.2 mg/kg b.w. 
per day  in any of the parameters monitored (axolemma invaginations and Schwann cells of with 
different types of alterations). The percentages of fields examined showing any alterations  were  15,  
9, 12, 25, 34 and 55 % at levels of 0 (control), 0.05, 0.2, 1, 5 or 20 mg/kg b.w. per day. The main 
alterations observed were sciatic nerves showing axolemma invaginations or axolemma invaginations 
with cell organelles and/or dense bodies. Total incidences were 36, 24, 27, 30, 33, 8, or 32, 15, 17, 78, 
109, 48, respectively, at the levels of 0 (control), 0.05, 0.2, 1, 5 or 20 mg/kg b.w. per day when 
pooling the 435–450 fields from the three blocks and the three rats in 90-day toxicity study. No 
individual data per animal were reported. From these findings JECFA (FAO/WHO, 2006, 2011) 
identified a NOAEL of 0.2 mg/kg b.w. per day and a LOAEL of 1 mg/kg b.w. per day for 
morphological changes in the sciatic nerve of male rats. The CONTAM Panel noted that the NOAEL 
of 0.2 mg/kg b.w. per day was derived from electron microscopic observations on several types of 
sciatic nerve lesions from a low number of animals per group (n = 3), and obtaining 150 dependent 
data points from each rat. It was also noted that the data showed no clear dose-response, and that the 
determination of the NOAEL was not based on a statistical analysis of the data, e.g. by testing for 
differences between dose groups and the controls.  
Tannii and Hashimoto (1983) administered AA to male Wistar rats (4 animals per group) at 
concentrations of 0, 0.73, 1.12, 1.76 or 2.81 mM (estimated 0, 5.19, 7.96, 12.51 or 19.97 mg/kg b.w. 
per day) in the drinking water for up to 90 days. All treated animals showed a slight reduction in body 
weight, and rotarod performance at 90 days exposure was affected for the two highest dose groups.  
Other signs of toxicity included weakness, tendency towards spreading and dragging hindlimbs and 
occasionally urinary incontinence. Light microscopy examination revealed moderate to severe changes 
in tibial and sural nerves including shrinkage and loss of myelinated fibres, myelin retraction and 
corrugation of myelin sheaths at the highest dose level.  
Johnson et al. (1986) applied AA to male and female F344 rats in the drinking water at levels resulting 
in estimated doses of 0.01, 0.1, 0.5, or 2.0 mg/kg b.w. per day for 2 years. Although there were no 
overt signs of neurotoxicity in any of the dose groups, tibial nerve degeneration was detected 
histopathologically in the dose groups receiving 2 mg/kg b.w. per day after 18 and 24 months. The 
CONTAM Panel noted that the data on tibial nerve degeneration did not show a clear dose-response 
since only the value in the highest dose group was increased, but without statistical significance (Table 
20). The NOAEL was 0.5 mg/kg b.w. per day. 
Schulze and Boysen (1991) administered AA by gavage to male and female Sprague-Dawley rats 
(10 animals per group) at doses of 10 or 30 mg/kg b.w. per day, 7 days per week over 35 days. After 
24 days of treatment and a recovery period of 10 days, survivors in the high-dose group received 
20 mg/kg b.w. per day for the remaining 11 days. After 2 weeks of treatment, the high-dose group but 
not the 10 mg/kg b.w. per day group, showed a significant decrease in rearing, significant changes in 
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posture, increased mean gait scores, a significant decrease in forelimb and hind-limb grip strength, and 
a significant decrease in locomotor activity. Histopathological changes such as axonal fragmentation, 
degeneration, and swelling were found in both dose groups. Most severely affected sites were the 
tibial nerve, and the cervical and lumbar portions of the spinal cord. 
Yoshimura et al. (1992) analyzed the effects of dose level and duration of treatment on 
histopathological changes related to neurotoxic effects. When female Sprague-Dawley rats received 
AA via gavage at doses of 50 mg/kg b.w. per day signs of neurotoxicity emerged after 2 to 3 weeks of 
treatment. The animals exhibited vacuolisation of cells in the cerebellar cortex and degeneration of 
Purkinje cell organelles. Also, a distal axonopathy was restricted to the long tracts of their spinal cord 
and peripheral nerves. Also in rats that received 20 mg/kg per day (7 to 8 weeks), a distal axonopathy 
with accumulation of neurofilamentous material in the axoplasm of the central and peripheral nerve 
fibres was observed.  
Male and female Sprague-Dawley rats (10 rats per group) received 0 (control), 12.5, 25 or 50 mg/kg 
b.w. per day AA by oral gavage for 7 days (Newton et al., 1992; Hughes et al., 1994, as cited in 
FAO/WHO, 2006). Reduced activity was recorded for all exposed animals with the highest prevalence 
in the highest dose group. Body weight gain was reduced for all exposed animals but this was only 
statistically significant for the highest dose group. At this highest dose level hindlimbs were splayed 
with a corresponding impairment of mobility and a reduced number of rearing counts. Mean forelimb 
and hindlimb grip strength were reduced for both males and females in the highest dose group. 
Landing foot splay was increased in a dose dependent manner. Histopathological examination 
revealed axonal degeneration in all animals at the highest dose level and to a lesser extent in a small 
number of animals in the 25 mg/kg b.w. per day group.  
Friedman et al. (1995) exposed male and female F344 rats to AA for 2 years. AA was administered via 
the drinking water at concentrations resulting in estimated dose levels of 0, 0.1, 0.5 or 2.0 mg/kg b.w. 
per day in males, or 0, 1.0 or 3.0 mg/kg b.w. per day in females. Although there were no symptoms of 
overt neurotoxicity, histopathological examination revealed sciatic nerve degeneration in the male rats 
receiving 2.0 mg/kg b.w. per day and in the female rats receiving 3.0 mg/kg b.w. per day. The 
CONTAM Panel noted the data on sciatic nerve degeneration in male and female F344 rats did not 
reveal a clear dose-response since only the value in the highest dose group was increased, but without 
statistical significance (Table 20). The NOAEL was 0.5 mg/kg b.w. per day. 
Male Fischer 344 rats (n = 7 or 8) were treated with AA at 44 mg/kg b.w. per day (Bowyer et al., 
2009). Changes in mRNA levels in the striatum, substantia nigra and parietal cortex were measured 
by complementary DNA (cDNA) array and/or reverse transcriptase polymerase chain reaction (RT-
PCR) analysis. Treatment resulted in significantly decreased body weight and reduced locomotor 
activity. These physiological effects were not accompanied by prominent changes in gene expression 
in the forebrain.  
The NTP conducted a 13-week study (drinking water and diet) and a 2-year study (drinking water) in 
F344/N rats administered AA (NTP, 2012). In the 13-week range finding study, groups of eight male 
and eight female rats were treated with AA at concentrations of 0, 0.14, 0.35, 0.70, 1.41 or 3.52 mM/L 
in drinking-water (0, 10, 25, 50, 100 or 250 mg AA/L, equivalent to 0, 0.8, 2.1, 4.5, 8.6 and 
22.3 mg/kg b.w. per day for males, and to 0, 1.1, 2.7, 6.0, 12.3 and 26.3 mg/kg b.w. per day for 
females) or 0, 7.4, 18.5, 37, 74 or 185 mg/kg diet (equivalent to 0, 0.5, 1.4, 2.8, 5.5 and 14.2 mg/kg 
b.w. per day for males and to 0, 0.6, 1.6, 3.2, 6.6 and 17.9 mg/kg b.w. per day in females). Body 
weights were affected at the highest dose level of AA (both administrations), as well as hind-leg 
paralysis. Four out of eight females administered 1.41 mM/L also displayed hind-leg paralysis. 
Radiculoneuropathy involving the sciatic nerve and lumbar spinal cord was observed in all rats treated 
via drinking water or dietary with the high dose of AA. A low incidence of radiculoneuropathy was 
also noted in females fed 74 mg AA/kg diet. The neuronal degenerative changes were accompanied, at 
times, by atrophy in skeletal muscle of the hind-limb and luminal dilation of the urinary bladder. All 
rats treated with 3.52 mM/L AA displayed increased hemosiderin pigment in their spleens and 
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hyperplasia of red blood cell precursors in their bone marrow. Two of eight male rats fed 185 mg 
AA/kg diet also had increased hemosiderin pigment in their spleens. Degeneration of the germ cells in 
the testes was observed in all male rats given 3.52 mM and 1.41 mM AA and in five of eight male rats 
treated with 0.70 mM AA, and in all dose groups of male rats fed diet containing AA, with the 
incidence increasing with increasing dose. The NOAEL was 0.35 mM for exposure via drinking water, 
equivalent to 2.1 mg/kg b.w. per day, and the LOAEL was 7.4 mg/kg diet, equivalent to 0.5 mg/kg 
b.w. per day. 
In the 2-year study (NTP, 2012), groups of 48 male and 48 female F344/N rats were administered AA 
ad libitum in drinking water at concentrations of 0.0875, 0.175, 0.35 and 0.70 mM (equivalent to 0.33, 
0.66, 1.32 and 2.71 mg/kg b.w. per day for males, and 0.44, 0.88, 1.84 and 4.02 mg/kg b.w. per day 
for females). Control animals received the same tap water with no chemical added. No effect on the 
male survival was observed. For females, a decreased survival compared to control was observed in all 
groups except at the lowest dose. A significant dose-related decreasing trend in body weight was 
observed for both male and female rats. Feed consumption was in general not affected while water 
consumption was increased at later time points in female rats. Degeneration of the retina in the eyes of 
both sexes was observed at the highest dose levels, and for females also at the second highest dose 
level. A dose-related increasing trend in axonal degeneration of the sciatic nerve in male and female 
rats was reported, being significant at the highest dose administered (Table 20). Mean severity of the 
sciatic nerve axon degeneration was not dose-related and was minimal-mild in all dose groups. The 
doses of AA used in the chronic study did not produce hind-leg paralysis in either male of female rats. 
In male rats, a significant increased prevalence of duct ectasia in preputial glands was observed at all 
but the lowest dose. In female rats, the following non-neoplastic effects were observed: lesions 
involving the adrenal cortex (significant at the highest dose administered), an increased prevalence of 
excessive hematopoietic cell proliferation in the spleen, bone marrow hyperplasia and ovarian atrophy, 
the last two significant at the two highest dose levels. The NOAEL for the non-neoplastic effects was 
0.0875 mM, equivalent to 0.33 mg/kg b.w. per day, based on the increase of duct ectasia in preputial 
glands observed at 0.175 mM. The neoplastic findings of this study are described under Section 
7.3.3.1.  
Table 20:  Incidences of peripheral nerve (sciatic) and tibial nerve degeneration in F344 rats exposed 
to AA in drinking water for 2 years (Johnson et al., 1986; Friedman et al., 1995; NTP, 2012) 
Endpoint Gender 
Dosage 
(mg/kg b.w. per day) 
Incidence Reference 
Tibial nerve 
degeneration in 
F344 rats  
(slight and 
moderate) 
Males 
0  
0.01 
0.1 
0.5 
2.0 
27/60 (45 %) 
27/60 (45 %) 
33/60 (55 %) 
32/60 (53 %) 
33/60 (55 %) 
Johnson et al. 
(1986)  
Tibial nerve 
degeneration in 
F344 rats  
(slight and 
moderate) 
Females 
0 
0.01 
0.1 
0.5 
2.0 
3/60 (5 %) 
7/60 (12 %) 
5/60 (8 %) 
7/60 (12 %) 
16/60 (26 %) 
Johnson et al. 
(1986)  
Sciatic nerve 
degeneration in  
F344 rats 
Males 
0
(a)
 
0  
0.1 
0.5 
2.0 
30/83 (36 %) 
29/88 (33 %) 
21/65 (32 %) 
13/38 (34 %) 
26/49 (53 %) 
Friedman et al. 
(1995) 
Sciatic nerve 
degeneration in  
F344 rats 
Females 
0
(a)
 
0  
1.0 
3.0 
7/37 (19 %) 
12/43 (28 %) 
2/20 (10 %) 
38/86 (44 %) 
Friedman et al. 
(1995) 
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Endpoint Gender 
Dosage 
(mg/kg b.w. per day) 
Incidence Reference 
Peripheral nerve 
(sciatic) axonal 
degeneration in 
F344/N rats 
Males 
0 
0.33 
0.66 
1.32 
2.71 
5/48 (10 %)* 
7/48 (15 %) 
7/48 (15 %) 
11/48 (23 %) 
23/48 (48 %)** 
NTP (2012)
(b)
 
Peripheral nerve 
(sciatic) axonal 
degeneration in 
F344/N rats 
Females 
0  
0.44 
0.88 
1.84 
4.02 
4/48 (8 %)* 
3/48 (6 %) 
1/48 (2 %) 
4/48 (8 %) 
19/48 (40 %)** 
NTP (2012)
(b)
 
(a):  The control groups were split into two groups to better establish the variability of low-incidence of background tumours 
(Friedman et al., 1995). 
(b):  The concentrations in drinking water correspond to daily consumed doses over the entire 2-year study of 0, 0.0875, 
 0.175, 0.35 and 0.70 mM. 
*  Significant dose-related trend (p for trend < 0.001).  
**   Significantly different from control (p for trend < 0.001).  
 
NTP also conducted a 13-week and a 2-year study in F344/N Nctr rat administered GA in drinking 
water using equimolar concentrations to those used in the corresponding AA studies (NTP, 2014). For 
the 13-week study, rats were administered GA in the drinking water at doses of 0.0, 0.14, 0.35, 0.70, 
1.41 or 3.52 mM (or 0, 12.2, 30.6, 61.2, 122 or 306 mg/L, equivalent to 0, 1.0, 2.4, 5.0, 10.1 or 
26.9 mg GA/kg b.w. per day in males and 0, 1.3, 3.4, 6.6, 13.5 or 33.8 mg GA/kg b.w. per day in 
females). Male and female rats at the two highest doses showed a reduction in the body weight. 
Necropsy body weights and liver weights were decreased in males at the two highest doses. Brain 
weights were decreased in males at the highest dose. Liver weights were decreased at all dose levels in 
females and brain weights were decreased at the three highest doses. There were significant decreases 
in water consumption in males and females at the two highest doses and in food consumption in males 
at the highest dose. At the highest dose of 3.52 mM, all rats showed hind-limb paresis. Marked 
dilatation of the urinary bladder was noted in two males at the highest dose. Treatment-related changes 
were observed at the highest dose in sciatic nerve (peripheral neuropathy with axon degeneration and 
Schwann cell degeneration in one female), spinal cord (myelopathy of the lumbar spinal cord with 
lumbar axon degeneration in three females and two males) and spleen (congestion in one male). 
Testicular germ cell degeneration was observed in all male rats given 0.70, 1.41 or 3.52 mM GA. A 
lower incidence of this lesion was also detected in all other doses of GA (in three animals at 0.35 mM 
and in two animals at 0.14 mM) (see Section 7.3.5.1). A corresponding lesion that consisted of 
exfoliated degenerating germ cells, cellular debris and hypospermia was observed in the epididymides. 
The LOAEL was 0.14 mM, equivalent to 1.1 mg GA/kg b.w. per day, based on the testicular germ cell 
degeneration observed at the lowest dose. 
In the 2-year study, groups of 48 male and 48 females rats were administered GA ad libitum in 
drinking water at 0, 0.0875, 0.175, 0.35 or 0.70 mM (equivalent to 0, 0.39, 0.79, 1.56 or 3.34 mg/kg 
b.w. per day for males, and to 0, 0.54, 1.08, 2.23 or 4.65 mg/kg b.w. per day for females) (NTP, 2014). 
A significant dose-related decreasing trend in body weight in both sexes was observed. Significant 
decreases in body weight gain were noted in males at the highest dose and in females at the three 
highest doses. Sporadic dose-related trends in food and water consumption were reported. A decreased 
survival compared to controls was reported at the two highest dose levels for both sexes. There was no 
hind-limb paresis observed for any dose in this study and an increase in axonal degeneration of 
minimal severity was observed in the lumbar spinal cord only in female rats treated with the highest 
dose of GA. Increases in brain gliosis were observed in males at the highest dose and in females at the 
three highest doses. In addition, for male rats the following dose-related lesions were observed: 
exfoliated germ cells epididymes, hepatocytes degeneration and liver necrosis, and for females: bone 
marrow hyperplasia, and uterine endometrial hyperplasia. The LOAEL for non-neoplastic effects was 
0.0875 mM, equivalent to 0.39 mg GA/kg b.w. per day. The neoplastic findings of this study are 
described under Section 7.3.4.2. 
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Rawi et al. (2012) investigated the hematological, biochemical, neurological and histopathological 
effects of AA on immature male and female rats given 0 (control) or 15 mg AA/kg b.w. per day for 
28 days. The results obtained indicate that AA administration induced some behavioural disorders in 
the movement of immature male and female rats as well as loss of body weight. AA treatment also 
induced a significant decrease in haemoglobin, erythrocytes, haematocrit and lymphocyte levels of 
young female rats. AA significantly increased serum glucose, total cholesterol and triglycerides 
concentrations of both immature male and female rats. In the immature rats AA also caused a 
significant increase in the total urea concentration. Moreover, AA induced a marked increase in the 
activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the immature 
male and female rats. The activities of serum alkaline phosphatase (ALP) and acetylcholinesterase 
(AChE) were significantly decreased in both treated groups. In addition, AA caused a significant 
increase in norepinephrine, glutamate, aspartate and taurine, while it reduced dopamine and serotonin 
levels.   
Toker et al. (2013) investigated serum homocysteine, arginine, citrulline and asymmetric dimethyl 
arginine levels and conducted a histopathological examination of the abdominal aorta in rats given AA 
via drinking water at dose levels of 2 or 5 mg/kg b.w. per day for 90 days. At the highest dose level, 
serum homocysteine, citrulline and asymmetric dimethyl arginine levels were significantly higher than 
in controls. Serum levels of citrulline were also significantly increased at the lowest dose level. 
Histopathological examination of the abdominal aorta revealed degeneration of the external elastic 
lamina in rats at the highest dose level. The authors concluded that long term ingestion of high dose 
AA with food might contribute to the development of atherosclerosis. 
Nurullahoglu-Atalik et al. (2013) evaluated the influence of AA on urinary bladder responses to 
carbachol and potassium chloride. Animals of each gender were segregated into three groups each 
containing 6 animals, one control group and two groups treated with AA at 2 or 5 mg/kg b.w. per day 
for 90 days. In rats treated with AA, the EC50 values of carbachol and KCl, but not the maximal 
response to both agents, were significantly higher than in control group. Histopathological parameters 
such as oedema, congestion, inflammatory cells, microvascular proliferation, fibrosis, eosinophils, 
mast cells and epithelial damage were all higher in the AA-treated groups than in the controls treated 
with carbachol or KCl. The authors concluded that the results demonstrate that AA-treatment can 
induce urinary bladder injury. 
Raju et al. (2015) fed male rats over 10 weeks with a diet containing 0, 5, 10 or 50 mg AA/kg diet 
(equivalent to 0, 0.45, 0.9 and 4.5 mg/kg b.w. per day). At the two highest doses, serum total high 
density lipoprotein and total testosterone were decreased significantly, while serum lipase was 
increased significantly. At 50 mg/kg diet, blood haematocrit and lymphocyte counts were significantly 
lower than in the controls. 
Maronpot et al. (2015) exposed Wistar Han rats to 0, 0.5, 1.5 or 3.0 mg AA/kg b.w. per day in 
drinking water starting at GD6 until 2 years of age. Significant dose-related increases in the incidences 
of spinal cord degeneration and gliosis and sciatic nerve neuropathy were reported in male and female 
Wistar Han rats, which was consistent with previous reports of neurological effects of high doses of 
AA in male and female F344 rats.  
7.3.2.3. Cats 
McCollister et al. (1964) carried out a feeding study in groups of cats of unknown origin (2 cats per 
AA dose group) receiving 0 (control), 0.03, 0.1, 1, 3 or 10 mg/kg b.w. per day AA by dietary 
administration 5 days per week up to 1 year. In the 10 mg/kg b.w. per day group progressive hindlimb 
weakness was noted over a period of 52 days leading to complete hind limb paralysis. In the 3 mg/kg 
per day dose group, hind limb weakness was observed after 26 days progressing over the whole 
treatment period. In the 1 mg/kg b.w. per day group, the same symptoms were seen at 26 days but 
disappeared later on. Lower dose levels did not result in any observed effects. There were no 
pathological abnormalities attributable to AA at any exposure level. However, the animals in this 
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study were in poor condition and several animals died due to intercurrent infections. The CONTAM 
Panel also noted the limited number of animals included in the study and concluded the study was of 
too limited quality to derive a NOAEL. 
A group of 17 cats of unknown breed were administered AA at a dose level of 15 mg/kg b.w. per day 
by dietary administration for 7 days per week up to 16 weeks (Post and McLeod, 1977). A control 
group of 23 animals received control diet. In the exposed group abnormal gait (hindlimbs) was 
observed within 4 to 6 weeks. From 12 to 16 weeks animals were unable to walk and showed weight 
loss and diarrhoea. Motor conduction velocity in several nerves was significantly reduced and the 
amplitude of externally recorded muscle action potential for foot muscles as well as the action 
potential in the greater splanchnic nerve were reduced. Fibre density of large diameter nerve fibres in 
the left gastrocnemius muscle and small fibres in the vagus nerve and greater splanchnic nerves were 
reduced. Histopathological examination of several nerve fibres showed a reduced number of 
myelinated fibres. Electron microscopy revealed an increased density of neurofilaments and abnormal 
membraneous configurations between the axolemma and Schwann cell membrane. Degenerating 
fibres of the gastrocnemius muscle, loss of myelin for the splanchnic nerve and signs of degeneration 
for unmyelinated fibres were also reported.  
7.3.2.4. Dogs 
Fourteen dogs received AA at a dose level of 7 mg/kg b.w. per day by dietary administration for about 
10 weeks (Satchell and McLeod, 1981). No control animals were included in the study. The dogs 
showed severe impairment of hindlimb function, ‘toe-folding’, ataxia, muscle weakness, and 
regurgitation.  
Four dogs received 6 mg/kg b.w. per day AA via gelatine capsules for 6-7 weeks, followed by up to 
8 weeks recovery (Hersch et al., 1989). Parameters of the animals pre-exposure served as control. 
Animals showed loss of use of hindlimbs and ‘toe-folding’. Several respiratory parameters were also 
affected but were restored during the recovery period. 
7.3.2.5. Hamsters 
Imai and Kitahashi (2014) reported a 13-week toxicity study of AA administered in drinking water to 
Syrian hamsters, of which the authors indicated that they are sensitive to the induction of pancreatic 
ductal carcinogenesis. Male and female hamsters were exposed to AA at concentrations in drinking 
water required to provide 0 (control), 20, 30 and 50 mg/kg b.w. per day. At 50 mg/kg b.w. day, AA 
treatment caused abnormal gait advancing to hind limb paralysis in all males and females. Body 
weights at the two highest dose levels in male and the highest dose level in females were reduced. 
Microscopically, a dose dependent axonal/myelin degeneration of sciatic nerves was observed in all 
AA-treated groups. No obvious changes were found in pancreatic ducts/ductules in any group of 
animals.  
7.3.2.6. Monkeys 
Non-human primate female monkeys (species not specified, 1 animal per group) received 0 (control), 
0.03, 0.1, 0.3 (2 animals), 1, 3 or 10 mg /kg b.w. per day AA by oral gavage or dietary administration 
5 days per week for up to 1 year (McCollister et al., 1964). The animal in the highest dose group 
showed clear and severe clinical signs of neuropathy. At 3 mg/kg b.w. per day occasional 
abnormalities were reported. Due to limited reporting and the use of only one animal per dose groups 
clear conclusions cannot be derived from this study. 
Four macaque monkeys were given 10 mg/kg b.w. per day AA in fruit juice for 5 days per week and 
44–61 days until the onset of clinical signs of toxicity and two control animals received tap water for 
about 13 weeks (Maurissen et al., 1983). Animals were allowed to recover and examined up to 
146 days. Body weight loss occurred in 3 of 4 exposed animals and 1 of 2 control animals. Clinical 
signs of toxicity detected included loss of balance, deceased activity, hindlimb weakness and forelimb 
tremor. All clinical signs (except the forelimb tremor) resolved within 2 weeks post treatment. A 
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decreased sensitivity towards a vibration stimulus was noted during the treatment phase. An increased 
time taken to pick up a food reward was observed in exposed animals towards the end of the treatment 
period. Sural nerve biopsies revealed no visible axons in some areas and myelin that had formed balls. 
Light microscopical evaluation of nerve fibre showed some abnormalities. 
In a second study, three adult macaque monkeys were given 10 mg/kg b.w. AA in fruit juice for 5 days 
per week during 6-9 weeks and two additional monkeys served as controls (Maurissen et al., 1990). 
After a 30 week recovery period the animals were exposed a second time. Changes in body weight, 
time taken to pick up a food reward, response to an electrical stimulus and response to a vibration 
stimulus were essentially similar as reported in the earlier study described above (Maurissen et al., 
1983). 
Seven macaque monkeys were administered 10 mg/kg b.w. per day AA in fruit juice for 5 days per 
week and 13 weeks followed by a 20–30 weeks recovery period and two additional monkeys were 
used as control (Eskin et al., 1985). Histopathological examination of brain sections, optic nerve and 
eyes revealed various adverse effects including distal axonal swelling, disproportionally thin myelin 
sheaths, degeneration of myelin and shrunken axons. Swellings were not seen in the retinal nerve fibre 
layer and there were very few in the optic nerve. 
Three adult macaque monkeys were administered 10 mg/kg b.w. AA in fruit juice 5 days per week for 
6 to 10 weeks and one control animal was included in the study (Merigan et al., 1982). Induction of 
ataxia was pronounced. After 4 weeks of AA exposure a marked increase in cortical evoked potential 
was observed which preceded a decrease in visual acuity and flicker-fusion frequency which were 
apparent 2 weeks later. Towards the end of the treatment period a marked increase in time taken for a 
pick-up test was observed. AA exposure also resulted in weight loss, hindlimb weakness, gait 
disturbances and tremors. 
Three macaque monkeys were administered AA at 10 mg/kg b.w. in fruit juice for 5 days per week 
and about 6-10 weeks with one animal used as control (Merigan et al., 1985). Parameters for visual 
capacity were evaluated. Reduced contrast sensitivity, impaired visual acuity, reduced flicker-fusion 
frequency, and impaired visual evoked potentials were noted. The authors suggested that the effects 
observed related to a conduction block in large-diameter optic nerve fibres. 
7.3.2.7. Summary of repeated dose toxicity  
The repeated dose toxicity of AA has been investigated in various animal models, including rats, mice, 
cats, dogs, hamsters and monkeys, and by numerous dosing regimens and durations of dosing. 
Adverse effects reported in all these species consisted of loss of body weight and neurotoxicity 
reflected by hind-limb paralysis, reduction in rotorod performance and/or histopathological changes in 
peripheral nerves and CNS structures.   
In mice, effects reported in addition to the neurotoxicity consisted of effects on the testes, including 
degeneration of epithelia in spermatids and spermatocytes, reduction of spermatozoa and the presence 
of multinucleate giant cells, as well as forestomach hyperplasia, haematopoietic cell proliferation of 
the spleen and preputial gland inflammation, lung alveolar epithelium hyperplasia and cataract and for 
female mice ovarian cysts. 
In B6C3F1 mice, the NOAELs were 13.3 mg/kg b.w. per day and 12 mg/kg b.w. per day for 
administration of AA for 13 weeks via drinking water or dietary, respectively. A NOAEL could not be 
established for the non-neoplastic effects in the 2-year drinking water study based on the increase of 
ovarian cyst observed at the lowest dose 1.04 mg/kg b.w. per day. 
In rats, effects reported in addition to the neurotoxicity, included atrophy of skeletal muscle, testicular 
atrophy, distended urinary bladders, increased prevalence of duct ectasia in preputial glands, 
haematopoietic cell proliferation in the spleen, bone marrow hyperplasia, ovarian atrophy, 
degeneration of the retina in the eyes, exfoliated germ cells epididymis, hepatocyte degeneration and 
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liver necrosis, bone marrow hyperplasia, mesenteric lymph node cellular infiltration and pituitary 
gland hyperplasia.   
In F344/N rats, the NOAEL was 2.1 mg/kg b.w. per day for administration of AA for 13 weeks via 
drinking water, whereas the LOAEL was 0.5 mg/kg b.w. per day for dietary administration. In the 
2-year study, the NOAEL for non-neoplastic effects was 0.33 mg/kg b.w. per day, based on the 
increase of duct ectasia in preputial glands observed at 0.66 mg/kg b.w. per day 
The 13-week and 2-year NTP studies in mice and rats dosed with GA (NTP, 2014) revealed adverse 
effects that were generally similar to those reported for AA, including in mice: body weight reduction, 
cataracts, increasing trend in epithelial hyperplasia of the forestomach, haematopoietic cell 
proliferation of the spleen, ductal dilation and inflammation of the preputial gland, and for females 
ovarian cysts, hepatic angiectasis and necrosis, and axonal degeneration of the cervical spinal cord 
atrophy in the skeletal muscle of the hindlimb and/or urinary bladder dilatation. In addition, for male 
rats exfoliated germ cells epididymes, hepatocytes degeneration and liver necrosis, and for females: 
bone marrow hyperplasia, axonal degeneration of the lumbar spinal cord, and uterine endometrial 
hyperplasia, and for both sexes, brain gliosis were reported. In the 2-year drinking water studies, the 
NOAELs for non-neoplastic effects were 1.20 mg GA/kg b.w. per day in mice and the LOAEL was 
0.39 mg GA/kg b.w. per day in rats. 
Rats were more sensitive to the neurotoxic effects of AA and GA than mice, and neurotoxicity in rats, 
such as hind-leg paralysis and peripheral neuropathy, was consistently associated with lower doses and 
greater severity from treatment with AA when compared to equimolar concentrations of GA.  
7.3.3. Genotoxicity 
The genotoxicity of AA, as well as of its reactive metabolite epoxide GA, has been studied 
extensively. It has been reviewed by IARC (1994), JECFA (FAO/WHO, 2002, 2006, 2011), EFSA 
(2008), UK Committee on Mutagenicity of Chemicals in Food, Consumers Products and the 
Environment (COM, 2009), US-EPA (2010), ATSDR (2012), and Dearfield et al. (1995) and Carere 
(2006). A summary of the genotoxicity of AA and GA is reported hereafter and the more recent 
studies are described in more detail.  
7.3.3.1. In vitro genotoxicity of AA and GA  
Table 21 summarises the experimental design and results of recent in vitro gene mutation tests, Comet 
assays, micronucleus tests, chromosomal aberration tests and SCE assays with AA and GA. 
In general, AA did not induce reverse mutations in bacterial gene mutation assays with and without 
activation. The available literature includes the use of strains of Salmonella typhimurium (Ames test), 
Escherichia coli and Klebsiella pneumonia (see ATSDR, 2012). One exception was a weakly positive 
result in a study where TA98 and TA100 strains were used, but only with S9 activation (Zeiger et al., 
1987). The absence of mutagenic effects in presence of a metabolic activation system (rat liver S9) is 
very likely related to the scarce presence or lack in the S9 mix of the specific isozyme (the P450 
CYP2E1) capable of metabolizing small hydrophilic molecules like AA. Therefore, the conversion of 
AA to GA will not be in sufficient quantities for an effect to be detectable in the Ames test. Negative 
results have also been obtained in S. typhimurium YG7108pin3ERb5 (a strain engineered to express 
CYP2E1). However, a number of compounds which should have been mutagenic following activation 
by CYP2E1 also gave negative results suggesting that the test system may not be adequate (Emmert et 
al., 2006). AA did not cause gene mutations in umu S. typhimurium strain OY1002/2E1 (a strain that 
does express human CYP2E1, reductase and bacterial O-acetyl-transferase) in the absence of 
exogenous metabolic activation, or in its parental strain S. typhimurium strain TA1535/pSK1002 (a 
strain that does not express these enzymes) either with or without exogenous metabolic activation. GA 
clearly produced a dose-related increase in mutations in S. typhimurium strain TA1535/pSK1002 in 
the absence of exogenous metabolic activation (Koyama et al., 2011b). GA induced gene mutations in 
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Salmonella typhimurium strains TA1535 and TA100 with and without metabolic activation (S9 mix) 
(Hashimoto and Tanii, 1985), but not in Klebsiella pneumonia (Voogd et al., 1981).  
AA showed equivocal, negative or weakly positive results in mammalian gene mutation assays (TK 
locus mouse lymphoma cells or HPRT locus V79 cells), whereas GA was clearly positive (Baum et 
al., 2005, 2008; Thielen et al., 2006; ATSDR, 2012) (see Table 21).  
In human lymphoblastoid TK6 cells AA was negative in the absence of metabolic activation in a first 
TK assay but statistically positive in the second (at cytotoxic concentrations), whereas GA was 
significantly genotoxic even at concentrations that were not severely cytotoxic (Koyama et al., 2006). 
Two distinct phenotypic classes of TK mutants were detected: normally growing (NG) and slowly 
growing (SG) mutants which are associated with large-scale mutagenic effects. AA did not affect the 
proportion of SG mutants, while GA treatment lowered it. This implies that GA induced primarily 
point mutations. Genomic DNA extracted from the mutants was subjected to the PCR-based LOH 
(loss of heterozygosity) analysis thus allowing the classification of the mutants into 3 types: non-LOH, 
hemizygous LOH and homozygous LOH. In general, hemi-LOH is the result of deletion and homo-
LOH of inter-allelic homologous recombination. The fraction of hemi-LOH in AA-induced mutants 
was higher than in spontaneous mutants, indicating that AA induced primarily deletions. GA induced 
primarily NG mutants and most of them were the non-LOH type, which is presumably generated by 
point mutations and other small intragenic mutations. These results indicate that the genotoxic 
characteristics of AA and GA are distinctly different: AA is clastogenic and GA is mutagenic. The 
cytotoxicity and genotoxicity of AA were not enhanced by metabolic activation (rat liver S9), 
implying that the rat liver S9 did not activate AA. 
Koyama et al. (2011b) reported a weakly positive result for gene mutation in human lymphoblastoid 
cell lines (TK6, h2E1v2 (a cell line that overexpresses human CYP2E1) and AHH-1 (its parental cell 
line) at high AA concentrations (> 10 mM) and in the absence of exogenous activation. In assays with 
the TK6 cell line with exogenous activation, it was noted that human liver microsomes induced a 
stronger positive response than rat liver S9 mix, however the induction of mutations was still weak. 
GA induced a dose-dependent increase of TK mutations starting from the lowest concentration of 
0.5 mM. AA induced trace amounts of N7-GA-Gua adducts in TK6 cells (with and without S9) (about 
22 N7-GA-Gua/10
8
 nucleotides at 14 mM AA without S9 and up to 40 N7-GA-Gua/10
8
 nucleotides at 
10 mM AA with S9) and in AHH-1 (about 22 N7-GA-Gua/10
8
 nucleotides at 1.4 mM AA without S9) 
and h2E1v2 cells (about 15 N7-GA-Gua/10
8
 nucleotides at 1.4 mM AA without S9), whereas GA 
induced a substantial number of N7-GA-Gua adducts in TK6 cells (about 1 100 N7-GA-
Gua/10
8
 nucleotides at 4.8 mM GA). These results suggest that genotoxicity is associated with DNA 
adduct formation and that AA was not metabolically activated to GA in vitro. 
A concentration related increase in mutation frequency in the cII transgene assay was observed in 
cultured Big Blue mouse embryonic fibroblasts following exposure to AA (3.2, 32 and 320 µM) 
(Besaratinia and Pfeifer, 2003). The mutations may be ascribed to AA DNA-adduct-inducing property. 
Specific mutations were induced (an excess of A→G transitions and G→C transversions). 
Besaratinia and Pfeifer (2004) compared the mutagenicity and DNA adduct formation by AA and GA 
in normal human bronchial epithelial cells and Big Blue mouse embryonic fibroblasts that carry a 
λ phage cII transgene. Human and mouse cells were treated in vitro with water, AA (3.2, 32 and 
320 µM) or GA (50 and 500 nM, 5, 50, 500 µM and 5 mM) and then subjected to terminal transferase-
dependent PCR to map the formation of DNA adducts within the p53 gene and the cII transgene. DNA 
adduct formation was higher after GA than AA treatment at all doses tested and occurred at similar 
specific locations within p53 and cII. It is of note that AA induced adduct formation was saturable 
suggesting that the conversion of AA to DNA reactive intermediates is limiting whereas the GA 
adduct formation was dose-dependent. Treatment with either AA or GA led to significant increases in 
mutation frequency and GA was more mutagenic than AA at all doses tested. The spectrum of GA 
induced cII mutations was statistically significantly different from the spectrum of spontaneously 
occurring mutations in the control cells. Compared with spontaneous mutations in control cells, cells 
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treated with AA or GA had more A→G transitions and G→C transversions and GA-treated cells had 
more G→T transversions as distinct mutational signature. The mutational specificity of GA may 
reflect differences in the pathways of DNA adduct formation between AA and GA. However, the 
overall mutational spectra of GA and AA are consistent with N7-GA-Gua as predominant DNA 
adduct induced by both chemicals and N3-GA-Ade and N1-GA-dA as minor adducts induced by GA 
and AA, respectively. These adducts may be mutagenic either by depurination or by inducing directly 
mispairing. The overlapping in the location of mutations induced by AA and GA supports the idea that 
GA-induced adducts are involved in AA-induced mutagenesis. 
Ao et al. (2008) examined HPRT mutation frequencies in HL-60 and NB4 leukaemia cell lines 
exposed to AA. A significant increase in mutation frequency was only observed at the highest 
concentration (10 mM = 700 mg/L). The mutation spectrum was different from the spontaneous 
mutation spectrum in control cells. The most frequent spontaneous mutations were point mutations, 
whereas AA-induced mutations were mainly single exon deletions besides point mutations, and an 
increase in the proportion of partial deletions was associated with the increase of AA treatment. There 
was no difference in mutational spectra between the two cell lines. There was no evidence of 
metabolic competency of these cell lines. 
Mei et al. (2008a) evaluated the mutagenic potential of 4 hours treatment with AA (2–18 mM) and GA 
(0.125 to 4 mM) on the TK locus in L5178Y mouse lymphoma cells. DNA adduct formation, mutant 
frequencies and the types of mutations were examined. Dose-dependent increases for both cytotoxicity 
and mutagenicity were induced by AA or GA treatment. Both small and large colony TK mutants 
were induced by both chemicals. GA was much more mutagenic than AA. To determine the types of 
mutations, loss of heterozygosity analysis of mutants was conducted using four microsatellite loci 
spanning the entire chromosome 11. Compared to GA-induced mutations, AA induced more mutants 
whose LOH extended to more than half of the chromosome. Statistical analysis of the mutational 
spectra revealed a significant difference between the types of mutations induced by AA and GA 
treatments. GA induced DNA adducts of adenine and guanine (N3-GA-Ade and N7-GA-Gua) in a 
linear dose-dependent manner. The levels of guanine adducts were consistently about 60-fold higher 
across the dose range than those of adenine. In contrast, no GA-derived DNA adducts were found in 
the cells treated with any concentrations of AA, consistent with a lack of metabolic conversion of AA 
to GA. Based on these results, the authors suggested that although both AA and GA generate 
mutations through a clastogenic mode of action in mouse lymphoma cells, GA induces mutations via a 
DNA adduct-mediated mechanism whereas AA induces mutations by a mechanism not involving the 
formation of GA adducts. 
Johansson et al. (2005) investigated the mutagenicity and DNA repair of GA-induced adducts in 
Chinese hamster cell lines deficient in base excision repair (BER) (EM9), nucleotide excision repair 
(NER) (UV4) or homologous recombination (irs1SF) in comparison to parent wild-type cells (AA8). 
The DRAG (detection of repairable adducts by growth inhibition) assay, monitoring growth inhibition 
and reduced survival in these cell lines, was used to provide information of the type of DNA repair 
pathways needed for sustained growth after GA treatments. A DNA repair deficient cell line is 
expected to be affected in growth and/or survival more than a repair proficient cell line. The alkaline 
DNA unwinding (ADU) assay was used to investigate induction of SSBs. The hprt assay was applied 
to assess mutagenic potential in an endogenous locus. The authors reported a significant induction of 
mutations by GA in the hprt locus of wild-type cells but not in BER deficient cells. The authors 
emphasized the low mutagenic effect of GA in the assay in wild-type cells. The detection of mutations 
in BER-deficient cells could be hampered by the high cytotoxicity observed when compared to wild-
type cells. Cells deficient in homologous recombination or BER were three or five times, respectively, 
more sensitive to GA in terms of growth inhibition than were wild-type cells. A similar dose-
dependent increase in the level of SSBs was observed in wild-type (AA8) versus XRCC1 defective 
(EM9) cells (although the authors claim that there is an enhanced levels of SSB in EM9 cells but do 
not provide adequate statistical analysis) and the SSB level was not modulated by the PARP inhibitor 
1,5-isoquinolinediol (ISQ). An apparently increased level of SSB was observed in the NER defective 
(UV4) cells as compared to AA8 cells but no effect on SSB level was detected when using inhibitors 
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of replicative DNA polymerases. Although on the basis of these data the authors concluded that short-
patch BER is involved in GA-induced repair, the CONTAM Panel noted that these data do not allow 
identifying the pathway involved in the repair of GA-induced lesions. In conclusion, this study 
suggests that BER and homologous recombination are involved in the cytotoxic processing of GA-
induced lesions but what type of lesions are their substrate and/or lead to mutagenesis cannot be 
concluded from these results.  
In mammalian cells, AA induced chromosomal aberrations, micronuclei (containing whole 
chromosomes or acentric fragments), sister chromatid exchanges (SCE), polyploidy, aneuploidy and 
other spindle disturbances (e.g. c-mitosis) in the absence of metabolic activation (Baum et al., 2005; 
Koyama et al., 2006; Jiang et al., 2007; Martins et al., 2007; Katic et al., 2010; ATSDR, 2012; 
Pingarilho et al., 2013) (Table 21). GA induced also chromosomal aberrations, micronuclei or SCE 
(Table 21), however at lower concentrations that are not severely cytotoxic. These data confirm that 
AA is a direct acting clastogen in mammalian cells in vitro, and is also an aneugen. 
Pingarillo et al. (2013) studied the induction of SCE by AA and GA in human lymphocytes (see Table 
21). In addition, the authors studied the role of individual genetic polymorphisms in key genes 
involved in detoxification and DNA-repair pathways (BER, NER, HRR and NHEJ) on the induction 
of SCE by GA. They compared the induction of SCE at a dose of 250 µM GA (a dose inducing an 
increase in SCEs of approximately 4-5 fold when compared with non-treated control lymphocytes) in 
cultured lymphocytes from 13 donors. The results show that lymphocytes from certain donors clearly 
responded to a GA insult to a lesser extent that did other donors. GSTM1 and GSTT1 deletion 
polymorphisms did not influence the level of SCE induced by GA. Conversely, for GSTP1 Ile105Val, 
lymphocytes from wild-type individuals have a higher level of GA-induced SCE than those with at 
least one variant allele. For GSTA2 Glu210Ala the level of SCE was lower for lymphocytes of 
heterozygous individuals when compared with wild-type homozygous individuals. For the DNA-
repair pathways studied, no associations with the level of GA-induced SCE were found. By combining 
DNA damage in GA-treated lymphocytes and data on polymorphisms, the authors suggested 
associations between the induction of SCEs with GSTP1 (Ile105Val) and GSTA2 (Glu210Ala) 
genotypes in this exploratory study. 
Koyama et al. (2011b) exposed human lymphoblastoid cell lines (TK6, AHH-1, and h2E1v2 lines) to 
AA at concentrations in the range of 5–15 mM (TK6 cells) or up to 3 mM (AHH-1 and h2E1v2 cells). 
The micronucleus assay in TK6 cells was performed with and without exogenous S9 mix. AA induced 
micronuclei in the absence, but not in the presence, of S9. A weak induction of micronuclei was 
observed in the AHH-1 and h2E1v2 cell lines that were assayed only in the absence of exogenous 
metabolic activation. 
Several studies were conducted to investigate DNA damage induced by AA or GA by using the Comet 
assay (Table 21). Negative results have been reported in TK6 cells or human lymphocytes treated with 
AA, while GA indicated clearly positive results (Baum et al., 2005, 2008; Koyama et al., 2006; 
Thielen et al., 2006). The only exception is a positive result that was observed in human HepG2 cells 
treated for 1 hour with 2.5, 5, 10 and 20 mM AA (Jiang et al., 2007). Several studies have shown that 
after post-treatment with the DNA repair enzyme formamidopyrimidine-DNA-glycosylase (fpg), DNA 
damage induced by GA became detectable at much lower doses than in the absence of the fpg 
treatment (Thielen et al., 2006; Baum et al., 2008). Disappearance of DNA strand breaks was 
measured after 4 hours treatment with 100 and 800 µM GA (concentrations that have been shown to 
induce significant DNA damage in the Comet assay). Within 8 hours, strand breaks induced by GA 
(100 µM) decreased by 80 %. The authors indicated that this is probably the result of efficient BER 
(Baum et al., 2008). 
Galdo et al. (2006) investigated the induction by AA of DNA damage in rat thyroid cell lines PC Cl3 
(more stable and normal karyotype) and FRTL5 (cells displaying a high level of aneuploidy which 
could make them more prone to DNA alterations) and in thyrocytes primary cultures from dog, human 
and sheep. The detection of DNA damage was done by the Comet assay under alkaline conditions. AA 
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treatment (14 µM, 3 hours) increased significantly the number of PC Cl3 cells with a comet. In 
addition, dose-related increases were observed after 3 hours exposure from 10 µM to 3 mM AA. In 
FRTL5 cells, an overnight treatment with 140 µM AA increased approximately twice the percentage 
of cells showing a comet; in dog, sheep and human thyrocyte primary cultures, similar increases were 
observed after overnight exposure to 1 mM AA. Dose-related increases in the % of comet were also 
observed in human thyrocytes after 48 hours exposure from 10 µM to 3 mM. The positive control 
H2O2 also induced DNA damage in these different cells. The authors also investigated the persistence 
of DNA damage. The damage induced by H2O2 was transient; H2O2 being quickly degraded by the 
cells and the damage induced being quickly repaired. In contrast, no degradation of AA by the cells 
was observed and no repair of the DNA lesions induced by AA occurred. The effect of AA, GA and 
etoposide were studied on H2AX phosphorylation by using an anti-phosphohistone H2AX (ser 139) 
antibody. Etoposide, an inhibitor of topoisomerase II, increased the phosphorylation of histone H2AX 
measured after 1 hour incubation, whereas AA (140 µM, 17 hours) and H2O2 were without effect. The 
effect of AA (14 or 140 µM) and GA (115 µM) was also studied at shorter times (15, 30 or 60 
minutes) and longer time of action (3, 17, 40 hours). No effect was observed although in each 
experiment a strong effect of etoposide was always present. The authors concluded that the absence of 
effect of AA on H2AX histone phosphorylation suggests that the positive Comet assay observed with 
AA does not reflect the induction of DNA double strand breaks. The aim of the study was to develop 
an in vitro model for the tumorigenic action of AA on thyroid cells. The authors concluded also that 
the effects of AA demonstrated in this study could explain the in vivo tumorigenesis but not its relative 
thyroid specificity. 
Hansen et al. (2010) investigated the induction and repair of DNA damage induced by AA and GA in 
mouse male germ cells (prior to spermatid elongation) and in human and mouse peripheral blood 
lymphocytes, to assess inter-species and cell-type differences in DNA damage susceptibility. The 
Comet assay was used in combination with the DNA repair enzymes fpg and hOGG1 to measure 
specific DNA lesions. Millimolar concentrations of AA (up to 6 mM) did not induce a detectable 
increase in DNA lesions (strand breaks and alkali-labile sites) in mouse testicular cells and human 
peripheral blood lymphocytes. In contrast to AA, GA induced significant levels of DNA lesions at 
doses ≥ 1 mM. Using fpg, the GA-induced DNA damage was measured at 20–50-fold lower 
concentrations, in all cell types investigated. GA-induced DNA damage could not be recognised by 
hOGG1, suggesting that, based on the known affinities of these repair enzymes, alkylation rather than 
oxidation of guanine is involved. Early spermatogenic and somatic cells from mice showed similar 
susceptibility to GA. Human lymphocytes showed two-fold higher levels of GA-induced DNA lesions 
than mouse cells. The repair of GA-induced DNA lesions was explored with cells from mice either 
proficient (Ogg1
+/+
) or deficient (Ogg1
-/-
) in Ogg1 (mouse 8-oxoguanine DNA glycosylase). Low 
repair of GA-induced fpg-sensitive lesions was observed in primary male germ cells and lymphocytes 
from both Ogg1
+/+
 and Ogg1
−/−
 mice, showing that these lesions are highly persistent. The authors 
concluded that there may be differences between mice and humans in the susceptibility to AA and 
GA-induced DNA damage, and in this study, mouse male germ cells do not appear to be more 
sensitive to GA than somatic cells. The authors suggested that the inter-species differences in AA 
susceptibility may be related to differences in DNA repair or other cellular defence factors such as 
GSH status and activity of glutathione-S-transferases (Hansen et al., 2010). 
Oliveira et al. (2009) analyzed the cytotoxicity and clastogenic potential of AA in V79 cells (cells 
essentially devoid of CYP2E1 activity). The experiments include the evaluation of the effect of BSO, 
an effective inhibitor of GSH synthesis, GSH-monoethyl ester (GSH-EE), a compound that is taken up 
by cells and intracellularly hydrolysed to GSH (thus producing an intracellular GSH enrichment), and 
also GSH exogenously added to culture medium. Pre-treatment with BSO increased the cytotoxicity 
and the frequency of aberrant cells excluding gaps (ACEG) induced by AA. While pre-treatment with 
GSH-EE did not modify the cytotoxicity or the frequency of ACEG induced by AA (fail to show a 
protective effect of GSH-EE), co-treatment with AA and GSH decreased both parameters. In vitro 
studies in a cell-free system, using monochlorobimane (MCB), a fluorescent probe for GSH, were also 
performed in order to evaluate the role of AA in GSH depletion. Based on these results, the authors 
concluded that spontaneous conjugation of AA with GSH in the extracellular medium is involved in 
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the protection given by GSH, reinforcing the role of GSH in the modulation of the cytotoxic and 
clastogenic effects induced by AA. 
AA did not induce unscheduled DNA synthesis (UDS) in rat hepatocytes and a weak response in 
human mammary epithelial cells, while GA induced a strong UDS response in both cell types 
(Butterworth et al., 1992). 
AA induced cell transformation in three different mouse cell lines (BALB/c, 3T3, NIH/3T3 and 
C3H/10T1⁄2) in the presence as well as in the absence of exogenous metabolic activation (ATSDR, 
2012). 
Bandarra et al. (2013, 2014) addressed the cytotoxicity, generation of ROS, formation of MN and 
induction of specific GA-DNA adducts in human mammary cells exposed to GA. For the cytokinesis-
blocked micronucleus assay, human MCF10A epithelial cells were exposed to GA at concentrations 
up to 2 mM. These cells express multiple CYPs, including low levels of CYP2E1. The impairment of 
cell proliferation by GA was first evaluated using the % of binucleated cells and the nuclear division 
index (NDI). A linear concentration-dependent decrease in cell viability was observed from 0.25 to 
2 mM GA. The highest concentration tested profoundly affected the cell proliferation indices. The % 
of binucleated (BN) cells was so low at this concentration (< 10 %) that a correct assessment of MN 
was precluded. In the presence of GA, a dose-response increase of the frequency of micronucleated 
BN (MNBN) cells was observed, although a significant increase of (more than 2-fold) was only 
detected at the highest concentration tested (1 mM). The depurinating adducts, N7-GA-Gua (major) 
and N3-GA-Ade (minor), were assessed by HPLC-ESI-MS/MS. A linear dose-response relationship 
was observed for N7-GA-Gua up to 1 mM GA. The adduct was quantified at GA concentrations as 
low as 1 μM. N3-GA-Ade could only be quantified at GA concentrations ≥ 250 μM due to the fact that 
it is found at ~ 1 % of the level of N7-GA-Gua. At these very high concentrations, a linear 
dose-response relationship was also found. By integrating GA adducts, MN and cell viability data, it 
becomes clear that while the primary DNA damage (i.e. DNA adducts) is evident at low levels of 
exposure, its consequences, either in terms of MN formation or in decreased cell proliferation kinetics, 
are only observed at much higher GA concentrations. DNA repair mechanisms may be contributing to 
this differential outcome. The formation of double stand breaks (DSBs) may be responsible for the 
clastogenic effects of GA observed using the cytokinesis-blocked micronucleous (CBMN) assay. The 
accumulation of DSBs eventually leads to cell-death. In view of this, and with the purpose of 
understanding DNA repair mechanisms triggered in GA-exposed cells, the authors used a specific 
inhibitor at the ATM kinase, KU55933. ATM is recruited and activated by DSBs thus playing a 
controlling role in homologous recombination. When ATM was inhibited, the cytotoxicity of GA in 
MCF10A cells was significantly increased, suggesting an important role of this kinase and 
homologous recombination in the repair of GA-induced lesions. The homologous recombination 
pathway has been reported as a possible repair pathway for GA-induced lesions (Johansson et al., 
2005; Martins et al., 2007).  
Nixon et al. (2014) examined the mechanisms of AA toxicity in male germ cells in vitro. The authors 
showed that CYP2E1 is expressed particularly in spermatocytes and the expression is up-regulated 
following exposure to AA. The induction of DNA adducts was investigated using the alkaline Comet 
assay after exposure of spermatocytes for 18 hours to 1 µM AA or 0.5 µM GA. A significant increase 
in tail DNA % was observed following GA exposure, however, only a modest effect was found in 
cells exposed to AA. The inclusion of fpg in the Comet assay led to enhanced detection of DNA 
damage in both AA and GA treated cells, with slightly higher levels of damage after GA exposure. 
Further characterisation of oxidative DNA damage using hOGG1 in the Comet assay failed to identify 
significant increases in the AA treated spermatocytes and only a modest increase was found in GA 
treated cells indicating that oxidative stress plays a minor role in the induction of this damage. No 
significant differences in GSH levels were also observed following treatment with either AA or GA. 
The analysis of damage by the fpg modified Comet assay following treatment of spermatocytes with 
AA (1 µM) or GA (0.5 µM) in the presence of resveratrol, an inhibitor of CYP2E1, showed that in the 
case of AA the co-treatment reduced the level of DNA adducts to control levels whereas no effect was 
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observed in the case of GA. These data show that spermatocytes are able to metabolise AA to GA via 
CYP2E1 and that direct adduction by GA is a major source of DNA damage induced by AA in male 
germ cells.  
The genotoxicity of AA was assessed in human Caco-2 cells with the Comet assay. Cells were 
exposed for 24 hours to 0, 4, 8, 12, 16 and 20 mM AA. Concentration-response relationships were 
observed. EC50 (concentration at which 50 % of the effect was observed) was 12.97 mM (Syberg et al., 
2015). 
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Table 21:  Experimental design and results for selected in vitro genotoxicity test with acrylamide (AA) and glycidamide (GA) 
Test Cell system Dose 
Metabolic 
activation 
Exposure time Result Reference 
Gene mutation 
test 
V79 cells/hprt 
AA 100–10 000 µM 
C+: MNNG 
C−: DMSO 0.1 % w/o S9 
 
Incubation time: 24 h 
No significant induction of 
mutations 
Baum et al. (2005) 
GA 400–2 000 µM 
C+: MNNG 
C−: DMSO 0.1 % 
Dose-related significant induction 
of mutations from 800 µM upwards 
Gene mutation 
test 
V79 cells/hprt 
GA: 400–2 000 µM 
C+: NOZ-2 
C−: DMSO 0.1 % 
w/o S9 Incubation time: 24 h 
Dose-related increase mutations 
from 800 µM 
Baum et al. (2008) 
Gene mutation 
test 
V79 cells/hprt 
GA: 400–2 000 µM 
C+: (±)-BPDE and 
α-A-NDELA 
w/o S9 - 
GA: dose-related increase 
mutations from 800 µM  
 
(±)-BPDE and α-A-NDELA: 
significant increase mutations at 
3 µM and 10 µM, respectively 
Thielen et al. 
(2006) 
Gene mutation 
test 
Human 
lymphoblastoid 
TK6 cells/TK 
AA: 2.5–14 mM 
C−: PBS 
C+: DBN 
w and w/o S9 Exposure: 4 h 
Negative in 1st experiment. 
Positive at 14 mM in 
2nd experiment. 
Dose-dependent cytotoxicity (about 
20 % RS at high dose) 
Koyama et al. 
(2006) 
GA: 0.5–2.2 mM 
C−: PBS 
C+: DBN 
Dose-dependent increase 
Positive even at non cytotoxic 
concentrations 
Gene mutation 
test 
Human 
promyelocytic 
leukaemia HL-60 
and NB4 cell lines 
AA: 50–700 mg/L 
C−: distilled water 
w/o S9 Exposure: 6 h 
Dose-related increase of 
cytotoxicity (decrease plating 
efficiency): statistically significant 
at ≥ 50 mg/L in HL-60 and 
≥ 300 mg/L in NB4 cells. 
Dose-related linear increase in 
mutation frequency: statistically 
significant at the highest dose in 
two cell lines (about five times 
higher than in the control) 
Ao et al. (2008) 
Table continued overleaf. 
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Table 21: Experimental design and results for selected in vitro genotoxicity test with acrylamide (AA) and glycidamide (GA) (continued) 
Test Cell system Dose 
Metabolic 
activation 
Exposure time Result Reference 
Comet assay 
(ASCGE) 
Human 
lymphocytes 
AA: 1 000–6 000 µM 
C+: bleomycin 
C−: DMSO 1 % 
w/o S9 Incubation: 1–4 h 
Negative 
Baum et al. (2005) 
GA: 100–3 000 µM 
C+: bleomycin 
C−: DMSO 1 % 
Dose-dependent significant increase 
DNA damages from 300 µM 
upwards 
Comet assay 
(ASCGE) 
w and w/o fpg 
treatment 
Human 
lymphocytes 
GA: 3–300 µM 
C+: (±)-BPDE and α-
A-NDELA 
w/o S9 - 
GA: w/o fpg: DNA damage at 
300 µM (4 h) 
w fpg: significant increase DNA 
damage at 10 µM (4 h) 
 
(±)-BPDE and α-A-NDELA: 
genotoxic at 30 µM and 10 µM, 
respectively (1 h) 
Genotoxicity not enhanced by fpg 
treatment 
Thielen et al. 
(2006) 
Comet assay 
Human 
lymphoblastoid 
TK6 cells 
AA: 2.5–14 mM 
C−: PBS 
C+: DBN 
w/o S9 Exposure: 4 h 
Negative  
Koyama et al. 
(2006) GA: 0.5–2.2 mM 
C−: PBS 
C+: DBN 
Positive (from 0.6 mM) even at non 
cytotoxic concentrations 
Comet assay 
Human hepatoma 
G2 cells 
AA: 0–20 mM 
C−: PBS 
C+: H2O2 
w/o S9 Exposure: 1 h 
Dose-related increase in DNA 
damage from 2.5 mM 
Jiang et al. (2007) 
Comet assay 
Chinese hamster 
lung fibroblasts 
V79 cells 
GA: 3–300 µM w/o S9 - 
w/o fpg: statistically significant 
increase DNA strand breaks at 
300 µM after 4 h and at 100 µM 
after 24 h (detectable at 300 µM 
after 1 h) 
w fpg: statistically significant 
increase DNA strand breaks at 
10 µM after 4 h 
Baum et al. (2008) 
Table continued overleaf. 
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Table 21: Experimental design and results for selected in vitro genotoxicity test with acrylamide (AA) and glycidamide (GA) (continued) 
Test Cell system Dose 
Metabolic 
activation 
Exposure time Result Reference 
Comet assay 
with and w/o fpg 
Mouse 
spermatocytes 
AA: 1 µM 
GA: 0.5 µM 
C−: untreated 
C+: H2O2 
w/o S9 
Exposure: 18 h 
(5 min for C+) 
w/o fpg: modest increase in tail 
DNA % with AA (about 2 times), 
significant increase in tail DNA % 
with GA (about 3–4 times) 
w fpg: significant increase in tail 
DNA % with AA and GA (about 9–
10 times) 
Nixon et al. (2014) 
Comet assay 
with fpg 
Mouse 
spermatocytes 
AA: 10 nM–10 µM 
GA: 5 nM–5 µM 
C−: untreated 
C+: H2O2 
w/o S9 
Exposure: 18 hours 
(5 min for C+) 
Significant dose-related increases in 
tail DNA % following exposure to 
≥100 nM AA or ≥ 5 nM GA 
Nixon et al. (2014) 
Comet assay 
with and w/o 
hOGG1 
 
Mouse 
spermatocytes 
AA: 1 µM 
GA: 0.5 µM 
C−: untreated 
C+: H2O2 
w/o S9 
Exposure: 18 h 
(5 min for C+) 
AA +/- hOGG1: no significant 
levels of DNA damage 
GA - hOGG1: modest  but 
significant increase in tail DNA % 
(about 1.5 times) 
GA + hOGG1: greater statistically 
significant increase in tail DNA % 
(about 2 times) 
 
 
Nixon et al. (2014) 
Comet assay 
with fpg 
Mouse 
spermatocytes 
AA: 1 µM 
GA: 0.5 µM 
C−: untreated 
C+: H2O2 
Resveratrol: 0.1 µM 
w/o S9 
Exposure: 18 h 
(5 min for C+) 
AA w fpg: significant increase in 
tail DNA % (about 2 per control w 
fpg) 
GA w fpg: significant increase in 
tail DNA % (about 1.5 times 
control w fpg) 
Resveratrol w fpg: no effect 
AA + resveratrol w fpg: no effect 
GA + resveratrol w fpg: significant 
increase in tail DNA % (about 2 
times control w fpg) 
Nixon et al. (2014) 
Table continued overleaf. 
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Table 21: Experimental design and results for selected in vitro genotoxicity test with acrylamide (AA) and glycidamide (GA) (continued) 
Test Cell system Dose 
Metabolic 
activation 
Exposure time Result Reference 
Comet assay 
With hOGG1 
 
Mouse 
spermatocytes 
AA: 1 µM 
GA: 0.5 µM 
C−: untreated 
C+: H2O2 
Resveratrol: 0.1 µM 
w/o S9 
Exposure: 18 h 
(5 min for C+) 
AA w hOGG1: significant increase 
in tail DNA % (about 1.2 times 
control) 
GA w hOGG1: no effect 
Resveratrol: no effect 
AA + resveratrol w hOGG1: no 
effect 
GA + resveratrol w hOGG1: no 
effect 
Nixon et al. (2014) 
MN test 
Human 
lymphocytes 
(15 donors) 
AA: 500–5 000 µM 
C+: bleomycin 
C−: untreated 
w/o S9 Exposure: 23 h 
5 000 µM: about 2-fold increase in 
mean MN frequency (7/15 donors) 
Overall: no significant increase MN 
frequency Baum et al. (2005) 
GA: 50–1 000 µM 
C+: bleomycin 
C−: untreated 
No significant increase MN 
frequency 
MN test 
Human 
lymphoblastoid 
TK6 cells 
AA: 2.5–14 mM 
C−: PBS 
C+: DBN  
w/o S9 Exposure: 4 h 
Statistically significant positive 
increase in two experiments 
Koyama et al. 
(2006) GA: 0.5–2.2 mM 
C−: PBS 
C+: DBN 
Dose-dependent increase. 
Positive even at non cytotoxic 
concentrations 
MN test 
Human hepatoma 
G2 cells 
AA: 0, 0.625, 1.25, 
2.5 mM 
C−: PBS 
C+: CP 
w/o S9 Exposure: 24 h 
Dose-dependent increase MN in 
BNC from 0.625 mM (3-fold 
increase at high dose) 
Jiang et al. (2007) 
MN test 
Human 
lymphocytes 
AA: 500 µM, 5 and 
50 mM 
w/o S9 
Exposure: 20 h 
Harvesting at 72 h 
Cytotoxicity at 5 and 50 mM 
Statistically significant increase 
MNBN at 500 µM (1/2 laboratory) 
Katic et al. (2010) 
Table continued overleaf. 
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Table 21: Experimental design and results for selected in vitro genotoxicity test with acrylamide (AA) and glycidamide (GA) (continued) 
Test Cell system Dose 
Metabolic 
activation 
Exposure time Result Reference 
CA 
Chinese hamster 
V79 cells 
AA: 250–2 000 µM 
GA: 1–2 000 µM 
C+: MMC 
w/o S9 
Exposure: 16 h 
Harvesting 2.5 h after 
end of treatment 
AA and GA induced dose-
dependent cell death (MTT 
cytotoxicity assay) 
GA more cytotoxic than AA 
(survival values < 5 % at ≥ 4 mM 
GA and 10 mM AA) 
Increased CA by AA (especially at 
2 000 µm) and GA (especially at 
≥ 500 µM) 
Martins et al. 
(2007) 
SCE assay 
Chinese hamster 
V79 cells 
AA: 250–2 000 µM 
GA: 1–2 000 µM 
C+: MMC 
w/o S9 
Exposure: 27 h 
Harvesting 2.5 h after 
end of treatment 
GA consistently induces SCE 
(≥ 10 µM) 
AA: significant increase SCE/cell at 
2 000 µM 
Martins et al. 
(2007) 
SCE assay 
Human 
lymphocytes 
AA: 0–2 000 µM 
C−: PBS 
C+: MMC 
w/o S9 Incubation 46 h 
Slight increase SCE/metaphase at 
2 000 µM 
Pingarilho et al. 
(2013) GA: 0–2 000 µM 
C−: PBS 
C+: MMC 
Marked dose-dependent increase 
SCE/metaphase up to 750 µM. 
(±)-BPDE: (±)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide; -A-NDELA: -acetoxy-N-nitroso-diethanolamine; ASCGE: alkylating single cell electrophoresis; C+: positive control; C−: 
negative control; CA: chromosomal aberrations; fpg: formamido-pyrimidine-DNA-glycosylase; h: hour(s); min: minutes; MN: micronucleous; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide; SCE: sister chromatid exchange; w: with; w/o: without.   
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7.3.3.2. In vivo genotoxicity of AA and GA  
Table 22 summarized the experimental design and results of recent in vivo Comet assays, and 
micronucleus tests with AA. 
Induction by AA of structural chromosome aberrations, micronuclei or polyploidy was observed in 
various studies in mice treated in vivo (doses 25–100 mg/kg b.w.) (Witt et al., 2008; ATSDR, 2012). 
The effects were observed in various tissues: bone marrow, spleen lymphocytes, splenocytes, 
peripheral blood reticulocytes, erythrocytes, spermatocytes, etc. AA produces chromosome damage in 
mouse, but not in rat somatic cells (Paulsson et al., 2002; Rothfuss et al., 2010; ATSDR, 2012) (Table 
22). However, in some tests an increase in MN frequency has also been reported in rat somatic cells 
(Witt et al., 2008; Yener and Dikmenli, 2009). Low doses of AA (i.p. doses of 0–100 mg/kg b.w. and 
oral doses of 4–6 mg/kg b.w. per day) have been shown to induce MN in the flow cytometer-based 
MN assay in mice (Abramsson-Zetterberg, 2003; Zeiger et al., 2009). A clear increase of the 
frequency of micronucleated erythrocytes was seen. The dose-response was found to be linear with a 
tendency to have a steeper rise at the lowest doses. This tendency is opposite as compared to what 
detected with typical aneugenic agents (i.e. colchicine) which have no effect below a threshold dose. A 
significant dose response increase in the  frequency of MNs in PCE was observed within an interval as 
low as 0–6.5 mg/kg b.w. The low DNA content of the MN from AA-treated mice supports the view 
that AA has no typical aneugenic effects (Abramsson-Zetterberg, 2003). 
Paulsson et al. (2003) showed that GA induces MN in bone marrow cells of mice and rats treated with 
GA by i.p. injection.  
Induction of DNA damage by AA as measured by the Comet assay has been reported in several tissues 
of mice or rats (Manière et al., 2005; Dobrzynska, 2007; Recio et al., 2010; Rothfuss et al., 2010) 
(Table 22).  
Both the presence of DNA damage, measured by the Comet assay, and the formation of N7-GA-Gua 
and N3-GA-Ade were assessed in selected tissues from rats treated by gavage with 0, 18, 36 or 54 mg 
AA/kg b.w. (Manière et al., 2005). DNA damage was recorded in blood, brain, bone marrow, liver, 
testes and adrenal glands. AA induced DNA lesions in blood leucocytes and brain at the two highest 
doses and in testes at the highest dose 24 hours after exposure. No statistically significant increase in 
Comet parameters was observed in the other organs. No histopathological findings were observed in 
liver, brain and testes at the highest dose tested. In order to study a possible earlier increase in DNA 
damage in organs showing no response in the Comet assay 24 hours after exposure to AA, the extent 
of DNA migration was recorded 2 and 5 hours after administration of 54 mg AA/kg b.w. A 
statistically significant increase in DNA damage was observed in leucocytes, bone marrow, liver and 
adrenals 5 hours after administration of AA and 2 hours after administration in testes and adrenals. For 
the DNA adduct assay, tissue samples from brain, liver and testes were collected 5, 24, 48 and 
72 hours after dosing and samples of blood were taken 5, 24 and 48 hours after dosing of rats treated 
with mg AA/kg b.w. In rat organs, the N3-GA-Ade DNA adduct was found in much less quantity than 
the N7-GA-Gua one (about 50–100-fold). After administration of the high dose, N7-GA-Gua was the 
major DNA adduct detected, at similar levels in brain and liver and at lower levels in testes. The 
profiles of N7-GA-Gua DNA adducts were similar in all the tested organs, with adduct levels peaking 
between 5 and 24 hours after dosing and then slightly decreasing until 72 hours. The N7-GA-Gua 
DNA adduct disappeared slowly from the rat organs, remaining at relatively high levels 3 days after 
treatment. The formation and elimination rate of N7-GA-Gua DNA adducts in the liver, brain and 
testes after administration of the low dose were very similar except that the levels reached were about 
2-fold lower than with the highest dose of AA. The half-lives for N7-GA-Gua were 50–70 hours and 
50–80 hours at high and low dose, respectively. For N3-GA-Ade, they were  about  20  hours  and  
20–30 hours, at high and low dose, respectively. The results of this study relate the occurrence of AA-
induced DNA damage detected by the Comet assay to the formation of DNA adducts in selected 
organs and tissues. 
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A weak, positive result was reported in the mouse spot test after single or 3 daily i.p. injections of 0, 
50 or 75 mg AA/kg b.w. in pregnant females indicating that AA is able to induce somatic mutations in 
fetal cells after transplacental absorption of the test compound (IARC, 1994; FAO/WHO, 2002; 
Carere, 2006).  
AA did not cause UDS in the liver of rats receiving single or repeated (5 times) i.p. injections of 0, 30 
or 100 mg/kg b.w. (see IARC, 1994; FAO/WHO, 2002; ATSDR, 2012).  
UDS was measured in early spermatids of mice receiving single i.p. injections of 0–125 mg AA/kg 
b.w. (Sega et al., 1990). The testes were injected with tritiated thymidine either at the time of AA 
treatment or at later times, up to 48 hours following AA exposure. Sperm were recovered from the 
caudal epididymes 16 days after treatment. In addition, groups of male mice received a single i.p. 
injection of 0 or 125 mg AA/kg b.w. with tritiated thymidine injected into the testes 6 hours later. 
Sperm were then recovered from the caudal epididymes at 2 or 3 days intervals between 1 and 30 days 
after treatment (spermatozoal to early spermatocyte stages). Also, groups of 4 male mice received i.p. 
injections of 46 mg 
14
C-AA/kg b.w.; DNA was extracted from liver and testes samples 1–24 hours 
after treatment and analysed for radioactivity. In the first experiment, a clear increase of UDS was 
noted in the testes with the maximum response occurring 6 hours after tritiated thymidine injection. 
The UDS response appeared to be linear over exposures up to 125 mg AA/kg b.w. For the second 
experiment non-significant increases of UDS were observed during the first 10 days after exposure to 
AA (late spermatid through spermatozoal stages at time of treatment) but an increase of UDS was 
noted from days 12–27 (early spermatocyte through mid spermatid stages at time of AA treatment). In 
the third experiment, DNA alkylation was observed (by measuring DNA adduct formation), with the 
maximum levels 4–6 hours post-administration in the testes and 1–2 hours post-administration in the 
liver. The DNA alkylation levels in the testes were about 10-fold lower than in the liver. Based on 
these results, the authors concluded that AA or, more likely a metabolite, is able to interact with DNA 
and elicit a UDS response in early spermatocytes through mid-spermatid stages (Sega et al., 1990). 
UDS induction in hepatocytes and spermatocytes was studied in an in vivo test in F344 rats that 
received single oral doses (by gavage) of 100 mg AA/kg b.w. or repeated (5 times) oral doses of 
30 mg AA/kg b.w. (Butterworth et al., 1992). A statistically significant increase of UDS was noted in 
spermatocytes only after repeated administration of 30 mg AA/kg b.w. No UDS response was 
observed in the liver. 
Dominant lethal mutations were induced following administration of AA via oral route, dermal 
application or i.p. injection in rodents (ATSDR, 2012). Exposure via i.p. injection was also associated 
with specific locus mutations in offspring of male mice exposed to 50–125 mg AA/kg before mating 
to untreated females and in offspring of pregnant female mice exposed to 50 or 75 mg/kg. Heritable or 
reciprocal translocations were noted in offspring of male mice exposed to 50–100 mg AA/ kg or 
100 mg GA/kg via i.p. injection or dermal application before mating to untreated females (Favor and 
Shelby, 2005). The authors concluded that these results indicate an increase in the frequency of 
translocation carriers in offspring following paternal exposure to AA or GA in spermatid or 
spermatozoa. The i.p. exposure to AA on PND1–8 also increased mutations at the TK and hprt loci in 
spleen lymphocytes of mice (von Tungeln et al., 2009) and at lac Z loci in transgenic mice 
(Muta®Mouse) (Hoorn et al., 1993).   
Three studies showed positive results in the specific locus mutation assay in mice, which allowed 
detection of both small and large gene deletions (ATSDR, 2012). In one study (Russell et al., 1991), 
male mice received 5 repeated i.p. injection doses of 50 mg/kg b.w. per day. Increased frequencies of 
specific locus mutations were observed for males mated with females on days 8–14 and 15–21 after 
treatment suggestive of specific locus mutations in the late stages of spermatogenesis (spermatids and 
spermatozoa). 
Favor and Shelby (2005) reviewed seven published studies that assessed the effectiveness of AA and 
GA in inducing transmitted reciprocal translocations or gene mutations in the mouse. Results indicated 
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an increase in the frequency of translocation carriers in offspring following paternal exposure to AA or 
GA in spermatid and spermatozoa (Shelby et al., 1987; Adler, 1990; Adler et al., 1994, 2004; 
Generoso et al., 1996). Even the dose of 50 mg AA/kg b.w. i.p., significantly increased the frequency 
of translocation carriers when compared to the historical control (0.6 % compared to 0.04 %) (Adler et 
al., 1994). A detailed cytogenetic analysis of the semi-sterile and sterile offspring recovered in the 
heritable translocation test indicated that the animals were often carriers of more complicated 
chromosomal rearrangements (reciprocal translocations between two chromosomes, translocation 
among three chromosomes, two independent reciprocal translocations each between two 
chromosomes). Two studies screened for specific-locus mutations (Russell et al., 1991; Ehling and 
Neuhäuser-Klaus, 1992). In addition to the specific-locus results, the studies included data on fertility 
(in the first study: litter size and number of offspring/male and in the second study: % fertile matings, 
number of corpora lutea/female, number of implants/female, number of live embryos/female and % of 
dead implants) and data on dominant lethality. The results were consistent between both laboratories 
and indicated that AA was mutagenic in the first two weeks post-treatment, corresponding to germ 
cells exposed in the spermatozoa or spermatid stages. Results for AA treatment of earlier 
spermatogenic stages differed between the two studies. Russell et al. (1991) reported no increase in the 
frequency of specific-locus mutations in offspring derived from germ cells exposed as stem-cell 
spermatogonia. By contrast, Ehling and Neuhäuser-Klaus (1992) observed a significant increase in the 
frequency of specific-locus mutations following exposure of spermatogonia to AA. The heritable 
translocation test detects per se clastogenic events. The extensive cytogenetic and fertility analyses of 
the heritable translocations and specific-locus mutations recovered in offspring of AA treated parental 
male mice clearly indicates that the transmitted mutations are associated with clastogenic events. The 
authors also concluded that in these spermatogenic stages AA is mainly or exclusively a clastogen; per 
unit dose, i.p. exposure is more effective than dermal exposure; and per unit dose, GA is more 
effective than AA. 
The in vivo genotoxicity of AA and GA was investigated in Big Blue mice. Manjanatha et al. (2006) 
exposed mice to 0, 100 or 500 mg/L AA or an equimolar amount of GA (120 and 600 mg/L) dissolved 
in drinking water for 7 days per week and for up to 4 weeks. Micronucleated reticulocytes were 
assessed in peripheral blood within 24 hours of the last treatment and lymphocyte HPRT and liver cII 
mutagenesis assays were conducted 21 days following the last treatment. In addition, the types of cII 
mutations were determined by sequence analysis. The frequency of micronucleated reticulocytes was 
increased in males treated with the high doses of AA (3.3 fold) and GA (1.7 fold). Both doses of AA 
and GA produced increased HPRT mutant frequencies in lymphocytes, with the high doses inducing 
mutation frequencies 16–25 fold higher than the controls. The high doses of AA and GA produced 
significant 2–2.5 fold increases in cII mutant frequency in the liver. Molecular analysis of the mutants 
indicated that AA and GA produced similar mutation spectra and that these spectra were significantly 
different from that of spontaneous mutants. The predominant types of mutations in the liver cII gene 
from AA and GA treated mice were G:C → T:A transversions and -1/+1 frameshifts in a 
homopolymeric run of Gs. The authors concluded that the mutation frequencies and types of mutations 
induced by AA and GA in the liver were consistent with AA exerting its genotoxicity in Big Blue 
mice via metabolism to GA (Manjanatha et al., 2006). In the study of Mei et al. (2010), Big Blue rats 
were exposed to 0, 0.7 and 1.4 mM AA or GA dissolved in drinking water (50 or 60 mg/L and 100 or 
120 mg/L, respectively; equivalent to approximately 4 and 12 mg/kg b.w. per day of AA and GA) for 
7 days per week and for up to 60 days. The concentrations of AA and GA in drinking water were 
equal to and double the maximum dose used in 2-year carcinogenesis studies of AA and GA in F344 
rats (see Section 7.3.3.2). After 2 months of dosing, the rats were euthanized and blood was taken for 
the micronucleus assay; spleens for the lymphocyte HPRT mutant assay; and liver, thyroid, bone 
marrow, testis (from males), and mammary gland (females) for the cII mutant assay. Neither AA nor 
GA increased the frequency of micronucleated reticulocytes, and the authors speculated that the doses 
used in the study were too low to produce a measurable positive response and that rats may be 
relatively insensitive to MN induction by AA and GA. Both compounds produced small 
(approximately 2-fold to 3-fold above background) but significant increases in lymphocyte HPRT 
mutant frequency. The spectrum of mutations from AA-treated rats was significantly different from 
that of control rats and of GA-treated rats, while the spectrum of mutations from GA-treated rats was 
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marginally different from that of control rats.  Neither compound increased the cII mutation frequency 
in testis, mammary gland (tumour target tissues), or liver (non-target tissue), while both induced weak 
positive increases in bone marrow (non-target tissue) and thyroid (target tissue). The overall patterns 
of mutations in the thyroid cII mutants in the AA and GA-treated groups did not differ significantly 
from the controls. In addition, there were no significant differences between the spectra for AA and 
GA treated rats in either the male or the female groups. The authors concluded that although the 
genotoxicity in tumour target tissue was weak, in combination with the responses in surrogate tissues, 
the results were consistent with AA being a gene mutagen in the rat via metabolism to GA. 
Wang et al. (2010a) investigated whether AA and GA induced mutagenic effects in the germ cells of 
male mice. Male Big Blue transgenic mice were administered 1.4 or 7.0 mM of AA or GA (100 or 
120 mg/L and 500 and 600 m/L, respectively, equivalent to approximately 19 or 35 and 88 or 
111 mg/kg b.w. per day) in the drinking water for up to 4 weeks. Testicular cII mutant frequency (MF) 
was determined 3 weeks after the last treatment, and the types of the mutations in the cII gene were 
analyzed by DNA sequencing. The testes cII MFs were significantly increased in all treatment groups. 
There was no significant difference in the cII MFs between AA and GA at the low exposure 
concentration. At the high concentration, the MF induced by GA was higher than that induced by AA. 
The mutation spectra in mice treated with AA (1.4 mM) or GA (both 1.4 and 7.0 mM) differed 
significantly from those of controls, but there were no significant differences in mutation patterns 
between AA and GA treatments. The mutagenic effect was found at exposure concentrations of AA 
and GA where no testicular atrophy was observed, indicating that the mutagenic effect is independent 
of the reproductive toxicity of AA and GA. The Big Blue mouse may be more sensitive for detecting 
the mutations in testes caused by AA and GA than the Big Blue rat since there was no increase in the 
MFs in testes of rats treated with AA or GA at 1.4 mM for 60 days and killed after 60-day treatment 
(Mei et al., 2010). However, this may be related to the difference in received effective doses in rats 
and mice. Comparison of the mutation spectra between testes and livers (data from previous study 
Manjanatha et al., 2006) showed that the spectra differed significantly between the two tissues 
following treatment with AA and GA, whereas the mutation spectra in the two tissues from control 
mice were similar. In testes, the treatments with AA and GA induced substantial increases in A:T → 
G:C transition and G:C → C:G transversion, whereas in liver, the predominant types of mutations 
were G:C → T:A transversions and −1:+1 frameshifts. The authors concluded that these results 
suggest that AA possesses mutagenic effects on testes by virtue of its metabolism to GA possibly 
targeting spermatogonial stem cells, but possibly via different pathways when compared to mutations 
in liver. 
El-Bohi et al. (2011) measured CYP2E1 protein and transcript levels as well as DNA damage as 
measured by the in vivo alkaline single cell gel electrophoresis (Comet assay) in hepatic tissues of rats 
treated with AA. Male albino rats received 0 (distilled water), 50 or 100 mg/kg b.w. per day AA by 
oral gavage for 21 days. AA caused marked alterations in animal behaviour, revealing nervous 
manifestations and induced mortality in both treated groups which reached 30 % (in the first group) 
and 40 % (in the second group). AA elicited a highly significant increase in serum AST and ALT 
activities, and a significant decrease of total protein, albumin and globulin levels were recorded. AA 
caused down regulation of both CYP 2E1 protein and mRNA levels concomitant with a dose 
dependent significant increase in the number of DNA single strand breaks. Histopathological 
investigation revealed necrotic and degenerative changes in the liver of AA treated rats. 
To explore the role of CYP2E1 metabolism in the germ cell mutagenicity of AA, CYP2E1-null and 
wild-type male mice were treated by i.p. injection with 0, 12.5, 25 or 50 mg AA/kg b.w. per day for 
5 consecutive days. At defined times after exposure (2 days or 1 week), males were mated to untreated 
B6C3F1 females. Females were killed in late gestation (about 13 days after the end of cohabitation 
period) and uterine contents were examined. No changes in any fertility parameters (% pregnant 
females, mean number of implants per pregnant female, % live fetuses per pregnant female and 
% resorptions per pregnant female) were seen in females mated to AA-treated CYP2E1-null mice. In 
contrast, AA exposure induced marked reproductive effects in wild-type male mice. The clearest 
indicator of dominant lethality is the % resorptions in females mated to treated males. Dose-related 
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increases in resorptions (chromosomally aberrant embryos) and decreases in the numbers of pregnant 
females and in the proportion of living fetuses were seen in females mated to AA-treated wild-type 
mice. AA exposure produced dose-related decreases in the mean number of implantation sites per 
pregnant female in females mated with wild type males in the second mating period (mating 1 week 
after exposure). These results demonstrated that AA-induced germ cell mutations in male mice require 
CYP2E1-mediated epoxidation of AA. Thus, induction and polymorphisms of CYP2E1 in human 
populations, resulting in variable enzyme metabolic activities, may produce differential susceptibilities 
to AA toxicities (Ghanayem et al., 2005b). 
Female wild-type and CYP2E1-null mice were treated by i.p. injection with 0, 25, or 50 mg AA/kg 
b.w. per day for 5 consecutive days (Ghanayem et al., 2005c). Twenty-four hours after the final 
treatment, blood and tissue samples were collected. Erythrocyte micronucleus frequencies were 
determined using flow cytometry and DNA damage was assessed in leukocytes, liver, and lung using 
the alkaline Comet assay (pH > 13). Significant dose-related increases in micronucleated erythrocytes 
and DNA damage in liver cells and leukocytes were induced in AA-treated wild-type but not in the 
CYP2E1-null mice. No increases in the percentage of cells with low molecular weight (LMW) DNA 
(indication of necrosis or apoptosis) were seen in leukocytes of either genotype of mice, indicating an 
absence of cytotoxicity. No significant increases in LMW DNA in liver cells was seen in wild-type 
mice, however, in CYP2E1-null mice treated with 50 mg/kg b.w. per day AA, a small but statistically 
significant increase in the percentage of cells with LMW DNA was detected. No treatment-related 
increases in DNA damage were seen in lung cells of wild-type or CYP2E1-null mice and no 
treatment-related increases in the percentage of cells with LMW DNA were observed in either 
genotype of mice. This result is unexpected since the lung has been reported to be a target for AA-
induced carcinogenesis in female mice and significant amounts of GA in lung tissue of female B6C3F1 
mice treated with AA have been detected (Doerge et al., 2005b). Lack of exposure of lung tissue is 
unlikely to be a factor in the negative results for DNA damage in this tissue. According to the authors, 
it is possible that the relatively small sample of cells analysed in the Comet assay may not have 
contained sufficient numbers of the particular cell type in which DNA damage is induced and from 
which tumours derive. These results support the hypothesis that genetic damage in somatic and germ 
cells of mice treated with AA is dependent upon metabolism of the parent compound by CYP2E1 
(Ghanayem et al., 2005a). 
Von Tungeln et al. (2009) compared the extent of DNA adduct formation and induction of micronuclei 
and mutations in mice treated neonatally with AA and GA. Male and female B6C3F1/tk mice were 
treated i.p. on postnatal day (PND) 1, 8 or 15 or PND1–8 with 0, 0.14 or 0.70 mM AA or GA/ kg b.w. 
per day (corresponding to about 0, 10 and 50 mg AA/kg b.w. per day and 0, 12 and 61 mg GA/kg b.w. 
per day). On PND9, small samples of tail tissue were obtained to establish the genotype of the mice (to 
distinguish between B6C3F1/tk +/+ and B6C3F1 tk +/− mice). On PND16, the B6C3F1/tk +/+ mice 
were killed to measure DNA adduct (N7-GA-Gua and N3-GA-Ade) levels in liver, spleen, lungs and 
bone marrow and blood was obtained by cardiac puncture to assess the induction of micronuclei. 
Three weeks after the last treatment, the B6C3F1/tk+/− mice were killed to determine the mutant 
frequency in the hprt and tk genes. In the second experiment, male and female B6C3F1 mice were 
treated i.p. on PND1–8 with 0, 0.14 or 0.70 mM AA of GA/kg b.w. per day. Tail samples were taken 
on PND8 to establish the genotype of the mice. The B6C3F1/tk +/+ mice were killed on PND9 to 
determine the induction of MN in peripheral blood and DNA adducts levels in lung, liver and spleen. 
The B6C3F1/tk +/− mice were killed 3 weeks after the last treatment to determine the mutant 
frequency in the HPRT and TK genes in splenic T-lymphocytes. An ENU-treated positive control 
group was included in the experiment. Both adducts were readily detected in mice treated with AA or 
GA. The highest levels of N7-GA-Gua were found in lung DNA, followed by the liver, spleen and 
bone marrow DNA. The levels of N7-GA-Gua decreased in the order 0.70 mM/kg b.w. per day GA > 
0.70 mM AA/kg b.w. per day  > 0.14 mM GA/kg b.w. per day ~ 0.14 mM AA/kg b.w. per day. The 
levels of N3-GA-Ade were approximately 100-fold lower than the levels of N7-GA-Gua. The relative 
ranking of N3-GA-Ade levels within tissues was similar to that observed with N7-GA-Gua and the 
levels of adducts decreased in the same order. Only the high dose of GA increased the frequency of 
micronucleated reticulocytes (MN-RET) and normochromatic erythrocytes (MN-NCE). In mice 
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treated on PND1, 8 and 15 the HPRT mutant frequency was increased by 0.70 mM GA/kg b.w. per 
day. None of the treatments affected the TK mutant frequency. In mice dosed on PND1–8, 0.70 mM 
GA/kg b.w. per day caused extensive mortality; each of the other treatments increased the TK mutant 
frequency, whereas AA (at both doses) increased the HPRT mutant frequency. Treatment with 
0.14 mM GA/kg b.w. per day caused an increase in MN-NCE in peripheral blood at PND9. None of 
the other treatments affected the percentage of MN-RET or MN-NCE. The authors concluded that the 
mutagenic response in neonatal mice treated on PND1, 8 and 15 was due to GA, whereas mutations 
resulting from dosing on PND1-8 were due to another mechanism. 
In a follow-up study, Von Tungeln et al. (2012) examined the tumourigenicity of AA and GA in mice 
treated neonatally. Male B6C3F1 mice were injected i.p. on PND1, 8 and 15 with 0 (deionized water), 
0.14 or 0.70 mM AA or GA/kg b.w. per day and the tumourigenicity was assessed after 1 year (see 
Section 7.3.3.2). There was an increased incidence of combined hepatocellular adenoma or carcinoma 
in the group treated with the high dose GA. Analysis of the hepatocellular tumours indicated that the 
increased incidence observed in mice administered 0.70 mM GA/kg b.w. per day was associated with 
A→G and A→T mutations at codon 61 of H-ras. The authors concluded that these results, combined 
with the previous data on DNA adduct formation and mutation induction, suggested that the 
carcinogenicity of AA was dependent on its metabolism to GA, a pathway that is deficient in neonatal 
mice. 
To compare the susceptibility to AA-induced genotoxicity of young versus adult animals, Koyama et 
al. (2011a) treated 3- and 11-week-old male gpt delta transgenic F344 rats with 0, 20, 40 or 80 mg/L 
AA via drinking water (equivalent to 0, 3.01, 5.95 and 12.19 mg/kg b.w. per day in young rats and 0, 
1.83, 3.54 and 7.05 mg/kg b.w. per day in adult rats) for 4 weeks and then examined genotoxicity in 
the bone marrow, liver and testis. They also analysed the level of N7-(2-carbamoyl-2-hydroxyethyl)- 
guanine (N7-GA-Gua), the major DNA adduct induced by AA, in the liver, testis, mammary gland and 
thyroid. At 40 and 80 mg/L, both age groups yielded similar results in the Comet assay in liver, but at 
80 mg/L, the bone marrow micronucleus frequency and the gpt-mutant frequency in testis increased 
significantly only in the young rats. AA did not increase the gpt-mutant frequency in the liver of either 
age group at any dose. The N7-GA-Gua adduct levels were increased in a dose-dependent manner in 
all tissues. In the mammary glands and thyroid, adduct levels did not differ significantly between 
young and adult rats. In the liver and testis, the level was higher in the young rats than in the adult rats 
(about 6 times that of adult rats). The authors concluded that these results implied that young rats were 
more susceptible than adult rats to AA-induced testicular genotoxicity. 
To determine whether chronic AA exposure produces genetic damage in male germ cells in vivo, male 
Swiss mice (3 animals per group) were exposed to AA via drinking water (Nixon et al., 2012, 2013). 
AA was administered at doses of 0–10 µg/mL (equivalent to 0.0001–2 mg/kg b.w. per day) for up to 
1 year. At 1, 3, 6, 9 and 12 months, DNA damage in isolated spermatocytes was measured using an 
alkaline Comet assay with the addition of formamidopyrimidine-DNA glycosylase (fpg), a restriction 
enzyme used to detect and cleave sites of GA-DNA adducts and γH2A.X expression, a marker of 
double-strand breaks. AA treatment did not significantly affect body weight or testis weight. A 
significant dose-dependent increase in DNA damage was observed in mouse spermatocytes following 
6 months of exposure in the two highest dosage groups (0.15 and 1.4 mg/kg b.w. per day). After 
12 months of exposure, increases in damage were detected at doses as low as 0.001 mg/kg b.w. per 
day. γH2A.X staining was more prominent in testes from mice exposed to AA, particularly at 0.17 and 
1.53 mg/kg b.w. per day and was predominantly localized in spermatocytes. Thus AA exposure in 
male mice leads to an increased frequency of double-strand breaks in spermatocytes. The authors 
concluded that the results of this study demonstrated that chronic exposure to AA, at doses equivalent 
to human exposures, generated DNA damage in male germ cells of mice in the absence of major 
effects on mouse health or defects in spermatogenesis (Nixon et al., 2012). The CONTAM Panel noted 
that the Comet assay is indicative for DNA damage via genotoxic events but also via apoptosis. 
However, at the chronic exposures used in this study, no signs of germ cell apoptosis were observed in 
testis histology of mice. The CONTAM Panel considered that the small number of mice used per dose 
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group constitutes a potential limitation of the study.
36
 The Panel also noted that the higher sensitivity 
of the Comet assay when used in conjunction with fpg for the detection of GA-induced DNA damage 
(Hansen et al., 2010) might explain why an effect was observed at so low doses in this study in 
comparison with the Manière et al. (2005) study, in which effects were only detected at higher doses. 
The CONTAM Panel, however, considers that the findings of the Nixon et al. (2012) study are of 
potential relevance for the evaluation of male germ cells genotoxicity following chronic exposure to 
AA and that further studies should be carried out to better characterize the genotoxicity at doses 
equivalent to human exposure using additional endpoints for DNA damage, including especially DNA 
adducts, and with an appropriate number of animals as indicated by EFSA (2012b).    
Altaeva et al. (2011) studied the mutagenic effect of AA on thyroid gland cells by an extended 
micronucleus test (Cytoma test). Male Wistar rats received AA solution in distilled water orally (by 
gavage) 48, 96 and 144 hours after hemithyroidectomy (HTE, to stimulate proliferative activity of the 
thyroid gland). Cells were collected on day 9 after HTE. The following doses of AA were studied: 0, 
0.496, 2.48 and 12.4 mg/kg b.w. (corresponding to 0.004, 0.02 and 0.1 LD50). Cytogenetic and 
cytotoxic parameters were recorded. No thyroid gland (TG) cells with MN were detected in intact rats 
after HTE (control). The relative content of cells with protrusions was 0.83 ‰, with internuclear 
bridges 0.33 ‰, the sum of cytogenetic disorders 1.16 ‰, the proliferation index 13.2 ‰ and the 
apoptic index 3.5 ‰. The incidence of TG cells with cytogenetic disorders increased in AA exposed 
cells but decreased with increasing dose (respectively 8-fold, 3.6-fold and 4.9-fold higher vs. the 
control). A few micronuclei (small size, presumably the result of clastogenicity) were detected in the 
thyroid gland cells of treated rats (not dose-related). Mainly the number of cells with protrusions (an 
indication of aneugenicity) were increased, again the effect was maximal in the low dose rats. The low 
dose of AA led to a 2-fold increase of the apoptosis, whereas the medium and high dose led to a 4.8- 
and 4.7-fold increase of the apoptotic index, respectively. The proliferative activity also increased 
2-fold in the low dose AA cells, was inhibited in the medium dose (reached the control level) and 
again increased by 2.5 times in the high dose cells. Cell elimination and restoration in the population 
were balanced in the low dose, but this was paralleled by the maximum level of cytogenetic effects. In 
the medium dose there was a significant elimination of cells with cytogenetic aberrations, which did 
not recover in the absence of proliferative activity. The apoptotic index remained high in response to 
further increase in AA dose; the total count of cells in the populations presumably decreased and this 
fact triggered the compensatory reaction and hence proliferative activity. Increase of proliferation 
indicates a stronger toxic effect of the test substance, leading to compensatory reactions and 
necessitating cell population restoration. This was again paralleled by an increase in the level of 
cytogenetic effects. The authors concluded that a mutagenic effect of AA on thyroid gland cells was 
detected which along with an increase in proliferative activity leads to the development of tumours in 
this organ. 
Yener (2013) investigated whether long term low dose exposure to AA increased micronucleus 
frequency in rat bone marrow polychromatic erythrocytes. Doses of 0, 2 or 5 mg AA/kg b.w. per day 
were administered to Wistar rats in their drinking water for 90 days. No obvious symptoms of sickness 
or decreased activity and no mortality were observed during the study. Cytotoxicity, indicated by a 
decrease in polychromatic erythrocytes/normochromatic erythrocytes ratio, was observed at both AA 
doses. Both doses of AA significantly increased the frequency of MN in polychromatic erythrocytes in 
both males and females. The difference between the two AA doses was not statistically significant. 
Marchetti et al. (2009) used multicolour fluorescence in situ hybridization painting to investigate 
whether paternally transmitted chromosomal aberrations result in mosaicism in mouse two-cell 
embryos. Male B6C3F1 mice were exposed by i.p. to 5 consecutive daily doses of 0 (distilled water) or 
50 mg/kg AA. Groups of treated males were mated with untreated superovulated females at 2.5, 6.5, 
                                                     
36 According to EFSA (2012b), ‘Five scorable animals for each dose group, including vehicle and control groups, should be 
used (JaCVAM, 2009). Providing clear positive response is observed in the positive control group, a lower number of 
animals would be acceptable in this group. EFSA is aware that the use of a lower number of animals might be possible but 
the slight decrease in the statistical power might require additional testing, therefore for the time being, the use of five 
animals is recommended. If a lower number of animals is used, this should be scientifically justified’. 
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9.5, 12.5, 20.5, 27.5, 41.5 and 48.5 days after the last AA injection. Control males were mated with 
untreated females at 2.5, 6.5, 9.5 and 12.5 days after the last injection. AA treatment of male mice 
prior to mating induced prefertilization toxicity only after matings that sampled late spermatids 
(9.5 days post-treatment, dpt) (reduction of frequency of fertilized embryos from 83 % in controls to 
71 %). It induced also a significant reduction in the numbers of two-cell embryos that reached the 
metaphase stage in matings within the repair deficient window of spermatogenesis (2.5–12.5 dpt) with 
respect to control value. The percentages of asynchronous two-cell embryos were not affected by 
paternal exposure to AA. Paternal treatment with AA induced high frequencies of chromosomally 
abnormal two-cell embryos (> 50 %) after treatment of epididymal sperm (2.5 dpt), testicular sperm 
(6.5 dpt), and late spermatids (9.5 dpt). Testicular sperm were the most sensitive cell type for the 
induction of chromosome structural aberrations (statistically different from 2.5 and 9.5 dpt) with 82 % 
of the two-cell embryos presenting with chromosome structural aberrations. The frequencies of 
embryos with structural aberrations decreased to 19 % after treatment of elongating spermatids 
(12.5 dpt) and 5.0 % after treatment of round spermatids (20.5 dpt). Chromosomal aberrations were 
not significantly increased with respect to the control value after treatment of pachytene spermatocytes 
(27.5 dpt), differentiating spermatogonia (41.5 dpt), or stem cells (48.5 dpt). Testicular spermatozoa 
were also the germ-cell type with the highest amount of chromosomal damage. Each type of aberration 
was most prevalent at 6.5 dpt mating time when the total number of chromosomal aberrations per 
embryo was above 3.3 by both PAINT and DAPI analyses, whereas it was less than 2.4 per embryo at 
2.5 dpt and decreased to around 1.5 at 9.5 dpt. PAINT/DAPI analysis of mouse two-cell embryos 
showed that paternal treatment with AA induced mosaicism for structural chromosomal aberrations. 
The majority of abnormal embryos, irrespective of mating time point, were mosaics, that is, the two 
metaphases had a different karyotype. In the treated groups, the majority of two-cell embryos had 
chromosomal structural aberrations in both metaphases, but the aberrations were of different types. In 
a second group, mosaic embryos had chromosomal aberrations in only one metaphase. A third group 
of embryos were structurally abnormal with the apparently same chromosomal aberration in both 
metaphases. Conversely, all abnormal embryos found in the control group had one metaphase with a 
chromosomal aberration, whereas the other appeared to be normal.  
Paternal exposure to AA also induced numerically abnormal two-cell embryos. The majority of the 
embryos were hypodiploid in one or both metaphases. At 6.5 dpt, the most sensitive time for the 
induction of chromosomal structural aberrations, over 72 % of the embryos were hypodiploid. 
Hyperdiploid nonmosaic embryos and triploid nonmosaic embryos were also found, but their 
frequencies were not different with respect to controls. An increase of numerically abnormal mosaic 
two-cell embryos was also observed. The authors also analysed the persistence of the various types of 
chromosomal structural aberrations in two-cell embryos. Their results show that there is a tendency for 
loss of acentric fragments during the first mitotic division, whereas both dicentrics and translocations 
apparently undergo proper segregation without loss. 
In previous studies (Marchetti et al., 1997, 2001, 2004, 2007), the authors reported a correlation 
between the percentages of zygotes with unstable chromosomal aberrations and embryonic lethality 
and between stable chromosomal aberrations and the percentages of offspring with reciprocal 
translocations. They therefore determined whether PAINT/DAPI analysis of two-cell embryos also 
provided good estimates of embryonic lethality and of translocation carriers at birth. Using 
PAINT/DAPI analysis, the frequencies of two-cell embryos with unstable aberrations, which are 
expected to die in utero because of loss of genetic material, were: 66 %, 80 %, 48 % and 19 % at 2.5, 
6.5, 9.5 and 12.5 dpt mating times, respectively. The proportion of two-cell embryos with stable 
aberrations (24 %, 8 out of 33, two-cell embryos) is in agreement with the frequencies of offspring 
with heritable translocations (HT) reported using the standard HT method and paralleled the findings 
obtained in zygotes (Marchetti et al., 1997). The authors concluded that the frequencies of 
chromosomal aberrations in zygotes and two-cell embryos are consistent with each other and are a 
good predictor of embryonic fate for death after implantation and birth with reciprocal translocations.  
The authors also concluded that embryonic development can proceed up to the end of the second cell 
cycle of development in the presence of abnormal paternal chromosomes. The high incidence of 
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chromosomally mosaic two-cell embryos suggests that the first mitotic division of embryogenesis is 
prone to missegregation errors and that paternally transmitted chromosomal abnormalities increase the 
risk of missegregation leading to embryonic mosaicism. 
Ao and Cao (2012) reviewed the relevant mutations induced by AA and GA on both HPRT and TK 
gene loci in various test systems involving in vivo and in vitro tests. The individual studies have 
already been reported in this section. The authors concluded that mutation changes at the HPRT gene 
and TK gene confirm that AA is mainly a directly-acting clastogen, causing chromosomal aberrations. 
AA also produces weakly mutagenic effects at the HPRT gene by metabolic conversion of AA to GA. 
The genotoxic characteristics of GA are distinctly different from AA. GA is a strong mutagen with 
high reactivity to DNA, inducing predominantly point mutations.  
In a review of the toxicity of AA, Exon (2006) reported that it was postulated by several investigators 
that the clastogenic effects of AA on germ cells may not be by direct interaction with DNA. These 
effects may be mediated through interference with the kinesin motor proteins that are involved in 
spindle fibre formation and chromosomal segregation during cell division or alkylation of protamines 
in sperm (Shiraishi, 1978; Costa et al., 1992; Adler et al., 1993, 2000). Alternatively, AA may alkylate 
DNA proteins via its affinity for sulfhydryl groups, resulting in clastogenesic effects (Sega et al., 
1989; Sega, 1991).  
Ishii et al. (2015) performed reporter gene mutation assays and quantitative analyses of specific DNA 
adducts in the lungs (carcinogenic target) of male B6C3F1 gpt delta mice (3 and 11 weeks old, 
10 mice/group) that were given an AA solution at concentrations of 0, 100, 200 and 400 mg/L in 
drinking water (equivalent to 0, 22.5, 38.6 and 59.2 mg/kg b.w. in mature mice and 0, 21.8 and 
41.2 mg/kg b.w. per day for 0, 100 and 200 mg AA/L in immature mice), seven days a week for up to 
4 weeks. Six immature mice in the high dose group died after 2 weeks of exposure because of the 
neurotoxicity of AA. To examine the mutation spectra of Spi-mutants observed in the lungs of mice 
treated with the high dose, additional animals using mature mice were performed. Five animals served 
as control and five were exposed to 400 mg/L AA. In the high dose group, hind-leg paralysis and 
sluggish movement associated with neurotoxicity of AA were observed in immature and mature mice 
1 and 3 weeks after the beginning of treatment, respectively. In the high dose mature group, final body 
and lung weights were significantly decreased. In immature mice, final body weights were 
significantly decreased in all AA-treated mice. Absolute lung weights were significantly decreased in 
the 200 mg/L group. No remarkable changes were observed in the lungs of AA-treated mice. N7-GA-
Gua was detected in all AA-treated mice in a dose-dependent manner. N7-GA-Gua levels in the lungs 
of AA-treated mice were 3 to 5 times higher than those in the livers of mice at any of the doses and 
ages. The gpt mutation frequency in AA-treated mice increased in a dose-dependent manner and 
significantly increased above 200 mg/L. In the 400 mg/L AA-treated mature mice, gpt mutation 
frequencies were increased 6-fold compared with control mice. Age-related differences were not 
observed in N7-GA-Gua or in gpt mutation frequencies. In addition, the mutation spectra in the gpt 
mutant colonies were determined. Specific mutation frequencies of G:C → T:A transversions and 
single bp deletions were significantly increased in mature mice treated with 400 mg/L. A tendency for 
increases of single bp deletion mutations was also observed in immature mice treated with 200 mg 
AA/L. Elevated Spi-mutation frequencies were observed in the 200 mg/L group of mature and 
immature mice, albeit without statistical significance, and significant increases were observed only in 
400 mg/L AA-treated mature mice. Spi-MFs in the 200 mg/L group between the two age groups 
showed a similar tendency to increase. Significant increases of Spi-mutation frequencies were also 
observed in the lungs of mice treated with AA 400 mg/L compared to the control group. Specific 
mutation frequencies of single base deletions in runs of G:C and A:T and base substitution were 
significantly increased in mice treated with 400 mg AA/L. In the AA-treated mice, single base 
deletions and point mutations were observed throughout the coding region. In particular, single base 
deletions in runs of A, C and G at positions 227, 238 and 286 were increased. The majority of point 
mutations were G to T and C to A (58 %). In addition, relatively small deletions (4–21 bp) were also 
frequently observed in AA-treated mice. The authors concluded that a causal relationship was 
observed between the amount of DNA adducts and the extent of gene mutation. The data indicate that 
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the susceptibility to AA-induced genotoxicity in the immature group is almost the same as that in the 
mature group. However, neurological abnormalities in the immature groups occurred earlier and 
disease progression was faster. 
To investigate whether or not gene mutation is involved in the etiology of AA- or GA-induced mouse 
lung carcinogenicity, Manjanatha et al. (in press) screened for CII mutant frequency in lungs from 
male and female Big Blue mice administered 0, 1.4 and 7.0 mM AA (0, 100, and 500 mg/L 
corresponding to 0, 19 and 88 mg/kg b.w. per day) or GA (0, 120 and 600  mg/L, corresponding to 0, 
35 and 111 mg/kg b.w. per day) in drinking water for up to 4 weeks. The treatment of mice exposed to 
the high dose of AA was halted after 3 weeks of exposure because of hind-leg paralysis and sluggish 
movement. Both doses of AA and GA produced significant increases in cII mutation frequencies, with 
the high doses producing responses 2.9–5.6-fold higher than the corresponding controls. Molecular 
analysis of the mutants from high doses indicated that AA and GA produced similar mutation spectra 
and that these spectra were significantly different from the spectra in control mice. The predominant 
types of mutations in the lung cII gene from AA- and GA-treated mice were A:T → T:A, and G:C → 
C:G transversions, and −1/+1 frameshifts at a homopolymeric run of Gs. The authors concluded that 
the mutation frequencies and types of mutations induced by AA and GA in the lung are consistent 
with AA exerting its genotoxicity via metabolism to GA. The predominant types of mutations induced 
by AA and GA in lungs are quite different from the types of mutations induced under the same 
treatment conditions in non-target tissues (predominantly G:C → T:A transversion and −1/+1 
frameshifts in liver and A:T → G:C transition and G:C → transversion in testis), suggesting that the 
predominant types of mutations, A → T and G → C, in the lung may be involved in tumour induction 
in lungs. 
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Table 22:  Experimental design and results for selected in vivo genotoxicity tests with acrylamide (AA) 
Test Species 
Route of 
administration 
Dose Exposure time Result Reference 
Micronucleus 
test 
Male B6C3F1 mice. 
Peripheral blood 
and bone marrow  
 
Male F344/N rats. 
Peripheral blood 
and bone marrow 
 
Oral  
(gavage) 
 
0 (PBS), 12.5, 25, 
37.5 or 50 mg 
AA/kg b.w. 
 
0 (PBS), 12.5, 25, 
37.5 or 50 mg 
AA/kg b.w.  
3 days at 24 h intervals, 
sacrifice 24 h after last 
administration 
Positive from 25 mg/kg b.w. in 
bone marrow and peripheral blood 
(microscopy and flow cytometry) 
 
No increase MN in bone marrow or 
peripheral blood (flow cytometry). 
Positive in PB (microscopy) at 25 
and 50 mg/kg b.w. 
Witt et al. (2008)  
Micronucleus 
test 
Male Sprague 
Dawley rats. 
Bone marrow 
Oral  
(gavage) 
0, 125, 150 or 
175 mg AA/kg b.w. 
48 h treatment 
Dose-related increased frequency of 
MN in PCE (3.75-fold at high dose) 
AA decreased PCE/NCE (bone 
marrow cytotoxicity) 
Yener and 
Dikmenli (2009) 
Comet assay 
Male Sprague 
Dawley rats. 
Blood, brain, liver, 
bone  marrow, 
adrenals, testes 
Oral  
(gavage) 
0 (dist. water), 18, 
36 or 54 mg AA/kg 
b.w. 
C+: MMS 
Single dose, sacrifice 24 
hafter dosing and additional 
sacrifice for 0 and 54 mg 
AA/kg b.w. 2 h and 5 h after 
dosing 
DNA lesions in blood leucocytes 
and brain at 36 and 54 mg/kg b.w. 
and in testes at 54 mg/kg bw 24 h 
after exposure. No statistically 
significant increase in comet 
parameters in liver, bone marrow 
and adrenals. 
5 h after dosing: statistically 
significant increase in DNA 
damage in leucocytes, bone 
marrow, liver and adrenals. 
2 h after dosing: increased DNA 
damage in testes and adrenals. 
Manière et al. 
(2005) 
Comet assay 
Male Pzh:SFIS 
mice. 
Bone marrow, 
testes, liver, 
kidneys, spleen, 
lungs 
i.p. injection 
0, 50, 75, 100 and 
125 mg AA/kg b.w. 
Single exposure 
Sacrifice 24 h after dosing 
Dose-related increase DNA damage 
(statistically significant from 
75 mg/kg b.w. in spleen, liver, 
kidneys and testes, and from 
50 mg/kg b.w. in lungs and bone 
marrow) 
Dobrzynska 
(2007) 
Table continued overleaf. 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 138 
Table 22: Experimental design and results for selected in vivo genotoxicity tests with acrylamide (AA) (continued) 
Test Species 
Route of 
administration 
Dose Exposure time Result Reference 
Comet assay 
Male B6C3F1 mice. 
Cell types: blood 
leukocytes, liver, 
duodenum and 
testes (somatic and 
germ cells) 
 
Male F344/N rats. 
Cell types: blood 
leukocytes, liver, 
thyroid, duodenum 
and testes 
Oral  
(gavage) 
 
 
 
 
 
 
Oral  
(gavage) 
 
0 (PBS), 12.5, 25, 
37.5 or 50 mg 
AA/kg b.w. 
 
 
 
 
0 (PBS), 12.5, 25, 
37.5 or 50 mg 
AA/kg b.w. 
4 days at 24 h intervals, 
sacrifice 4 h after last 
administration 
 
 
 
 
 
4 days at 24 h intervals, 
sacrifice 4 h after last 
administration 
Positive (based on olive tail 
moment) in all tissues at all dose 
levels except at 12.5 mg/kg b.w. in 
testicular somatic cells 
 
 
 
Positive (based on olive tail 
moment) in blood leukocytes, 
testicular somatic cells, thyroid and 
duodenum. (magnitude lower than 
in mice) No increase DNA damage 
in liver cells or in presumptive 
sperm cells 
Recio et al. 
(2010) 
Comet assay 
Male Wistar rats. 
Liver cells 
Bone marrow cells 
 
Male Wistar rats. 
Liver cells 
Bone marrow cells 
Oral 
 (gavage) 
0, 10, 20 or 100 
mg/kg b.w. per day 
 
0, 5, 10 or 20/20* 
mg/kg b.w. per day 
3 days, sacrifice 2 h after 
final treatment 
 
 
29 days, sacrifice 2 h or 
24 h* after final treatment 
Positive at the two highest doses 
Positive at high dose 
 
Positive at all doses 
Positive at the two highest doses 
Rothfuss et al. 
(2010) 
MN test 
Male Wistar rats. 
Bone marrow cells 
Peripheral blood** 
Oral  
(gavage) 
0, 10, 20 or 100 
mg/kg b.w. per day 
(= maximum 
tolerated dose) 
 
 
0, 5, 10 or 20 
mg/kg b.w. per day 
(= maximum 
tolerated dose) 
3 days, sacrifice 24 h after 
final treatment 
** sacrifice day 4 
 
 
 
29 days, sacrifice 24 h after 
final treatment 
** sacrifice day 15 and 
day 29 
Negative 
 
 
 
 
Negative  
 
 
 
Rothfuss et al. 
(2010) 
Table continued overleaf. 
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Table 22: Experimental design and results for selected in vivo genotoxicity tests with acrylamide (AA) (continued) 
Test Species 
Route of 
administration 
Dose Exposure time Result Reference 
Micronucleus 
test 
Male B6C3F1 mice. 
Peripheral blood 
cells 
Oral  
(gavage) 
0 (water), 0.125, 
0.25, 0.5, 1, 2, 4, 6, 
8, 12, 16 or 24 
mg/kg b.w. per day 
28 days 
Increase MN-NCE from 4 mg/kg 
b.w. per day and MN-RET from 
6 mg/kg b.w. per day (less than a 
doubling at high dose) 
Zeiger et al. 
(2009) 
Micronucleus 
test 
Male and female 
Wistar rats. 
Bone marrow cells 
Oral  
(drinking water) 
0 (water), 2 and 5 
mg/kg b.w. per day 
90 days, sacrifice 24 h after 
last treatment 
Decrease PCE/NCE ratio in treated 
animals 
Statistically significant increase 
MNPCE in treated animals 
(M: 2.8, 8.0 and 8.4 MNPCE/2000 
PCE, F: 2.6, 6.8 and 7.6 
MNPCE/2000 PCE in control, low 
dose and high dose, respectively)  
Yener (2013) 
h: hour(s); MN: micronucleous; NCE: normochromatic erythrocytes; PBS: phosphate buffered saline; PCE: polychromatic erythrocytes; RET: reticulocytes. 
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7.3.3.3. Conclusions  
AA is not mutagenic in bacterial cells. In mammalian cells in vitro, AA is a weak, direct-acting 
mutagen, but an effective direct-acting clastogen. It induces also, to a lower extent, aneuploidy, 
polyploidy and other mitotic disturbances. With the exception of a positive result in HepG2 cells, AA 
did not induce DNA damage as measured by the Comet assay.  
In in vivo mammalian somatic cells assays, AA appears to be clearly genotoxic but at relatively high 
doses, producing positive results particularly in the micronucleus and in the Comet assays. In vivo 
studies have also shown the induction by AA of mutations at different genetic loci in lymphocytes and 
target organs such as liver, lung, testes in mice and bone marrow and thyroid in rats.  
AA is clearly positive in a number of different germ cell assays (dominant lethal assays, heritable 
translocation and specific locus mutation assays) indicating that it induces heritable genetic damage at 
the gene and chromosome level. AA showed stronger germ cell effects in mice after repeated 
administration of low doses compared with a single high dose. DNA damage generated in male germ 
cells of mice by chronic exposure to AA was observed in the absence of major effects on mouse health 
or defects in spermatogenesis.   
The metabolism of AA to GA is the crucial prerequisite for the genotoxicity of AA. Therefore, the 
mutagenic effects will be higher in cells or tissues with elevated capability of metabolic conversion of 
AA to GA. Studies using knockout (CYP2E1-null) and wild-type mice showed that CYP2E1-mediated 
oxidation is the predominant pathway leading to the formation of DNA adducts. Studies in wild-type 
and CYP2E1 knockout mice have also shown that GA is the active metabolite of AA responsible for 
somatic and germ cell mutations and dominant lethality.  
The level of DNA adducts produced by AA in rats was generally lower than in mice at similar doses. 
These findings are consistent with the greater proficiency of the mouse to produce GA from AA 
(Tables 16 and 17).  
In situations of limited CYP2E1 activity (as occurs in neonatal mice, mouse lymphoma cells, and 
possibly TK6 cells, and Big Blue mouse embryonic fibroblasts), AA can induce gene mutations by a 
pathway not involving GA. This may involve the generation of ROS and induction of oxidative DNA 
damage. This alternative pathway appears to take place only with very high toxic doses of AA. 
Young rats are more susceptible than adult rats to AA-induced testicular genotoxicity (gpt-mutant 
frequency and N7-GA-Gua adducts), whereas in the mammary gland and thyroid, adduct levels did 
not differ significantly between young and adults. 
In contrast to AA, GA is a strong mutagen in vitro via a DNA adduct-mediated mechanism. GA-
induced damage is revealed by the Comet assay and significantly amplified in its detection when fpg 
sensitive sites are measured. GA induced also clastogenic effects. 
In vivo, GA is clearly positive in the micronucleus assay in mice and, with lower potency, in rats, with 
a predominant chromosome-breaking mechanism instead of chromosome loss. GA is also a potent 
mutagen in vivo. It interacts with DNA bases, predominantly by forming N7 adducts with guanine and, 
to a much lower extent, N3 adducts with adenine. GA induced dominant lethal mutations, similarly to 
AA. 
Dosing mice or rats with GA generally produced higher DNA adduct levels than observed with AA. 
In conclusion, in vitro genotoxicity studies indicate that AA is a weak mutagen in mammalian cells 
but an effective clastogen. GA is a strong mutagen and a clastogen. It induces mutations via a DNA 
adduct mechanism. In vivo, AA is clearly genotoxic in somatic and germ cells. AA exerts its 
mutagenicity via metabolism by CYP2E1 to GA. At high concentrations AA can also induce gene 
mutations by a pathway involving the generation of ROS and oxidative DNA damage. 
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7.3.4. Long-term toxicity and carcinogenicity 
Since a large portion of the available long-term toxicity studies in laboratory animals had a focus on 
neurotoxic effects, these are dealt with under the previous Section 7.3.2. Thus, this section is limited to 
the carcinogenic effects of AA observed in long-term animal studies.  
7.3.4.1. Studies in mice 
In mice (A/J, SENCAR, BALB/c, Swiss-ICR and B6C3F1), AA was tested for carcinogenicity in five 
chronic/subchronic studies. 
In a study by Bull et al. (1984a), groups of 16–40 male and female A/J mice were treated with AA by 
gastric gavage or i.p. injection over 8 weeks starting from an age of 8 weeks. The dose levels were 0, 
6.25, 12.5 and 25 mg/kg b.w. applied by gavage three times a week, or 0, 1, 3, 10, 30 and 60 mg/kg 
b.w. applied three times a week by i.p. injection. The treatment resulted in a significant increase in 
lung tumours both in male and female animals, but the strain of mice used shows a high background 
incidence of lung tumours. In the same study, female SENCAR mice were treated following an 
initiation-promotion protocol with i.p. injection of AA and dermal application of the skin tumour 
promoter TPA (12-O-Tetradecanoylphorbol-13-acetate). This experimental approach resulted in an 
increase in skin tumours after the combined AA/TPA treatment only. In a second study from the same 
laboratory (Bull et al., 1984b), female Swiss-ICR mice were treated with AA by oral gavage six times 
over two weeks. Afterwards, the animals were treated with TPA. In a study by Robinson et al. (1986), 
female SENCAR, Balb/c, A/J, and Swiss-ICR mice were treated once with 50 mg/kg b.w. AA by i.p. 
injection followed by treatment with TPA over 20 weeks. Only in SENCAR mice, a significant 
increase in lung adenoma and skin papilloma was found. The CONTAM Panel noted that the data 
from both studies (Bull et al., 1984b; Robinson et al., 1986) cannot be used for quantitative risk 
assessment of AA since the effects were likely due, at least in part, to the tumour promoter TPA.   
In the study from NTP (2012) (Table 23), B6C3F1 mice received drinking water containing 6.25, 12.5, 
25 or 50 mg/L of AA in groups of 50 male and female mice for 2 years (details on the mean amount of 
AA consumed by the mice are given in Section 7.3.2.1). At the end of the study tissues from more 
than 40 sites were examined for every animal. In males, the incidence of Harderian gland adenoma 
and combined Harderian gland adenoma or adenocarcinoma was increased significantly in all AA 
dose groups. The incidence of lung alveolar/bronchiolar adenoma and combined lung 
alveolar/bronchiolar adenoma or carcinoma was increased significantly at 12.5 and 50 mg/L, and the 
incidence of stomach (forestomach) squamous cell papilloma and combined stomach (forestomach) 
squamous cell papilloma or carcinoma was increased significantly at 25 and 50 mg/L AA. In female 
B6C3F1 mice, the incidence of Harderian gland adenoma was increased significantly in all dosed 
groups. The combined incidence of mammary gland adenoacanthoma or adenocarcinoma was 
increased significantly at 12.5, 25, and 50 mg/L AA, and the incidence of mammary gland 
adenocarcinoma was increased significantly at 12.5 and 50 mg/L AA. Incidences of lung 
alveolar/bronchiolar adenoma, combined lung alveolar/bronchiolar adenoma or carcinoma, and 
malignant mesenchymal skin tumours (fibrosarcoma, haemangiosarcoma, liposarcoma, myxosarcoma, 
neurofibrosarcoma, or sarcoma) were increased significantly at 25 and 50 mg/L AA. A significant 
increase was also observed in the incidence of ovary granulosa cell tumour (benign) and mammary 
gland adenoacanthoma at 50 mg/L AA.  
Von Tungeln et al. (2012) examined the tumourigenicity of AA and GA in mice treated neonatally. 
Male B6C3F1 mice were injected i.p. on PND1, 8 and 15 with 0.0, 0.14 or 0.70 mmol AA (0, 10 or 
50 mg) or GA (0, 12 or 61 mg) per kg b.w. per day and the tumourigenicity was assessed after 1 year. 
The only treatment-related neoplasms involved the liver. There was an increased incidence of 
combined hepatocellular adenoma or carcinoma in the group treated with the high dose GA (8.3 % in 
the low dose AA and GA, and 4.2 % in the high dose AA and 71.4 % in the high dose GA). In this 
group, mice had primarily multiple hepatocellular adenoma (61.9 %). In addition, hepatocellular 
carcinoma was observed only in this group (9.5 %). The CONTAM Panel noted that there was no 
clear dose-response relationship with respect to AA-induced tumours. Furthermore the effects of AA 
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were not statistically significant, while there was a significantly increased incidence of combined 
hepatocellular adenoma or carcinoma in the group treated with the high dose of GA. 
Treatment of female CD1 rats (20 animals) with AA in the drinking water (leading to a daily oral dose 
of 3–4 mg/kg b.w.) over 8 months did not result in tumours in the organs inspected histopathologically 
(pituitary, thyroid, and adrenal glands, reproductive tract) (Jin et al., 2008).  
B6C3F1/Nctr mice received GA in drinking water for 2 years (NTP, 2014, see Section 7.3.2.1). Male 
mice showed an increased incidence of Harderian gland, lung, skin and forestomach neoplasms. In 
female mice, also increased incidences of Harderian gland, lung, mammary gland, forestomach and 
skin neoplasms were observed. Benign granulose cell tumours of the ovary were also observed, 
possibly related to treatment with GA (NTP, 2014).   
Table 23:  Tumour incidence and statistical analysis results derived from the 2-year NTP 
carcinogenicity assays with acrylamide (AA) in B6C3F1 mice (NTP, 2012). Only the major tumour 
sites and/or those showing significant effects at the lower dose are listed. 
Tumour Gender 
Dosage 
(mg/kg b.w. per day) 
Incidence 
Harderian gland adenoma female 
0 
1.10 
2.23 
4.65 
9.96 
0/45 (0 %) 
8/44 (18 %) 
20/48 (42 %) 
32/47 (68 %) 
31/43 (72 %) 
Mammary gland 
adenocanthoma and 
adenocarcinoma 
female 
0 
1.10 
2.23 
4.65 
9.96 
0/47 (0 %) 
4/46 (9 %)
 
7/48 (15 %)
 
4/45 (9 %) 
17/42 (41 %) 
Lung alveolar, bronchiolar 
adenoma  
female 
0 
1.10 
2.23 
4.65 
9.96 
1/47 (2 %) 
4/47 (9 %) 
6/48 (13 %) 
11/45 (24 %) 
19/45 (42 %) 
Ovary granulosa cell 
tumours (benign)  
female 
0 
1.10 
2.23 
4.65 
9.96 
0/46 (0 %) 
1/45 (2 %) 
0/48 (0 %) 
1/45 (2 %) 
5/42 (12 %) 
Skin, various types of 
sarcoma 
female 
0 
1.10 
2.23 
4.65 
9.96 
0/48 (0 %) 
0/46 (0 %) 
3/48 (6 %)
 
10/45 (22 %) 
6/43 (14 %) 
Stomach, forestomach 
squamous cell papilloma 
female 
0 
1.10 
2.23 
4.65 
9.96 
4/46 (9 %) 
0/46 (0 %) 
2/48 (4 %) 
5/45 (11 %) 
8/42 (19 %) 
Harderian gland adenoma 
and adenocarcinoma 
male  
0 
1.04 
2.20 
4.11 
8.93 
2/46 (4 %) 
13/46 (28 %) 
27/47 (57 %) 
37/47 (77 %) 
39/47 (83 %) 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 143 
Tumour Gender 
Dosage 
(mg/kg b.w. per day) 
Incidence 
Lung alveolar, bronchiolar 
combined adenoma and 
carcinoma 
male 
0 
1.04 
2.20 
4.11 
8.93 
6/47 (13 %) 
6/46 (13 %) 
14/47 (30 %) 
10/45 (22 %)
 
20/48 (42 %)
 
Stomach squamous 
combined papilloma or 
carcinoma  
male 
0 
1.04 
2.20 
4.11 
8.93 
0/46 (0 %) 
2/45 (4 %) 
2/46 (4 %) 
7/47 (15 %) 
8/44 (18 %) 
Statistically significant effects are shown in bold. 
b.w.: body weight. 
 
7.3.4.2. Studies in rats 
In Fischer 344 rats, AA was tested for carcinogenicity in three long-term studies (Table 24).  
In a study by Johnson et al. (1986), rats were treated via the drinking water over 2 years starting from 
an age of 5–6 weeks. The average calculated daily doses were 0, 0.01, 0.1, 0.5, and 2.0 mg/kg b.w. In 
females, significant increases in the incidence of tumours (malignant and benign) of the mammary 
gland, clitoral gland, central nervous system, thyroid gland (follicular epithelia), oral cavity, uterus, 
and pituitary gland were found. All effects were statistically significant at a dose level of 2.0 mg/kg 
b.w. per day. In males, significant increases in the incidence of tumours (malignant and mostly 
benign) of the thyroid gland, oral cavity, adrenal gland (pheochromocytoma) and peritesticular 
mesothelium (processus vaginalis peritonei) were found. All effects were statistically significant at a 
dose level of 2.0 mg/kg b.w. per day, and the increase in peritesticular tumours at 0.5 mg/kg b.w. per 
day.  
In a study from the same laboratory, published by Friedman et al. (1995), a similar outcome was 
obtained. The rats were treated in the same way as in the Johnson et al. (1986) study using the same 
and two additional (1.0 and 3.0 mg/kg b.w. per day) dose levels and the same route of exposure. 
Female showed significant increases in the incidence of tumours of the thyroid gland (follicular 
epithelia) and mammary gland. In males the incidence of peritesticular mesothelioma and thyroid 
tumours was increased. The effects were significant at a dose level of 3.0 mg/kg b.w. per day except 
for the peritesticular mesothelioma which showed a significant increase at 2.0 mg/kg b.w. per day, and 
the mammary gland tumours which showed a significant increase at 1.0 mg /kg b.w. per day. 
In the NTP (2012) 2-year study, Fischer F344/N male and female rats received drinking water at 
concentrations of 0.0875, 0.175, 0.35 and 0.70 mM (equivalent to 0.33, 0.66, 1.32 and 2.71 mg/kg 
b.w. per day for males, and 0.44, 0.88, 1.84 and 4.02 mg/kg b.w. per day for females) (details on the 
study design are given in Section 7.3.2.2). At the end of the study tissues from more than 40 sites were 
examined for every animal. The rates of several types of cancer increased in each of the animal 
studies. Male and female rats receiving AA had increased incidence of thyroid gland and heart 
tumours; male rats also had increased incidence of cancer in the pancreatic islets and of malignant 
mesotheliomas, and female rats also had increased incidence of cancers in the clitoral gland, liver, 
mammary gland, skin, and mouth or tongue.  
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Table 24:  Tumour incidence and statistical analysis results derived from male and female F344 rats 
from 2-year carcinogenicity assays with acrylamide (AA). Only the major tumour sites and/or those 
showing significant effects at the lower dose are listed. 
Tumour Gender 
Dosage 
(mg/kg b.w. per day) 
Incidence Reference 
Mammary gland adenoma, 
fibroadenoma or fibroma 
 
female 
0 
0.01 
0.1 
0.5 
2.0 
10/60 (17 %) 
11/60 (18 %) 
9/60 (15 %) 
19/58 (33 %) 
23/61 (38 %)(a) 
Johnson et al. (1986) 
Mammary gland 
fibroadenoma 
female 
0 
1.0 
3.0 
5/46 (11 %) 
20/94 (21 %)(b) 
26/95 (27 %)(b) 
Friedman et al. (1995) 
Mammary gland 
fibroadenoma 
female 
0 
0.44 
0.88 
1.84 
4.02 
16/48 (33 %) 
18/48 (38 %) 
24/46 (52 %)(c) 
22/47 (47 %)(c) 
31/48 (65 %)(c) 
NTP (2012) 
Thyroid gland follicular 
cell adenoma or carcinoma 
female 
0 
0.01 
0.1 
0.5 
2.0 
1/58 (2 %) 
0/59 (0 %) 
1/59 (2 %) 
1/58 (2 %) 
5/60 (8 %)(a) 
Johnson et al. (1986) 
Thyroid gland follicular 
cell adenoma or carcinoma 
female 
0 
1.0 
3.0 
1/50 (2 %) 
10/100 (10 %) 
23/100 (23 %)(b) 
Friedman et al. (1995) 
Thyroid gland follicular 
cell adenoma or carcinoma 
female 
0 
0.44 
0.88 
1.84 
4.02 
0/48 (0 %) 
0/48 (0 %) 
2/48 (4 %) 
3/48 (6 %) 
4/47 (9 %)(c) 
NTP (2012) 
Thyroid gland follicular 
cell adenoma 
male 
0 
0.01 
0.1 
0.5 
2.0 
1/60 (2 %) 
0/58 (0 %) 
2/59 (15 %) 
1/59 (2 %) 
7/59 (12 %)(a) 
Johnson et al. (1986) 
Thyroid gland follicular 
cell adenoma 
male 
0 
0.1 
0.5 
2.0 
2/100 (2 %) 
9/203 (4 %) 
5/101 (5 %) 
12/75 (16 %)(b) 
Friedman et al. (1995) 
Thyroid gland follicular 
cell adenoma or carcinoma 
male 
0 
0.33 
0.66 
1.32 
2.71 
1/48 (2 %) 
3/48 (6 %) 
4/47 (9 %) 
6/48 (13 %) 
9/48 (19 %)(c) 
NTP (2012) 
Mesothelioma of the testes 
tunica albuginea 
male 
0 
0.01 
0.1 
0.5 
2.0 
3/60 (5%) 
0/60 (0 %) 
7/60 (12 %) 
11/60 (18 %)(a) 
10/60 (17 %)(a) 
Johnson et al. (1986) 
Mesothelioma of the testes 
tunica 
male 
0 
0.1 
0.5 
2.0 
4/102 (4 %) 
9/204 (4 %) 
8/102 (8 %) 
13/75 (17 %)(b) 
Friedman et al. (1995) 
Mesothelioma of the 
epididymis or testes tunica 
vaginalis 
male 
0 
0.33 
0.66 
1.32 
2.71 
2/48 (4 %) 
3/48 (4 %) 
1/48 (2 %) 
5/48 (10 %) 
8/48 (17 %)(c) 
NTP (2012) 
(a):  Statistically significantly different from controls at α = 0.05 after mortality adjustment as described by Peto (1974). 
(b):  Statistically significantly different at p < 0.001 using the method of Peto et al. (1980). 
(c):  Statistically significantly different from controls using continuity-corrected Poly-3 tests (Bailer and Portier, 1988), 
as modified by Bieler and Williams (1993). 
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In three less-than lifetime studies, rats received initiating agents were treated with AA subsequently 
(Raju et al., 2011, 2013; Yener et al., 2013a).  
Male F344 rats were subcutaneously injected with azoxymethane and received either low fat (7 % 
corn oil) or high fat (23.9 % corn oil) diet and AA at 0, 5, 10 or 50 mg/kg diet (w/w) for 8 weeks 
(8 rats per group). Irrespective of the dietary fat level, rats with the highest tested dose of AA 
(50 mg/kg diet) had significantly lower total aberrant crypt foci (ACF) of the colon and lower large 
ACF compared with their respective controls. A significantly lower number of large ACF was noted in 
rats treated with 10 mg/kg diet AA exclusively in the high fat group, compared to the high fat control 
(Raju et al., 2011). 
When male F344 rats received AA (2 mg/kg b.w.) and were then treated with azoxymethane (AOM), 
20 weeks after AOM treatment the mean tumour size and the total area occupied by tumours in the 
colon were significantly higher than after AOM only (Raju et al., 2013).   
In another study, 14 days-old male rats received azaserine, an initiator of pancreatic tumours, and AA 
in the drinking water (calculated daily doses: 5 and 10 mg/kg b.w.) for over 16 weeks (Yener et al., 
2013a). Animals dosed AA only showed a significant increase in average diameters of atypical acinar 
cell foci (AACF) of the pancreas, while azaserine/AA treated rats exhibited significant increases in 
average diameter, total area, and total volume of AACF of the pancreas (Yener et al., 2013a).  
In the recent study by Maronpot et al. (2015) Wistar Han rats were exposed to 0, 0.5, 1.5 or 3.0 mg 
AA/kg b.w. per day in drinking water starting at gestational day (GD) 6 until 2 years of age (see 
Section 7.3.2.2). After two years of AA treatment, significantly increased incidences were observed 
for mammary gland fibroadenomas in females and thyroid follicular cell adenomas in females and 
thyroid follicular cell adenomas and adenocarcinomas in males. This is consistent with previous 2-year 
studies in F344 rats. The authors observed no mesothelioma in the tunica vaginalis (testis) and no 
significant increase in testicular Leydig cell tumours, which were interpreted as strain differences 
between Fischer 344 and Wistar Han male rats.  
For GA, in the NTP (2014) study where F344/N Nctr rats received GA in drinking water for 2 years 
(see Section 7.3.2.2), male rats had an increased incidence of testicular, thyroid, heart and oral cavity 
neoplasms, as well as an increased incidence of leukaemia. For females, an increased incidence of 
mammary gland, thyroid gland, clitorial gland, oral cavity and forestomach neoplasms, as well as 
leukaemia, were observed.  
7.3.4.3. Conclusions 
AA is carcinogenic in multiple tissues of both male and female mice and rats.  
In rats the major tumours produced by AA are adenomas, fibroadenomas and fibromas of the 
mammary gland, thyroid gland follicular cell adenomas or carcinomas, and in F344 rats, testes or 
epididymis tunica vaginalis mesotheliomas.  
In mice, the major tumours produced by AA are Harderian gland adenomas, mammary gland 
adenoacanthomas and adenocarcinomas, lung alveolar and bronchiolar adenomas, benign ovary 
granulosa cell tumours, skin sarcomas of various types, and stomach and forestomach squamous cell 
papillomas in females, and Harderian gland adenomas and adenocarcinomas, lung alveolar and 
bronchiolar adenomas and carcinomas, and stomach squamous papillomas and carcinomas in males.  
GA produced increased incidences of testicular, thyroid, heart, and oral cavity neoplasms and 
leukaemia in male rats and of mammary gland, thyroid gland, clitoral gland, oral cavity, and 
forestomach neoplasms, and leukaemia in female rats. It led to increased incidences of Harderian 
gland, lung, skin, and forestomach neoplasms in male and of Harderian gland, lung, mammary gland, 
forestomach, and skin neoplasms in female mice. 
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These results are in agreement with the fact that AA is efficiently metabolized to GA as a genotoxic 
and carcinogenic AA metabolite in both sexes of both species. Based upon the concordance of tumour 
sites between AA and GA, it can be concluded that carcinogenic activity of AA is due to its metabolic 
conversion to GA. 
7.3.5. Reproductive and developmental toxicity  
7.3.5.1. Reproductive toxicity 
The reproductive and developmental toxicity studies on AA in experimental animals have been 
evaluated before by the SCF (2002), JECFA (FAO/WHO, 2006) and ATSDR (2012). These previous 
evaluations referred to several studies reporting on the reproductive and developmental toxicity of 
orally administered AA (Zenick et al., 1986; Sakamoto and Hashimoto, 1986; Smith et al., 1986; 
Working et al., 1987; Sublet et al., 1989; Chapin et al., 1995; Tyl et al., 2000a,b).  
In its 2005 evaluation, JECFA concluded that the overall NOEL for reproductive and developmental 
effects was 2 mg/kg b.w. per day (FAO/WHO, 2006). In 2010, JECFA indicated that ‘no reproductive 
toxicity studies were identified’ since its evaluation in 2005 (FAO/WHO, 2011). 
AA did not significantly affect mating performance in female rats, e.g. pregnancy rates, litter size, or 
survival. However, it significantly depressed pup body weight at birth and weight gain during lactation 
through post-weaning (Zenick et al., 1986). 
Sublet et al. (1989) reported statistically significantly decreased sperm mobility in Long-Evans rats 
administered AA by gavage at dose levels of 45 mg/kg b.w. per day for 5 days, but suggested that this 
effect was not solely responsible for poorer reproductive performance.  
Tyl et al. (2000a) reported a two-generation reproduction toxicity study in rats in which Fischer 344 
weanling rats were exposed to AA via their drinking water at 0, 0.5, 2.0 or 5.0 mg/kg b.w. per day. 
Dose levels of 2.0 and 5.0 mg/kg b.w. per day resulted in systemic toxicity and increased head tilt 
and/or foot splay was observed for rats in all dosed groups. F0 and F1 reproductive indices relating to 
mating and pregnancy were unaffected. The NOEL for adult systemic toxicity including neurotoxicity 
was reported to be ≤ 0.5 mg/kg b.w. per day. In the dominant lethal phase of the study, no treatment-
related effects were observed on the mating parameters, but effects on the pregnancy parameters were 
observed at 5.0 mg/kg b.w. per day (reduction of total implants/litter, increase percentage 
preimplantaion loss).  
Tyl et al. (2000b) found no significant effects on sperm parameters in Long-Evans hooded rats 
following repeated oral dosing at levels as high as 60 mg/kg b.w. per day and also suggested that 
indicators of AA induced reproductive toxicity may be at least partly due to impaired mating 
performance due to AA neurotoxicity. 
Histologic indicators of degenerative effects were reported in spermatids of ddY mice administered 
AA by daily gavage for 5 days at dose levels of 100 or 150 mg/kg b.w. per day (Sakamoto et al., 
1988). 
Other studies reported evidence of AA-induced testicular atrophy in F344 rats receiving AA in the 
drinking water for 28 or 90 days at concentrations resulting in estimated AA doses of 19 or 5 mg/kg 
b.w. per day, respectively (American Cyanamid Company, 1991, as cited in ATSDR, 2012; Burek et 
al., 1980). Atrophy of the testes and/or seminal vesicles was reported in F344 rats receiving AA at 
19 or 25 mg/kg per day from the drinking water for 28 days; this effect was not seen at 12 mg/kg per 
day (American Cyanamid Company, 1991, as cited in ATSDR, 2012). 
Gross and histopathologic examinations of reproductive organs and tissues from male rats receiving 
AA from the drinking water for up to 2 years at estimated doses as high as 2 mg/kg per day revealed 
no signs of AA-induced effects (Johnson et al., 1984, as cited in ATSDR, 2012; Johnson et al., 1986; 
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Friedman et al., 1995). Pre-breeding exposure of female mice to AA at a dose level of 18.7 mg/kg b.w. 
per day (Sakamoto and Hashimoto, 1986) or of female Long-Evans rats at doses up to 14.6 mg/kg b.w. 
per day (Zenick et al., 1986) did not adversely affect reproductive performance variables such as 
fertility or implantation when the animals were bred with non-exposed males. Gross and 
histopathologic examinations of reproductive organs and tissues from female rats receiving AA from 
the drinking water for up to 2 years at estimated doses as high as 2–3 mg/kg per day revealed no signs 
of AA-induced effects (Johnson et al., 1984, as cited in ATSDR, 2012;  Johnson et al., 1986; Friedman 
et al., 1995). 
In 2003, Tyl and Friedman published a review on the effects of AA on rodent reproductive 
performance. They reported that at low doses (5 mg/kg b.w. per day) AA decreases litter size with rats 
being more sensitive than mice. The overview also showed that at higher doses (15–60 mg/kg b.w. per 
day) male reproductive toxicity was clearly present, since sperm morphology and motility and 
neurotoxicity were affected resulting in decreased mating frequency. In addition, the authors indicated 
that AA does not affect female reproduction even in females showing neurotoxicity. 
Exon (2006) reported a review of the toxicology of AA and concluded that neurotoxicity of AA can 
result in behavioural changes that affect reproductive performance. In addition, the author stated that 
AA may affect kinesin motor proteins that are important in sperm motility and that the mechanism 
underlying effects on sperm motility may also be related to direct interaction with sulfhydryl groups 
on proteins essential to the function of germ cells. 
Male C57Bl/6J mice were fed a normal diet or a high-fat diet (60 % of the kilocalories were from lard) 
from week 5 to week 30 of age. Age-matched vehicle controls from each group, obese and lean mice, 
were included (Ghanayem et al., 2010). AA-induced reproductive toxicity was assessed in lean or 
obese males treated with water or 25 mg AA/kg b.w. per day via gavage for 5 days and then mated to 
control females. Treatment with AA exacerbated male infertility of obese and lean mice. However, 
this effect was more pronounced in obese mice. Further, females partnered with AA-treated obese 
mice exhibited a further decrease in the percentage of live fetuses, whereas the percentage of 
resorptions increased. The authors concluded that diet-induced obesity in mice caused a significant 
reduction in male fertility and exacerbated AA-induced reproductive toxicity and germ cell 
mutagenicity. 
Wang et al. (2010b) administered AA by gavage to male Sprague-Dawley weanling rats at 0, 5 or 
10 mg/kg b.w. per day for 8 weeks. The results indicated that the growth of rats treated with AA was 
retarded (p for trend < 0.05), but relative weights of testes and epididymides compared to body weight 
were not significantly different (p for trend > 0.05). The results also indicate that the epididymal sperm 
reserves decreased significantly (p for trend < 0.05), suggesting partial depletion of germ cells. Mean 
epididymal sperm concentrations in the 5 and 10 mg/kg b.w. per day dose groups were approximately 
24 and 40 % lower, respectively, than those of controls. In addition, histopathologic lesions were also 
present in the testes of treated rats. The study also reported increased concentrations of Leydig cells 
and serum testosterone at a dose of 5 mg/kg b.w. per day and a statistically significant approximately 
2-fold increase in these concentrations at 10 mg/kg b.w. per day. 
Kermani-Alghoraishi et al. (2010) conducted a study on thirty male NMRI mice, aged 8–10 weeks, 
receiving AA via drinking water for 2 months at an estimated dose of 0, 5 and 10 mg/kg per day.  
Total sperm motility and progressive motility (fast and slow) in both groups exposed to AA decreased 
significantly, but no significant change was observed in non-progressive motility. The total motile 
sperm percentage decreased significantly only in the 10 mg/kg b.w. per day group. Sperm morphology 
did not significantly change in the experimental groups compared to the controls. In sperm membrane 
integrity evaluation, functional intact membrane of sperm tail in both AA exposed groups had a 
significant decrease, but membrane integrity of the sperm head decreased significantly only in the 
highest dose group. Based on these results, the authors concluded that AA decreased sperm vitality as 
well as causing abnormal sperm parameters in progressive motility and total motility. 
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Zhang et al. (2010) investigated the effect of enhanced fat consumption on deficits of spermatogenesis 
induced by AA in mice. This was investigated because AA and high contents of fat could be found 
co-existent in many foods processed by high temperature. Forty-eight male Kunming mice were 
randomly distributed into four groups administered AA at 0, 10 mg/kg b.w. per day and 10 mg/kg b.w. 
per day and corn oil or pork fat (0.25–0.30 mL), 5 times a week for 10 consecutive weeks. The results 
obtained revealed that in mice fed diets enriched with corn oil or pork fat, AA induced decreases of 
spermatogonia and spermatozoa quality were more pronounced. In addition, enhanced consumption of 
corn oil or pork fat increased the AA induced malondialdehyde production in epididymal sperm and 
cauda epididymides, and the AA mediated increase in the levels of protein carbonyls in cauda 
epididymides. Enhanced consumption of corn oil or pork fat also potentiated the AA induced 
reduction in superoxide dismutase activity in epididymal sperm, corpus, and cauda epididymides, and 
the reduced activity of glutathione peroxidase in cauda epididymides. The authors concluded that the 
data suggest that enhanced feeding of corn oil and pork fat potentiates AA-induced oxidative stress in 
the epididymis and epididymal sperm and subsequent effects on spermatogenesis. The CONTAM 
Panel noted that this study did not include control groups on corn oil or pork fat diet without AA and 
that this hampers the interpretation of the results. 
NTP (2012) noted degeneration in the seminiferous tubules (decreased number of germinal cells and 
presence of multinucleated spermatids in the lumen of seminiferous tubules) of male F344/N rats 
receiving AA via the drinking water for up to 14 days at an approximate dose of 7.03 mM 
corresponding to 68 mg/kg b.w. per day. The NOAEL for this effect was 3.52 mM, corresponding to 
37 mg/kg b.w. per day. In other males exposed via the food, degeneration in the seminiferous tubules 
was observed at an approximate dose of 370 mg AA/kg food, corresponding to 52 mg/kg b.w. per day. 
The NOAEL for this effect was 185 mg AA/kg food, corresponding to 22 mg/kg b.w. per day (NTP, 
2012). In similar 14-day studies of male B6C3F1 mice, no histopathologic evidence of reproductive 
toxicity was observed at AA doses from the drinking water or food as high as 67 and 73 mg/kg b.w. 
per day, respectively (NTP, 2012).  
In the 13-week oral studies in F344/N rats and B6C3F1 mice (see Sections 7.3.2.2 and 7.3.2.1 for 
details on the doses administered) degeneration of testicular germinal epithelium of both rats and mice 
was observed. The effect was observed in all male rats given 22.3 and 8.6 mg AA/kg b.w. per day and 
in five of eight male rats treated with 4.5 mg AA/kg b.w. per day, and in all dose groups of male rats 
fed diet containing AA (0.5–14.2 mg AA/kg b.w. per day), with the incidence increasing with 
increasing dose. The average severity of the degenerative change was mild to moderate in the 
22.3 mg/kg b.w. per day group and minimal-to-mild in the 8.6 and 4.5 mg/kg b.w. per day groups and 
in the AA diet groups. Moderate hypospermia in the epididymes was also observed in male rats 
exposed via the diet at 59 mg/kg b.w. per day. In mice degeneration of testicular epithelium was only 
observed in animals of the high dose group corresponding to 59 (dietary) and 70 (drinking water) 
mg/kg b.w. per day, respectively. Anestrus was observed in female F344/N rats and B6C3F1 mice at 
doses of 26 (drinking water) and 64 (dietary) and 83 (drinking water) mg/kg b.w. per day, respectively 
(NTP, 2012). An increased number of ovarian cysts was observed in female B6C3F1 mice receiving 
AA from the drinking water for 2 years at doses of 1.1, 4.7 and 10 mg/kg b.w. per day (NTP, 2012). 
The CONTAM Panel considered the NOAEL for degeneration of testicular germinal epithelium in 
mice to be 32.8 mg/kg b.w. per day for AA in drinking water and 32.1 mg/kg b.w. per day for AA in 
diet. In rats, the NOAEL for degeneration of testicular germinal epithelium was 2.1 mg/kg b.w. per 
day for AA in drinking water and the LOAEL was 0.5 mg/kg b.w. per day for AA in diet. The 
CONTAM Panel considered the NOAEL for anestrus in rats to be 12.3 mg/kg b.w. per day for AA in 
drinking water, and in mice to be 31.4 mg/kg b.w. per day for AA in drinking water and 35.1 mg/kg 
b.w. per day for AA in diet. 
Takami et al. (2012) reported a study of F344 rat pups whose mothers were exposed to AA via 
drinking water during 3 weeks of lactation followed by 9 weeks of exposure of the pups directly via 
their drinking water to doses of 0, 10, 20 and 40 mg/L (equivalent after weaning to 0, 1.0/1.2, 2.1/2.5 
and 4.4/4.9 mg/kg b.w. per day in males and females, respectively). Adverse effects observed included 
degenerative effects on seminiferous epithelium of the testis and epididymis at an estimated pup dose 
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of 4.4 mg/kg per day. The CONTAM Panel considered the NOAEL in this study to be 2.1 mg/kg b.w. 
per day.  
In order to assess age-dependence of susceptibility to AA-induced neural and testicular toxicity, 3- and 
7-week-old male SD rats were given AA at 0, 50, 100, or 200 mg/L in the drinking water for 4 weeks 
(corresponding to 0, 8.3, 16 and 26 mg AA/kg b.w. per day in young and 0, 6.3, 13 and 19 mg AA/kg 
b.w. per day in adults), and the nervous and male reproductive systems were examined 
histopathologically (Takahashi et al., 2011). Testicular genotoxicity was evaluated with the Comet 
assay and the MN test. Suppression of body weight gain was observed in the young groups at the two 
highest doses. In both young and adult animals, neurotoxicity (gait abnormality, central chromatolysis 
of ganglion cells in the trigeminal nerves, increase density of axons in the sciatic nerve in young, 
increase in degenerated axons in the sciatic nerve) was evident from 100 mg/L and increased in 
proportion to AA intake per body weight. Decreases in absolute weights of the testis and epididymides 
were observed in young and adult rats. In the testis, marked degeneration, loss of or decrease, 
exfoliation and appearance of multinucleated giant cells, mainly of spermatids, were observed from 
100 mg/L limited to young animals. The Comet assay revealed that AA induced significant DNA 
damage from 100 mg/L in both life stages, while MNs were found only in young rats exposed to 
100 mg/L or higher. These results suggest that susceptibility to neurotoxicity might not differ between 
young and adult rats when exposure levels are adjusted for body weight. Regarding testicular toxicity, 
young animals around puberty proved more susceptible than adult animals. The CONTAM Panel 
derived a NOAEL from this study of 6.3 mg/kg b.w. per day. 
Rajeh et al. (2011) studied histopathological effects of AA on testis and epididymis in male Sprague-
Dawley rats orally exposed to 0, 5, 15, 30, 45 or 60 mg AA/kg b.w. per day for five consecutive days. 
AA induced a significant body weight reduction, increase in testis/body weight ratio and a significant 
reduction in sperm count, in the groups treated with 45 mg and 60 mg/kg b.w. per day. Abnormal 
sperm shapes were detected in all groups. Histopathological signs of AA toxicity on testes and 
epididymis included: degeneration of spermatogonia, widening of intercellular junctions and 
degeneration of peritubular myoid cell. Sertoli cells showed darkening of the nuclei, detachment from 
the basement membrane, increase in the number and size of lipid droplets in their cytoplasm, failure of 
sperm release and phagocytosis of some sperms. Leydig cell atrophy was observed which contributed 
to sperm defects and various abnormal histopathological lesions including apoptosis in rat testis. A 
possible cause of tail inter segmentation (partial dissolution of fibrous sheath in the principal piece) 
seen in mature sperm tails was clarified by electron microscope (EM) examination. The authors 
concluded that AA induced harmful effects on the testis evidenced by degeneration of spermatogenic 
and Sertoli cells and Leydig cells atrophy in addition to reducing sperm count and appearance of 
abnormal sperms with the lowest dose level tested of 5 mg/kg b.w. per day. The CONTAM Panel 
considered this dose level a LOAEL. 
Ma et al. (2011) reported adverse effects on sperm parameters in 3-week-old male Sprague-Dawley 
rats treated for 4 weeks (5 times per week) with AA at various doses (0, 5, 15 or 30 mg/kg b.w. per 
day). Most weaning rats in the 15 and 30 mg/kg b.w. per day groups showed decreased body weight, 
reduced consumption of food and water, and less activity. In addition, the animals of the 30 mg/kg 
b.w. per day dose group exhibited distinct hind-leg splay, abnormal gait and muscle weakness. 
Reproductive organ (testis, prostate and seminal vesicle) indexes of the weaning male rats decreased at 
the two highest dose levels. Levels of follicle-stimulating hormone (FSH) and testosterone in serum 
increased while luteinizing hormone (LH) in serum decreased. Histopathological lesions (testis: 
chaotic cells of epithelia, degeneration of all kinds of cells in seminiferous tubules, reduction of the 
spermatozoa and Leydig cell; epididymis: disarrangement of epithelial structure, degeneration of cells, 
hyperplasia of connective tissue and significant reduction of sperm), decrease spermatozoal motility, 
sperm survival rate and sperm count and abnormal sperms were observed in weaning rats after AA 
treatment. The results point at adverse effects of AA on the reproductive system of weaning male rats. 
Jangir et al. (2012) studied the effects of AA toxicity on the male reproductive system and its 
correlation with histological changes in testes of rats. Male Wistar rats were administered AA via oral 
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gavage (in distilled water) at doses of 0, 10, 15 and 20 mg/kg b.w. per day for 28 days. There was no 
statistical difference between the mean weights of prostate of different treatment groups.  A significant 
decrease in testes weight was observed in treated groups (12 %, 13 % and 17 %, respectively) 
compared to control group. When relative weights were compared, no statistically significant 
difference was recorded. There was a significant dose-related reduction in total sperm counts in caput, 
corpus, cauda and testes and a significant dose-related increase in dead sperm counts in treated rats. 
No gross changes were observed in testes and prostate of treated rats. Histopathological changes in 
treated rats included destruction of seminiferous tubules with detachment of spermatogonial cells 
observed at periphery of seminiferous tubules. Atrophy of seminiferous tubules was a constant 
finding. Some sections of testes of high dose treated rats showed vacuolar degenerative changes in 
germinal epithelium. Less severe lesions were observed at the two lower doses. There was no 
significant difference among the different groups in lipid peroxidation (although there was a small 
increase of 5, 11 and 25 % in the low, medium and high dose groups, respectively), and GSH values. 
There was a significant dose-related increase in values of superoxide dismutase in testes from treated 
rats. The authors concluded that pathological alterations in testes were responsible for reduced 
spermatogenesis in rats and suggested that the increase in lipid peroxidation status of testes could be 
an alternative mechanism of AA toxicity to spermatogonial cells. 
Mustafa (2012) treated male albino Sprague-Dawley rats with AA at 50 mg/kg b.w. per day over 
10 days. Degeneration of testicular germ cells, numerous multinucleated giant cells with sloughed 
seminiferous epithelium, and vacuolation in-between the germ cells were reported. 
Exposure of male F344 rats to 50 mg AA/kg b.w. per day via drinking water for 14 days induced 
several testicular lesions, including exfoliated germ cells, depletion of germ cells, spermatid retention 
and apoptosis (Camacho et al., 2012). Both the incidence and the severity of the testicular lesions was 
high in the rats dosed with 50 mg/kg b.w. per day, but decreased to near control levels in the 10 and 
2.5 mg/kg b.w. per day groups, with the exception of the incidence (but not the severity) of the 
spermatid retention, which remained elevated in all AA groups compared to the control. There was 
also an increase in the incidence and severity of exfoliated germ cells in the epididymis at the high 
dose. Testicular absolute weight was decreased in the high dose group compared to control. There was 
a decrease in Leydig cell total and cytoplasmic volume, with no appreciable change in their nuclear 
size. Furthermore, the estimated cell count in the high dose group was not significantly different from 
control (Camacho et al., 2012). 
For GA, in the NTP (2014) study where groups of eight male and eight female mice were administered 
GA in drinking water for 13-week (see Section 7.3.2.1 for details on the doses administered), 
degeneration of the germ cells in the testes was observed in seven out of eight male mice give the 
highest GA dose (3.52 mM, equivalent to 81.5 mg GA/kg b.w. per day) (NTP, 2014). The NOAEL for 
testicular germ cell degeneration was 1.41 mM corresponding to 36.0 mg GA/kg b.w. per day. 
Likewise, for rats (see Section 7.3.2.2 for details of the doses administered), degeneration of the germ 
cells in testes were observed in all male animals at the three highest doses of GA (0.70, 1.41 and 
3.52 mM, equivalent to 5.0, 10.1 and 26.9 mg GA/kg b.w. per day) in three of eight male rats given 
0.35 mM GA (2.4 mg GA/kg b.w. per day), and in two of eight male rats given 0.14 mM GA (1.0 mg 
GA/kg b.w. per day). The severity of the effect was moderate to marked in the two highest dose 
groups and minimal to mild in the three lowest dose groups. In the epididymides, exfoliated 
degenerating germ cells and cellular debris were observed in all males at the three highest doses and in 
three males at 0.35 mM, and hypospermia was observed at the three highest doses (NTP, 2014). The 
LOAEL for testicular germ cell degeneration was 0.14 mM corresponding to 1.0 mg GA/kg b.w. per 
day.  
Groups of eight male mice received basal diet or basal diet and 10 mg/kg AA dissolved in the drinking 
water for 35 days (Pourenterazi et al., 2014). Analysis of sperm parameters showed that sperm count, 
rapid, slow and total motility, morphology and viability significantly decreased in treated males 
compared to control animals. To determine the sperm DNA integrity and chromatine condensation, 
cytochemical techniques were used. In sperm chromatin assessments, except toluidine blue, significant 
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differences were found in all of the tests (aniline blue, acridine orange and chromomycin A3) between 
the two groups. A significant decrease in concentration of blood testosterone was also observed in 
AA-treated animals compared to controls which may explain the sperm abnormalities observed 
(Pourenterazi et al., 2014). 
AA was administered via drinking water to female mice at doses of 0, 20 or 40 mg/kg b.w. per day for 
30 consecutive days (Wei et al., 2014). This led to significantly reduced body weights, uteri and 
ovaries weights and the number of corpora lutea (almost no corpus luteum observed in the high dose 
group). There was also a dose-related decrease in the proportion of primordial follicles and a dose-
related increase in the proportion of antral follicles in the ovaries of treated mice. The proportion of 
primary follicles was increased at the low dose, but there was no difference between the high dose and 
the control group. The results from immunohistochemistry provided evidence that nitric oxide 
synthase (NOS) signalling was involved in the process of follicular development and atresia. Total 
NOS, iNOS and eNOS activities were significantly increased with increasing doses of AA. Serum 
progesterone concentrations were dose-dependently significantly reduced, however, 17β-estradiol 
concentrations were unchanged with treatment. In addition an in vitro study has been conducted, 
where granulosa cells collected from mouse ovaries were exposed for 48 hours to AA at 
concentrations of 0, 0.5 and 5 mM. The results from this study indicated that AA reduced the viability 
of mouse granulosa cells in a dose-dependent manner (Wei et al., 2014). 
Conclusions 
Several rodent studies have demonstrated adverse effects of AA on male reproductive parameters 
particularly reduced sperm counts and effects on sperm and testis morphology with a NOAEL of 
approximately 2 mg/kg b.w. per day (Tyl et al., 2000a; NTP, 2012; Takami et al., 2012). Minimal to 
mild degeneration of the testicular germinal epithelium was observed in male rats treated with AA in 
the 90-day dietary and drinking water studies. The incidence was dose-related. This lesion was not 
observed in control animals. In the drinking water study, the NOAEL was 2.1 mg/kg b.w. per day, 
however a low incidence (2/8 animals) was already observed at the lowest doses of 0.5 and 1.4 mg/kg 
b.w. per day in the dietary study. This lesion was also observed in the 14-day NTP (2012) studies, in 
other studies which used higher doses of AA and in the 90-day study with GA and at higher doses in 
mice. However, in the 2-year studies with either AA (at doses up to 2 or 2.71 mg/kg b.w. per day 
(Johnson et al., 1986; Friedman et al., 1995; NTP, 2012) or GA (NTP, 2014), from which more 
reliable dose-response would be expected, treatment-related changes in the testicular germ cell 
epithelium were not observed (Beland F, 2015, personal communication). This lesion is judged to be 
secondary to primary effects of AA/GA on the Leydig or Sertoli cells (Camacho et al., 2012). The 
adversity of this lesion at minimal-mild severity is questionable since changes in sperm count or 
fertility in this low dose range are not observed in the reproductive toxicity studies (Tyl et al., 2000a).  
Therefore, the CONTAM Panel concluded that there was too much uncertainty about the biological 
relevance of the findings in the 90-day AA dietary study to be used to establish a reference point for 
use in the risk characterisation. The CONTAM Panel therefore considered the NOAEL of 
approximately 2 mg/kg b.w. per day as the relevant one for reproductive toxicity.  
A study has also demonstrated that oral administration of AA may affect female reproduction having 
an effect on body weight, on uteri and ovarian weight, affecting follicular development and corpus 
luteum formation, possibly acting through NOS signaling pathway (Wei et al., 2014).  
The CONTAM Panel noted that besides the Tyl et al. (2000a) study, no other one- or two-generation 
studies investigating the effects of AA on reproduction upon pre- and post-natal continuous exposure 
could be identified. 
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7.3.5.2. Developmental toxicity 
Developmental toxicity was assessed in the offspring of rat or mouse dams administered AA via the 
diet or daily gavage, during gestation and/or lactation. It has been reviewed by SCF (2002), JECFA 
(FAO/WHO, 2011) and ATSDR (2012). 
Husain et al. (1987) reported significantly decreased levels of selected catecholamines (noradrenaline, 
dopamine, 5-hydroxytryptamine) in brains of pups of Wistar albino rat dams administered AA at 
25 mg/kg per day during lactation. Levels of brain catecholamines were affected in a similar way in rat 
pups at 12–21 days of age at the beginning of a 5-day period in which they were administered AA by 
gavage at 25 mg/kg per day, whereas these effects were not seen in rat pups that were 60 days of age 
at the initiation of dosing. 
Field et al. (1990) studied developmental toxicity of AA in CD rats and CD-1 mice. AA was dosed by 
gavage once a day to mice on GD6–17 at dose levels of 0, 3, 15 or 45 mg/kg b.w. per day, and to rats 
on GD6–20 at dose levels of 0, 2.5, 7.5 or 15 mg/kg b.w. per day. Fetuses were examined for external, 
visceral and skeletal malformations. During treatment, maternal toxicity was observed at the highest 
dose levels reflected in reduced body weight in both species and hindlimb splaying in treated mice 
only. Weight gain corrected for gravid uterine weight was also reduced in rats at the two highest 
doses, and gravid uterine weight was reduced in mice at the two highest doses. Embryo/fetal toxicity 
was not observed in rats, but fetal weight was reduced in mice of the 45 mg/kg b.w. per day dose 
group. No increased incidence of malformations was observed in either species, however, the 
incidence of variations (mainly extra ribs) dose-dependently increased. The authors concluded that the 
NOAEL for maternal toxicity in rats was 2.5 mg/kg b.w. per day, that 15 mg/kg b.w. per day 
represented a NOAEL for developmental toxicity in rats, and that the NOAEL for maternal and fetal 
toxicity in mice was 15 mg/kg b.w. per day. The CONTAM Panel noted that in mice effects were 
already observed at this dose level and therefore did not agree with the NOAEL derived for mice by 
the authors.   
In a study of developmental neurotoxicity, in which Sprague-Dawley rats were given AA orally from 
GD 6 until day 10 of lactation, the NOEL for developmental neurotoxicity was 10 mg/kg b.w. per day 
(Wise et al., 1995). 
Friedman et al. (1999) reported increased mortality and reduced body weights in pups of Wistar rat 
dams dosed at 25 mg/kg per day during lactation, but this effect was accompanied by serious maternal 
toxicity. 
Tyl et al. (2000a) reported a two-generation reproduction and dominant lethal study in rats. Fischer 
344 weanling rats (30 per sex and group) were exposed to AA via their drinking water at 0, 0.5, 2.0 or 
5.0 mg/kg b.w. per day for 10 weeks and then mated. Exposure of F0 females continued during 
gestation and lactation of F1 litters. F1 weanlings (30 per sex and group) were exposed for 11 weeks 
to the same dose levels and then mated to produce the F2 generation. Dose levels of 2.0 and 5.0 mg/kg 
b.w. per day resulted in systemic toxicity and increased head tilt and/or foot splay was observed for 
rats in all dose groups. Reproductive indices and gestational length were unaffected. Implantations and 
live pups per litter were reduced and survival for PND0 through PND4 was reduced at the highest 
dose group. At the highest dose group peripheral nerves in the F1 exhibited axonal fragmentation 
and/or swelling. The NOEL for prenatal developmental toxicity was 2.0 mg/kg b.w. per day. The 
NOEL for adult systemic toxicity including neurotoxicity was reported to be  0.5 mg/kg b.w. per day. 
Takahashi et al. (2008) evaluate the developmental effects of exposure to AA on the nervous and male 
reproductive system using pregnant Sprague-Dawley rats given AA at 0, 50, 100 or 200 mg/L in the 
drinking water from GD10 to PND21 and histopathological assessment of offspring was performed at 
weaning and postnatal week 11. Mean daily intake of AA by dams during the gestation and lactation 
periods was 0, 9.9, 17 and 22 mg/kg b.w. per day. Decreases of food and water consumption and 
suppression of body weight gain were observed in the dams at ≥100 mg/L. Maternal neurotoxicity was 
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evident at 100 mg/L (abnormal gait, central chromatolysis of ganglion cells in the trigeminal nerves 
(already observed at 50 mg/L), dose-related increases of degenerated axons and myelinated nerves of 
< 3 µm in diameter, increase of dot-like SYP-immunoreactive structures in cerebellar molecular 
layer), but at this dose level no neurotoxicity or testicular toxicity was observed in offspring. AA did 
not affect the gestation period, the number of implantations, or the live birth ratio of the male pups. 
Significant depression of body weight was observed from PND 2 through weaning from 50 mg/L in 
males and 100 mg/L in females. At necropsy at weaning, body weights of pups in both sexes were 
significantly decreased from 100 mg/L and pups in the 100 and 200 mg/L groups showed little milk 
content in their stomach. Maternal malnutrition was apparent at ≥ 100 mg/L during the lactation 
period, indicating that poor lactational AA-exposure due to maternal toxicity might account for the 
lack of AA-induced offspring toxicity except for retarded body growth. After weaning, body weights 
of male and female pups was still lower as compared to the control from 100 mg/L in a dose-
dependent manner. 
In another study, Takahashi et al. (2009) gave AA to pregnant Sprague-Dawley rats in the drinking 
water at 0, 25, 50 or 100 mg/L (mean AA intake 0, 3.72, 7.89 or 14.56 mg/kg b.w. per day) from GD6 
through PND21. The 100 mg/L dams exhibited increasing severity of gait abnormalities from PND2 
onwards and abnormal gait was observed in 50 mg/L dams from PND18 onwards. Their body weights 
were suppressed in parallel with the progression of neurotoxic symptoms. Histopathological analysis 
of dams showed central chromatolysis of ganglion cells in the trigeminal nerves from 50 mg/L. 
Morphometric assessment of the nervous tissues of dams showed significant increases of degenerated 
axons and myelinated nerves of < 3 µm in diameter at 100 mg/L. No effect on the gestation period, 
number of implantations, live birth ratio and male pup ratio was observed. At PND21, body weights of 
dams decreased (without statistical significance). At the highest dose the male and female pups 
exhibited approximately 42 and 46 % lower mean body weights, respectively, compared to unexposed 
control pups. No changes suggestive of neurotoxicity or testicular toxicity were observed in the 
offspring. Free AA was neither detected in the serum of the dams or their offspring, nor in the stomach 
milk of offspring. The CONTAM Panel derived a NOAEL from this study for both maternal toxicity 
and development amounting to 25 mg/L, equivalent to 3.72 mg/kg b.w. per day.  
Delayed pinnae detachment (a developmental landmark) and deficient negative geotaxis and rotarod 
performance were reported in F344 rat pups that had been exposed via their mothers (10 mg AA/kg 
b.w. per day by gavage) during gestation followed by gavage of the pups at the same dose from PND1 
through PND22. These effects were not seen at doses ≤ 5 mg/kg b.w. per day (Garey et al., 2005). 
Decreases in body weight gain (2–8 % for females and 5–10 % for males on PND22) were observed in 
pups exposed at doses of 1, 2.5, 5 or 10 mg AA/kg b.w. per day. The CONTAM Panel noted that these 
decreases are not considered to be biologically relevant. Furthermore, there was no consistent dose-
response on body weight gain in the male pups. No effect was observed on fur development or eye 
opening, on performance of righting reflex, duration of forelimb hang time or open field activity. The 
NOAEL for maternal toxicity was 10 mg AA/kg b.w. per day based on the absence of effects on b.w., 
food and water intake, while the NOAEL for developmental toxicity was 5 mg AA/kg b.w. per day. 
The effects of daily AA exposure on food-motivated behaviour were studied in Fischer 344 rats by 
Garey and Paule (2007). Exposures began prenatally on GD6 and continued up to PND85. 
Plug-positive dams were gavaged with AA (0, 0.1, 0.3, 1.0, 5.0 mg/kg b.w. per day).  On PNDs 1–22, 
pups were gavaged with the same dose their dam had received. At weaning (PND 22), pups were 
pair-housed with a same-sex littermate and AA exposure continued at 0, 1, 3, 10 and 50 ppm in 
drinking water. A decreased performance in an operant test of cognitive motivation was observed at 
5 mg AA/kg b.w. per day. The NOAEL for developmental toxicity was 1 mg AA/kg b.w. per day. 
Garey and Paule (2010) also evaluated the effects of AA on learning task performance in Fischer 344 
rats exposed daily beginning prenatally and continuing throughout the lifespan. Dams were gavaged 
with AA from GD6 onwards at dose levels of 0, 0.1, 0.3, 1.0 or 5.0 mg/kg b.w. per day through 
parturition. Pups were administered the same dose levels by gavage through weaning until PND22 
after which dosing continued via their drinking water. One male and one female per litter (8–9 per 
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treatment group) were tested. AA-exposed rats exhibited altered performance in an incremental repeat 
acquisition (IRA) task to assess learning ability by 4 months of age. From approximately 1–8 months 
of age (through ~ PND240), over 52 testing sessions, a significant treatment effect was found on 
per cent task completed (PTC), with a significantly lower PTC for the 5.0 mg/kg b.w. per day group 
compared to controls. While there was no treatment effect on accuracy, a significant decrease in 
response rate was seen at 5.0 mg/kg b.w. per day pointing at a NOAEL of 1.0 mg/kg b.w. per day. The 
CONTAM Panel noted that the data on IRA response, from which the NOAEL was derived, revealed 
only a reduction at the highest dose level tested which made the data not suitable for dose-response 
modelling 
Allam et al. (2010) studied the effect of prenatal and perinatal AA exposure on the biochemical and 
morphological changes in the liver of developing albino rats. Pregnant albino rats were given saline 
(group A) or AA by gastric intubation at a dose of 10 mg/kg b.w. per day, from GD7 till birth 
(prenatal intoxication, group B) or from GD7 till PND28 (perinatal intoxication, group C). Pups from 
each group were killed at PND7, 14, 21 and 28. Pups from prenatally and perinatally AA-treated 
groups showed significant increase in lipid peroxidation with maximum increase in thiobarbituric 
acid-reactive substances (TBARS) at PND7 in the perinatally intoxicated group and decreasing 
thereafter with age. The pups from treated animals showed marked decrease in liver GSH at PND7 
and 14 compared to controls. Total thiol content was significantly reduced in treated groups compared 
to the control group. AA treatment produced a significant decrease in peroxidase and superoxide 
dismutase (SOD) activities. AA treatment significantly increased ALT in both treated groups at all 
ages of the pups compared to the controls. AP activity was significantly reduced in treated groups at 
all ages except at PND21 in group B. Total lipids including cholesterol and triglycerides were 
significantly increased in the serum of treated animals. Sodium and potassium concentrations were 
increased, but calcium, phosphorus and iron levels were significantly reduced in the serum of treated 
animals. AA also produced significant electrophoretic changes in serum proteins. The most noticeable 
change was splitting of β-globulin into β1- and β2-globulins. Light microscopy showed AA-induced 
fatty deposits (both groups), congested central vein (group C), vacuolisation (both groups) and 
chromatolysis (group C) in hepatocytes. Ultrastructural studies revealed vacuolated cytoplasm, lipid 
droplets of variable size and mitochondria with damaged cristae and vacuolisation. The nuclei in AA-
treated groups showed marked decrease in the staining of nuclear DNA. The authors concluded that 
AA affects the liver of the developing rat during gestation and lactation periods. AA-induced 
structural changes in the liver may be caused by oxidative stress and perturbation of lipid and protein 
metabolism. Perinatal exposure increased the toxicity of AA compared to the prenatal exposure. 
In another study, Allam et al. (2011) examined the effects of AA on the development of external 
features and cerebellum in albino rats when pregnant females were exposed to 0 or 10 mg AA/kg b.w. 
per day by gastric intubation, either from GD7 till birth (prenatal intoxicated group); or from GD7 till 
PND28 (perinatally intoxicated group). Signs of AA toxicity were observed postnatally on the treated 
mothers represented by ataxia, splayed hind limb, weakness of hind-limb muscles and finally paralysis 
causing alteration in maternal behaviour, so their newborns suffered from bad lactation and 
consequently malnutrition. At birth, the newborns of all groups were hairless. The time of fur 
appearing and ear and eye opening was retarded in newborns from treated dams. AA administered 
either prenatally or perinatally was shown to induce significant retardation in the body weights 
development of the newborn rats, and to increase thiobarbituric acid-reactive substances (TBARS) and 
oxidative stress (significant reductions in GSH, total thiols, SOD and peroxidase activities) in the 
developing cerebellum. AA treatment delayed the proliferation in the granular layer and delayed both 
cell migration and differentiation. AA treated animals also displayed Purkinje cell loss. Ultrastructural 
studies of Purkinje cells in the perinatal group showed microvacuolations and cell loss. The authors 
concluded that prenatal and perinatal exposure to AA caused oxidative stress, resulted in a marked 
suppression of the antioxidant defence system and induced structural changes in the developing rat 
cerebellum. 
The effects of AA on the development of the medulla oblongata and of oxidative stress during pre- 
and perinatal maternal AA exposure was studied in newborn rats by the same authors (Allam et al., 
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2013). Pregnant albino rats were given saline (group A) or AA by gastric intubation at a dose of 
10 mg/kg b.w. per day, from GD7 till birth (prenatal intoxication, group B) or from GD7 till PND28 
after birth (perinatal intoxication, group C). The pups from each group were killed on PND7, 14, 21 
and 28. Signals of AA toxicity were observed postnatally in the treated mothers and were represented 
by ataxia, splayed hind limbs, weakness of the hind limb muscles, and paralysis, which caused 
alterations in maternal behaviour. Newborns suffered from poor lactation, and consequently, 
malnutrition, particularly in group C. The newborns of all groups were hairless at birth. The time when 
fur appeared and ears and eyes opened was delayed in groups B and C. The maternal AA exposure 
during the gestation and lactation periods produced a pronounced increase in oxidative stress and 
marked suppression in the antioxidant defence system in the medulla oblongata of newborn rats. The 
lipid peroxidation level was markedly elevated, whereas the GSH and total thiol content were greatly 
depleted. Moreover, the antioxidant enzyme activities (SOD and peroxidase) were also depressed in 
the treated groups. The increase in TBARS observed in the study paralleled the decrease in the GSH 
concentration in the medulla oblongata of AA-treated newborns. The authors indicated that the 
enhanced lipid peroxidation and deterioration of the antioxidant defence system that resulted from AA 
exposure may play a significant role in the pathogenesis and deleterious histological effects on the 
medulla oblongata of newborns. The pathological cases reflected CNS neuropathy caused by AA. AA 
affected the medulla oblongata of developed newborn rats if their mothers were exposed to AA during 
gestation and lactation. These effects, which appeared as histopathological changes within the medulla 
oblongata, resulted from perturbations of oxidative stress. 
Pregnant Fischer 344 dams were given 0.0, 0.1, 0.3, 1.0 or 5.0 mg AA/kg b.w. per day by gavage 
beginning on GD6 and ending on the day of parturition (Ferguson et al., 2010). Beginning on PND1 
and continuing through PND21, all pups/litter were gavaged with the same dose as their dam. There 
were no AA related effects in offspring on parameters including fur development, pinnae detachment 
or eye opening. Offspring body weight was somewhat decreased in the 5.0 mg/kg b.w. per day group, 
particularly in males. AA treatment did not significantly alter righting reflex (PNDs 4–7), slant board 
(i.e. negative geotaxis) (PNDs 8–10), forelimb hang (PNDs 12–16), and rotarod behaviour (PNDs 21–
22). Male and female offspring of the 5.0 mg/kg b.w. per day group were 30–49 % less active in the 
open field at PNDs 19–20. The fact that serum AA levels of GD20 dams and their fetuses were 
comparable, indicated that AA is able to cross the placental barrier. The authors concluded that these 
data demonstrate that overt preweaning neurobehavioral effects are apparent in rats exposed to AA 
pre- and postnatally. A NOAEL of 1.0 mg/kg b.w. per day was identified by the CONTAM Panel. The 
CONTAM Panel noted that the data on off spring body weight, from which the NOAEL was derived, 
revealed only a reduction at the highest dose level tested which made the data not suitable for dose-
response modelling. 
Ogawa et al. (2011) performed immunohistochemical analysis of the offspring of pregnant Sprague-
Dawley rats treated with AA at 0, 25, 50 or 100 mg/L in drinking water from GD6 until weaning on 
PND21 (0, 3.7, 7.9 and 14.6 mg/kg b.w. per day) in the study described above (Takahashi et al., 2009). 
Offspring were immunohistochemically examined at the end of exposure. Dams in the 100 mg/L 
group exhibited gait abnormality from PND2, which progressed to a moderate or severe degree at 
PND21. Body weight in this group was suppressed in parallel with the progression of neurotoxic 
symptoms. At 50 mg/L, a slightly abnormal gait appeared from PND18. Tendencies for decreased 
food and water consumption were observed at 100 mg/L during the lactation period. No apparent 
abnormalities were found on clinical observation in offspring exposed to AA maternally at any dose. 
Maternally exposed offspring showed decreased body weight at 100 mg/L (nearly 50 %), increased 
dose-dependently the number of Reelin-immunoreactive cells (a molecule regulating neuronal 
migration and positioning in the hilus of the hippocampal dentate gyrus) (from 25 mg/L AA) and 
glutamic acid decarboxylase 67-immunoreactive cells (from 50 mg/L AA), confirming an increase in 
γ-aminobutyric acid-ergic interneurons. The results revealed decreased apoptosis in the neuroblast-
producing subgranular zone of the dentate gyrus of maternally exposed pups at 100 mg/L, and the 
authors determined the LOAEL to be 25 mg/L (3.72 mg/kg b.w. per day). 
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Pregnant Sprague-Dawley rats were given drinking water containing AA at 0, 4, 20, 100 mg/L from 
GD10 to PND21 (Ogawa et al., 2012). There was no observable gait abnormality of dams through to 
the day 21 after delivery and no significant changes were observed in food intake and water intake 
consumption during the whole exposure period as compared with the controls. A slight reduction in 
the absolute liver weight was observed at high dose. No effect was observed on the duration of 
pregnancy, number of implantation sites, live birth ratio or male pup ratio. At the necropsy on PND 
21, statistically significant decreases were found in the body and absolute brain weights of offspring at 
the high dose that continued to PND77, however, gait abnormalities were not observed. Male 
offspring were examined immunohistochemically on PND21 and PND77. On PND21, maternal 
AA-exposure decreased progenitor cell proliferation in the subgranular zone (SGZ) at the two highest 
dose levels, accompanied with increased density of reelin-producing interneurons and 
NeuN-expressing mature neurons within the hilus at 100 mg/L. In the SGZ of the 100 mg/L group, 
cellular populations immunoexpressing doublecortin or dihydropyrimidinase-like 3, were decreased 
suggesting postmitotic immature granule cells. On PND77, the SGZ cell proliferation and reelin-
producing interneuron density recovered, while the hilar mature neurons sustained to increase at the 
two highest dose levels. The authors concluded that developmental exposure to AA reversibly affects 
hippocampal neurogenesis targeting the proliferation of type-3 progenitor cells resulting in a decrease 
in immature granule cells in rats and that a sustained increase in hilar mature neurons could be the 
signature of the developmental effect of AA. The authors considered the lowest dose level of 4 mg/L 
(corresponding to 0.36–0.89 mg/kg b.w. per day, based on water intake) to be the NOAEL. The 
authors concluded that while the neurotoxic effect of AA on neurogenesis and following neuronal 
migration in the dentate gyrus observed from 20 mg/L was subtle and reversible, the sustained 
increase in mature neurons in the hilus at the later stages after AA-exposure from 20 mg/L was 
considered to be irreversible. As pointed out by the authors, the biological significance of the findings 
needs to be assessed in relation to functional endpoints (i.e. behavioural alterations). The CONTAM 
Panel also noted that the methodology used for counting cells in both Ogawa et al. (2011, 2012) does 
not comply with the principle of stereology, which is the best-practice method for quantitative 
histology to accurately quantify the number of cells. The analysis is performed on restricted 
hippocampal regions and it is not clear whether all the slices examined came from the same animal or 
from different pups from the same litter. A factor that has to be considered when working with fixed 
material is the shrinkage due to tissue processing, which can cause important variations in volume, and 
thereby lead to under- or overestimation of the effects under investigation. As pointed out in Ogawa et 
al. (2012), differences in the size of the dentate gyrus hilar area may explain the increase in cell 
density. However, the reason why the hilar area varies in size is not approached.  Even if the findings 
reported are of potential interest, they need to be confirmed by suitable methodological approaches 
before being used for establishing a NOAEL. Therefore, the CONTAM Panel did not consider the data 
suitable for identifying a NOAEL.  
El-Sayyad et al. (2011a) investigated the neurotoxic effects of AA on postnatal development. In this 
study, female rats were treated with AA at a dose of 30 mg/kg b.w. per day during pregnancy, or fed a 
standard diet (control), and their offspring were examined. Female rats treated with AA gave birth to 
litters with delayed growth and decreased body and brain weights. Light microscopic studies of the 
cerebellar cortex of treated animals revealed decreases in Purkinje cells and internal granular layers. 
Pups born to treated mothers showed different patterns of cell death in Purkinje cells and neurons in 
the brain. Ultrastructural analysis of Purkinje cells revealed changes in the endoplasmic reticulum, loss 
of the normal arrangement of polyribosomes, swollen mitochondria with abnormally differentiated 
cristae, and an abnormal Golgi apparatus. The gastrocnemius muscle in the AA group showed 
extensive degeneration of myofibrils as evidenced by poorly differentiated A, H, and Z bands. This 
study reveals that rat fetal exposure to AA via dosing pregnant dams at a dose level of 30 mg/kg b.w. 
per day, causes cerebellar cortical defects and myodegeneration of the gastrocnemius muscle during 
the postnatal development of pups.  
In another study, El-Sayyad et al. (2011b) investigated the effects of fried potato chips (i.e. likely 
potato crisps) on the development of the retina in albino rats. Pregnant rats (n = 15) were maintained 
on control diet or from GD6 on a diet formed of potato chips obtained from the market mixed (50:50) 
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with standard diet and their offspring was maintained on the same control and fried potato chips diet 
till day 7 or 14 post partum. Histological examination of the retina of the exposed offspring revealed 
many histopathological changes but since the dose of AA in the fried potato chip diet was not 
quantified, the CONTAM Panel did not considered the study of use for the risk assessment of AA. 
El-Sayyad et al. (2011c) also investigated the effects of fried potato chip supplementation on mouse 
pregnancy and fetal development. Pregnant mice were divided into three groups. Group 1 (n = 20) 
contained the non-treated control mice, and group 2 (n = 40) consisted of mice treated with AA at a 
daily dose of 25 mg/kg b.w. per day given orally by stomach tube to pregnant mice from day 6 of 
gestation until parturition. Group 3 (n = 20) consisted of mice that were given a diet containing fried 
potato chips which was mixed with the standard diet at a concentration of about 33 % starting from 
day 6 of gestation to days 14, 16, or 17 of fetal age and at parturition. The standard diet mixed with 
fried potato chips matched the diet given to the control group and was well balanced for gestating and 
lactating mice, containing all the ingredients required, including vitamins and minerals. In the 
pregnant mice, similar histologic abnormalities were found in various tissues (especially liver, kidney, 
heart muscle, and epiphyseal cartilage of experimental dams) for the AA and the fried potato chips 
group. AA and fried potato chip exposure increased the rate of abortion and neonatal mortality and 
decreased the total number, body weight, size, and crown-rump length of the offspring before and after 
birth. Higher rates of congenital malformations were observed in the fried potato chip-treated group. 
Ossification of axial and appendicular bones was markedly retarded during fetal development, and 
some ossified bones were missing in newly born offspring of treated groups. In the fried potato chip-
treated neonates the incidence of missing ossification centres was higher than in the AA-treated 
neonates.  
Hułas-Stasiak et al. (2013) reported the effects of maternal AA treatment on ovarian follicle number in 
newborn guinea pig offspring. Ninety day-old pregnant guinea pigs (n = 5 per group) were exposed to 
0 (control) or 3 mg/kg b.w. per day beginning on GD32 until parturition via drinking water. After 
prenatal AA treatment, the pool of primordial and primary follicles was significantly reduced and the 
number of caspase 3 and TUNEL positive oocytes increased compared to the control group. The 
authors concluded that the data suggest that prenatal exposure to AA reduced the number of ovarian 
follicles by inducing follicular atresia mediated by oocyte apoptosis. 
Sen et al. (2015) investigated how AA and alcohol may affect the male reproductive system of the 
offspring when consumed by the mother during pregnancy and lactation. Sexual development in male 
mice was evaluated after oral gavage with 14 mg/kg AA and/or 2 g/kg alcohol from GD6 to PND21 or 
only during gestation or during lactation. Control group was exposed to saline during gestation and/or 
lactation period. The weight of the offspring was reduced at birth and PND21 for those exposed to AA 
and alcohol. The gonadosomic index of male offspring was reduced except for the AA-treated 
lactation group. AA and alcohol treatment induced multinuclear giant cells in the lumen of the 
seminiferous tubules, degenerative cells, atrophic tubules and maturation-arrested tubules, and 
decreased Leydig, Sertoli and spermatogenic cell (spermatogonia, primary spermatocytes, secondary 
spermatocytes and round spermatids) numbers. Lipid peroxidation level and superoxide dismutase 
enzyme activity increased in both alcohol-treated and AA and alcohol-treated groups. Catalase activity 
was not altered in the treated groups during only gestation or lactation periods, while the activity 
decreased in the treated groups treated both during the gestation and lactation periods. AA and alcohol 
exposure were more toxic during gestation compared with the lactation period and the toxic effects 
were more significant in groups treated with AA and alcohol during both periods. The authors 
concluded that these findings suggest that consumption of AA together with alcohol may induce 
impairments on testicular spermatogenesis in male offspring and that long-term AA exposure may 
enhance the toxic effects of alcohol. 
Conclusions 
The CONTAM Panel concluded that in rats and mice some signs of developmental toxicity (increased 
incidence of skeletal variations, slightly impaired body weight gain, histological changes in the CNS, 
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and neurobehavioural effects) are observed at exposure levels that are in some cases also associated 
with maternal toxicity (including neurotoxicity and decreased maternal body weight). The lowest 
NOAEL reported for developmental toxicity was 1.0 mg/kg b.w. per day from studies in rats exposed 
gestationally and neonatally (Garey and Paule, 2007, 2010; Ferguson et al., 2010).    
7.3.6. Mechanisms and modes of action 
7.3.6.1. Chemical reactivity of AA  
AA acts as an electrophilic molecule which can bind directly to nucleophilic sites in proteins, nucleic 
acids, etc. and may act in this way to perturb cellular functions in various cell types including neuronal 
cells (LoPachin and Gavin, 2012), immune cells (Yener et al., 2013b), and germ cells (Shipp et al., 
2006) eventually leading to apoptosis (Park et al., 2010). As an α,ß-unsaturated carbonyl derivative, 
AA can form Michael-type adducts with nucleophiles via second-order addition reactions to the 
β-carbon. AA is a soft electrophile which reacts preferentially with soft nucleophiles such as cysteine 
residues and is less reactive towards harder nucleophiles such as DNA bases, lysine or histidine. With 
respect to the cysteine side-chain, calculations have revealed that the thiolate ion, representing a 
particularly soft nucleophile, is likely to be a preferential target for AA (LoPachin and Gavin, 2012). 
Reaction of AA with proteins according to the aforementioned mechanism is thought to cause several 
of the adverse effects of AA. Likewise, AA has been demonstrated to target mitochondrial function in 
various cell types (Chen et al., 2013a) probably interacting with mitochondrial proteins. 
Efforts have been made to characterize target proteins of AA, e.g. in plasma (Feng and Lu, 2011) and 
dopaminergic cells (Martyniuk et al., 2013). In V79 cells, AA was shown to interact with 
topoisomerase II (Sciandrello et al., 2010). 
The motor protein kinesin is another example for a protein targeted by AA since microtubule-binding 
of kinesin, an element of microtubule motility in neurons, spermatids etc., was inhibited by 100 µM 
AA (Sickles et al., 2007), GA being more potent than AA. Kinesin-mediated microtubule motility is 
can be inhibited by both AA and GA in vitro (Friedman et al., 2008). 
7.3.6.2. Mode of action of neurotoxicity  
The neurotoxic action of AA was suggested to be due to effects on cells of the central and peripheral 
nervous system including changes in cellular metabolism (Howland et al., 1980; Brimijoin and 
Hammond,1985; Medrano and LoPachin, 1989; Exon, 2006), changes in gene transcription and 
protein synthesis (Cavanagh and Nolan, 1982a,b; Cavanagh, 1982; Cavanagh and Gysbers, 1983; 
Bisby and Redshaw, 1987; Lin et al., 2000; El-Alfy et al., 2011; Seale et al., 2012), effects on 
neurotransmitter levels and turn-over (Dixit et al., 1981; Uphouse and Russell, 1981; Aldous et al., 
1983; Shi et al., 2012), binding to cellular proteins including damage to microtubular and 
neurofilamental proteins (Hashimoto and Aldridge, 1970; Tanii and Hashimoto, 1983; Carrington et 
al., 1991; Reagan et al., 1994; Gupta and Abou-Donia, 1996, 1997; Lapadula et al., 1989; Xiwen et al., 
1992), changes in ion distribution (Lehning et al., 1998; LoPachin and Lehning, 1994), and axonal 
transport (Chretien et al., 1981; Miller and Spencer, 1984; Gold et al., 1985; Moretto and Sabri, 1988; 
Logan and McLean, 1988; Harry et al., 1989; Sabri and Spencer, 1990; Martenson et al., 1995; Sickles 
et al., 1995,1996; Stone et al., 2001). However, the minimal effects of AA-treatment, by up to a 
maximally tolerated dose, on: (i) gene expression related to cholinergic, noradrenergic, dopaminergic, 
GABAergic, or glutamatergic neurotransmitter systems; (ii) neurotransmitter levels related to 
dopaminergic and seratonergic transmission; and (iii) histological integrity (axonal, dendritic, neuronal 
cell body damage or microglial activation) of F344 rat forebrain motor and somatosensory areas of the 
brain (striatum, substantia nigra, parietal cortex) serve to emphasize the predominant role of peripheral 
neuropathic mechanisms (Bowyer et al., 2009).  
AA has been shown to react with certain cysteine residues (Cys) in neuronal proteins such as Cys342 
in the presynaptic Na+-dependent dopamine transporter (Barber et al., 2007). Although the cysteine 
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thiol moiety is basically present in the non-ionized form at intra-cellular pH-values, its position 
adjacent to polarizing amino acids in catalytic sites of proteins may lead to thiolate formation. 
Cysteine residues in such so-called catalytic triads have been demonstrated to react preferentially with 
AA, e.g. in the human erythrocyte glyceraldehyde-3-phosphate dehydrogenase (Thomas et al., 1995).   
Thiolates in catalytic triads are typical targets for regulatory nitrosylation by endogenous NO. NO 
signaling modulates synaptic transmission by reversibly inhibiting the function of several proteins 
involved in the synaptic neurotransmitter vesicle cycle, for example, N-ethylmaleimide (NEM)-
sensitive factor, the dopamine membrane transporter, and the vesicular monoamine transporter (Kiss, 
2000; LoPachin and Barber, 2006; Rudkouskaya et al., 2010).  
Determination of cysteine adduct levels in the CNS has revealed a progressive increase under AA 
exposure, which may explain the accumulative neurotoxicity observed during chronic AA treatment of 
animals. The low turnover of axonal proteins, when compared to proteins of other cell types, is likely 
to contribute to this observation (LoPachin et al., 2002, 2004, 2006).  
Allam et al. (2011) examined the effects of AA on the development of external features and 
cerebellum in albino rats (see Section 7.3.5.2). AA treatment increased markers of oxidative stress in 
the developing cerebellum.  
The effects of AA on the development of the medulla oblongata and of oxidative stress during pre- 
and perinatal maternal AA exposure was studied in newborn rats by the same authors (Allam et al., 
2013; see Section 7.3.5.2). The maternal AA exposure during the gestation and lactation periods 
produced a pronounced increase in oxidative stress and marked suppression in the antioxidant defence 
system in the medulla oblongata of newborn rats.  
There is also indication that GA can exert some neurotoxicity. When administered to rats in the 
drinking water over 13 week (NTP, 2014) (see Section 7.3.2.2), the highest dose of 3.52 mM GA 
(250 mg/L) caused hind-leg paralysis and low incidence of radiculoneurophathy involving the sciatic 
nerve and lumbar spinal cord. This was accompanied at times, by atrophy in the skeletal muscle of the 
hindlimb and urinary bladder dilatation. In mice, hindlimb paresis was observed in two of eight males 
administered 3.52 mM GA. Peripheral neuropathy, involving primarily the sciatic nerve, was noted in 
male and female mice treated with 3.52 mM GA. The neuronal degenerative changes were 
accompanied, in some cases, by atrophy in skeletal muscle of the hindlimb and dilation of the urinary 
bladder lumen.  
In neuronal cells, obtained from isolated embryonic stem cells, Sisnaiske et al. (2014) found a 
reduction of acetylcholine- and glutamate-induced calcium responses after treatment with AA. In 
primary cortical neurons isolated from newborn rats (Zhang et al., 2014), AA (> 2.5 mM) reduced 
viability, and induced apoptosis and mitochondrial telomerase reverse transcriptase activity. 
A study by Lee et al. (2014b) analysed the effects of AA on rat primary astrocytes and three human 
astrocytoma-derived cell lines. Treatment with 1 and 2 mM AA for 24–72 hours resulted in decreased 
cell viability. Decreases in cell viability could be blocked in most cell types by the caspase inhibitor 
Z-DEVD FMK. AA-induced concentration-dependent apoptotic effects were also demonstrated by 
increases in the sub-G1 phase and by interruption of mitochondrial membrane. 
Yao et al. (2014) found that i.p. injection of AA can damage the blood-cerebrospinal barrier in the rat 
CNS, an effect, which, according to the authors, may be related to neurotoxicity. 
7.3.6.3. Mode of action of genotoxicity 
The electrophilic character of AA in principle enables this compound to react with nucleophilic targets 
in nucleic acids (Exon, 2006; Besaratinia and Pfeifer, 2007). AA is slow to react with DNA and only 
forms adducts under forced chemical conditions and after extended reaction time (Solomon et al., 
1985). The latter carried out an in vitro assay in order to analyse the direct alkylation of 
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2’-deoxynucleosides and calf thymus DNA following reaction at neutral pH and 37 °C with AA 
(1.4 M). This resulted in the formation of 2-formamidoethyl and 2-carboxyethyl (CE) adducts via 
Michael addition. After 40 days, 1-(2-carboxyethyl)-dAdo (1-CE-dAdo), n6-CE-dAdo, 1-CE-dGuo, 
7-(2-formamidoethyl)-Gua (7-FAE-Gua), 7,9-bis-FAE-Gua, and 3-FAE-dThd were the alkylated 
2-deoxynucleoside adducts isolated at a percentage of 8, 21, 4, 6, 1 or 4, respectively. Following 
reaction of AA with calf thymus DNA, the products isolated included 1-CE-dAdo, N6-CE-dAdo, 
3-CEdCyd, 1-CE-dGuo, and 7-FAE-Gua at a level of 5.5, 1.4, 2.8, 0.3 or 1.6 nmol/mg DNA.  
The relevance of these AA reaction products in vitro appears minimal given the extreme reaction 
conditions used in vitro and the absence of evidence for AA-DNA adducts in vivo. 
AA has been shown to produce reactive oxygen species in vitro that can attack all cellular constituents 
and induce oxidative DNA damage (Blasiak et al., 2004; Jiang et al., 2007). Oxidative stress can cause 
DNA damage including double-strand breakage. The clastogenicity of AA without metabolic 
activation might result from the relatively increased reactive oxygen species (ROS) and/or the 
impaired oxidative defence system (Puppel et al., 2005). Jiang et al. (2007) evaluated (i) the 
generation of ROS and (ii) the level of oxidative DNA damage by immuno cytochemical analysis of 
8-hydroxydeoxyguanosine in human HepG2 cells treated with (i) 5-40 mM AA for 1 hour or with (ii) 
0, 1.25, 2.5, 5, 10 and 20 mM AA for 3 hours. AA induced significant and dose-related increase in 
intracellular generation of ROS from 10 mM onwards. Following AA treatment, the staining intensity 
of 8-OHdG increased in a dose-dependent manner (4-fold at 20 mM). The authors concluded that AA 
exerts genotoxic effects in HepG2 cells, probably through oxidative DNA damage induced by 
intracellular ROS and depletion of GSH. The CONTAM Panel noted that HepG2 cells do not express 
CYP2E1, and that the effective AA concentration of 10 mM is extremely high. 
The AA metabolite GA is a harder electrophile than AA, being more reactive with hard nucleophiles, 
like DNA bases, than AA. It readily reacts with nuclophilic targets such as proteins and nucleic acids 
with a broad spectrum of consequences for their integrity, function and for long-term effects such as 
cancer. GA is significantly cytotoxic at concentrations above 0.5 mM. When MCF10A cells were pre-
incubated with 100 μM BSO for 24 hours to deplete GSH, the increased cytotoxicity showed that 
endogenous GSH is crucial for detoxification of GA. The role of antioxidants with distinct modes of 
action was also studied in MCF10A cells treated with GA. The results obtained with three 
complementary redox modulators suggest that oxidative stress is not involved in GA-induced 
cytotoxicity in MCF10A cells. The results with oxidant-sensitive probes obtained in these assays 
demonstrate that GA, up to a concentration in the millimolar range (4 mM), does not induce ROS. 
Taken together, the data presented in this work consistently suggest that oxidative stress is not the 
mode of action of GA in human mammary cells (Bandarra et al., 2013). 
It has been suggested that the metabolic formation of GA is the primary pathway responsible for the 
genotoxicity of AA in animal experiments (Gamboa da Costa et al., 2003) and in mammalian cells 
(Besaratinia and Pfeifer, 2004).  
The electrophilic character of GA enables this compound to react with nucleophilic targets in nucleic 
acids (Exon, 2006) when it is formed during AA metabolism. In vivo, the following studies were 
conducted (reviewed in Shipp et al., 2006). Male Sprague-Dawley rats and male BALB/c mice were 
given single i.p. injections of [
14
C]-AA at doses of 46 or 53 mg/kg b.w., respectively (Segerbäck et al., 
1995). In addition, an in vitro experiment was conducted in which DNA was incubated with [
14
C]-AA 
in the presence of S9 liver mix prepared from non-induced male Sprague-Dawley rats. In both species, 
the major adduct formed was N7-GA-Gua, which according to the authors is formed by the reaction of 
DNA with the AA metabolite GA. Similar levels of the N7-GA-Gua were found in different organs of 
the rat, indicating that GA adducts were evenly distributed in the rat. In the mouse, the levels of 
N7-GA-Gua were not as evenly distributed and the overall levels were higher in organs than those 
seen in the rat. The authors concluded that the organ-specific carcinogenesis of AA in the rat cannot be 
explained by selective accumulation of the DNA-reactive metabolites in target organs. 
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Gamboa da Costa et al. (2003) administered 50 mg/kg b.w. of AA or an equimolar dose of GA by i.p. 
injection to adult male and female mice. N7-GA-Gua and N3-GA-Ade adducts were detected in the 
liver, kidney, and lung. Approximately 100-fold more N7-GA-Gua adducts were formed than N3-Ga-
Ade adducts. More of these DNA adducts were noted following administration of GA compared to 
AA (1.2- to 1.5-fold higher). However, in neonatal mice, treatment with GA produced 5- to 7-fold the 
number of these adducts than following administration of AA, which is consistent with a deficiency of 
CYP450 activity in neonates resulting in less metabolism of AA to GA. According to the authors, 
these data demonstrated that GA, and not AA, is the DNA-reactive compound likely responsible for 
the genotoxicity seen in mouse studies. 
Adult B6C3F1 mice and adult F344 rats were dosed with single i.p. injections of AA at a dose of 
50 mg/kg b.w. or GA at 61 mg/kg b.w. (Doerge et al., 2005c). In both rats and mice the major adduct 
formed was N7-GA-Gua. In mice dosed with AA, N7-GA-Gua was found in all tissues examined, 
including liver, lung, kidney, leukocytes, and testis, with little variation. DNA adduct levels were 
significantly higher in males in liver and lung tissue, and significantly higher levels were seen in 
females in kidney tissue. GA also produced similar levels of N7-GA-Gua adducts in all tissues 
examined in mice. Similarly, rats dosed with AA had DNA adducts in all tissues examined. In males, 
DNA adduct levels were found to be significantly higher in testes, leukocytes, and brain tissue than in 
thyroid. Female rats contained significantly higher adduct levels in leukocytes and mammary-gland 
tissue as opposed to that of the brain, liver and thyroid. When compared to AA, GA produced higher 
levels of DNA adducts (160–560 %) in all tissues examined in male and female rats. The authors 
concluded that while the evidence provides some support for a genotoxic mechanism of AA 
carcinogenicity, other factors beyond the formation of GA and its DNA adducts may be important in 
determining the organ specificity of tumour formation in chronic bioassays with AA in rodents. 
Doerge et al. (2005c) evaluated the formation of DNA adducts in the liver after administration of AA 
in groups of male and female B6C3F1 mice and F344 rats following a single dose by the gavage route 
at a dose of 0.1 mg AA/kg b.w. In mice, the major adduct formed was N7-GA-Gua, as in other DNA 
adduct studies. DNA adduct levels were approximately four times higher than in controls but differed 
little between males and females, in contrast to the slower production of GA in female mice. However, 
according to the authors, the small size of the study may have precluded detection of statistically 
significant differences. When compared to data from a previous study (Gamboa da Costa et al., 2003), 
the adduct data are in agreement with the conclusion that (relative) metabolic conversion to GA 
decreases as AA dose increases. 
In another study, Sprague-Dawley rats were given either 18 or 54 mg AA/kg b.w. by gavage (Manière 
et al., 2005). Tissue samples from brain, liver, and testes were collected at 5, 24, 48 and 72 hours, and 
blood samples at 5, 24 and 48 hours after dosing. DNA adducts were measured in all tissues sampled. 
The N3-GA-Ade DNA adduct levels were considerably lower than the N7-GA-Gua (about 50- to 
100-fold). The predominant adduct disappeared slowly from the rat organs, remaining at relatively 
high levels 3 days after treatment with a half-life of 50 to 70 hours. 
As a consequence of the genotoxic properties, AA is expected to cause mutations in genes critical for 
the process of carcinogenesis. Choi et al. (2009) reported that co-administration of MNU and AA to 
rats resulted in a significant increase in codon 12 mutations in the H-ras gene of mammary tumours 
when compared to tumours in rats treated with MNU only. 
7.3.6.4. Modes of action of carcinogenicity 
There is strong evidence for a major role of metabolic activation to GA in the genotoxicity of AA, 
which is derived from various lines of evidence. Absence of CYP2E1, which converts AA into GA, 
led to an almost complete loss of DNA adduct formation (Ghanayem et al., 2005c). Furthermore, 
formation of GA-derived DNA adducts was reported after application of AA to rodents (Gamboa da 
Costa et al., 2003). Finally, the general patterns of tumour sites in rodents were similar after 
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application of either AA or GA, indicating that activation of AA to GA is also important in the 
carcinogenicity (NTP, 2012, 2014). 
Although GA-mediated DNA damage is considered as the crucial initiating effect leading to AA-
induced carcinogenesis, the level of GA-derived DNA adducts cannot predict the localization and 
incidence of tumours with respect to organ specificity. This is particularly evident for the liver which 
shows high levels of DNA adducts in AA-treated rodents and, however, do not develop increased rates 
of hepatic tumour. 
These and other arguments have been brought forward suggesting that other (additional) effects of AA 
may be important if not crucial for the carcinogenic mode of action of AA. These are based on 
observations of occurrence of mostly benign tumours in AA-treated rats, late age of tumour onset 
supported by findings from interim kills that did not demonstrate early tumour response (Johnson et 
al., 1986), tumours in a variety of highly hormone-responsive tissues, etc (Maier et al., 2012).  
A number of non-genotoxic modes of action of carcinogenicity of AA have been discussed in the 
literature. Since tumours originating from endocrine tissues were significantly increased in rat 
bioassays, it was argued that AA may act as a carcinogen via adverse effects on endocrine regulation. 
It was proposed that AA acts as an agonist at dopamine D1-receptors in rat ovaries thus increasing 
prolactin release (reviewed in Shipp et al., 2006). Upon prolactin increase, the corpora lutea increase 
gestagen formation which, together with increased prolactin, may stimulate the mammary gland 
resulting in increased rates of mammary gland fibroadenoma in female F344 rats. 
This mode of action was hypothesized to be active in older rats, while in young adult animals, AA 
failed to enhance circulating prolactin levels (Friedman et al., 1999; Khan et al., 1999). It has to be 
noted that this hypothesis requires experimental confirmation.   
Maier et al. (2012) reviewed linear dose-response modelling of AA tumour data on mammary tumours 
in rats. The study compared a linear low-dose response assessment based only on the combined 
incidences of adenomas and adenocarcinomas and a mutagenic mode of action and a non-linear 
extrapolation using data from tumour promotion potency based on the combined incidence of 
adenomas, adenocarcinomas, fibroadenomas and fibromas that occur as a result of ‘endocrine 
disruption’. The authors concluded that a weight of evidence approach evaluating several hypothesised 
modes of action indicated that a non-linear approach would be more appropriate for evaluation of AA-
induced mammary tumours.  
Analysing data on AA-related tunica vaginalis mesothelium (TVM) tumours in rats, a tumour which is 
almost unknown in humans, and taking into account general biological considerations and modes of 
action, Haber at al. (2009) concluded that the overall weight of evidence concerning the mode of 
action leads to the conclusion that the most appropriate estimate of human cancer risk based on the rat 
TVMs associated with AA exposure is either de minimis or nil. It was concluded that the modes of 
action that were most likely driving this tumour response were either not relevant to humans, or would 
be properly modelled with a non-linear dose-response leading to quantitative difference in response 
between rat and human. 
In two cancer studies in F344 rats, increased incidences of tumours of the TVM were found in males 
after AA treatment (Johnson et al., 1986; Friedman et al., 1995). In the Johnson et al. study and in a 
retrospective examination of the study slides from the Friedman et al. study by Iatropoulos et al. 
(1998, as cited by Shipp et al., 2006), a large number of Leydig cell adenomas were found. The 
malignant mesotheliomas, classified by Iatropoulos, were only seen in animals that had more than 
75 % of their testicular parenchyma replaced by Leydig cell tumours. The CONTAM Panel noted the 
difficulty of interpreting this hypothesis given the historically high incidences of Leydig cell tumours 
in untreated 2-year old male F334 rats. In a recent study by Maronpot et al. (2015) where Wistar Han 
rats were exposed AA starting at GD6 until 2 years of age (see Section 7.3.2.3), the authors observed 
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no mesothelioma in the tunica vaginalis (testis) and no significant increase in testicular Leydig cell 
tumours, which were interpreted as strain differences between Fischer 344 and Wistar Han male rats. 
Dourson et al. (2008) evaluated mode of action based formation of thyroid tumours in rats as reported 
by Johnson et al. (1986) and Friedman et al. (1995) including both mutagenic and thyroid growth 
stimulation based modes of action. Based on the weight of evidence they concluded that both modes 
of action may be relevant with the mutagenic mode of action determining the low dose response and 
growth stimulation dominating the response at higher doses.  
Shipp et al. (2006) suggested that enhanced dopamine signalling via AA would trigger down-
regulation of LH receptors). The local release of growth-stimulating factors into the testicular vicinity 
would thus enhance proliferation of the tunica vaginalis eventually resulting in TVM generation.  
In a review by Maronpot et al. (2009) on TVM, it was stated that both TVM and Leydig cell tumours 
are seen most frequently in F344 rats as opposed to other rat strains used in carcinogenicity bioassays. 
A large number of publications dealt with the potential protective effects reported for drugs, natural 
compounds and other chemicals towards biochemical and adverse effects of AA and GA. The 
protective effects observed are frequently interpreted as counteracting the modes of action of AA and 
GA (as described above) by antagonizing the electrophilic attack of target molecules/oxidative stress 
(Kurebayashi and Ohno, 2006; Mehri et al., 2012; Zhang et al., 2013) or by inhibiting CYP2E1 
(Taubert et al., 2006). Taken together, these studies confirm the current hypotheses on the modes of 
action of AA and GA. Table H1 (Appendix H) provides an overview of this type of studies, but does 
not claim for completeness.   
The CONTAM Panel noted a number of other studies on AA, that were either confirmative, performed 
at extremely high dose levels, or of unclear relevance, which are not described in detail (Begum 
Sheikh and Kedam, 2010; Céspedes-Camacho et al., 2010; Muthukumar et al., 2011; Zhang et al., 
2011; Yener and Dikmenli, 2011; Szewczyk et al., 2012; El-Alfy et al., 2013; Tarskikh et al., 2013; 
Yerlikaya et al., 2013). 
In summary, the CONTAM Panel noted that there is convincing evidence for an electrophilic 
interaction of AA with proteins resulting in a broad spectrum of cell damage in different tissues. 
Although a number of hypotheses have been presented on the detailed interaction with target 
structures, the underlying mechanisms resulting in adverse effects in certain tissues but not in others 
need further investigation. 
The metabolic conversion of AA into GA via CYP2E1 and subsequent binding of GA to DNA is 
thought to be the major initial event in AA-driven genotoxicity and carcinogenicity. Modifying factors 
such as tissue-specific biochemical/endocrine events could play a role in targeting certain tissues in 
AA-driven rodent carcinogenicity. However, these hypotheses need further elucidation and are 
currently ill-defined although a number have been proposed. In particular, it is unclear if those poorly 
defined modifying factors in rodents play a role in targeting the carcinogenicity of GA to certain 
organs in humans. The validity of rat-specific modes of action in endocrine-responsive tissues is 
questioned by the tumour target tissues for AA in lifetime mouse exposure (e.g. lung, Harderian 
grand). Furthermore, the concordance between tumour target tissues in AA- vs. GA-treated rats and 
mice is further evidence for a specific role of GA in the carcinogenic process in both rats and mice.   
7.3.6.5. Mode of action of thyroid toxicity 
In three experimental studies in rodents and one observational study in humans, the effects of oral AA 
on thyroid function were investigated.  
Female Fischer 344 rats were given AA at doses of 2 mg/kg b.w. per day and 15 mg/kg b.w. per day 
for 2 or 7 days by gavage. Twenty-four hours after the last dose, plasma thyroxine (T4), thyroid 
stimulating hormone (TSH), prolactin (PRL), and pituitary TSH and PRL were unchanged vs. 
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untreated animals. In the 7-day study, there was a slight dose-dependent increase in plasma T4 and a 
slight dose-dependent decrease in plasma TSH. In the thyroid gland a significant decrease in the 
colloid area and a significant increase in the follicular cell height were noted (Khan et al., 1999).  
Bowyer et al. (2008) treated male Fischer 344 rats over 14 days with doses of 2.5, 10 and 50 mg/kg 
b.w. per day. There were no significant changes in mRNA levels in hypothalamus or pituitary for 
thyrotropin-releasing hormone (TRH), TSH, thyroid hormone receptor alpha and beta, as well 10 other 
hormones or releasing factors, mRNA levels in thyroid for thyroglobulin, thyroid peroxidase, sodium 
iodide symporter, or type I deiodinases, serum TSH or triiodothyronine (T3) levels (T4 was decreased 
at high dose only), dopamine, serotonine and metabolites levels in the hypothalamus and pituitary or 
in cell proliferation (Mki67 mRNA and Ki-67 protein levels) in thyroid or pituitary. 
Hamdy et al. (2012) treated adult male Sprague-Dawley rats orally with AA with doses of 5, 10 or 
15 mg/kg b.w. per day for 8 weeks. The results indicated that T3 and T4 and corticosterone levels 
were lower in rats treated with AA than that in control rats. The authors concluded that this study 
provides evidence of endocrine disturbance to the thyroid and adrenal glands, which are also the 
organs in which AA has been shown to cause tumours in experimental animals. 
Furthermore, associations between urinary levels of AAMA and serum thyroid levels were 
investigated in one study in humans (Lin et al., 2015). In a cross-sectional study of 793 Taiwanese 
adolescents and young adults (62.5 % females; age range from 12 to 30 years old) a one unit change in 
natural log AAMA levels was statistically significantly associated with a decrease in serum free T4 
concentrations (β = − 0.041, p for trend 0.001). There were no statistically significant associations 
between AAMA levels and other thyroid concentrations (total T4, total T3, free T3, TSH and thyroid 
binding globulin). 
In summary, inconsistent changes in thyroid hormones were reported by some authors to occur in 
rodents at doses above 10 mg/kg b.w. One publication in humans based on a cross-sectional design did 
not permit causal inference.  
7.3.6.6. Mode of action of reproductive toxicity 
Hashimoto et al. (1981) reported that AA produced testicular atrophy in mice with degeneration of the 
epithelial cells of the seminiferous tubules, the interstitial cells being normal.  
In a study by Sakamoto et al. (1988) male mice received 100 or 150 mg AA/kg b.w. One day after 
treatment, degeneration of round spermatids, especially in the Golgi phase (stage I–III), was found by 
histological examination of the testis. 
A number of studies suggested that DNA damage may be involved in the adverse effects of AA on 
spermatogenesis in mice. Sega et al. (1990) found that 7.8 and 125 mg AA/kg b.w. applied to male 
mice resulted in DNA binding and increased UDS in testis or early spermatocytes, respectively. 
Increased incidence of micronuclei was found in early spermatids in male rats treated with a single 
dose of 100 or a fractionated dosing of 4 × 50 mg AA/kg b.w. (Xiao and Tates, 1994). AA treatment 
of male mice with single acute doses of 75 or 125 mg/kg b.w. or with five daily injections of 50 mg/kg 
b.w. resulted in significant increases of structural chromosomal aberrations in late 
spermatids/spermatozoa (Pacchierotti et al., 1994).  
In Fischer rats, AA had been reported to lead to a depression of serum testosterone and prolactin 
(Uphouse et al., 1982; Ali et al., 1983).  
In AA-treated male Sprague-Dawley rats (0, 5, 15, 30, 45 and 60 mg/kg b.w. per day for 5 consecutive 
days by oral gavage), 5 mg/kg b.w. reduced the sperm concentration in the Cauda epididymis and led 
to sperm degeneration, 30 mg/kg b.w. led to a decrease in serum testosterone and to a reduction of 
Leydig cell viability (Yang et al., 2005). 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 165 
Wang et al. (2010b) treated male Sprague-Dawley rats of 21 days of age with 0, 5 and 10 mg/kg b.w. 
per day for 8 consecutive weeks. Relative weights of testes and epididymides compared to body 
weight were not significantly different. The epididymal sperm reserves decreased significantly. In 
addition, histopathologic lesions were also present in the testes of treated rats. Furthermore, distinct 
changes in expression patterns of testicular soluble guanylate caclase (sGC) heterodimers were 
observed in AA-treated rats. 
Ma et al. (2011) investigated the reproductive toxicity of AA in 3-week-old weaning male Sprague-
Dawley rats treated with 0, 5, 15 or 30 mg/kg b.w. per day. Levels of follicle-stimulating hormone and 
testosterone in serum increased while luteinizing hormone in serum decreased. Histopathological 
lesions and abnormal sperms were found in weaning rats after AA treatment, effects on 
spermatozoidal motility and sperm survival rate being significant at all AA doses tested.  
In a study by Takahashi et al. (2011), 3- and 7-week-old male SD rats were given AA at 0, 50, 100 or 
200 mg/kg in the drinking water for 4 weeks. In the testis, marked degeneration and exfoliation, 
mainly of spermatids, were observed at > 100 mg/kg limited to young animals. The Comet assay 
revealed AA to significantly induce DNA damage at > 100 mg/kg in both life stages, while 
micronuclei were found only in young rats at > 100 mg/kg. The authors suggested that young animals 
around puberty were more susceptible than adult animals, possibly due to their lower level of testicular 
GST activity than that in adult animals. 
Camacho et al. (2012) evaluated the effects of a 14-day exposure to AA administered through the 
drinking water on reproductive tissues and the hypothalamic-pituitary-testes (HPG) axis in male F344 
rats. The doses were approximately 2.5, 10 and 50 mg/kg b.w. per day. Serum levels of testosterone 
were significantly decreased by 10 and 50 mg/kg b.w. per day. Serum levels of LH and the % area of 
LH-staining in the pituitary were significantly elevated by 10 and 50 mg/kg b.w. per day. Serum FSH 
was decreased at the highest dose, while serum levels of progesterone and estradiol were unchanged. 
Histopathological inspection revealed several types of testicular lesions at the highest dose, while 
spermatid retention was observed at all AA doses investigated including the lowest dose of 2.5 mg/kg 
b.w. per day. Exposure to 50 mg/kg b.w. per day significantly decreased the DNA labelling index 
(proliferation) of mesothelial cells of testis, epididymis, and along the combined length of the serosal 
surfaces. The authors concluded that the absence of evidence for increased proliferation of the peri-
testicular mesothelium (Ki-67 immunoreactivity) does not support hormonal dysregulation as a 
contributing factor to the predisposition of this tissue to the carcinogenic effects of AA. 
As described above, Hamdy et al. (2012) treated adult male Sprague-Dawley rats orally with AA with 
doses of 5, 10 or 15 mg/kg b.w. per day for 8 weeks. The results indicated that the plasma carcino-
embryonic antigen (CEA) and malondialdehyde (MDA) levels were higher, but free and total 
testosterone levels were lower in rats treated with AA than that in control rats. The authors concluded 
that this study provides evidence of endocrine disturbance to the testis, organ in which AA has been 
shown to cause tumours in experimental animals. 
Wang et al. (2010b) treated male Sprague-Dawley rats of 21 days of age with 0, 5 and 10 mg/kg b.w. 
per day for 8 consecutive weeks. Relative weights of testes and epididymides compared to body 
weight were not significantly different. The epididymal sperm reserves decreased significantly. In 
addition, histopathologic lesions were also present in the testes of treated rats. Furthermore, distinct 
changes in expression patterns of testicular soluble guanylate caclase (sGC) heterodimers were 
observed in AA-treated rats. 
Friedman et al. (2008) suggested that inhibition of nuclear kinesin is responsible for AA-induced 
clastogenicity and aneuploidy in isolated rat testicular cells. Two kinesin motors, KIFC5A and KRP2, 
which are responsible for spindle assembly and disassembly of kinetochore microtubules, were 
inhibited by AA.  
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In germ cell studies, analysis of DNA, total sperm head and sperm protamine alkylation suggest 
AA/GA binding to cysteine sulfhydryl groups in sperm protamine. In mid- to late-spermatid stages, 
chromosomal histones are replaced by protamines that are relatively rich in arginine and cysteine. 
Alkylation of free sulfhydryl groups of cysteine in the ‘immature’ protamine of late spermatids and 
early spermatozoa may perturb normal chromatin condensation (Shipp et al., 2006). 
Taking together the findings in rodents, AA acts as an agent which affects a variety of endocrine and 
reproductive functions, most notably of male reproduction. In the range of 1–10 mg AA/kg b.w. per 
day and above, sperm functionality was perturbed and sperm reservoirs in the Cauda epidymidis 
decreased. At the same dose levels, genotoxicity of AA was seen in several types of testicular cells.  
Furthermore, interactions of AA with endocrine/paracrine functions such as Leydig cell toxicity and 
changes in serum hormones such as testosterone and prolactin were reported by some authors to occur 
in rodents. These effects were not found by others.  
One study found enhanced DNA damage in the Comet assay in early male germ cells at a much lower 
dose level, i.e. at 1.1 µg/kg b.w. per day in male mice. 
In summary, AA has been shown to cause adverse effects on the male fertility in rodents, which may 
occur probably by both damage of proteins by interaction with AA and by damage of nucleic acids 
(and proteins) by the metabolite GA. Further effects related to systemic or paracrine changes in 
testosterone, prolactin or growth factor production or release as a mechanism of action for 
carcinogenicity and/or endocrine toxicity were not reported consistently in the literature. 
7.3.6.7. Mode of action of accompanying effects 
Clement et al. (2007) treated human MCF-7 tumour cells with GA and analyzed changes in gene 
expression. According to the authors, the results show that 1 µM GA elicited cytoprotective reactions 
whereas transcriptional signatures associated with tumour progression were observed at 10 µM or 
higher. 
In isolated rat cardiomyocytes, AA treatment was reported to result in extended contraction period, 
enhanced fraction of abnormal beats, and enhanced levels of connexin 43 (Walters et al., 2014).  
In addition to the primary effects described in the previous sub-chapters, AA treatment leads, probably 
as secondary events, to a broad spectrum of changes in metabolism and gene expression in muscle 
(Seale et al., 2012) or in the liver (Mei et al., 2008b; Lee et al., 2012; Al-Azkawi et al., 2013) of 
rodents.   
Furthermore, AA-mediated electrophilic stress was suggested to result in the induction of hepatic 
glutathione S-transferases (Begum Sheikh and Kedam, 2010; Ehlers et al., 2013). COX-2, AP-1 and 
NF kappa B (Lim et al., 2011) and casein kinase 2 (Lee et al., 2010) are among the genes/proteins 
reported to be activated by AA in certain cell types. Gene expression changes in non-tumourigenic 
mammary cells such as changes in inducible NO synthetase and COX-2 were suggested to contribute 
to AA carcinogenicity (Lyn-Cook et al., 2011).  
Allam et al. (2010) studied the effect of prenatal and perinatal AA exposure on the biochemical and 
morphological changes in the liver of developing albino rats (see Section 7.3.5.2) and found marked 
changes in biochemical parameters of oxidative stress, and serum enzyme levels, levels of certain 
lipids, inorganic ions and proteins in serum. At a very high single dose of 50 mg/kg b.w., Ozturan 
Özer et al. (2014) observed markers for oxidative stress in rat kidney and liver. 
Soluble guanylate cyclase (sGC) belongs to the NO-regulated enzymes, playing an important role in 
spermatogenesis, sperm motility, tight junctions in neuronal blood-brain barrier, etc. Wang et al. 
(2010b) reported that distinct changes in expression patterns of testicular sGC heterodimers were 
observed in AA-treated rats.  
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Immunotoxicity of AA was investigated in 6–8-weeks old female mice (Fang et al., 2014) treated over 
30 days. At the lowest daily dose (4 mg/kg b.w.) changes in phenotype distribution of peripheral 
lymphocytes (decrease in T cells) were found, while the highest dose (36 mg/kg b.w.) resulted in a 
large number of changes in immune parameters.  
In female rats, AA caused a number of changes in haematological parameters such as haemoglobin, 
red blood cell count, packed cell volume, mean corpuscular volume, mean corpuscular haemoglobin 
concentration and total white blood cells (Hammad et al., 2014). 
Kim et al. (2015b) treated a murine macrophage cell line with 0.5 mM AA and observed indicators for 
cellular senescence related to oxidative stress and adaptive cell signalling. 
7.3.6.8. Conclusions 
AA is an electrophilic molecule, which can undergo Michael addition-type reactions with nucleophilic 
target molecules. In particular, activated thiolate moieties in cysteine residues of enzymes and other 
functional proteins, e.g. in neuronal cells or spermatocytes, have been described as targets. The 
neurotoxic properties of AA are considered to originate mainly from this type of reactivity. 
AA shows some reactivity towards nucleic acids, whereas reports on the formation of DNA adducts in 
vivo suggest that GA is mainly if not exclusively responsible for the formation of DNA adducts in 
AA-treated animals.  
Evidence from the available studies in the literature on hormonal and endocrine effects of AA is 
equivocal. This is particularly true for changes in hormone levels in AA-treated animals which were 
reported in some studies. Mechanistic hypotheses on local endocrine effects of AA which may explain 
tumour formation in certain hormone- or paracrine-regulated target tissues lack experimental proof. 
7.4. Observations in humans 
7.4.1. Epidemiological studies: cancer 
The association between AA exposure and human cancer risk has been studied first in occupational 
studies. A few retrospective cohort studies have published several papers on the risk of cancer in 
workers who had been exposed occupationally to AA. Following the discovery in 2002 that AA is 
present in many foods, there was a great need for epidemiological data. Since then, the association of 
dietary AA intake and cancer risk has been studied in several case-control and prospective cohort 
studies. Different methods have been used to measure exposure and to adjust for confounding by, e.g. 
smoking. In these paragraphs the epidemiological evidence is summarized and discussed. 
7.4.1.1. Occupational studies and cancer 
The association of occupational exposure to AA has been reported in five publications from two 
retrospective cohort studies. The first cohort included 371 workers exposed to AA in a US factory 
(Sobel et al., 1986). This cohort has been updated in a publication with additionally exposed workers 
and follow-up was extended with 19 years (Swaen et al., 2007). The second cohort included more than 
8 800 workers from three AA factories in the US and one in the Netherlands and results have been 
published in three articles with different follow-up periods (Collins et al., 1989; Marsh et al., 1999, 
2007). 
The first cohort study (Swaen et al., 2007) included 696 workers (41 women and 655 men) who had 
worked in an AA facility between 1955 and 1997 and were followed-up until 2001. Exposure 
information was available as personal air samples. Workers employed in operations were estimated to 
have been exposed to 0.25 mg/m
3
 before 1970 and to 0.05 mg/m
3
 after 1970, and workers employed in 
administration or maintenance were estimated to have been exposed to 0.125 mg/m
3
 before 1970 and 
to 0.02 mg/m
3
 after 1970. Mean duration of employment in an AA job was 42 months and the mean 
estimated cumulative exposure score was 4.6 mg/m
3
 months per worker.  
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There were 43 deaths from cancer in the cohort compared to 45.4 expected (Standardised Mortality 
Ratio, SMR 0.95; 95 % Confidence Intervals, 95 % CI 0.69–1.28). SMRs were not statistically 
significant increased or decreased for most subtypes of cancer, although SMRs were increased for 
rectal cancer (SMR 2.43; 2 observed deaths and 0.8 expected deaths), pancreatic cancer (SMR 2.22; 
5 observed and 2.3 expected deaths), and kidney cancer (SMR 2.45; 3 observed and 1.2 expected 
deaths). For all deaths because of a malignancy, the SMR was higher in workers with a low 
cumulative exposure (< 1 mg/m
3
: SMR, 1.05; 95 % CI 0.64–1.61) than in workers with a high 
exposure (> 1 mg/m
3
: SMR, 0.88; 95 % CI 0.56–1.32). In both rectal and pancreatic cancer, SMRs 
were also higher in workers with a low than in workers with a high cumulative exposure. Only for 
kidney cancer the SMR for kidney cancer was higher in the high-exposure group.  
The second cohort (Marsh et al., 2007) included workers from three US plants and one Dutch plant. 
The most recent update of this study describes the mortality follow-up of 8 852 male workers who had 
worked between 1925 and 1973 in one of the four plants. Follow-up was updated until 2002 (US 
plants) or 2004 (Dutch plant). AA exposure was estimated using the job history of every worker and 
job- and time-specific exposure estimates. Workers were considered exposed to AA if their cumulative 
exposure score was larger than 0.001 mg/m
3
-years.  
In the follow-up until 1994 in that cohort (Marsh et al., 1999) a statistically significant increased risk 
of pancreatic cancer was observed for high cumulative AA exposure (SMR 2.26; 95 % CI 1.03–4.29). 
In workers from the Dutch plant of the cohort (follow-up until 2004; Marsh et al., 2007), 21 cancer 
deaths were observed as compared to 44.3 expected deaths (SMR 0.47, 95 % CI 0.29–0.73). The SMR 
for lung cancer was 0.54 (95 % CI 0.25–1.02), while there were no deaths from pancreatic and kidney 
cancer versus 1.9 and 1.3 deaths expected, respectively. Among workers in the US plants exposed to 
AA (Marsh et al., 2007), the SMRs (follow-up until 2002) were 0.99 (95 % CI 0.86–1.12) for all 
malignant neoplasms, 1.41 (95 % CI 0.81–2.29) for pancreatic cancer, 1.14 (95 % CI 0.92–1.40) for 
lung cancer, and 1.27 (95 % CI 0.55–2.50) for kidney cancer. There was no consistent evidence for 
these cancers of a dose-response relationship. 
Both cohort studies compared the observed number of cases in the cohort with expected numbers 
based on national (or regional) mortality rates. This could have caused bias in both directions. 
Workers could have had better diagnoses thus increasing their cancer risk (Swaen et al., 2007). But it 
is also possible that the workers are healthier than the general population and experience lower cancer 
mortality rates (known as the ‘healthy-worker effect’). 
Siemiatycki et al. (2004) reviewed the evidence regarding AA as occupational carcinogen. Based on 
the IARC classification of AA and the available evidence the authors concluded that the strength of 
evidence for AA and pancreatic cancer was suggestive. The CONTAM Panel noted, however, that the 
authors were not able to include the evidence of the extended follow-up of the two cohorts that were 
published in 2007 (Marsh et al., 2007; Swaen et al., 2007).  
In conclusion, two epidemiological studies of occupational exposure to AA do not indicate an 
increased risk of cancer. There were indications of an increased risk of pancreatic cancer in both 
cohorts, although in one cohort the risk attenuated and was not statistically significant after longer 
follow-up (Marsh et al., 2007). In the Dutch subpopulation of this study, no pancreatic cancer cases 
were observed (Marsh et al., 2007). In the other cohort, the increased risk was not statistically 
significant and the excess risk was highest in workers with a low cumulative exposure to AA which is 
not in accordance with a dose-response relationship (Swaen et al., 2007). 
7.4.1.2. Dietary studies and cancer 
The following section includes a summary of epidemiological studies which analyzed the association 
between AA exposure through diet and the incidence or mortality from cancer. The section first 
provides a general description of the studies, including in particular the cancer sites considered and the 
instrument used to evaluate AA exposure (food frequency questionnaires, FFQs, national and 
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international databases of AA content in foods, ad hoc analyses of AA food content, or measures of 
Hb adducts), and the validity/reproducibility of information on dietary AA, if any. Such information is 
also summarized in Table J1 (Appendix J). Subsequently, the major results on AA exposure through 
diet and cancer risk are described (and also summarized in Appendix J,  Tables J2 to J6) by cancer 
sites, i.e. cancers of reproductive organs (breast, endometrial, ovarian, Table J2), cancers of the gastro-
intestinal tract (oesophageal, stomach, colorectal, pancreatic, Table J3), cancers of the urinary tract 
(prostate, renal cell, Table J4), cancers of the respiratory tract (oral and pharyngeal, laryngeal, lung, 
Table J5), and other cancers (brain, thyroid, lymphatic, Table J6). Moreover, a paragraph summarizes 
the results and conclusions of a meta-analysis and various reviews of epidemiological studies on 
dietary AA and cancer risk. 
A final conclusive section summarises the overall evidence of the role of dietary AA on cancer 
incidence and mortality and briefly discusses the strengths, limitations and drawbacks of the 
epidemiological studies considered.  
7.4.1.2.1. Studies of dietary exposure to AA 
At least 36 publications, based on 16 original studies, considered cancer risk in relation to AA 
exposure through diet (Table J1). Eleven of those studies had a cohort design, four case-control 
design, and one was a nested case-control study within a cohort. Six studies were conducted in 
Sweden, six in other European countries and four in the US.   
The first study was published in 2003 (Mucci et al., 2003a) and updated during the same year (Mucci 
et al., 2003b) adding further data on coffee. This was a population-based case-control study from 
Sweden, including 591 colorectal, 263 bladder, and 133 kidney cancer cases, and 538 healthy controls. 
AA intake was calculated for each subject by multiplying data from a semi-quantitative FFQ by the 
AA level ranking of 12 foods, derived from the Swedish National Food Agency (SNFA). Mean AA 
intake was 27.5 µg per day (i.e. 0.39 µg/kg b.w. per day) among controls.  
The second study (Mucci et al., 2004) was a Swedish population-based case-control study of renal cell 
cancer, including 379 cases and 353 controls. AA intake was estimated from information on 
11 AA-rich food items included in the FFQ, and the corresponding AA content obtained from the 
SNFA and the US Food and Drug Administration (US-FDA). Mean AA intake was 27.6 µg per day 
(i.e. 0.39 µg/kg b.w. per day) among controls. 
The Women’s Lifestyle and Health Cohort (Mucci et al., 2005) examined the association between AA 
intake and breast cancer in 43 404 Swedish women followed-up between 1991 and 2002 for a total of 
490 000 person-years and including 667 incident breast cancer cases. The study used a semi-
quantitative FFQ, including information on about 10 AA-rich foods and derived AA food contents 
from the SNFA (2002). Mean AA intake in the study population was 25.9 µg per day (i.e. 0.37 µg/kg 
b.w. per day). 
Another Swedish prospective study, the Swedish Mammography Cohort (SMC) (Mucci et al., 2006; 
Larsson et al., 2009a,b,c), included about 61 500 women enrolled in a screening program between 
1987 and 1990, that were followed for cancer outcome up to the end of 2007 (except for colorectal 
cancer, that ended in 2003). Cancer incidence was obtained through linkage of the cohort to Swedish 
Cancer registries, and four sites were investigated in relation to AA intake: colorectum (741 cases), 
breast (2 952 cases), endometrium (687 cases), and ovary (368 cases). Two FFQs were used to collect 
dietary information, a 67-item FFQ at baseline and a 96-item FFQ in a second interview in 1997. 
Dietary AA was estimated by combining data of 21 of food items (15 for colorectal cancer) to their 
AA content, obtained from a Swedish study (Bergström et al., 1991) and from the SNFA (2002). 
Cumulative average AA intake was considered in order to account for dietary changes during follow-
up and to better represent long-term dietary intake. Mean intake of AA was 24.6 ± 7.6 µg per day (i.e. 
0.38 ± 0.17 µg/kg b.w. per day). The validity of the baseline FFQ was assessed on 129 women 
randomly chosen in the cohort, by comparing information collected through the FFQ with that 
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collected through four 1-week dietary records. The correlation coefficients were 0.6 for coffee, 0.5 for 
whole grain bread, and 0.6 and breakfast cereals/muesli. 
A multicentric network of hospital-based case-control studies conducted in Southern Europe between 
1991 and 2002 considered dietary AA and cancer risk. These data are published in three papers: the 
first one (Pelucchi et al., 2006) referred to cancer of the oral cavity and pharynx (749 cases), 
oesophagus (395 cases), colorectum (2 280 cases), larynx (527 cases), breast (2 900 cases), ovary 
(1 031 cases), and prostate (1 294 cases). The second one to renal cell cancer (767 cases) (Pelucchi et 
al., 2007) and the third one (Pelucchi et al., 2011a) to pancreatic cancer (326 cases). In all studies, 
dietary information was based on a 78-item FFQ. Dietary AA intake was obtained linking information 
on nine food items included in the FFQ, and data on AA content of foods obtained from the WHO and 
the Swiss Federal Office of Public Health (SFOPH). The average AA intake among different control 
groups ranged between 23.3 and 37 µg per day (i.e. between 0.33 and 0.48 µg/kg b.w. per day). 
Reproducibility of dietary information was evaluated by comparing the FFQ administered twice at an 
interval of 3-10 months to 452 volunteers. The correlation coefficients were between 0.52 and 0.75 for 
main AA-containing foods. 
The Netherlands Cohort Study (NLCS) considered the relation between dietary AA and several 
neoplasms using a case-cohort approach (Hogervorst et al., 2007, 2008a,b, 2009a,b; Schouten et al., 
2009; Pedersen et al., 2010; Bongers et al., 2012; Hogervorst et al., 2014). This prospective study 
included 58 279 men and 62 573 women aged 55–69 years at baseline, followed between 1986 and 
1997-2002. The following cancer sites were examined: oral cavity (101 with data allowing analyses on 
AA intake), oro-pharynx (83), oesophagus (216 cases), stomach (563 cases), colorectum (2 190 cases), 
pancreas (349 cases), larynx (180), lung (1 895 cases), breast (2 225 cases), endometrium (221 cases), 
ovary (195 cases), prostate (2 246 cases), bladder (1 210 cases), renal cell (339 cases), brain 
(216 cases), thyroid (66 cases), and lymphatic malignancies (1 233 cases). The NLCS included a FFQ 
with 150 food items, 16 of which were reported to contain AA. To estimate AA intake, data were 
taken from the Dutch Food and Consumer Product Safety Authority and from ad hoc analyses 
conducted by this authority for the NLCS to estimate the AA exposure. Mean AA intake in the overall 
population was 21.8 ± 12.0 µg per day, i.e. 0.30 ± 0.18 µg/kg b.w. per day (22.6 ± 12.2 µg per day in 
men and 21.0 ± 11.9 µg per day in women, i.e. 0.29 ± 0.16 and 0.32 ± 0.19 µg/kg b.w. per day, 
respectively). Validity of the dietary information was assessed on 109 random subjects of the cohort 
comparing information from a FFQ completed 2 years after the baseline one with reference 
information collected through dietary record kept over three 3-days periods, 4–5 months apart 
(Goldbohm et al., 1994). The correlation was 0.74 for potatoes, 0.80 for bread, 0.65 for cakes and 
cookie. Similarly, correlations were between 0.70 and 0.75 for carbohydrates, fibre, and energy intake. 
Reproducibility was estimated on 400 random subjects comparing the FFQ information at baseline and 
that collected in five repeated measurements (Goldbohm et al., 1995). Correlation coefficients were 
0.66–0.71 for carbohydrates and fibre. 
Within the Cohort of Swedish Men (Larsson et al., 2009d,e), AA intake was analysed in relation to 
colorectal and prostate cancer. The cohort included 45 306 men enrolled in 1997 and follow-up until 
the end of 2007, for a total of over 400 000 person-years. During this period, 676 incident colorectal 
cancer cases and 2 696 incident prostate cancer cases were identified through linkage to Swedish 
Cancer registries. AA intake was estimated using the same methods of the SMC study. Mean AA 
intake in the study population was 36.1 ± 9.6 µg per day (i.e. 0.52 ± 0.14 µg/kg b.w. per day). 
The Cancer of the Prostate in Sweden (CAPS) study (Wilson et al., 2009a), included 1 499 incident, 
prostate cancer cases and 1 130 male controls. The self-administered FFQ included 261 food items, 
18 of which were reported to contain AA. To estimate total AA intake of each subject, information 
collected from the FFQ was combined to data of the SNFA (2002). Mean intake of AA was 
44.5 ± 14.5 µg per day among controls (i.e. 0.56 ± 0.20 µg/kg b.w. per day).  
The Nurses’ Health Study II (NHS-II) was the first non-European study that considered the issue of 
AA and cancer risk (Wilson et al., 2009b). This prospective study included 90 628 premenopausal 
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women enrolled in 1991. Until 2005, it collected almost 950 000 person-years of follow-up, and 
recorded 1 179 cases of breast cancer. Subjects’ dietary habits were assessed through a 130-item FFQ 
completed every four years of investigation. For 42 food items, data on AA content were available 
from the US-FDA or the SNFA. Cumulative average AA intake was computed, to account for dietary 
changes during follow-up and to better represent long-term dietary intake. The mean of the middle 
quintile of AA intake was 20.2 µg per day (i.e. 0.32 µg/kg b.w. per day). FFQ information was 
compared with 28-day diet records from a subset of 173 women within the NHS (Salvini et al., 1989; 
Wilson et al., 2009b). The correlation between the two measures of AA intake was 0.60 for potato 
crisps, 0.73 for French fries, 0.78 for coffee, and 0.79 for breakfast cereals. 
Further information on the association between AA and female hormonal cancers were provided by 
the NHS (Wilson et al., 2010), a prospective study on 88 672 women enrolled in 1980. Between 1980 
and 2006, 6 301 cases of breast, 484 of endometrial and 416 of ovarian cancer were identified. Dietary 
habits were investigated using a 61-item FFQ, which was expanded to 116 items in 1984. AA food 
content was estimated as in the companion NHS II study (Wilson et al., 2009b). Median intake of AA 
was 16 µg per day (i.e. 0.24 µg/kg b.w. per day) 
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study in Finland (Hirvonen et al., 
2010), a cohort investigation including 27 111 male smokers recruited in 1985-1988, investigated AA 
in relation to various cancer sites. After an average 10.2 year of follow-up, 1 703 cases of lung cancer, 
799 of prostate, 365 of urothelial cancers, 316 of colorectal, 224 of stomach, 192 of pancreatic, 184 of 
renal cell and 175 of lymphomas were recorded. Diet was assessed using a self-administered modified 
diet-history method with 276 items. AA intake was estimated mainly using published Finnish data 
(Eerola et al., 2007) and by chemical analyses conducted particularly for the present study on the basis 
on 26 foods. In order to be eligible for the ATBC study, participants had to have smoked at least five 
cigarettes per day at study entry. Restriction to never- or former-smokers was therefore not possible 
and it is not possible to rule out the possibility of residual confounding by smoking. Median intake of 
AA was 36.7 µg per day (i.e. 0.52 µg/kg b.w. per day). Reproducibility of dietary information was 
tested by comparing information collected at interview and that provided in a second questionnaire 
filled at the end of the pilot study. Validity was tested comparing information collected at interview 
with that from 24 days food records (Pietinen et al., 1988; Hirvonen et al., 2010). The correlation 
coefficient of dietary AA was 0.73 for reproducibility and 0.43 for validity. 
The UK Women’s Cohort Study included 33 731 women enrolled in 1995–1998 followed-up to for a 
median of 11 years for breast cancer occurrence (1 084 cases) (Burley et al., 2010). A validated 
217-item FFQ, adopted in the UK arm of the EPIC study, was used to assess dietary information. 
Estimates of AA intake were computed on the basis of 24 foods using EU estimates of AA content of 
food (EC, 2006). Mean dietary AA was 15 µg per day (i.e. 0.23 µg/kg b.w. per day). To test for 
reproducibility of dietary information, the FFQ was repeated in a random subsample of 1 859 women 
5 years after the first questionnaire was filled in. The correlation coefficient for dietary AA was 0.61, 
with similar values across all dietary sources of AA. 
A Swedish population-based case-control study was conducted between 1995 and 1997 on 189 cases 
of oesophageal adenocarcinoma, 262 gastroesophageal junctional adenocarcinomas, and 167 cases of 
squamous cell oesophageal cancer, and 520 controls. Habitual diet 20 years before interview was 
assessed using a validated FFQ with 63 items (Lin et al., 2011). Dietary information in the distant past 
(chosen by the authors to reflect latency between exposure and cancer) has been shown to have a fairly 
good reliability, although lower than the reliability of the current diet (Wolk et al., 1997). AA intake 
was derived from nine foods on the basis of data from the SNFA (2002). Mean dietary AA was 
36.3 ± 14.3 µg per day among controls (i.e. 0.52 ± 0.20 µg/kg b.w. per day) (Lin et al., 2011). 
The Health Professionals’ Follow-up study (HPFS, Wilson et al., 2012) analyzed the association 
between AA and prostate cancer. This prospective cohort study included 47 869 US men interviewed 
for the first time in 1986 and followed-up to 2006 for a total of 5 025 prostate cancers (642 lethal). 
Dietary habits and AA intake was assessed as in the companion NHS and NHS II studies (Wilson et 
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al., 2009a). The median of the middle quintile of AA intake was 20.8 µg per day (i.e. 0.30 µg/kg b.w. 
per day). 
In the EPIC study, a large prospective study enrolling over 500 000 men and women from 
10 European countries between 1992 and 1998, the relation between AA intake and cancer risk was 
investigated on 341 oesophageal cancers, 865 adenocarcinomas of the exocrine pancreas, 
1 191 epithelial ovarian cancers, and 1 382 endometrial cancers identified after a mean follow-up of 
11 years (Obón-Santacana et al., 2013; Luján-Barroso et al., 2014; Obón-Santacana et al., 2014, 2015). 
In this study, food and alcohol consumption was assessed at cohort enrolment by country-specific 
validated FFQs. Information on AA levels was obtained from an EU database (JRC-IRMM), further 
integrated with additional sources. The main determinants of dietary AA intake in the EPIC cohort 
were eight foods. Mean dietary AA was 26.2 ± 14.8 µg per day (i.e. 0.38 ± 0.21 µg/kg b.w. per day) in 
the overall cohort, 31.9 ± 16.9 µg per day (i.e. 0.40 µg/kg b.w. per day) in men and 23.8 ± 13.1 µg per 
day (i.e. 0.37 µg/kg b.w. per day) in women. Comparing dietary estimates of AA from FFQ and a 
random sample of 510 subjects from 9 European countries with a 24-hour dietary recall interview, 
gave a correlation coefficient of 0.17, while comparison with AA adducts in Hb gave a correlation 
coefficient of 0.08 (Ferrari et al., 2013). Four epidemiological studies examined the relation between 
AA and cancer risk using biomarkers of AA exposure, the Danish Diet, Cancer and Health study 
(Olesen et al., 2008), the CAPS study (Wilson et al., 2009a), the NHS and NHS II prospective studies 
(Xie et al., 2013) and a Danish study which analysed survival from breast cancer (Olsen et al., 2012).   
The Danish Diet, Cancer and Health is a prospective study conducted in Denmark between 1993 and 
1997 (Olesen et al., 2008) on 24 697 post-menopausal women followed-up until the end of 2000. A 
nested case-control study was conducted on 374 breast cancer cases and 374 controls. Levels of AA 
and GA were estimated from Hb adducts: median concentrations were 47 pmol/g Hb for AA-Hb and 
26 pmol/g Hb for GA-Hb adducts in controls, with similar values in cases. In both cases and controls, 
smokers had 3-3.5-fold higher AA and GA adduct levels as compared with non-smokers. Within the 
same cohort (Olsen et al., 2012), the mortality of 420 breast cases was investigated in relation to 
AA-Hb and GA-Hb. In this population, median AA and GA-Hb adducts was 57 pmol/g Hb among 
non-smokers and 187 pmol/g Hb among smokers.  
The CAPS study (Wilson et al., 2009a) measured AA adducts to Hb in blood samples of a subsample 
of 170 cases and 161 controls. In this study, mean AA-Hb adduct levels were 53.7 pmol/g Hb among 
controls. GA-Hb adducts were not measured. After adjustment for selected covariates, including 
energy intake, the partial correlation between AA as estimated from FFQ and AA adducts to Hb was 
0.25.  
AA exposure was also evaluated using red blood cell AA and GA Hb adducts among women from the 
NHS and NHS II prospective studies (Xie et al., 2013). The association was then evaluated on 
263 ovarian cancer cases. In this study, median values of total adducts were 113.9 pmol/g Hb in 
controls; corresponding AA adducts and GA adducts were 62.2 and 51.1 pmol/g Hb. Among a sample 
of 296 non-smoking women, the correlation between AA as estimated from the FFQ in 1999 and the 
sum of AA and GA Hb-adducts was 0.34 (Wilson et al., 2009c; Xie et al., 2013). 
7.4.1.2.2. Cancers of reproductive organs (Appendix J, Table J2) 
Breast cancer  
At least nine studies provided information on dietary AA and breast cancer risk (Mucci et al., 2005; 
Pelucchi et al., 2006; Hogervorst et al., 2007; Olesen et al., 2008; Larsson et al., 2009a; Wilson et al., 
2009b, 2010; Burley et al., 2010; Pedersen et al., 2010). Moreover, one study (Olsen et al., 2012) 
analyzed survival from breast cancer in relation to pre-diagnostic AA-Hb and GA-Hb.  
The Swedish Women's Lifestyle and Health Cohort study (Mucci et al., 2005) reported a relative risk 
(RR) of breast cancer of 1.19 (95 % CI 0.91–1.55) for the highest (≥ 34 µg per day, i.e. ≥ 0.49 µg/kg 
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b.w. per day) versus lowest quintile ( 17 µg per day, i.e.  0.24 µg/kg b.w. per day) of AA intake, 
with no evidence of a dose-risk relationship.  
In a case-control study from Italy and Switzerland (Pelucchi et al., 2006), the RRs of breast cancer  
were 1.01 (95 % CI 0.85–1.20), 1.01 (95 % CI 0.85–1.20), 1.09 (95 % CI 0.92–1.31) and 1.06 (95 % 
CI 0.88–1.28) for increasingly higher quintiles (up to ≥ 34 µg per day, i.e. ≥ 0.49 µg/kg b.w. per day) 
of AA intakes as compared with the first quintile (< 11 µg per day, i.e. < 0.16 µg/kg b.w. per day), 
with no significant linear trend in risk.  
The NLCS did not find an association between dietary AA and breast cancer (Hogervorst et al., 2007). 
The RR was 0.93 (95 % CI 0.73–1.19) for the highest quintile of intake (~ 37 µg per day, i.e. 
~ 0.53 µg/kg b.w. per day) versus the lowest (~ 10 µg per day, i.e. ~ 0.14 µg/kg b.w. per day) and 
0.99 (95 % CI 0.92–1.06) for an increase in AA intake of 10 μg per day (i.e. ~ 0.14 µg/kg b.w. per 
day). In never-smokers, the RRs were only slightly higher (RR 1.10, 95 % CI 0.80–1.52 and 1.01, 
95 % CI 0.93–1.11, respectively).  
In the nested case-control study within the Danish Diet, Cancer and Health, which examined the 
relation between AA and cancer risk using biomarkers of AA exposure (Olesen et al., 2008), the RR of 
breast cancer for a 10-fold increase in concentration was 1.05 (95 % CI 0.66–1.69) for AA-Hb and 
0.88 (95 % CI 0.51–1.52) for GA-Hb. No association emerged for either adduct according to 
oestrogen receptor (ER) status of breast cases. After careful adjustment for smoking, including past 
smoking, amount and duration, the RRs increased to 1.9 (95 % CI 0.9–4.0) for a 10-fold increase in 
concentration of AA-Hb and to 1.3 (95% CI 0.6–2.8) for GA-Hb. The corresponding estimates for 
ER+ cases were 2.7 (95 % CI 1.1–6.6) and 1.5 (95 % CI 0.6–3.8), respectively. Inclusion of both types 
of adducts in the same models resulted in a decrease of the risk estimate for GA-Hb adducts, while 
that for AA-Hb adduct remained virtually unchanged.  
In a survival analysis among 420 women with breast cancer from the Danish Diet, Cancer and Health 
(Olsen et al., 2012), higher concentration of AA-Hb and GA-Hb were associated with a higher hazard 
ratio (HR)  of  breast  cancer  specific  mortality (HR 1.21, 95 % CI 0.98–1.50 and 1.63, 95 % CI 
1.06–2.51, respectively, for 25 pmol/g globin). Higher risks were observed in ER+ women. 
The SMC study (Larsson et al., 2009a) reported a multivariate RR for breast cancers of 0.91 (95 % CI 
0.80–1.02) for high (≥ 29 µg per day, i.e. ≥ 0.41 µg/kg b.w. per day) versus low (< 20 µg per day, i.e. 
< 0.29 µg/kg b.w. per day) long-term AA intake (p for trend 0.06). Similar RRs were found according 
to ER and progesterone receptor (PR) status and smoking habit.  
The US NHS II found no relation between dietary AA and breast cancer risk among premenopausal 
women (Wilson et al., 2009b), the multivariate RRs for the fifth (~ 38 µg per day, i.e. ~ 0.58 µg/kg 
b.w. per day) versus first (~ 11 µg per day, i.e. ~ 0.17 µg/kg b.w. per day) quintile of intake being 
0.92 (95 % CI 0.76–1.11) for all breast cancers. Corresponding RRs were 0.82 (95 % CI 0.64–1.05) 
for  never-smokers,  1.11 (95 % CI 0.85–1.46) f or ER+/PR+  breast  cancer,  and  0.90 (95 % CI 
0.57–1.43) for ER−/PR− breast cancer. No significant difference was found in strata of other 
covariates analyzed, including age, BMI and alcohol drinking.  
An update (Pedersen et al., 2010) of the NLCS cohort with the follow-up extended from 1997 
(Hogervorst et al., 2007) to December 1999 reported no association for overall breast cancer (RR for 
the highest (~ 37 µg per day, i.e. ~ 0.57 µg/kg b.w. per day) quintile as compared to the lowest 
(~ 10 µg per day, i.e. ~ 0.14 µg/kg b.w. per day) 0.92, 95 % CI 0.73–1.15). Similarly, no associations 
were found in ER or PR-negative cancers and in never-smoking women. However, non significant 
increased risks were found for ER+ (RR 1.31, for the highest versus the lowest quintile, p for trend 
0.26), PR+ (RR 1.47, p for trend 0.14) and ER+PR+ (RR 1.43, p for trend 0.16) cancers in never-
smoking women. 
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In the US NHS (Wilson et al., 2010), no association was found between AA and breast cancer overall 
(RR 0.95, 95 % CI 0.87–1.03, for the highest versus the lowest quintile of intake, i.e. for ~ 25 versus 
~ 9 µg per day, i.e. for ~ 0.36 versus ~ 0.13 µg/kg b.w. per day) or according to ER or PR status. 
Comparable results were observed in strata of smoking, menopausal status, and BMI. 
The UK Women’s Cohort Study (Burley et al., 2010) reported no overall association between AA 
intake and breast cancer (RR 1.16, 95 % CI 0.88–1.52 for ~ 32 versus ~ 6 µg per day, i.e. 
~ 0.46 versus ~ 0.09 µg/kg b.w. per day, and 1.08, 95 % CI 0.98–1.18, per 10 µg per day, i.e. 
~ 0.14 µg/kg b.w. per day).  The  risk  was  higher in pre-menopausal women (RR 1.18,  95 % CI  
1.05–1.34, p for trend 0.008), while no association was found in post-menopausal ones (RR 1.00). 
Similar RR findings were reported in never-smokers. 
Endometrial cancer  
The risk of endometrial cancer was examined in three cohort studies, the NLCS (Hogervorst et al., 
2007), the SMC (Larsson et al., 2009b), and the NHS (Wilson et al., 2010).  
In the NLCS study of postmenopausal women (Hogervorst et al., 2007), the multivariate RRs of 
endometrial cancer were  0.95 (95 % CI  0.59–1.54),  0.94  (95 % CI 0.56–1.56), 1.21  (95 %  CI 
0.74–1.98), and 1.29 (95 % CI 0.81–2.07) for increasingly higher quintiles (fifth quintile, ~ 37 µg per 
day, i.e. ~ 0.5 µg/kg b.w. per day) of AA intake as compared to the first one (~ 10 µg/day, i.e. 
~ 0.14 µg/b.w. per day). To eliminate the possibility of residual confounding by smoking, analyses 
were also carried out in never-smokers (150 cases). RRs were higher in never-smokers, the RRs being 
1.16 (95 % CI 0.63–2.15), 1.35 (95 % CI 0.73–2.51), 1.30 (95 % CI 0.69–2.46), and 1.99 (95 % CI 
1.12–3.52, p for trend = 0.03), for increasingly higher quintiles of AA intake as compared to the first 
one, and 1.12 (95 % CI 0.95–1.33) for an increase in AA intake of 10 μg per day, i.e. ~ 0.49 µg/kg 
b.w. per day.  
A Swedish cohort study (Larsson et al., 2009b) reported multivariate RRs for endometrial cancer of 
1.10 (95 % CI 0.89-1.36), 1.08 (95 % CI 0.88-1.34), and 0.96 (95 % CI 0.76-1.21) for increasingly 
higher quartiles of AA intake (last quartile ≥ 29 µg per day, i.e. ≥ 0.41 µg/kg b.w. per day) as 
compared to the first one (< 20 µg per day, i.e. < 0.29 µg/kg b.w. per day), with no meaningful 
differences across menopausal status. In a subanalysis using only 273 cases interviewed in 1997 (using 
a more extensive FFQ), corresponding the RRs were  1.08  (95 % CI  0.76–1.53),  1.20  (95 % CI 
0.85–1.69) and 1.12 (95 % CI 0.79–1.59) in all women, and 1.31 (95 % CI 0.85–2.04), 1.30 (95 % CI 
0.83–2.02) and 1.20 (95 % CI 0.76–1.90) in never-smokers.  
In the US NHS (Wilson et al., 2010), an increased risk of endometrial cancer was found for high AA 
intake (RR 1.41, 95 % CI 1.01–1.97 for ~ 25 µg per day versus ~ 9 µg per day, i.e. for ~ 0.36 versus 
~ 0.13 µg/kg b.w. per day, p for trend = 0.03). Comparable results were observed in strata of smoking 
and menopausal status, while a stronger increased risk was found in non overweight/obese women 
(RR 2.51, 95 % CI 1.32–4.77). 
The EPIC cohort (Obón-Santacana et al., 2014) reported no overall association between AA intake and 
endometrial cancer (RR 0.98, 95 % CI 0.78–1.25, for ≥ 32.1 µg per day, i.e. ≥ 0.46 µg/kg b.w. per day, 
versus < 14.5 µg per day, i.e. < 0.21 µg/kg b.w. per day, and 0.98, 95 % CI 0.92–1.05, for 10 µg per 
day, i.e. 0.14 µg/kg b.w. per day). Similarly, AA was not associated to type-I endometrial cancer. 
However, an excess risk of type-I endometrial cancer was found for AA intake among women who 
were both never smokers and non-users of oral contraceptives (RR 1.97, 95% CI 1.08–3.62 for 
≥ 32.1 µg per day, i.e. ≥ 0.46 µg/kg b.w. per day, versus < 14.5 µg per day, i.e. < 0.21 µg/kg b.w. per 
day). 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 175 
Ovarian cancer  
Data on ovarian cancer were available from the same cohort studies of endometrial cancer (Hogervorst 
et al., 2007; Larsson et al., 2009c; Wilson et al., 2010), the case-control study from Italy and 
Switzerland (Pelucchi et al., 2006), and the study on the NHS and the NHS II which measured AA and 
GA adducts (Xie et al., 2013).  
In the study from Italy and Switzerland (Pelucchi et al., 2006), the RRs of ovarian cancer were 
1.03 (95 % CI 0.79–1.34), 1.09 (95 % CI 0.83–1.44), 1.01 (95 % CI 0.76–1.34), and 0.97 (95 % CI 
0.73–1.31) for increasingly higher quintiles of AA intake (last quintile ≥ 32 µg per day, i.e. 
≥ 0.46 µg/kg b.w. per day) as compared with the lowest one (< 10 µg per day, i.e. < 0.14 µg/kg b.w. 
per day).  
The NLCS (Hogervorst et al., 2007) reported  RRs of  1.22 (95 %  CI 0.73–2.01), 1.12  (95 % CI 
0.65–1.92), 1.28 (95 % CI 0.77–2.13), and 1.78 (95 % CI 1.10–2.88) for increasing quintiles of intake 
(fifth quintile ~ 37 µg/day, i.e. ~ 0.53 µg/kg b.w. per day) as compared with the first one (~ 10 µg per 
day, i.e. ~ 0.14 µg/kg b.w. per day, p for trend 0.02). The RR was 1.11 (95 % CI 0.99–1.25) for an 
increment of 10 μg per day (i.e. 0.14 µg/kg b.w. per day) of dietary AA. Analyses in never-smokers 
were carried out to eliminate the possibility of residual confounding by smoking. As for endometrial 
cancer, the RR were somewhat higher in never-smokers, with RRs of 1.60 (95 % CI 0.85–3.02), 
1.64 (95 % CI 0.84–3.19), 1.86 (95 % CI 1.00–3.48), and 2.22 (95 % CI 1.20–4.08, p for trend = 0.01), 
and of 1.17 (95 % CI 1.01–1.36) increased risk for an increment of 10 μg/day of dietary AA.  
In the SMC study (Larsson et al., 2009c), no association emerged with ovarian cancer on the whole 
database (RRs 0.91, 95 % CI 0.68–1.21, 0.97, 95 % CI 0.73–1.29, and 0.86, 95 % CI 0.63–1.16, for 
increasing quartiles of long-term AA intake, up to ≥ 29 µg per day, i.e. ≥ 0.41 µg/kg b.w. per day, as 
compared to the lowest one, < 20 µg per day, i.e. < 0.29 µg/kg b.w. per day) nor in the subgroup that 
participated in the second interview in 1997 (corresponding RRs of 1.09, 1.03, and 1.17, respectively). 
In the latter subgroup, the RR for the highest versus the lowest quartile of intake was 0.97 (95 % CI 
0.49–1.93) in never-smokers.  
The US NHS (Wilson et al., 2010) found that the risk of ovarian cancer increased (though not 
significantly) for increasing AA intake (RR 1.25, 95 % CI 0.88–1.77 for the highest (~ 26 µg per day, 
i.e. ~ 0.42 µg/kg b.w. per day) versus the lowest (~ 9 µg per day, ~ 0.13 µg/kg b.w. per day) quintile 
of intake, p for trend 0.12), and a significantly for serous tumours (RR 1.58, 95 % CI 0.99–2.52, p for 
trend 0.04). Comparable results were observed in strata of smoking and menopausal status, while a 
significant increased risk was found in women of normal weight (RR 1.84, 95 % CI 1.14–2.97, p for 
trend 0.01). 
In the analysis of the NHS and NHS II cohorts (Xie et al., 2013) where AA exposure was measured 
using Hb-adducts, a non significant reduced risk was reported for the highest (> 134 pmol/g Hb) 
versus the lowest tertile (< 99 pmol/g Hb) of exposure of total adducts (RR 0.79, 95 % CI 0.50–1.24). 
Results were consistent when AA or GA adducts were considered separately. Moreover, similar 
results were reported in non-smokers and according to tumour histology subtypes. 
The EPIC cohort (Obón-Santacana et al., 2015) found no association between AA intake and epithelial 
ovarian cancer (RR 0.97, 95 % CI 0.76 1.23, for ≥ 32.4 µg per day, i.e. ≥ 0.46 µg/kg b.w. per day, 
versus < 14.6 µg per day, i.e. < 0.21 µg/kg b.w. per day, and 1.02, 95 % CI 0.96 1.09, for 10 µg per 
day, i.e. 0.14 µg/kg b.w. per day). No differences were observed between various ovarian cancer 
subtypes, and across strata of various covariates, including smoking status. 
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7.4.1.2.3. Cancers of the gastro-intestinal tract (Appendix J, Table J3) 
Oesophageal cancer 
The association between AA and oesophageal cancer was analyzed in two case-control studies 
(Pelucchi et al., 2006; Lin et al., 2011) and one cohort study (Hogervorst et al., 2008a). 
In the case-control study from Italy and Switzerland (Pelucchi et al., 2006), the RRs of oesophageal 
cancer for increasing quintiles of AA exposure (from < 13 to ≥ 40 µg per day, i.e. from 0.19 to 
≥ 0.57 µg/kg b.w. per day) were 1.16 (95 % CI 0.75–1.81), 1.20 (95 % CI 0.75–1.93), 0.74 (95 % CI 
0.44–1.24) and 1.10 (95 % CI 0.65–1.86), with non-significant trend in risk.  
The NLCS study (Hogervorst et al., 2008a) found no association between AA intake and oesophageal 
cancer,  the  RR  being 0.83  (95 % CI 0.54–1.30)  for  the  highest (~ 40–42 µg  per day, i.e.  ~ 0.57–
0.60 µg/kg b.w. per day) versus the lowest (~9-10 µg/day i.e. ~ 0.13–0.14 µg/b.w. per day) level of 
exposure. The RRs for an increase in AA intake of 10 μg/day, i.e. 0.14 µg/kg b.w. per day, were 0.96 
(95 % CI 0.85–1.09) for all oesophageal cancers, 1.00 (95 % CI 0.85–1.17) for oesophageal 
adenocarcinoma, and 0.95 (95 % CI 0.78–1.16) for oesophageal squamous cell carcinoma. The results 
were not meaningfully different in never-/ex-smokers. A significant effect modification by obesity 
was found, with RR of all oesophageal cancers in obese subjects of 1.55 (95 % CI 1.08–2.21) for an 
increment of 10 μg/day of AA, although the estimate was based on a small number of obese cases 
(n = 20). 
In a Swedish case-control study (Lin et al., 2011), a significant increased risk of oesophageal cancer 
was observed for the highest quartile of AA intake (≥ 44 µg per day, i.e. ≥ 0.63 µg/kg b.w. per day) as 
compared to the lowest (< 27 µg per day, i.e. < 0.39 µg/kg b.w. per day, RR 1.23, 95 % CI 1.02–1.75), 
although with no significant trend in risk. Comparable results were found for various tumour subtypes, 
i.e. oesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, oesophageal squamous 
cell carcinoma, and gastrooesophageal junction. Stronger associations were observed in overweight 
subjects (RR 1.88, 1.06–3.34 for all neoplasms) and in non-smokers (RR 1.46, 95 % CI 0.96–2.21 for 
all neoplasms) only. 
The EPIC cohort (Luján-Barroso et al., 2014) observed increased risks of oesophageal cancer for the 
middle quartiles of AA intake, but there was no evidence of a dose-response trend. Multivariable 
hazard ratios were 1.75 (95 % CI 1.12–2.74), 1.66 (95 % CI 1.05–2.61) and 1.41 (95 % CI 0.86–2.71) 
for increasingly higher quartile of intake (up to ≥ 34 µg per day or ≥ 0.49 µg/kg b.w. per day) vs the 
lowest one (< 15.7 µg per day or < 0.22 µg/kg b.w. per day). Estimates by histological subgroups 
(adenocarcinoma and squamous cell carcinoma) as well as in never-smokers/quitters since ≥ 20 years 
were comparable with the overall ones, although they were not statistically significant due to lower 
power. When energy-adjusted AA intake was used most risk estimates were attenuated. 
Stomach cancer 
Two studies investigated AA exposure in relation to gastric cancer (Hogervorst et al., 2008a; Hirvonen 
et al., 2010). 
The NLCS (Hogervorst et al., 2008a) found no relationship between dietary AA and stomach cancer 
(RR 1.06, 95 % CI 0.78–1.45 for the highest (~ 40–42 µg per day, i.e. ~ 0.57-0.60 µg/kg b.w. per day) 
versus the lowest (~ 9–10 µg per day, i.e. ~ 0.13–0.14 µg/kg b.w. per day) intake, 1.02, 95 % CI  
0.94–1.10, for an increase in intake of 10 μg per day). No significant association was also found for 
gastric cardia adenocarcinoma (RR 1.05, 95 % CI 0.91–1.20) and noncardia gastric cancer (RR 0.99, 
95 % CI 0.89–1.11) nor in never-/former-smokers (RR 1.09, 95 % CI 0.98–1.22).  
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No association was also found in the ATBC study on male smokers (Hirvonen et al., 2010), the RR for 
the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) as compared to the lowest (~ 22 µg per 
day, i.e. ~ 0.31 µg/kg b.w. per day) quintile of AA intake being 0.96 (95 % CI 0.60–1.53). 
Colorectal cancer 
Six studies investigated AA exposure in relation to colorectal cancer (Mucci et al., 2003a, 2006; 
Pelucchi et al., 2006; Hogervorst et al., 2008a; Larsson et al., 2009d; Hirvonen et al., 2010).  
A Swedish case-control study (Mucci et al., 2003a) found a decreased colorectal cancer risk (RR 0.6, 
95 % CI 0.4–1.0, for the highest versus the lowest quartile of ranked AA intake, p for trend 0.01).  
The SMC study (Mucci et al., 2006) reported a multivariate RR of 0.9 (95 % CI 0.7–1.3) for women in 
the highest (≥ 31 µg per day, i.e. ≥ 0.44 µg/kg b.w. per day) versus lowest (< 16 µg per day, i.e. 
< 0.23 µg/kg b.w. per day) quintile of AA intake. The corresponding RRs were 0.9 (95 % CI 0.6–1.4) 
for colon (504 cases) and 1.0 (95 % CI 0.6–1.8) for rectal (237 cases) cancer. Results were consistent 
across strata of age and BMI.  
In the case-control study from Italy and Switzerland (Pelucchi et al., 2006), no association was found 
between dietary AA and large bowel cancer (RRs for the highest, > 40 µg per day, i.e. > 0.87 µg/kg 
b.w. per day, versus the lowest, < 12 µg per day, i.e. < 0.17 µg/kg b.w. per day, quintile of intake 0.97, 
95 % CI 0.80–1.18, for colorectal; 0.98, 95 % CI 0.78–1.23, for colon; and 0.96, 95 % CI 0.73–1.26, 
for rectal cancer).  
In the NLCS study (Hogervorst et al., 2008a), the RR for the highest level of intake (~ 40–42 µg per 
day, i.e. ~ 0.57–0.60 µg/kg b.w. per day) versus the lowest one (~ 9–10 µg per day, ~0.13–0.14 µg/kg 
b.w. per day) was 1.00 (95 % CI 0.84–1.20). The RRs for an increment of 10 μg/day of AA were 
1.00 (95 % CI 0.96–1.06) for colorectal, 1.03 (95 % CI 0.98–1.09) for colon, and 0.97  (95 % CI  
0.89–1.05) for rectal cancers. In never-smokers, corresponding RRs were 1.03 (95 % CI 0.94–1.12), 
1.04 (95 % CI 0.94–1.14), and 1.02 (95 % CI 0.86–1.20). 
Within the NLCS, a case-cohort analysis was conducted on 733 colorectal cancer cases followed-up 
for 7.3 years for whom mutations in Kristen-ras (KRAS) and adenomatous polyposis coli (APC) genes 
were measured (Hogervorst et al., 2014). This analyses showed AA intake was associated with a 
significant increased colorectal cancer risk (HR for the fourth versus the first quartile of AA intake 
2.12, 95 % CI 1.16–3.87, p for trend 0.01) in men with an activating KRAS mutation, but not in those 
with an APC mutation (HR = 1.16, 95 % CI 0.67–2.02). On the other hand, AA intake was associated 
with a non significant reduced colorectal cancer risk (HR for the fourth versus the first quartile of AA 
intake 0.61, 95 % CI 0.30–1.20, p for trend 0.01) in women with an activating KRAS mutation, and 
with a significant reduced risk in those with an APC mutation (HR = 0.47, 95 % CI 0.23–0.94, p for 
trend 0.02). 
In the cohort of Swedish Men (Larsson et al., 2009d), the multivariate RRs for the highest (≥ 42 µg per 
day, i.e. ≥ 0.60 µg/kg b.w. per day) versus the lowest (< 30 µg per day, i.e. < 0.43 µg/kg b.w. per day) 
quartile of dietary AA were 0.95 (95 % CI 0.74–1.20) for colorectal, 0.97 (95 % CI 0.71–1.31) for 
colon, and 0.91 (95 % CI 0.62–1.32) for rectal cancer. The results were comparable in never-, past and 
current smokers.  
The ATBC  study  on  male smokers  (Hirvonen et al., 2010) reported  an  RR  of  0.93 (95 % CI  
0.65–1.34) for the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) as compared to the lowest 
(~ 22 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) quintile of AA intake for colorectal cancer. 
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Pancreatic cancer 
Four studies considered AA from diet in relation to pancreatic cancer risk (Hogervorst et al., 2008a; 
Hirvonen et al., 2010; Pelucchi et al., 2011a; Obón-Santacana et al., 2013). 
The NLCS database (Hogervorst et al., 2008a) found no overall association. For increasingly higher 
quintiles of AA intake (up to ~ 40–42 µg per day, i.e. 0.57–0.60 µg/kg b.w. per day) as compared to 
the first one (~ 9-10 µg per day, i.e. 0.57–0.60 µg/kg b.w. per day), the RRs of pancreatic cancer were 
1.02 (95 % CI 0.72–1.44), 0.96 (95 % CI 0.66–1.38), 0.87 (95 % CI 0.60–1.27) and 0.98 (95 % CI 
0.68–1.40). The RRs in never-/former-smokers  were  0.72 (95 % CI  0.43–1.20),  1.07 (95 % CI  
0.65–1.76), 0.73 (95 % CI 0.43–1.26) and 0.80 (95 % CI 0.48–1.32). There was significant effect 
modification by obesity, the RR being higher in obese subjects (RR 1.59, 95 % CI 0.87–1.59, for an 
increase of 10 μg/day, based on 14 cases).  
The ATBC study on male smokers (Hirvonen et al., 2010) found no meaningful association between 
AA intake and pancreatic cancer, with a RR of 1.00 (95 % CI 0.62–1.62) for the highest (~ 56 µg per 
day, i.e. ~ 0.80 µg/kg b.w. per day) as compared to the lowest (~ 22 µg per day, i.e. ~ 0.31 µg/kg b.w. 
per day) quintile of AA intake. 
In the Italian case-control study (Pelucchi et al., 2011a), the RRs for increasingly higher quintiles of 
AA intake as compared to the lowest one were 1.48 (95 % CI 0.88–2.50), 1.57 (95 % CI 0.91–2.69), 
1.70 (95 % CI 0.98–2.96), and 1.49 (95 % CI 0.83–2.70). 
The EPIC cohort (Obón-Santacana et al., 2013) found no association between AA intake and 
pancreatic cancer (RR 0.77, 95 % CI 0.58–1.04, for ≥ 37 µg per day, i.e. ≥ 0.53 µg/kg b.w. per day, 
versus < 14 µg per day, i.e. < 0.20 µg/kg b.w. per day, and 0.95, 95 % CI 0.89–1.01, for 10 µg per 
day, i.e. 0.14 µg/kg b.w. per day). Consistent results were found across strata of smoking. However, a 
significant inverse association was found in obese subjects (RR 0.73, 95 % CI 0.61–0.88) defined by 
BMI, but not by waist or hip circumference or their ratio. 
7.4.1.2.4. Cancers of the urinary tract (Appendix J, Table J4) 
Prostate cancer 
The relation between dietary AA and prostate cancer was examined in four cohorts (Hogervorst et al., 
2008b; Larsson et al., 2009e; Hirvonen et al., 2010; Wilson et al., 2012) and two case-control studies 
(Pelucchi et al., 2006; Wilson et al., 2009a). 
In the Italian case-control study (Pelucchi et al., 2006), no significant association between AA and 
prostate cancer was found, the RR for the highest (≥ 36 µg per day, i.e. ≥ 0.51 µg/kg b.w. per day) 
versus the lowest (< 12 µg per day, i.e. < 0.14 µg/kg b.w. per day) quintile of dietary AA being 
0.92 (95 % CI 0.69–1.23).  
Similarly, in the NLCS (Hogervorst et al., 2008b), the RRs were 1.06 (95 % CI 0.87–1.30) for the 
highest (~ 41 µg per day, i.e. ~ 0.59 µg/kg b.w. per day) versus lowest (~ 10 µg per day, i.e. 
~ 0.14 µg/kg b.w. per day) level of AA intake and 1.01 (95 % CI 0.96–1.07) for an increment of 
10 μg/day. Comparable results were reported in never-/former-smokers, while a non significant 
inverse association was reported for advanced cancer in never-smokers. 
In the Cohort of Swedish Men (Larsson et al., 2009e), the RR was 0.88 (95 % CI 0.70–1.09) for high 
(~ 43 µg per day, i.e. ~ 0.61 µg/kg b.w. per day) versus low (~ 28 µg per day, i.e. ~ 0.40 µg/kg b.w. 
per day) AA intake. No association was found according to smoking habit or progression status of 
prostate cancer. 
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In the CAPS study (Wilson et al., 2009a), the RRs of prostate cancer were 0.97 (95% CI 0.75–1.27) 
for the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) versus lowest (~ 32 µg per day, i.e. 
~ 0.46 µg/kg b.w. per day) quintile of dietary AA and 0.99 (95 % CI 0.94–1.05) for an increment of 
10 μg/day. In the same study, the RR for the upper quartile (≥ 56 pmol/g globin) of AA-Hb adduct as 
compared with the lowest one (< 33 pmol/g globin) was 0.93 (95 % CI 0.47–1.85), and the RR for a 
10-unit increment of AA-Hb was 1.00 (95 % CI 0.86–1.16). No significant associations were found by 
stage, grade or prostate-specific antigen (PSA) level.  
The ATBC study on male smokers (Hirvonen et al., 2010) reported no association, with an RR of 
1.05 (95 % CI 0.83–1.32) for the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) quintile of 
AA intake versus the lowest (~ 22 µg per day, i.e. ~ 0.31 µg/kg b.w. per day). 
The US HPFS (Wilson et al., 2012) gave a multivariate RR of prostate cancer for the highest (~ 35 µg 
per day, i.e. ~ 0.50 µg/kg b.w. per day) versus the lowest (~ 12 µg per day, i.e. ~ 0.17 µg/kg b.w. per 
day) quintile of AA intake of 1.02 (95 % 0.92–1.13). Comparable results were reported in non 
smokers and in men who had PSA tests. Moreover, no associations were found in lethal, advanced or 
localized cancers nor in high and low-grade cancers. 
Bladder cancer 
Three studies considered the association between AA exposure through diet and bladder cancer risk 
(Mucci et al., 2003a; Hogervorst et al., 2008b; Hirvonen et al., 2010). 
The Swedish case-control study (Mucci et al., 2003a) reported no association between AA intake and 
bladder cancer, with a RR of 0.8, 95 % CI 0.5–1.5, for the highest versus the lowest intake. Similar 
results were observed in nonsmokers (RR 0.7) and current smokers (RR 1.0).  
The NLCS study (Hogervorst et al., 2008b) showed no relation between AA intake and bladder cancer 
(RR 0.91, 95 % CI 0.73–1.15, for the highest, ~ 41 µg per day, i.e. ~ 0.59 µg/kg b.w. per day, versus 
the lowest intake, ~ 10 µg per day, i.e. ~ 0.14 µg/kg b.w. per day ) in the overall dataset, while found a 
significant inverse relation in never-smokers (RR 0.55, 95 % CI 0.33–0.93).  
In the ATBC study on male smokers (Hirvonen et al., 2010), no association was observed between AA 
intake and urothelial cancers, the RR being 1.99 (95 % CI 0.71–1.39) for the highest quintile of AA 
intake (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) versus the lowest (~ 22 µg per day, i.e. 
~ 0.31 µg/kg b.w. per day). 
Renal cell cancer 
Two cohort (Hogervorst et al., 2008b; Hirvonen et al., 2010) and three case-control (Mucci et al., 
2003a, 2004; Pelucchi et al., 2007) studies provided information on the relation of AA with kidney 
cancer.  
In the Swedish case-control study (Mucci et al., 2003a), the RRs for kidney cancer were 1.0 (95 % CI 
0.6–1.9), 1.1 (95 % CI 0.6–2.0), and 0.8 (95 % CI 0.4–1.7) for increasingly higher quartiles of AA 
intake. Considering coffee in the estimate of AA intake, the RRs of kidney cancer slightly decreased 
(Mucci et al., 2003b).  
Another Swedish case-control study (Mucci et al., 2004) reported a RR for kidney cancer of 1.1 (95 % 
CI 0.7–1.8) for the highest (> 32 µg per day, i.e. ≥ 0.49 µg/kg b.w. per day) versus the lowest (< 20 µg 
per day, i.e. < 0.29 µg/kg b.w. per day) quartile of intake, with no trend in risk. Results were not 
different across strata of smoking.  
The Italian case-control study (Pelucchi et al., 2007) reported RRs of 1.21 (95 % CI 0.94–1.57), 
1.14 (95 % CI 0.86–1.51), and 1.20 (95 % CI 0.88–1.63) for increasingly higher quartiles of dietary 
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AA (highest quartile > 44 µg per day, i.e. > 0.63 µg/kg b.w. per day) as compared with the lowest one 
(< 20 µg per day, i.e. < 0.29 µg/kg b.w. per day). The continuous RR for an increase of 18.1 μg per 
day, i.e. 0.26 µg/kg b.w. per day, (one standard deviation) of AA was 1.05 (95 % CI 0.94–1.16).  
Among the cohort studies, the NLCS study (Hogervorst et al., 2008b) showed an association between 
AA and kidney cancer, with RRs of 1.25 (95 % CI 0.86–1.83), 1.48 (95 % CI 1.02–2.15), 1.23 (95 % 
CI 0.83–1.81), and 1.59 (95 % CI 1.09–2.30) for increasingly higher quintiles of AA intake (highest 
quintile ~ 41 µg per day, i.e. ~ 0.59 µg/kg b.w. per day) as compared with the lowest one (~ 10 µg per 
day, ~ 0.14 µg/kg b.w. per day, for trend 0.04). The continuous RR for an increment of 10 μg/day of 
AA was 1.10 (95 % CI 1.01–1.21). Results were consistent in the two sexes and in never-smokers.  
In the ATBC study on male smokers (Hirvonen et al., 2010), the RRs of kidney cancer were 
1.25 (95 % CI 0.86–1.83), 1.65 (95 % CI 1.02–2.67), 1.47 (95 % CI 0.89–2.41) and 1.28 (95 % CI 
0.76–2.15) for increasingly higher quintiles (highest quintile ~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. 
per day), compared with the lowest (~ 22 µg per day, i.e. ~ 0.31 µg/kg b.w. per day) quintile of AA 
intake, with no significant trend in risk (p for trend 0.12). Moreover, because the ATBC study only 
included smokers, residual confounding by smoking cannot be ruled out completely. 
7.4.1.2.5. Cancers of the respiratory tract (Appendix J, Table J5) 
Oral and pharyngeal cancer 
The case-control study conducted in Italy and Switzerland found no association between dietary AA 
and cancer of the oral cavity/pharynx (Pelucchi et al., 2006), with multivariate RRs of 1.10 (95 % CI 
0.78–1.57), 1.27 (95 % CI 0.89–1.81), 1.04 (95 % CI 0.72–1.51) and 1.12 (95 % CI 0.76–1.66) for 
increasingly higher quintiles of AA intake (highest quintile ≥ 40 µg per day, i.e. ≥ 0.57 µg/kg b.w. per 
day) as compared with the lowest one (< 12 µg per day, i.e. < 0.17 µg/kg b.w. per day). 
In the NLCS study (Schouten et al., 2009), the RRs for the third tertile (~ 40–42 µg per day, i.e. 
~ 0.57–0.60 µg/kg b.w. per day) of AA intake as compared to the first one (~ 9–10 µg per day, i.e. 
~ 0.13–0.14 µg/kg b.w. per day) were 0.72 (95 % CI 0.36–1.42) for oral cavity, and 0.61 (95 % CI 
0.33–1.12) for oro-hypopharyngeal cancer. RRs for an increment of 10 µg per day (i.e. ~ 0.14 µg/kg 
b.w. per day) were 0.90 (95 % CI 0.73–1.10) and 0.74 (95 % CI 0.53–1.03) for the two neoplasms, 
respectively. A significant association was reported for oral cancer in non-smoking women (RR 1.28, 
95 % CI 1.01–1.62 per 10 µg per day), although the result was based on 21 cases only. 
Laryngeal cancer 
The same two studies considered the association between AA and laryngeal cancer risk (Pelucchi et 
al., 2006; Schouten et al., 2009). 
In the case-control study from Italy and Switzerland (Pelucchi et al., 2006), the RRs for laryngeal 
cancer were 1.04 (95 % CI 0.70–1.57), 0.85 (95 % CI 0.56–1.29), 0.89 (95 % CI 0.59–1.36), and 1.23 
(95 % CI 0.80–1.90) for increasingly higher quintiles of AA intake (highest quintile ≥ 38 µg per day, 
i.e. ≥ 0.54 µg/kg b.w. per day) as compared to the first one (< 13 µg per day, i.e. < 0.19 µg/kg b.w. per 
day). None of the estimates was significant, and no significant trend in risk was found.  
In the NLCS study (Schouten et al., 2009), no association was observed between AA and laryngeal 
cancer, the RR being 0.93 (95 % CI 0.54–1.58) for the highest (~ 37 µg per day, i.e. ~ 0.53 µg/kg b.w. 
per day) versus the lowest (~ 10 µg per day, i.e. ~ 0.14 µg/kg b.w. per day) quintile of AA and 1.05 
(95 % CI 0.91–1.21) for an increment of 10 µg per day. 
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Lung cancer 
The NLCS (Hogervorst et al., 2009a) and ATBC (Hirvonen et al., 2010) cohort studies considered AA 
in relation to lung cancer.  
In the NLCS study (Hogervorst et al., 2009a), no association was observed between AA intake and 
lung cancer in men (RR 1.03, 95 % CI 0.77–1.39, for the highest (~ 42 µg per day, i.e. ~ 0.60 µg/kg 
b.w. per day) versus the lowest (~ 10 µg per day, i.e. ~ 0.14 µg/kg b.w. per day) quintile of AA 
intake), while an inverse relation was observed in women (RR 0.45, 95 % CI 0.27–0.76, for ~ 40 µg 
per day, i.e. ~ 0.57 µg/kg b.w. per day, versus ~ 9 µg per day, i.e. ~ 0.13 µg/kg b.w. per day), p for 
trend 0.01), particularly for adenocarcinoma. RRs were somewhat higher in male never-smokers 
(RR 2.18, 95 % CI 0.61–7.82), but these results were based on a small number of subjects.  
In the ATBC cohort (Hirvonen et al., 2010), a significant RR for lung cancer of 1.18 (95 % 1.01–1.38) 
was reported for the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) quintile of AA intake as 
compared to the lowest (~ 22 µg per day, i.e. ~ 0.31 µg/b.w. per day), although in the absence of a 
significant trend in risk. However, because the ATBC study only included smokers, residual 
confounding by smoking cannot be ruled out completely. 
7.4.1.2.6. Other cancers (Appendix J, Table J6) 
Brain cancer 
Only the NLCS study (Hogervorst et al., 2009b) investigated the relation between AA intake and brain 
cancer. No evidence of an association was found (RR 0.87, 95 % CI 0.54–1.41, for ~ 40–42 µg per 
day, i.e. ~ 0.57–0.60 µg/kg b.w. per day, versus ~ 9–10 µg per day, i.e. ~ 0.13–0.14 µg/b.w. per day, 
of AA intake) both in the total dataset and in never-smokers. 
Thyroid cancer 
The association between AA intake and thyroid cancer was considered only in the NLCS study 
(Schouten et al., 2009),  which reported  RRs  of  1.14 (95 % CI  0.58–2.26)  and  1.33 (95 % CI  
0.70–2.53) for the second and third tertile (~ 40–42 µg per day, i.e. ~ 0.57–0.60 µg/kg b.w. per day) of 
intake, respectively versus the first (~ 9–10 µg per day, i.e., ~ 0.13–0.14 µg/kg b.w. per day). The RR 
was 1.03 (95 % CI 0.82–1.27) for a 10 µg/day increment of AA. No significant associations were 
found also in non-smokers.  
Lymphatic/myeloid malignancies 
Data on AA and lymphatic/myeloid neoplasms were provided by the ATBC (Hirvonen et al., 2010) 
and the NLCS (Bongers et al., 2012) cohort studies. 
In the ATBC study on male smokers (Hirvonen et al., 2010), no meaningful association was reported 
with lymphomas, the multivariate RR for the highest (~ 56 µg per day, i.e. ~ 0.80 µg/kg b.w. per day) 
quintile of AA intake versus the lowest (~ 22 µg per day, i.e. ~ 0.31 µg/kg b.w. per day) being 
1.10 (95 % CI 0.67–1.80). 
Similarly, in the NLCS study (Bongers et al., 2012) no significant associations were observed for most 
malignancies investigated, including among others multiple myeloma (RR for the highest as compared 
to the lowest quintile of AA intake 1.54, 95 % CI 0.92–2.58 in men and 0.93, 95 % CI 0.50–1.73 in 
women), diffuse large-cell lymphoma (RR  1.06,  95 % CI 0.61–1.38, in men and 1.38,  95 % CI  
0.63–3.02, in women), and chronic lymphocytic leukaemia (RR for an increment of 10 µg per day 
0.88, 95 % CI 0.74–1.09 in men and 0.83, 95 % CI 0.64–1.09 in women). For multiple myeloma a 
significant trend in risk was found for increasing levels of AA intake in men only. For all lymphatic 
malignancies considered, no significant associations were found in never-smokers.  
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7.4.1.2.6. Results from meta-analysis studies and reviews 
Pelucchi et al. (2015) conducted a systematic review and meta-analysis of 32 studies on dietary AA 
intake and cancer risk published up to July 2014. This publication is an update of a previous meta-
analysis from the same authors (Pelucchi et al., 2011b). In the current meta-analysis the authors were 
able to calculate summary RRs for high versus low AA intake for fourteen sites. The summary RRs 
were 0.87 for oral and pharyngeal (95 % CI 0.52–1.46; two studies), 1.14 for oesophageal (95 % CI 
0.93–1.38; four studies), 1.03 for stomach (95 % CI 0.79–1.33; two studies), 0.94 for colorectal 
(95 % CI 0.85–1.04; seven studies), 0.93 for pancreatic (95 % CI 0.76–1.12; four studies), 1.10 for 
laryngeal (95 % CI 0.79–1.54; two studies), 0.88 for lung (95 % CI 0.57–1.34; two studies), 0.96 for 
breast (95 % CI 0.91–1.02; seven studies), 1.06 for endometrial (95 % CI 0.92–1.23; four studies), 
1.12 for ovarian (95 % CI 0.85–1.47; four studies), 1.00 for prostate (95 % CI 0.93–1.08; six studies), 
0.93 for bladder cancer (95 % CI 0.78–1.11; three studies) and lymphoid malignancies (95 % CI, 
0.89–1.43; two studies). The authors noted that the RR for kidney cancer was of borderline 
significance (RR 1.20; 95 % CI 1.00–1.45). Among never-smokers, they reported borderline 
significant associations for endometrial (RR 1.23; 95 % CI 1.00–1.51) and ovarian cancer (RR 1.39; 
95 % CI 0.97–2.00). The authors conclude that AA intake is not associated with most cancers. A 
modest association of AA intake with kidney cancer, and with endometrial and ovarian cancer in 
never-smokers, cannot be excluded.  
Je (2015) conducted a meta-analysis on dietary AA intake and endometrial cancer risk and reported a 
summary RR of 1.10 (95 % CI 0.91–1.34) for all women and of 1.39 (95 % CI 1.10–1.77) for women 
who had never smoked. Although based on the same four prospective cohort studies, these estimates 
were slightly higher compared to those provided by Pelucchi et al. (2015) since random-effects models 
were used, instead of the fixed-effects models used by Pelucchi et al. (2015). 
Several review papers also considered the epidemiologic evidence on dietary AA and cancer risk up to 
2009-2011 but did not provide a quantification of cancer risk (Mucci and Wilson, 2008; Hogervorst et 
al., 2010; Lipworth et al., 2012; Pelicioli et al., 2014; Virk-Baker et al., 2014). An updated report from 
the World Cancer Research Fund concluded that data on dietary AA and endometrial cancer risk are 
too limited to draw any conclusion (World Cancer Research Fund
37
). The review papers summarised 
the epidemiological evidence that was available at the time of the review. These reviews concluded 
that there was no association between AA exposure through diet and the risk of most common cancers. 
7.4.1.2.7. Considerations on the interpretation of the epidemiological studies 
In the interpretation of the epidemiological data, it is important to consider possible limitations of the 
methodologies used to estimate AA intake from food, i.e. the self-reported FFQ used to assess the 
subject’s food intake and databases of AA content in foods (Ferrari et al., 2013; Virk-Baker et al., 
2014). In particular,  
(i) the FFQ used to assess food intake in many cases were not specifically designed to estimate 
AA intake and may not have been able to capture the high variation on AA content of foods. 
This applies in particular to the earlier studies that reported on the association between AA 
exposure and cancer, which had shorter FFQs and used incomplete AA databases;  
(ii) Most FFQ did not include specific questions on cooking methods, which have been shown 
to influence AA content of foods;  
(iii) The sources of AA contents of foods are often referring to other populations and calendar 
periods than those under investigation, thus reducing the specificity of country-specific 
                                                     
37  World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, 
Physical Activity, and the Prevention of Endometrial Cancer. 2013. Available at: http://www.dietandcancerreport.org 
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estimates. Nevertheless, there was an about 2-fold difference in the estimates of AA intake 
between various populations;  
(iv) The ability to measure subject’s intake of AA using a single value based on the mean of 
several samples of the same foods has also been questioned. A study using 39 24-hour 
duplicate diets which compared AA exposure estimated by using a questionnaire and the 
mean AA values for food items from the national AA database to the AA levels as 
measured by direct chemical analyses (Konings et al., 2010), reported a Spearman 
correlation of 0.82 between the two measures, thus indicating that a single mean – instead of 
the actual – AA value may well classify subjects according to their AA exposure in 
epidemiological studies using questionnaires. Despite the good correlation, the two highest 
measured levels (regarded as outliers), were more than five-fold the estimated intake from 
the questionnaire. In one case the fries, prepared at home, contained apparently more than 
the average AA level, in the other case no clear explanation was found. This study therefore 
shows also the difficulties in human studies measuring AA intake by questionnaires, in 
particular for food products prepared at home.   
(v) Although a few studies have shown that information on dietary AA collected through FFQs 
had satisfactory validity (and reproducibility) of information on dietary AA, multiple-day 
dietary records may also be subject to measurement errors.  
All these limitations may have introduced some misclassification of subjects into the appropriate AA 
exposure quantile. Such misclassifications are likely to be non-differential (i.e. similar in cases and 
non-cases) with respect to cancer outcome, and thus tend to lead to an underestimation of the strength 
of an association.  
The limited size of certain studies (or subgroups within), the low incidence of specific cancers, as well 
as a potential misclassification of AA exposure as described in the previous paragraph, has likely 
decreased the statistical power of the epidemiological studies (Freedman et al., 2011). This is 
especially relevant if possible small effects are to be detected and the variation of exposure is 
relatively small. Furthermore, measurement error of potential confounders, like energy intake and 
smoking, may have additionally contributed to the limited statistical power. 
A few studies compared AA levels estimated from FFQs to biomarkers of AA exposure (AA-Hb and 
GA-Hb) and reported low correlations (Wilson et al., 2009c, 2010; Vikström et al., 2012; Ferrari et al., 
2013). However, this is not surprising since FFQs and Hb-adducts measure different aspects of AA 
exposure, i.e. intake a few years before (usually one or two) for the former, and exposure, absorption 
and metabolism over the previous four months for the latter. AA-Hb are also prone to large intra-
individual variation due to incidental intake of high-level AA foods. Moreover, biomarkers represent 
AA exposure from other sources too, including in particular tobacco smoking. For prostate cancer, the 
only study that used biomarkers of AA exposure did not observe an association (Wilson et al., 2009a), 
in agreement with the result of prostate cancer studies using FFQs for the assessment of AA intake. 
Similarly, for ovarian cancer, Xie et al. (2013) did not observe an association using biomarkers, as 
shown in most studies using FFQs. For overall breast cancer, most studies using FFQs showed no 
association, while two studies using biomarkers for AA assessment for breast cancer risk (Olesen et 
al., 2008), and breast cancer survival (Olsen et al., 2012), showed positive associations.  
The inherent limitations of the study-design used (i.e. case-control or cohort studies), including 
possible selection and recall bias, are also to be considered. In particular, in case-control studies, 
dietary habits of the cases may have changed because of prediagnostic symptoms of the disease, and 
reporting of dietary (and other lifestyle) information may differ between cases and controls. Usually, 
dietary information from the period preceeding the cancer diagnosis is collected (or interview for 
controls), and cases and controls are interviewed by the same interviewers under similar conditions, 
which reduces the recall bias. Moreover, in hospital-based case-control studies information is likely to 
be more consistently reported between cases and controls. However, the reasons for admission to the 
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hospitals for these controls may be linked to exposures like smoking, alcohol consumption and diet. 
Although cohort studies are less prone to selection and recall bias, they are limited by the fact that 
information is often collected only at subjects’ enrolment and subjects may have changed their habits 
in the course of study conduction. 
Another limitation is the possible confounding, since the observed associations with AA may be due 
(partly or totally) to the effects of other independent factors associated with both AA intake and the 
neoplasm of interest. However, in most studies, estimates for the association between AA exposure 
and cancer risk were adjusted for age, sex, education, and various other risk factors for the cancers 
considered, including tobacco smoking, body mass index, alcohol drinking, energy intake, and 
hormonal and reproductive factors for female cancers. Moreover, most epidemiological studies have 
conducted subgroup analyses in never- or non-smokers. This is a particularly important issue, since 
exposure to AA in humans is not restricted to the diet, but is also possible through smoking (see 
Section 6.4). Indeed, cigarette smoking is an important source of AA, smokers having on average 
three to four times higher levels of AA-Hb adducts than non-smokers (Schettgen et al., 2004a; Vesper 
et al., 2008). Thus, smoking may bias (or obscure) the association between AA through diet and 
cancer risk. For this reason, restriction to never-smokers is the most appropriate way to control 
possible confounding by smoking.  
Although a hormonal mechanism of AA has been hypothesized to explain the observed associations 
with cancers of the female genital tract (Hogervorst et al., 2007, 2010), there is at the moment only 
suggestive epidemiologic evidence. A study among 687 postmenopausal and 1 300 premenopausal 
women from the Nurses’ Health Studies did not show conclusive associations between AA intake and 
serum levels of sex hormones, thus not supporting the biological plausibility of the hormonal 
hypothesis. However, some associations between AA intake and sex hormones in subgroups of 
women were observed (Hogervorst et al., 2013). Statistically significant positive associations were 
observed between AA intake and levels of luteal oestradiol and free oestradiol levels in normal weight 
premenopausal women. In postmenopausal women, statistically significant inverse associations were 
observed between AA intake and oestrone, free oestradiol and prolactin levels in normal weight 
women,
38
 while statistically significant positive associations were observed between AA intake and 
testosterone and androstenedione levels in overweight women. In a cross-sectional Japanese study 
(Nagata et al., 2015), the association of dietary acrylamide intake (measured by a food-frequency 
questionnaire) with levels of sex hormones and prolactin was studied in 393 smoking and non-
smoking pre-menopausal women. Higher intake of dietary AA was associated with lower levels of 
total and free oestrogen and a higher level of Follicle-Stimulating Hormone (FSH). When stratified by 
BMI, the association of AA intake and total and free oestrogen was limited to women with a BMI 
higher than 20.5 kg/m
2
. The association of AA intake and FSH levels was not dependent upon BMI. 
AA was not associated with other hormone levels (total and free testosterone, dehydroepiandrosteron, 
Sex Hormone Binding Globulin, Luteinizing Hormone and Prolactin). Although AA intake was 
associated with levels of sex-hormones, there was inconsistency between the two studies, and not all 
associations supported the hypothesised hormonal mechanism (Hogervorst et al., 2010) that would 
link AA intake to an increased risk of cancers of the female genital tract. Furthermore, the cross-
sectional study design, the differences in hormone levels between pre- and post-menopausal women, 
and in particular the major fluctuations of hormone levels in the different phases of the menstrual 
cycle in pre-menopausal women impede the interpretation of the outcomes.   
The association between AA exposure and cancer risk has been studied in occupational and dietary 
studies, as summarized in previous paragraphs. The (cumulative) exposure to AA from occupational 
and dietary exposure is, however, difficult to compare quantitatively. As compared to dietary studies, 
occupational studies are likely to measure AA exposure more accurately. Moreover, workers have 
been exposed to higher doses of AA (particularly in the past, Swaen et al., 2007), although individual 
occupational exposure may be variable and limited in time. Accordingly, various studies which have 
                                                     
38  BMI Normal Range: 18.5–24.99 kg/m2. WHO (1995). Physical status: the use and interpretation of anthropometry. WHO 
Technical report Series 854. 
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measured AA- and GA-Hb adducts in different populations (as biomarkers for AA exposure) showed 
that occupational exposures to AA have been considerably higher than in the general population, 
either in non-smoking or smoking groups. In the study by Moorman et al. (2012), the average adduct 
level in AA production workers was 220 pmol/g Hb (range: 29–1 884 pmol/g Hb). AA adduct levels 
in the general population have been reported to be consistently lower, both in never-smokers (median: 
43 pmol/g Hb, 5th–95th percentile: 24–88 pmol/g Hb) and in smokers (median: 121 pmol/g Hb, 5th–
95th percentile: 44–285 pmol/g Hb) (Vesper et al., 2008), which is in agreement with other studies for 
the general population (Schettgen et al., 2003; Olesen et al., 2008; Kütting et al., 2009). The NTP-
CERHR Expert Panel estimated the mean occupational inhalation exposure to range between 1.4 to 
18 µg/kg b.w. per day (with an upper boundary of 43 µg/kg b.w. per work day based on the 
Occupational Safety and Health Administration permissible exposure levels). However, this estimate 
of occupational intake includes exposure from inhalation only, exposure from dermal uptake is 
unknown and difficult to measure (Manson et al., 2005). Occupational studies, with temporarily higher 
AA exposures, have not shown consistent increased risk for cancer.   
7.4.1.2.8. Conclusions  
In the epidemiological studies available to date, AA intake was not associated with an increased risk 
of most common cancers, including those of the GI or respiratory tract, breast, prostate and bladder. A 
few studies suggested an increased risk for renal cell, and endometrial (in particular in never-smokers) 
and ovarian cancer, but the evidence is limited and inconsistent. Moreover, one study suggested a 
lower survival in non-smoking women with breast cancer with a high pre-diagnostic exposure to AA 
but more studies are necessary to confirm this result.  
7.4.2. Epidemiological studies: pre-natal exposure 
7.4.2.1. Developmental consequences 
In a Danish study, Hb-AA and Hb-GA adduct levels were measured in 87 maternal blood and 
219 cord blood samples (von Stedingk et al., 2011). The correlation between cord and maternal blood 
were 0.69 (p for trend < 0.001) and 0.78 (p for trend < 0.001) for AA and GA, respectively. This study 
suggested that AA from food consumed by pregnant women passes the placenta. Furthermore, in vitro 
studies showed that rates of adduct formation are lower in the cord blood probably because of 
structural differences between fetal and adult Hb. The authors therefore conclude that the fetus is 
exposed to the same AA and GA doses as the mother (von Stedingk et al., 2011). 
In a prospective mother child study with 1 101 singleton pregnant women from Denmark, England, 
Greece, Norway and Spain it was investigated whether AA and GA exposures are associated with the 
development of the child during pregnancy (Pedersen et al., 2012). AA and GA adduct levels were 
measured in cord blood. Both AA and GA adduct levels were significantly associated with a reduced 
birth weight and head circumference as well as increased risk of being small for gestational age. The 
difference in birth weight of newborn children for the highest quartile versus the lowest quartile of AA 
adducts was −132 g (95 % CI: −207, −56), a reduction reported by the authors to be comparable with 
that observed for children exposed in utero to maternal smoking (Li et al., 1993). The corresponding 
difference for head circumference was −0.33 cm (95 % CI: −0.61, −0.06). Results were similar in 
children from non-smoking mothers, and remained statistically significant after adjustment for factors 
that are associated with reduced birth weight. Monotonic dose-response associations of AA exposure 
with birth outcomes were observed in women who were non-smokers during pregnancy, as well as in 
never-smokers, even after adjusting for passive smoking based on self-reporting or using ethylene 
oxide Hb adducts as biomarkers of exposure to tobacco smoke. The associations between AA 
exposure and birth weight were consistent across the five countries. The authors also showed that a 
food score for AA was associated with AA and GA adduct levels in the cord blood of 801 children of 
non-smoking mothers. A one-unit change in this AA food score was associated with an increase of 
0.68 pmol/g in AA Hg adduct cord blood levels (95 % CI: 0.30–1.06). The AA food score was also 
associated with reduced birth weight, although not statistically significant.  
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A Norwegian Mother and Child Study assessed the association between prenatal dietary AA intake 
and indicators of fetal growth (Duarte-Salles et al., 2013). The study included 50 561 women 
(including 46 420 non-smokers) and AA exposure was estimated using a FFQ. In a subset of 79 non-
smoking women, the FFQ estimated dietary AA intake was validated by comparison to Hb adduct 
measurements. The correlation with AA and GA adducts was 0.24 and 0.48, respectively. Fetal growth 
was measured by determining whether an infant was small for gestational age (birth weight below the 
10th percentile according to week of gestational age and parity). Children of non-smoking mothers 
with a high dietary AA intake were at increased risk of being small for gestational age, the adjusted 
odds ratio (OR) being 1.13 (95 % CI, 1.03–1.23) for children of women with the highest quartile of 
AA intake versus those in the lowest quartile of intake. The point estimate was similar in children of 
smoking women, although not statistically significant because of low power. Birth weight was 
inversely associated with mother’s AA intake: children of mothers with the highest quartile of dietary 
AA intake had a multivariable adjusted coefficient of −25.7 g (95 % CI: −35.9, −15.4) compared to the 
lowest quartile. This coefficient was similar in non-smoking women. Results were adjusted for 
confounding by coffee intake, but not for caffeine, as the type of coffee was not known.  
Conclusions 
Epidemiological studies on the association between dietary AA intake and fetal growth are still 
limited. However, both prospective cohort studies suggested that a high dietary AA intake during 
pregnancy was associated with a lower fetal growth. The findings were similar in smoking and non-
smoking women. In one of the two studies, AA exposure was measured using Hb adducts, and the 
association between AA exposure and birth weight was present as well. In both studies the possibility 
of residual confounding by cigarette smoking was adequately addressed by stratified analyses 
according to smoking status.  
Two studies have studied the associations between dietary AA and birth weight, both suggesting an 
inverse association. However, such an association can be attributed to other unidentified exposures 
correlated with AA intake and there is no clear biological explanation of this association. Therefore, it 
cannot be established whether the association between dietary AA and birth weight is causal. More 
epidemiological studies are needed to confirm such a relationship in other populations, as well as 
experimental studies that may identify possible mechanisms. However, the CONTAM Panel noted that 
in rats and mice some signs of developmental toxicity (increased incidence of skeletal variations and 
slightly impaired body weight gain) are only observed at exposure levels that are also associated with 
maternal toxicity, and that these effects are considered likely to be secondary to maternal toxicity. 
These dose levels are extremely high compared to those considered in the human studies of Pedersen 
et al. (2012) and of Duarte-Salles et al. (2013). The CONTAM Panel therefore concluded that there 
are yet too many uncertainties to conduct a risk assessment based on these human data. 
7.4.2.2. Effects on gene expression 
In a substudy of the Norwegian Mother and Child Cohort (the BraMat cohort), umbilical blood cord 
samples of 45 male and 66 female newborn children were investigated (Hochstenbach et al., 2012). 
Eighty-four per cent of the mothers were non-smokers. AA-Hb and GA-Hb adducts were measured, 
and mean values were 16.5 (± 6.6) pmol/g Hg and 10.0 (± 4.0) pmol/g Hb, respectively, with no major 
differences between male and female newborn children. Gene expression analysis using microarray 
was conducted to investigate whether AA and GA-Hb adduct levels were associated with alterations of 
gene expression. GA-Hb adduct levels were not associated with altered gene expression, while AA-Hb 
adduct levels were associated with activation of the Wnt-signaling pathway in males, but not in 
females. The deregulation of this pathway has been reported in different malignancies (Polakis, 2012). 
The CONTAM Panel noted that the association was observed with an intermediate biomarker and the 
functional implications of the findings are unknown.  
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7.4.3. Epidemiological studies: neurological alterations 
AA exposure can cause neurological symptoms in humans following skin absorption, inhalation, and 
ingestion. The variety of reported symptoms suggests possible involvement of the peripheral and the 
central nervous system, as well as the autonomic nervous system. Reported symptoms include 
muscular weakness, paraesthesia, numbness in hands, feet, lower legs and arms, and unsteadiness 
(WHO, 1985).  
No studies were identified on the association of dietary AA intake and neurological alterations. 
Several dozens of cases of AA poisoning have been reported in the literature. Acute and high 
exposures to AA more often result in early central nervous system involvement, while prolonged 
exposure to AA are associated with peripheral neuropathy (WHO, 1985). 
Duration of exposure was associated with the number of neurological symptoms in a small study with 
15 exposed workers by Takahashi et al. (1971). He et al. (1989) studied neurotoxicological effects of 
AA exposure in 71 exposed workers (45 males and 26 females) aged between 17 and 41 years old. A 
referent group of 51 workers (33 males and 18 females) from the same town were examined as well. 
Production of AA started in May 1984 and symptoms of workers exposed to AA were investigated up 
to October 1985. The atmospheric concentration of AA had reached a maximum of 5.56 to 9.02 mg/m
3
 
between March and June 1985 and decreased to an average of 0.0324 mg/m
3
 after a renovation of the 
workplace. An AA level of 410 mg/L was measured in the water in which three of the workers washed 
their hands. In October 1985, three cases had severe AA poisoning (involvement of the cerebellum 
with polyneuropathy), six moderate poisoning and 43 mild poisoning.  
The AA exposed workers reported significantly more frequent symptoms like skin peeling from the 
hands, numbness in the hands and feet, lassitude, sleepiness, muscle weakness, clumsiness of the 
hands, anorexia, unsteady gait, coldness of hands and feet, difficulty in grasping and stumbling and 
falling. Electromyographic investigation revealed a decrease in the sensory action potential amplitude, 
prolonged duration of motor units and increased polyphasic potentials. The results of this study are 
difficult to interpret, however, because of different exposure routes and poor control of confounding 
by e.g. smoking. 
Myers and Macun (1991) investigated AA related neuropathy in a cohort of 66 people who had 
worked in a South African factory. The mean duration of AA exposure was two years. AA exposure 
levels ranged from 0.07 to 2.50 times the NIOSH recommended exposure limit (REL) of 0.3 mg/m
3
. 
Workers were classified as being exposed to AA when exposure levels exceeded the REL (n = 22) and 
as unexposed when exposure levels were below REL (n = 41). The exposed group showed an 
increased prevalence of neurological symptoms, signs and reflexes, but only abnormal sensation 
symptoms were statistically significant increased. Overall prevalence of AA-related symptoms was 
66.7 % among exposed and 14.3 among unexposed workers (p for trend < 0.05). Bachmann et al. 
(1992) conducted a follow-up study in the same South African factory (Myers and Macun, 1991). 
Workers were classified, based on job titles, into a high-dose group (average exposure 0.33 mg/m
3
 
during on average 5.2 years) and a low-dose group (average exposure 0.02 mg/m
3
 during on average 
5.8 years). Numbness of hands and feet, weakness of arms and legs, sweating hands, and pain in arms 
and legs were statistically significantly more frequently reported in the high-dose group. 
Calleman et al. (1994) studied neurological health effects in 41 workers exposed to AA and 
acrylonitrile and different groups of unexposed healthy adults. Workers were exposed from 1 month to 
11.5 years to AA and acrylonitrile in a Chinese factory. Of the exposed workers, 13 were synthesis 
workers (mean air concentration 1.07 mg/m
3
 of AA), 12 were polymerisation workers (mean air 
concentration 3.27 mg/m
3
 AA), and 16 were exposed otherwise. For the biomarker and neurotoxicity 
analysis in this study 10 unexposed male workers from the same city were selected as controls. 
Several biomarkers of exposure were measured, e.g. free AA in plasma, mercapturic acids in urine 
(measured as S-(carboxyethyl)cysteine), and AA-Hb adducts (Table 25). Neurotoxicity was measured 
by calculating a weighted sum score of symptoms of neuropathy (14 items; maximum 50 points). The 
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neurotoxicity index predicted a clinical diagnosis of peripheral neuropathy. Average neurotoxicity 
scores were 22.2 ± 7.1 and 7.4 ± 5.3 in workers with and without peripheral neuropathy, respectively. 
AA adducts, acrylonitrile adducts and accumulated AA dose, were positively associated with the 
neurotoxicity index (Table 26).  
In a cohort of 210 tunnel workers, who had been exposed during about two months, to a chemical-
grouting agent containing AA and N-methylol AA, AA-Hb adducts were measured as well as health 
effects (Hagmar et al., 2001). Forty-seven workers had Hb-adduct levels of AA within the normal 
background range (0.02–0.07 nmol/g globin) and 74 workers had Hb-adduct levels of AA exceeding 
0.30 nmol/g globin. Repeated sampling from five workers within five months showed a decrease 
consistent with the 120-days lifespan of human erythrocytes. Self-reported exposure was positively 
associated with the measured levels of Hb-adduct (p for trend < 0.0001). There were statistically 
significant associations between Hb-adduct levels and prevalence of peripheral nervous symptoms 
(Table 27). 
 
Table 25:  Mean and standard deviation of acrylamide (AA) biomarkers and neurological health 
effects in 41 exposed workers and 105 unexposed controls according to job title (adapted from 
Calleman et al., 1994) 
Group 
Free AA 
µmol/l* 
MAs 
µmol/24 h 
AA Val 
nmol/g Hb 
AN Val 
nmol/g Hb 
Hand VU Foot VU 
AccDAA 
mM/hour 
Neurotox. 
index 
Controls 
(n = 10) 
0.92 3.0 ± 1.8 0.0 ± 0.0 0.23 ± 0.18 1.6 ± 0.3 3.0 ± 0.9 0.0 ± 0.0 0.0 ± 0.0 
Packaging 
(n = 5) 
2.2 93 ± 72 3.9 ± 2.5 19.1 ± 5.7 2.5 ± 1.3 5.5 ± 3.2 8.1 ± 6.6 8.9 ± 9.1 
Polymerisati
on (n = 12) 
1.3 58 ± 75 7.7 ± 3.4 19.1 ± 12.9 2.1 ± 1.0 4.3 ± 2.5 27.0 ± 23.9 10.0 ± 5.8 
Ambulatory 
(n = 6) 
2.0 53 ± 35 9.5 ± 7.3 16.3 ± 3.7 2.4 ± 1.0 5.0 ± 1.8 37.6 ± 21.9 11.3 ± 9.8 
Synthesis 
(n = 13) 
1.8 ± 0.8 64 ± 46 13.4 ± 9.8 19.5 ± 7.6 2.9 ± 1.3 7.2 ± 5.1 68.3 ± 64.2 19.2 ± 10.6 
AccDAA: accumulated in vivo dose of AA throughout the duration of employment; AN: acrylonitrile; h: hour(s); MAs: 
mercapturic acid (S-(2 carboxyethyl)cysteine/24 hours in hydrolyzed urine); Val: valine; VU: vibration units. 
 
Table 26:  Correlations between acrylamide (AA) biomarkers of exposures and neurotoxicity index 
(adapted from Calleman et al., 1994) 
 Correlation coefficient 
with neurotoxicity index 
p value 
Free AA 0.15 0.31 
Urinary mercapturic acid 0.42 < 0.01 
Hb adducts with AA 0.67 < 0.001 
Hb adducts with acrylonitrile 0.69 < 0.001 
Accumulated in vivo AA dose 0.60 < 0.001 
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Table 27:  Prevalences (%) of work-related symptoms according to levels of Hb-adducts of AA 
among 210 tunnel workers (adapted from Hagmar et al., 2001). 
Symptoms 
AA-Hb adducts (nmol/g globin) 
p value < 0.08 
(n = 47) 
0.08-0.29 
(n = 89) 
0.30-1.00 
(n = 36) 
> 1.00 
(n = 38) 
Numbness or tingling in hands 13 13 31 29 0.04 
Numbness or tingling in feet or legs 4 11 25 37 < 0.001 
Leg cramps 6 7 6 26 0.003 
Increased hand or foot sweating 2 3 17 11 0.02 
Skin peeling in hands 6 2 8 24 0.001 
Irritation of the eyes 14 23 47 47 < 0.001 
Irritation of the nose 14 21 36 53 < 0.001 
Irritation of the throat 10 23 47 47 < 0.001 
Coughing 10 11 31 50 < 0.001 
Dyspnea or wheezing 2 9 17 24 0.02 
Irritation of the skin 14 18 31 39 0.02 
Headache 14 33 31 63 < 0.001 
Nausea 5 13 14 47 < 0.001 
Dizziness 7 13 31 24 0.02 
 
Fifty symptomatic workers had been referred for further neurophysiological examinations and 29 had 
objective findings in the clinical examination. These 29 workers had adduct levels of at least 
0.30 nmol/g globin. Of these 29 workers, two showed neurographic signs of polyneuropathy, eight had 
a slight impairment of nerve conduction or amplitude, nine had increased sensory thresholds, and the 
remaining nine subjects had no neurophysiological abnormalities. Almost all workers recovered 
18 months after exposure had been stopped. 
Kjuus et al. (2004) investigated toxic effects on the peripheral nerves in 74 Norwegian tunnel workers 
of whom 24 had been exposed to AA and N-methyloacrylamide during an average of 19.4 months. 
Mean AA adduct concentration (measured 2–5 months after cessation of the exposure) was 82 pmol/g 
Hb (range 33-85) for non-smoking exposed workers (n = 11) and 33 pmol/g Hb for non-smoking 
referents (n = 6). Neurological symptoms (paresthesia, pain and weakness of hands and feet) were 
reported more often during exposure than 16 months after exposure, although the differences were not 
statistically significant. Neurophysiological measurements showed a statistically significant reduction 
in mean sensory nerve conduction value of the ulnar nerve in exposed workers, and a prolonged distal 
delay in the ulnar nerve. Most effects were reversible, with a change to normal after one year. 
Goffeng et al. (2008a) compared 44 workers exposed to AA in the past (2 to 10 years before), 
24 workers recently exposed to AA (16 months before) and 49 workers who were not exposed to AA. 
Exposure to AA was measured using questionnaires. In this cross-sectional study, slight but persistent 
subclinical nervous system effects on the sural nerve as well as signs of retinal and optic nerve 
impairment were shown. 
In the same cross-sectional study, Goffeng et al. (2008b) investigated colour vision and light 
sensitivity in 44 workers who had been exposed to AA and N-methylolacrylamide (NMA) 2 to 
10 years before the study, as well as in 44 controls. Exact levels of exposure were not available. Based 
on questionnaire information, a sum score of intensity and time of exposure was calculated. A slightly, 
although statistically significant, reduced light sensitivity and colour discrimination was observed in 
exposed workers compared to non-exposed workers. However, there was no dose-response 
relationship between exposure intensity and light sensitivity and colour discrimination. 
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Finally, Goffeng et al. (2011) in the same 44 exposed and 49 non-exposed workers, investigated 
whether self-reported symptoms and neuropsychological test results were different during work and at 
the time of examination. The retrospectively self-reported prevalence of symptoms like paresthesia in 
hands and legs and leg cramps during work periods were higher in the exposed workers. Current self-
reported symptoms like impaired memory and concentration were also higher in exposed workers. No 
association was observed between neuropsychological test results and estimated AA exposure. 
Conclusions 
Occupational exposure to AA in humans has been shown to cause neurotoxicity in the peripheral 
nervous system; however involvement of the central nervous system cannot be ruled out. In most cases 
symptoms were reversible. The first reports were published forty years ago, but reports had a poor 
characterisation of exposure to AA and/or exposure to multiple chemicals, and/or had a cross-sectional 
design and/or included a limited number of subjects. The CONTAM Panel concluded that these 
limitations preclude the use of these data in the risk assessment.  
7.5. Considerations of critical effects and possibilities for derivation of a health based 
guidance value 
7.5.1. Considerations of critical effects 
A large body of evidence has been published that demonstrates that AA exposure by oral and 
parenteral routes can result in peripheral neuropathy in humans (Hagmar et al., 2001) and 
experimental animals (Spencer and Schaumberg, 1974; Tilson, 1981; Sickles et al., 2002; Tyl and 
Friedman, 2003; LoPachin, 2004; Beland et al., 2013). Peripheral neuropathy in rats is manifested as 
hindlimb weakness, foot splay, and gait abnormalities. Peripheral nerve degeneration was also 
observed in the three long-term carcinogenicity studies of AA (Johnson at al., 1986; Friedman et al., 
1995; NTP, 2012). In addition, studies in experimental animals have documented effects on male 
reproduction, developmental toxicity and carcinogenicity as critical effects (Garey and Paule, 2007, 
2010; Fergusson et al., 2010; NTP, 2012; Takami et al., 2012). 
From all data available, the CONTAM Panel identified four possible critical endpoints for AA 
toxicity, i.e. neurotoxicity, effects on male reproduction, developmental toxicity and carcinogenicity.  
7.5.2. Dose-response assessment  
The data from human studies were not adequate for dose-response assessment. Therefore, the 
CONTAM Panel considered the data from studies on experimental animals to establish reference 
points.  
Regarding non-neoplastic effects, for the evaluation of the data on neurotoxicity, the CONTAM Panel 
decided to use the data from the 2-year NTP study in rats (NTP, 2012) instead of the data from Burek 
et al. (1980) as used, e.g. by JECFA (FAO/WHO, 2006, 2011). This was based on the following 
considerations: (i) the NTP (2012) study is a 2-year study as compared to a 90-day study performed by 
Burek et al. (1980), (ii) the Burek et al. (1980) data did not show a clear dose-response, (iii) the Burek 
et al. (1980) data were based on only 3 rats per group obtaining 150 dependent data points from each 
rat, and (iv) the determination of the NOAEL was not based on a statistical analysis of the data.  
The CONTAM Panel also considered the data on sciatic nerve degeneration in male and female F344 
rats exposed to AA via drinking water for 106 weeks (Friedman et al., 1995) and on tibial nerve 
degeneration in male and female F344 rats exposed to AA via drinking water for 2 years (Johnson et 
al., 1986). Dose-response analysis of these data by Doerge et al. (2008) provided BMDL10 values of 
0.65 mg/kg b.w. per day for males and 0.60 mg/kg b.w. per day for females from the data from 
Johnson et al. (1986), and of 0.37 mg/kg b.w. per day for males and 0.90 mg/kg b.w. per day for 
females from the data from Friedman et al. (1995). The Panel noted, however, that the data from these 
studies as well as the data for peripheral nerve (sciatic) axonal degeneration observed in female F344 
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rats exposed to AA in drinking water for 2 years (NTP, 2012) did not reveal a clear dose-response 
since the incidence was increased only in the highest dose group, and for the Friedman et al. (1995) 
and Johnson et al. (1986) study without statistical significance.  
Therefore the Panel concluded that the most suitable dose-response was observed for the data on 
peripheral nerve (sciatic) axonal degeneration in male F344 rats exposed to AA in drinking water for 
2 years (NTP, 2012) (Table 20). For this endpoint, a structural change which is clearly adverse, the 
CONTAM Panel derived a BMDL10 value of 0.43 mg/kg b.w. per day (the lowest BMDL10 obtained) 
as the reference point for non-neoplastic effects. Details on the BMD analysis are given in Appendix 
K, and Table 28 provides a summary of the BMD and BMDL10 values obtained. Support for this 
analysis is provided by the recent study of Maronpot et al. (2015). 
Rodent studies have demonstrated adverse effects of AA on male reproductive parameters, particularly 
reduced sperm counts and effects on sperm and testis morphology (degeneration of the testicular 
germinal epithelium). A NOAEL of 2 mg/kg b.w. per day was established in the 2-generation toxicity 
study in rats of Tyl et al. (2000a) for effects on fertility and development. Overall, the lowest NOAEL 
for degeneration of the testicular germinal epithelium was 2.1 mg/kg b.w. per day in a 90-day drinking 
water study in rats (NTP, 2012). The lowest NOAEL reported for developmental toxicity was 
1.0 mg/kg b.w. per day from studies in rats exposed gestationally and neonatally (Ferguson et al., 
2010; Garey and Paule, 2010). Based on the fact that these NOAELs of approximately 2 mg/kg b.w. 
per day for reproductive toxicity and 1 mg/kg b.w. per day for developmental toxicity are higher than 
the BMDL10 value of 0.43 mg/kg b.w. per day obtained for neurotoxicity, the CONTAM Panel 
concluded that using the BMDL10 for neurotoxicity as the reference point is conservative when 
considering possible non-neoplastic effects. 
For neoplastic effects, the CONTAM Panel selected as reference point the value of 0.17 mg/kg b.w. 
per day derived as the lowest BMDL10 from data on incidences of Harderian gland adenomas and 
adenocarcinomas in male B6C3F1 mice exposed to AA for 2 years (NTP, 2012) (see Table 23). Details 
on the BMD analysis are given in Appendix K.   
The CONTAM Panel considered that even though the Harderian gland is not present in humans, this 
rodent organ represents a sensitive endpoint for detecting compounds that are both genotoxic and 
carcinogenic (Cohen, 2004; Maronpot et al., 2004; Edler et al., 2014). Harderian gland tumours and 
tumours in other rodent organs including the lung in mice, the brain in rats, and the mammary gland 
and forestomach in both species are prone to tumour formation upon exposure to epoxides or epoxide-
forming carcinogens (Melnick, 2002), such as AA. Furthermore, tumour formation at the tunica 
vaginalis testis in male rats observed with AA, is also in agreement with findings reported for 
carcinogenic epoxides such as glycidol (Irwin et al., 1996) and ethylene oxide (Lynch et al., 1984).  
Therefore, the CONTAM Panel concluded that the results on the Harderian gland in mice cannot be 
disregarded in the risk assessment of AA. This is also supported by the fact that the benchmark dose 
ranges for Harderian gland and mammary gland tumours in female rats are overlapping. 
Table 28:  BMD10 and BMDL10 values for critical effects of AA on neurotoxicity and 
carcinogenicity. For details of the dose-response assessment see Appendix K. 
Critical endpoint 
BMD10 
mg/kg b.w. per day 
BMDL10 
mg/kg b.w. per day 
Reference Appendix K 
Neurotoxicity      
Peripheral nerve (sciatic) 
axonal degeneration in male 
F344 rats 
0.61 0.43 NTP (2012) Table K1
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Critical endpoint 
BMD10 
mg/kg b.w. per day 
BMDL10 
mg/kg b.w. per day 
Reference Appendix K 
Carcinogenicity     
Mesothelioma of the testes 
tunica in male F344 rats 
1.32 0.51 
Friedman et al. 
(1995) 
Table K3 
Mesothelioma of the 
epididymis or testes tunica 
vaginalis in male F344 rats 
2.25 1.13 NTP (2012) Table K4 
Various types of sarcomas 
in female B6C3F1 mice 
2.80 1.56 NTP (2012) Table K5 
Lung tumours in male 
B6C3F1 mice  
2.25 1.13 NTP (2012) Table K6 
Harderian gland adenomas 
in female B6C3F1 mice 
0.47 0.28 NTP (2012) Table K10 
Harderian gland adenomas 
and adenocarcinomas in 
male B6C3F1 mice 
0.37 0.17 NTP (2012) Table K11 
Mammary gland 
fibroadenomas in female 
F344 rats 
0.55 0.30 NTP (2012) Table K12 
   
7.5.3. Possibilities for derivation of a health based guidance value 
The fact that AA and also its metabolite GA are positive in a variety of genotoxicity tests indicates that 
AA is of concern with respect to genotoxicity. Therefore, the CONTAM Panel considered it 
inappropriate to establish a TDI.  
Risk characterisation for non-neoplastic effects was performed using the margin of exposure (MOE) 
approach and the BMDL10 value of 0.43 mg/kg b.w. per day for the most relevant and sensitive 
endpoint for neurotoxicity, i.e. the incidence of peripheral nerve (sciatic) axonal degeneration 
observed in F344 male rats exposed to AA in drinking water for 2 years (NTP, 2012). 
For risk characterisation for neoplastic effects, the MOE approach for compounds that are both 
genotoxic and carcinogenic is considered appropriate, using as the reference point the BMDL10 of 
0.17 mg/kg b.w. per day, i.e. the lowest BMDL10 from data on incidences of Harderian gland 
adenomas and adenocarcinomas in male B6C3F1 mice exposed to AA for 2 years (NTP, 2012).   
8. Risk characterisation 
Non-neoplastic effects 
The CONTAM Panel evaluated the risks of neurotoxicity, which is considered to be due to parent AA 
rather than to a metabolite, using the BMDL10 value of 0.43 mg/kg b.w. per day derived from the 
incidence of peripheral nerve (sciatic) axonal degeneration observed in male F344 rats exposed to AA 
in drinking water for 2 years (NTP, 2012) as the reference point.  
Data on human exposure levels to AA across surveys and age groups are presented in Table 8 and 
show mean exposure values that range from 0.4 (minimum LB) to 1.9 µg/kg b.w. per day (maximum 
UB). The 95th percentile exposure levels range from 0.6 (minimum LB) to 3.4 µg/kg b.w. per day 
(maximum UB). Using the BMDL10 value for neurotoxicity and these data for exposure to AA, the 
MOE values range from 1 075 (minimum LB) to 226 (maximum UB) for the mean exposure, and from 
717 (minimum LB) to 126 (maximum UB) for the 95th
 
percentile exposure estimates across surveys 
and age groups (Table 29).  
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Table 29:  Margins of exposure (MOE) values for neurotoxicity of acrylamide (AA) across surveys 
and age groups 
Age group 
Mean P95 
Minimum LB Maximum UB Minimum LB Maximum UB 
Infants (n
(a)
 = 6/5) 860 269 307 172 
Toddlers (n = 10/7) 478 226 307 126 
Other children (n = 17/17) 478 269 307 134 
Adolescents (n = 16/16) 1 075 478 478 215 
Adults (n = 16/ 6) 1 075 717 538 331 
Elderly (n = 13/13) 1 075 860 614 430 
Very elderly (n = 11/9) 1 075 860 717 430 
n: number of surveys; LB: lower bound; UB: upper bound.  
(a):  Number of surveys used to derive the minimum/median/maximum mean exposure levels/number of surveys used to 
derive the minimum/median/maximum 95th percentile exposure levels.   
 
Usually for non-genotoxic compounds, unless there are major gaps in the toxicological database, a 
MOE of 100 is considered sufficient to conclude that there is no health concern. This MOE covers 
uncertainties and variability with regard to both kinetic and dynamic differences between experimental 
animals and humans (factor 4 × 2.5 = 10), and within the human population (factor 3.2 × 3.2 = 10) 
(EFSA SC, 2012a).   
It is of interest to note that the PBPK models allow derivation of compound-specific adjustment 
factors for AA that could replace default uncertainty factor for toxicokinetics as it relates to use of the 
BMDL10 for AA-induced axonal degeneration in male F334 rats. Given that the standard MOE value 
of 100 includes a default uncertainty factor of 4 for toxicokinetics (EFSA SC, 2012a), the CONTAM 
Panel considered whether the use of a compound-specific adjustment factor (i.e. HED) would 
influence the risk characterisation for AA-induced neurotoxicity. The three PBPK modelling studies in 
male rats reported that the dose of AA required to produce an equivalent AUC for AA was 4- to 6-fold 
higher than in a human (mean value = 5, see Table 19). This approach would substitute an HED (5 at 
the mean) for the default uncertainty factor for interspecies differences in toxicokinetics (4-fold). This 
would result in an adjusted MOE of 125 ((100/4) × 5) obtained from substituting the mean AA HED 
of 5 for the default uncertainty factor of 4.  
All MOEs obtained for the current exposure to AA across surveys and age groups (Table 29) are 
above the adjusted MOE of 125, which is considered sufficient to conclude that there is no health 
concern for neurotoxicity. However, for the 95th percentile UB exposure estimates, the CONTAM 
Panel noted that the maximum UB MOEs of 126 and 134 for toddlers and other children, respectively, 
are close to the adjusted MOE of 125.  
Neoplastic effects 
The reference point for risk characterisation of the neoplastic effects of AA derived by the CONTAM 
Panel is the BMDL10 of 0.17 mg/kg b.w. per day derived as the lowest BMDL10 from data on 
incidences of Harderian gland adenomas and adenocarcinomas in male B6C3F1 mice exposed to AA 
for two years (NTP, 2012).  
Comparison of the data on human exposure levels to AA across surveys and age groups reported 
above (Table 8) to this BMDL10 of 0.17 mg/kg b.w. per day, reveals MOE values (Table 30) that range 
from 425 (minimum LB) to 89 (maximum UB) for the mean exposure estimates, and from 
283 (minimum LB) to 50 (maximum UB) for the 95th percentile exposure estimates across surveys 
and age groups.  
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Table 30:  Margins of exposure (MOE) values for neoplastic effects of AA across surveys and age 
groups 
Age group 
Mean P95 
Minimum LB Maximum UB Minimum LB Maximum UB 
Infants (n
(a)
 = 6 / 5) 340 106 121 68 
Toddlers (n = 10 / 7) 189 89 121 50 
Other children (n = 17 / 17) 189 106 121 53 
Adolescents (n = 16 / 16) 425 189 189 85 
Adults (n = 16 / 16) 425 283 213 131 
Elderly (n = 13 / 13) 425 340 243 170 
Very elderly (n = 11 / 9) 425 340 283 170 
n: number of surveys; LB: lower bound; UB: upper bound. 
(a):  Number of surveys used to derive the minimum/median/maximum mean exposure levels/number of surveys used to 
derive the minimum/median/maximum 95th percentile exposure levels.   
 
The EFSA Scientific Committee concluded that, for substances that are both genotoxic and 
carcinogenic, an MOE of 10 000 or higher, based on a BMDL10 from an animal study, and taking into 
account overall uncertainties in the interpretation, would be of low concern from a public health point 
of view (EFSA, 2005b; EFSA SC, 2012a). Since the calculated MOE values are all substantially lower 
than 10 000, the CONTAM Panel concluded that the MOEs across surveys and age groups indicate a 
concern with respect to neoplastic effects.  
As noted above for AA-induced neurotoxicity, it is also possible to use the PBPK models to derive 
compound-specific adjustment factors that could replace default uncertainty factors for toxicokinetics 
of GA, the most plausible cause of the genotoxicity and carcinogenicity of AA. The MOE of 
10 000 covers uncertainties and variability with regard to both kinetic and dynamic differences 
between experimental animals and humans (factor 4 × 2.5 = 10), and within the human population 
(factor 3.2 × 3.2 = 10), as well as uncertainties related to the carcinogenic process (EFSA, 2005b). 
Given that the value of 10 000 includes a default uncertainty factor of 10 for interspecies variation, 
which includes a factor of 4 for toxicokinetics (EFSA, 2005b), the CONTAM Panel considered 
whether information on inter-species difference in toxicokinetics would modify the risk 
characterisation. PBPK modelling revealed that the dose of AA required to produce an equivalent 
AUC for GA in male and female mice was 0.5–0.7-fold lower, respectively, than in humans (see Table 
19, Young et al. (2007)), which underscores the proficiency of mice in converting AA to GA (see 
Table 18). This approach could support elimination of the default uncertainty factor for interspecies 
differences in toxicokinetics (4-fold). The CONTAM Panel concluded that even if this inter-species 
difference is taken into account, and although the human studies have not demonstrated AA to be a 
human carcinogen, the MOEs across dietary surveys and age groups indicate a concern with respect to 
neoplastic effects. The CONTAM Panel also noted that the MOEs for those tumour sites other than 
Harderian gland with the lowest BMDL10 values are also substantially below 10 000 and thus also 
indicate a concern.   
The CONTAM Panel noted that AA is a germ cell mutagen and that there are at present no established 
procedures for risk assessment using this endpoint.  
9. Uncertainty  
The evaluation of the inherent uncertainties in the risk assessment on AA has been performed 
following the guidance of the Opinion of the Scientific Committee related to Uncertainties in Dietary 
Exposure Assessment (EFSA, 2006). In addition, the report on ‘Characterizing and Communicating 
Uncertainty in Exposure Assessment’ (WHO/IPCS, 2008) has been considered. According to the 
guidance provided by the EFSA opinion (2006) the following sources of uncertainties have been 
considered: Assessment objectives, exposure scenario, exposure model, and model input (parameters). 
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9.1. Assessment objectives 
The objectives of the assessment were clearly specified in the terms of reference. 
9.2. Exposure scenarios/Exposure models 
A total of 7 448 samples submitted by 24 European countries and 35 971 samples submitted by six 
food associations were used in the exposure assessment. The amount of occurrence data submitted 
differs considerably depending on food product and reporting data provider. While the data from the 
food associations widely reflect a representative overview on the AA levels in the respective products, 
there is some uncertainty whether the results submitted by the European countries cover possible 
regional differences. Regarding the data provided by the European countries, 70 % of the samples for 
which the information is available are indicated to be taken from targeted sampling design. In general, 
the analytical methods for the determination of AA in food are adapted to the indicative values set by 
the EU Commission and not necessarily to follow lower background levels. Therefore, the use of the 
upper bound approach (UB) for left-censored data in combination with the targeted sampling may 
have led to bias towards an over estimation of the AA levels used as input of the exposure 
model/scenarios. Some food groups, not covered by any occurrence data submitted, could not be taken 
into account in the exposure assessment. However, these foods are not known to contain considerable 
AA concentrations, so the absence of data for these foods is unlikely to contribute to any 
underestimation of exposure as those food products that are known to potentially contain AA are 
covered.  
The food consumption habits reported in the Comprehensive Database are not described in a manner 
fully compatible with the exposure assessment to heat-induced contaminants. The consumption data 
have been mostly reported at the level of raw commodities such as potato, without systematic 
information on how the potatoes were cooked before consumption. Consumption of coffee was also 
most often reported without any detail on the kind of coffee beverage consumed. Such cases, 
representing 11 % of the total consumption events of potato products (potato crisps and other snacks 
excluded) and 40 % of the total consumption events of coffee beverages, were handled by 
assumptions. The kind of coffee beverage most frequently consumed in the corresponding survey and 
age group was attributed to the unspecified coffee beverage. The unspecified potato was assumed to be 
consumed as fried or not fried depending whether more or less than 5 % of oil/fat for frying was 
consumed during the same meal. The impact of such assumption was assessed using two extreme 
scenarios (see Section 6.2.4). When considering the unspecified potato as not fried, this could result in 
exposure estimates for a few consumption surveys and age groups up to 33 % lower compared to the 
baseline scenario. When considering the unspecified potato as fried, this could result in exposure 
estimates for a few consumption surveys and age groups up to 78 % (or 121 %, in the case of one 
survey of infants) higher compared to the baseline exposure scenario. This adds to the uncertainty of 
the total dietary exposure to AA. 
Second, the consumers’ preferences regarding the degree of potato frying and bread toasting, the 
coffee and potato crisps brand, as well as the place of consumption of potato fried products are not 
reported in the Comprehensive Database. Some exposure scenarios were set in order to address 
specific consumer’s behaviours and preferences. Scenarios on the preference for particular products 
for potato crisps and on bread toasting resulted in variation less than 4 % and 8 %, respectively, in the 
final estimates of the total exposure to AA. Scenarios on the preference for particular products for 
coffee products and on the potato frying resulted in variation up to respectively 14 % and 80 % in the 
final estimates of the total exposure to AA.  
Finally, it should also be noted that all available occurrence data have been used altogether in order to 
produce a single ‘European’ estimate without taking into account possible variability throughout 
Europe. As a consequence, the exposure estimates at population group level may either be over- or 
underestimated. 
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9.3. Model input (parameters) 
Laboratories may use any appropriate method of analysis provided it can be demonstrated in a 
traceable manner that they fulfil the requirements according to ISO 17025. As some harmonised 
performance criteria, especially regarding LODs, are laid down, and taking into account that the 
analytical results were generated with MS based methods in accredited laboratories, this add only 
slightly to the uncertainty of the analytical results. 
9.4. Other uncertainties 
Epidemiological studies have used FFQs to estimate AA exposure in individuals. FFQs in most cases 
were not designed specifically to measure AA intake and may not have been able to capture the high 
variation on AA content of foods. As a consequence, the ability of FFQs to measure AA intake 
accurately is probably low, and the uncertainties in the measurement of AA intake in epidemiological 
studies may thus hamper to reliably assess the association between dietary exposure and cancer risk.  
Epidemiological studies did not indicate an increased risk of cancer in workers occupationally exposed 
to AA, although they generally included only men, and were thus not able to analyse possible risk of 
endometrial and ovarian cancer. Similarly, they did not provide consistent evidence for 
carcinogenicity of dietary intake of AA in humans. It remains therefore unclear if AA, although being 
carcinogenic in rodents, is a human carcinogen. 
Epidemiologic studies observed that maternal exposure to AA was inversely associated with birth 
weight and was positively associated with an increased risk of being small for gestational age. AA 
doses in these studies were much lower than doses in rats and mice that caused developmental 
toxicity, that occurred at levels that also caused maternal toxicity. It remains uncertain whether AA 
exposure causes developmental toxicity in humans. 
Although GA-mediated DNA damage is considered as the crucial initiating effect leading to AA-
induced carcinogenesis, the level of GA-derived DNA adducts cannot predict the localization and 
incidence of tumours with respect to organ specificity. This is particularly evident for the liver which 
shows high levels of DNA adducts in AA-treated rodents and, however, do not develop increased rates 
of hepatic tumour. Furthermore, it appears unclear if the target organs affected by the carcinogenic 
action of AA in rodents are also targets for tumour formation in humans. In general, it cannot be 
expected that the patterns of target organs for a given carcinogen are similar between rodents and 
humans. Likewise, the general uncertainty originating from this fact is not considered to be increased 
by the use of data on the carcinogenic action of AA on the Harderian gland of rodents, an organ not 
found in the human body.  
Dose-response analysis has revealed that increases in Harderian gland tumour frequency was the most 
sensitive tumour responses towards AA in rodents. It remains uncertain if there is/are human organ(s) 
as sensitive to AA carcinogenicity as the Harderian gland.  
AA is a germ cell mutagen but there are at present no accepted procedures for using AA doses relevant 
for human dietary exposure in the risk characterisation.  
The toxic effects of AA might be influenced by other dietary components (e.g. ethanol, garlic, other 
Maillard reaction products). 
9.5. Summary of uncertainties 
In Table 31 a summary of the uncertainty evaluation is presented, highlighting the main sources of 
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led 
to an over- or underestimation of the dietary exposure or the resulting risk.  
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Table 31:  Summary of qualitative evaluation of the impact of uncertainties on the risk assessment of 
exposure of acrylamide (AA) in food 
Sources of uncertainty Direction
(a)
  
Lack of representativeness of the occurrence data for certain food commodities +/− 
Use of lower/upperbound estimation −/+ 
Heterogeneity of the data regarding the mode of preparation of the products before analysis +/− 
Limited number of samples available in some food groups − 
Lack of information in the consumption data on the way potato and coffee are prepared +/− 
Long-term (chronic) exposure assessed from few days of consumption without removing the 
within-individual variability  
+ 
Use of the Harderian gland as the target tissue + 
Relatively wide variation in the outcomes of the benchmark dose modelling  +/− 
Lack of support from the occupational studies for the major critical effects, except for 
neurotoxicity 
+/− 
Inconsistency in the epidemiological studies of associations between AA dietary exposure and 
cancer 
+/− 
Uncertainty in the epidemiological studies regarding whether AA dietary exposure is 
associated with developmental toxicity 
− 
(a):  +: uncertainty with potential to cause over-estimation of exposure/risk; −: uncertainty with potential to cause under-
estimation of exposure/risk. 
 
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of human 
exposure to AA through consumption of food is moderate. 
 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
Background 
 Acrylamide (AA) is produced for a wide variety of industrial applications. In view of the 
known toxic effects of AA, including genotoxicity and carcinogenicity, concerns about human 
exposure to AA arose in 2002 when it was discovered that it is formed when certain foods are 
prepared at high temperatures.  
 AA forms predominantly from free asparagine and reducing sugars during high temperature 
processing, such as frying, roasting and baking.  
 An important initiative to reduce AA in various food categories is the development of the 
FoodDrinkEurope ‘Acrylamide toolbox’. The aim of the toolbox is to provide national and 
local authorities, manufacturers and other relevant bodies, with brief descriptions of 
intervention steps which may prevent and reduce formation of AA in specific manufacturing 
processes and products. 
Sampling and methods of analysis 
 A detailed description of sampling time, point and procedure is of special importance for the 
interpretation of analytical results as seasonality, storage and processing of the respective food 
product may have a substantial impact on their AA levels. 
 The analytical determination of AA in food products is most frequently performed by high 
performance liquid chromatographic (HPLC) or gas chromatographic (GC) separation 
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methods with mass spectrometric detection (MS), either in selected ion monitoring (SIM) or 
by tandem mass spectrometry (MS/MS) in multiple reaction mode (MRM). 
 Isotope labelled standards of AA are readily commercially available, either as AA-D3, AA-D5, 
13
C1-AA or as 
13
C3-AA. 
 Certified reference materials (CRMs) containing AA in various food products are 
commercially available. 
 Several proficiency tests and interlaboratory studies comprising AA in various food products 
were performed. In general, there was no evident trend in performance or bias in results 
obtained with GC-MS or HPLC-MS based methods. 
Occurrence 
 Occurrence data on AA in food generated with analytical methods based on GC or HPLC, 
collected since 2010 and representing products available in the European market were 
considered. This represented a total of 7 448 results reported by 24 European countries and 
35 971 results reported by six food associations.  
 Data provided by food associations and those provided by European countries gave overall 
consistent and complementary information. The Panel on Contaminants in the Food Chain 
(CONTAM Panel) concluded that the datasets could be combined to perform the exposure 
assessment of the European population.  
 AA was found at the highest levels in ‘Coffee substitutes (dry)’ (average MB levels of 
1 499 µg/kg) and ‘Coffee (dry)’ (average MB levels of 522 µg/kg). However, due to dilution 
effects, lower levels are expected in‘Coffee beverages’ and ‘Coffee substitutes beverage’ as 
consumed by the population. High levels were also found in ‘Potato crisps and snacks’ 
(average MB level of 389 µg/kg) and ‘Potato fried products (except potato crisps and snacks)’ 
(average MB level of 308 µg/kg). Lower levels were found in ‘Processed cereal-based baby 
foods’ (average MB level of 73 µg/kg), ‘Soft bread’ (average MB level of 42 µg/kg) and 
‘Baby foods, other than cereal-based’ (average MB level of 24 µg/kg).  
 Fried products made from fresh potato, including potato crisps and snacks, contained higher 
AA levels than those made from potato dough. 
 Higher AA levels were observed in ‘Crisp bread’ than in ‘Soft bread’. In both ‘Crisp bread’ 
and ‘Soft bread’, higher AA levels were observed in products mainly made from rye 
compared to products mainly made from wheat.    
 Mean and 95th percentile AA levels were higher in ‘Bran and whole grains breakfast cereals’ 
than in ‘Wheat and rye based breakfast cereals’ and in ‘Maize, oat, spelt, barley and rice based 
breakfast cereals’. 
 ‘Gingerbread’ contained higher AA levels than ‘Crackers’ and ‘Biscuits and wafers’. 
 A roasting effect was also observed, light roasting being associated with higher levels than 
medium and dark roasting.  
 ‘Coffee substitutes (dry), based on chicory’ contained higher AA levels than ‘Coffee 
substitutes (dry), based on cereals’.  
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 Higher AA levels were observed in ‘Processed cereal-based baby foods’ than in ‘Baby foods, 
other than cereal based’. Within this last category, ‘Baby foods, containing prunes’ contained 
higher levels than ‘Baby foods, not containing prunes’. 
Human dietary exposure 
 Infants, toddlers and other children were the most exposed groups. Depending on the survey 
and age group, chronic dietary exposure of children was estimated to be on average between 
0.5 and 1.9 µg/kg b.w. per day and the 95th percentile between 1.4 and 3.4 µg/kg b.w. per day. 
Chronic dietary exposure of adolescents, adults, elderly and very elderly was estimated to be 
on average between 0.4 and 0.9 µg/kg b.w. per day and the 95th percentile between 0.6 and 
2.0 µg/kg b.w. per day depending on the survey and age group. 
 The main contributor to the total exposure of infants was the ‘Baby foods, other than 
processed cereal-based’ followed by ‘Other products based on potatoes’ and ‘Processed 
cereal-based baby foods’. The main contributor to the total exposure of toddlers, other 
children and adolescents was ‘Potato fried products (except potato crisps and snacks)’ 
representing up to half the total exposure, followed by ‘Soft bread’, ‘Breakfast cereals’, 
‘Biscuits, crackers, crisp bread’, ‘Other products based on cereals’ and ‘Other products based 
on potatoes’. These foods groups were also the main contributors to the total exposure of 
adults, elderly and very elderly together with ‘Coffee’.   
 Specific scenarios were considered in order to assess the influence of specific behaviours 
(preference for particular products, places of consumption, home-cooking habits) on the total 
dietary exposure to AA. Scenarios on the preference for particular potato crisps and coffee 
products resulted in variations of less than 4 and 14 %, respectively, of the total dietary 
exposure to AA. In scenarios on home-cooking behaviours, degree of bread toasting resulted 
in variations of less than 8 %, while for conditions of potato frying the total dietary exposure 
to AA could be increased up to 80 %.      
 Substantial uncertainties were associated with the exposure assessment regarding the mode of 
preparation of ‘Potato fried products (except potato crisps and snacks)’, present in both the 
consumption and occurrence datasets.   
Hazard identification and characterisation 
Toxicokinetics 
 AA is extensively absorbed from the gastrointestinal tract in humans and experimental 
animals. 
 In experimental animals it has been shown that AA is rapidly distributed into the tissues. 
 AA crosses the placenta and is transferred to a small extent into human milk. 
 AA is metabolised to glycidamide (GA), which is a reactive epoxide and is widely distributed 
into the tissues. The main enzyme involved in the AA epoxidation is CYP2E1. 
 Mice are more proficient in converting AA into GA than either rats or humans.  
 Both AA and GA are conjugated with glutathione (GSH), primarily mediated by glutathione-
S-transferases, and the GSH adducts are subsequently converted to mercapturic acids. This 
reaction is considered a detoxification pathway. The mercapturic acids of AA and GA 
represent the major metabolites and are excreted in urine. They can be used as biomarkers of 
AA exposure.  
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 AA and GA can react with proteins to form covalent adducts, e.g. with haemoglobin (Hb). 
The Hb adducts represent important biomarkers of AA exposure.  
 Covalent adducts of AA with DNA have been generated in chemical reactions, but have never 
been detected in vivo or in vitro in animal or human tissues. In contrast, covalent DNA 
adducts of GA have been amply demonstrated in vitro and in experimental animals. These are 
used as biomarkers of AA exposure.  
 Physiologically based pharmacokinetic (PBPK) models allow derivation of human-equivalent 
doses (HEDs), which could be used to convert external doses of AA that produce critical 
effects in animal studies to the human external doses required to produce equivalent area 
under the curve (AUC) values for either AA or GA, depending on the toxic endpoint used.  
 The HEDs derived from equivalent AA-AUCs in rats and mice suggest that endpoints related 
to AA-mediated effects (e.g. neurotoxicity) require 4- to 6-fold higher doses in rats when 
compared to humans, based on inter-species differences in toxicokinetics. However, 0.5- to 
0.7-fold lower doses of AA would be required in mice to produce equivalent GA-AUCs for 
genotoxicity-related endpoints when compared to humans.  
Biomarkers of exposure/effects 
 The three main types of biomarkers for internal exposure to AA and GA are: (i) urinary 
mercapturic acids, (ii) Hb adducts of AA and GA and (iii) DNA adducts of GA. They reflect 
different timescales for the detection of the exposure. There are correlations both between 
these types of biomarkers, and between them and exposure to AA. 
 The N7-guanine adduct derived from GA (N7-GA-Gua) is the most abundant DNA adduct 
following AA exposure.  
 GA-DNA adducts in experimental animals are found at similar levels in various tissues of the 
body, although CYP2E1 is primarily located in the liver.   
Toxicity 
 Toxicological studies with AA have been conducted in rats, mice, monkeys, cats and dogs, 
using various dosing protocols and routes of exposure.  
 The major non-neoplastic findings were adverse effects on the peripheral nervous system, 
such as hind-limb strength, rotorod performance or histopathological changes in nerves and 
nervous system structures. The results are consistent with the notion that AA causes 
neurotoxic effects in various mammalian species in a similar dose range. 
 Rodent studies have demonstrated adverse effects of AA on male reproductive parameters, 
particularly reduced sperm counts and effects on sperm and testis morphology.  
 Rat and mouse studies have shown some signs of developmental toxicity (increased incidence 
of skeletal variations, slightly impaired body weight gain, histological changes in the central 
nervous system, and neurobehavioural effects) at exposure levels that in some cases are also 
associated with maternal toxicity.  
Genotoxicity 
 In vitro genotoxicity studies indicate that AA is a weak mutagen in mammalian cells but an 
effective clastogen.  
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 GA is a strong mutagen and a clastogen. It induces mutations via a DNA adduct mechanism. 
 In vivo, AA is clearly genotoxic in somatic and germ cells. 
 AA exerts its mutagenicity via metabolism by CYP2E1 to GA. AA can also induce gene 
mutations by a pathway involving the generation of reactive oxygen species (ROS) and 
oxidative DNA damage.  
Carcinogenicity 
 AA is carcinogenic in multiple tissues from both male and female mice and rats.  
 In rats, the major tumours produced by AA are: adenomas, fibroadenomas and fibromas of the 
mammary gland, thyroid gland follicular cell adenomas or carcinomas, and in F344 rats, testes 
or epididymis tunica vaginalis mesotheliomas.  
 In mice, the major tumours produced by AA are: Harderian gland adenomas, mammary gland 
adenoacanthomas and adenocarcinomas, lung alveolar and bronchiolar adenomas, benign 
ovary granulosa cell tumours, skin sarcomas, and stomach and forestomach squamous cell 
papillomas in females, and Harderian gland adenomas and adenocarcinomas, lung alveolar 
and bronchiolar adenomas and carcinomas, and stomach squamous papillomas and 
carcinomas in males.  
 A similar spectrum of tumours is observed when equimolar concentrations of GA were 
administered in drinking water to rats and mice, which is consistent with GA being the 
proximate carcinogenic metabolite of AA.  
Mode of action 
 AA is an electrophilic molecule, which can undergo Michael addition-type reactions with 
nucleophilic target molecules. In particular, activated thiolate moieties in cysteine residues of 
enzymes and other functional proteins, e.g. in neuronal cells or spermatocytes, have been 
described as targets. The neurotoxic properties of AA are considered to originate mainly from 
this type of reactivity. 
 AA shows some reactivity towards nucleic acids, whereas reports on the formation of DNA 
adducts in vivo suggest that GA is mainly if not exclusively responsible for the formation of 
DNA adducts in AA-treated animals.  
 Evidence from the available studies in the literature on hormonal and endocrine effects of AA 
is equivocal. This is particularly true for changes in hormone levels in AA-treated animals 
which were reported in some studies. Mechanistic hypotheses on local endocrine effects of 
AA which may explain tumour formation in certain hormone- or paracrine-regulated target 
tissues lack experimental proof. 
Observations in humans 
 Two cohort studies considered occupational exposure to AA and did not indicate an increased 
cancer risk.  
 Associations between AA exposure through diet and cancer risk have been analysed in at least 
36 publications, based on 16 epidemiological studies considering several cancer sites. For 
most cancers there is no consistent indication for an association between AA exposure and 
increased risk. A few studies suggested an increased risk for renal cell, and endometrial (in 
particular in never-smokers) and ovarian cancer, but the evidence is limited and inconsistent. 
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Moreover, one study suggested a lower survival in non-smoking women with breast cancer 
with a high pre-diagnostic exposure to AA but more studies are necessary to confirm this 
result. 
 Two studies reported an inverse relation between AA exposure (measured by levels of AA and 
GA adducts) and birth weight and other markers of fetal growth. It has not been established 
whether the association between dietary AA exposure and these outcomes is causal. 
 Studies among workers occupationally exposed to AA showed an increased risk of 
neurological alterations, including mostly the peripheral, but also the central nervous system. 
However, in most cases symptoms were reversible.  
Consideration of critical effects and dose-response modelling 
 From all data available, the CONTAM Panel identified four possible critical endpoints for AA 
toxicity, i.e. neurotoxicity, effects on male reproduction, developmental toxicity and 
carcinogenicity.  
 The data from human studies were not adequate for dose-response assessment.   
 The CONTAM Panel performed benchmark dose (BMD) analyses on data for neurotoxicity 
and on the tumour incidences of AA in rats and mice.  
 For the adverse effects of AA on male reproductive parameters in rodents, particularly 
reduced sperm counts and effects on sperm and testis morphology, the no-observed-adverse-
effect level (NOAELs) were about 2 mg/kg b.w. per day. 
 The lowest NOAEL reported for developmental toxicity was 1 mg/kg b.w. per day from 
studies in rats exposed gestationally and neonatally. 
 The CONTAM Panel selected the value of 0.43 mg/kg b.w. per day derived as the lowest 
BMDL10 from the data on incidences of peripheral nerve (sciatic) axonal degeneration in male 
F344 rats exposed to AA in drinking water for two years as the reference point for non-
neoplastic effects. 
 Based on the fact that this BMDL10 value of 0.43 mg/kg b.w. per day obtained for 
neurotoxicity is lower than the NOAEL of approximately 2.0 mg/kg b.w. per day for adverse 
effects on male reproductive parameters and of 1.0 mg/kg b.w. per day for developmental 
toxicity, the CONTAM Panel concluded that using the BMDL10 for neurotoxicity as the 
reference point is conservative when considering possible non-neoplastic effects of AA. 
 For neoplastic effects, the CONTAM Panel selected as the reference point the value of 
0.17 mg/kg b.w. per day derived as the lowest BMDL10 from data on incidences of Harderian 
gland adenomas and adenocarcinomas in male B6C3F1 mice exposed to AA for two years.  
 The CONTAM Panel noted that the Harderian gland is an organ absent in humans, but that in 
rodents this organ is a sensitive target tissue to detect compounds that are both genotoxic and 
carcinogenic. Taking into account that target tissues for tumour formation by a given 
genotoxic carcinogen may differ between rodents and humans, the CONTAM Panel 
considered the most sensitive target tissue in rodent bioassays, the Harderian gland, a 
conservative endpoint for assessment of the risk for neoplastic effects of AA in humans. 
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Risk characterisation 
 The CONTAM Panel calculated margin of exposure (MOE) values for the neurotoxic effects 
(ranging from 1 075 (minimum lower bound (LB)) to 226 (maximum upper bound (UB)) for 
the mean exposure, and from 717 (minimum LB) to 126 (maximum UB) for the 
95th percentile exposure estimates across surveys and age groups). Taking into account 
differences between species and within the human population, the Panel concluded that the 
MOEs across surveys and age groups are not of concern. However, the Panel noted that the 
MOEs for the 95th percentile UB exposure estimates for toddlers and other children are close 
to the value that might be of concern for neurotoxicity.  
 Comparison of the reference point for risk characterisation of the neoplastic effects of AA to 
the estimates of human dietary exposure to AA across surveys and age groups reveals MOEs 
that range from 425 (minimum LB) to 89 (maximum UB) for the mean exposure estimates, 
and from 283 (minimum LB) to 50 (maximum UB) for the 95th percentile exposure estimates. 
The EFSA Scientific Committee concluded that for substances that are both genotoxic and 
carcinogenic, an MOE of 10 000 or higher, based on a BMDL10 from an animal study, and 
taking into account overall uncertainties in the interpretation, would be of low concern from a 
public health point of view. Since the MOEs are all substantially lower than 10 000, the 
CONTAM Panel concluded that although the available human studies have not demonstrated 
AA to be a human carcinogen, the MOEs based on the current levels of dietary exposure to 
AA across surveys and age groups indicate a concern with respect to neoplastic effects. 
 The CONTAM Panel noted that AA is a germ cell mutagen and that there are at present no 
established procedures for risk assessment using this endpoint. 
RECOMMENDATIONS  
 The reporting of AA occurrence data should be improved regarding the mode of preparation 
of the products before analysis.  
 Duplicate diet studies are recommended in order to improve exposure assessment, since they 
provide a more accurate indication of AA levels in food as prepared and consumed at home.   
 Data on urinary metabolites levels from individuals participating in the duplicate diet studies 
should be generated for the purpose of validation of the biomarkers. 
 An up-to-date OECD compliant extended one-generation or two-generation reproductive 
toxicity study investigating the effects of AA on sperm parameters and including a detailed 
histopathological examination of the testis and accessory glands as well as investigating the 
effects on development until puberty should be conducted. 
 If further epidemiological studies are conducted to assess possible associations between 
dietary AA intake and risk of cancers (e.g. endometrium, ovary and renal cells), they should 
have improved measurement of AA exposure, and should be sufficiently powered. 
 Further epidemiological studies are required to confirm or refute the inverse relation between 
dietary AA intake and birth weight and other markers of fetal growth observed in two studies.  
 Improved approaches for the detection and risk assessment of germ cell mutagens should be 
developed, and applied to AA and GA.   
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APPENDICES 
Appendix A. Identification and selection of evidence relevant for the risk assessment of 
acrylamide (AA) in food 
For the risk assessment of AA in food, the CONTAM Panel applied the general principles of the risk 
assessment procedure as follows: 
 The potential health effects of AA were identified and characterised on the basis of the 
available scientific studies published in the open literature (hazard identification and 
characterisation, see Section 7). 
 An exposure assessment for AA in food was performed in order to compute the current level 
of intake of AA in the population and to cover specific consumption habits (see Sections 4, 5 
and 6). 
 The risk was characterised by comparing the reference point(s) identified with the exposure 
estimates to conclude on the likelihood of adverse effects (see Section 8).  
The principles stated in the following EFSA publications were applied in the various steps of the 
process: 
 EFSA (European Food Safety Authority), 2005b. Opinion of the Scientific Committee on a 
request from EFSA related to a harmonised approach for risk assessment of substances which 
are both genotoxic and carcinogenic. The EFSA Journal 2005, 282, 1–31.  
 EFSA (European Food Safety Authority), 2006. Guidance of the Scientific Committee on a 
request from EFSA related to uncertainties in Dietary Exposure Assessment. The EFSA 
Journal 2006, 438, 1–54.  
 EFSA (European Food Safety Authority), 2009b. Guidance of the Scientific Committee on use 
of the benchmark dose approach in risk assessment. The EFSA Journal 2009, 150, 1–72.  
 EFSA (European Food Safety Authority), 2009c. Guidance of the Scientific Committee on 
transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: General 
principles. The EFSA Journal 2009, 1051, 1–22. 
 EFSA (European Food Safety Authority). 2010b. Management of left-censored data in dietary 
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. 
doi:10.2903/j.efsa.2010.1557 
 EFSA (European Food Safety Authority), 2011d. Use of BMDS and PROAST software 
packages by EFSA Scientific Panels and Units for applying the Benchmark Dose (BMD) 
approach risk assessment. Technical Report. EFSA Supporting Publications 2011, EN-113, 
190 pp. 
 EFSA (European Food Safety Authority), 2011e. Overview of the procedures currently used at 
EFSA for the assessment of dietary exposure to different chemical substances. EFSA Journal 
2011;9(12):2490, 33 pp. doi:10.2903/j.efsa.2011.2490 
 EFSA SC (EFSA Scientific Committee), 2012a. Guidance on selected default values to be 
used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual 
measured data. EFSA Journal 2012;10(3):2579, 32 pp. doi:10.2903/j.efsa.2012.2579 
 EFSA SC (EFSA Scientific Committee), 2012b. Scientific Opinion on Risk Assessment 
Terminology. EFSA Journal 2012;10(5):2664, 43 pp. doi:10.2903/j.efsa.2012.2664 
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A.1.  Hazard identification and characterisation 
A.1.1.  Identification of scientific evidence 
The CONTAM Panel published in 2005 a statement based on the principal conclusions and 
recommendations of the summary report of the JECFA risk assessment performed in 2005 (full report 
published in 2006), that considered the scientific evidence available until that date. The CONTAM 
Panel agreed with the principal conclusions and recommendations of the JECFA summary report and 
concluded that an additional evaluation by the Panel was not necessary at that time (see Section 1.1). 
For the current risk assessment, the Panel considered the information available until the publication of 
the CONTAM Panel statement as well as new information that has become available since then as 
follows: 
 The background information was taken from earlier scientific evaluations on AA in food 
performed by national agencies, national and international independent expert advisory 
committees (see Section 1.1).  
The information provided in these assessments was complemented by a scientific  literature search 
(Web of Science) covering the period between 1 January 1950 and 31 December 2004 using as search 
terms ‘acrylamide’ and ‘cancer*’ or ‘carcin*’ or ‘develop*’ or ‘epidem*’ or ‘genotox*’ or ‘neur*’ or ‘ 
neurotox*’ or ‘ reproductive tox*’. This search strategy identified a total of 7 479 records. 
 Search in scientific databases aimed at identifying studies published in the open scientific 
literature and in scientific peer-reviewed journals 
The collection of scientific studies available in the public domain published since 2005 was done 
through searching scientific literature databases (Web of Science and PubMed). The approach for 
searching was sensitive to retrieve as many studies as possible relevant for the hazard identification 
and characterisation of AA. The search terms contained only the term ‘acrylamide’ and ‘glycidamide’ 
(its main metabolite) without additional search terms. The search was performed to cover the period 
between 1 January 2005 and 31 December 2013. The search strategy identified a total of 14 796 (Web 
of Science) and 3 619 (PubMed) records relevant to AA in food, respectively. In order to update the 
database, a search was conducted regularly until 13 March 2015 (EFSA, 2015). 
 A consultation procedure with the EFSA Stakeholder Consultative Platform (SHP) 
This consultation aimed at obtaining information on research projects or risk assessments the SHP 
organisations were performing or had completed which were not in the public domain and could be of 
interest for EFSA’s risk assessment on AA in food. The consultation was launched on 23 April 2013 
(closure date, 24 May 2013).
40
 This call resulted in the documents and information listed under the 
section ‘Documentation provided to EFSA’.  
Within the comments submitted by FoodDrinkEurope (FDE), a (non-exhaustive) list of publications  
considered by FDE as relevant were provided. This list consisted of 20 studies published after the 
2010 JECFA evaluation (FAO/WHO, 2011), i.e. between 2010 and 2013. 
A.1.2.  Study selection process and its results 
The literature database retrieved as above, included scientific peer-reviewed papers published in 
scientific journals and relevant non-peer reviewed papers (such as conference proceedings, risk 
assessment reports by national/international bodies and book chapters).  
                                                     
40
 http://registerofquestions.efsa.europa.eu/roqFrontend/questionsListLoader?mandate=M-2013-0002     
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The following criteria were considered for the inclusion of studies in the selection process: 
 Experimental toxicity studies on AA or GA in vitro,   
 Experimental toxicity studies on AA or GA in laboratory animals (oral route),   
 Epidemiological studies in humans addressing associations between AA exposure and adverse 
health outcome(s) in the general population (via the diet) and in occupationally exposed 
populations (via inhalation), 
The following criteria were considered for the non-inclusion of studies in the selection process: 
 Studies in the field of ecotoxicity, i.e. not in the field of laboratory animals and human health,   
 Studies on polyacrylamide gels or AA used as vehicle/polymers and other similar 
applications.   
In addition, the following criteria were used for the inclusion/non-inclusion of scientific papers and 
reports in the selection process:  
 only scientific papers in English were considered, 
 abstracts of conference proceedings were not considered,  
 reviews were considered as source of background information and as an additional source of 
scientific evidence. These were not considered as the basis for the hazard characterization.  
 book chapters were considered as sources of background information. These were not 
considered as the basis for the hazard characterization.  
A.1.3.  Result of the study selection process 
The result of the study selection process was as follows: 
 1 070 scientific papers published in the open literature were identified by the literature 
searches for the period indicated related to the hazard identification and characterisation of 
acrylamide in food.   
 The 20 scientific papers listed by FDE and submitted through the consultation with the EFSA 
Stakeholder Consultative Platform were all identified in the literature searches as described 
above.  
 The scientific papers mentioned in the proposal from organisations belonging to four EU 
Member States (Denmark, France, Germany and Sweden) to consider new scientific findings 
on the possible carcinogenicity of acrylamide sent to EFSA September 2012 were also all 
identified in the literature searches as described above.  
 The scientific paper were grouped according to topics of interest, e.g. toxicokinetics, general 
toxicity, genotoxicity, reproductive and developmental effects, and study type, i.e. human, 
experimental animal or in vitro study. 
 The selection of the scientific papers for inclusion or non-inclusion in the hazard identification 
and characterisation of AA was based on consideration of the extent to which the study was 
relevant to the assessment and general study quality considerations (e.g. sufficient details on 
the methodology, performance or outcome of the studies, route of administration, clear dose-
response relationship, statistical description of the results (EFSA, 2009c), irrespective of 
whether they yielded positive, negative, or null results. 
 The further application of the selection process described above resulted in the scientific 
papers cited in the opinion.  
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A. 2.  Exposure assessment 
A.2.1.  Identification of evidence 
The following sources of evidence were used: 
 The official monitoring data collected by the Member States/European Countries submitted in 
the framework of the EFSA continuous call for data.
41
  
 An ad-hoc call for data entitled ‘Call for acrylamide occurrence data in food and beverages 
intended for human consumption collected outside official controls’ was launched on 25 April 
2013 with a closure date of 30 June 2013. This call aimed at the submission of occurrence data 
on AA in food from food business operators and other stakeholders collected from 2010 
onwards.
42
   
 The EFSA Comprehensive European Food Consumption Database as a source of information 
on food consumption across the EU.
43
  
A.2.2.  Data selection process and its results 
The consideration of the selection criteria for occurrence and consumption data for the AA dietary 
exposure assessment and the results thereafter are described in Sections 4, 5 and 6. 
A.3.  Other sections of the scientific opinion  
The sections on Introduction (Section 1 and sub-section therein), Legislation (Section 2), Sampling 
and methods of analysis (Section 3 and sub-section therein), Previously reported literature data on AA 
in food (Section 4.3) and Previously reported human exposure assessment (Section 6.3 and sub-
sections therein) provide generic background information on AA to support the overall conclusions. 
The identification of evidence for these chapters was limited to the most relevant information.  
The following sources of evidence were used: 
 Previous scientific evaluations by national agencies, national and international independent 
expert advisory committees.  
 A consultation procedure with the EFSA Stakeholder Consultative Platform. The documents 
provided by BEUC, the European Consumers Association, have been considered under 
Section 4.3.2.  
 Search in scientific databases (Web of Science) aimed at identifying studies and reviews that 
have appeared in the open scientific literature and published in scientific peer-reviewed 
journals. These were identified in the search performed as explained in A.1.1. 
 Respective legislation on AA with special emphasis on food.    
The selection of the scientific papers for inclusion in the aforementioned sections to give a 
comprehensive but not exhaustive background information on AA, was therefore based on 
consideration of the extent to which the study was informative and relevant to the assessment and 
general study quality considerations. 
 
                                                     
41
 http://www.efsa.europa.eu/en/data/call/datex101217.htm  
42 http://www.efsa.europa.eu/en/dataclosed/call/130425.htm    
43
 http://www.efsa.europa.eu/en/datex/datexfoodcdb.htm  
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Appendix B. Distribution of acrylamide (AA) levels according to additional information from 
the data suppliers 
Table B1:  Distribution of acrylamide (AA) levels in µg/kg 
 
Type n
(a)
 LC
(b)
 
Mean  
MB [LB-UB]
(c)
 
P95  
MB [LB-UB]
(c)
 
 Potato fried products (except 
potato crisps and snacks) 
    
1 Fresh  977 14.4 275 [270–280] 775 
2 Pre-fabricate  48 20.8 197 [190–203] - 
 French fries     
1 Baked in the oven  161 13.7 257 [254–260] 1035 
2 Deep fried  411 18.5 243 [238–249] 632 
 
Potato crisps made from fresh 
potatoes and potato dough 
    
1 Batch process 1 412 0.0 327 767 
2 Continuous process 32 289 0.0 387 923 
 
Potato crisps made from fresh 
potatoes only 
    
1 Batch process 1 412 0.0 327 767 
2 Continuous process 29 557 0.0 391 941 
 Bread     
1 Soft bread  504 50.0 43 [36–49] 158 
2 Toasted bread
(d)
 39 33.3 43 [37–48] - 
3 Crisp bread and rusk  389 22.4 163 [158–167] 444 
 Soft bread     
1 Rye  85 37.6 57 [53–61] 240 
2 Wheat  302 45.0 38 [33–44] 120 
 Crisps and rusks     
1 Rye  180 1.1 245 [244–245] 529 
2 Wheat  116 34.5 126 [119–133] 400 
 Roasted coffee     
1 Dark  15 0 187 - 
2 Medium  44 0 266 - 
3 Light  45 0 374 - 
 Roasted coffee     
1 Regular coffee  561 6.4 245 [244–247] 510 
2 Decaffeinated 34 14.7 319 [317–321] - 
 Instant coffee     
1 Regular Coffee  788 0.8 718 1133 
2 Decaffeinated  74 5.4 630 [629–631] 941 
(a):  n: number of samples.  
(b):  LC: percentage of censored results.  
(c)  Mean MB [LB-UB], P95 MB [LB-UB]: mean and 95th percentile contamination level presented as the middle bound 
estimate (lower bound estimate; upper bound estimate). When the middle, lower and upper bound estimates are equal, 
only one estimate is given. In case of too few observations (less than 60 for the 95th percentile), the estimation may be 
biased and is not provided.  
(d):  Samples taken from the market. 
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Appendix C. French fries and potato fried, potato crisps and coffee consumption levels estimates from the Comprehensive Database 
Table C1:  Overview on ‘French fries and potato fried’ consumption (g/day) by age group. Minimum, median and maximum of the mean and 95th percentile 
(P95) values across European countries and dietary surveys are shown. 
 Infants Toddlers Other children Adolescents Adults Elderly Very elderly 
All population  
Average (g/day)        
Minimum  0 1.3 9.6 11 11 7.5 5.8 
Median 0.4 7.5 19 27 24 18 14 
Maximum 1.6 22 57 70 58 34 28 
P95 (g/day)
(a)
        
Minimum  0 9.3 41 57 55 50 63 
Median 4.2 34 72 122 101 93 73 
Maximum 12 86 185 200 155 120 107 
Consumers only 
Percentage of consumers        
Minimum  0 11 21 18 15 10 12 
Median 3.6 40 43 43 40 26 28 
Maximum 16 61 85 83 80 64 67 
Average (g/day)        
Minimum  4.5 6 20 28 26 27 17 
Median 10 28 40 67 66 59 52 
Maximum 26 52 88 100 104 83 92 
P95 (g/day)
(a)
        
Minimum  12 14 46 70 67 79 116 
Median 23 49 93 147 153 129 130 
Maximum 33 102 200 265 225 160 160 
In order to avoid the impression of too high precision, the numbers for all consumption estimates are rounded to 2 figures. A ‘0’ indicates the absence of consumption. 
(a):  The 95th percentile (P95) estimates obtained on dietary surveys/age groups with less than 60 observations may not be statistically robust (EFSA, 2011b) and therefore they were not 
included in this table. 
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Table C2:  Overview on ‘Potato crisps’ consumption (g/day) by age group. Minimum, median and maximum of the mean and 95th percentile (P95) values 
across European countries and dietary surveys are shown. 
 Infants Toddlers Other children Adolescents Adults Elderly Very elderly 
 All population  
Average (g/day)        
Minimum  0 0 0 1.2 0.5 0 0 
Median 0 0.8 3 4.1 2.2 0.3 0.1 
Maximum 0.1 4.4 6.4 11 7 2.1 1.4 
P95 (g/day)
(a)
        
Minimum  0 0 0 7.1 0 0 0 
Median 0 3.3 17 23 14 0 0 
Maximum 0 13 38 80 45 13 7.5 
 Consumers only 
Percentage of consumers        
Minimum  0 0 0 9.7 1.6 0 0 
Median 0 9.9 17 20 9.6 3.1 0.8 
Maximum 2.8 29 53 59 40 23 19 
Average (g/day)        
Minimum  2.2 1.3 4.5 5.6 5.7 4 3.8 
Median 2.6 7.6 14 20 21 14 11 
Maximum 3 75 37 45 53 50 33 
P95 (g/day)
(a)
        
Minimum  - 8.6 14 15 18 - - 
Median - 9.9 32 48 50 - - 
Maximum - 11 50 113 125 - - 
In order to avoid the impression of too high precision, the numbers for all consumption estimates are rounded to 2 figures. A ‘0’ indicates the absence of consumption. 
(a):  The 95th percentile (P95) estimates obtained on dietary surveys/age groups with less than 60 observations may not be statistically robust (EFSA, 2011b) and therefore they were not 
included in this table. 
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Table C3:  Overview on ‘Coffee’ consumption (g dry equivalent/day) by age group. Minimum, median and maximum of the mean and 95th percentile (P95) 
values across European countries and dietary surveys are shown. 
 Infants Toddlers Other children Adolescents Adults Elderly Very elderly 
 All population  
Average (g/day)        
Minimum  0 0 0 < 0.05 2.5 2.1 1.9 
Median 0 < 0.05 < 0.05 0.8 9.8 19 14 
Maximum < 0.05 0.2 1.5 2.7 29 34 40 
P95 (g/day)
(a)
        
Minimum  0 0 0 0 6.7 11 13 
Median 0 0 0 4 27 43 37 
Maximum 0 0 5 13 76 74 66 
 Consumers only 
Percentage of consumers        
Minimum  0 0 0 2 50 50 34 
Median 0 0.4 2.2 14 75 90 88 
Maximum 0.2 2.8 14 35 89 97 100 
Average (g/day)        
Minimum  < 0.05 < 0.05 0.8 1.1 4 4.1 3.9 
Median 0.1 0.3 2.9 4.5 14 21 17 
Maximum 0.3 7.6 12 10 36 35 40 
P95 (g/day)
(a)
        
Minimum  - - 3.3 7.3 8 20 27 
Median - - 3.3 16 37 45 40 
Maximum - - 3.3 27 80 74 66 
In order to avoid the impression of too high precision, the numbers for all consumption estimates are rounded to 2 figures. A ‘0’ indicates the absence of consumption. 
(a):  In some surveys, the coffee consumption level has been reported as coffee bean or instant powder and water, whereas in some other surveys, coffee has been reported directly as a beverage. 
For sake of consistency, all the coffee consumption levels have been converted in dry equivalent basis, using the following dilution factors: 0.2 for ‘Coffee drink, espresso’, 0.05  for  
‘Coffee drink, café Americano’  and ‘Coffee drink , cappuccino’, 0.1 for ‘Coffee drink, café macchiato’, 0.04 for ‘Iced coffee’ and ‘Coffee with milk (café latte, café au lait), 0.02 for 
‘Instant coffee, liquid’, and 0.05 for unspecified coffee beverage.       
(b):  The 95th percentile (P95) estimates obtained on dietary surveys/age groups with less than 60 observations may not be statistically robust (EFSA, 2011b) and therefore they were not 
included in this table. 
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Appendix D. Acrylamide (AA) mean occurrence levels used in the exposure assessment 
Baseline exposure scenario 
Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
Foodex 
level 
Food group Occurrence data n LB* UB** 
1 Grains and grain-based products 
 
   
2 Grains for human consumption 
10.4 - Grains for human 
consumption 
73 46 46 
2 Grain milling products 
10.4 - Grains milling 
products 
17 117 117 
2 Bread and rolls 
    
3 Wheat bread and rolls 4.1  
   
ahg 4 Wheat bread and rolls, not toasted 4.1 302 39 39 
ahg 4 Wheat bread and rolls, toasted 4.1 302 39 39 
4 Unspecified wheat bread and rolls 4.1 302 39 39 
3 Rye bread and rolls 
    
ahg 4 Rye bread and rolls, not toasted 4.2 – Rye 85 57 57 
ahg 4 Rye bread and rolls, toasted 4.2 – Rye 85 57 57 
4 Unspecified wheat bread and rolls 4.2 – Rye 85 57 57 
3 Mixed wheat and rye bread and rolls 
    
ahg 4 Mixed bread and rolls, not toasted 4.1 – 4.2 - Rye 387 43 43 
ahg 4 Mixed bread and rolls, toasted 4.1 – 4.2 - Rye 387 43 43 
4 Unspecified mixed bread and rolls 4.1 – 4.2 - Rye 387 43 43 
3 Multigrain bread and rolls 
    
ahg 4 Multigrain bread and rolls, not toasted 4.1 - 4.2 – 4.3 543 43 43 
ahg 4 Multigrain bread and rolls, toasted 4.1 - 4.2 – 4.3 543 43 43 
4 Unspecified multigrain bread and rolls 4.1 - 4.2 – 4.3 543 43 43 
3 Unleavened bread, crisp bread and rusk 
    
ahg 4 Crisp bread, rye 6.2 - Crisp and rusk - rye 178 233 233 
ahg 4 Crisp bread, wheat 
6.2 - Crisp and rusk - 
wheat 
101 107 107 
ahg 4 Rusk, unspecified 6.2 - Crisp and rusk 389 163 163 
ahg 4 Other unleavened bread (pita, matzo) 4.1 - 4.2 - 4.3 543 43 43 
4 
Unspecified unleavened bread, crisp bread and 
rusk 
6.2 528 171 171 
3 Other bread 
    
4 Extruded bread 6.2 - Other 22 287 287 
ahg 4 Potato and potato-rye bread 10.5 - Bread 3 570 570 
ahg 4 Rice and soya bread 4.2 - Other - 6.2 Other 34 193 193 
ahg 4 Other bread (corn, muesli, etc…) 4.2 - Other 12 8 33 
4 Unspecified other bread 4.2 - Other - 6.2 Other 34 193 193 
3 Bread products 
    
ahg 4 Breadcrumbs and croutons 6.2 - Other 22 287 287 
4 Bread stuffing Not taken into account - 0.0 0.0 
4 Other bread products 4.1 - 4.2 - 4.3 - 6.2 1 071 106 106 
Table continued overleaf. 
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Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
(continued) 
Foodex 
level 
Food group Occurrence data n LB* UB** 
3 Unspecified bread and rolls 4.1 - 4.2 - 4.3 543 43 43 
2 Pasta (Raw) 10.4 - Pasta 9 < 1 25 
2 Breakfast cereals 
 
   
3 Cereal flakes 
 
   
4 Barley, rice, millet, spelt flakes 5.1 - 5.3 730 180 180 
ahg 4 Corn flakes 5.1 210 102 102 
4 Millet flakes 5.1 210 102 102 
ahg 4 Oat bran / wholemeal flakes 5.3 520 211 211 
ahg 4 Oat flakes 5.1 210 102 102 
4 Rye flakes 5.2 151 170 170 
ahg 4 Wheat flakes 5.2 - 5.3 671 202 202 
4 Wheat germs flakes 5.2 151 170 170 
4 Mixed cereal flakes 5.1 - 5.3 730 180 180 
4 Rice and wheat flakes with chocolate 5.1 - 5.2 - 5.3 881 178 178 
4 Unspecified cereal flakes 5.1 - 5.2 - 5.3 881 178 178 
3 Muesli 5.1 - 5.2 - 5.3 881 178 178 
3 Cereal bars 5.1 - 5.2 - 5.3 881 178 178 
3 Popped cereals 5.3 520 211 211 
3 Mixed breakfast cereals 5.1 - 5.2 - 5.3 881 178 178 
3 Grits 10.1 9 29 29 
3 Porridge 10.1 9 29 29 
3 Unspecified breakfast cereals 5.1 - 5.2 - 5.3 - 10.1 890 176 176 
2 Fine bakery wares 
    
3 Pastries and cakes 
    
ahg 4 Gingerbread and lebkuchen 6.4 693 407 407 
4 Waffles 6.3 682 201 201 
4 Macaroons 6.3 682 201 201 
4 Other and unspecified pastries and cakes 10.2 198 66 66 
3 Biscuits (cookies) 
    
4 Speculoos 6.4 693 407 407 
ahg 4 Biscuits, sticks, crackers, salty 6.1 162 231 231 
4 Other biscuits (cookies) 6.3 682 201 201 
4 Unspecified biscuits (cookies) 6.1 - 6.3 - 6.4 1 537 297 297 
3 Unspecified fine bakery wares 6.1 - 6.3 - 6.4 - 10.2 1 735 271 271 
2 Unspecified grains and grain-based products Not taken into account - - - 
1 Vegetables and vegetable products 
    
2 Cocoa beans and cocoa products 
    
3 Cocoa powder 10.6 – powder 13 179 179 
3 Cocoa beverage-preparation, powder 10.6 – powder 13 179 179 
Table continued overleaf. 
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Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
(continued) 
Foodex 
level 
Food group Occurrence data n LB* UB** 
2 Coffee beans and coffee products (Solid) 
    
ahg 3 Coffee beans 7.1 595 249 249 
3 Coffee beans, decaffeinated 7.1 - decaffeinated 34 319 319 
3 Instant coffee, powder 7.2 - regular 788 718 718 
3 Instant coffee, powder, decaffeinated 7.2 - decaffeinated 74 630 630 
2 Coffee substitutes (Solid) 
    
ahg 3 Malt, barley and wheat coffee 7.3 20 510 510 
3 Chicory coffee 7.4 37 2 942 2 942 
3 Other and unspecified coffee substitutes (Solid) 7.3 - 7.4 - 7.5 88 1 499 1 499 
2 
Other and unspecified vegetables and 
vegetable products 
Not taken into account - - - 
1 Starchy roots and tubers 
    
2 Potatoes and potatoes products 
    
ahg French fries and potato fried 1.1 - 1.2 - 1.3 - 1.4 1 598 290 290 
ahg Potato pancake (fritter, rösti, etc) 1.5 96 606 606 
ahg 
Non fried potato products (potato boiled, baked, 
mashed, etc…) 
10.5 - other 37 66 75 
2 
Other and unspecified starchy roots and 
tubers 
Not taken into account - - - 
1 Legumes, nuts and oilseeds 
    
2 Legumes, beans, dried 
    
3 Peanut (Arachis hypogaea) 11.1 40 93 93 
3 Other and unspecified legumes, beans, dried Not taken into account - 0 0 
2 Tree nuts 11.1 40 93 93 
2 Oilseeds 11.1 40 93 93 
2 Unspecified legumes, nuts and oilseeds Not taken into account  - - - 
1 Fruit and fruit products 
    
2 Citrus fruits Not taken into account - - - 
2 Pome fruits Not taken into account - - - 
2 Stone fruits Not taken into account - - - 
2 Berries and small fruits Not taken into account - - - 
2 Oilfruits Not taken into account - - - 
2 Miscellaneous fruits 
    
3 Table olives (Olea europaea) 11.2 3 454 454 
3 Other and unspecified miscellaneous fruits Not taken into account - - - 
2 Dried fruits 
    
3 Dried prunes (Prunus domestica) 11.3 18 89 89 
3 Dried dates (Phoenix dactylifera) 11.3 18 89 89 
3 Other and unspecified dried fruits Not taken into account - - - 
2 Jam, marmalade and other fruit spreads 
    
3 Jam 
    
4 Jam, Plums (Prunus domestica) 11.3 18 89 89 
4 Other and unspecified jam Not taken into account - - - 
Table continued overleaf. 
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Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
(continued) 
Foodex 
level 
Food group Occurrence data n LB* UB** 
3 
Other and unspecified jam, marmalade and other 
fruit spreads 
Not taken into account - - - 
2 Other fruit products (excluding beverages) 
    
3 Fruit, canned 
    
4 Canned fruit, Plum (Prunus domestica) 11.3 18 89 89 
4 Other and unspecified fruit, canned Not taken into account - - - 
3 Fruit compote 
    
4 Fruit compote, Plum (Prunus domestica) 11.3 18 89 89 
4 Other and unspecified fruit compote Not taken into account - - - 
3 
Other and unspecified fruit products (excluding 
beverages) 
Not taken into account - - - 
2 Unspecified fruit and fruits products Not taken into account - - - 
1 Meat and meat products Not taken into account - - - 
1 Fish and other seafood 
    
3 Fish fingers 10.4 - Composite dishes 25 129 129 
3 Other and unspecified fish and other seafood Not taken into account - - - 
1 Milk and dairy products Not taken into account - - - 
1 Eggs and egg products Not taken into account - - - 
1 Sugar and confectionary 
    
2 Chocolate (Cocoa) products 10.6 - chocolate 31 73 73 
2 
Other and unspecified sugar and 
confectionary 
Not taken into account - - - 
1 Animal and vegetable fats and oils Not taken into account - - - 
1 Fruit and vegetable juices 
    
2 Fruit juice 
    
3 Juice, Prune 11.3 - - - 
3 Other and unspecified fruit juice Not taken into account - - - 
2 
Other and unspecified fruit and vegetable 
juices 
Not taken into account - - - 
1 Non-alcoholic beverages 
    
2 Coffee (Beverage) 
    
3 Coffee drink, espresso 7.1 - dilution factor of 0.2 595 50 50 
3 Coffee drink, café américano 7.1 - dilution factor of 0.05 595 13 13 
3 Coffee drink, cappuccino 7.1 - dilution factor of 0.05 595 13 13 
3 Coffee drink, café macchiato 7.1 - dilution factor of 0.10 595 25 25 
3 Iced coffee 7.1 - dilution factor of 0.04 595 10 10 
3 Coffee with milk (café latte, café au lait) 7.1 - dilution factor of 0.04 595 10 10 
3 Instant coffee, liquid 7.2 - dilution factor of 0.02 862 14 14 
3 Unspecified coffee (Beverage) 
7.1 + dilution factor of 
0.05 - 7.2 + dilution factor 
of 0.02 
1 457 14 14 
Table continued overleaf. 
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Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
(continued) 
Foodex 
level 
Food group Occurrence data n LB* UB** 
2 Coffee substitutes beverage 
7.3 - 7.4 - 7.5 - dilution 
factor of 0.05 
88 75 75 
2 Cocoa beverage 
10.6 – powder - dilution 
factor of 0.028 
13 5 5 
2 Other and unspecified non-alcoholic beverages Not taken into account - - - 
1 Alcoholic beverages Not taken into account - - - 
1 Drinking water Not taken into account - - - 
1 Herbs, spices and condiments Not taken into account - - - 
2 Spices 
    
3 Paprika powder 11.5 30 379 379 
3 Other and unspecified spices Not taken into account - - - 
2 
Other and unspecified herbs, spices and 
condiments 
Not taken into account - - - 
1 Food for infants and small children 
    
Ahg 2 Infant and follow-on formulae, powder(a) 8.1 - infant formula 33 3 26 
Ahg 3 Cereals which have to be reconstituted (a) 9.2 - flours 159 125 125 
3 Biscuits, rusks and cookies  9.1 235 111 111 
3 Ready-to-eat meal, cereal-based 9.2 - ready to eat meal 73 13 13 
3 Unspecified cereal-based food  9.1 - 9.2 - 9.3 736 73 73 
Ahg 2 
Ready-to-eat meal and desserts, not cereal-
based  
8.1 - ready to eat meal 291 14 27 
Agh Fruit puree, without prunes 8.1 - puree - 8.3 - puree 34 30 44 
Agh Fruit puree, unspecified 8.1 - 8.2 - 8.3 - puree 47 55 55 
2 Fruit juice and herbal tea Not taken into account - - - 
1 Products for special nutritional use 
    
2 Dietetic food for diabetics (labelled as such) 
    
3 Fine bakery products for diabetics 
10.4 – fine bakery wares 
for diabetics 
1 139 139 
3 Other and unspecified dietetic food for diabetics Not taken into account - - - 
2 
Other and unspecified products for nutritional 
use 
Not taken into account - - - 
1 Composite food 
    
2 Cereal-based dishes 
    
3 Sandwich and sandwich-like meal 
4.1 - 4.2 - 4.3 - Conversion 
factor of 0.56(b) 
543 24 24 
3 Pizza and pizza-like pies 
4.1 - 4.2 - 4.3 - Conversion 
factor 
543 24 24 
3 Pasta, cooked 10.4 – Pasta 9 < 1 25 
3 Other and unspecified cereal-based dishes 
4.1 - 4.2 - 4.3 - conversion 
factor of 0.56 - 10.4 - 
Pasta 
552 23 23 
2 Potato-based dishes 
10.5 - other - conversion 
factor of 0.47(b) 
37 31 35 
2 Meat-based meals 
    
Ahg 3 Meat burger and meat balls 10.4 - Composite dishes 25 129 129 
Ahg 3 Goulash and meat stew Not taken into account - - - 
3 Unspecified meat-based meals 10.4 - Composite dishes 25 129 129 
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Table D1:  Acrylamide (AA) mean occurrence levels used in the baseline exposure scenario 
(continued) 
Foodex 
level 
Food group Occurrence data n LB* UB** 
2 Vegetable-based meals 
    
3 Vegetables, gratinated 10.4 - Composite dishes 25 129 129 
3 Other and unspecified vegetable-based meals Not taken into account - - - 
2 Prepared salads 
    
3 Prepared pasta salad 10.4 - Pasta 9 < 1 25 
3 Prepared potato-based salad 
10.5 - other - conversion 
factor of 0.47(b) 37 31 35 
3 Other and unspecified prepared salads Not taken into account - - - 
2 Other and unspecified composite food Not taken into account - - - 
1 Snacks, desserts, and other foods 
    
2 Snack food 
    
3 Potato crisps 2.1 - 2.2 - 2.3 34 478 389 389 
Ahg Other potato snacks 2.4 23 283 283 
Ahg 3 Corn snacks 10.3 - corn 114 168 168 
Ahg 3 Fish-based snacks and seafood chips Not taken into account - - - 
Ahg 3 Other snacks 10.3 - other 21 184 184 
2 Unspecified snack food 2.1 - 2.2 - 2.3 - 6.1 - 10.3 34 775 387 387 
2 Desserts and other foods Not taken into account - - - 
LB: lower bound: n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
(a):  A conversion factor of 0.14, 0.1, 0.2 were respectively applied to ‘Infant/follow-up formulae, liquid’, ‘Simple cereals 
reconstituted with milk’ and ‘Cereals with an added high protein food reconstituted with water’ in order to express them 
in dry equivalent (Kersting et al., 1998).  
(b): The conversion factor applied to the sandwich and sandwich-like meal reflects the average content of bread. The 
conversion factor applied to the potato-based dishes and salads reflect the average content of potato. These values are 
derived from the draft European food conversion model.  
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Scenarios reflecting specific consumption habits  
In Tables D2 to D8, only the estimates which are different from those used in the main scenario are 
detailed.   
Influence of home-cooking 
Table D2:  Acrylamide (AA) mean occurrence levels used in the scenario A1 for French fries and 
fried potatoes 
Foodex 
Level 
Food group Occurrence data n LB* UB** 
Ahg 
French fries and 
potato fried 
1.3  
provided by food associations  
(see Table 5) 
316 201 201 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
Table D3:  Acrylamide (AA) mean occurrence levels used in the scenario A2 for French fries and 
fried potatoes 
Foodex level Food group Occurrence data n LB* UB** 
Ahg 
French fries and 
potato fried 
1.1  
(see Table 6) 
877 308 308 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
 
Table D4:  Acrylamide (AA) mean occurrence levels used in the scenario A3 for French fries and 
fried potatoes 
Foodex level Food group Occurrence data n LB* UB** 
Ahg 
French fries and 
potato fried 
95th percentile of 1.3  
(see Table 6) 
557 656 656 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
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Table D5:  Acrylamide (AA) mean occurrence levels used in the scenario B1 for toasted bread 
Foodex level Food group Occurrence data n LB* UB** 
ahg 4 Wheat bread and rolls, toasted Claus et al. (2005) - 100 100 
ahg 4 Rye bread and rolls, toasted Claus et al. (2005) - 100 100 
ahg 4 Mixed bread and rolls, toasted Claus et al. (2005) - 100 100 
ahg 4 Multigrain bread and rolls, toasted Claus et al. (2005) - 100 100 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
Influence of preference for particular products 
Table D6:  Acrylamide (AA) mean occurrence levels used in the scenario C1 for potato crisps 
Foodex level Food group Occurrence data n LB* UB** 
3 Potato crisps 
2.1 – continuous process 
(see Table B1) 
29 557 391 391 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).   
Table D7:  Acrylamide (AA) mean occurrence levels used in the scenario C2 for potato crisps 
Foodex level Food group Occurrence data n LB* UB** 
3 Potato crisps 2.2 (see Table 6) 2 795 338 338 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates: occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).  
Table D8:  Acrylamide (AA) mean occurrence levels used in the scenario D1 for coffee 
Foodex level Food group Occurrence data n LB* UB** 
ahg 3 Coffee beans 
7.1 – light 
(see Table B1) 
45 374 374 
3 Coffee drink, espresso 
7.1 - light - dilution factor of 
0.20 
45 
75 75 
3 Coffee drink, café américano 
7.1 – light - dilution factor of 
0.05 
45 
19 19 
3 Coffee drink, cappuccino 
7.1 – light - dilution factor of 
0.05 
45 
19 19 
3 Coffee drink, macchiato 
7.1 – light - dilution factor of 
0.10 
45 37 37 
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Foodex level Food group Occurrence data n LB* UB** 
3 Iced coffee 
7.1 – light - dilution factor of 
0.04 
45 
15 15 
3 
Coffee with milk (café latte, 
café au lait) 
7.1 – light - dilution factor of 
0.04 
45 
15 15 
3 Unspecified coffee (Beverage) 
7.1 + dilution factor of 0.05 – 
7.2 + dilution factor of 0.02 
911 15 15 
LB: lower bound; n: number of samples; UB: upper bound. 
* Mean occurrence level used to derive the LB exposure estimates:  occurrence values below the LOD/LOQ were set at 0 for 
the food and food groups with more than 60 % of left-censored results, or were set to half the LOD/LOQ for the food and 
food groups with less than 60 % of left-censored results (EFSA, 2010b).  
** Mean occurrence level used to derive the UB exposure estimates: occurrence values below the LOD/LOQ were set at the 
LOD/LOQ for the food and food groups with more than 60 % of left-censored results, or to half the LOD/LOQ for the food 
and food groups with less than 60 % of left-censored results (EFSA, 2010b).   
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Appendix E. Chronic exposure to acrylamide (AA) across population groups, results for the 
baseline exposure scenario 
Table E1:  Chronic exposure levels to AA resulting from the baseline exposure scenario, expressed in 
µg/kg b.w. per day for each survey and age group 
Country Survey acronym n
(a)
 
Mean               
LB-UB
(b)
 
P95                
LB-UB
(c)
 
Infants 
Bulgaria NUTRICHILD 859 0.9–1.0 2.3–2.5 
Germany VELS 159 1.3–1.6 2.3–2.5 
Denmark IAT 2006_07 826 0.8–1.0 1.5–1.7 
Finland DIPP_2001_2009 500 0.7–0.8 1.4–1.6 
United Kingdom DNSIYC_2011 1 369 0.8–1.1 1.8–2.1 
Italy INRAN_SCAI_2005_06 16 0.5–0.7 –* 
Toddlers 
Belgium Regional_Flanders 36 1.9 –* 
Bulgaria NUTRICHILD 428 1.5 3.4 
Germany VELS 348 1.3–1.4 2.3–2.4 
Denmark IAT 2006_07 917 0.9 1.4–1.5 
Spain enKid 17 1.4 –* 
Finland DIPP_2001_2009 500 1.2–1.3 2.0–2.2 
United Kingdom NDNS-RollingProgrammeYears1-3 185 1.6 2.9–3.1 
United Kingdom DNSIYC_2011 1 314 1.4–1.5 2.6–2.8 
Italy INRAN_SCAI_2005_06 36 1.1–1.2 –* 
Netherlands VCP_kids 322 1.3 2.3–2.4 
Other children 
Belgium Regional_Flanders 625 1.6 2.8–2.9 
Bulgaria NUTRICHILD 433 1.4 3.2 
Czech Republic SISP04 389 1.2 2.5 
Germany EsKiMo 835 1.0–1.1 1.9–2.0 
Germany VELS 293 1.2 2.1 
Denmark DANSDA 2005-08 298 0.9 1.4 
Spain enKid 156 1.3–1.4 3.0 
Spain NUT_INK05 399 1.1 2.0 
Finland DIPP_2001_2009 750 1.0 1.6–1.7 
France INCA2 482 1.1 1.8–1.9 
United Kingdom NDNS-RollingProgrammeYears1-3 651 1.5 2.6–2.7 
Greece Regional_Crete 838 1.4 2.9 
Italy INRAN_SCAI_2005_06 193 1.0–1.1 2.2–2.4 
Latvia EFSA_TEST 187 1.1 2.3–2.4 
Netherlands VCP_kids 957 1.1–1.2 2.0 
Netherlands VCPBasis_AVL2007_2010 447 1.2 2.3 
Sweden NFA 1 473 1.2 2.0–2.1 
Adolescents 
Belgium Diet_National_2004 576 0.6 1.3 
Cyprus Childhealth 303 0.7 1.4 
Czech Republic SISP04 298 0.9 2.0 
Germany National_Nutrition_Survey_II 1 011 0.4 0.9 
Germany EsKiMo 393 0.8 1.4–1.5 
Denmark DANSDA 2005-08 377 0.5 1.0 
Spain AESAN_FIAB 86 0.7 1.3–1.4 
Spain enKid 209 0.8 1.9 
Spain NUT_INK05 651 0.7 1.3 
Finland NWSSP07_08 306 0.5 0.9 
France INCA2 973 0.6 1.2 
United Kingdom NDNS-RollingProgrammeYears1-3 666 0.8–0.9 1.6–1.7 
Italy INRAN_SCAI_2005_06 247 0.7 1.4 
Latvia EFSA_TEST 453 0.9 2.0 
Table continued overleaf. 
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Table E1:  Chronic exposure levels to AA resulting from the baseline exposure scenario, expressed in 
µg/kg b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean               
LB-UB
(b)
 
P95                
LB-UB
(c)
 
Netherlands VCPBasis_AVL2007_2010 1 142 0.9 1.7–1.8 
Sweden NFA 1 018 0.8 1.5–1.6 
Adults 
Belgium Diet_National_2004 1 292 0.5 1.0–1.1 
Czech Republic SISP04 1 666 0.5 1.1 
Germany National_Nutrition_Survey_II 10 419 0.4 0.9 
Denmark DANSDA 2005-08 1 739 0.4–0.5 0.8 
Spain AESAN 410 0.4 1.0 
Spain AESAN_FIAB 981 0.5 1.1 
Finland FINDIET2012 1 295 0.5 0.9 
France INCA2 2 276 0.4 0.8 
United Kingdom NDNS-RollingProgrammeYears1-3 1 266 0.5 1.0 
Hungary National_Repr_Surv 1 074 0.5 0.9–1.0 
Ireland NANS_2012 1 274 0.6 1.0–1.1 
Italy INRAN_SCAI_2005_06 2 313 0.4–0.5 0.9 
Latvia EFSA_TEST 1 271 0.6 1.3 
Netherlands VCPBasis_AVL2007_2010 2 057 0.6 1.2 
Romania Dieta_Pilot_Adults 1 254 0.4 0.8 
Sweden Riksmaten 2010 1 430 0.4–0.5 0.8–0.9 
Elderly 
Belgium Diet_National_2004 511 0.5 0.9–1.0 
Germany National_Nutrition_Survey_II 2 006 0.4 0.9 
Denmark DANSDA 2005-08 274 0.4–0.5 0.8 
Finland FINDIET2012 413 0.4–0.5 0.8–0.9 
France INCA2 264 0.4 0.7 
United Kingdom NDNS-RollingProgrammeYears1-3 166 0.4–0.5 0.8 
Hungary National_Repr_Surv 206 0.4 0.8 
Ireland NANS_2012 149 0.5 0.9 
Italy INRAN_SCAI_2005_06 290 0.4 0.7 
Netherlands VCPBasis_AVL2007_2010 173 0.5 1.0 
Netherlands VCP-Elderly 289 0.5 0.9 
Romania Dieta_Pilot_Adults 83 0.4 0.7 
Sweden Riksmaten 2010 295 0.5 0.8–0.9 
Very elderly 
Belgium Diet_National_2004 704 0.5 0.9 
Germany National_Nutrition_Survey_II 490 0.4–0.5 1.0 
Denmark DANSDA 2005-08 12 0.5 –* 
France INCA2 84 0.4 0.6 
United Kingdom NDNS-RollingProgrammeYears1-3 139 0.5 0.9 
Hungary National_Repr_Surv 80 0.4–0.5 0.9 
Ireland NANS_2012 77 0.4–0.5 0.8 
Italy INRAN_SCAI_2005_06 228 0.4 0.7 
Netherlands VCP-Elderly 450 0.5 0.9 
Romania Dieta_Pilot_Adults 45 0.4 –* 
Sweden Riksmaten 2010 72 0.5 0.8 
Specific population groups 
Latvia FC_PREGNANTWOMEN_2011 1 002 0.6 1.1 
Greece DIET LACTATION GR 65 0.4 0.6 
Note: In order to avoid the impression of too high precision, the numbers for all exposure estimates are rounded to 2 figures.  
*  The 95th percentile (P95) for dietary surveys/age groups with less than 60 subjects were not reliable and therefore not 
presented.  
(a):  n: number of subjects.  
(b):  Mean LB–UB: mean lower bound – upper bound.  
(c):  P95 LB–UB: 95th percentile lower bound – upper bound. When lower bound and upper bound are equal, only one 
estimate is given. 
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Appendix F. Contribution of food groups to the acrylamide (AA) total exposure  
Table F1:  Minimum and maximum relative contribution of food groups, expressed in percentage, to the acrylamide (AA) total lower bound (LB) exposure 
Food category Infants Toddlers Other children Adolescents Adults Elderly Very elderly 
Potato fried products (except potato crisps and 
snacks) 
0–8.8 3.0–32 11–49 10–51 9.7–49 6.6–32 6.2–27 
Potato crisps and snacks 0–1.2 0.1–7.9 0.4–7.6 1.7–11 0.7–6.7 0–2.6 0–1.7 
Soft bread 0–19 0.4–32 0.2–27 0.1–23 9.9–22 11–21 10–23 
Breakfast cereals 0–19 0.2–25 0.6–13 1.5–12 0.9–10 0.3–9 0.4–9.9 
Biscuits, crackers, crisp bread  0–20 2.3–25 2.4–27 2.2–24 2.4–17 2.8–21 2.8–24 
Crackers  0–3.6 0–8.3 0–7.8 0–7.5 0–7.5 0–3.8 0–1.4 
Crisp bread  0–3.4 0.5–5.1 0.4–6.6 0–6.9 0–7.2 0.8–7.7 0.7–8.7 
Biscuits and wafers  0–17 1.4–18 < 0.05–21 < 0.05–17 0.8–9.8 0.7–11 0.7–12 
Gingerbread  0–0.7 0–6.0 0–7.1 0–6.2 0–6.0 0–10 0–12 
Coffee   0 0–0.3 0–1.5 < 0.05–2.7 3.1–24 2.1–28 1.9–34 
Roasted coffee  0 0–0.3 0–1.5 < 0.05–2.0 0.7–20 0.9–24 0.6–29 
Instant coffee  0 0 0–0.2 0–1.4 0.1–7.2 0–7.7 0–6.1 
Coffee substitutes 0 0–0.1 0–0.8 0–0.3 0–2.9 0–8.7 0–5.4 
Baby foods, other than processed cereal-based 1.8–60 0–8.6 0–0.5 0–0.1 0 0 0 
Infant formulae 0.6–2.1 0–0.6 0 0 0 0 0 
Fruit purée 0–34 0–6.0 0–0.4 0–0.1 0 0 0 
Ready-to-eat meal and dessert 0–25 0–3.0 0–0.1 0 0 0 0 
Processed cereal-based baby foods 0–30 0–14 0–3.5 0–0.2 0–0.1 0 0 
Biscuits and rusks 0–11 0–8.9 0–3.5 0–0.2 0–0.1 0 0 
Other cereal-based foods  0–28 0–14 0–1.6 0–0.1 0 0 0 
Other products based on potatoes, cereals and cocoa 16–78 27–67 23–69 20–72 18–36 23–40 25–43 
Porridge 0–2.5 0–1.2 0–1.4 0–0.4 0–5.8 0–11 0–7.6 
Cake and pastry 0–1.5 0–7.7 0–15 0–14 0.3–12 < 0.05–12 0–14 
Savoury snacks other than potato-based                                 0–1.4 0–4.2 < 0.05–3.3 < 0.05–1.8 < 0.05–1 0–0.6 0–0.2 
Other products based on cereals 0.9–29 4.4–29 5.6–40 3.9–47 2.1–18 2.0–17 1.4–18 
Other products based on potatoes  7.7–48 6.3–38 2.3–25 1.6–21 2.2–17 12–24 13–24 
Other products based on cocoa < 0.05–1.3 0.2–7.1 1.6–7.6 2.3–6.7 0.9–3.3 0.4–1.7 0.6–2.4 
Other products  0–3.2 0.2–2.5 0.2–2.9 0.3–4.2 1.0–6.0 1.1–5.6 1–3.7 
Roasted nuts and seeds 0–0.4 < 0.05–0.5 0.1–1.1 0.1–2.0 0.4–1.7 0.4–1.5 0.2–1.3 
Black olives in brine 0–0.2 < 0.05–2.0 0–1.8 0–3.2 < 0.05–4.7 0–4.4 0–1.6 
Prunes and dates                               0–3.2 0–0.6 0–0.5 0–0.4 < 0.05–0.3 < 0.05–1.1 0.2–2.4 
Paprika powder 0 0–0.1 0–0.2 0–0.4 0–0.9 0–1.1 0–1.0 
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Table F2:  Minimum and maximum relative contribution of food groups, expressed in percentage, to the AA total upper bound (UB) exposure 
Food category Infants Toddlers 
Other 
children 
Adolescents Adults Elderly 
Very 
elderly 
Potato fried products (except potato crisps and snacks) 0–6.5 2.7–32 10–48 9.8–50 9.5–48 6.4–31 6.1–26 
Potato crisps and snacks 0–0.9 0.1–7.8 0.4–7.3 1.6–11 0.7–6.6 0–2.5 0–1.6 
Soft bread 0–15 0.4–31 0.2–27 0.1–22 9.7–22 11–21 9.9–23 
Breakfast cereals 0–15 0.2–23 0.5–13 1.5–11 0.9–10 0.3–8.8 0.3–9.6 
Biscuits, crackers, crisp bread  0–17 2.2–24 2.3–26 2.1–23 2.4–16 2.7–21 2.7–23 
Crackers  0–3.0 0–7.8 0–7.4 0–7.1 0–7.3 0–3.7 0–1.4 
Crisp bread  0–2.8 0.5–4.9 0.4–6.1 0–6.6 0–7.0 0.8–7.2 0.7–8.1 
Biscuits and wafers  0–14 1.4–18 < 0.05–21 < 0.05–17 0.8–9.3 0.7–9.9 0.7–11 
Gingerbread  0–0.6 0–5.8 0–7.0 0–6.1 0–5.9 0–10 0–12 
Coffee   0 0–0.3 0–1.4 < 0.05–2.6 3.0–23 2.1–27 1.8–33 
Roasted coffee  0 0–0.3 0–1.4 < 0.05–1.9 0.6–20 0.9–23 0.6–28 
Instant coffee  0 0 0–0.2 0–1.3 0.1–7.0 0–7.5 0–6.0 
Coffee substitutes 0 0–0.1 0–0.8 0–0.3 0–2.8 0–8.4 0–5.2 
Baby foods, other than processed cereal-based 15–68 0–10 0–0.6 0–0.1 0 0 0 
Infant formulae 4.9–16 0–5.4 0–0.1 0 0 0 0 
Fruit purée  0–26 0–5.4 0–0.4 0–0.1 0 0 0 
Ready-to-eat meal and dessert 0–33 0–5.0 0–0.3 0 0 0 0 
Processed cereal-based baby foods 0–25 0–14 0–3.4 0–0.2 0 0 0 
Biscuits and rusks 0–7.6 0–8.0 0–3.4 0–0.2 0 0 0 
Other cereal-based foods  0–23 0–14 0–1.6 0–0.1 0 0 0 
Other products based on potatoes, cereals and cocoa 14–68 29–66 25–70 21–73 20–39 25–43 27–45 
Porridge 0–2.1 0–1.1 0–1.4 0–0.4 0–5.7 0–11 0–7.4 
Cake and pastry 0–1.2 0–7.5 0–14 0–14 0.3–12 < 0.05–12 0–13 
Savoury snacks other than potato-based                                 0–1.1 0–4.1 < 0.05–3.3 < 0.05–1.8 < 0.05–1.0 0–0.6 0–0.2 
Other products based on cereals 1.2–24 6.4–27 6.5–40 4.7–46 2.6–21 2.2–18 1.5–19 
Other products based on potatoes  6.1–44 6.9–38 2.5–26 1.8–23 2.4–18 13–26 14–26 
Other products based on cocoa < 0.05–0.9 0.1–6.9 1.6–7.4 2.2–6.4 0.8–3.1 0.4–1.7 0.5–2.3 
Other products  0–2.6 0.2–2.5 0.2–2.8 0.3–4.2 1.0–5.9 1.1–5.5 0.9–3.6 
Roasted nuts and seeds 0–0.3 < 0.05–0.5 0.1–1.1 0.1–1.9 0.4–1.7 0.4–1.4 0.2–1.3 
Black olives in brine 0–0.2 < 0.05–1.9 0–1.7 0–3.2 < 0.05–4.6 0–4.3 0–1.6 
Prunes and dates                               0–2.6 0–0.5 0–0.5 0–0.4 < 0.05–0.3 < 0.05–1.1 0.2–2.4 
Paprika powder 0 0–0.1 0–0.2 0–0.4 0–0.9 0–1.0 0–0.9 
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Appendix G. Chronic exposure to acrylamide (AA) across population groups – results from the other scenarios 
Table G1:  Chronic exposure levels to acrylamide (AA) resulting from the scenarios A1, A2 and A3 compared to the baseline scenario, expressed in µg/kg 
b.w. per day for each survey and age group 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE A1 A2 A3 BASE A1 A2 A3 
Infants 
Bulgaria NUTRICHILD 859 0.9–1.0 0.9–1.0 0.9–1.0 0.9–1.0 2.3–2.5 2.3–2.5 2.3–2.5 2.4–2.6 
Germany VELS 159 1.3–1.6 1.3–1.6 1.3–1.6 1.4–1.7 2.3–2.5 2.3–2.5 2.3–2.5 2.5–2.8 
Denmark IAT 2006_07 826 0.8–1.0 0.8–1.0 0.8–1.0 0.8–1.0 1.5–1.7 1.5–1.7 1.5–1.7 1.5–1.8 
Finland DIPP_2001_2009 500 0.7–0.8 0.7–0.8 0.7–0.8 0.7–0.8 1.4–1.6 1.4–1.6 1.4–1.6 1.4–1.6 
United Kingdom DNSIYC_2011 1 369 0.8–1.1 0.8–1.1 0.8–1.1 0.9–1.2 1.8–2.1 1.7–2 1.8–2.1 2.1–2.4 
Italy INRAN_SCAI_2005_06 16 0.5–0.7 0.5–0.7 0.5–0.7 0.5–0.7 –* –* –* –* 
Toddlers 
Belgium Regional_Flanders 36 1.9 1.7–1.8 1.9 2.4–2.5 –* –* –* –* 
Bulgaria NUTRICHILD 428 1.5 1.4 1.5–1.6 1.9–2.0 3.4 2.8–2.9 3.4–3.5 5.5–5.6 
Germany VELS 348 1.3–1.4 1.2–1.3 1.3–1.4 1.5–1.6 2.3–2.4 2.2–2.3 2.3–2.4 3.1–3.2 
Denmark IAT 2006_07 917 0.9 0.9 0.9 1.0 1.4–1.5 1.4 1.4–1.5 1.7 
Spain enKid 17 1.4 1.3 1.4–1.5 2.0 –* –* –* –* 
Finland DIPP_2001_2009 500 1.2–1.3 1.2–1.3 1.2–1.3 1.2–1.4 2.0–2.2 2.0–2.2 2.0–2.2 2.1–2.3 
United Kingdom NDNS-RollingProgrammeYears1-3 185 1.6 1.5–1.6 1.6–1.7 2.0 2.9–3.1 2.9 2.9–3.2 4.0–4.2 
United Kingdom DNSIYC_2011 1 314 1.4–1.5 1.3–1.4 1.4–1.5 1.6–1.8 2.6–2.8 2.5–2.6 2.6–2.8 3.7–3.9 
Italy INRAN_SCAI_2005_06 36 1.1–1.2 1.0–1.2 1.1–1.2 1.3–1.4 –* –* –* –* 
Netherlands VCP_kids 322 1.3 1.2–1.3 1.3 1.5 2.3–2.4 2.2 2.4 3.3 
Other children 
Belgium Regional_Flanders 625 1.6 1.5 1.6 2.0 2.8–2.9 2.5–2.6 2.9 3.9–4.0 
Bulgaria NUTRICHILD 433 1.4 1.3 1.4–1.5 1.9–2.0 3.2 2.6 3.3 5.3–5.4 
Czech Republic SISP04 389 1.2 1.1–1.2 1.2 1.4 2.5 2.3 2.5–2.6 3.2–3.3 
Germany EsKiMo 835 1–1.1 1.0 1.0–1.1 1.2 1.9–2 1.8 2.0 2.5–2.6 
Germany VELS 293 1.2 1.1–1.2 1.2–1.3 1.4–1.5 2.1 2.0 2.1 2.9 
Denmark DANSDA 2005-08 298 0.9 0.8 0.9 1.1 1.4 1.3 1.4–1.5 2–2.1 
Spain enKid 156 1.3–1.4 1.1–1.2 1.4 2.2 3.0 2.5 3.1 5.3–5.4 
Spain NUT_INK05 399 1.1 1.0 1.1 1.3 2.0 1.8 2–2.1 2.8–2.9 
Finland DIPP_2001_2009 750 1.0 0.9–1.0 1.0 1.2 1.6–1.7 1.5–1.6 1.7 2.5 
France INCA2 482 1.1 1.0 1.1 1.3–1.4 1.8–1.9 1.7 1.8–1.9 2.5–2.6 
United Kingdom NDNS-RollingProgrammeYears1-3 651 1.5 1.3–1.4 1.5 1.9–2 2.6–2.7 2.4 2.7 3.9–4 
Table continued overleaf. 
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Table G1:  Chronic exposure levels to acrylamide (AA) resulting from the scenarios A1, A2 and A3 compared to the baseline scenario, expressed in µg/kg 
b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE A1 A2 A3 BASE A1 A2 A3 
Greece Regional_Crete 838 1.4 1.2 1.4–1.5 2.2 2.9 2.3–2.4 3.0 5.1–5.3 
Italy INRAN_SCAI_2005_06 193 1.0–1.1 1.0 1–1.1 1.3–1.4 2.2–2.4 1.9–2 2.3–2.4 3.2–3.3 
Latvia EFSA_TEST 187 1.1 1.1 1.1 1.4 2.3–2.4 2.2 2.4–2.5 3.3 
Netherlands VCP_kids 957 1.1–1.2 1.1 1.1–1.2 1.3–1.4 2.0 1.9 2.1 2.9 
Netherlands VCPBasis_AVL2007_2010 447 1.2 1.1 1.2–1.3 1.6 2.3 2.0 2.3 3.7 
Sweden NFA 1 473 1.2 1.1–1.2 1.2 1.4 2.0–2.1 1.9–2 2.0–2.1 2.8–2.9 
Adolescents 
Belgium Diet_National_2004 576 0.6 0.6 0.6 0.8 1.3 1.2 1.3 1.8 
Cyprus Childhealth 303 0.7 0.6 0.7–0.8 1.1–1.2 1.4 1.1–1.2 1.5 2.5–2.6 
Czech Republic SISP04 298 0.9 0.9 0.9 1.1 2.0 1.8–1.9 2.0–2.1 2.9 
Germany National_Nutrition_Survey_II 1 011 0.4 0.4 0.4 0.5 0.9 0.9 0.9–1.0 1.2–1.3 
Germany EsKiMo 393 0.8 0.8 0.8 0.9 1.4–1.5 1.4 1.4–1.5 1.8 
Denmark DANSDA 2005-08 377 0.5 0.5 0.5 0.6 1.0 0.9 1.0 1.4 
Spain AESAN_FIAB 86 0.7 0.6 0.7 1.1 1.3–1.4 1.1 1.4 2.1 
Spain enKid 209 0.8 0.7 0.8–0.9 1.3–1.4 1.9 1.5 2.0 3.3 
Spain NUT_INK05 651 0.7 0.6 0.7 0.9 1.3 1.2 1.3–1.4 1.9 
Finland NWSSP07_08 306 0.5 0.5 0.5 0.6 0.9 0.8 0.9 1.3 
France INCA2 973 0.6 0.6 0.6 0.8 1.2 1.1 1.2 1.7 
Italy INRAN_SCAI_2005_06 247 0.7 0.6–0.7 0.7 0.9 1.4 1.3 1.5 2.2 
Latvia EFSA_TEST 453 0.9 0.8 0.9 1.2 2.0 1.7 2.0 3.1–3.2 
Netherlands VCPBasis_AVL2007_2010 1 142 0.9 0.8 0.9 1.1 1.7–1.8 1.5–1.6 1.8 2.7 
Sweden NFA 1 018 0.8 0.8 0.8–0.9 1.0 1.5–1.6 1.4 1.6 2.2 
Belgium Diet_National_2004 576 0.6 0.6 0.6 0.8 1.3 1.2 1.3 1.8 
Adults 
Belgium Diet_National_2004 1 292 0.5 0.5 0.5 0.6 1.0–1.1 0.9 1.0–1.1 1.5 
Czech Republic SISP04 1 666 0.5 0.5 0.5 0.6 1.1 1.1 1.1–1.2 1.5–1.6 
Germany National_Nutrition_Survey_II 10 419 0.4 0.4 0.4 0.5 0.9 0.8–0.9 0.9 1.1 
Denmark DANSDA 2005-08 1 739 0.4–0.5 0.4 0.5 0.5 0.8 0.7–0.8 0.8 1.0 
Spain AESAN 410 0.4 0.4 0.5 0.7 1.0 0.8–0.9 1.0 1.8 
Spain AESAN_FIAB 981 0.5 0.4 0.5 0.8 1.1 0.9 1.1 1.9 
Table continued overleaf. 
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Table G1:  Chronic exposure levels to acrylamide (AA) resulting from the scenarios A1, A2 and A3 compared to the baseline scenario, expressed in µg/kg 
b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE A1 A2 A3 BASE A1 A2 A3 
Finland FINDIET2012 1 295 0.5 0.4–0.5 0.5 0.5 0.9 0.9 0.9 1.2 
France INCA2 2 276 0.4 0.4 0.4 0.5 0.8 0.7 0.8 1.0 
United Kingdom NDNS-RollingProgrammeYears1-3 1 266 0.5 0.4–0.5 0.5 0.7 1.0 0.8–0.9 1.0 1.6 
Hungary National_Repr_Surv 1 074 0.5 0.4–0.5 0.5 0.6 0.9–1.0 0.8 1.0 1.5 
Ireland NANS_2012 1 274 0.6 0.5 0.6 0.8 1.0–1.1 0.9 1.1 1.6–1.7 
Italy INRAN_SCAI_2005_06 2 313 0.4–0.5 0.4 0.4–0.5 0.5–0.6 0.9 0.8 0.9 1.3 
Latvia EFSA_TEST 1 271 0.6 0.5 0.6 0.7 1.3 1.2 1.3–1.4 2.0 
Netherlands VCPBasis_AVL2007_2010 2 057 0.6 0.5 0.6 0.7 1.2 1.0 1.2 1.8 
Romania Dieta_Pilot_Adults 1 254 0.4 0.4 0.4 0.5 0.8 0.7 0.9 1.2–1.3 
Sweden Riksmaten 2010 1 430 0.4–0.5 0.4 0.4–0.5 0.5 0.8–0.9 0.8 0.9 1.2 
Elderly 
Belgium Diet_National_2004 511 0.5 0.5 0.5 0.6 0.9–1.0 0.9 1.0 1.4 
Germany National_Nutrition_Survey_II 2 006 0.4 0.4 0.4 0.5 0.9 0.8 0.9 1.1 
Denmark DANSDA 2005-08 274 0.4–0.5 0.4–0.5 0.5 0.5 0.8 0.7 0.8 0.9 
Finland FINDIET2012 413 0.4–0.5 0.4 0.4–0.5 0.5 0.8–0.9 0.8 0.8–0.9 1.1 
France INCA2 264 0.4 0.4 0.4 0.5 0.7 0.7 0.7 1.0 
United Kingdom NDNS-RollingProgrammeYears1-3 166 0.4–0.5 0.4 0.4–0.5 0.6 0.8 0.7 0.8 1.3 
Hungary National_Repr_Surv 206 0.4 0.4 0.4 0.5 0.8 0.7 0.8–0.9 1.1–1.2 
Ireland NANS_2012 149 0.5 0.4 0.5 0.6 0.9 0.7–0.8 0.9 1.3 
Italy INRAN_SCAI_2005_06 290 0.4 0.3–0.4 0.4 0.4 0.7 0.6–0.7 0.7 1.0 
Netherlands VCPBasis_AVL2007_2010 173 0.5 0.5 0.5 0.6 1.0 1.0 1.0 1.4 
Netherlands VCP-Elderly 289 0.5 0.5 0.5 0.6 0.9 0.8 0.9 1.3 
Romania Dieta_Pilot_Adults 83 0.4 0.3 0.4 0.5 0.7 0.6 0.7 1.1 
Sweden Riksmaten 2010 295 0.5 0.4 0.5 0.5–0.6 0.8–0.9 0.8 0.8–0.9 1.2 
Very elderly 
Belgium Diet_National_2004 704 0.5 0.4–0.5 0.5 0.5–0.6 0.9 0.9 0.9 1.2 
Germany National_Nutrition_Survey_II 490 0.4–0.5 0.4 0.4–0.5 0.5 1.0 0.9 1.0 1.2 
Denmark DANSDA 2005-08 12 0.5 0.5 0.5 0.5 –* –* –* –* 
France INCA2 84 0.4 0.3 0.4 0.4–0.5 0.6 0.6 0.6–0.7 1.0 
United Kingdom NDNS-RollingProgrammeYears1-3 139 0.5 0.4 0.5 0.6 0.9 0.8 0.9 1.3 
Hungary National_Repr_Surv 80 0.4–0.5 0.4 0.5 0.6 0.9 0.8 0.9 1.5 
Table continued overleaf. 
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Table G1:  Chronic exposure levels to acrylamide (AA) resulting from the scenarios A1, A2 and A3 compared to the baseline scenario, expressed in µg/kg 
b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE A1 A2 A3 BASE A1 A2 A3 
Ireland NANS_2012 77 0.4–0.5 0.4 0.4–0.5 0.5 0.8 0.8 0.8 1.2 
Italy INRAN_SCAI_2005_06 228 0.4 0.3–0.4 0.4 0.4 0.7 0.6 0.7 0.9–1.0 
Netherlands VCP-Elderly 450 0.5 0.5 0.5 0.6 0.9 0.8 0.9 1.3 
Romania Dieta_Pilot_Adults 45 0.4 0.3–0.4 0.4 0.5 –* –* –* –* 
Sweden Riksmaten 2010 72 0.5 0.4–0.5 0.5 0.5 0.8 0.7–0.8 0.8 1.1 
In order to avoid the impression of too high precision, the numbers for all exposure estimates are rounded to 2 figures. 
*  The 95th percentile (P95) for dietary surveys/age groups with less than 60 subjects were not reliable and therefore not presented.  
(a):  n: number of subjects.  
(b):  Mean LB–UB: mean lower bound – upper bound.  
(c): P95 LB–UB: 95th percentile lower bound – upper bound. When lower bound and upper bound estimates are equal, only one estimate is provided. 
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Table G2: Chronic exposure levels to acrylamide (AA) resulting from the scenarios B1, C1, C2 and D1 compared to the baseline (BASE) scenario, expressed 
in µg/kg b.w. per day for each survey and age group 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE B1 C1 C2 D1 BASE B1 C1 C2 D1 
Infants 
Bulgaria NUTRICHILD 859 0.9–1.0 0.9–1.0 0.9–1.0 0.9–1.0 0.9–1.0 2.3–2.5 2.3–2.5 2.3–2.5 2.3–2.5 2.3–2.5 
Germany VELS 159 1.3–1.6 1.3–1.6 1.3–1.6 1.3–1.6 1.3–1.6 2.3–2.5 2.3–2.5 2.3–2.5 2.3–2.5 2.3–2.5 
Denmark IAT 2006_07 826 0.8–1.0 0.8–1.0 0.8–1.0 0.8–1.0 0.8–1.0 1.5–1.7 1.5–1.7 1.5–1.7 1.5–1.7 1.5–1.7 
Finland DIPP_2001_2009 500 0.7–0.8 0.7–0.8 0.7–0.8 0.7–0.8 0.7–0.8 1.4–1.6 1.4–1.6 1.4–1.6 1.4–1.6 1.4–1.6 
United Kingdom DNSIYC_2011 1369 0.8–1.1 0.8–1.1 0.8–1.1 0.8–1.1 0.8–1.1 1.8–2.1 1.8–2.1 1.8–2.1 1.8–2.1 1.8–2.1 
Italy INRAN_SCAI_2005_06 16 0.5–0.7 0.5–0.7 0.5–0.7 0.5–0.7 0.5–0.7 –* –* –* –* –* 
Toddlers 
Belgium Regional_Flanders 36 1.9 1.9 1.9 1.9 1.9 –* –* –* –* –* 
Bulgaria NUTRICHILD 428 1.5 1.5 1.5 1.5 1.5 3.4 3.4 3.4 3.4 3.4 
Germany VELS 348 1.3–1.4 1.3–1.4 1.3–1.4 1.3–1.4 1.3–1.4 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 
Denmark IAT 2006_07 917 0.9 0.9 0.9 0.9 0.9 1.4–1.5 1.4–1.5 1.4–1.5 1.4–1.5 1.4–1.5 
Spain enKid 17 1.4 1.4 1.4 1.4 1.4 –* –* –* –* –* 
Finland DIPP_2001_2009 500 1.2–1.3 1.2–1.3 1.2–1.3 1.2–1.3 1.2–1.3 2.0–2.2 2.0–2.2 2.0–2.2 2.0–2.2 2–2.2 
United Kingdom NDNS-
RollingProgrammeYears1-3 
185 1.6 1.6 1.6 1.5–1.6 1.6 2.9–3.1 2.9–3.1 2.9–3.1 2.9–3.1 2.9–3.1 
United Kingdom DNSIYC_2011 1314 1.4–1.5 1.4–1.5 1.4–1.5 1.3–1.5 1.4–1.5 2.6–2.8 2.6–2.8 2.6–2.8 2.5–2.8 2.6–2.8 
Italy INRAN_SCAI_2005_06 36 1.1–1.2 1.1–1.2 1.1–1.2 1.1–1.2 1.1–1.2 –* –* –* –* –* 
Netherlands VCP_kids 322 1.3 1.3 1.3 1.3 1.3 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 
Other children 
Belgium Regional_Flanders 625 1.6 1.6 1.6 1.6 1.6 2.8–2.9 2.8–2.9 2.8–2.9 2.8 2.8–2.9 
Bulgaria NUTRICHILD 433 1.4 1.4 1.4 1.4 1.4 3.2 3.2 3.2 3.2 3.2 
Czech Republic SISP04 389 1.2 1.2 1.2 1.2 1.2 2.5 2.5–2.6 2.5 2.5 2.5 
Germany EsKiMo 835 1.0–1.1 1.0–1.1 1.0–1.1 1.0–1.1 1.0–1.1 1.9–2.0 1.9–2.0 2.0 1.9–2.0 1.9–2.0 
Germany VELS 293 1.2 1.2 1.2 1.2 1.2 2.1 2.1 2.1 2.1 2.1 
Denmark DANSDA 2005-08 298 0.9 0.9 0.9 0.9 0.9 1.4 1.4 1.4 1.4 1.4 
Spain enKid 156 1.3–1.4 1.3–1.4 1.3–1.4 1.3 1.3–1.4 3.0 3.0 3.0–3.1 2.9–3.0 3.0 
Spain NUT_INK05 399 1.1 1.1 1.1 1.0–1.1 1.1 2.0 2.0 2.0 2.0 2.0 
Finland DIPP_2001_2009 750 1.0 1.0 1.0 1.0 1.0 1.6–1.7 1.6–1.7 1.6–1.7 1.6–1.7 1.6–1.7 
France INCA2 482 1.1 1.1 1.1 1.1 1.1 1.8–1.9 1.8–1.9 1.8–1.9 1.8–1.9 1.8–1.9 
United Kingdom NDNS-
RollingProgrammeYears1-3 
651 1.5 1.5 1.5 1.4–1.5 1.5 2.6–2.7 2.6–2.7 2.6–2.7 2.6 2.6–2.7 
Greece Regional_Crete 838 1.4 1.4 1.4 1.4 1.4 2.9 2.9 2.9 2.9 2.9 
Italy INRAN_SCAI_2005_06 193 1.0–1.1 1.0–1.1 1.0–1.1 1.0–1.1 1.0–1.1 2.2–2.4 2.3–2.4 2.2–2.4 2.2–2.4 2.2–2.4 
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Table G2:   Chronic exposure levels to acrylamide (AA) resulting from the scenarios B1, C1, C2 and D1 compared to the baseline (BASE) scenario, 
expressed in µg/kg b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE B1 C1 C2 D1 BASE B1 C1 C2 D1 
Latvia EFSA_TEST 187 1.1 1.1 1.1 1.1 1.1 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 2.3–2.4 
Netherlands VCP_kids 957 1.1–1.2 1.1–1.2 1.1–1.2 1.1 1.1–1.2 2.0 2.0 2.0 2.0 2.0 
Netherlands VCPBasis_AVL2007_2010 447 1.2 1.2 1.2 1.2 1.2 2.3 2.3 2.3 2.2–2.3 2.3 
Sweden NFA 1 473 1.2 1.2 1.2 1.1–1.2 1.2 2.0–2.1 2.0–2.1 2.0–2.1 2.0–2.1 2.0–2.1 
Adolescents 
Belgium Diet_National_2004 576 0.6 0.6 0.6 0.6 0.6 1.3 1.3 1.3 1.2–1.3 1.3 
Cyprus Childhealth 303 0.7 0.7 0.7 0.7 0.7 1.4 1.4 1.4 1.4 1.4 
Czech Republic SISP04 298 0.9 0.9 0.9 0.9 0.9 2.0 2.0 2.0 1.9 2.0 
Germany National_Nutrition_Survey_I
I 
1 011 0.4 0.4 0.4 0.4 0.4 0.9 0.9–1 0.9 0.9 0.9 
Germany EsKiMo 393 0.8 0.8 0.8 0.8 0.8 1.4–1.5 1.4–1.5 1.4–1.5 1.4–1.5 1.4–1.5 
Denmark DANSDA 2005-08 377 0.5 0.5 0.5 0.5 0.5 1.0 1.0 1.0 1.0 1.0 
Spain AESAN_FIAB 86 0.7 0.7 0.7 0.7 0.7 1.3–1.4 1.3–1.4 1.3–1.4 1.3 1.3–1.4 
Spain enKid 209 0.8 0.8 0.8 0.8 0.8 1.9 1.9 1.9 1.9 1.9 
Finland NWSSP07_08 306 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 0.9 
France INCA2 973 0.6 0.6 0.6 0.6 0.6 1.2 1.2 1.2 1.2 1.2 
United Kingdom NDNS-
RollingProgrammeYears1-3 
666 0.8–0.9 0.8–0.9 0.8–0.9 0.8 0.8–0.9 1.6–1.7 1.6–1.7 1.6–1.7 1.6–1.7 1.6–1.7 
Italy INRAN_SCAI_2005_06 247 0.7 0.7 0.7 0.7 0.7 1.4 1.4 1.4 1.4 1.4 
Latvia EFSA_TEST 453 0.9 0.9 0.9 0.9 0.9 2.0 2.0 2.0 1.9 2.0 
Netherlands VCPBasis_AVL2007_2010 1142 0.9 0.9 0.9 0.8–0.9 0.9 1.7–1.8 1.7–1.8 1.7–1.8 1.7 1.7–1.8 
Sweden NFA 1018 0.8 0.8 0.8 0.8 0.8 1.5–1.6 1.5–1.6 1.5–1.6 1.5–1.6 1.5–1.6 
Adults 
Belgium Diet_National_2004 1292 0.5 0.5 0.5 0.5 0.5 1.0–1.1 1.0–1.1 1.0–1.1 1.0 1.0–1.1 
Czech Republic SISP04 1666 0.5 0.5 0.5 0.5 0.5 1.1 1.1 1.1 1.1 1.1–1.2 
Germany National_Nutrition_Survey_I
I 
10419 0.4 0.4 0.4 0.4 0.4 0.9 0.9 0.9 0.9 0.9 
Denmark DANSDA 2005-08 1739 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.8 0.8 0.8 0.8 0.9 
Spain AESAN 410 0.4 0.4–0.5 0.4 0.4 0.4–0.5 1.0 1.0 1.0 1.0 1.0 
Spain AESAN_FIAB 981 0.5 0.5 0.5 0.5 0.5 1.1 1.1 1.1 1.1 1.1 
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Table G2:   Chronic exposure levels to acrylamide (AA) resulting from the scenarios B1, C1, C2 and D1 compared to the baseline (BASE) scenario, 
expressed in µg/kg b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE B1 C1 C2 D1 BASE B1 C1 C2 D1 
Finland FINDIET2012 1295 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 1.0 
France INCA2 2276 0.4 0.4 0.4 0.4 0.4–0.5 0.8 0.8 0.8 0.8 0.8 
United Kingdom NDNS-
RollingProgrammeYears1-3 
1266 0.5 0.5 0.5 0.5 0.5 1.0 1.0 1.0 1.0 1.0 
Hungary National_Repr_Surv 1074 0.5 0.5 0.5 0.5 0.5 0.9–1.0 0.9–1.0 0.9–1.0 0.9–1.0 1.0 
Ireland NANS_2012 1274 0.6 0.6 0.6 0.5–0.6 0.6 1.0–1.1 1.0–1.1 1.0–1.1 1.0 1.0–1.1 
Italy INRAN_SCAI_2005_06 2313 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.9 0.9 0.9 0.9 0.9 
Latvia EFSA_TEST 1271 0.6 0.6 0.6 0.6 0.6 1.3 1.3 1.3 1.3 1.3 
Netherlands VCPBasis_AVL2007_2010 2057 0.6 0.6 0.6 0.6 0.6 1.2 1.2 1.2 1.2 1.2 
Romania Dieta_Pilot_Adults 1254 0.4 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8 0.8 
Sweden Riksmaten 2010 1430 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.8–0.9 0.8–0.9 0.8–0.9 0.8–0.9 0.9 
Elderly 
Belgium Diet_National_2004 511 0.5 0.5 0.5 0.5 0.5 0.9–1.0 0.9–1.0 0.9–1.0 0.9–1.0 1.0 
Germany National_Nutrition_Survey_I
I 
2006 0.4 0.4 0.4 0.4 0.4 0.9 0.9 0.9 0.9 0.9 
Denmark DANSDA 2005-08 274 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.8 0.8 0.8 0.8 0.8–0.9 
Finland FINDIET2012 413 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.8–0.9 0.8–0.9 0.8–0.9 0.8–0.9 0.9 
France INCA2 264 0.4 0.4 0.4 0.4 0.4 0.7 0.7 0.7 0.7 0.7–0.8 
United Kingdom NDNS-
RollingProgrammeYears1-3 
166 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.8 0.8 0.8 0.8 0.8 
Hungary National_Repr_Surv 206 0.4 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8 0.8 
Ireland NANS_2012 149 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.8 0.9 
Italy INRAN_SCAI_2005_06 290 0.4 0.4 0.4 0.4 0.4 0.7 0.7 0.7 0.7 0.7 
Netherlands VCPBasis_AVL2007_2010 173 0.5 0.5 0.5 0.5 0.5 1.0 1.0 1.0 1.0 1.0 
Netherlands VCP-Elderly 289 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 0.9 
Romania Dieta_Pilot_Adults 83 0.4 0.4 0.4 0.4 0.4 0.7 0.7 0.7 0.7 0.7 
Sweden Riksmaten 2010 295 0.5 0.5 0.5 0.5 0.5 0.8–0.9 0.8–0.9 0.8–0.9 0.8–0.9 0.9 
Very elderly 
Belgium Diet_National_2004 704 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 0.9 
Germany National_Nutrition_Survey_II 490 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 1.0 1.0 1.0 1.0 1.0 
Denmark DANSDA 2005-08 12 0.5 0.5 0.5 0.5 0.5 –* –* –* –* –* 
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Table G2:   Chronic exposure levels to acrylamide (AA) resulting from the scenarios B1, C1, C2 and D1 compared to the baseline (BASE) scenario, 
expressed in µg/kg b.w. per day for each survey and age group (continued) 
Country Survey acronym n
(a)
 
Mean LB-UB
(b)
 P95 LB-UB
(c)
 
BASE B1 C1 C2 D1 BASE B1 C1 C2 D1 
France INCA2 84 0.4 0.4 0.4 0.4 0.4 0.6 0.7 0.6 0.6 0.6–0.7 
United Kingdom NDNS-
RollingProgrammeYears1-3 
139 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 0.9 
Hungary National_Repr_Surv 80 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.5 0.9 0.9 0.9 0.9 1.0 
Ireland NANS_2012 77 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.4–0.5 0.8 0.8 0.8 0.8 0.8 
Italy INRAN_SCAI_2005_06 228 0.4 0.4 0.4 0.4 0.4 0.7 0.7 0.7 0.7 0.7 
Netherlands VCP-Elderly 450 0.5 0.5 0.5 0.5 0.5 0.9 0.9 0.9 0.9 0.9 
Romania Dieta_Pilot_Adults 45 0.4 0.4 0.4 0.4 0.4 –* –* –* –* –* 
Sweden Riksmaten 2010 72 0.5 0.5 0.5 0.5 0.5 0.8 0.8 0.8 0.8 0.8 
In order to avoid the impression of too high precision, the numbers for all exposure estimates are rounded to 2 figures.  
*  The 95th percentile (P95) for dietary surveys/age groups with less than 60 subjects were not reliable and therefore not presented.  
(a):  n: number of subjects.  
(b):  Mean LB-UB: mean lower bound – upper bound.  
(c):  P95 LB–UB: 95th percentile lower bound – upper bound. When lower bound and upper bound estimates are equal, only one estimate is provided.  
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Appendix H. Previously reported human exposure assessments  
Table H1:  Previous dietary exposure estimates for acrylamide (AA) for the adult population as published in the literature since 2010 
Country Sampling year Type of survey 
Mean (P95) exposure  
(µg/kg b.w. per day) 
Comments Reference 
31 countries 2004–2009 Different depending on the country 1 (4)  
The estimates include 
children 
FAO/WHO 
(2011) 
Poland 2005–2007 24-h dietary recall 0.33 (0.69) 19–96 years old 
Mojska et al. 
(2010) 
Poland 2006 Semi-quantitative FFQ 0.85 (1.70) 
Chosen population (South 
of Poland) 
Zając et al. (2013) 
Belgium 2002–2007 
Repeated non-consecutive 24-h recall 
and self-administered FFQ 
0.35 (1.58
(a)
) - 
Claeys et al. 
(2010)  
Finland 
Published data  
(2002, 2004) 
48-h recall and  
3-d food record 
0.44
(b) 
(1.16
(a)
)  
0.41
(b) 
(0.87
(a)
) 
Women 
Men 
Hirvonen et al. 
(2011)  
France 2007–2009 7-d food record diary  0.43 (1.02)  TDS  Sirot et al. (2012) 
France 2007–2009 
FFQ in the year before pregnancy and 
during the last 3 months of pregnancy  
0.404 (0.969) 
0.285 (0.712)  
Before pregnancy  
Third trimester of 
pregnancy  
Chan-Hon-Tong 
et al. (2013)  
10 European 
countries  
EU monitoring database 
(JRC-IRMM) (2002–
2006) and US-FDA 
database (2002–2004) 
24-h dietary recall 
12–41 μg per day (women)(c)(d) 
15-48 μg per day (men)(c)(d) 
EPIC study  
27 centres of 10 European 
countries 
Freisling et al. 
(2013) 
United States 2002–2004 
24-h dietary recall 
and FFQ 
0.33 (0.75) (women) 
0.39 (0.91) (men) 
> 20 years old Tran et al. (2010) 
China 2007 
3-day household dietary survey and  
24-h recall 
0.29 (0.49)  
TDS 
Medium bound  
Zhou et al. (2013) 
Hong Kong n.s.  FBQ, FFQ and 24-h dietary recalls  0.13 (0.69
(a)
) - FEHD (2012) 
New Zealand  2011 24-h dietary recall 
1.36 
1.01 
0.84  
11–14 years old  
19–24 years old 
> 25 years old  
MAF (2012) 
b.w.: body weight; d: day; FBQ: food behaviour questionnaire; FFQ: food frequency questionnaire; h : hour(s) ; n.s.: not specified; P95: 95th percentile; TD: typical diet; TDS: total diet study.  
(a):  P97.5 (97.5th percentile).  
(b):  Median.  
(c):  Minimally adjusted by gender.  
(d): Corresponding to 0.17–0.58 µg/kg b.w. per day for women and to 0.21–0.68 µg/kg b.w. per day for men when using a default body weight of 70 kg (EFSA SC, 2012b).   
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Table H2:  Previous dietary exposure estimates for acrylamide (AA) for infants, children and adolescents as reported in the literature 
Country Sampling year Dietary survey method 
Mean (P95) exposure  
(µg/kg b.w. per day) 
Comments Reference 
31 countries 2004–2009 Different depending on the country 1 (4)  The estimates include children FAO/WHO (2011) 
United States 2002–2004 
24-h dietary recall 
and FFQ 
0.86 (2.39)  3–12 years old  Tran et al. (2010) 
United States 2002–2004 24-h dietary recall 
0.44 (0.64) 
0.50 (0.73) 
Teenagers - Western diet  
Teenagers - Guideline based diet  
Katz et al. (2012) 
Finland 
Published data 
(2002, 2004)  
3-d food record 
0.4(b) 
1.01(b)  (1.95(a)) 
0.87(b)  (1.53(a)) 
1 year old  
3 years old  
6 years old 
Hirvonen et al. (2011) 
Poland 2005–2007 24-h dietary recall 
0.75 (2.88) 
0.62 (2.45) 
1–6 years old  
7–18 years old  
Mojska et al. (2010)  
Spain  
Published data 
(2005–2007). 
Other foods: n.s.  
Design diets based on eating patterns 
and following the recommended 
Intakes for the Spanish Population 
0.53 11–14 years old (males) 
Delgado-Andrade et al. 
(2012) 
Poland 2006 Semi-quantitative FFQ 1.51 (2.86)  
6–12 years old 
Chosen population (South of Poland) 
Zając et al. (2013) 
France 2007–2009 7-d food record diary 
0.89 (1.86) 
0.69 (1.80) 
3–6 years old 
3–17 years old 
Sirot et al. (2012)  
Poland 2007–2011 
Theoretical infant daily intake of 
individual foodstuff  
0.4–0.6  
Minimum AA levels 
Non breast-fed infants (6–12 months old)  
Mojska et al. (2012)   2.1–4.3 
Average AA levels  
Non breast-fed infants (6–12 months old)  
7.5–12.4 
Highest AA levels  
Non breast-fed infants (6–12 months old) 
Turkey 2012 24-h dietary recall 1.43 (3.76) 1–3 years old Cengiz and Gündüz (2013) 
Canada  n.s. 
2-d food record 
FFQ 
0.58 (2.19)  
0.20 (0.44)  
10–17 year old non-smoking adolescents Normandin et al. (2013) 
b.w.: body weight; FFQ: food frequency questionnaire; n.s.: not specified; P95: 95th percentile.  
(a):  P97.5.  
(b):  Median.  
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Appendix I. Studies in the literature reporting potential protective effects against acrylamide (AA) and glycidamide (GA) toxicity 
Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications. 
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Wang et al. (2015) 
Protective effect of allicin against 
GA-induced toxicity in male and 
female mice. 
Oral administered allicin with a concentration of 5, 10, and 20 mg/kg b.w. per day could significantly 
decrease the damage indexes of AST, ALT, LDH, BUN, ROS, 8-OHdG, MDA, and MPO induced by 
GA, while increase the antioxidant indicators of SOD, GST and GSH. The authors concluded that ‘allicin 
could be used as an effective dietary supplement for the chemoprevention of GA genotoxicity internally, 
and to prevent the tissue damage and toxicity induced by GA’. 
Mehri et al. (2015) 
Linalool as a neuroprotective agent 
against AA-induced neurotoxicity in 
Wistar rats 
Exposure to AA led to severe gait abnormalities and treatment with linalool significantly reduced 
abnormalities. AA reduced GSH content and increased level of MDA in cerebral cortex. Linalool 
increased GSH content while decreased AA-induced lipid peroxidation in rat brain tissue. The authors 
concluded that ‘the best protocols were initiation of supplementation before or simultaneous with AA 
administration’. 
Zhao et al. (2015) 
Evaluation of protective effect of 
freeze-dried strawberry, grape, and 
blueberry powder on AA toxicity in 
mice 
Compared with the control diet, the diets containing berries could reverse the AA-induced alterations in 
liver antioxidant enzymes activities (P < 0.05). The AA-induced genotoxicity could be prevented by the 
diet containing berries. The DNA damage in the lymphocyte and liver cells and the micronucleus 
formation in bone marrow cell were significantly alleviated (P < 0.05). The mice fed with diets containing 
berries showed a recovery in the sperm count, the sperm activity rate, sperm motility parameters, and the 
abnormal sperm rate (P < 0.05). The authors concluded that ‘berry powders have remarkable intervention 
against the AA-induced general toxicity, genotoxicity, reproductive toxicity. Abundant phenolics, 
especially anthocyanins, may contribute to the intervention’. 
Huang et al. (2015b) 
Simple analytical strategy for 
MALDI-TOF-MS and nanoUPLC–
MS/MS: Quantitating curcumin in 
food condiments and dietary 
supplements and screening of AA-
induced ROS protein indicators 
reduced by curcumin 
Nano ultra performance liquid chromatographic system (nanoUPLC) coupled with tandem mass 
spectrometry was used to evaluate the potential proteins and protein modifications induced by AA. The 
authors concluded that ‘the results indicate that curcumin reduces the effects of ROS induced by AA’. 
Table continued overleaf. 
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Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications. (continued) 
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Chen et al. (2014) 
Hispidin derived from Phellinus 
linteus affords protection against AA-
induced oxidative stress in Caco-2 
cells 
The cytoprotective effect of hispidin against AA-induced oxidative stress was verified upon Caco-2 cells 
according to evaluate the cell viability, intracellular ROS, mitochondrial membrane potential and GSH in 
the presence or absence of AA (5 mM) in a dose-dependent manner. The authors concluded that ‘the 
results demonstrated for the first time that hispidin was able to inhibit AA-induced oxidative stress, which 
might have implication for the dietary preventive application’. 
Yassa et al. (2014) 
Camellia sinensis (green tea) extract 
attenuate acrylamide induced 
testicular damage in albino rats 
Testosterone hormone level in serum, and histopathological findings were significantly improved with the 
co-administration of green tea extract with the AA. Green tea extract reversed all the toxic effects of AA 
even in high dose for long period (90 days). The authors concluded that ‘green tea extract is a potent 
antioxidant antidote for the AA toxic effects upon testicular function’. 
Song et al. (2014)  
Effective suppression of AA 
neurotoxicity by lithium in mouse. 
Treatment with lithium effectively alleviated behavioral deficits in animals elicited by AA. The reduction 
of hippocampal neurogenesis resulting from AA injection was promoted by administration of lithium. 
Lithium treatment significantly offset AA-induced depletion in p-GSK-3beta (Ser9) levels in 
hippocampus. The authors concluded that ‘our data clearly demonstrate the beneficial effects of lithium 
on AA-induced neuropathy in mice and suggest its possible therapeutic application as an adjuvant in the 
management of other forms of neuropathy in humans’. 
Muralidhara (2014) 
Mitigation of AA-induced behavioral 
deficits, oxidative impairments and 
neurotoxicity by oral supplements of 
geraniol (a monoterpene) in a rat 
model 
Rats treated with AA and provided with daily oral supplements of geraniol and curcumin exhibited 
marked improvement in behavioral tests. Both markedly attenuated AA-induced oxidative stress as 
evidenced by the diminished levels of ROS, malondialdehyde and nitric oxide and restored the reduced 
glutathione levels in sciatic nerve and brain regions. AA mediated elevation in the acetylcholinesterase 
activity was reduced by both actives. The depletion in dopamine levels was restored only by curcumin in 
brain regions. The authors concluded that ‘these findings for the first time demonstrate that the 
neuromodulatory propensity of geraniol is indeed comparable to that of curcumin and may be exploited 
as a therapeutic adjuvant in the management of varied human neuropathy conditions’.  
Lebda et al. (2014) 
Effects of lipoic acid on AA induced 
testicular damage 
The administration of AA resulted in significant elevation in testicular and epididymal malondialdehyde 
level (MDA) and significant reduction in the level of reduced GSH and the activities of GST, GPX and 
GR. AA significantly reduced serum total testosterone and progesterone but increased estradiol levels. 
Treatment with alpha-lipoic acid prior to AA induced protective effects and attenuated these biochemical 
changes. The authors concluded that ‘Alpha-lipoic acid has been shown to possess antioxidant properties 
offering promising efficacy against oxidative stress induced by acrylamide administration’. 
Table continued overleaf. 
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Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications. (continued) 
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Ali et al. (2014) 
Effectiveness of selenium on AA 
toxicity to retina 
AA caused many adverse effects in the tissues reflected in significant increase in lipid peroxidation. The 
decrease in glutathione levels and GSH-Px activity might be one of the primary events in the AA-induced 
hematological and retinal lesions. The authors concluded that ‘the administration of selenium, as a 
component of GSH-Px in combination with ACR significantly lowered lipid peroxidation, and enhanced 
glutathione levels’. 
Mehri et al. (2014a) 
Neuroprotective effect of 
thymoquinone in AA-induced 
neurotoxicity in Wistar rats 
Exposure to AA led to severe gait abnormalities and treatment with thymoquine (the main constituent of 
volatile oil from Nigella sativa seeds) significantly decreased abnormalities. Level of MDA was elevated 
in cerebral cortex after exposure to AA while thymoquine treatment significantly and in a dose-dependent 
manner reduced lipid peroxidation. The authors concluded that ‘the neuroprotective effect of thymoquine 
in this model in part, may be because of due the antioxidant activity of this natural compound’. 
Mehri et al. (2014b) 
Chrysin reduced AA-induced 
neurotoxicity in both in vitro and in 
vivo assessments 
AA decreased cell viability and pre-treatment with chrysin (0.5–5 μM) significantly decreased AA-
induced cytotoxicity in the time- and dose-dependent manner. In Wistar rats, exposure to AA 
significantly induced severe gait abnormalities, but treatment with chrysin (50 mg/kg) reduced AA-
induced neurotoxicity in animals. The authors concluded that ‘In the current study, chrysin exhibited 
neuroprotective effect on PC12 cells as an in vitro model and also on Wistar rats’. 
Siahkoohi et al. 
(2014) 
The effects of vitamin E on the liver 
integrity of mice fed with AA diet 
Following AA consumption, the serum levels of liver enzymes significantly increased and light 
microscopy showed lymphocytes infiltration, inflammation of portal space and central vein, apoptosis, 
chromatolysis and fibrous expansion in some portal areas in AA-treated mice. There was a statistically 
considerable difference between biochemical parameters, index apoptosis and histological features when 
the AA plus vitamin E-treated group was compared with acrylamide-treated group. The authors 
concluded that ‘Acrylamide induced disturbance in hepatocytes activity and increased the serum levels of 
liver and structural changes in the liver. Administration of vitamin E significantly reduced the increased 
level of serum aminotransferase and the pathological changes, also effectively suppressed the 
acrylamide–induced liver injury’ 
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Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications. (continued) 
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Zhang et al. (2013) 
Potential protective effects of oral 
administration of allicin on AA-
induced toxicity in male mice 
Orally administered allicin could significantly decrease TBARS and MPO levels, and remarkably 
increased the SOD activity, GST and GSH levels in the kidney, liver, and brain of the AA-treated mice. 
Oral administration of allicin significantly decreased AST, ALT, LDH, BUN, TNF-α, IL-1β, IL-6, ROS 
and 8-OHdG, and increased IL-10 in the serum of AA-treated mice. The authors concluded that ‘oral 
administration of allicin had a significant in vivo protective effect against the AA induced toxicity’. 
Song et al. (2013) 
Protection of cyanidin-3-glucoside 
(Cy-3-glu) against oxidative stress 
induced by AA in human MDA-MB-
231 cells 
Compared to MDA-MB-231 cells treated with AA only, pre-treatment of Cy-3-glu significantly inhibited 
AA-induced cytotoxicity, reduced ROS generation, recovered GSH depletion and decreased the activities 
of GPx and GST. The expression of GPx1, GSTP1 and γ-GCS were enhanced, and CYP2E1 expression 
was inhibited by the pre-treatment of Cy-3-glu. The authors concluded that ‘Cy-3-glu presents the 
protective role against oxidative stress induced by AA in MDA-MB-231 cells’. 
Shinomol et al. 
(2013) 
Prophylaxis with Bacopa monnieri 
attenuates AA induced neurotoxicity 
and oxidative damage via elevated 
antioxidant function 
Pretreatment with Bacopa monnieri protected the N27 cells against AA-induced cell death and associated 
oxidative damage. Co-treatment and pre-treatment of Drosophila melanogaster with Bacopa monnieri 
extract protected against AA-induced locomotor dysfunction and GSH depletion. The authors concluded 
that ‘Bacopa monnieri displays prophylactic effects against AA induced oxidative damage and 
neurotoxicity with potential therapeutic application in human pathology associated with neuropathy’.  
Muralidhara (2013)  
Neuroprotective efficacy of eugenol 
and isoeugenol in AA-Induced 
neuropathy in rats: behavioral and 
biochemical evidence. 
Treatment of rats with AA and with spice active principles caused marked improvement in gait score and 
responses in a battery of behavioral tests. Both spice active principles markedly attenuated AA-induced 
markers of oxidative stress viz., ROS, MDA and NO in SN as well as brain regions (cortex Ct, 
cerebellum Cb). Treatment with eugenol restored the reduced glutathione levels in SN and brain regions. 
Interestingly, both spice active principles effectively diminished AA-induced elevation in cytosolic 
calcium levels and acetylcholinesterase activity in SN and Ct. The diminished activity of ATPase among 
AA rats was enhanced in SN and restored in brain regions. Eugenol treatment significantly offset AA-
induced depletion in dopamine levels in brain regions. The authors concluded ‘on the propensity of these 
spice active principles to attenuate AA-induced neuropathy’.  
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Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications (continued).  
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Hasseeb et al. (2013)  
Impacts of grape seed oil 
supplementation against the AA 
induced lesions in male genital 
organs of rats.  
Compared to the group of AA-intoxication, similar scales of lesions were seen in the group administrated 
by AA with low levels of grape seed oil, while the lesions in the other group of administration by AA 
with the high levels of grape seed oil were of less scales. The authors concluded on ‘the occurrence of a 
less and level-dependent impact ameliorating effect of grape seed oil supplementation against AA-
induced lesions in male genital organs of the adult rats’. 
Chen et al. (2013b)  
Myricitrin inhibits AA-mediated 
cytotoxicity in human Caco-2 cells 
by preventing oxidative stress  
Myricitrin can effectively scavenge multiple free radicals (including DPPH free radical, hydroxyl radical, 
and ABTS free radical) in a concentration-dependent manner. The presence of myricitrin (2.5–10 𝜇g/mL) 
was found to significantly inhibit AA-induced cytotoxicity in human gastro-intestinal Caco-2 cells. 
Myricitrin was able to suppress AA toxicity by inhibiting ROS generation. The authors concluded that 
‘these results demonstrate that myricitrin had a profound antioxidant effect and can protect against AA-
mediated cytotoxicity’. 
Alturfan et al. (2012a) 
Resveratrol ameliorates oxidative 
DNA damage and protects against 
AA-induced oxidative stress in rats 
In the resveratrol-treated AA group, oxidant responses reversed significantly. Serum enzyme activities, 
cytokine levels and leukocyte late apoptosis which increased following AA administration, decreased 
with resveratrol treatment. The authors concluded that ‘supplementing with resveratrol can be useful in 
individuals at risk of AA toxicity’. 
Alturfan et al. 
(2012b) 
Protective effect of N-acetyl-L-
cysteine against AA-induced 
oxidative stress in rats.  
In the AA group, GSH levels decreased significantly, while the MDA levels, MPO activity, and collagen 
content increased in the tissues suggesting oxidative organ damage. In the NAC + AA group, oxidant 
responses reversed significantly. Serum enzyme activities, cytokine levels, and leukocyte apoptosis, 
which increased following AA administration, decreased with NAC treatment. The authors concluded 
that ‘supplementing with NAC can be useful when there is a risk of AA toxicity, as NAC inhibited 
neutrophil infiltration, balanced the oxidant-antioxidant status, and regulated the generation of 
inflammatory mediators to protect tissues’. 
Dobrowolski et al. 
(2012) 
Potato fiber protects the small 
intestinal wall against the toxic 
influence of AA 
The two potato fiber preparations that were used abolished the negative influences of AA on the small 
intestinal wall and had no influence on the haemoglobin adduct levels of AA. The authors concluded that 
‘the negative impact of AA on the histologic structure, regeneration, and innervation of the small 
intestinal wall and the absorptive function of the small intestinal mucosa can be abolished by dietary 
potato fiber preparations’. 
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Table I1:  Overview of publications reporting on the potential protective effects of drugs, natural compounds and other chemicals towards biochemical and 
adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
conclusions are those expressed by the authors of the studies in the publications (continued).  
Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
El-Halim and 
Mohamed (2012) 
Garlic powder attenuates AA-induced 
oxidative damage in multiple organs 
in rat 
The administration of AA resulted in significant elevation in kidney, spleen, testes and brain 
malondialdehyde level (MDA) and significant reduction in the level of reduced glutathione (GSH) and 
the activity of copper-zinc superoxide dismutase (Cu/Zn SOD) in the same organs. Also serum urea and 
creatinine levels and LDH and alkaline phosphatase activities were significantly elevated whereas serum 
total proteins and albumin were significantly reduced in AA-treated rats as compared with negative 
control. The authors concluded that ‘treatment with garlic prior to AA produced protective effects and 
attenuated these biochemical changes‘  
El-Kholy et al. (2012) 
A trail of using green tea for 
competing toxicity of AA on liver 
function 
The authors concluded that ‘in rats, supplementation with antioxidant (green tea) reduced the effect of 
AA on the hepatological markers in serum AST and ALT and ALP, and that green tea enhanced 
antioxidative abilities in liver and protected liver cells membrane against AA action’. 
Lakshmi et al. (2012) 
Ameliorating effect of fish oil on AA 
induced oxidative stress and neuronal 
apoptosis in cerebral cortex 
AA administered rats showed increased levels of lipid peroxidative product, protein carbonyl content, 
hydroxyl radical and hydroperoxide which were significantly modulated by the supplementation of fish 
oil. The activities of enzymic antioxidants and levels of reduced glutathione were markedly lowered in 
AA-induced rats. Fish oil treatment augmented these antioxidant levels in cortex. Free radicals generated 
during AA administration reduced the activities of membrane adenosine triphosphatases and 
acetylcholine esterase. Fish oil enhanced the activities of these enzymes near normal level. Histological 
observation represented the protective role of fish oil in AA-induced neuronal damage. Fish oil reduced 
the AA-induced apoptosis through the modulation in expressions of B-cell lymphoma 2 (Bcl2)-associated 
X protein and Bcl2-associated death promoter. Further, fish oil increases the expression of heat shock 
protein 27 (Hsp27). The authors concluded that ‘there is evidence for the neuroprotective effect of fish oil 
on AA-induced neurotoxicity by reducing oxidative stress and apoptosis with modulation in the 
expression of Hsp27’.  
Mehri et al. (2012) 
 
Neuroprotective effect of crocin on 
AA-induced cytotoxicity in PC12 
cells 
Crocin significantly attenuated AA cytotoxicity in a dose-dependent manner. Crocin inhibited the 
downregulation of Bcl-2 and the upregulation of Bax and decreased apoptosis in treated cells, and 
inhibited ROS generation in cells exposed to AA. The authors concluded that ‘pre-treatment with crocin 
protected cells from AA-induced apoptosis partly by inhibition of intracellular ROS production’. 
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adverse effects of acrylamide (AA) and glycidamide (GA). This overview covers studies published from 2010 and does not claim for completeness. The 
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Reference Title of the study Conclusions from the authors as indicated in the abstract of the studies 
Sadek (2012) 
Antioxidant and immunostimulant 
effect of carica papaya linn. aqueous 
extract in AA intoxicated rats  
Administration of Carica papaya fruit aqueous extract significantly ameliorated the increased levels of 
MDA and decline of GSH, SOD and CAT activity in the stomach, liver and kidney tissues caused by AA 
toxicity. Carica papaya fruit  aqueous extract significantly increased immune functions (IgG and IgM) 
while AA significantly decrease it specially IgG. The authors concluded that ‘AA-induced oxidative 
stress in rats can be ameliorated by administration of Carica papaya fruit aqueous extract’. 
Rahangadale et al. 
(2012)  
Evaluation of protective effect of 
Vitamin E on AA induced testicular 
toxicity in Wistar rats 
At recovery period, there was significant increase in the total sperm count of vitamin-E-treated group of 
animals as compared to untreated toxicated rats. But, values were significantly lower than control 
animals.  Somewhat better architecture of the seminiferous tubules was also observed. Late spermatids 
were seen in few seminiferous tubules and other revealed starting of spermatogenesis. The authors 
concluded that ‘Vitamin E is not able to protect testes from AA toxicity during active feeding, but after 
cessation of AA feeding treatment with vitamin E revealed faster recovery as compare to not treated 
group’. 
Zhang et al. (2012) 
Protective effect of allicin against 
AA-induced hepatocyte damage in 
vitro and in vivo 
Allicin significantly decreased the levels of MDA and 8-OHdG both in vitro and in vivo study. Allicin 
markedly increased the activity of total SOD and level of GSH. The authors concluded that ‘the 
protective effects of allicin against AA-induced hepatocyte damage may be due to its ability to scavenge 
free radicals and its effective recovery of the antioxidative defense system, and its ability to block the 
epoxidation process of AA to GA by inhibiting P450 enzyme’. 
Rodríguez-Ramiro  
et al. (2011a) 
Olive oil hydroxytyrosol reduces 
toxicity evoked by AA in human 
Caco-2 cells by preventing oxidative 
stress 
AA cytotoxicity was counteracted by hydroxytyrosol by powerfully reducing ROS generation, recovering 
the excited enzyme antioxidant defences and decreasing phospho-Jun kinase concentration and caspase-3 
activity induced by AA. The authors concluded that ‘the olive oil natural dietary antioxidant 
hydroxytyrosol was able to contain AA toxicity by improving the redox status of Caco-2 cells and by 
partly restraining the apoptotic pathway activated by AA’. 
Rodríguez-Ramiro  
et al. (2011b) 
Procyanidin B2 and a cocoa 
polyphenolic extract inhibit AA-
induced apoptosis in human Caco-2 
cells by preventing oxidative stress 
and activation of JNK pathway 
AA cytotoxicity was counteracted by cocoa polyphenolic extract or Procyanidin B2 by inhibiting GSH 
consumption and ROS generation, increasing the levels of gamma-glutamyl cysteine synthase and 
glutathione-S-transferase and blocking the apoptotic pathways activated by AA. The authors concluded 
that ‘natural dietary antioxidant such as Procyanidin B2 and cocoa polyphenolic extract were able to 
suppress AA toxicity by improving the redox status of Caco-2 cells and by blocking the apoptotic pathway 
activated by AA’. 
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Khan et al. (2011) 
Protective potential of methanol 
extract of Digera muricata on AA 
induced hepatotoxicity in rats 
Treatment of methanol extract of Digera muricata dose dependently ameliorated the toxicity of AA and 
the studied parameters were reversed towards the control level. Hepatic lesions induced with AA were 
reduced with treatment with methanol extract of Digera muricata. Phytochemical screening indicates the 
presence of flavonoids, alkaloids, terpenoids, saponins, tannins, phlobatanin, coumarins, anthraquinones 
and cardiac glycosides. The authors concluded that ‘the results obtained suggested that the 
hepatoprotective effects of the methanol extract of Digera muricata against AA-induced oxidative injuries 
could be attributed to the phenolics and flavonoids’. 
Alzahrani (2011) 
Protective effect of L-carnitine 
against AA-induced DNA damage in 
somatic and germ cells of mice 
Treatment with AA induced a statistically significant increase in the % of chromosomal aberrations and 
micronuclei in bone- marrow cells. This was reduced significantly in all groups treated with AA and the 
protective agent L-carnitine. The morphological sperm abnormalities observed in the AA treated animals 
were reduced in the group treated with the same dose of AA and L-carnitine. The authors concluded that 
‘the results confirmed the protective role of L-carnitine against the mutagenicity of AA’. 
Mohareb et al. (2011) 
Development of new indole-derived 
neuroprotective agents 
Treatment with the indole derivatives 9b, 12c, 14a, and 17 (i.p., 50 mg kg/b.w.) prior to AA produced 
neuroprotective activity with various intensities depending on the structure of each compound. Compound 
17 in which the tetrazole ring was attached to the L-tryptophan moiety ranked as the strongest 
neuroprotective agent. The authors concluded that ‘all the tested compounds have been shown to possess 
antioxidant properties offering promising efficacy against oxidative stress induced by AA administration’. 
Ghareeb et al. (2010) 
Ameliorated effects of garlic (Allium 
sativum) on biomarkers of subchronic 
AA hepatotoxicity and brain toxicity 
in rats 
Co-administration of garlic powder with AA significantly attenuated oxidative stress, MAO activity, and 
inflammation in brain and hepatic tissues but did not ameliorate AChE activity. The authors concluded 
that ‘the results obtained emphasized the role of garlic as a potential adjuvant therapy to prevent AA 
neurotoxicity and hepatotoxicity’. 
Ahmed et al. (2010) 
Potent neuroprotective role of novel 
melatonin derivatives for 
management of central neuropathy 
induced by AA in rats 
Treatment with melatonin derivatives prior to AA produced significant decrease in brain MDA level and 
LDH activity with concomitant significant increase in brain monoamines and antioxidant enzymes 
activity. The authors concluded that ‘the new synthesized melatonin derivatives exhibited promising 
protective activity against AA-induced neurotoxicity’. 
 γ-GCS: gamma-glutamyl cysteine synthase; 8-OHdG: 8-hydroxy-desoxyguanosine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; GPx: 
glutathione peroxidase; GSH: glutathione; GST: glutathione S-transferase; IL-1β: interleukin-1β; IL-6: interleukin-6; IL-10: interleukin-10; LDH: lactate dehydrogenase; MDA: 
malondialdehyde; MPO: myeloperoxidase; NO: nitric oxide; ROS: reactive oxygen species; SOD: superoxide dismutase; SN: sciatic nerve; TBARS: thiobarbituric reactive substances; TNF-α: 
tumour necrosis factor α.  
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Appendix J. Epidemiological studies  
Table J1:  Features of epidemiological studies on dietary acrylamide (AA) and cancer risk 
Reference Study design Country 
Exposure 
measurement 
Details of exposure 
measurement 
Used AA data 
Validity and 
reproducibility 
Mucci et al. (2003a,b) 
Population-based 
case-control study 
Sweden FFQ  with 188 items 
Foods were ranked 
according to AA content 
(1,2,4,8), multiplied with 
frequency and summed up 
Swedish data not reported 
Mucci et al. (2004) 
Population-based 
case-control study 
Sweden FFQ  with 63 items  
Swedish and US 
data 
not reported 
Mucci et al. (2005) 
Prospective 
cohort study 
Sweden 
(Women's 
Lifestyle and 
Health Cohort) 
FFQ with 80 items  Swedish data not reported 
Mucci et al. (2006); 
Larsson et al. 
(2009a,b,c) 
Prospective 
cohort study 
Swedish 
Mammography 
Cohort (SMC) 
FFQ with 67 items (at 
baseline) and with 96 
items (in 1997) 
 
Swedish and US 
data 
Validity 1st FFQ: 
correlation 0.6 for coffee, 
0.5 for whole grain bread 
and 0.6 and breakfast 
cereals/muesli 
Pelucchi et al. (2006, 
2007, 2011b) 
Hospital-based 
case-control study 
Italy and 
Switzerland 
FFQ with 78 items  
WHO, French and 
Swiss data 
Reproducibility: 
correlation 0.52–0.75 for 
AA-containing foods 
Table continued overleaf. 
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Table J1:  Features of epidemiological studies on dietary acrylamide (AA) and cancer risk (continued) 
Reference Study design Country 
Exposure 
measurement 
Details of exposure 
measurement 
Used AA data 
Validity and 
reproducibility 
Hogervorst et al. (2007, 
2008a,b, 2009a,b);  
Pedersen et al. (2010); 
Schouten et al. (2009); 
Bongers et al. (2012); 
Hogervorst et al. (2014) 
Prospective 
cohort study 
Netherlands 
Cohort Study 
(NLCS) on Diet 
and Cancer 
FFQ with 150 items  Dutch data 
Reproducibility: 
correlation 0.66–0.71 for 
carbohydrates and fiber. 
Validity: correlation 0.65–
0.80 for carbohydrates, 
fibre, energy intake, 
potatoes, bread, cakes and 
cookies. 
Olesen et al.( 2008) 
Nested case-
control study  
Danish Diet, 
Cancer and 
Health Study 
AA-Hb and GA-Hb 
adducts 
 n.a. n.a. 
Larsson et al. 
(2009d,e) 
Prospective 
cohort study 
Cohort of 
Swedish Men 
FFQ with 96 items  Swedish data not reported 
Wilson et al. (2009a) 
Population-based 
case-control study 
Cancer of the 
Prostate in 
Sweden Study 
(CAPS) 
FFQ with 261 items 
and AA-Hb adducts 
in subgroups 
 Swedish data 
Correlation 0.25 with AA-
HB adducts (0.15 in cases 
and 0.35 in controls)  
Wilson et al. (2009b) 
Prospective 
cohort study 
USA, Nurses' 
Health Study  
(NHS) II 
FFQ with >130 items, 
at baseline and 
repeated every 4 
years 
 
US data and US 
foods measured in 
Sweden 
Validity correlation 0.6–
0.8 for potato crisps, 
French fries, coffee and 
breakfast cereals 
Wilson et al. (2010) 
Prospective 
cohort study 
USA, NHS 
FFQ with 61 to 116 
items at baseline and 
repeated every 2–4 
years 
Frequency and individual 
portion size 
US data and US 
foods measured in 
Sweden 
Correlation 0.34 with AA- 
and GA-HB adducts (see 
Wilson et al., 2009c) 
Table continued overleaf. 
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Table J1:  Features of epidemiological studies on dietary acrylamide (AA) and cancer risk (continued) 
Reference Study design Country 
Exposure 
measurement 
Details of exposure 
measurement 
Used AA data 
Validity and 
reproducibility 
Hirvonen et al. (2010) 
Prospective 
cohort study 
Finland, Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention  
(ATBC) study 
Self-administered 
modified diet-history 
method with 276 
items 
Frequency and individual 
portion size 
Mainly Finnish 
data, some Swedish 
data 
Reproducibility 
correlation 0.73 
Validity correlation 0.43 
Burley et al. (2010) 
Prospective 
cohort study 
United 
Kingdom, UK 
Women's 
Cohort Study 
FFQ with 217 items 
Individual frequency and 
standard portion size 
EU data 
Reproducibility: 
correlation 0.61 for dietary 
AA 
Lin et al. (2011) 
Case-control 
study 
Sweden FFQ with 63 items 
Individual frequency and 
sex-specific portion size 
Swedish data Not reported  
Olsen et al. (2012) 
Prospective 
cohort study 
Denmark, 
Danish Diet, 
Cancer and 
Health Study 
AA-Hb and GA-Hb 
adducts 
Prediagnostic 
measurements 
n.a. n.a. 
Wilson et al. (2012) 
Prospective 
cohort study 
USA, Health 
Professionals 
Follow-up 
Study 
FFQ with >130 items, 
at baseline and 
repeated every 4 years 
Frequency and individual 
portion size 
US data and US 
foods measured in 
Sweden 
Correlation 0.34 with AA- 
en GA-Hb adducts (see 
Wilson et al., 2009c) 
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Table J1:  Features of epidemiological studies on dietary acrylamide (AA) and cancer risk (continued) 
Reference Study design Country 
Exposure 
measurement 
Details of exposure 
measurement 
Used AA data 
Validity and 
reproducibility 
Xie et al. (2013) 
Prospective 
cohort study 
USA, NHS and 
NHS II 
AA-Hb and GA-Hb 
adducts 
 n.a. 
Correlation 0.34 with AA- 
and GA-Hb adducts (see 
Wilson et al., 2009c) 
Obón-Santacana et al. 
(2013, 2014, 2015); 
Lujan-Barroso et al. 
(2014)  
Prospective 
cohort study 
European 
Prospective 
Investigation 
into Cancer 
(EPIC) 
Country-specific 
FFQs  
Frequency and individual 
portion size 
Database using data 
from 7 European 
countries, 
completed with data 
from the USA 
Validity: correlation 0.17. 
Correlation 0.08 between 
FFQ and Hb-AA adducts 
(see Ferrari et al., 2013) 
FFQ: food frequency questionnaire; GA: glycidamide; Hb: haemoglobin; n.a.: not available; US: United States. 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
BREAST CANCER 
Mucci et al. 
(2005) 
Breast, mainly 
pre-menopausal 
Cohort:  
667 cases; 
43 404 cohort members 
12–44 µg/day 
(mean Q1-Q5) 
Q2: 0.9 (0.7–1.1)  
Q3: 1.0 (0.8–1.3) 
Q4: 1.0 (0.8–1.3) 
Q5: 1.2 (0.9–1.6) 
n.a. 
Age, education, smoking, alcohol, 
fibre, saturated fat, family history 
of breast cancer, energy intake, 
parity, OAC use, age first child 
birth, menopausal status 
Pelucchi et al. 
(2006) 
Breast, pre- and 
post-menopausal 
Case-control study:  
2 900 cases  
3 122 controls 
11–34 µg/day 
(p20-p80) 
Q2: 1.01 (0.85–1.20) 
Q3: 1.01 (0.85–1.20) 
Q4: 1.09 (0.92–1.31) 
Q5: 1.06 (0.88–1.28) 
p for trend, 0.37 
n.a. 
Age, study centre, education, 
BMI, energy intake, family 
history of breast or ovarian 
cancer, parity 
Hogervorst et al. 
(2007) 
Breast, post-
menopausal 
Cohort:  
1 835 cases;  
62 573 cohort members 
10–37 µg/day 
(median Q1-
Q5) 
Q2: 0.80 (0.64–1.02) 
Q3: 0.92 (0.72–1.17) 
Q4: 0.86 (0.67–1.10) 
Q5: 0.93 (0.73–1.19) 
p  for trend 0.79 
Comparable results 
for never-smokers 
Age, age menarche and 
menopause, age first child birth, 
OAC use, post-menopausal 
hormone use, BMI, height, 
cigarette smoking, SES, 
education, energy intake, 
saturated fat, carbohydrates, 
family history of breast cancer, 
benign breast disease 
Olesen et al. 
(2008) 
Breast, post-
menopausal 
Nested case-control 
study in a cohort; 
374 cases; 
374 controls 
AA-Hb adducts 
20-209 pmol/g 
globin 
GA-Hb adducts 
9–99 pmol/g 
globin (p5–
p95) 
IRR: 1.9 (0.9-–4.0) and 
IRR: 1.3 (0.6–2.8) per 
10-fold increase AA-
Hb adducts and GA-
Hb adducts, 
respectively. 
ER+ tumours: IRR: 
2.7 (1.1–6.6) per 10-
fold increase AA-Hb 
adducts. Stronger 
associations for 
smokers 
Age, BMI, age at first child birth, 
parity, postmenopausal hormone 
use, education, alcohol, tobacco 
use, past smoking, smoking years 
and mutually adjusted for AA-Hb 
and GA-Hb adducts 
Table continued overleaf. 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs (continued) 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
Larsson et al. 
(2009a)  
Breast, 
pre- and post- 
menopausal  
Cohort:  
2 592 cases; 
61 433 cohort 
members  
20–29 µg/day  
(p25–p75)  
Q2: 1.02 (0.92–1.14)  
Q3: 0.95 (0.85–1.06)  
Q4: 0.91 (0.80–1.02)  
p for trend, 0.06  
Comparable results  
for ER- and PR- 
subgroups 
and according to 
smoking status  
Age, education, BMI, height, 
parity, age first child birth, age 
menarche  and menopause, OAC 
use, PMH treatment, family 
history of breast cancer, benign 
breast disease,  and intakes of 
alcohol, coffee, cereal fibre, and 
total energy 
Wilson et al. 
(2009b)  
Breast, 
pre-menopausal  
Cohort:  
1 179 cases; 
90 628 participants  
11–38 µg/day 
(mean Q1-Q5)  
Q2: 0.95 (0.79–1.14) 
Q3: 0.94 (0.78–1.13) 
Q4: 1.03 (0.87–1.24) 
Q5: 0.92 (0.76–1.11) 
p for trend, 0.61  
Comparable results  
according to 
hormone receptor  
and smoking status  
Age, calendar year, BMI, height, 
OAC use, parity and age at first 
birth, age at menarche, family 
history of  breast cancer, history 
of benign breast disease, smoking, 
physical activity, animal fat, 
glycaemic load, alcohol and total 
energy intake 
Pedersen et al. 
(2010)  
Breast, 
post-
menopausal  
Cohort:  
2 225 cases; 
62 573 cohort members  
10–37 µg/day  
(median Q1-
Q5)  
Q2: 0.91 (0.73–1.23)  
Q3: 0.96 (0.76–1.19)       
Q4: 0.89 (0.72–1.12)           
Q5: 0.92 (0.73–1.15) 
p for trend, 0.48 
Positive associations 
for never-smokers 
and for ER+, PR+ 
and ER+PR+ 
  
Age, age menarche and 
menopause, age first child birth, 
parity, BMI, family history of 
breast cancer, benign breast 
disease, OAC use, PMH use, 
energy intake, cigarette smoking 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs (continued) 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
Wilson et al. 
(2010)  
Breast, 
post-
menopausal  
Cohort:  
6 301 cases; 
88 672 participants  
9–26 µg/day 
(mean Q1–Q5)  
Q2: 0.93 (0.86–1.01) 
Q3: 0.98 (0.91–1.06) 
Q4: 0.98 (0.90–1.06) 
Q5: 0.95 (0.87–1.03) 
p for trend, 0.50  
Comparable results  
in strata of 
smoking, 
menopausal status, 
and BMI  
Age, calendar year, smoking, 
BMI, height, menopausal status/ 
age at menopause/ PMH use, 
parity and age at first birth, family 
history of breast cancer, benign 
breast disease physical activity, 
glycaemic index, folate, animal 
fat, alcohol, energy intake  
Burley et al. 
(2010)  
Breast, 
pre- and post- 
menopausal  
Cohort:  
1 084 cases; 
33 731 participants  
6–32 µg/day 
(mean Q1–Q5)  
Q2: 1.06 (0.83–1.35) 
Q3: 1.05 (0.82–1.34) 
Q4: 1.12 (0.87–1.45) 
Q5: 1.16 (0.88–1.52) 
p for trend, 0.1  
Premenopausal 
cases: 
Q2: 1.06 (0.71–1.59) 
Q3: 1.15 (0.77–1.71) 
Q4: 1.15 (0.76–1.73) 
Q5: 1.47 (0.96–2.27) 
p-trend, 0.008 
No association for 
Post-menopausal 
cases 
Age, smoking status, weight, 
height, physical activity, parity, 
OAC use, PMH use, age at 
menarche, alcohol intake, energy 
intake, level of education.  
Olsen et al. 
(2012) 
Breast, 
post-menopausal 
Cohort:  
420 cases; 
80 breast cancer 
deaths (survival) 
AA and GA-Hb  
adducts: 
non-smokers: 
30–137 pmol/ 
g globin 
Smokers: 60–
389 pmol/g 
globin (p5–
p95) 
Non-smoking women 
AA-Hb adducts: 1.21 
(0.98–1.50) per 25 
pmol/g globin. 
GA-Hb adducts: 1.63 
(1.06–2.51) per 25 
pmol/g globin. 
Significant 
associations 
ER+ cases 
No or slightly 
weaker 
associations in 
smoking women  
Time from blood draw to 
diagnosis, baseline levels of 
alcohol intake, PMH use 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs (continued) 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
ENDOMETRIAL CANCER 
Hogervorst et al. 
(2007)  
Endometrial  
Cohort:  
221 cases; 
62 573 cohort members  
10–37 µg/day  
(median Q1–
Q5)  
Q2: 0.95 (0.59–1.54) 
Q3: 0.94 (0.56–1.56) 
Q4: 1.21 (0.74–1.98) 
Q5: 1.29 (0.81–2.07) 
p for trend, 0.18  
Never-smokers: 
Q2: 1.16 (0.63–2.15) 
Q3: 1.35 (0.73–2.51) 
Q4: 1.30 (0.69–2.46) 
Q5: 1.99 (1.12–3.52) 
p-trend, 0.03  
Age, age at menarche, age at 
menopause, age at first childbirth, 
parity, duration OAC use, 
duration PMH use, BMI, height, 
cigarette smoking, physical 
activity, energy, transunsaturated 
fat acid, and carbohydrate intake, 
alcohol intake 
Larsson et al. 
(2009b)  
Endometrial  
Cohort:  
687 cases; 
61 226 participants  
17–33 µg/day 
(median Q1–4)  
Q2: 1.10 (0.89–1.36) 
Q3: 1.08 (0.88–1.34) 
Q4: 0.96 (0.59–1.78) 
p for trend, 0.72  
Never-smokers: 
Q2: 1.31 (0.85–2.04) 
Q3: 1.30 (0.83–2.02) 
Q4: 1.20 (0.76–1.90) 
p-trend, 0.52 
no association in 
smoking women 
Age, education, BMI, parity, age 
at first birth, age at menarche, age 
at menopause, OAC use, PMH 
use, history of diabetes, smoking 
status, physical activity, 
carbohydrate intake, total energy 
intake  
Wilson et al. 
(2010)  
Endometrial  
Cohort:  
484 cases; 
88 672 participants  
9–26 µg/day 
(mean Q1–Q5) 
  
Q2: 1.12 (0.83–1.50) 
Q3: 1.31 (0.97–1.77) 
Q4: 1.35 (0.99–1.84) 
Q5: 1.41 (1.01–1.97) 
p for trend, 0.03  
Never-smokers: 
Q2: 0.97 (0.64–1.46) 
Q3: 1.35 (0.90–2.02) 
Q4: 1.47 (0.97–2.24) 
Q5: 1.43 (0.90–2.28) 
p-trend, 0.04 
Comparable results 
in strata of 
menopausal status. 
Significant 
association in 
women with normal 
BMI (< 25 kg/m
2
) 
Age, calendar year, smoking, 
BMI, height, menopausal status/ 
age at menopause/ PMH use, 
OAC use, age at menarche, high 
blood pressure, diabetes, physical 
activity, caffeine and energy 
intake 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs (continued) 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
Obón-Santacana 
et al. (2014)  
Endometrial 
Cohort:  
1 382 cases 
>500 000 cohort 
members 
10–41 µg/day 
(p10–p90) 
Q2 : 1.05 (0.86–1.29) 
Q3 : 1.11 (0.90–1.36) 
Q4 : 0.88 (0.71–1.10) 
Q5 : 0.98 (0.78–1.25) 
Comparable results 
across strata of 
smoking. 
An excess risk of 
type-I endometrial 
cancer in never-
smoking women not 
using OAC (RR Q5 
vs Q1, 1.97; 95% CI, 
1.08–3.62) 
Stratified by age at recruitment, 
centre, smoking status, OAC use, 
HRT use; adjusted for total energy 
intake, BMI, diabetes, menopausal 
status, age at menopause, parity 
and age at menarche 
OVARIAN CANCER 
Pelucchi et al. 
(2006)  
Ovarian  
Case-control study: 
1 031 cases 
2 411 controls  
10–32 µg 
(p20–p80)  
Q2: 1.03 (0.79–1.34) 
Q3: 1.09 (0.83–1.44) 
Q4: 1.01 (0.76–1.34) 
Q5: 0.97 (0.73–1.31) 
p for trend, 0.80 
n.a.  
Age, study centre, education, 
BMI, energy intake, family 
history of breast and/or ovarian 
cancer, parity  
Hogervorst et al. 
(2007)  
Ovarian  
Cohort:  
195 cases; 
62 573 cohort members  
10–37 µg/day  
(median Q1–Q5)  
Q2: 1.22 (0.73–2.01) 
Q3: 1.12 (0.65–1.92) 
Q4: 1.28 (0.77–2.13) 
Q5: 1.78 (1.10–2.88) 
p for trend, 0.02  
Never-smokers: 
Q2: 1.60 (0.85–3.02) 
Q3: 1.64 (0.84–3.19) 
Q4: 1.86 (1.00–3.48) 
Q5: 2.22 (1.20–4.08) 
p for trend, 0.01 
Age, age at menarche, age at 
menopause, parity, duration OAC 
use, duration PMH use, BMI, 
height, cigarette smoking, 
saturated fat intake, trans-
unsaturated fatty  
acid intake 
Larsson et al. 
(2009c)  
Ovarian  
Cohort:  
368 cases; 
61 057 cohort members  
17–33 µg/day 
(median Q1–Q4)  
Q2: 0.91 (0.68–1.21) 
Q3: 0.97 (0.73–1.29) 
Q4: 0.86 (0.63–1.16) 
p for trend, 0.39  
No association 
for serous ovarian 
cancer cases  
age, education, BMI, parity, age at 
first childbirth, age at menarche, 
age at menopause, OAC use, 
PMH use, total energy intake, 
dietary fat, carbohydrate, fibre 
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Table J2:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of reproductive organs (continued) 
Reference Cancer site Study design and size 
Range of 
intake 
Overall Results: 
OR/RR (95 % CI) 
Subgroup analyses 
Confounders allowed for in the 
analyses 
Wilson et al. 
(2010) 
  
Ovarian 
  
Cohort:  
416 cases; 
88 672 participants  
9–26 µg/day 
(mean Q1–
Q5)  
Q2: 0.93 (0.68–1.29) 
Q3: 1.29 (0.94–1.76) 
Q4: 1.17 (0.84–1.64) 
Q5: 1.25 (0.88–1.77) 
p for trend, 0.12  
Never-smokers: 
Q2: 1.17 (0.72–1.88) 
Q3: 1.04 (0.63–1.74) 
Q4: 1.11 (0.63–1.94) 
Q5: 1.19 (0.66–2.15) 
p for trend, 0.63 
Comparable results in 
strata of menopausal 
status. Significant 
association 
in women with normal 
BMI (<25 kg/m
2
) 
Age, calendar year, smoking, 
BMI, parity, OAC use, 
menopausal status/PMH use, tubal 
ligation, physical activity, caffeine 
intake, energy intake  
Xie et al. (2013)  Ovarian  
Cohort,  
263 cases 
and 526 matched  
controls  
AA+GA 
adducts 
74–226 pmol/ 
g Hb 
(p10–p90)  
T–2: 0.83 (0.56–1.24) 
T–3: 0.79 (0.50–1.24) 
p for trend, 0.08  
Comparable results 
in non-smokers and for 
histological subtypes  
Matching factors and height,  
family history of ovarian cancer, 
tubal ligation, OAC use, BMI, 
parity, alcohol, smoking, physical 
activity, caffeine intake 
Obón-Santacana 
et al. (2015)  
Ovarian 
Cohort:  
1191 cases 
>500 000 cohort 
members 
14.7–30.4 
µg/day 
(p25–p75) 
Q2 :0.89 (0.72–1.11) 
Q3 : 0.87 (0.70–1.09) 
Q4 : 1.08 (0.87–1.34) 
Q5 : 0.97 (0.76–1.23) 
Comparable results for 
various subtypes  
 across strata of smoking 
Stratified by age at recruitment 
and centre, adjusted for total 
energy intake, BMI, tobacco 
smoking, OAC use, menopausal 
status, age at menopause, and 
parity 
AA: Acrylamide; BMI: Body Mass Index; ER: Estrogen receptor; GA: Glycidamide; Hb: Hemoglobin; IRR: Incidence Rate Ratio; n.a.: not applicable; OAC: Oral contraceptives; OR: Odds 
Ratio; PMH: post- menopausal hormones; pmol: picomol; PR: Progesterone receptor; Q1–Q4: quartile 1–4; Q1–Q5: Quintile 1–5; RR: relative risk; SES: Social Economic Status. T: tertile. 
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Table J3:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the gastro-intestinal tract 
Reference 
Cancer site  
and sex 
Study design and 
size 
Range of intake 
Overall Results: OR/RR 
(95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
OESOPHAGEAL CANCER 
Pelucchi et al. 
(2006)  
Oesophagus 
Men and women  
Case-control study: 
395 cases 
1 066 controls  
13–40 µg/day 
(p20–p80)  
Q2: 1.16 (0.75–1.81) 
Q3: 1.20 (0.75–1.93) 
Q4: 0.74 (0.44–1.24) 
Q5: 1.10 (0.65–1.86) 
p for trend, 0.67 
n.a.  
Age, sex, study centre, education, 
BMI, energy intake, alcohol  
consumption, smoking habits  
Hogervorst et al. 
(2008a)  
Oesophagus 
Men and women  
Cohort:  
216 cases 
120 852 cohort 
members  
M: 10–42  
µg/day 
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 0.73 (0.47–1.15) 
Q3: 0.86 (0.56–1.33) 
Q4: 0.83 (0.54–1.28) 
Q5: 0.83 (0.54–1.30) 
p for trend, 0.68  
Comparable results 
in never- and former 
smokers, and in  
oesophageal 
adenocarcinomas or 
squamous cell 
carcinomas. 
Increased risks in 
overweight and 
obese persons 
Age, sex, BMI, consumption of 
tea, vegetables, fruits, dairy and 
alcohol, cigarette smoking, family 
history of oesophageal cancer  
Lin et al. (2011)  
Oesophagus and 
Gastroesophageal 
junction 
Men and women  
Case-control study: 
618 cases 
820 controls  
27–44 µg/day 
(p25–p75)  
Q2: 1.35 (0.96–1.99) 
Q3: 1.12 (0.91–1.58) 
Q4: 1.23 (1.02–1.75) 
p for trend, 0.46  
Comparable results 
for adenocarcinoma, 
squamous cell 
carcinoma and 
gastroesophageal 
junction. 
Stronger 
associations in 
overweight persons, 
and non-smokers  
only 
Age, sex, smoker, alcohol intake, 
fruit intake, BMI, education, 
reflux, H. Pylori infection  
Table continued overleaf. 
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Table J3:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the gastro-intestinal tract (continued) 
Reference 
Cancer site  
and sex 
Study design and 
size 
Range of intake 
Overall Results: OR/RR 
(95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Luján-Barroso et 
al. (2014) 
Oesophagus 
Men and women 
Cohort: 
341 cases 
>500,000 Cohort 
members 
14–37 µg/day 
(p20–p80) 
Q2: 1.75 (1.12–2.74) 
Q3: 1.66 (1.05–2.61) 
Q4: 1.41 (0.86–2.71) 
Comparable results 
for adenocarcinoma 
and squamous-cell 
carcinoma, and 
never-smokers. 
Attenuated HRs 
using energy-
adjusted AA intake 
Sex, total energy intake, fruit, 
smoking intensity, processed meat, 
and stratified for age and country 
STOMACH CANCER 
Hogervorst et al. 
(2008a)  
Stomach 
Men and women  
Cohort:  
563 cases 
120 852 cohort 
members  
M: 10–42 µg/day 
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 1.09 (0.81–1.47) 
Q3: 1.09 (0.81–1.48) 
Q4: 1.18 (0.87–1.60) 
Q5: 1.06 (0.78–1.45) 
p for trend, 0.77 
No increased risks 
in never- and former 
smokers, and in  
gastric cardia or 
other stomach 
cancers 
Age, sex, BMI, energy intake, 
consumption of tea, vegetables, 
fruits and fish, socioeconomic  
status, cigarette smoking,  
family history of stomach cancer 
Hirvonen et al. 
(2010)  
Stomach 
Men   
Cohort:  
224 cases; 
27 111 cohort  
members  
22–56 µg/day 
(median Q1–Q5)  
Q2: 1.42 ( 0.94–2.13) 
Q3: 0.78 (0.49–1.26) 
Q4: 1.34 (0.88–2.05) 
Q5: 0.96 (0.60–1.53) 
p for trend, 0.78 
n.a. 
  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI, 
energy-adjusted fibre intake  
COLORECTAL CANCER 
Mucci et al. 
(2003a)  
Colorectal 
cancer 
Men and 
women  
Case-control study: 
591 cases; 
538 controls  
28 (0.6) µg/day 
Mean (SE)*  
Q2: 0.9 (0.6–1.3) 
Q3: 0.6 (0.4–0.9) 
Q4: 0.6 (0.4–1.0) 
p for trend, 0.01 
Comparable results 
for nonsmokers and 
current smokers  
Age, gender, smoking, BMI, 
alcohol intake, fruit and vegetable 
intake, saturated fat density, red 
meat density and total energy 
Table continued overleaf. 
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Table J3:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the gastro-intestinal tract (continued) 
Reference 
Cancer site  
and sex 
Study design and 
size 
Range of intake 
Overall Results: OR/RR 
(95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Mucci et al. 
(2006)  
Colorectal 
cancer 
Women  
Cohort:  
741 cases; 
61 467 cohort members  
13–38 µg/day 
(mean Q1–Q5)  
Q2: 1.1 (0.9–1.4) 
Q3: 1.2 (0.9–1.5) 
Q4: 1.1 (0.8–1.4) 
Q5: 0.9 (0.7–1.3) 
p for trend, 0.85 
Comparable results 
for colon and rectal 
cancer  
Age at screening, BMI, education, 
alcohol intake, energy intake,  
saturated fat intake, fibre intake.  
Pelucchi et al. 
(2006)  
Colorectal 
cancer 
Men and 
women  
Case-control study: 
2 280 cases 
4 765 controls  
12–40 µg/day 
(p20–p80)  
Q2: 0.89 (0.75–1.05) 
Q3: 1.06 (0.89–1.26) 
Q4: 1.05 (0.88–1.26) 
Q5: 0.97 (0.80–1.18) 
p for trend, 0.56 
Comparable results 
for colon and rectal 
cancer  
Age, sex, study centre, education, 
BMI, energy intake, alcohol 
consumption, smoking habits, 
physical activity  
Hogervorst et al. 
(2008a)  
Colorectal 
cancer 
Men and 
women  
Cohort:  
2 190 cases 
120 852 cohort members  
M: 10–42 µg/day 
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 0.96 (0.81–1.15) 
Q3: 1.06 (0.89–1.27) 
Q4: 0.96 (0.80–1.14) 
Q5: 1.00 (0.84–1.20) 
p for trend, 0.94  
No increased risks 
in never-smokers, 
and in colon or 
rectal cancer  
Age, sex, BMI, height, energy, 
fibre and vitamin B-6 intake, 
consumption of vegetables, fruits, 
dairy, meat and alcohol, physical 
activity, smoking and family 
history of colorectal cancer 
Larsson et al. 
(2009d)  
Colorectal 
cancer 
Men  
Cohort:  
676 cases; 
45 306 cohort members  
25–49 
µg/day(median Q1–
Q4)  
Q2: 1.02 (0.83–1.25) 
Q3: 1.03 (0.83–1.28) 
Q4: 0.95 (0.74–1.20) 
p for trend, 0.69  
Comparable results 
for different 
subsites of 
colorectal cancer, 
and in never-, past 
and current 
smokers  
Age, education, family history of 
colorectal cancer, BMI, exercise, 
history of diabetes, cigarette 
smoking, aspirin use, total energy 
intake, alcohol, calcium and 
dietary fibre intake 
Hirvonen et al. 
(2010)  
Colorectal 
cancer 
Men  
Cohort:  
316 cases; 
27 111 cohort members 
  
22–56 µg/day 
(median Q1–Q5)  
Q2: 0.93 (0.66–1.32) 
Q3: 0.89 (0.62–1.26) 
Q4: 0.95 (0.67–1.36) 
Q5: 0.93 (0.65–1.34) 
p for trend, 0.75 
n.a.  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI 
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Table J3:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the gastro-intestinal tract (continued) 
Reference 
Cancer site  
and sex 
Study design and 
size 
Range of intake 
Overall Results: OR/RR 
(95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Hogervorst et al. 
(2014)  
Colorectal 
cancer 
Men and 
women  
Cohort:  
733 cases 
120 852 cohort members 
M: 10–42 µg/day 
W: 9–40 µg/day 
(median Q1–Q5)  
Subset of cases from 
Hogervorst (2008a)  
AA intake is 
positively 
associated with an 
activating mutation 
in the KRAS gene 
in CRC among 
men, and has a 
statistically 
significant inverse 
association with the 
risk of tumors with 
a truncating 
mutation in the 
APC gene among 
women. 
Age, sex, smoking, BMI, family 
history of colorectal cancer, total 
energy intake 
PANCREATIC CANCER 
Hogervorst et al. 
(2008a)  
Pancreatic 
cancer 
Men and 
women  
Cohort:  
349 cases 
120 852 cohort members  
M: 10–42 and 
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 1.02 (0.72–1.44) 
Q3: 0.96 (0.66–1.38) 
Q4: 0.87 (0.60–1.27) 
Q5: 0.98 (0.68–1.40) 
p for trend, 0.75 
No increased risks 
in never- and former 
smokers, and in  
microscopically  
confirmed cancers 
Age, sex, BMI, height, energy 
intake, consumption of vegetables, 
fruits and alcohol, cigarette 
smoking, diabetes, family history 
of pancreatic cancer 
Hirvonen et al. 
(2010)  
Pancreatic 
cancer 
Men   
Cohort:  
192 cases; 
27 111 cohort members  
22–56 µg/day 
(median Q1–Q5)  
Q2: 0.98 (0.61–1.56) 
Q3: 1.08 (0.69–1.71) 
Q4: 1.06 (0.66–1.69) 
Q5: 1.00 (0.62–1.62) 
p for trend, 0.89 
n.a. 
  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI, 
consumption of vegetables  
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Table J3:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the gastro-intestinal tract (continued) 
Reference 
Cancer site  
and sex 
Study design and 
size 
Range of intake 
Overall Results: OR/RR 
(95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Pelucchi et al. 
(2011)  
Pancreatic 
cancer 
Men and 
women  
Case-control study 
326 cases; 
652 controls  
32 (20) µg/day 
Mean (SD)  
Q2: 1.48 (0.88–2.50) 
Q3: 1.57 (0.91–2.69) 
Q4: 1.70 (0.98–2.96) 
Q5: 1.49 (0.83–2.70) 
p for trend, 0.21 
n.a. 
  
study centre, sex, age, year of 
interview, education, tobacco 
smoking, history of diabetes, 
energy intake  
Obón-Santacana 
et al. (2013)  
Pancreatic 
cancer 
Men and 
women 
Cohort:  
865 cases 
>500 000 cohort 
members 
14–37 µg/day 
(p20–p80) 
Q2 :0.90 (0.71–1.15) 
Q3 : 0.78 (0.60–1.01) 
Q4 : 0.68 (0.52–0.90) 
Q5 : 0.77 (0.58–1.04) 
Comparable results 
across strata of 
smoking. 
Lower risks in 
women and in obese 
persons (BMI ≥30 
kg/m
2
) 
Stratified by age at recruitment and 
centre, adjusted for sex, total 
energy intake, smoking intensity, 
diabetes and alcohol intake 
BMI: Body Mass Index; n.a.: not applicable; OR: Odds Ratio; Q1–Q4: quartile 1–4; Q1–Q5: Quintile 1–5; RR: relative risk; SD: Standard Deviation; SE: Standard Error.  
* among controls. 
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Table J4:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the urinary tract 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
PROSTATE CANCER 
Pelucchi et al. 
(2006)  
Prostate cancer 
Men   
Case-control study: 
1 294 cases 
1 451 controls  
12–36 µg/day 
(p20–p80)  
Q2: 1.00 (0.77–1.30) 
Q3: 1.22 (0.94–1.58) 
Q4: 1.01 (0.77–1.33) 
Q5: 0.92 (0.69–1.23) 
p for trend, 0.65 
n.a.  
Age,  study centre, education, 
BMI, energy intake, alcohol  
consumption, smoking habits, 
family history of prostate cancer, 
physical activity 
Hogervorst et al. 
(2008b)  
Prostate cancer 
Men   
Cohort:  
2 246 cases 
58 279 male cohort 
members  
10–42 µg/day 
(median Q1–
Q5)  
Q2: 1.07 (0.88–1.31) 
Q3: 1.01 (0.82–1.24) 
Q4: 1.02 (0.83–1.26) 
Q5: 1.06 (0.87–1.30) 
p for trend, 0.69  
Comparable results 
in never- and former 
smokers, possibly an 
inverse association 
with advanced 
cancer  in never-
smokers 
Age, socioeconomic status,  
prostate cancer in the family,  
alcohol intake, smoking status  
Larsson et al. 
(2009c)  
Prostate cancer 
Men  
Cohort:  
2 696 cases; 
45 306 cohort members  
28–43 µg/day 
(p20–p80)  
Q2: 0.86 (0.71–1.04) 
Q3: 1.02 (0.84–1.23) 
Q4: 0.90 (0.73–1.10) 
Q5: 0.88 (0.70–1.09) 
p for trend, 0.34  
Comparable results 
in never-smokers, 
in localized and in 
advanced cancer  
Age, education, smoking status, 
BMI, height, physical activity, 
history of diabetes, family history 
of prostate cancer, intakes of total 
energy, alcohol, dietary calcium 
and red meat. 
Wilson et al. 
(2009a)  
Prostate cancer 
Men  
Case-control study: 
170 cases; 
161 controls 
  
 
 
1 499 cases 
1 118 controls  
32–56 pmol/g  
globin AA  
adducts 
(median Q1–
Q4) 
  
33–56 µg/day 
(p20–p80)  
Q2: 0.74 (0.37–1.49) 
Q3: 0.98 (0.50–1.93) 
Q4: 0.93 (0.47–1.85) 
  
 
 
Q2: 1.14 (0.89–1.47) 
Q3: 0.99 (0.76–1.28) 
Q4: 1.06 (0.82–1.37) 
Q5: 0.97 (0.75–1.27) 
Comparable results 
in advanced and  
localized cancers; 
in high- and low-
grade cancers. 
 
 
 
n.a.  
Age, region, laboratory batch,  
BMI, former smoking  age, region, 
education, former and current 
smoking, BMI, zinc intake,  energy 
intake 
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Table J4:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the urinary tract (continued) 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Hirvonen et al. 
(2010)  
Prostate cancer 
Men   
Cohort:  
799 cases; 
27 111 cohort members  
22–56 µg/day 
(median Q1–
Q5)  
Q2: 0.95 (0.76–1.19) 
Q3: 1.03 (0.83–1.29) 
Q4: 1.06 (0.84–1.33) 
Q5: 1.05 (0.83–1.32) 
p for trend, 0.43 
n.a.  
age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI  
Wilson et al. 
(2012)  
Prostate cancer 
Men  
Cohort:  
5 025 cases; 
47 896 cohort members  
12–35 µg/day 
(median Q1–
Q5)  
Q2: 1.10 (1.01–1.20) 
Q3: 1.08 (0.99–1.18) 
Q4: 1.06 (0.97–1.16) 
Q5: 1.02 (0.92–1.13) 
p for trend, 0.90  
Comparable results 
in advanced and  
localized cancers; 
in high- and low-
grade cancers  
age, calendar time, race, height, 
BMI at age 21, current BMI, 
vigorous physical activity, 
smoking, diabetes, family history 
of prostate cancer, multivitamin 
use, intakes of red meat, tomato 
sauce, calcium, alpha linolneic 
acid, suppl. Vitamin E, alcohol 
intake, energy intake, PSA testing 
BLADDER CANCER 
Mucci et al. 
(2003a)  
Bladder cancer 
Men and women  
Case-control study: 
263 cases; 
538 controls 
  
28 (0.6) 
µg/day 
Mean (SE)*  
Q2: 1.1 (0.7–1.8) 
Q3: 0.7 (0.4–1.3) 
Q4: 0.8 (0.5–1.5) 
p for trend, 0.26 
Comparable results 
for nonsmokers and 
no association 
in smokers 
Age, gender, smoking, BMI, 
alcohol intake, fruit and vegetable 
intake, saturated fat density, red 
meat density and total energy 
Hogervorst et al. 
(2008b)  
Bladder cancer 
Men and women  
Cohort:  
1 210 cases 
120 852 cohort 
members  
M: 10–42 and  
W: 9–40 
µg/day 
(median Q1–
Q5)  
Q2: 0.96 (0.77–1.20) 
Q3: 0.89 (0.71–1.12) 
Q4: 1.01 (0.81–1.26) 
Q5: 0.91 (0.73–1.15) 
p for trend, 0.60  
Indications for  
increased risk in 
heavy smokers. 
Indications for  
for decreased risks 
in women 
Age, sex, vegetables, fruits, 
tea, bladder cancer in the family, 
smoking status  
Hirvonen et al. 
(2010)  
Urothelial cancer 
Men   
Cohort:  
365 cases; 
27 111 cohort members  
22–56 µg/day 
(median Q1–
Q5)  
Q2: 0.91 (0.65–1.27) 
Q3: 1.06 (0.77–1.47) 
Q4: 0.78 (0.55–1.11) 
Q5: 0.99 (0.71–1.39) 
p for trend, 0.71 
n.a.  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI, 
consumption of vegetables  
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Table J4:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the urinary tract (continued) 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
RENAL CELL CANCER 
Mucci et al. 
(2003a) 
  
Kidney cancer 
Men and women 
  
Case-control study: 
133 cases; 
538 controls 
  
28 (0.6) 
µg/day 
Mean (SE) 
  
Q2: 1.0 (0.6–1.9) 
Q3: 1.1 (0.6–2.0) 
Q4: 0.8 (0.4–1.7) 
p for trend, 0.64 
Slightly increased 
risks for smokers, 
although not 
statistically 
significant 
Age, gender, smoking, BMI, 
alcohol intake, fruit and vegetable 
intake, 
saturated fat density, red meat 
density and total energy 
Mucci et al. 
(2004) 
  
Renal cell cancer 
Men and women 
  
Case-control study: 
379 cases; 
353 controls 
  
20–32 µg/day 
(p25–p75) 
  
Q2: 1.1 (0.7–1.8) 
Q3: 1.0 (0.7–1.6) 
Q4: 1.1 (0.7–1.8) 
p for trend, 0.8 
no difference 
between smokers 
and non-smokers 
  
Age, sex, smoking, education, BMI 
and total energy 
  
Pelucchi et al. 
(2007)  
Renal cell cancer 
Men and women  
Case-control study: 
767 cases and 
1 534 controls  
20–44 µg/day 
(p25–p75)  
Q2: 1.21 (0.94–1.57) 
Q3: 1.14 (0.86–1.51) 
Q4: 1.20 (0.88–1.63) 
p for trend, 0.35  
n.a.  
Study centre, sex, age, year of 
interview, education, smoking 
habit, alcohol consumption, BMI, 
occupational physical activity, 
family history of kidney cancer, 
energy intake 
Hogervorst et al. 
(2008b)  
Renal cell cancer 
Men and women  
Cohort:  
339 cases 
120 852 cohort 
members  
M: 10–42 and  
W: 9–40 
µg/day 
(median Q1–
Q5)  
Q2: 1.25 (0.86–1.83) 
Q3: 1.48 (1.02–2.15) 
Q4: 1.23 (0.83–1.81) 
Q5: 1.59 (1.09–2.30) 
p for trend, 0.04 
Stronger association 
in long-term 
smokers   
Age, sex, hypertension, BMI, 
energy intake, fruit and vegetable 
consumption, smoking habits  
Hirvonen et al. 
(2010)  
Renal cell cancer 
Men   
Cohort:  
184 cases; 
27 111 cohort members  
22–56 µg/day 
(median Q1–
Q5)  
Q2: 0.94 (0.55–1.62) 
Q3: 1.65 (1.02–2.67) 
Q4: 1.47 (0.89–2.41) 
Q5: 1.28 (0.76–2.15) 
p for trend, 0.12 
n.a.  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI, 
consumption of vegetables  
BMI: Body Mass Index; n.a.: not applicable; OR: Odds Ratio; Q1–Q4: Quartile 1–4; Q1–Q5: Quintile 1–5; RR: relative risk; SD: Standard Deviation; SE: Standard Error. 
* among controls.  
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Table J5:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the respiratory tract 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
ORAL CAVITY AND PHARYNGEAL CANCER 
Pelucchi et al. 
(2006)  
Oral cavity and 
pharynx 
Men and women  
Case-control study: 
749 cases 
1 772 controls  
13–40 µg 
(p20–p80)  
Q2: 1.10 (0.78–1.57) 
Q3: 1.27 (0.89–1.81) 
Q4: 1.04 (0.72–1.51) 
Q5: 1.12 (0.76–1.66) 
p for trend, 0.70 
n.a.  
Age, sex,  study centre, education, 
BMI, energy intake, alcohol  
consumption, smoking habits.  
Schouten et al. 
(2009)  
Oral cavity 
Men and women  
Cohort:  
101 cases 
120 852 cohort 
members  
M: 10–42 and 
W: 9–40 
µg/day 
(median Q1–
Q5)  
Q2: 0.70 (0.37–1.33) 
Q3: 0.77 (0.39–1.52) 
Q4: 0.77 (0.39–1.53) 
Q5: 0.72 (0.36–1.42) 
p for trend, 0.49 
Positive association 
in non-smoking 
women (21 cases): 
HR 1.28 (1.01–1.62) 
per 10 µg/day 
Age, sex, cigarette smoking, 
energy intake, alcohol intake 
niacin intake  
Schouten et al. 
(2009) 
Oro- and 
hypopharynx 
Men and women 
Cohort:  
83 cases 
120 852 cohort 
members 
M: 10–42 and 
W: 9–40 
µg/day 
(median Q1–
Q5) 
T–2: 0.44 (0.23–0.85) 
T–3: 0.61 (0.33–1.12) 
p for trend, 0.17 
No significant 
differences between 
men and women 
Age, sex, cigarette smoking, 
energy intake, alcohol intake 
niacin intake 
LARYNGEAL CANCER 
Pelucchi et al. 
(2006)  
Larynx  
Case-control study: 
527 cases 
1 297 controls  
13–38 µg 
(p20–p80)  
Q2: 1.04 (0.70–1.57) 
Q3: 0.85 (0.56–1.29) 
Q4: 0.89 (0.59–1.36) 
Q5: 1.23 (0.80–1.90) 
p for trend, 0.54 
n.a.  
Age, sex,  study centre, education, 
BMI, energy intake, alcohol  
consumption, smoking habits.  
Table continued overleaf. 
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Table J5:  Results of epidemiological studies on dietary acrylamide (AA) intake and cancers of the respiratory tract (continued) 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Schouten et al. 
(2009)  
Larynx 
Men and women  
Cohort:  
180 cases 
120 852 cohort 
members  
M: 10–42 and 
W: 9–40 
µg/day 
(median Q1–
Q5)  
Q2: 0.66 (0.38–1.16) 
Q3: 1.06 (0.62–1.80) 
Q4: 1.02 (0.60–1.74) 
Q5: 0.93 (0.54–1.58) 
p for trend, 0.85 
No significant 
differences between 
men and women  
Age, sex, cigarette smoking, 
energy intake, alcohol intake 
niacin intake  
LUNG CANCER 
Hogervorst et al. 
(2009a)  
Lung 
Men    
Cohort:  
1 600 cases 
58 279 male cohort 
members  
M: 10–42 and 
(median Q1–
Q5)  
Q2: 1.05 (0.81–1.38) 
Q3: 0.94 (0.71–1.26) 
Q4: 1.00 (0.75–1.34) 
Q5: 1.03 (0.77–1.39) 
p for trend, 0.85 
No significant 
differences between 
histological 
subtypes  
Age, BMI, energy intake, alcohol, 
vegetables and fruit intake,  
processed meat (in males only), 
family history of lung cancer,  
non-occupational physical activity,  
Lung 
Women  
Cohort:  
295 cases 
62 573 female cohort 
members  
W: 9–40 
µg/day 
(median Q1–
Q5)  
Q2: 0.66 (0.42–1.04) 
Q3: 0.60 (0.38–0.96) 
Q4: 0.58 (0.36–0.95) 
Q5: 0.45 (0.27–0.76) 
p for trend, 0.01 
Strongest inverse 
association 
observed for 
adenocarcinomas  
Education, niacin, and cigarette  
smoking  
Hirvonen et al. 
(2010)  
Lung, 
men  
Cohort:  
1 703 cases; 
27 111 cohort members  
22–56 µg/day 
(median Q1–
Q5)  
Q2: 1.01 (0.86–1.18) 
Q3: 1.11 (0.95–1.29) 
Q4: 0.93 (0.79–1.10) 
Q5: 1.18 (1.01–1.38) 
p for trend, 0.11 
n.a.  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI  
BMI: Body Mass Index; HR: hazard ratio; n.a.: not applicable; OR: Odds Ratio; Q1–Q4: Quartile 1–4; Q1–Q5: Quintile 1–5; RR: Relative risk; SD: Standard Deviation;  SE: Standard Error; T–
3: Tertile 1–3. 
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Table J6:  Results of epidemiological studies on dietary acrylamide (AA) intake and other cancers 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
BRAIN CANCER 
Hogervorst et al. 
(2009b)  
Brain cancer 
Men and women  
Cohort:  
216 cases 
120 852 cohort 
members  
M: 10–42 and 
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 0.92 (0.59–1.44) 
Q3: 1.20 (0.78–1.83) 
Q4: 1.07 (0.68–1.68) 
Q5: 0.87 (0.54–1.41) 
p for trend, 0.61  
No association in 
never-smokers and 
subgroups like 
microscopically 
verified cancers, and 
astrocytic gliomas 
Age, sex, educational level, BMI, 
height, energy intake, cigarette 
smoking.  
THYROID CANCER  
Schouten et al. 
(2009)  
Larynx 
Men and women  
Cohort:  
66 cases 
120 852 cohort 
members 
M: 10–42 and 
W: 9–40 µg/day 
(median Q1–Q5) 
T–2: 1.14 (0.58–2.26) 
T–3: 1.33 (0.70–2.53) 
p for trend, 0.42 
No significant 
associations in 
women 
or in non-smokers 
Age, sex, cigarette smoking, 
energy intake, vegetable intake 
niacin intake 
LYMPHATIC MALIGNANCIES  
Hirvonen et al. 
(2010)  
Lymphomas 
men  
Cohort:  
175 cases; 
27 111 cohort 
members  
22–56 µg/day 
(median Q1–Q5)  
Q2: 0.93 (0.56–1.53) 
Q3: 1.17 (0.73–1.88) 
Q4: 0.98 (0.59–1.61) 
Q5: 1.10 (0.67–1.80) 
p for trend, 0.67 
n.a.  
Age, supplementation group,  
cigarette smoking, physical 
activity, alcohol intake, BMI  
Table continued overleaf. 
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Table J6:  Results of epidemiological studies on dietary acrylamide (AA) intake and other cancers (continued) 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Bongers et al. 
(2012)  
Multiple  
myeloma, men   
Cohort:  
170 cases 
58 279 male cohort 
members  
M: 10–42 and 
(median Q1–Q5)  
Q2: 0.65 (0.36–1.16) 
Q3: 1.14 (0.67–1.94) 
Q4: 1.14 (0.67–1.94) 
Q5: 1.54 (0.92–2.58) 
p for trend, 0.02 
Statistical significant 
positive association 
in never-smoking 
men, HR: 1.98 per 
10 µg/day 
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat, carbohydrates and 
niacin 
Multiple  
myeloma, women  
Cohort:  
153 cases 
62 573 female cohort 
members  
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 1.46 (0.85–2.49) 
Q3: 1.19 (0.67–2.12) 
Q4: 0.73 (0.39–1.37) 
Q5: 0.93 (0.50–1.73) 
p for trend, 0.22 
No clear association 
in never-smoking 
women  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Bongers et al. 
(2012)  
Diffuse large-  
cell lymphoma, 
men  
Cohort:  
159 cases 
58 279 male cohort 
members  
M: 10–42 and 
(median Q1–Q5)  
Q2: 0.93 (0.54–1.59) 
Q3: 1.23 (0.74–2.04) 
Q4: 1.26 (0.74–2.17) 
Q5: 1.06 (0.61–1.38) 
p for trend, 0.73 
n.a.  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Diffuse large-  
cell lymphoma, 
women  
Cohort:  
100 cases 
62 573 female cohort 
members  
W: 9–40 µg/day 
(median Q1–Q5)  
Q2: 1.05 (0.51–2.15) 
Q3: 1.71 (0.87–3.36) 
Q4: 1.72 (0.84–3.50) 
Q5: 1.38 (0.63–3.02) 
p for trend, 0.43 
No clear association 
in never-smoking 
women  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Table continued overleaf. 
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Table J6:  Results of epidemiological studies on dietary acrylamide (AA) intake and other cancers (continued) 
Reference 
Cancer site  
and sex 
Study design and size Range of intake 
Overall Results: 
OR/RR (95 %CI) 
Subgroup 
analyses 
Confounders allowed for in 
the analyses 
Bongers et al. 
(2012)  
Chronic 
lymphocytic 
leukaemia, men  
Cohort:  
134 cases 
58 279 male cohort 
members  
M: 10–42 and 
(median Q1–Q5)  
0.88 (0.74–1.09) 
per 10 µg/day  
no association in 
never-smoking men  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Chronic 
lymphocytic 
leukaemia,  
women  
Cohort:  
66 cases 
62 573 female cohort 
members  
W: 9–40 µg/day 
(median Q1–Q5)  
0.83 (0.64–1.09)  
per 10 µg/day  
No  association 
in never-smoking 
women  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Bongers et al. 
(2012)  
Follicular 
lymphoma, 
Men and women  
Cohort:  
42 male 
and 47 female cases, 
58 279 male and  
62 573 female cohort 
members 
M: 10–42 and 
W: 9–40 µg/day 
(median Q1–Q5)  
M: 1.28 (1.03–1.61) 
F: 1.12 (0.80–1.57) 
per 10 µg/day  
No statistical 
significant 
association 
in never-smoking 
women  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat,  
carbohydrates and niacin 
Bongers et al. 
(2012)  
Waldenström 
Macroglobulinemia 
and 
immunocytoma, 
Men and women 
Cohort:  
54 male 
and 35 female cases, 
58 279 male and  
62 573 female cohort 
members 
M: 10–42 and 
W: 9–40 µg/day 
(median Q1–Q5)  
M: 1.21 (0.93–1.50) 
F: 1.21 (0.88–1.66) 
per 10 µg/day  
No statistical 
significant 
association 
in never-smoking 
women  
Age, height, education level,  
fibre, total fatty acids, trans 
unsaturated fat acids, mono 
unsaturated fat acids, poly 
unsaturated fat, carbohydrates and 
niacin 
BMI: Body Mass Index; F: Female; HR: hazard ratio; M: Male; n.a.: not applicable; OR: Odds Ratio; Q1–Q4: Quartile 1–4; Q1–Q5: Quintile 1–5; RR: Relative risk; SD: Standard Deviation; 
SE: Standard Error; T–: Tertile. 
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Appendix K. Benchmark Dose Modelling (BMD) 
Previous studies reporting dose-response modelling for AA 
Several studies report on dose response modelling for data on AA. The CONTAM Panel noted that the 
experimental design including dose and time regime for the exposure may vary between the different 
studies requiring correction of doses used for the modelling to reflect daily lifetime exposure. 
Bolger et al. (2010) applied the MOE approach to AA and derived BMD and BMDL values for a wide 
range of reported tumour types taking data from the two-year carcinogenicity studies of Friedman et 
al. (1995) and Johnson et al. (1986) as compiled by Rice (2005). The CONTAM Panel noted that the 
NTP data were not available at that time. The BMDL10 values, taken as reference point for calculation 
of the MOE values by Bolger et al. (2010) were derived using the tumour types with the lowest 
BMDLs. These BMDL10 values amounted to 1.00 mg/kg b.w. per day for male rat peritesticular 
mesotheliomas and 0.16 mg/kg b.w. per day for female rat mammary gland tumours.  
BMD modelling of the data from the NTP (2012) study was previously performed by Beland et al. 
(2013). BMD modelling of neoplastic incidences in male and female B6C3F1 mice and F344/N rats 
administered AA in the drinking water for two years (NTP, 2012) resulted in the lowest BMDL10 
values for the Harderian gland adenomas in male and female mice and for the mammary gland 
adenomas in female rats. In male mice the log-logistic and log-probit models resulted in BMDL10 
values for Harderian gland adenomas of 0.173 and 0.159 mg/kg b.w. per day, respectively and for 
female mice these values amounted to 0.282 and 0.230 mg/kg b.w. per day, respectively. In female 
rats BMDL10 values for mammary gland fibroadenomas varied from 0.296–0.649 mg/kg b.w. per day 
depending on the model used. The value of 0.008 mg/kg b.w. per day obtained using the log-probit 
model was not taken into further account by Beland et al. (2013) due to the disparity between the 
BMDL10 obtained from the log-probit model and the BMDL10 values obtained from other models 
(Beland et al., 2013). 
Dose-response modelling for AA as performed by the CONTAM Panel 
The CONTAM Panel performed BMD analyses on:  
(i) Data on neurotoxicity, consisting of incidences of peripheral nerve (sciatic) axonal 
degeneration in F344 male rats exposed to AA in drinking water for 2 years (NTP, 2012) (see 
Table 20), and  
(ii) The tumour incidences of AA from the 2-year-studies in mice and rats (see Tables 23 and 24).  
Details on these BMD analyses and the data used for further dose-response modeling and the 
subsequent risk assessment are shown in Tables K1 to K12.  
The BMD/L values were calculated by means of the software BMDS v.2.4 (US-EPA). All models for 
dichotomous (quantal) data available there were selected for the BMD analysis using the default 
benchmark response (BMR) of 10 % extra risk as advised by the EFSA guidance on the use of 
benchmark dose (EFSA, 2009b). In the first instance all models were run without restrictions. 
Since the BMDL is the lower 95 % one-sided confidence bound of the BMD and the BMDU is the 
upper 95 % confidence bound of the BMD, the interval BMDL/BMDU represents the 90 % 
confidence interval of the BMD. It was also noted (EFSA, 2011d) that when the BMD/BMDL ratios 
for the different models are very large or when the BMDL values from different models are very 
different the data are not informative enough to derive an RP. EFSA also stated (EFSA 2009b) that as 
a general rule, dose-response data should not result in a range of BMDL values from different 
accepted models that substantially exceeds one order of magnitude. EFSA also indicated (EFSA, 
2009b) that when this value is exceeded, several options are available and should be considered on a 
case-by-case basis, e.g. increasing the BMR, re-evaluating the set of models, or model averaging. 
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Acceptance of a model (and its BMDL) was defined through the log-likelihood value and its 
goodness-of-fit test with a p for trend > 0.05. The lowest BMDL of all accepted models fitted to the 
data of one endpoint and one dose-response data set, was determined as the BMDL of that data set. 
The CONTAM Panel noted that the results of the BMD analysis of the data on: (i) incidences of 
Harderian gland adenomas in female B6C3F1 mice (NTP, 2012) (Table K7), (ii) incidences of 
Harderian gland adenomas and adenocarcinomas in male B6C3F1 mice (NTP, 2012) (Table K8) and 
(iii) incidences of mammary gland fibroadenomas in female rats (NTP, 2012) (Table K9), revealed 
several models for which the BMD/BMDL ratio was very large, or for which there was disparity 
between the BMDL10 obtained for a specific model and the BMDL10 values obtained from other 
models. This indicated that the set of models applied did not result in an adequate reference point, and 
were therefore not considered further. Instead, the set of models was re-evaluated choosing restricted 
models for further BMD analysis of the data. The results obtained using only restricted models 
applying default values are shown in Tables K10, K11 and K12, respectively. For these, the ratio 
BMD/BMDL did not exceed one order of magnitude, and disparity between the BMDL10 values 
obtained by different models was no longer observed. Therefore, these results were the ones further 
considered for the selection of the reference point.  
For non-neoplastic effects, the CONTAM Panel selected the value of 0.43 mg/kg b.w. per day derived 
as the lowest BMDL10 obtained from the data on incidences of peripheral nerve (sciatic) axonal 
degeneration in male F344 rats exposed to AA in drinking water for two years (NTP, 2012) obtained 
from  unrestricted models (Table K1 and Figure K1) as reference point for non-neoplastic effects. 
For neoplastic effects, the CONTAM Panel selected as reference point the value of 0.17 mg/kg b.w. 
per day derived from data on incidences of Harderian gland adenomas and adenocarcinomas in male 
B6C3F1 mice exposed to AA for two years (NTP, 2012) (Table K11 and Figure K2) as the lowest 
BMDL10 from the data on tumour incidences using restricted models only as explained above.   
Table K1: Results from the BMD analysis of the data on incidences of peripheral nerve (sciatic) 
axonal degeneration in male F344 rats exposed to AA in drinking water for two years (NTP, 2012). 
The benchmark dose (BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for 
a BMR of 10 % extra risk with characteristics of the model fit. Model with lowest BMDL10 is given in 
bold.  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 114.99 - - - - 
Null (reduced) model n.a. 1 126.71 - - - - 
Probit n.a. 2 115.14 0.96 yes 0.91 0.74 
LogProbit none 3 115.17 0.83 yes 1.19 0.48 
Logistic n.a. 2 115.09 0.97 yes 0.96 0.79 
LogLogistic none 3 115.12 0.87 yes 1.15 0.46 
Quantal-Linear n.a. 2 115.84 0.63 yes 0.61 0.43 
Multistage Cancer n.a. 3 115.09 0.90 yes 1.55 0.48 
Multistage
 
 none 3 115.09 0.90 yes 1.08 0.47 
Weibull
 
 none 3 115.11 0.88 yes 1.12 0.44 
Gamma
 
 none 3 115.13 0.87 yes 1.14 0.43 
b.w.: body weight; n.a.: not applicable.   
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Table K2:  Results from the BMD analysis of the data on incidences of mesothelioma of the testes 
tunica albuginea in male F344 rats exposed to AA for two years (Johnson et al., 1986). None of the 
models could be accepted and therefore only the  characteristics of the model fit are reported.   
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 89.14 - - - - 
Null (reduced) model n.a. 1 99.70 - - - - 
Probit n.a. 2 96.85 0.00 no - - 
LogProbit none 3 93.51 0.01 no - - 
Logistic n.a. 2 96.94 0.00 no - - 
LogLogistic none 3 93.81 0.01 no - - 
Quantal-Linear n.a. 2 96.14 0.00 no - - 
Multistage Cancer n.a. 2 96.14 0.00 no - - 
Multistage
 
 none 3 92.32 0.04 no - - 
Weibull
 
 none 3 93.88 0.01 no - - 
Gamma
 
 none 3 93.95 0.01 no - - 
b.w.: body weight; n.a.: not applicable.  
Table K3:  Results from the BMD analysis of the data on incidences of mesothelioma of the testes 
tunica in male F344 rats exposed to AA for two years (Friedman et al., 1995). The benchmark dose 
(BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % extra 
risk with characteristics of the model fit. Model with lowest BMDL10 is given in bold.  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 116.39 - - - - 
Null (reduced) model n.a. 1 123.00 - - - - 
Probit n.a. 2 116.58 0.82 yes 1.59 1.19 
LogProbit none 3 116.39 0.97 yes 1.31 0.63 
Logistic n.a. 2 116.63 0.79 yes 1.63 1.25 
LogLogistic none 3 116.40 0.87 yes 1.34 0.66 
Quantal-Linear n.a. 2 116.41 0.98 yes 1.37 0.84 
Multistage Cancer n.a. 2 116.41 0.98 yes 1.37 0.84 
Multistage
 
 none 3 116.40 0.88 yes 1.32 0.51 
Weibull
 
 none 3 116.41 0.86 yes 1.35 0.67 
Gamma
 
 none 3 116.41 0.86 yes 1.35 0.68 
b.w.: body weight; n.a.: not applicable.   
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Table K4:  Results from the BMD analysis of the data on incidences of mesothelioma of the 
epididymis or testes tunica vaginalis in male F344 rats exposed to AA for two years (NTP, 2012). The 
benchmark dose (BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for a 
BMR of 10 % extra risk with characteristics of the model fit. Model with lowest BMDL10 is given in 
bold.  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 62.06 - - - - 
Null (reduced) model n.a. 1 66.42 - - - - 
Probit n.a. 2 63.09 0.56 yes 2.21 1.60 
LogProbit none 3 62.98 0.40 yes 2.19 1.21 
Logistic n.a. 2 63.09 0.56 yes 2.25 1.68 
LogLogistic none 3 63.02 0.38 yes 2.21 1.21 
Quantal-Linear n.a. 2 63.26 0.50 yes 2.15 1.21 
Multistage Cancer n.a. 3 63.05 0.37 yes 2.25 1.26 
Multistage
 
 none 3 63.05 0.37 yes 2.25 1.13 
Weibull
 
 none 3 63.03 0.38 yes 2.23 1.22 
Gamma
 
 none 3 63.02 0.38 yes 2.22 1.23 
b.w.: body weight; n.a.: not applicable.  
 
Table K5:  Results from the BMD analysis of the data on incidences of various types of sarcomas in 
female B6C3F1 mice exposed to AA for two years (NTP, 2012). The benchmark dose (BMD10), the 
95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % extra risk with 
characteristics of the model fit. Model with lowest BMDL10 is given in bold. For models which could 
not be accepted only the characteristics of the model fit are reported.  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 52.44 - - - - 
Null (reduced) model n.a. 1 65.57 - - - - 
Probit n.a. 2 60.51 0.00 no - - 
LogProbit none 2 56.40 0.05 no - - 
Logistic n.a. 2 60.90 0.00 no - - 
LogLogistic none 2 56.72 0.04 no - - 
Quantal-Linear n.a. 1 56.96 0.06 yes 4.09 2.86 
Multistage Cancer n.a. 1 56.96 0.06 yes 4.09 2.86 
Multistage
 
 none 2 55.91 0.07 yes 2.80 1.56 
Weibull
 
 none 2 56.83 0.03 no - - 
Gamma
 
 none 2 56.83 0.03 no - - 
b.w.: body weight; n.a.: not applicable. 
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Table K6:  Results from the BMD analysis of the data on incidences of lung tumours in male B6C3F1 
mice exposed to AA for two years (NTP, 2012). The benchmark dose (BMD10), the 95 % benchmark 
dose lower confidence limit (BMDL10) values for a BMR of 10% extra risk with characteristics of the 
model fit. Model with lowest BMDL10 is given in bold.  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 62.06 - - - - 
Null (reduced) model n.a. 1 66.42 - - - - 
Probit n.a. 2 63.09 0.56 yes 2.21 1.60 
LogProbit none 3 62.98 0.40 yes 2.19 1.21 
Logistic n.a. 2 63.09 0.56 yes 2.25 1.68 
LogLogistic none 3 63.02 0.38 yes 2.21 1.21 
Quantal-Linear n.a. 2 63.26 0.50 yes 2.15 1.21 
Multistage Cancer n.a. 3 63.05 0.37 yes 2.25 1.26 
Multistage
 
 none 3 63.05 0.37 yes 2.25 1.13 
Weibull
 
 none 3 63.03 0.38 yes 2.23 1.22 
Gamma
 
 none 3 63.02 0.38 yes 2.22 1.23 
b.w.: body weight; n.a.: not applicable.   
Table K7: Results from the BMD analysis of the data on incidences of Harderian gland adenomas in 
female B6C3F1 mice exposed to AA for two years (NTP, 2012). The benchmark dose (BMD10), the 
95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % extra risk with 
characteristics of the model fit.
44
   
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 108.36 - - - - 
Null (reduced) model n.a. 1 152.85 - - - - 
Probit n.a. 2 124.13 < 0.01 no - - 
LogProbit none 2 109.78 0.42 yes 0.52 0.23 
Logistic n.a. 2 124.25   < 0.01 no - - 
LogLogistic none 2 109.74 0.43 yes 0.42 0.20 
Quantal-Linear n.a. 1 112.07 0.12 yes 0.57 0.47 
Multistage Cancer n.a. 1 112.07 0.12 yes 0.57 0.47 
Multistage
 
 none 2 109.30 0.60 yes 0.39 0.30 
Weibull
 
 none 2 110.57 0.22 yes 0.29 0.088 
Gamma
 
 none 2 110.78 0.18 yes 0.26 0.054 
b.w.: body weight; n.a.: not applicable.   
                                                     
44  The CONTAM Panel noted that BMD analysis produced results from several models for which the BMD/BMDL ratio was 
very large, or for which there was disparity between the BMDL10 obtained for a specific model and the BMDL10 values 
obtained from other models. This indicated that the set of models applied did not result in an adequate reference point, and 
were therefore not considered further. Instead, the set of models was re-evaluated choosing restricted models applying 
default values (see Table K10).  
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Table K8:  Results from a BMD analysis of the data on incidences of Harderian gland adenomas and 
adenocarcinomas in male B6C3F1 mice exposed to AA for two years (NTP, 2012). The benchmark 
dose (BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % 
extra risk with characteristics of the model fit.
45
  
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 113.44 - - - - 
Null (reduced) model n.a. 1 161.48 - - - - 
Probit n.a. 2 127.93 < 0.01 no - - 
LogProbit none 3 114.84 0.25 yes 0.39 0.16 
Logistic n.a. 2 127.00    < 0.01 no - - 
LogLogistic none 3 114.64 0.30 yes 0.37 0.15 
Quantal-Linear n.a. 2 117.24 0.055 yes 0.38 0.31 
Multistage Cancer n.a. 2 117.24 0.055 yes 0.38 0.31 
Multistage
 
 none 3 114.39 0.39 yes 0.26 0.20 
Weibull
 
 none 3 115.72 0.10 yes 0.17 0.05 
Gamma
 
 none 3 115.98 0.08 yes 0.14 0.02 
b.w.: body weight; n.a.: not applicable  
Table K9:  Results from the BMD analysis of the data on incidences of mammary gland 
fibroadenomas in female F344 rats exposed to AA for two years (NTP, 2012). The benchmark dose 
(BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10% extra 
risk with characteristics of the model fit.
46
 
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 157.83 - - - - 
Null (reduced) model n.a. 1 163.80 - - - - 
Probit n.a. 2 158.89 0.55 yes 0.91 0.65 
LogProbit none 3 158.72 0.41 yes 0.43 0.008 
Logistic n.a. 2 158.90  0.55 yes 0.91 0.65 
LogLogistic none 3 158.72 0.41 yes 0.41 0.006 
Quantal-Linear n.a. 2 158.80 0.59 yes 0.71 0.44 
Multistage Cancer n.a. 2 158.80 0.59 yes 0.71 0.44 
Multistage
 
 none 3 158.76 0.39 yes 0.58 0.24 
Weibull
 
 none 3 158.69 0.42 yes 0.40 0.004 
Gamma
 
 none 3 158.69 0.42 yes 0.38 0.002 
b.w.: body weight; n.a.: not applicable.  
 
                                                     
45  The CONTAM Panel noted that BMD analysis produced results from several models for which the BMD/BMDL ratio was 
very large, or for which there was disparity between the BMDL10 obtained for a specific model and the BMDL10 values 
obtained from other models. This indicated that the set of models applied did not result in an adequate reference point, and 
were therefore not considered further. Instead, the set of models was re-evaluated choosing restricted models applying 
default values (see Table K11). 
46  The CONTAM Panel noted that the BMD analysis produced results from several models for which the BMD/BMDL ratio 
was very large, or for which there was disparity between the BMDL10 obtained for a specific model and the BMDL10 
values obtained from other models. This indicated that the set of models applied did not result in an adequate reference 
point, and were therefore not considered further. Instead, the set of models was re-evaluated choosing restricted models 
applying default values (see Table K12). 
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Table K10: Results from the BMD analysis of the data on incidences of Harderian gland adenomas in 
female B6C3F1 mice exposed to AA for two years (NTP, 2012). The benchmark dose (BMD10), the 
95 % benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % extra risk with 
characteristics of the model fit. Model with lowest BMDL10 is given in bold. Where possible models 
were restricted using default restrictions. 
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 108.36 - - - - 
Null (reduced) model n.a. 1 152.85 - - - - 
LogProbit default 1 112.51 0.08 yes 0.91 0.77 
LogLogistic default 2 109.74 0.43 yes 0.47 0.28 
Multistage
 
 default 1 112.07 0.12 yes 0.57 0.47 
Weibull
 
 default 1 112.07 0.12 yes 0.57 0.47 
Gamma
 
 default 1 112.07 0.12 yes 0.57 0.47 
b.w.: body weight; n.a.: not applicable.  
 
Table K11: Results from the BMD analysis of the data on incidences of Harderian gland adenomas 
and adenocarcinomas in male B6C3F1 mice exposed to AA for two years (NTP, 2012). The 
benchmark dose (BMD10), the 95 % benchmark dose lower confidence limit (BMDL10) values for a 
BMR of 10 % extra risk with characteristics of the model fit. Model with lowest BMDL10 is given in 
bold. Where possible models were restricted using default restrictions. 
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 113.44 - - - - 
Null (reduced) model n.a. 1 161.48 - - - - 
LogProbit default 2 116.15 0.14 yes 0.62 0.51 
LogLogistic default 3 114.64 0.30 yes 0.37 0.17 
Multistage
 
 default 2 117.24 0.055 yes 0.38 0.31 
Weibull
 
 default 2 117.24 0.055 yes 0.38 0.31 
Gamma
 
 default 2 117.24 0.055 yes 0.38 0.31 
b.w.: body weight; n.a.: not applicable. 
 
Table K12: Results from a BMD analysis of the data on incidences of mammary gland fibroadenomas 
in female F334 rats exposed to AA for 2 years (NTP, 2012). The benchmark dose (BMD10), the 95 % 
benchmark dose lower confidence limit (BMDL10) values for a BMR of 10 % extra risk with 
characteristics of the model fit. Model with lowest BMDL10 is given in bold. Where possible models 
were restricted using default restrictions. 
Models Restriction 
Number of 
parameters 
Minus 
Log-
likelihood 
p 
value 
Accepted 
BMD10 
(mg/kg 
b.w. per 
day) 
BMDL10 
(mg/kg 
b.w. per 
day) 
Full model n.a. 5 157.83 - - - - 
Null (reduced) model n.a. 1 163.80 - - - - 
LogProbit default 2 159.28 0.41 yes 1.31 0.85 
LogLogistic default 2 158.74 0.61 yes 0.55 0.30 
Multistage
 
 default 2 158.80 0.59 yes 0.71 0.44 
Weibull
 
 default 2 158.80 0.59 yes 0.71 0.44 
Gamma
 
 default 2 158.80 0.59 yes 0.71 0.44 
b.w.: body weight; n.a.: not applicable.  
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Figure K1: Graphical display of the result from the BMD analysis using the quantal linear model of 
the data on incidences of peripheral nerve (sciatic) axonal degeneration in male F344 rats exposed to 
AA in drinking water for 2 years (NTP, 2012) 
 
 
Figure K2:  Graphical display of the result from the BMD analysis using the LogLogistic model of 
the data on incidences of Harderian gland adenomas and adenocarcinomas in male B6C3F1 mice 
exposed to AA for 2 years (NTP, 2012) 
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ABBREVIATIONS 
 
-A-NDELA   -acetoxy-N-nitroso-diethanolamine 
γ-GCS    Gamma-glutamyl cysteine synthase 
ΣAA   Sum of AA+AAMA+AAMA-sulfoxide 
ΣGA   Sum of GA+GAMA 
1-CE-dAdo  1-(2-carboxyethyl)-dAdo 
3-HPMA  N-acetyl-S-(3-hydroxypropyl)cysteine 
3-MCPD  3-monochloropropanediol 
7-FAE-Gua  7-(2-formamidoethyl)-Gua 
8-OHdG  8-hydroxy-deoxyguanosine 
AA   Acrylamide 
AACF   Atypical acinar cell foci 
AA-GSH  Glutathione adduct of AA 
AAMA   N-acetyl-S-(2-carbamoylethyl)-L-cysteine 
AAMA-SO  Sulfoxide of AAMA 
AC   Acrolein 
ACEG   Aberrant cells excluding gaps 
ACF   Aberrant crypt foci 
AccDAA   Accumulated in vivo dose of AA throughout the duration of employment 
ACGIH   American Conference of Governmental Industrial Hygienists 
AChE   Acetylcholinesterase 
ADU   Alkaline DNA unwinding 
ALP   Alkaline phosphatase 
ALT    Alanine aminotransferase 
AN   Acrylonitrile 
ANSES Agency for Food, Environmental and Occupation Health and Safety, former 
Afssa  
AOM Azoxymethane 
APC Adenomatous polyposis coli 
APCI   Atmospheric pressure chemical ionisation 
ASCGE  Alkylating single cell electrophoresis 
AST   Aspartate aminotransferase 
AUC   Area under the curve 
AUC/D   Dose-adjusted AUC 
ATBC   Alpha-Tocopherol, Beta-Carotene Cancer Prevention  
ATSDR  Agency for Toxic Substances and Disease Registry  
BAM   German Federal Institute for Materials Research and Testing 
BCF   Bioconcentration factor 
BER   Base excision repair 
BEUC   European Consumers Association 
BfR   German Federal Institute for Risk Assessment 
BMD   Benchmark dose 
BMDL   95 % benchmark dose lower confidence limit  
BMI   Body Mass Index 
BMR   Benckmark response 
BN   Binucleated 
BSO   Buthionine sulfoximine 
BPDE   Anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide 
BUN   Blood urea nitrogen 
BVL   German Federal Office for Consumer Protection and Food Safety 
b.w.   Body weight 
C+   Positive control 
C-   Negative control 
Acrylamide in food 
 
EFSA Journal 2015;13(6):4104 318 
CA   Chromosomal aberration 
CAPS   Cancer of the Prostate in Sweden  
Cbl(I)   Cob(l)alamin 
CBMN assay  Cytokinesis-blocked micronucleous assay 
CE   Capillary electrophoresis  
CEA   Carcino-embryonic antigen 
cDNA   Complementary DNA 
CEN   European Committee for Standardization 
CERHR   Center for the Evaluation of Risks to Human Reproduction 
CI   Confidence interval 
CNS   Central nervous system 
CONTAM Panel EFSA Scientific Panel on Contaminants in the Food Chain 
CRM   Certified reference material 
CYP   Cytochrome P450 
Cys   Cysteine residues 
CZE   Capillary zone electrophoresis  
DDC   Diethyldithiocarbamate 
DMSO   Dimethylsulfoxide 
dpt   Days post treatment 
DRAG   Detection of repairable adducts by growth inhibition 
DSB   Double stand break 
DTU   Danish National Food Institute 
EEA   European Economic Area 
EC   European Commission 
DAD   Diode array detector 
DDC   Diethyldithiocarbamate 
DHPA   2,3-dihydroxypropionamide or glyceramide 
DTU   Danish National Food Institute 
EH   Epoxide hydrolase 
EI   Electron ionisation mode 
EM   Electron microscope 
EPIC   European Prospective Investigation into Cancer   
ER   Estrogen receptor 
ESI   Electrospray ionisation 
F   Female 
FA   Food Associations 
FAO   Food and Agriculture Organization of the United Nations 
FASI   Field amplified sample injection  
FBQ   Food behaviour questionnaire 
FDE   FoodDrinkEurope 
FFQ   Food frequency questionaire 
FITC   Fluorescein isothiocyanate 
fpg   formamidopyrimidine-DNA glycosylase  
FSANZ   Food Standards Australia New Zealand 
FSH   Follicle-stimulating hormone 
FT-IR   Fourier Transform Infrared Analysis 
GA   Glycidamide 
GA-Cbl  GA-alkylcobalamin 
GA-GSH  Glutathione adduct of glycidamide 
GAMA   N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine 
GC   Gas chromatography 
G:C   guanine:cytosine 
GD   Gestation day 
GEMS   Global Environment Monitoring System 
GI   Gastro-intestinal 
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GPx   Glutathione peroxidase 
GSH     Glutathione 
GSH-EE  GSH-monoethyl ester 
GST   Glutathione-S-transferases 
HACCP  Hazard Analysis and Critical Control Points 
Hb   Hemoglobin 
HED   Human equivalent dose  
HOMA-IR  Homeostasis model assessment of insulin resistance 
HPG   Hypothalamic-pituitary-testes 
HPFS   The Health Professionals’ Follow-up study 
HR   Hazard ratio 
HSAB   Hard-soft-acid-base 
HT   Heritable translocation 
HTE   Hemithyroidectomy 
HPLC   High performance liquid chromatography 
IARC   Insitute Research on Cancer 
ICPS   International Programme on Chemical Safety  
IL   Interleukin 
ILUAE   Ionic Liquid Based Ultrasonic Assisted Extraction 
IPCS   International Programme on Chemical Safety 
IRA   Incremental repeat acquisition 
IRMM   Institute for Reference Materials and Measurements 
IRR   Incidence Rate Ratio 
Iso-GAMA  N-acetyl-S-(1-carbamoyl-2-hydroxyethyl)-L-cysteine 
ISQ   1,5-isoquinolinediol 
i.p.   Intraperitoneal 
i.v.   Intravenous 
JECFA   Joint FAO/WHO Expert Committee on Food Additives  
Km   Michaelis-Menten constant 
LB   Lower bound 
LC   Percentage of censored results  
LDH   Lactate dehydrogenase 
LH   Luteinizing hormone 
LMW   Low molecular weight 
LOAEL  Lowest-observed-adverse-effect level 
LOD   Limit of detection 
LOH   Loss of heterozygosity 
LOQ   Limit of quantification 
M   Male 
MA   Mercapturic acid 
MB   Middle bound 
MCB   Monochlorobimane 
MDA   Malondialdehyde 
MEKC   Micellar electrokinetic chromatography  
MF   Mutant frequency 
MN   Micronucleus 
MN-NCE  Micronucleated normochromatic erythrocytes 
MN-RET  Micronucleated reticulocytes 
MNBN   Micronucleated binucleated cells 
MoA   Mode of action 
MOE   Margin of exposure 
MPO   Myeloperoxidase 
MRM   Multiple reaction mode 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
MS   Mass spectrometry 
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MS/MS   Tandem mass spectrometry 
MSPD   Matrix solid phase dispersion 
n Number of samples/number of population groups used to derive the 
corresponding statistics 
N1-GA-dA  N1-(2-carboxy-2-hydroxyethyl)-2'deoxyadenosine) 
N3-GA-Ade  GA (N3-(2-carbamoyl-2-hydroxyethyl) adenine 
N7-GA-Gua   GA, N-7-(2-carbamoyl-2-hydroxyethyl)guanine 
n.a.   Not applicable 
NACE   Non aqueous capillary electrophoresis   
NCEs   Normochromatic erythrocytes 
NCTR   National Centre for Toxicological Research 
ND   Not determined 
NDI   Nuclear division index 
NEM   N-ethylmaleimide 
NER   Nucleotide excision repair 
NFA   National Food Administration 
NG   Normally growing 
NHANES  National Health and Nutrition Examination Survey 
NHS   Nurses’ Health Study   
NLCS   Netherlands Cohort Study 
NMA   N-methylolacrylamide 
NMR   Nuclear magnetic resonance 
NO   Nitric oxide 
NOAEL  No-observed-adverse-effect level 
NOEL   No-observed-effect level 
NQ   Not quantified 
n.s.   Not specified 
NTP   National Toxicology Programe 
Ogg1   8-oxoguanine DNA glycosylase 
OR   Odds ratio 
P   Percentile 
PBS   Phosphate-buffered saline 
PCE   Polychromatic erythrocytes 
PCI   Positive chemical ionisation 
PBPK   Physiologically Based PharmacoKinetic 
PD   Pharmacodynamic 
PMH   Post-menopausal hormones 
pmol   Picomol 
PMTDI   Provisional maximum tolerable daily intake 
PND   Postnatal day 
PR   Progesterone receptor 
PRL   Prolactin 
PSA   Prostate-specific antigen  
Py-GC-MS  Pyrolysis gas chromatography/mass spectrometry 
Q1-Q4   Quartile 1-4 
Q1-Q5   Quintile 1-5 
RA   Radioactivity 
REACH  Registration, Evaluation, Authorisation and Restriction of Chemicals 
REL   Recommended exposure limit 
RET   Reticulocytes 
RfC   Reference concentration 
RfD   Reference dose 
ROS   Reactive oxygen species 
RR   Relative risk  
RT-PCR  Reverse transcriptase polymerase chain reaction 
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S   Scenario 
s.c.   Subcutaneous 
SCE   Sister Chromatid Exchange 
SCF   Scientific Committee on Food 
SES   Social economic status 
SG   Slowly growing 
sGC   Soluble guanylate cyclase 
SGZ   Subgranular zone 
SHP   EFSA Stakeholder Consultative Platform 
SIM   Selected Ion Monitoring 
SMC   Swedish Mammography Cohort  
SME   Small and medium size enterprise 
SMR   Standardised Mortality Ratio 
SN   Sciatic nerve 
SOD   Superoxide dismutase 
SPE   Solid phase extraction 
SPFF   Sweetpotato French Fries 
SPME   Solid phase micro extraction  
SSB   Single strand breaks 
SVHC   Substances of Very High Concern 
T3   Thriiodothyronine 
T4   Thyroxine 
T-   Tertile- 
T:A   thymine:adenine 
TBARS  Thiobarbituric acid-reactive substance 
TD   Typical diet 
TDI   Tolerable daily intake 
TDS   Total Diet Study 
TG   Thyroid gland 
TNF-α   Tumour necrosis factor α 
TPA   12-O-Tetradecanoylphorbol-13-acetate 
TRH   Thyrotropin-releasing hormone  
TSH   Thyroid stimulating hormone 
TVM   Tunica Vaginalis Mesothelioma 
UB   Upper bound 
UDS   Unscheduled DNA synthesis 
UF   Uncertainty factor 
UPLC   Ultra-performance liquid chromatography  
US-EPA  United States Environmental Protection Agency 
US-FDA  United States Food and Drug Administration 
Val   Valine 
Vmax   Maximum formation rate 
VU   Vibration units 
WHO   World Health Organization 
 
